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Abstract 
Cancer is the collective name given to an extensive group of diseases which is mainly characterised by the 
uncontrolled growth of abnormal cells that either ignore or evade biological processes or display enhanced biological 
processes. Cancer is the second leading cause of death worldwide, claiming an estimated 9 million lives and 
accounting for 1 in 6 deaths in 2016. In a post-genomic era, rapid advances in molecular cancer biology and 
genomics has led to the identification of defining characteristics and traits of this complex disease, known as the 
hallmarks of cancer. Consequently, the last two decades has seen a shift from the use of conventional chemotherapy 
to the era of targeted cancer therapy. 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor which belongs to the ErbB/HER family of 
protein-tyrosine kinases. Owing to its expansive role in signal transduction pathways, EGFR regulates a host of 
essential aspects of cellular life, including division, growth and apoptosis. Oncogenic activation of this receptor, 
resulting in overexpression or hyperactivation, has been implicated in a variety of malignancies. To overcome this, 
researchers make use of tyrosine kinase inhibitors (TKIs) to effectively inhibit the receptor and cease uncontrolled 
cellular growth. 
The past 16 years has seen the development of four generations of EGFR inhibitors attempting to overcome the 
emergence of multiple resistance mechanisms which are brought about by point mutations within the enzyme. Most 
recently, the emergence of resistance mediated by the EGFR-C797S mutation in 2015 has presented a challenging 
therapeutic endeavour. To date, no major breakthroughs have been achieved in targeting this clinically relevant 
mutant variant. As such, the research efforts documented within this thesis focus on the development of new 
therapeutic strategies to overcome this resistance mutation. 
The first of these approaches entails the synthesis of highly potent reversible and irreversible EGFR inhibitors. Building 
on a previously identified lead compound, and drawing inspiration from dual EGFR/HER2 inhibitors, we 
incorporated several glycol chain functionalities at strategic positions to introduce favourable reversible interactions 
within the active site of the enzyme. Furthermore, studies on the effects of derivatisation and interchange of other 
structural elements, such as the solubilising group and acryl amide electrophile, were undertaken. 
Departing from traditional inhibition methods, our second strategy sought the re-establishment of irreversible 
inhibition by targeting the EGFR catalytic Lys745 residue with novel electrophiles. To induce covalent bond 
formation, inhibitors containing 1,4-dicarbonyl warheads, able to undergo Paal-Knorr pyrrole formation with the 
Lys745 residue, were synthesised. Furthermore, potential reversible and irreversible interactions with the catalytic 
lysine residue were investigated with inhibitors containing nitrile and reactive sulfonyl fluoride moieties. 
Lastly, we pursued covalent bond formation of the mutated Ser797 residue - the main mechanism by which 
resistance is conferred in the EGFR-C797S mutant variant. To accomplish this, inhibitors containing a multitude of 
reactive serine-targeting electrophiles were synthesised, including nitrogen-, boron-, phosphorous-, sulphur- and 
fluorine-containing warheads. 
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Biochemical and cellular evaluation of the 48 final compounds synthesised during this research project provided 
encouraging results. This included picomolar IC50 values for biochemical inhibition of the clinically relevant EGFR-
L858R/T790M/C797S triple mutant variant of the enzyme by the synthesised reversible inhibitors. However, these 
results were unfortunately not reflected in the cellular-based assays. Additionally, several inhibitors containing the 
conventional acrylamide electrophile exhibited low nanomolar and picomolar range activity against the EGFR-
L858R/T790M double mutant in a biochemical and cellular setting respectively, alluding to irreversible inhibition of 
the enzyme.  A crystal structure of the most efficacious irreversible inhibitor complexed with the cSrc-T338M/S345C 
surrogate was obtained, providing confirmation of covalent bond formation with the Cys797 residue and reinforcing 
our postulates regarding the observed trends in activity. Finally, several lead compounds were appropriately 
evaluated and shown to be effective dual EGFR/HER2 inhibitors. 
The use of covalent mass spectrometry experiments revealed a reversible binding mode for all inhibitors targeting 
the catalytic Lys745 and mutant Ser797 residue. However, several functional groups were identified for their ability 
to create favourable interactions with these residues, as reflected in their effective biochemical and cellular activity 
profiles against the EGFR-C797S mutant. This included the 1,4-dialkene-, boronic ester-, vinyl sulfonyl fluoride-, 
imidazole- and nitrile-bearing compounds. 
Ultimately, novel synthetic methodology was established en route towards these inhibitors and their respective 
electrophiles. Highlights include development of a new and convenient one-pot installation of an acetamide- or 
propanamide-imidazole functional group to aniline derivatives utilising 1,1’-carbonyldiimidazole and the 
corresponding α-, β-halo-carboxylic acid. Furthermore, optimised methods were derived for future access to the
variety of electrophiles and heterocyclic scaffolds synthesised throughout this research project.  
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Opsomming 
Kanker is die kollektiewe naam wat gegee word aan 'n uitgebreide groep siektes, wat hoofsaaklik gekenmerk word 
deur die onbeheerde groei van abnormale selle. Hierdie selle vermy, of bevat negatiewe of verbeterde biologiese 
prosesse. Kanker is die wêreld se tweede grootste oorsaak van dood, wat ongeveer 9 miljoen lewens geeis het in 
2016. Dit reken vir 1 uit 6 van die totale jaarlikse sterftes wêreldwyd. In 'n post-genomiese era het vinnige 
vooruitgang in molekulêre kankerbiologie en genomika gelei tot die identifisering van kenmerkende vermoëns van 
hierdie komplekse siekte. Gevolglik het die afgelope twee dekades 'n verskuiwing vanaf konvensionele chemoterapie 
na die era van geteikende kankerterapie gesien. 
Epidermale groeifaktor reseptor (EGFR) is 'n transmembrane reseptor wat behoort aan die ErbB/HER familie van 
proteïen-tyrosien kinases. As gevolg van sy uitgebreide rol in seintransduksiepaaie, reguleer EGFR verskeie 
noodsaaklike aspekte van sellulêre lewe, insluitend verdeling, groei en apoptose. Onkogene aktivering van hierdie 
reseptor, wat tot ooruitdrukking of hiperaktivering lei, is in 'n verskeidenheid maligniteite betrokke. Navorsers 
gebruik tyrosienkinase-inhibeerders (TKI) om die reseptor effektief te inhibeer en onbeheerde sellulêre groei te staak. 
Deur die afgelope 16 jaar is vier generasies EGFR-inhibeerders ontwikkel wat die opkoms van meervoudige 
weerstandsmeganismes probeer oorkom. Hierdie meganismes word deur puntmutasies binne die ensiem 
veroorsaak. Die onlangse opkoms van weerstand in 2015, wat deur die EGFR-C797S-mutasie veroorsaak is, het 'n 
uitdagende terapeutiese poging aangewend. Geen groot deurbrake om hierdie klinies relevante mutantvariant te 
oorkom is nie tot op datum bereik nie. Die navorsingspogings in hierdie proefskrif fokus op die ontwikkeling van 
nuwe terapeutiese strategieë om hierdie weerstandsmutasie te oorkom. 
Die sintese van hoe-kragtige omkeerbare en onomkeerbare EGFR-inhibeerders was die eerste van hierdie 
benaderings. Hierdie werk was gebaseer op 'n voorheen geïdentifiseerde suksevolle inhibeerder. Verskeie glikkol-
funksionaliteite, wat by strategiese posisies ingevoer is om gunstige omkeerbare interaksies binne die aktiewe plek 
van die ensiem voor te stel, was geinspireer van dubbele EGFR/HER2-inhibeerders. Verdere studies was onderneem 
oor die gevolge van derivatisering en verwisseling van ander strukturele elemente, soos die oplosbare groep en 
akrielamiedelektrofil. 
Ons tweede strategie, wat afwyk van tradisionele inhibisiemetodes, het gesoek na die herstelling van onomkeerbare 
inhibisie deur die EGFR katalitiese lysine 745 residu met nuwe elektrofiele. Om kovalente bindingsvorming te 
veroorsaak was inhibeerders met 1,4-dikarbonyl-koppe gesintetiseer wat Paal-Knorr-pyrrolvorming kon ondergaan 
met die Lys745 residu. Verder is potensiële omkeerbare en onomkeerbare interaksies met die katalitiese lysienresidu 
ondersoek met inhibeerders wat nitril- en reaktiewe sulfonielfluorieddele bevat.  
Laastens het ons kovalente binding vorming nagestreef met die gemuteerde serine 797 residu - die hoofmeganisme 
van weerstand in die EGFR-C797S mutant variant. Inhibeerders wat 'n verskeidenheid reaktiewe seriene-teiken-
elektrofiele bevat, insluitende boron-, fosfor-, swael- en fluoorbevattende hoofkoppies, was gesintetiseer om dit te 
bereik.  
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Bemoedigende resultate was opgelewer in die biochemiese en sellulêre evaluering van die 48 finale inhibeerders, 
wat tydens hierdie navorsingsprojek gesintetiseer is. Dit sluit in pikomolêre IC50 waardes vir biochemiese inhibisie 
van die klinies relevante EGFR-L858R/T790M/C797S triple mutant variant van die ensiem deur die gesintetiseerde 
omkeerbare inhibeerders. Hierdie resultate is egter ongelukkig nie weerspieël in die sel-gebaseerde toetse nie.  
Daarbenewens het verskeie inhibeerders wat die konvensionele akrylamiedelektrofil bevat, lae nanomolêre en 
pikomolêre reeks aktiwiteit vertoon teen die EGFR-L858R/T790M dubbelmutant in ‘n onderskeidelik biochemiese 
en sellulêre omgewing. Hierdie resultate het die onomkeerbare inhibisie van die ensiem aangedui. 'N Kristalstruktuur 
was verkry van die mees effektiewe onomkeerbare inhibeerder gekompleks saam met die cSrc-T338M/S345C-
surrogaat. Hierdie struktuur het die kovalente bindingvorming met die Cys797-residu beverstig en ons postulate oor 
die waargenome tendense in aktiwiteit ondersteun. Laastens was verskeie van die mees suksesvolle inhibeerders 
geëvalueer en getoon dat dit ‘n effektiewe dubbele EGFR/HER2 inhibeerder is.  
'n Omkeerbare bindingsmodus deur die gebruik van kovalente massaspektrometrie-eksperimente was bewys vir alle 
inhibeerders wat die katalitiese Lys745 en mutant Ser797 residu geteiken het. Verskeie funksionele groepe is egter 
geïdentifiseer vir die vermoë om gunstige interaksies met hierdie residue te skep, soos wat weerspieël was in hul 
effektiewe biochemiese en sellulêre aktiwiteitsprofiele teen die EGFR-C797S mutant. Dit sluit in die 1,4-dialkeen-, 
boronester-, vinielsulfonylfluoried-, imidasool- en nitril-draende verbindings. 
Op pad na die sintese van hierdie inhibeerders en hul onderskeie elektrofiele is nuwe sintetiese metodologie 
gevestig. Hoogtepunte sluit in die ontwikkeling van 'n nuwe en gerieflike eenpot-installasie van 'n asetamied- of 
propanamiedimidasool funksionele groep na anilienderivate, wat gebruik maak van 1,1'-karbonyldiimidasool en die 
ooreenstemmende α-, β-halo-karboksielsuur. Geoptimaliseerde metodes was afgelei vir toekomstige toegang tot die 
verskeidenheid elektrofiele en heterosikliese strukture wat deur hierdie navorsingsprojek gesintetiseer word. 
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Chapter 1 
The Burden of Cancer, Cancer Biology and Targeted Treatment 
Abstract 
In this chapter, the burden of cancer and its effects on all of mankind will be discussed. Emphasis will be placed on its human, 
societal and economic costs and preventative measures available. An understanding of cancer biology, and the inherent events 
and characteristics that confer selective growth and survival advantages to its cells, is essential to deciphering the pathogenesis of 
the disease. These enabling and sustaining capabilities, known as the hallmarks of cancer, will be reviewed. Finally, an overview 
of chemo- and targeted-therapy, limitations and challenges in the field, and how the hallmarks have influenced cancer drug 
development, will be reflected on.  
1.1 The Burden of Cancer 
Cancer is the collective name given to an extensive group of diseases which is mainly characterised by the 
uncontrolled growth of abnormal cells that either ignore or evade biological processes or display enhanced biological 
processes. This unregulated cellular growth results in the rapid division of these aberrant cells, leading to the 
formation of malignant neoplasm or tumours.
1
 These cells have the ability to detach from primary tumour sites and 
penetrate surrounding tissue, entering blood or lymphatic vessels and allowing for circulation via the vascular or 
lymphatic system. This results in the invasion of adjoining body parts or vital organs and the formation of secondary 
tumour sites – a process known as metastasis.2 Cancer can evolve from nearly all cells and can develop in and spread 
to all parts of the human body. It is an incredibly complex disease group which has many anatomic and molecular 
subtypes, each of which require tailored management strategies.  
1.1.1 Incidence and Mortality 
Cancer is a costly burden and first and foremost is the cost of human life. Cancer is the second leading cause of 
death worldwide, claiming an estimated 9 million lives and accounting for 1 in 6 deaths in 2016.
3
 Of the estimated 
57 million deaths globally in 2016, deaths occurring due to noncommunicable diseases (NCD) accounted for a 
staggering 41 million (71%) of these.
3
 The clear majority of these deaths can be attributed to four main culprits, 
namely: cardiovascular disease (17.9 million, 44% of NCD deaths), cancer (9 million, 22%), chronic respiratory 
disease (3.8 million, 9%) and diabetes (1.6 million, 4%).
3
 The five leading behavioural risks for cancer, and the shared 
risk factors for the four main NCDs, are: not maintaining a healthy body weight, lack of regular exercise, inadequate 
intake of fruits and vegetables, use of tobacco products and increased alcohol consumption.
4, 5 
Tobacco use is the 
single greatest avoidable risk factor for cancer and is responsible for 22% of all cancer related deaths.
5
 While globally, 
the risk of death from one of the four major NCDs has fallen from 22% in 2000 to 18.3% in 2016, adults in lower- 
and middle-income countries still face nearly double the risk (22%) of that of adults in high-income countries (12%).
6
 
Locally, the continental average risk for Africa was estimated at 20.6%, with South Africa (26.2%) placed 5
th
 highest 
amongst the 47 countries taken into consideration.
6
 Thus, these noncommunicable diseases constitute a major 
obstacle to human development and well-being.  
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Figure 1.1: The estimated cancer incidence (left) and mortality (right) by major site, in both sexes combined in 2012. Figure 
reproduced from Stewart et al.
7
 
According to the World Cancer Report 2014, the incidence of cancer has increased from 12.7 million in 2008 to 
14.1 million in 2012.
7
 As illustrated in Figure 1.1, the five most common sites for cancer diagnosed in both men 
and woman combined were the lung (13.0% of total cases), breast (11.9%), colorectal (9.7%), prostate (7.9%) and 
stomach (6.8%) – constituting half of the overall global cancer burden.7, 8 A similar pattern is observed for the five 
deadliest cancers, with cancer of the lung (19.4% of total deaths), liver (9.1%), stomach (8.8%), colorectum (8.5%) 
and breast (6.4%) having the highest mortality rates (Figure 1.1).
8
 Over the next two decades the incidence of cancer 
is set to rise by a further 75%, bringing the expected number of cancer cases close to 25 million in 2035.
7
 The 
projected escalation in cancer will undoubtedly have the greatest impact in low- and middle-income countries.  
1.1.2 Cancer Disparity 
Whilst the harrowing experience of being diagnosed with cancer is a truly universal and unbiased one, patients find 
their paths post-diagnosis to be uniquely diverse. The personal experiences of these patients frequently reflect the 
disparity and inequality found globally, and the future of a patient depends largely on where they find themselves 
in the world. More than 60% of the world’s cancer incidents, and approximately 70% of deaths from cancer, occur 
in the regions of Africa, Asia and Central and South America.
7
 This can be attributed to health care systems that are 
ill equipped to cope with the burden of cancer. Worldwide, only 1 in 5 low- to middle-income nations have the 
requisite data to drive cancer policy.
9
 Consequently, cancer is typically diagnosed at more advanced stages of the 
disease and access to diagnosis, effective treatment or palliative care are often inaccessible. In 2017, it was found 
that only 26% of low-income nations reported having publicly available pathology and treatment services, in stark 
contrast to over 90% for that of high-income countries.
10
  
Many low- to middle-income countries find themselves having to contend with cancers from two vastly different 
worlds. Cancers associated with poverty, such as those attributable to the infectious agents of helicobacter pylori, 
Epstein-Barr virus, hepatitis and human papilloma virus (HPV) remain a problem. In 2012, infection-attributable 
cancers made up 15% of global cancer cases, of which more than 66% percent of these occurred in low-income 
countries and less than 5% from Australia, Canada, New Zealand, the United States and select countries in Western 
and Northern Europe combined.
11
 Infection-related cancers accounted for 25% of total cancer cases in developing 
countries, and more than 50% in sub-Saharan Africa.
11
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Additionally, cancers associated with the world of plenty are becoming increasingly prevalent. This can be ascribed 
to the adoption of Western lifestyles – lack of physical activity, consumption of unhealthy, processed foods and 
alcohol and increased use of tobacco. It has been estimated that nearly 80% of the 1 billion smokers worldwide now 
reside in low- to middle-income nations.
5
  The rising incidence of cancer and other NCDs will place immense strain 
on the already struggling healthcare systems of developing countries, leading to the divide between experiences of 
individual cancer patients to broaden. 
1.1.3 Economic Impact 
Treatment for an increasing number of cancer patients also has an escalating economic impact. In 2010, the total 
annual cost of cancer, with regards to prevention, treatment and the economic value of lives lost and disability 
caused, was estimated to be $1.16 trillion.
7
 Further analysis, which adds the long-term costs to patients and their 
family members, estimate the annual global cost at $2.5 trillion.
7
 High-income countries spend between 5-10 times 
more on cancer management and prevention on a per capita basis than low- and middle-income nations.
12
 Whilst 
many assessments have been undertaken on the cost of cancer in these high-income regions, a recent study 
estimated the value of productivity lost in 2012 due to cancer mortality in Brazil, Russia, India, China and South 
Africa – also known as the BRICS countries.13 Utilising data from GLOBOCAN 2012, the total cost of lost productivity 
from cancer deaths in all five BRICS countries was valued at $46.3 billion, constituting 0.33% of their combined 
gross domestic product and equating to $45926 per premature cancer mortality.
13
 It was found that China suffered 
the greatest loss in years of productive life (5.9 million years) and total productivity ($28 billion), while South Africa 
had the highest cost per cancer death ($101105) – more than five times the cost estimated in India ($19 691).13 
Factors such as ageing, population growth and the spiralling costs of cancer treatment will place increasing demands 
on the health-care budgets of wealthy and impoverished nations alike. 
1.1.4 Prevention 
Given the overwhelmingly heavy burden of cancer globally, and the projected impact on developing countries 
particularly, prevention is fundamental to diminishing and reversing this burden. It is estimated that 30 – 50% of all 
cancer cases are preventable by avoiding or modifying the five leading behavioural and dietary risks.
4
 In low- to 
middle-income regions of the world, it has been estimated that an investment of $11.4 billion in a set of core 
prevention strategies could lead to savings of up to $100 billion in future cancer treatment costs.
14
 Approaches with 
the greatest potential for clinical and economic results include tobacco and obesity control, vaccines, early detection 
and the creation of cancer registries.
14
 Through the implementation of vaccination against HPV and hepatitis B 
viruses alone, it is estimated that 1 million cancer cases can be prevented annually.
11
 By adopting similar strategies 
for cancer control in the BRICS (Brazil, Russia, India, China and South Africa) nations, 41% of the world’s population 
will increase their chances of a cancer-free life.
13
 Elucidating the causes and creating effective prevention strategies 
will thus be essential components of combating the growing cancer burden in the future. 
Parallel to efforts engaged in the causes and prevention of cancer, exceptional progress has been made in the 
understanding of the molecular and biological events that transform a normal functioning cell into a malignant 
growth, capable of replicating and spreading throughout our bodies.
15
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These advances have in turn led to new avenues in early detection and prevention, clues relating to causation and 
the classification of different types of cancer.
16
 This integrative and complementary approach is imperative to 
translating knowledge about the mechanisms of carcinogenesis into freeing as many people as possible from the 
threat of this disease.  
1.2 Cancer Biology: Enabling Characteristics and Hallmarks 
A grasp and comprehension of cancer biology is pivotal to the development of rationally designed therapeutics and 
preventive recourse. At the dawn of the new millennium, the Human Genome Project revealed the specification of 
the human genome, providing a comprehensive view of a “normal” human sequence and its components.17 In the 
following years, the investigation of how cancer cells differ from normal cells has yielded an invaluable amount of 
relevant knowledge to the field – with acquisition of this knowledge proceeding exponentially faster in a post-
genomic era. The hallmarks of cancer, shown in Figure 1.2, were first laid out in an influential review in 2000 by 
Hanahan and Weinberg, providing an enumeration of the traits and defining characteristics of this complex disease.
18
 
These principles were further elaborated in an update published in 2011, proposing new hallmarks and mechanisms 
of cancer.
15
 These hallmarks and the pathogenesis of cancer will be discussed within this section, placing emphasis 
on the enabling characteristics of somatic mutations and altered gene expression within the cancer genome. These 
mutations may occur through epigenetic change and mediate selective growth advantages conferred by the hallmark 
capabilities. In parallel, the role of the tumour microenvironment in facilitating tumorigenesis through inflammation, 
growth of new blood vessels and the spread and growth of cancer cells in metastatic sites will also be discussed.  
 
Figure 1.2: The six hallmark capabilities as proposed by and reproduced from Hanahan and Weinberg.
15
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1.2.1 Cancer Genomics and Epigenetics 
1.2.1.1 The Complexity of Cancer Genomics  
Cancer is a disease of the genome and all cancers harbour genetic mutations within their own genomes. The 
biological complexity of the disease stems from several factors regarding these mutations, the first being the 
numerous types of cancer-causing mutations.
19
 The simplest of these mutations can be as a result of the insertion, 
deletion or substitution of only one nucleotide that affects single DNA bases. Consequently, segments of 
chromosomes can undergo gene amplification, deletion or inversion of gene sequences.
20, 21
 Translocation of 
chromosomes may also occur, most notably exemplified in the Philadelphia translocation which results from the 
joining of chromosomes 9 and 22, a mutation prevalent in over 95% of patients suffering from chronic myeloid 
leukaemia (CML).
22
 Viral carcinogenesis can also occur through the acquisition of DNA from viruses such as HPV, 
hepatitis and the Epstein-Barr virus.
23
  
In addition to the extensive mutational aetiology of cancer, the sheer number of different mutations present in 
tumours adds to their complexity. Using whole cancer genome sequencing, the mutational spectrum of cancer cells 
has been elucidated, revealing a substantial number of putative somatic mutations in every cancer genome. A total 
of 22910 somatic base substitutions were observed in the first small cell lung cancer genome sequenced, and 33345 
in the first sequencing of the melanoma genome.
24, 25
 Multiple mutation signatures could be traced to repeated 
exposure to carcinogens such as ultraviolet radiation and chemicals found in tobacco smoke, and their proclivity 
towards defective DNA repair pathways.  
Lastly, tumour heterogeneity, or the composition of different cancer cell subpopulations in tumour masses bearing 
related but distinct mutation profiles, can be highly problematic. Over time and through the process of metastasis, 
the mutational spectrum of lesions in a single patient can evolve. This evolution can have significant ramifications, 
the most serious being the acquisition of drug resistance.
26
 Tumour heterogeneity promotes the emergence of more-
competitive cancer sub-clones that are insensitive to therapy, as they outlive those clones that are not. Genomic 
instability can also alter the pharmacogenomic pathway or the drug receptor site of the therapeutic target, resulting 
in an adverse drug reaction or rendering the treatment ineffective.
27
 This is particularly relevant in the treatment of 
non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) as the therapeutic target. In the 
last 15 years alone, the two single point mutations T790M and C797S have mediated resistance to a number of FDA 
approved blockbuster drugs including gefitinib, erlotinib and osimertinib.
28, 29
 The aforementioned case remains the 
exception as the development of cancer can be seen as a multistep, multigenic process arising not from a single 
polymorphism in a single gene, but rather the accumulation of a number mutations over time.  
1.2.1.2 Driver and Passenger Mutations  
Mutations have profound effects on the biological processes that drive cancer cell growth and differentiation. While 
all cancers arise from somatic changes in the DNA of cancer cells, not all the somatic abnormalities acquired in a 
cancer genome are implicated in the development of the cancer. Mutations that confer selective growth advantages 
to cancer cells are known as driver mutations.
30
 Driver mutations are causally implicated in oncogenesis and are 
found within the subset of genes known as cancer genes.  
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While they are not required for preservation of the final cancer, they have been positively selected at some point 
during the evolution of the cancer.
31
 The remaining majority of somatic mutations with no biological consequence 
are called passenger mutations. Passenger mutations are without functional significance as they do not confer clonal 
growth advantages and do not contribute to the incidence of cancer. These mutations often occur during mitosis 
and are carried along during clonal expansion so that they are found in all cells of the final cancer.
30
  
For more than 25 years, a central aim of cancer research has been the identification of cancer genes which harbour 
driver mutations.
31
 Recently, through the use of cancer genome sequencing, a comprehensive analysis of 9423 
tumour exomes was undertaken. This combined all 33 of The Cancer Genome Atlas categorized cancer types and 
made use of 26 different computational tools to provide the most up to date catalogue of driver genes and 
mutations.
16, 32
 The study was able to identify 299 cancer driver genes and over 3400 putative driver mutations.
32
 
The research also found that 57% of the tumours analysed harboured potentially actionable oncogenic events, a 
finding that can serve as a foundation for future clinical and therapeutic endeavours.
32
 Driver genes causing 
alterations which result in carcinogenesis can be can be divided into three broad groups, namely: proto-oncogenes 
and oncogenes, tumour suppressor genes and DNA repair genes.
31
 These three groups can be further classified into 
12 signalling pathways that control three central cellular processes: cell fate, cell survival and genome maintenance 
as shown below in Figure 1.3.
31
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Selective growth advantages (inner ring) is associated with driver gene mutations in one or more of 12 cell signalling 
pathways (middle ring). These pathways are responsible for the regulation of three core cellular processes (outer ring). Figure 
reproduced from Vogelstein et al.
31
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1.2.1.3 Oncogenes  
In normal cells, proto-oncogenes code for the proteins that stimulate cell division, inhibit cell differentiation and halt 
cell death through a series of steps called signal transduction cascades and pathways. Upon acquiring an activating 
mutation, a proto-oncogene becomes a tumour inducing-agent known as an oncogene, leading to upregulation and 
over expression of these proteins.
33
 This activation is induced by three main mechanisms, namely: mutations within 
regulatory regions changing the structure of the encoded protein to enhance its transforming activity, gene 
amplification or duplication leading to an increase in protein concentration and expression and chromosomal 
rearrangements including inversions and translocations.
34, 35
 Mutations and translocations can occur as initiating 
events or during tumour progression, whilst amplification is mainly associated with tumour progression.
33
 All three 
mechanisms confer a growth advantage and increased cell survival to cancer cells through an increase in or 
deregulation of protein expression.
36
 Oncogenes are almost always dominant as only a single allele mutation is 
required for the gene to possess a new molecular function or pattern of gene expression. This is referred to as a “gain 
of function” mutation.37  
The products of oncogenes can be divided into six categories: transcription factors, chromatin remodelers, apoptosis 
regulators, signal transducers, growth factors and growth factor receptors – being implicated in the majority of the 
hallmark capabilities of cancer.
33
 Notable examples of oncogenes include the RAS gene superfamily, where single 
point mutations typically produce constitutive constant activation of the RAS signalling pathway. About 25% of all 
human tumours contain an activating mutant isoform of RAS genes.
38
 MYC oncoproteins belong to a family of super 
transcription factors that regulate the transcription of at least 15% of the entire human genome. The MYC family of 
oncogenes are deregulated in over 50% of human cancers, being often associated with adverse prognosis and poor 
patient survival rate.
39
 Oncogenic proteins in cancer cells remain therapeutic targets for cancer treatment, as their 
targeted inactivation results in sustained loss of neoplastic growth.
40
 Growth factors and growth factor receptors form 
an integral part of this research project and their signalling pathways, relevance as therapeutic targets and current 
therapies will be comprehensively reviewed in the following chapter. 
1.2.1.4 Tumour Suppressor Genes 
Tumour suppressor genes, or anti-oncogenes, are distinct from oncogenes. Where proto-oncogenes can be seen as 
the accelerator in the vehicle that is the cell, tumour suppressor genes act as the brakes. Tumour suppressor genes 
code for the proteins that have a dampening or restraining effect on cell growth and differentiation and stimulate 
programmed cellular death.
41
 Unlike oncogenes, abnormalities within tumour suppressor genes are typically 
recessive and follow the “two hit hypothesis”.42 This requires that both alleles which code for a particular protein 
must be mutated for the effect to manifest and the trait to be expressed. This is referred to as a “loss of function” 
mutation.
41
 Tumour suppressor genes can be classified into three groups, namely: caretaker, gatekeeper and 
landscaper genes.
43
 TP53 is an example of one of the most frequently mutated tumour suppressor genes, being 
implicated in more than 50% of human cancers.
44
 Furthermore, TP53 encodes for at least 15 protein isoforms, 
known as the p53 protein isoforms, and has been described as “the guardian of the genome.”45  These proteins 
provide genomic stability by binding to DNA and regulating gene expression to prevent mutations, whilst also 
enforcing a system of checks and balances to monitor cell division and apoptosis.
41  
Stellenbosch University https://scholar.sun.ac.za
Chapter 1 – The Burden of Cancer, Cancer Biology and Targeted Treatment 
 
8 
 
1.2.1.5 DNA Repair Genes 
The third group of genes associated with cancer are the DNA repair genes. Our cellular DNA is under continual 
attack from environmental agents such as radiation and chemicals, resulting in molecular lesions that cause structural 
damage. This may induce mutations in the cells genome, affecting the daughter cells survival after mitosis and altering 
or eliminating the cells ability to transcribe genes.
46
 These toxic and mutagenic consequences are minimized by the 
action of DNA repair genes and the distinct repair pathways. These genes code for enzymes that repair point 
mutations and chromosomal aberrations before replication and chromosomal divide. Additionally, they are involved 
in cell-cycle checkpoints and, as a last resort, induce apoptosis if repair is not possible.
47
 When these genes are 
mutated, the DNA damage response is silenced, leading to irreparable damage in cells which avoid programmed 
cellular death and undergo unregulated cellular growth. This results in the accumulation of subsequent mutations 
and ultimately in cancer.
48
 Notable examples of DNA repair genes include BRCA, which encodes for protein 
products that are important for the repair of double strand breaks through homologous recombination. Mutations of 
these genes are typically implicated in breast cancer.
49
  
1.2.1.6 Cancer Epigenetics 
Cancer epigenetics is the study of heritable modifications to the DNA of cancer cells that are not caused by genetic 
mutations and their biochemical pathways.
50
 Epigenetic abnormalities participate with genetic mutations to cause 
dysregulation in gene silencing, playing a pivotal role in key biological processes which are fundamental to the 
genesis of cancer.
51
 These epigenetic alterations are regulated and brought about by DNA methylation, nucleosome 
remodelling by histone modifications and non-coding RNA-mediated targeting of various genes.
51
 The correlation 
between microRNAs (miRNAs), an abundant class of small non-protein-coding RNA molecules, and human cancers 
is especially well documented. When miRNAs are mutated or mis-expressed they are known as oncomirs.
52
 
Oncomirs may act as both oncogenes - as overexpression of the gene results in uncontrolled cellular growth - and 
as tumour suppressors in normal cells, where under-expression of the gene is linked to cancerous growth.
 53 
With the recent advances in genomic technologies and the availability of an abundance of genomic information 
pertaining to cancer, the field of cancer genomics has shown a convergence in discovery science and clinical 
medicine. The successful translation of cancer genomics into diagnostics and therapeutics has reinforced the prospect 
of personalised cancer treatment.
54
 Genomes of cancerous tumours will continue to be scrutinised and mined to 
further our understanding of cancer cells, to provide biomarkers as indicators of prognosis and treatment response 
and to identify future targets for the evaluation and implementation of new cancer drugs.  
1.2.2 Tumour Microenvironment 
1.2.2.1 Inflammation 
Inflammation is an essential protective response that sporadically goes awry and becomes a major contributing factor 
in the pathogenesis of several chronic human diseases, including cancer. Since the discovery of leukocytes within 
neoplastic tissue in 1863 by Rudolf Virchow, the link between inflammation and cancer has become well 
established.
55
 Whilst the genetic changes that occur within cancer cells allow for tumour initiation and promotion, 
this is not sufficient for the facilitation of tumour progression.  
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Ancillary processes orchestrated by inflammatory cells within the tumour microenvironment are an indispensable 
participant and frequently play requisite roles in all stages of tumour development, from initiation and promotion to 
proliferation, invasion and metastasis.
56
 Inflammatory responses enable and drive tumorigenesis through the supply 
of bioactive molecules to the tumour microenvironment such as growth factors for sustained proliferative signalling, 
survival factors limiting apoptosis and enzymes that expedite angiogenesis, invasion and metastasis.
57
 As such, it is 
considered one of the enabling characteristics of cancer development.  
1.2.2.2 Angiogenesis 
Due to mutations that stimulate uncontrolled proliferation of cancer cells, tumours require substantially more 
nutrients and oxygen to sustain their growth and an enhanced ability to evacuate metabolic waste and carbon 
dioxide in comparison to normal tissues. This need is addressed by tumour-associated neovasculature or 
angiogenesis. During the development of an embryo, endothelial cells assemble into tubes and form blood vessels 
(vasculogenesis), which is followed by the sprouting of new vessels from these existing ones (angiogenesis) - a process 
which becomes largely quiescent in adulthood. However, during tumour progression, this “angiogenic switch” is 
unceasingly activated and remains on, resulting in the continuous sprouting of dilated and irregularly shaped tumour 
blood vessels that sustain expanding neoplastic tissue.
58
 This “angiogenic switch” is controlled by counteracting 
factors that may either induce or oppose angiogenesis. Tumours secrete growth factors such as vascular endothelial 
growth factors (VEGF) that bind to receptors and induce capillary growth, and typically halt production of anti-VEGF 
enzymes such as protein kinase G (PKG) which prohibits angiogenesis in normal cells.
15
 Angiogenesis is induced in 
the early stages of tumour initiation and is fundamental to their characteristic large size. Angiogenesis also plays a 
role in tumour metastasis and has become one of the most relevant hallmarks of cancer in a therapeutic context.
59
  
1.2.2.3 Metastasis  
Metastases result from the spread of cancer cells from a primary to a distant secondary tumour site and are 
responsible for more than 90% of all cancer-related deaths.
2
 Metastasis, depicted in Figure 1.4a, is an intricate and 
multistep process where cancer cells migrate and flow through vastly different microenvironments such as the stroma, 
the vascular or lymphatic system and tissue at the secondary site. The success of this relies heavily on the physical, 
mechanical and molecular interactions of cancer cells with the micro- and external environment.
60
 As mentioned 
previously, angiogenesis plays a pivotal role in the metastatic process, not only by providing nourishment through 
vascularisation, but also by providing an escape route by which cancer cells can enter the blood circulatory system.
61
 
Investigation into the detachment of carcinoma cells have revealed a process resembling the epithelial-to-
mesenchymal transition (EMT). This results in the loss of cell polarity and intercellular adhesion properties, enabling 
elastic morphological deformations of the cancer cells. These factors facilitate detachment of the cancer cells from 
the primary tumour and invasion through the basal membrane into the blood or lymphatic system – also known as 
intravasation (Figure 1.4a).
60
 Once inside the circulatory system, tumour cells are subjected to several stresses such 
as haemodynamic forces, collisions with host cells and immunosurveillance. Only a fraction of these circulating 
tumour cells will thus survive to form metastases.
61
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Figure 1.4: a) The metastatic process resulting in invasion and formation of secondary tumours b) Vascular and lymphatic flow 
patterns and the corresponding movement of cancer cells and tumour formation in favoured organs. Figures reproduced from 
a) Wirtz and b) Chambers et al.
2, 60 
This survival requires adhesion to a blood vessel wall and extravasation from the circulation into the surrounding 
tissue which is largely dependent on the cancer cell and capillaries diameter.
60
 After arrest, their ability to grow in 
secondary sites is governed by molecular interactions within the microenvironment of the new organ.  
It is recognized that different types of cancer show an organ-specific pattern of metastasis, as exemplified in Figure 
1.4b.
2
 Breast cancer is frequently observed to metastasize in the lung, brain and bone of patients, while in contrast 
colorectal cancer preferentially spreads to the liver. These predispositions derive from a combination of vascular flow 
patterns and the theory of “seed and soil” or the propensity of a cancer cell (seed) to flourish in a specific secondary 
organ (soil). As an example, breast cancer cells leaving the primary tumour by blood vessels will flow firstly through 
the heart and then to the capillary bed of the lung (Figure 1.4b, blue arrows). Some cells may form metastases within 
the lung, while others may pass through the tissue and enter the arterial system (Figure 1.4b, red arrows), spreading 
to remote areas such as the brain and bones. Breast cancer cells have been known to invade the lymphatic system 
(Figure 1.4b, yellow arrows), taken to the draining lymph node and then entering the venous system. By contrast, 
colorectal cancer cells travel via the hepatic-portal circulatory system (Figure 1.4b, pink arrow) and are taken first to 
the capillaries of the liver.
2
 
While still an emerging field with many unanswered questions, research into the mechanisms of this complex 
hallmark capability has gained traction over the past two decades. New technologies and research tools, coupled 
with refined experimental models and the identification of critical regulatory genes and interactions, has made 
significant progress possible in unravelling the important features of metastasis.  
1.2.3 Emerging Hallmarks 
The hallmark principles of cancer have been defined as capabilities that ensure cancer cell survival, proliferation and 
growth.
15
 The acquisition and activation of these functions, in different tumour types at different stages of 
tumorigenesis, is made possible by the two chief enabling characteristics outlined previously, namely: genome 
instability and inflammation within the tumour microenvironment as shown on the following page in Figure 1.5. In 
recent years, the addition of two other distinct attributes of cancer cells have been proposed.  
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Figure 1.5: The two main enabling characteristics of genome instability and inflammation are shown above. Both cellular 
metabolism and immuno-evasion have also been recognised as hallmarks. Figure reproduced from Hanahan and Weinberg.
15
 
These two features, illustrated in Figure 1.5, involve the reprogramming of cellular metabolism and energetics to 
sustain the uncontrolled and continuous cell growth associated with tumours, as well as the active ability of cancer 
cells to evade attack and elimination by the host’s immune system. These capabilities have been deemed functionally 
important to tumour growth and progression in various forms of human cancer and will be discussed briefly. 
1.2.3.1 Cellular Metabolism 
Genetic alterations which drive abnormal cellular proliferation in tumours place a significant demand on nutrient 
utilisation and biosynthetic requirements for increased cell growth and division. Corresponding energy metabolism 
adjustments allow malignant cells to meet these requirements. Under aerobic conditions, normal cells rely primarily 
on mitochondrial oxidative phosphorylation to generate energy. In contrast, malignant tumours rely on glycolysis in 
the presence or absence of oxygen, a phenomenon first observed by Otto Warburg in 1930 and termed the 
“Warburg effect.”62 A functional rationale for this glycolytic switch in cancer cells has been enigmatic in the past 
decades, owing to the reduced efficiency of generating adenosine 5´-triphosphate (ATP) in comparison to normal 
mitochondrial oxidative phosphorylation. It is now understood that the metabolism of cancer cells has adapted for 
this increased glycolysis, allowing for an increased uptake and incorporation of glycolytic intermediates into various 
biosynthetic pathways. This in turn facilitates the biosynthesis of macromolecules and organelles necessary for 
production of new cells.
62
 Mutations within signalling pathways implicated in cell growth have been shown to 
regulate these metabolic pathways and enable cancer cells to obtain and metabolise nutrients in a way conducive 
to cell division, rather than efficient ATP production.
62
 The reprogramming of energy metabolism has been 
highlighted as an emerging hallmark of tumorigenesis and key to its promotion within neoplastic tissue.
15
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1.2.3.2 Immune Evasion 
The theorem of immune surveillance postulates that cells and tissues are continually being policed by the immune 
system, recognizing arising mutations and eradicating the vast majority of incipient neoplasms.
63
 However, tumours 
that do survive and spread have done so by managing to avoid detection and evade the immunological eradication 
response. Recently, studies involving genetically engineered animal models and clinical epidemiology, have 
increased our understanding in this area and began to elucidate this phenomenon.
64
 The physiological barriers which 
impede an antitumor response operate within the tumour microenvironment and make use of various components 
of the innate immune system. On such impediment, immunoediting, allows tumours to lay dormant through 
equilibrium and senescence before resurfacing. Others include inhibiting the secretions of regulatory T-cells, 
modifying production of immune suppressive mediators and immune deviation.
65
 The immune evasion capability 
of tumours, and its significance in tumour initiation and progression, has established it as an emerging hallmark and 
enabling factor in the pathogenesis of cancer.
15
 
1.3 Chemo- and Targeted Therapy of Cancer 
Of all the obstacles faced and progress made in the field of medicine, few have been as arduous and hard-fought as 
the treatment and cure of cancer. Tremendous strides made in molecular cancer biology and genomics has 
expedited the development and transformation of cancer therapeutics from a low-budget, government-run research 
endeavour to a lucrative, multibillion-dollar industry. The intellectual foundations of this revolution can be traced 
back 110 years ago, when the founder of chemotherapy, Paul Ehrlich, received the Nobel Prize for Physiology or 
Medicine. His coining of the term “magic bullets”, for the treatment of human diseases, inspired generations of 
scientists and led to multiple ground-breaking studies, paving the road towards modern targeted disease therapy.
66
 
A chronicle of the history of chemo- and targeted therapy, focusing on clinical successes and remaining challenges 
and limitations within the field, will be discussed within this section. Finally, we will consider how the previously 
outlined hallmark principles of cancer have begun to shape the landscape of therapeutic development in oncology 
and will continue to do so in the future.  
1.3.1 History  
1.3.1.1 Chemotherapy 
Prior to two major discoveries in the 1940s, cancer treatment remained largely the territory of the surgeon. The 
invention of the linear accelerator enabled widespread use of radiation therapy in the 1960s, but, as with surgery, 
failed to eradicate the spread and metastasis of tumours. The first four decades of the 20
th
 century saw breakthroughs 
in screening methods and model development. In 1910, George Clowes successfully developed the first 
transplantable tumour system for rodents, allowing for standardisation and model systems for cancer drug testing.
67
 
Murray Shear later initiated the most organised program for cancer drug screening in 1935, leading to the testing of 
over 3000 compounds, including natural products.
67
 The dawn of the modern era of chemotherapy can be traced 
back to two breakthroughs during World War II , the first of these being the discovery of nitrogen mustard as an 
efficacious cancer therapeutic by Louis Goodman and Alfred Gilman.
68
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Autopsies of soldiers exposed to mustard gas in World War I revealed markedly depleted bone marrow and lymph 
nodes. This led the pair to experiments with nitrogen mustard on mice bearing transplanted lymphoid tumours, 
resulting in tumour regression. These results were successfully replicated in a patient with non-Hodgkin’s lymphoma. 
The remission was short lived, and the disease progressed, but the principle of drug induced tumour regression was 
established.
68
 The investigation into the effects of folic acid on patients with acute lymphoblastic leukaemia (ALL) by 
the pathologist Sydney Faber is regarded as the second major discovery. His collaboration with medicinal chemists 
in the synthesis of folate analogues led to the folate antagonist methotrexate, which acts by blocking the enzymes 
that require folic acid to synthesize DNA and promote cell division. Farber administered methotrexate to children 
with ALL in the late 1940s, it becoming the first drug to successfully induce remission in the disease.
67
 
In the early 1950s, several other antileukemic agents were developed which reached clinical trials and eventually 
induced long term remission in patients with ALL. This success resulted in legislation by the United States to initiate 
the National Cancer Chemotherapy Service Centre (NCCSC) at the National Cancer Institute (NCI) in 1955, known 
today as the Cancer Therapy Evaluation Program (CTEP).
68
 This program continues to play a critical role in 
development of cancer therapeutics to this day. Combination therapy began in the 1960s for treatment of childhood 
ALL and was extended to lymphomas with startling results - complete remission rates jumped from near zero to over 
80%, with some patients still not showing relapse after 40 years.
67
 For the first time in cancer treatment the concept 
of cure became a reality. This advance was a scientific boon and had a remarkably permissive effect for the use of 
chemotherapy, resulting in the passing of the National Cancer Act of 1971 and President Nixon’s declaration of the 
“war on cancer.” 
While there were successes in the period from 1970 to 1990, such as the discovery of cisplatin and improved 
screening methods, researchers continually encountered problems with the long-term toxicity of chemotherapeutic 
agents affecting nearly every organ. Less than 10% of new drugs that entered clinical trials attained FDA approval 
and mouse models for solid tumours were unreliable in predicting clinical success and cytotoxicity.
68
 There was thus 
a clear need for a change in strategy in the fight against cancer. 
1.3.1.2 The Targeted Therapy Revolution 
While attempts to improve the stagnation of chemotherapeutics proceeded in the late 1980s, an understanding of 
cancer biology using molecular and genetic approaches was beginning to be uncovered by cell biologists. The 
discovery of wholly new signalling networks, responsible for the regulation of cell proliferation and survival, were 
found to be dramatically altered in cancer cells. This sparked an industrial revolution, particularly in small biotech 
start-ups, as scientists set out to target these molecular switches and defects including signalling molecules, growth 
factors, apoptosis modulators and angiogenesis promoters.
68
 By the 1990s, the explosion of new drug targets ushered 
in the era of targeted therapy.   
The success of finding inhibitors for these new targets was compounded by innovations in technology at the time 
and the emergence of combinatorial chemistry - furnishing thousands of novel scaffolds for high throughput screening 
(HTS). Lead compounds were identified and optimized for enhanced bioavailability and selectivity. Throughout this 
period, it became clear that promising drug candidates should exhibit certain favourable characteristics.  
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These include metabolic stability, good oral bioavailability and low toxicity profile at effective doses. Adoption of 
this approach led to marked successes within the targeted therapy industry in the ensuing decades.   
A landmark event in the targeted therapy revolution was the development of the natural product derived imatinib 
mesylate, a structurally simple compound bearing all the desirable features of an ideal targeted therapeutic.
69
 
Synthesized by chemists at Novartis, imatinib is used to treat CML and ALL by inhibiting the kinase BCR-ABL, a 
fusion protein produced by the Philadelphia chromosomal translocation. Imatinib has proven remarkably successful, 
with over 90% of chronic-phase patients achieving complete haematological remission.
69
 It received FDA approval 
in 2001 and has merited a position on the World Health Organisation’s List of Essential Medicines.70 In the acute-
phase of CML, treatment with imatinib produces brief remission, which is followed by the rapid emergence of 
resistant cells that arise from mutations in the catalytic domain of the kinase. These drug resistant mutations were 
also found to be present in patients before treatment, providing valuable insights into the existence of inherent 
mutations and drug-resistant mutant subclones in cancer.
68
  
Another controversial class of compounds, which inhibit the epidermal growth factor receptor, has secured 
numerous FDA approvals over the last 15 years. Used in the treatment of NSCLC and breast cancer, these inhibitors 
have been plagued by the occurrence of mutations within the kinase active site which they target, rendering the 
agents largely ineffective.
71
 The discovery and efforts to overcome the mutations that nullify EGFR inhibitors has 
represented an important advancement in targeted therapy and forms the backbone of this body of research. An 
overview of this therapeutic target and its targeted therapy will be discussed in detail in the next chapter.  
1.3.2 Modern Targeted Therapy  
1.3.2.1 Industry Overview 
In the last two decades, oncology has experienced a tidal wave of innovation that has profoundly changed how we 
diagnose and treat cancer. In 2003, the worldwide expenditure for oncology-related and supportive care medicines 
was $36 billion.
68
 This number increased to $107 billion in 2015, a 300% market gain in 12 years, and is expected 
to exceed $150 billion by 2020.
72
 Oncology is a key driver of growth in the pharmaceutical industry and is projected 
to account for approximately 30% of the industries’ product pipeline and 25% of the total revenue in 2020.72  
Spanning the years from 1949 to 2015, a total of 150 anticancer drugs received FDA approval, as depicted in the 
graph in Figure 1.6 on the following page.
73
 This includes a total of 61 cytotoxic and 89 target-based drugs used to 
treat 33 different cancer types. A clear decline in cytotoxic and a rise in target-based drug approval and development 
can be seen from 1990 onwards, with over 90% of all target-based therapeutics receiving approval in the last 20 
years. In 2015, the WHO Model List of Essential Medicines added a total of 16 new anticancer drugs, targeting 26 
different cancer types.
74
 This was the largest ever addition to any therapeutic area since the lists inception in 1997, 
with first-time inclusions of 3 target-based agents, namely: imatinib, rituximab and trastuzumab.
70
 This amount was 
further supplemented by the addition of the two oral inhibitors, dasatinib and nilotinib, bringing the total number of 
essential medicines for cancer to 48.
70
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Figure 1.6: Anticancer drugs that have received FDA approval from 1949 to 2014. Graph reproduced from Sun et al.
73
  
1.3.2.2 Challenges and Limitations 
The establishment of targeted therapy in the treatment of human cancer is the remuneration of over three decades 
worth of research into the mechanisms surrounding the pathogenesis of cancer. This achievement has drawn 
intellectual momentum from the initial discoveries of Paul Ehrlich and his ideal of “aiming precisely.” Using a rational, 
targeted strategy remains the paradigm for modern cancer research and drug discovery today. The transition from 
cytotoxic drugs to targeted therapies constitutes a significant leap and we now have more and better drugs than ever 
before. However, cancer remains a multi-dimensional group of diseases and its complexity is revealed through 
resistance and off-target issues. This raises the question of requirement for such a “magic bullet” in this genetically 
complicated scenario. 
Most cancers possess numerous driver mutations and increasing evidence suggests that the use of drugs targeting 
multiple oncogenic functions offers a promising approach over the current stance of mono-specific drugs being used 
to overcome multifactorial diseases. However, this increase in the number of pathways targeted by a single 
compound raises the risk of adverse and off-target effects. Finding a balance between target specificity and efficacy 
remains a major challenge in drug development. The mutability of cancer cells and the onset of resistance to these 
compounds remains an unpredictable and devastating obstacle. A major scientific challenge of the future will be to 
find ways to predict and exploit these occurrences. It is now clear that understanding the molecular profile of human 
tumours is fundamental in the effective design and use of cancer drugs. Patient selection, and the use of molecular 
and genomic assays to identify subclones present within these patients, provides an enormous advantage in clinical 
design and increases the likelihood of successful treatment response. This also avoids the undesirable expense and 
toxicity of ineffective treatment, leading to cost-effective drug development. The hallmark principles of cancer, and 
our growing knowledge of their inner workings, are fundamental in cancer drug development at present and will 
continue to be in the future of patient-tailored molecular therapy.  
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1.3.2.3 Targeting the Hallmarks 
Figure 1.7: Therapeutic targeting of each of the hallmark capabilities by various inhibitors and agents. Figure reproduced from 
Hanahan and Weinberg.
15
 
While it is impossible to enumerate the myriad of targeted therapies that are in development or being introduced to 
patients globally, this expanding armamentarium can be categorised according to their respective effects on certain 
hallmark capabilities of cancer cells, as exemplified above in Figure 1.7.
15
 The observed efficacy of these drugs in 
each category validates the importance of that capability in tumour initiation and progression, and thus its targeting. 
Notably, most hallmark-targeting drugs have been developed to focus on one specific target involved in the enabling 
of a certain capability. While this is advantageous with regards to specificity and off-target toxicity, clinical responses 
have been temporary and inevitably end in relapse. Increasing experimental evidence suggests that inhibiting one 
key pathway in a tumour is not enough to completely stop a hallmark capability, allowing a subpopulation of cancer 
cells to survive with partial function and eventually to adapt and overcome the selective pressure imposed by the 
therapeutic.
15
 This re-establishment of a functional hallmark capability is known as adaptive resistance and may 
occur through mutations, epigenetic events or tumour microenvironment remodelling. As the number of parallel 
pathways promoting a hallmark must be finite, it is therefore theoretically possible to inhibit all these pathways 
therapeutically and avert adaptive resistance.  
Another form of acquired drug resistance exhibited by cancer cells is the ability to reduce their reliance on a specific 
targeted hallmark capability and shift their dependence to another. This has been unexpectedly demonstrated in 
recent responses to angiogenesis inhibitors.
75
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Clinical evaluation of these inhibitors exhibited successful suppression of angiogenic capabilities, only to be followed 
by a ramped-up activity in invasiveness and metastasis which allowed for access to pre-existing vasculature in nearby 
tissues. The applicability of this resistance is yet to be established in other cancers, but the concept of selective, 
mechanism-guided combination targeting of multiple hallmark capabilities could result in more efficacious and 
durable targeted therapeutics.   
The drug classes listed in Figure 1.7 are illustrative examples of a burgeoning pool of candidate and approved drugs 
with different molecular targets and mechanisms of action. These include targeting apoptosis,
76
 inflammation,
57
 
immunotherapy
77
 or epigenetics
78
 amongst a host of others. It has been recognized that targeting the crucial signalling 
proteins that regulate hallmark and enabling characteristics of cancer is the ultimate target for molecular therapy.
66
 
The body of research presented in this thesis focusses on the EGFR signalling pathway, its implication in cancer and 
the value of inhibiting the kinase domain of this receptor in the treatment of cancer. The following chapter will 
explore structural and functional features of the receptor, its oncogenic activation and its history as a therapeutic 
target in the development of tumour growth inhibiting drugs.  
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Chapter 2 
Epidermal Growth Factor Receptor and its Targeted Inhibition 
Abstract 
This chapter will introduce EGFR as the therapeutic target of relevance for this PhD thesis - from its discovery in the 1950s to its 
targeting in clinical treatment of NSCLC. A description of the structural makeup and receptor family, as well as its significance in 
the regulation of cellular process, will give insight into the mechanism of its activation and its complex network of downstream 
signalling cascades. Discussion of the factors which promote oncogenic signalling of these pathways, such as overexpression and 
hyperactivation, will serve to justify its selection, and inhibition thereof, in the treatment of various cancers. To gain an 
understanding of the targeted inhibition of EGFR, protein kinases and their central role in reversible phosphorylation will be 
considered, as the catalytic active site of this process forms the main binding site for the majority of inhibitors. The various types, 
binding modes and means of inhibition of these drugs candidates will be examined. Lastly, the history of EGFR as a targeted 
therapeutic will be discussed in detail, from the 1
st
 generation of inhibitors to the present 4
th
 generation. Additionally, critical 
successes and failures over the years, as well as future approaches needed to overcome the inevitable rise of drug resistance 
mutations within the receptor, will be analysed within this chapter.   
2.1 Epidermal Growth Factor Receptor 
EGFR is a transmembrane receptor which belongs to the ErbB/HER family of protein-tyrosine kinases. Since its 
discovery by Stanley Cohen, it has become one of the most studied receptors in biology, owing to its expansive role 
in signal transduction pathways.
1
 Through these signalling cascades, a host of essential aspects of cellular life are 
regulated, including division, growth and apoptosis.
2
 EGFR was the first receptor to provide evidence of a relationship 
between receptor overexpression and cancer, one of the various mechanisms that lead to oncogenic signalling and 
hyperactivation.
3
 In this section, we will discuss the uncovering of this receptor, its structural makeup, the machinery 
and mechanisms of the ErbB family signalling network, and lastly, the factors that lead to its oncogenic activation. 
2.1.1 Discovery 
The 1986 Nobel Prize in Physiology and Medicine was awarded to the Italian developmental biologist Rita Levi-
Montalcini and the American biochemist Stanley Cohen for their discovery of nerve growth factor (NGF) and 
epidermal growth factor (EGF), respectively.
4, 5
 These discoveries were fundamentally important in our understanding 
of the mechanisms which regulate cell and organ growth and were the first of many growth regulating substances to 
be discovered and characterised. 
Scientists in the 1950s did not understand how the development of the nervous system resulted in the complete 
innervation of the human body or how it was regulated. It was Levi-Montalcino, shown in Figure 2.1a, who first 
observed that when certain mouse tumours were implanted into chick embryos, they induced potent growth of the 
embryonic nervous system - specifically the sensory and sympathetic neurons.
5
 It was concluded that the tumour 
released a nerve growth-promoting factor which had a selective action on certain neurons.  
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Figure 2.1: The recipients of the Nobel Prize in Physiology and Medicine in 1986 a) Rita Levi-Montalcini, b) Stanley Cohen and 
c) Cohen’s structure of EGF. Figure reproduced from c) Cohen.5 
The development of a biological assay to detect NGF by Levi-Montalcino paved the way for Cohen, shown in Figure 
2.1b, to identify a rich source of the growth factor – the salivary gland in a male mouse. Experiments with snake 
venom and the extract from the salivary gland led to the purification and isolation of NFG and its antibodies. From 
this work, the chemical structure of NGF was elucidated – a milestone in developmental neurobiology.5 
During his research on NGF, Cohen observed unexpected side-effects not related to the activities of nerve growth 
factor when injecting the salivary gland extract into new-born mice. The new-born mice underwent an acceleration 
of development, displaying precocious eyelid opening (6-7 days, in comparison to 12-14 days for the control group) 
and tooth eruption (5-6 days, in comparison to 8-10 days for the control group). Cohen postulated the existence of 
another growth factor within the extract, and termed this substance epidermal growth factor, as it stimulated the 
growth of epithelial cells in the cornea and skin. As with NGF, Cohen raised antibodies against, isolated and purified 
EGF, leading to the determination of the amino acid sequence and structure, as can be seen in Figure 2.1c.
5
 
For the first time, scientists had access to a factor which stimulated epithelial cell growth, and this allowed Cohen to 
investigate the growth process. He found that EGF initiated a cascade of events which stimulated protein and DNA 
synthesis, cell division and growth of a large variety of cells. A prerequisite for the action of EGF was the existence 
of binding sites, termed receptors, which were found on the surface of target cells. The epidermal growth factor 
receptor (EGFR) was thus described to catch EGF and form a complex, activating the signalling cascade.  
The phosphorylation of the amino acid tyrosine on this receptor was found to be crucial to its biological action and 
was later found to be a general pathway through which many growth factors mediate their effects. Knowledge of the 
regulation of normal cell growth led to an understanding of the mechanisms of the aberrant and uncontrolled cellular 
growth of tumours. The structure and detailed mechanisms involved in the signalling pathway, as well as its 
oncogenic activation, will be discussed in the following sections. 
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2.1.2 Receptor Structure and Ligand Binding  
Figure 2.2: a) The domains of EGFR with corresponding amino acid residues and b) The inactive (left) and active dimer (right) 
of EGFR, with ligands shown in red and cell membrane in grey. Figures reproduced from a) Ferguson et al and b) Goodsell.
6, 7
 
The human EGFR family consists of four members that belong to the ErbB lineage of proteins.
2
 These include and 
are designated as follows: i) EGFR/ERBB1/HER1, ii) ERBB2/HER2/NEU, iii) ERBB3/HER3 and iv) ERBB4/HER4. These 
homologous proteins all consist of a glycosylated extracellular domain, a single hydrophobic transmembrane segment 
and an intracellular domain that facilitates protein kinase activity, as shown in Figure 2.2a, with amino acid numbers 
denoting each domain boundary.
6
 The large extracellular region is divided into four domains. Domain I and III are 
leucine-rich segments that share approximately 37% sequence identity and participate in ligand binding. Domain II 
and IV are abundant in cysteine residues which allow for disulphide bond formation, with domain II partaking in 
homo- and heterodimer formation exclusively. The extracellular region is followed by a short transmembrane 
segment, leading to an intracellular portion of roughly 550 amino acid residues. This intracellular portion consists of 
a juxtamembrane segment, a protein tyrosine kinase domain and a long, flexible carboxyterminal tail.
2
  
The ErbB family of proteins function as homo- and heterodimers. Dimerization is induced by binding of a specific 
ligand to the receptor site and is illustrated in Figure 2.2b.
7
 Prior to a ligand such as EGF (red) binding, the inactive 
form of the receptor (light blue) folds back on itself (Figure 2.2b, left). Successful ligand binding results in a 
conformational change and exposure of a dimerization arm in domain II of the extracellular portion. The two ligand-
bound EGFR complexes (light and dark blue) then unite to form a back-to-back dimer, with the ligands positioned 
on opposing sides of the dimer (Figure 2.2b, right).  
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Figure 2.3: A general model for the activation of the intracellular kinase domain of ErbB family members. Figure redrawn from 
Zhang et al.
8
 
Although EGFR was the first receptor tyrosine kinase to be discovered, and the structural and mechanistic basis for 
ligand-induced dimerization of its extracellular region has been well established, the mechanism of activation of its 
intracellular kinase domain was not clearly understood until recently. This is because its activation mechanism differs 
from other receptor kinases. The general mechanism of activation of most protein kinases is initiated by symmetric 
dimer formation and requires phosphorylation of one or more residues within the activation segment. This is 
accomplished in trans, i.e., the first member of the dimer mediates phosphorylation of the second and vice versa.
2
 
While this manner of phosphorylation of Tyr869 in the activation segment of EGFR does occur, this is not required 
for its activation.  
Using mutational analysis and protein crystallography, it was found that the ligand-activated EGFR kinase domains 
form an asymmetric homodimer, which resembles that of the heterodimer formed by cyclin-dependant kinase 2 
(CDK2) and its activating protein cyclin A.
8
  In this asymmetric homodimer, shown in the middle of Figure 2.3, one 
kinase domain plays the role of the activator/donor and the other the activated/acceptor. The amino-terminal lobe 
(N-lobe) of the activated/acceptor kinase interacts with the carboxyterminal lobe (C-lobe) of the donor kinase, 
leading to its allosteric stimulation and catalysing the phosphorylation of tyrosine residues on the C-terminal tail of 
the donor kinase (Figure 2.3, middle).
8
 The importance of the juxtamembrane segment of the receptor in this process 
has recently been recognized.
9
 The juxtamembrane potentiates kinase activity by latching the donor kinase domain 
to the acceptor, facilitating dimerization and phosphorylation. 
All members of the ErbB family of enzymes make use of a similar mechanism of activation after ligand-induced 
homo- or heterodimerization. The phosphorylated tyrosine residues serve as docking sites for signalling molecules 
which enable downstream signalling. Following EGFR activation, a rich network of some of the most extensively 
studied signalling pathways are triggered, initiating a cascade of events that play an important role in cell division, 
death, motility and adhesion. These pathways, and their implication in cancer, will be analysed and discussed in the 
following sections.  
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2.1.3 The ErbB Signalling Network 
Figure 2.4: The ErbB family signalling network. Figure reproduced from Yarden and Sliwkowski.
10
 
The components of the ErbB signalling pathways are evolutionarily ancient, with certain nematodes and fruit flies 
possessing primordial linear versions of this pathway. In higher eukaryotes, this simple pathway has evolved into a 
complex network, presumably due to the selective gains in terms of adaptation, mutation tolerance and 
diversification of signals conferred by an interconnected layered structure.
11
 This richly interactive and multi-layered 
network, depicted in Figure 2.4, provides context-specific biological responses through combinatorial expression 
and activation of various components.
10
 The network can be divided into three simplified layers, namely, the input, 
signal processing and output layers.  
2.1.3.1 Input Layer 
The input layer (Figure 2.4a), comprises of the growth factors (ligands) and the ErbB family of receptors. There are 
11 growth factors in the EGF-like family and the four ErB family members are able to form 28 homo- and 
heterodimers, with 26 being active. This amounts to a total of 614 possible ligand-bound, homo- and heterodimer 
combinations of receptors, with the number being reduced to 611 after omitting non-functional homodimers.
2
 EGFR 
is able to bind to 7 of the 11 growth factors, notably including EGF and transforming growth factor alpha (TGF-α). 
These growth factors are shown in Figure 2.4a as green squares, with the numbers in the boxes representing high 
affinity binding receptors. Receptor homo- and heterodimer combinations are shown with numbered partners, with 
only the specific pathways of receptors binding to EGF and neuregulin 4 (NG4) shown for simplicity. Ligand binding, 
followed by dimerization and kinase activation and phosphorylation, provide docking sites for various adaptor 
proteins or enzymes within the signalling-processing layer.  
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2.1.3.2 Signal-processing layer 
Several factors determine the specificity and potency of intracellular signalling pathways, with the main determinant 
being the vast array of phosphotyrosine binding proteins that interact with the phosphorylated C-tail molecules of 
each ErbB dimeric complex, shown in Figure 2.4b as purple circles.
10
 The phosphorylation site, and thus which of 
these enzymes are engaged, is determined by identity of the ligand, dimer composition and the structural makeup 
of the receptor in the input layer. For simplicity, only pathways to the signalling proteins from two dimeric complexes 
- the ErbB1 homodimer and the ErbB2-ErbB3 heterodimer - are shown in the signal-processing layer (Figure 2.4b).
10
 
The interaction of these adaptor enzymes with the phosphotyrosine molecules triggers a variety of downstream 
signalling cascade pathways (Figure 2.4b, blue rectangles).
10
 Activation of these signalling modules translate in the 
nucleus of the cell into distinct transcriptional programs through transcription factors, (Figure 2.4b, pink ovals).
10
 
These cascades are ultimately responsible for the correct output of core cellular processes such as cell growth, 
division and death. Only some of the pathways and transcription factors are represented in Figure 2.4b, with the 
three main downstream signalling modules being the i) RAS-RAF-MEK-MAPK, ii) PI3K-AKT and iii) PLCγ-PKC. The 
RAS-MAPK pathway is an invariable target of all ErbB ligands, highlighting its biological importance, and the PI3K-
AKT pathway is downstream from the majority of ErbB dimers. The activation of these cascades, and regulation of 
transcription factors translating to a specific type of biological output, is critical to a cells normal functioning.   
2.1.3.3 Output layer 
The output of the ErbB signalling network, shown in Figure 2.3c, can range from cell motility and division, to 
differentiation, adhesion and programmed cellular death.
2
 These specific outputs depend on the cellular context 
and, as discussed above, the particular ligand and ErbB dimer complex leading to signal processing. In terms of 
mitogenic and transforming outputs, homodimeric combinations of receptors are weaker than corresponding 
heterodimeric combinations, and heterodimeric combinations with ErbB2, such as EGFR-ErbB2, have been shown 
to be the most potent complexes.
10
 Following ligand binding and dimerization, the adaptor and effector proteins 
discussed in the signal-processing layer further stimulate the signalling cascades, leading to various cellular process 
outputs. The RAS-MAPK and PLCγ-PKC pathways participate in cell proliferation, whilst the PI3K-AKT pathway plays 
an important role in mediating cell survival. Other ErbB signalling modules not highlighted, participate in 
angiogenesis, cell adhesion, cell motility and organogenesis.
2
 Given the functional importance and involvement of 
EGFR and its related family members in these diverse cellular processes, their aberrant activity and its inference in 
cancer is not surprising. Mutations harboured and gained in proto-oncogenes, which code for the relevant proteins 
involved in the signalling cascade, often leads to deregulation of these cellular processes and uncontrolled growth of 
malignant cells, leading to tumorigenesis. This oncogenic activation is implicated in a multitude of cancers and has 
warranted its relevance as a therapeutic target.  
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2.1.4 Oncogenic Activation of EGFR and Cancer  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Mechanisms leading to oncogenic signalling in EGFR. Figure reproduced from Zandi et al.
12
 
Various cancers are associated with the mutation or increased expression of members of the ErbB family of receptors 
and their respective ligands. These malignancies include lung, breast, stomach, colorectal, head and neck, pancreatic 
carcinomas and glioblastoma.
2
 This is particularly prevalent in lung and breast cancer, with EGFR mutations occurring 
in up to 40% of lung cancer samples and being overexpressed in 60% of NSCLC tumours, and ErbB2/HER2 gene 
amplification or overexpression occurring in up to 30% of breast cancers.
2, 13
 Cancer cells make use of the potent 
cell proliferation signals generated by the ErbB network to carry over oncogenic mutations by clonal expansion. This 
is accomplished through several mechanisms of hyperactivation of ErbB pathways at different layers in the network, 
such as enhanced production of ligands, overproduction of receptors and mutations leading to constitutive activation 
of receptors.
10
 We will shift our focus specifically to EGFR, and the mechanisms for its oncogenic activation as 
illustrated in Figure 2.5, as it is the therapeutic target of importance for this body of research.  
2.1.4.1 EGFR Overexpression 
The aberrant activation of EGFR is often associated with EGFR overexpression. There are different mechanisms by 
which EGFR is overproduced within tumour cells and the role of the enhanced level of EGFR in tumorigenesis and 
correlation with poor prognosis in a variety of cancers has been well documented.
14
 Amplification of the EGFR gene 
leads to increased levels of EGFR and this amplification has been observed in NSCLC, breast carcinomas and 
glioblastoma multiforme (GBM).
15
 EGFR may also be overexpressed due to deregulation within the signal-processing 
layer, with EGFR transcription being directly activated by the binding of wild-type and mutant p53 proteins to specific 
promotors.
16
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Tumour cells typically contain an abundance of mutant p53 proteins, which results in continuous promotor binding 
and transcription activation, leading to overexpression of the receptor. With increased levels of EGFR on the cell 
surface, spontaneous receptor dimerization and constitutive activation has been documented even in the absence 
of ligand binding, as shown in Figure 2.5.1. These constitutively active receptors lead to continuous activation of 
downstream signalling cascades.  
2.1.4.2 Overproduction of Ligands  
The ligands EGF and TGF-α have frequently been found to be co-overexpressed with EGFR in various cancers. As 
these ligands act in an autocrine/paracrine manner, their overexpression in tandem with EGFR in cancer cells 
activates autocrine loops, shown in Figure 2.5.2.
12, 17 
Autocrine loops, where a cell produces the same ligands for 
which it has receptors, provides cancer cells with self-sustaining growth signals and results in hyperactivation and 
uncontrolled tumour growth. Studies in mouse models have shown that overexpression of these growth factors lead 
to the induction of tumour formation and a higher rate of tumour cell proliferation, and are frequently found in 
nearly all forms of human NSCLC.
12, 17 
  
2.1.4.3 EGFR Cross-talk and Heterodimerization 
The communication of EGFR with other cell-surface receptors plays a widely functional role in tumour development. 
This cross-talk takes place between other members of the ErbB family, other receptor tyrosine kinases (RTK), cell 
adhesion molecules and G-protein coupled receptors.
12
 As mentioned previously, the EGFR-ErbB2 heterodimer, 
shown in Figure 2.5.3, is the most potent inducer of mitogenic signalling and cell transformation and is commonly 
co-overexpressed in brain, breast and ovarian cancer.
12
 Furthermore, the importance of these heterodimers in cancer 
cells has been demonstrated by the administration of antibodies blocking specific receptor heterodimerization in 
breast and prostate cancer xenograft models, resulting in powerful anti-tumour effects.
18
 The cross-talk of EGFR with 
several cell adhesion molecules within the extracellular matrix (ECM), such as integrin, has been shown to induce 
tyrosine phosphorylation of EGFR, independent of ligand binding.
19
 This has been postulated to occur by association 
of macromolecular complexes with EGFR on the cell membrane (Figure 2.5.3) and involves various signalling and 
adaptor molecules.
12
  
 2.1.4.4 Defective EGFR downregulation 
While the hyperactivation of EGFR signalling pathways and its strong associations with carcinogenesis is well 
established, the impaired deactivation of these pathways has also been linked to neoplastic cell transformation.
20
 
The main mechanism by which EGFR signalling is deactivated, termed receptor downregulation, involves the ligand-
induced internalization of the receptor through endocytosis and subsequent degradation of this receptor in 
lysosomes, as shown in Figure 2.5.4.
12
 This process is carried out by complex molecular machinery that utilises the 
small protein ubiquitin as a key regulator, facilitating proper endocytosis and degradation.
20
 Oncogenic forms of 
EGFR escape downregulation due to the deregulation or lack of integral components of this process, such as ubiquitin 
ligase c-Cbl. By binding to phosphorylated sites in the EGFR intracellular domain, c-Cbl directs the activated receptor 
to the lysosome for degradation by mediating tagging with ubiquitin.
21
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EGFR mutants with deletions spanning the docking sites of c-Cbl lack this binding, and mutant forms of c-Cbl have 
been found to bind to EGFR but fail to ubiquitinate the receptor, resulting in downregulation being avoided and 
constant activation of the receptor.
12
 
2.1.4.5 Activating EGFR Mutations 
Mutations in the EGFR encoding gene that constitutively activate the receptor are recurrently found in human 
cancers. These mutations can be classified by the region that they occur and are divided into three main groups, 
namely: mutations within the extracellular domain, the intracellular domain and the intracellular kinase domain.
15
 
Mutations within the extracellular domain are typically observed in GBM, with amplification of the EGFR gene being 
particularly prominent.
15
 The majority of these occur through deletions of specific exons, encoding for all or parts of 
the extracellular domain. These shortened genes give rise to truncated receptors, forced into the active extended 
form, resulting in ligand-independent constitutive activation. A well-documented example of this is the EGFRvIII 
mutation, shown in Figure 2.5.5, which results from an in-frame deletion of exons 2 – 7.12 These genes encode for 
the whole of subdomain I and a large portion of subdomain II, giving rise to a receptor trapped in a partially activated 
state with most of its ligand-binding area missing. This is sufficient for oncogenic signalling, being constitutively 
phosphorylated and able to activate tumorigenic signalling pathways such as RAS-ERK and PI3K-ATK, but insufficient 
for receptor degradation as the truncated receptor is unable to be ubiquitylated, avoiding downregulation and 
prolonging oncogenic signalling.
22, 23
 Mutations within the intracellular domain primarily consist of large deletions 
and/or duplications of exons and as with extracellular mutations, are best described in GBM.
12
 These include 
mutations affecting the juxtamembrane and its stabilization of the asymmetric kinase dimer, and mutations in the C-
terminal tail region shifting the equilibrium of the kinase domain towards an active asymmetric dimer.
9, 24
  
The last group of EGFR mutations bring about small changes in the seven exons (18 – 24) that code for the 
intracellular kinase domain and are very frequently associated with NSCLC.
25
 These consist of small point mutations 
and deletions centred around the ATP binding cleft of the tyrosine kinase domain. These mutations can increase 
kinase activity by reorganizing critical amino acids and stabilizing ATP binding affinity, as well as allowing for 
autophosphorylation.
26
 Most importantly, mutations within this region may confer drug resistance, as one strategy to 
abrogate hyperactivation of EGFR and its oncogenic signalling is the inhibition of receptor kinase activity using 
tyrosine kinase inhibitors (TKI). These small molecule inhibitors target the intracellular kinase domain of EGFR and 
mutations within the kinase ATP binding site invariably induce a reduced affinity and acquired therapeutic resistance 
to these drugs.
27
 The understanding and development of novel drug candidates to combat these mutant, drug-
resistant forms of EGFR, embodies the basis of this research project. The origin and mechanism of protein 
phosphorylation within kinases, the characterization of the human kinome and an overview of kinase inhibition as 
a therapeutic strategy will be laid out in the next section. This will provide the foundation for discussing the successes 
and failures in the history of therapeutic targeting of EGFR and its present state. 
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2.2 Protein Kinases 
2.2.1 Origins of Reversible Protein Phosphorylation 
While its central and essential role is recognized today, the significance of reversible protein phosphorylation was 
slow to be appreciated. The foundation of its discovery lay in the collaboration of Edwin Krebs and Edmond Fischer 
in the early 1950s, who demonstrated that the interconversion of phosphorylase b into phosphorylase a occurred 
readily in the presence of magnesium adenosine triphosphate (Mg-ATP) and an enzyme that they coined 
phosphorylase kinase. This kinase was subsequently shown to catalyse the transfer of a γ-phosphoryl group of ATP 
to a specific serine residue on phosphorylase b, facilitating conversion into phosphorylase a.
28
 Furthermore, the 
reversion of phosphorylase a to b was shown to be activated by the release of this γ-phosphoryl group by a 
phosphate-releasing enzyme known today as phosphatase 1.
28
 These discoveries, and later work concerning 
reversible phosphorylation as a biological regulatory mechanism, led to the duo being awarded the 1992 Nobel 
Prize in Physiology or Medicine.
29, 30
 The discovery of protein kinase A (PKA), and its roles in the activation of 
phosphorylase kinase and the inhibition of glycogen synthase, were the first examples of a kinase activation cascade 
and enzyme inhibition by phosphorylation respectively.
31
 At the end of the 1960s however, phosphorylation was 
regarded as a specialised regulatory mechanism confined to glycogen metabolism. 
It was through discoveries in the 1970s and early 1980s that the significance of protein phosphorylation began to be 
acknowledged. Research undertaken by Lester Reed in 1969 revealed the inactivation of the mitochondrial pyruvate 
dehydrogenase complex by phosphorylation, alluding to its operation as a control mechanism in other metabolic 
pathways and organelles.
32
 The first example of multisite phosphorylation, where multiple residues of a protein are 
phosphorylated by multiple kinases, was witnessed in the 1970s.
33
 Geneticists were granted a deeper functional 
understanding of numerous regulatory genes through the unravelling of the first protein kinase A (PKA) amino-acid 
sequence.
34
 Finally, the landmark discovery by Ray Erikson that v-Src - the protein encoded by the Rous sarcoma 
virus transforming gene - was indeed a kinase, led Tony Hunter to the revelation that v-Src phosphorylates tyrosine 
residues in proteins, the first example of a protein tyrosine kinase.
35, 36
 In the following years, EGFR and many other 
growth factor receptors were shown to have protein tyrosine kinase domains, activated when the natural substrate 
engages the receptor in the extracellular membrane as discussed in Section 2.1.2.
37
 These discoveries sparked an 
investigation into the role of protein kinases and phosphorylation in signal transduction pathways.  
The 1990s has been dubbed by some as the decade of protein kinase cascades.
33
 Following the identification of 
MAPK in the late 1980s, it was found to be activated by the phosphorylation of a threonine and tyrosine residue, 
catalysed by another “dual specificity” MAPK kinase, through a RAS dependant signally pathway.38 This classical 
MAP kinase cascade was elucidated in the early 1990s through the collaborative efforts of several laboratories and 
followed by the dissection of many other MAP kinase cascades, including those that are activated in the ErbB 
signalling network.
39
 This in turn led to the discovery of other kinases and kinase cascades in the decade, including 
the PI3K-AKT-mTOR pathway. Since the discoveries of Fischer and Krebs nearly 70 years ago, our knowledge of 
reversible protein phosphorylation has dramatically increased, leading to the unravelling of the human kinome and 
identification of all human kinases and a deeper understanding of its mechanistic insights and regulatory functions.  
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2.2.2 The Human Kinome 
With the completion of the human genome sequence in 2001, the door was opened for the cataloguing of the 
protein kinase complement of the human genome. The human kinome consists of 518 putative protein kinase genes, 
making it one of the largest gene families.
40
 This is a strikingly large number, making up nearly 2% of the entire 
human genome. The enzymes encoded by these genes catalyse the phosphorylation of various OH groups present 
on proteins and are classified based upon the nature of this phosphorylated OH group. These are protein-
serine/threonine kinases (385 members), protein-tyrosine kinases (90 members) and tyrosine-kinase like proteins (43 
members).
40
 Of the 90 protein-tyrosine kinases, 58 are receptor kinases (of which EGFR is one) and 32 are non-
receptor kinases. A small group of dual-specificity kinases possess the ability to catalyse phosphorylation of both 
tyrosine and threonine residues in target proteins, such as MEK1 and MEK2 involved in the MAP pathways discussed 
in the previous section. These kinases are placed within the protein-serine/threonine kinase family due to molecular 
features. Protein kinases play a predominant regulatory role in cell differentiation and growth, development of the 
immune system and nervous system function, transcription and apoptosis.
2
 Consequently, the dysregulation of these 
enzymes has been connected to a variety of diseases such as cancer, cardiovascular, autoimmune, inflammatory and 
nervous diseases and diabetes.
41
 The understanding of the physiological and pathological functions of protein kinases 
and their underlying mechanisms has thus become a target of intense interest in the last 30 years.  
2.2.3 The Mechanism of Protein Phosphorylation and the Kinase Active Site 
The reversible phosphorylation of proteins regulates nearly every aspect of cellular life and is the most prevalent 
method of post-translational modification used in signal transduction pathways.
33, 42
 This process has a regulatory 
role in cellular metabolism, division, growth, motility, differentiation, membrane transport, muscle contraction, 
immunity, learning and memory.
42
 It is estimated that 30% of all cellular proteins are phosphorylated on at least one 
residue, equating to a typical kinase having to differentiate between approximately 700 000 potential 
phosphorylation sites.
42
 This exquisite specificity results from the contribution of multiple mechanisms from the 
kinase catalytic site, interaction between kinase and substrate and error correcting mechanisms. 
Protein phosphorylation is a process in which a protein kinase, shown in brown in Figure 2.6a, catalyses the transfer 
of a γ-phosphate group from ATP to a specific amino acid on a protein substrate (Figure 2.6a, yellow). In eukaryotes 
these substrate amino acids are usually serine, threonine or tyrosine residues and after this transfer ADP is liberated. 
Protein phosphatases catalyse the dephosphorylation of protein substrates, making this an overall reversible process 
(Figure 2.6a). Protein kinases share a basic catalytic cycle for phosphorylation, starting with the binding of ATP to 
the active site of the kinase as seen in the top left of Figure 2.6b. This is followed by binding of the substrate (Figure 
2.6b, green) to the active site, allowing for γ-phosphoryl (Figure 2.6b, red) transfer to a specific residue on the 
substrate. Following phosphorylation, the substrate and lastly ADP are released from the binding site of the kinase.
42
 
There is variation in the order of the steps of the catalytic cycle amongst different kinases. For instance, substrates 
may bind to the kinase active site prior to ATP binding and ADP may be released before the substrate following 
phosphorylation. The rate limiting step of this process may also vary between different kinases.
42
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Figure 2.6: a) The reversible phosphorylation of protein substrates by kinases and phosphatases and b) The basic catalytic cycle 
for substrate phosphorylation by a kinase. Figure reproduced from b) Ubersax et al.
42
 
Most eukaryotic protein kinases are structurally similar, with a catalytic domain of roughly 250 amino acids in length. 
The canonical protein fold consists of two lobes, a smaller N-lobe comprising of five antiparallel β-strands and one 
helix and a larger C-lobe consisting of α-helices, illustrated in Figure 2.7a with EGFR as example.43 The ATP-binding 
cleft is a narrow hydrophobic pocket found between the N- and C-terminus of these two lobes, linked by a flexible 
hinge region. The hinge region, shown in Figure 2.7b, typically has one hydrogen bond donor flanked by two 
hydrogen bond acceptors, derived from the protein backbone. ATP binds in a manner that facilitates the adenosine 
moiety (Figure 2.7b, dark grey) forming important reversible interactions with the hinge region residues and so that 
the hydrophilic phosphate backbone (Figure 2.7b, light grey) is oriented towards, and exposed to, the solvent.
44
 
Reversible hinge region interactions with certain kinase inhibitors is critical to their efficacy and is a primary 
consideration in the design of potential drug candidates. The P-loop, or the glycine rich loop, forms the roof of the 
active site, with C-terminal β-sheets covering the bottom. The important gatekeeper residues control access to the 
specificity pocket (Figure 2.7b, yellow).  
Figure 2.7: a) Protein ribbon view of EGFR showing the N- and C-lobes with the active site between (PDB: 2GS2) and b) A 
typical protein kinase ATP binding pocket. Figure reproduced from a) Warnault et al and b) Williams et al.
43, 45
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All protein kinases have a flexible activation loop (Figure 2.7b), starting with the conserved amino acid sequence 
Asp-Phe-Gly (DFG), which controls access to the active site and contains the serine, threonine and tyrosine residues 
which may be phosphorylated. When these residues are not phosphorylated, this loop occupies a large area of the 
active site, effectively blocking it. Upon activating-phosphorylation by another upstream kinase (or through 
asymmetric dimer formation in EGFR), the hydrophilic, charged activation loop unfolds and moves into the solvent 
to expose the ATP binding pocket. This enables ATP binding and transfer of the phosphate group to a substrate 
protein or downstream kinase.
44
 The conformation of the DFG motif plays an important role in the type of kinase 
inhibitor binding conformation and will be discussed in the following section.  
Human protein kinases share a high degree of similarity in their 3D structure, which is most pronounced in the 
kinase active site. However, structural features such as the difference in the charge distribution and hydrophobicity 
of their surface residues, and a deeper catalytic cleft found in protein tyrosine-specific kinases compared to that of 
serine/threonine-specific kinases, allow for substrate phosphorylation specificity.
42, 46
 Within the ATP binding pocket, 
important residues such as the gatekeeper side chain, dictates access to the hydrophobic regions (Figure 2.7b, light 
blue) and specificity pocket (Figure 2.7b, yellow) located within the active site. A deeper understanding of these 
structural subtleties has allowed for the informed design of kinase inhibitors and illuminated various mechanisms of 
inhibition. Over the past two decades, drug design strategies stimulated by these factors have given rise to one of 
the most intensively pursued and successful classes of targeted therapeutic agents – protein kinase inhibitors. We 
will examine this diverse class of inhibitors and its varied approaches in the following section.   
2.3 Protein Kinase Inhibitors 
2.3.1 Overview 
Many of the 518 protein kinases encoded by the human genome have been established as prominent therapeutic 
targets due to deregulation of their function in signal transduction networks and its implication in many diseases. 
This class of enzyme is the second most targeted group in drug discovery after the G-protein coupled receptors.
47
 
Since the 2001 milestone approval of the first kinase inhibitor for human use, Imatinib, 37 other drug candidates 
have won FDA approval to date.
48
 Strikingly, half of these approvals have occurred within the past 4 years, signifying 
the continued relevance of protein kinases as a therapeutic target. It is estimated that approximately 250 kinase 
inhibitors are undergoing clinical phase trials, with a database of nearly 220 000 papers in PubMed and more than 
47 000 patents and patent applications found in SciFinder on kinase inhibitors.
48
 Over 5000 crystal structures have 
been solved with or without small molecules, inhibition assays have been developed for more than 80% of the 
human kinome and small molecule kinase inhibitors have been developed to target nearly 20% of the human 
kinome.
49
 Kinase inhibitors are classified based upon the binding mode of the inhibitor and the unique 
conformational form of the kinase targeted. Kinase inhibitors can be ATP or non-ATP competitive, reversible or 
irreversible, allosteric, bi-valent or a combination of these features. This determines the category of the kinase 
inhibitor, which ranges from type I-VI. The different types and their properties will be explored in the following 
section. 
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2.3.2 Types of Kinase Inhibitors 
Figure 2.8: The four types of reversible binding modes for kinase inhibitors. Figure reproduced from Wu et al.
49
 
2.3.2.1 Type I and II Inhibitors 
Type I and II represent ATP-competitive inhibitors that mimic the purine ring of the adenine moiety of ATP, forming 
hydrogen bond interactions with one or more hinge residues. Their classification depends on the activation state of 
the protein kinase, or more specifically the disposition of the DFG-Asp motif, being either active in or inactive out. 
Type I inhibitors, as seen on the far left of Figure 2.8, bind to the phosphorylated active conformation of the kinase 
in a reversible manner, with the aspartate residue (Figure 2.8, white backbone) of the DFG motif facing into the 
ATP-binding pocket of the kinase (DFG-in).
49
 These inhibitors usually contain a heterocyclic ring system, or driving 
group, that occupies the purine binding site. This serves as a scaffold for various side chains to occupy and interact 
with adjacent hydrophobic regions, including the gatekeeper residue. Solubilising groups are typically employed in 
the hydrophilic regions of the enzyme usually occupied by the ribose moiety of ATP.
47
 Several type I inhibitors have 
received FDA approval for the treatment of cancer, including the EGFR inhibitors erlotinib, gefitinib and lapatinib.
50
 
Due to the conserved nature of the ATP binding pocket throughout the human kinome, type I inhibitors display an 
inclination for low selectivity, increasing the potential for off-target and adverse side effects. 
Type II inhibitors, (Figure 2.8, second from left) act by targeting and stabilizing the unphosphorylated inactive 
conformation of the kinase, with the now flipped aspartate residue (Figure 2.8, white backbone) of the DFG motif 
protruding outward from the ATP-binding site (DFG-out).
49
 In addition to reversible contacts with the hinge region, 
type II inhibitors exploit accessibility to, and new interactions within, specific lipophilic pockets adjacent to the ATP-
binging site, derived from the conformational change of the DFG motif. This enhances their selectivity profile 
between kinases, but overlap between type I and II inhibitors is still considerable.
47
 FDA approved type II inhibitors 
include imatinib, nilotinib and ponatinib used in the treatment of CML.
50
      
2.3.2.2 Type III and IV Inhibitors  
Type III and IV inhibitors bind outside of the catalytic domain/ATP-binding site and modulate kinase activity in an 
allosteric manner, as both ATP and the allosteric inhibitor can bind simultaneously to the kinase.
47
  Type III inhibitors, 
(Figure 2.8, second from right) bind in an allosteric pocket adjacent to the ATP-binding site without interacting with 
it, whilst type IV inhibitors (Figure 2.8, right) occupy an allosteric pocket distant from the substrate-binding sites.
49
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Type III and IV inhibitors are ATP non-competitive, as the binding of ATP does not prevent their interaction with the 
targeted kinase. Allosteric inhibitors show the highest degree of selectivity in targeted enzyme inhibition, as they take 
advantage of binding sites and physiological mechanisms that are exclusive to particular kinases.
47
 Owing to these 
attractive characterises, the use of allosteric inhibitors is thought to be critical in overcoming selectivity, off-target 
effects and drug resistance.
47
 Trametinib is currently the only type III FDA approved drug, used for the inhibition of 
the MAPK enzymes MEK1 and MEK2.
50
 
2.3.2.3 Type V Inhibitors  
Type V inhibitors have been labelled as bivalent molecules that span two regions of the protein kinase domain.
51
 As 
such, these bi-substrate or bivalent inhibitors exhibit more than one binding mode. Bi-substrate inhibitors target the 
ATP and other protein substrate binding sites, whilst bivalent inhibitors comprise of a ATP binding site moiety and a 
non-substrate ligand, targeting the ATP binding cleft and any surface except that of a protein substrate binding site.
51
 
These inhibitors display the high efficacy and potency associated with type I and II inhibitors, whilst retaining the 
selectivity of allosteric inhibitors.    
2.3.2.4 Type VI Inhibitors  
 The final class, type VI inhibitors, bind covalently to their protein kinase target and are known as covalent or 
irreversible inhibitors. The chemical rationale of these inhibitors is based on the presence of an exposed nucleophilic 
cysteine residue, in or around the ATP binding site of a small number of kinases, which is targeted for covalent 
modification with a suitable electrophile.
52
 This modification occurs via trapping of the cysteine residue either by an 
SN2 displacement of a leaving group or by a Michael addition reaction with a suitable Michael acceptor incorporated 
in the inhibitor. As illustrated in Figure 2.9a, the α-, β-unsaturated carbonyl undergoes a 1,4-conjugate addition 
with the nucleophilic cysteine, followed by proton abstraction, to form a covalent bond with the cysteine residue. 
The formation of the Michael adduct is a reversible process and the mechanism of the cysteine-involved Michael 
Addition reaction, with microenvironmental effects, has been widely studied within the scientific community.
53
  
Figure 2.9: a) Mechanism illustrating the Michael Addition reaction of cysteine to an acrylic electrophile and b) Electrophilic 
“warheads” used in irreversible inhibitors.52 
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It is broadly accepted that high affinity, reversible interactions within the binding pocket are primarily important, 
with the inhibitor initially binding non-covalently. This is followed by positioning of the reactive moiety into a suitable 
orientation that allows for irreversible enzyme modification.
52
 This underlines the importance of the correct 
positioning of the electrophile on the inhibitor scaffold, as well as the type of electrophile used. Most covalent 
inhibition strategies utilised to date target the nucleophilic cysteine thiolate and employ the use of a weakly reactive 
acrylamide moiety. Several other electrophilic “warheads”, shown in Figure 2.9b, which can react with cysteine and 
other nucleophiles such as lysine, tyrosine and serine are being increasingly explored. These include the Michael 
addition-specific vinyl sulfonates, quinones, alkyl amides and propargylic acid derivatives. Warheads such as α-halo 
ketones, thiocyanates, alkynes, nitriles, epoxides, sulfonyl fluorides or thiol itself which can undergo nucleophilic 
displacement or addition reactions.
52
 Lastly, in recent years the use of a cyano-acrylamide electrophile as a reversible 
covalent inhibitor has shown prolonged on-target residence times and superior efficacy.
54
 
The use of irreversible inhibition strategies holds many advantages over traditional reversible inhibitors, the first being 
afforded by targeting the potential protein kinase cysteinome. To date, 211 kinases have been identified as bearing 
approachable cysteine residues, while only six distinct sites have been targeted by a covalent inhibitor.
55
 The finite 
number of candidates with a druggable cysteine residue enhances selectivity profiles of potential inhibitors. As 
irreversible inhibitors are ATP non-competitive, they are unaffected by changes in ATP binding affinity brought about 
by mutations and do not have to compete with high concentrations of endogenous ATP. As these inhibitors form a 
covalent bond, they display a prolonged residence time and extended dissociation half-life, improved 
pharmacodynamics and greater potency.
47
 Historically, the risk of haptenization, recurrent toxicity profiles and 
promiscuity associated with irreversible inhibitors, has meant a reluctance to pursue this class of inhibitors.
52
 
However, in recent years, successes displayed by the FDA approved EGFR inhibitors afatinib and ibrutinib has 
sparked a resurgence in the development of covalent inhibition strategies.
50
  
The interaction of each inhibitor with a protein kinase target is unique. The classification of these interactions, and 
its application in the drug discovery process, has been invaluable, resulting in the FDA approving 2 – 4 small molecule 
kinase inhibitors per year.
50
 Owing to its clinical relevance, multiple strategies have been developed to overcome 
the inevitable emergence of resistance mechanisms. This is no more pronounced than in the colourful history of 
EGFR inhibition. A timeline spanning two decades, marred with the onset of numerous mutations and three 
generations of blockbuster drugs to combat it, tyrosine kinase inhibitors are now standard in the treatment of NSCLC, 
breast cancer and a host of other diseases. Next, we will delve into the history of EGFR as a therapeutic target, 
looking at successes and failures, the onset of mutations in patients and the strategies used to overcome these hurdles.   
2.4 EGFR as Therapeutic Target  
The two distinct therapeutic methods that have been employed in the targeted inhibition of EGFR are the use of 
monoclonal antibodies and protein tyrosine kinase inhibitors (TKI). Each of these approaches have a unique 
mechanism of action, with EGFR antibodies binding to the extracellular domain, and TKIs to the intracellular kinase 
domain. As it is the most pertinent to our research theme, we will focus solely on the history and development of 
FDA approved TKIs in the next section, which will be described in terms of inhibitor “generations.” 
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2.4.1 1
st
 Generation Inhibitors 
 
 
 
 
 
 
 
 
‘ 
 
Figure 2.10: 1
st
 generation EGFR inhibitors that have received FDA approval with red arrows denoting atoms forming reversible 
interactions with the hinge region. Figure reproduced from Wu et al.
49
 
In 2003, twenty years after it was proposed that therapeutic agents used to disrupt EGFR signalling could potentially 
treat cancer, gefitinib became the first TKI to receive FDA approval for treatment of NSCLC.
56
 The 
anilinoquinazoline-derived inhibitor, shown in Figure 2.10a, was first characterized in 1996 and is prescribed to 
patients after failure of platinum-based or docexatel chemotherapy.
57
 Gefitinib is a type I inhibitor which binds in 
the ATP pocket, with the 4-anilinoquinazoline moiety forming reversible interactions with the hinge region (Figure 
2.10a, red arrow). The drug shows a 200-fold greater affinity for EGFR in comparison to other ErbB family members 
and is orally active. A year later, another type I anilinoquinazoline-derived inhibitor, erlotinib (Figure 2.10b), 
received FDA approval for NSCLC.
58
 Similar to gefitinib, erlotinib functions as an ATP competitive inhibitor, 
approved for patients with relapsed NSCLC and maintenance therapy in advanced NSCLC with no progression after 
four cycles of first-line chemotherapy. These two drugs are considered the 1
st
 generation inhibitors of EGFR. Lapatinib 
(Figure 2.10c), was the first dual inhibitor of EGFR and HER2 to receive FDA approval in 2007.
59
 It has also been 
found to exhibit inhibitory activity against AKT overexpression in human tumour xenografts. Due to its nonspecific 
nature of inhibition, it accounts for a broader spectrum of antitumor activity with higher efficacy and has shown 
significant inhibitory effects on human breast cancer cells.
57
 Lastly, vandetanib (Figure 2.10d) acts an inhibitor of a 
number of cell receptors, including rearranged during transfection (RET) receptor protein tyrosine kinase, VEGFR 
and EGFR. Vandetanib received FDA approval in 2011 for the treatment of thyroid cancer.
60
 
In 2004, less than a year after receiving its FDA approval and in response to treatment with gefitinib, two 
independent research groups simultaneously identified the presence of somatic EGFR mutations in a sub-group of 
NSCLC patients.
26, 61
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The somatic mutations discovered chiefly targeted exons 18 – 21 of the EGFR gene, encoding for part of the tyrosine 
kinase domain around the ATP binding pocket of EGFR. The most frequent and well-documented of these mutations 
include in-frame deletions in exon 19, known as del19, eliminating the conserved residues 747 – 750 and the most 
famous exon 21 L858R substitution, which results in an amino acid substitution at position 858 from a leucine (L) to 
an arginine (R).
62
 These mutations make up between ~80 – 90% of all EGFR mutations in NSCLC and are referred 
to as activating mutations, altering the receptor into a constitutively activated oncogenic state which disrupts 
autoinhibitory interactions and accelerates catalysis by as much as 50 fold.
63, 64 
 
Interestingly, these mutant enzymes showed reduced binding affinity towards ATP and an increased sensitivity 
towards EGFR TKIs, such as gefitinib and erlotinib, as they bind in a reversible and ATP-competitive manner.
64
 
Gefitinib has also been shown to have a 20-fold increased binding affinity towards the L858R mutant than to the 
wild-type enzyme.
64
 Serendipitously, these two effects combine to yield the remarkable potency of gefitinib and 
erlotinib against tumours that exhibit an “oncogenic addiction” to the mutant activated form of EGFR for survival.65 
This afforded the excellent preliminary clinical activity and in vitro sensitivity of gefitinib, leading directly to its FDA 
approval.
63
 While this demonstrates that certain mutations, while oncogenic in nature, can be exploited and 
benefitted from in targeted therapy, other mutations may result in the opposite and confer resistance.  
2.4.2 2
nd
 Generation Inhibitors 
While the use of gefitinib and erlotinib as first line therapy for NSCLC patients with activating mutations was lauded 
as a scientific achievement, the success was short-lived. Nearly all patients who initially benefitted from this treatment 
eventually acquired resistance through the emergence of various mechanisms. The most notorious of these, the 
secondary mutation known as T790M, was uncovered by two independent groups in 2005.
27, 66
 The EGFR T790M 
mutation is the primary mechanism of acquired resistance in tumours of patients undergoing EGFR TKI therapy, 
accounting for ~50 – 60% of all cases.67 The mutation occurs in exon 20, with substitution of the threonine 790 
amino acid, shown in Figure 2.11a, with a bulky methionine (Figure 2.11b), located within the ATP binding 
pocket.
49
 Threonine 790 is the gatekeeper residue in EGFR, making it an important determinant of inhibitor 
specificity in protein kinases.
68
 The mutation resulted in the dramatic loss of binding affinity of 1
st
 generation 
inhibitors, rendering them ineffectual. Owing to the bulky nature of the molecular residue and key location at the 
entrance of the hydrophobic pocket within the ATP binding cleft, resistance was initially thought to be caused by 
steric interference of the methionine residue with 1
st
 generation inhibitors.
27
 This clash can be seen when comparing 
the binding mode of gefitinib to EGFR wild-type in Figure 2.11a, with that of the EGFR L858R/T790M double mutant 
shown in Figure 2.11b, altering the orientation and interactions of the inhibitor.
49
 
However, further studies indicated that the primary mechanism of resistance was mediated through an increase in 
protein binding affinity for ATP.
68
 The T790M mutation, in conjunction with activating mutations, was shown to 
lower the concentration of ATP required to achieve a half-maximal reaction rate. These biochemical changes 
returned the ATP binding affinity of the double mutant to a level similar to wild-type EGFR, nullifying the advantages 
of the ATP-competitive 1
st
 generation inhibitors and rendering them ineffective.
68
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Figure 2.11: Binding modes of gefitinib with the a) EGFR wild type (PDB: 2ITY), b) EGFR L858R/T790M double mutant (PDB: 
 4I22) and afatinib with the c) EGFR wild type (PDB: 4G5J), d) EGFR L858R/T790M double mutant (PDB: 4G5P). 
Figure reproduced from Wu et al.
49
 
Furthermore, studies showing that the single mutant T790M EGFR conferred a growth disadvantage in comparison 
to EGFR with activating mutations - with decreased ATP throughput and a lower enzymatic turnover - further 
supported this reasoning.
69
  
The onset of resistance mutations necessitated a paradigm shift and new strategy for targeted inhibitors of EGFR. 
Researchers turned their attention towards the development of irreversible inhibitors, specifically targeting covalent 
modification of cysteine residues within the ATP catalytic site with appropriate warheads, as discussed in Section 
2.3.2.4. Following the identification of the T790M mutation, a wealth of potential drug candidates was developed, 
collectively forming the 2
nd
 generation of EGFR inhibitors. While many of these entered late stage phase III clinical 
trials, almost all ended in limited success or discontinuation. One inhibitor developed within this period, afatinib, 
pictured above in Figure 2.11, was shown to confer a progression free survival (PFS) advantage over systematic 
chemotherapy and gefitinib as a first line treatment for NSCLC.
70, 71
  While structurally similar to gefitinib, afatinib 
binds irreversibly to cysteine 797 with a dimethylamino-acrylamide warhead (Figure 2.11). Tumours with activating 
mutations, such as L858R, were found to be particularly responsive to this 2
nd
 generation inhibitor, showing longer 
overall survival in patients when compared to systematic chemotherapy.
71
 For this reason, afatinib was the only 2
nd
 
generation inhibitor to win FDA approval in 2013 as a first line treatment for metastatic EGFR-mutated NSCLC.
72
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In preclinical models afatanib was shown to shown to inhibit the T790M mutant receptor.
73
 However, in clinical use 
as salvage therapy after 1
st
 generation inhibitors, afatinib was unable to effectively overcome resistance mutations at 
clinically achievable doses.
74
 The T790M mutation has been shown to be the main mechanism of resistance to 
afatinib in patients, originating from a combination of the steric interactions shown in comparison of Figure 2.11c 
and Figure 2.11d, as well as the enhanced binding affinity towards ATP discussed previously. 
While not represented visually, it is worthy to note that neither dacomitinib nor neratinib, another two 2
nd
 
generations inhibitors, were able to demonstrate significant activity as a single agent against patients harbouring the 
T790M resistance mutation.
75, 76
 Amidst negative reviews due to extreme side effects, neratinib has since received 
FDA approval as of July 2017 as adjuvant treatment for HER2 overexpression/amplified breast cancer, while an 
application for FDA approval was filed in August 2018 for dacomitinib. To overcome the limitations and failures 
experienced with the development of 2
nd
 generation inhibitors, researchers came to the realization that they would 
have to target the T790M mutation specifically. This led to the emergence of a novel class of mutant selective 
inhibitors, known as 3
rd
 generation inhibitors.   
2.4.3 3
rd
 Generation Inhibitors 
The lack of success, coupled with toxicity due to concurrent inhibition of wild-type EGFR associated with 
quinazoline-based 2
nd
 generation EGFR inhibitors, left an urgent need for a novel therapeutic treatment for NSCLC 
patients who suffered from T790M drug resistance. Researchers reassessed the development of EGFR inhibitors, with 
the EGFR-T790M receptor being considered as an entirely new enzyme and not a mutant form of the wild-type. 
The following features were identified as critical to overcome and to achieve clinical efficacy against T790M drug 
resistance: i) a novel scaffold core to specifically target the T790M gatekeeper mutant variant by avoiding the Met790 
steric clash, ii) sparing wild-type inhibition by being mutant selective and iii) forming a covalent bond with Cys797 
to increase drug-target residence time and circumvent ATP competition.
77
 By applying these considerations, a 
covalent aminopyrimidine-based EGFR inhibitor, WZ4002, was identified in 2009 and is shown in Figure 2.12a.
78
  
 
 
 
 
 
 
 
Figure 2.12: a) Structure of WZ4002 and b) Crystal structure illustrating binding mode and covalent inhibition (PDB: 3IKA). 
Figure reproduced from b) Zhou et al.
78
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WZ4002 is considered the prototype 3
rd
 generation inhibitor, displaying a 100-fold increase in potency against 
EGFR-T790M and being up to 100-fold less potent against wild-type EGFR in vitro when compared to the 
quinazoline-based 1
st
 and 2
nd
 generation inhibitors.
78
 WZ4002 was also shown to be effective in murine models of 
lung cancer driven by the T790M mutation. A crystal structure of the binding mode, shown in Figure 2.12b, revealed 
the structural basis for the increased potency and mutant selectivity, as WZ4002 was able to avoid the steric conflict 
with Met790 and form a covalent bond with Cys797.  
While WZ4002 did not progress into human clinical trials, the marked success and ability of the first in class inhibitor 
to overcome T790M mutation resistance sparked the development and synthesis of various aminopyrimidine-based 
structural analogues including rociletinib and olmutinib, shown in Figure 2.13 below. Rociletinib was developed 
in 2013, retaining the efficacy and mutant selective characteristics of WZ4002, with patients displaying impressive 
response rates and a median PFS of 13 months.
79
 Further development of rociletinib was halted due to adverse 
events of hyperglycaemia in patients, caused by a metabolite of the candidate binding and inhibiting insulin growth 
factor receptor 1 (IGFR1).
80
 Phase II clinical trials conducted with olmutinib delivered promising results, with little to 
no side effects, leading to a breakthrough therapy designation from the FDA in 2015 and approval for second line 
treatment in South Korea in 2016.
81
 However, amidst several controversies in the years following this approval, 
including the death of a patient from toxic epidermal necrolysis, the program was no longer considered commercially 
viable and terminated in early 2018.  
The gold standard in EGFR TKI treatment of NSCLC is undoubtedly osimertinib (Figure 2.13). The drug discovery 
program that began in 2009, and led to the discovery of osimertnib, followed an adaptive approach and involved 
close collaboration with industrial partners and the global regulatory bodies of the FDA and European Medicines 
Agency (EMA).
82
 The project progressed with exceptional speed, delivering the clinical candidate in under 36 
months. Following a clinical development of 2.5 years, osimertinib received breakthrough therapy designation in 
2014 and provisional accelerated approval by the FDA in 2015.
82
 This was followed by provisional approval under 
an accelerated process by the EMA in the following year, the first under this program.
82
 Osimertinib became the first 
TKI to receive approval from both regulatory bodies in 2017, as first line treatment for patients with the EGFR-T790M 
mutation.  
 
 
 
 
 
 
Figure 2.13: Chemical structures of 3
rd
 generation inhibitors rociletinib, olmutinib and osimertinib. 
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Osimertinib is architecturally unique, with a chemical structure distinct from other 3
rd
 generation TKIs. When 
comparing the inhibitors depicted in Figure 2.13, these distinctions become apparent and include the electrophilic 
functionality residing on a different ring, an indole substituent on the pyrimidine ring and the use of N,N,N′-
trimethylethylenediamine as solubilising group.
83
 Unlike rociletinib, osimertinib and its resulting metabolites were 
specifically designed to show selectivity against IGFR1, minimizing potential dose limiting toxicities.
80
 However, the 
unparalleled success of osimertinib for treatment of  patients with the EGFR-T790M mutation has been 
overshadowed by the development of a common mechanism of acquired drug resistance toward covalent inhibitors.   
Following treatment with 3
rd
 generation inhibitors, including osimertinib, lung cancer patients developed resistance 
within a period of 10 months.
84
 In 2015, researchers identified the emergence of a point mutation of the covalent 
anchor cysteine 797 to a less reactive serine residue, known as the EGFR-C797S mutation (Figure 2.14a). Irreversible 
inhibitors rely on the nucleophilicity of this cysteine residue to form a covalent bond with the receptor, as highlighted 
in yellow in Figure 2.14b, with WZ4002 as example. Following the tertiary C797S point mutation, formation of this 
covalent bond with currently available irreversible inhibitors is prevented (Figure 2.14b, highlighted in red), as the 
substituted hydroxyl of the serine residue is unlikely to undergo a Michael addition at physiological conditions, 
resulting in a considerable loss of efficacy.
77
  
Due to the selective pressure of 3
rd
 generation inhibitors, specifically targeting the EGFR-T790M mutant and forming 
this covalent bond, it is not surprising that cancer cells acquire resistance through a tertiary mutation and the cysteine 
797 position. This mechanism of resistance resembles the acquired C481S mutation observed in Bruton tyrosine 
kinase (BTK), which bears an analogous cysteine to EGFR, in response to the irreversible BTK inhibitor ibrutinib used 
for treatment of patients with chronic lymphocytic leukaemia (CLL).
85
 This suggests that cysteine point mutations 
may constitute a common mechanism of acquired resistance and should therefore be considered a recurring liability 
to irreversible kinase inhibitors in the future. 
Figure 2.14: a) The EGFR C797S variant mediates resistance through point mutation of cysteine 797 to a serine residue and b) 
WZ4002 covalently bound to Cys797 highlighted in yellow and the less nucleophilic Ser797 unable to undergo covalent bond 
formation, highlighted in red (PDB: 3IKA). Figure reproduced from b) Engel et al.
77
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Interestingly, the allelic/genomic context of resistance to 3
rd
 generation inhibitors has been shown to influence the 
sensitivity of the receptor to the other EGFR TKIs available.
86
 While C797S conferred resistance to all 3
rd
 generation 
inhibitors, it was found to be sensitive to 1
st
 and 2
nd
 generation inhibitors such as gefitinib and afatinib. This may 
prove helpful in future therapeutic strategies for patients with EGFR mutations, paving the way for use of different 
sequential and combinatory treatment as the mechanism of acquired resistance varies based on the molecular 
therapeutic and context.    
2.4.4 4
th
 Generation Inhibitors and the Future of EGFR Inhibition 
Since 2015, and the first evidence of 3
rd
 generation inhibitor resistance mediated by EGFR-C797S, no major 
breakthroughs have been achieved to target the clinically relevant mutant variant. In the subsequent three years, 
various research groups have adopted novel approaches to attempt to overcome this mechanism of drug resistance. 
The focus has been on improving the reversible binding affinity of established aminopyrimidine-based inhibitors, 
investigating innovative hinge binding motifs and interactions with the mutant serine residue and allosteric inhibitors 
of the EGFR kinase domain. Compounds utilising these strategies have become known as 4
th
 generation EGFR 
inhibitors.  
The first of these strategies sought to improve the degree of reversible binding by exploiting a hydrophobic pocket 
adjacent to the gatekeeper residue, in combination with a hydrophobic clamp motif within the active site, as shown 
in Figure 2.15a, highlighted in green.
87
 The lead compound, SKLB(5) (Figure 2.15a), is structurally similar to 
WZ4002, with the addition of a cyclopentyl moiety that interacts with the hydrophobic clamp and an aniline 
fragment which extends into the hydrophobic back pocket. Previously developed EGFR inhibitors have not made 
use of this hydrophobic pocket or clamp motif, providing favourable reversible interactions for the lead compound.  
Figure 2.15: 4
th
 Generation inhibitors and the various strategies undertaken to target the EGFR-C797S mutation. These include: 
a) Exploiting the hydrophobic pocket and clamp motif (green, PDB: 5GTZ), b) Reversible interaction with the mutated serine 
residue (orange, PDB: 5X2C), and c) Allosteric EGFR inhibitors (light blue, PDB: 5D41). Figure reproduced from Grabe et al.
88
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Another approach utilised a virtual de novo design to identify a novel scaffold as a potent inhibitor for the 
del19/T790M/C797S triple mutant variant.
89
  The most efficacious of these inhibitors, shown in Figure 2.15b, uses 
an unconventional hinge-binding motif, interacting with a phenolic hydroxyl moiety, as well as the 
aminomethylpyrazine forming two hydrogen bond interactions with Ser797 (Figure 2.15b, highlighted in orange).
89
 
This improved the binding affinity, while specifically exploiting the C797S mutant variant serine residue.  
Lastly, the first of its kind allosteric EGFR inhibitor, EAI045 (Figure 2.15c), was shown to overcome EGFR-C797S by 
targeting an allosteric pocket (Figure 2.15c, highlighted in blue) that emerges with the inactive conformation of the 
kinase.
90
 The inhibitor showed low nanomolar activity in biochemical assays, whilst sparing the wild-type enzyme. 
However, this efficacy is only achievable on a cellular level or in vivo setting in combination with the antibody 
cetuximab.
90
 Unfortunately, approaches based on EAI045 are limited to the L858R activating mutation, as these 
compounds show little to no efficacy against del19 activated EGFR, which is the predominant activating mutation 
found in osimertinib resistant patients.  
While these methods of drug development have afforded numerous biochemically active 4
th
 generation inhibitors, 
few have proven efficacious on a cellular level or in vivo. This reflects the current situation in the targeted inhibition 
of EGFR using TKIs. The emergence of the T790M mutation over a decade ago showed us that simply trying to 
improve on existing inhibitors, as was the case with the majority of 2
nd
 generation inhibitors derived from gefitinib 
and erlotinib, does not necessarily counteract new mechanisms of acquired drug resistance. Novel chemical 
structures and binding modes, making use of the combined innovative approaches discussed above, will thus be 
required to unravel the molecular complexities of multimutated EGFR to develop 4
th 
generation inhibitors for 
treatment of NSCLC patients. The primary goal of this body of research centres on the development, utilisation and 
evaluation of approaches to overcome the clinically relevant EGFR-C797S mutant variant. In the following chapter, 
the main aims and objectives of this work will be presented in summarised form, providing the reader with an 
overview of the strategies employed to overcome this resistance mechanism.  
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Chapter 3 
Overview of Aims, Objectives and General Practices 
3.1 Introduction 
The intention of this chapter is to provide the reader with an overview of the various research themes, aims and 
objectives of each chapter within this thesis. This will be achieved by briefly introducing the main research goals of 
each chapter, providing the premise for the undertaking of these ventures and summarizing the synthetic strategies 
employed to accomplish these endeavours. Additionally, general practices regarding the synthesis and biochemical 
and cellular evaluation of all compounds will be comprehensively discussed. All figures displayed within this chapter 
were appropriated from the respective chapter under summation.   
3.2 Chapter 4: Lead Optimization of Pyrrolopyrimidine-derived 
EGFR Inhibitors 
In the ensuing Chapter 4, we will attempt to develop potent irreversible and reversible inhibitors of the cysteine 
bearing L858R/T790M double mutant and serine bearing L858R/T790M/C797S triple mutant respectively. To do 
this, we will utilise and optimise the pyrrolopyrimidine-based lead compound 1, illustrated in Figure 3.1 on the 
following page. This compound was previously identified and synthesized by Mr. Philip Klövekorn, a student under 
the supervision of our research collaborator, Prof. Daniel Rauh. As such, all of the synthetic work pertaining to this 
chapter was completed in the laboraties of Prof. Rauh during a funded research visit to Dortmund, Germany.  
Following a discussion on the development and optimization towards lead compound 1, we will introduce the dual 
EGFR/HER2 inhbitiors which provided the inspiration for this project. These drug candidates contain glycol chain 
moeties of various lengths and substituents which were found to instate favourable reversible interactions with the 
glycine-rich loop within the ATP binding site.
1
 Wishing to emulate the enhanced reversible binding affinity afforded 
by these groups, and aided by the use of molecular modelling, we envisaged the incorporation of glycol chains at 
strategic positions on lead compound 1. This included derivatisation at the N-position (Figure 3.1a, R1) and ortho-
position (Figure 3.1b, R2) of the acrylamide Michael acceptor with the selected glycol fragments (Figure 3.1, blue). 
Thus, we would be able to examine the effects of substitiution at these positions with respect to binding affinity and 
formation of reversible interactions. In conjunction with this investigation, we would synthesise analogues of these 
compounds with, and without, the electrophilic acrylamide Michael acceptor (Figure 3.1, red). In doing so, we 
could determine their potential as irreversible inhibitors of the T790M double mutant and as reversible inhibitors of 
the C797S triple mutant respectively. Additionally, we would consider the necessity of the phenyl methyl-piperazine 
solubilising group (Figure 3.1, green) and the effect of its presence or absence on the cellular permeability and 
efficacy of these compounds. The derivatisation and interchange of these specific structural elements within the lead 
compound scaffold 1 will constitute the compounds displayed within the eight Series A – H, illustrated in Figure 
3.1. Following the successful synthesis of this combinatorial library, these compounds will undergo biochemical and 
cellular evaluation against both the wild-type and mutant variants of the EGFR enzyme to determine these effects. 
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Figure 3.1: Structure of lead compound 1 and the combinatorial synthetic library containing a) Series A – D, with the glycol 
chain on the N-position of the acrylamide and b) Series E – H, with the glycol chain in an ortho-position to the acrylamide.  
3.3 Chapter 5: 1,4-Dicarbonyl Electrophiles Targeting the EGFR 
Catalytic Lysine Residue Lys745 
Chapter 5 represents a departure from the traditional use of reversible and irreversible acrylamide electrophile- 
containing inhibitors which target cysteine residues within the active site. Instead, in the hopes of effectively 
combating resistance conferred by the C797S mutation, we will attempt to restore covalent inhibition in this mutant 
variant by targeting the EGFR catalytic lysine residue. The EGFR catalytic Lys745 residue plays a significant regulatory 
role in activation of the kinase, a prerequisite state and conformation which facilitates successful binding and 
phosphorylation of ATP and downstream signalling.
2
 However, mutation of this amino acid has been documented 
to create an inactive or “kinase-dead” form of the enzyme.3 Therefore, we found the targeted inhibition of this 
specific residue an attractive prospect in a therapeutic context, with the potential to switch off constitutively activated 
oncogenic signalling.  
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 Figure 3.2: a) Use of a 1,4-dicarbonyl electrophile to potentially undergo Paal-Knorr pyrrole synthesis with the EGFR catalytic 
Lys745 residue and b) Illustration of the selected heterocyclic driving group 2 and various 1,4-dicarbonyl electrophiles 
constituting the prospective synthetic library. 
Amongst several successful instances of lysine-targeting electrophiles that will be examined, we drew inspiration from 
our collaborator from Texas State University, Prof. Alexander Kornienko. His group was able to synthesise and 
investigate a series of analogues of the 1,4-dialdehyde-containing natural product polygodial, which displayed potent 
antiproliferative activity.
4
 The group hypothesised, and were able to successfully prove, that the dialdehyde moiety 
of the natural product underwent a modified Paal-Knorr condensation reaction with a lysine residue on the target 
protein.
4
 Seeking to reproduce this novel mechanism of covalent modification, we envisioned the incorporation of 
a 1,4-dicarbonyl electrophile on a suitable heterocyclic driving group to potentially undergo Paal-Knorr pyrrole 
synthesis with the EGFR catalytic Lys745 residue, as illustrated in Figure 3.2a.  
To investigate the feasibility and possibility of irreversibly inhibiting the catalytic lysine residue, we envisage the 
synthesis of a library of 1,4-dicarbonyl-containing inhibitors. Through structural analysis of scaffolds bound to the 
EGFR kinase domain and use of molecular modelling, the gefitinib-derived, quinazoline core 2, shown at the top 
right of Figure 3.2b, will be selected as our heterocyclic driving group. We will employ a variety of 1,4-dicarbonyl 
electrophiles (Figure 3.2b, blue), to compare the effects of respective electrophile reactivity, steric bulk/leaving 
groups, lipophilicity and stability of the formed covalent adducts on the promotion and rate of the Paal-Knorr 
condensation reaction. Following the successful synthesis of this library of compounds, these comparisons and the 
binding mode of the inhibitors will be explored through the results obtained from the biochemical and cellular 
assessment and covalent mass spectrometry experiments respectively. 
 
 
Stellenbosch University https://scholar.sun.ac.za
Chapter 3 – Overview of Aims, Objectives and General Practices 
 
55 
 
3.4 Chapter 6: Osimertinib-derived Inhibitors Targeting the EGFR 
Catalytic Lysine Residue Lys745 
Advancing on the premise of the previous chapter, we will pursue irreversible inhibition of the catalytic Lys745 
residue further throughout Chapter 6. However, at the onset of this research endeavour, Taunton and co-workers 
reported the first crystal structure of EGFR in which the catalytic Lys745 residue was covalently modified.
5
 As the 
group made use of a broad-spectrum chemical probe with excellent reversible binding affinity and a sulfonyl fluoride 
electrophile to undergo covalent modification with the catalytic Lys745 residue, we were compelled to re-evaluate 
the strategy implemented in the previous chapter. Therefore, we sought to identify an optimised and selective EGFR 
heterocyclic driving group to combine with reactive lysine-targeting electrophiles such as the sulfonyl fluoride 
employed in the publication by Zhao et al.
5
  
Experimental evidence within the literature, coupled with the incredible success and efficacy of osimertinib as a 3
rd
 
generation EGFR inhibitor, led to its selection as the driving group scaffold for our synthetic library.
6
 This scaffold 3, 
pictured in Figure 3.3 below, utilises the potent 2-aminopyrimidine group (green) as hinge binding motif, which has 
been documented to overcome resistance in both ALK and EGFR.
7
 For incorporation of the lysine-targeting 
electrophiles, the optimal position was identified as the N-position (Figure 3.3, R1, blue) of the indole heterocycle 
through use of molecular modelling. This will allow for a proximal location and favourable orientation towards the 
Lys745 residue for the proposed electrophiles. These functionalities (Figure 3.3, blue), are chosen for their ability to 
form favourable reversible interactions or covalently modify lysine residues, which we hope will improve the efficacy 
against and selectivity for enzymes bearing the C797S mutation.
8
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Target synthetic library for osimertinib-derived catalytic lysine-targeting inhibitors. 
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Lastly, we wish to synthesise the reversible propionamide and irreversible acrylamide analogues (Figure 3.3, R2, red) 
of our osimertnib-derived inhibitors. This could provide valuable insight and a comparative platform in the case of 
covalent bond formation at the catalytic lysine residue. Once again, the potency and binding mode of these 
synthesised inhibitors will be investigated according to the outcome of the biochemical and cellular evaluation and 
covalent mass spectrometry experiments respectively.   
3.5 Chapter 7: Osimertinib-derived Inhibitors Targeting the 
Mutated Serine Residue Ser797 
While the research efforts of the previous two chapters were centred on the covalent modification and targeted 
inhibition of the EGFR catalytic Lys745 residue, in our final chapter we seek to exploit and irreversibly inhibit the 
main mechanism of resistance to 3
rd
 generation EGFR inhibitors - the mutated Ser797 residue.
9
 In doing so, we 
would reinstate irreversible inhibition and produce selective inhibitors of the C797S mutation-bearing enzyme.   
As this serine residue contains a hardier, less nucleophilic hydroxyl group, our strategy will include the use of suitable 
electrophiles known to interact and irreversibly inhibit serine-containing enzymes. Building on the synthetic 
achievements of Chapter 6, and exploiting the favourable attributes of this driving group, these electrophiles will be 
installed onto the previously implemented osimertinib-derived scaffold 4, displayed in Figure 3.4. Derivatisation will 
take place at the aniline fragment (Figure 3.4, R1, purple) which conventionally houses the acrylamide Michael 
acceptor, thereby placing the warhead in a prime position to interact and potentially covalently modify the mutant 
Ser797 residue. We will employ numerous electrophiles (Figure 3.4, purple) with varying reactivities to give the 
highest probability for irreversible inhibition of the EGFR-C797S mutant variant. 
Figure 3.4: Target synthetic library for osimertinib-derived Ser797 targeting inhibitors. 
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Figure 3.5: a) Dual warhead able to potentially covalently modify both cysteine and serine, b) Envisaged dual warheads and c) 
Mechanism of activation based on the catalytic triad of serine proteases.   
Additionally, we wish to synthesise the dual-warhead-bearing compounds, illustrated above in Figure 3.5, which 
may show enhanced selectivity and efficiency in targeting the mutant Ser797 residue. These dual-warheads will 
include the vinyl sulfonyl fluoride (Figure 3.5a), able to potentially covalently modify both cysteine and serine 
residues through the Michael acceptor and adjacent sulfonyl centre respectively, and the cyano- and imidazole-
containing inhibitors (Figure 3.5b). The latter inhibitors, which will be based on the catalytic triad of serine proteases, 
will be able to potentially activate the Ser797 residue through hydrogen bond interactions with the imidazole (or 
cyano) moiety. This can then be followed by potential irreversible inhibition through nucleophilic attack of the 
sulfonyl fluoride centre (Figure 3.5c). 
As with all our synthesised libraries, these compounds will be assessed in a biochemical and cellular setting and 
undergo covalent mass spectrometry experiments to reveal the binding mode of the inhibitors. Special consideration 
will be given to the results of enzymes harbouring the C797S mutation, as we wish to selectively and effectively 
inhibit this mutant variant.   
3.6 Chapter 8: Project Summary and Concluding Remarks 
In the concluding chapter of this thesis we will provide commentary on the project as a collective and the future of 
EGFR as a therapeutic target. This will include a discussion of the present situation and outlook of EGFR inhibition 
and its relevance in the clinical treatment of cancer patients, a summary of the achievements and outcomes of this 
research project and the prospective application of this work.   
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3.7 General Practices 
3.7.1 Synthesis 
All compounds furnished and described within this thesis were synthesised by Luke Hodson. 
3.7.1.1 Solvents and Reagents 
Chemicals, starting reagents and solvents used in these experiments were purchased from VWR, Alfa Aeser, Acros 
Organics, Sigma Aldrich or Merck. Tetrahydrofuran, diethyl ether and toluene were distilled under nitrogen from 
sodium wire/sand using benzophenone as indicator. Dichloromethane, dimethylformamide and acetonitrile were 
distilled under nitrogen from calcium hydride. Methanol, ethanol and isopropanol were distilled under nitrogen from 
magnesium turnings and catalytic iodine. Alternatively, solvents were dried for at least two days in a sealed Schlenk 
flask, under argon, using 3 Å, 4 Å or 5 Å molecular sieves. Triethylamine and N, N-diisopropylethylamine were 
distilled under nitrogen from potassium hydroxide. Ethyl acetate, petroleum ether and dichloromethane used for 
flash column chromatography was distilled under open air conditions in bulk batches. All other reagents that required 
purification were purified according to standard procedures.
10
  
3.7.1.2 Chromatography and Purification 
Thin layer chromatography (TLC) was performed on Macherey Nagel aluminium TLC-plates, pre-coated with 0.20 
mm silica gel and fluorescent indicator UV254. Visualization was performed with UV light (λ = 254 nm), iodine on 
silica or by spraying with KMnO
4
, p-anisaldehyde, ceric ammonium molybdate (CAM), ninhydrin (NIN), vanillin or 
bromocresol green stains followed by heating. Universal pH test paper strips were used to determine pH. Flash 
column chromatography was performed using Merck silica gel 60 (particle size 0.040-0.063 mm) or neutral alumina. 
Mobile phase and Rf value solvent ratios are reported as v/v ratios. Automated flash column chromatography was 
carried out on a Biotage Isolera using Reverleris silica flash cartridges (25 – 120 g) monitored by UV at λ = 254 nm 
and 366 nm. A rotary evaporator was used to remove solvents in vacuo. High vacuum (~ 0.8 mm Hg) was used to 
dry products. All final compounds were purified to >95 % purity as determined by high-performance liquid 
chromatography (HPLC). Purity was measured using a Waters Acquity UPLC system fitted with a photodiode array 
detector (system: Waters BEH C18 column (1.7 μm, 100 mm × 2.1 mm) by the Central Analytical Facility of 
Stellenbosch University. Alternatively, purity was measured using an Agilent 1200 series HPLC system with UV 
detection at λ = 210 nm (system: Agilent Eclipse XDB-C18 4.6 mm × 150 mm, 5 µM, 10 – 100 % CH
3
CN in H
2
O, 
with 0.1 % TFA, for 15 min at 1.00 mL/min) at the Technische Universität Dortmund.  
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3.7.1.3 Spectroscopic Characterization and Physical Properties 
All infrared spectra were recorded on a Thermo Nicolet FT-IR, using an Attenuated Total Reflectance (ATR) 
attachment. OMNIC 7.0 software was used to analyse spectra. NMR spectra were recorded on a 300 MHz Varian 
VNMRS (75 MHz for 
13
C NMR spectra, 96 MHz for 
11
B NMR spectra, 282 MHz for 
19
F NMR spectra and 121 MHz 
for 
31
P NMR spectra), 400 MHz Varian Unity Inova (101 MHz for 
13
C NMR spectra, 162 MHz for 
31
P NMR spectra) 
or 600 MHz Varian Unity Inova (151 MHz for 
13
C NMR spectra) at the Central Analytical Facilities (CAF) of 
Stellenbosch University.  Alternatively, NMR spectra were recorded on a 400 MHz Bruker Avance-III HD (101 MHz 
for 
13
C NMR spectra), 500 MHz Bruker Avance DRX (126 MHz for 
13
C NMR spectra), 600 MHz Bruker Avance-III 
HD (151 MHz for 
13
C NMR spectra) or 700 MHz Bruker Avance DRX (176 MHz for 
13
C NMR spectra) at the 
Technische Universität Dortmund. All NMR spectra were obtained at 25 °C, chemical shifts (δ) are reported in parts 
per million (ppm), multiplicities are indicated as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), 
m (multiplet) and br s (broad singlet) and coupling constants (J) are expressed in Hertz (Hz). 
1
H and 
13
C spectra are 
referenced to the residual solvent signal DMSO-d6 (2.50 or 39.52 ppm), CDCl3 (7.26 or 77.16 ppm) or CD3OD 
(1.94 or 49.00 ppm) respectively. 
11
B, 
19
F and 
31
P NMR spectra are referenced to 15% BF3·OEt2 in CDCl3, CFCl3 and 
85% H3PO4 in H2O respectively, which served as the internal standard for these experiments. NMR spectra were 
processed using MestReNova version 6.0.2-5475. High-resolution mass spectrometry was performed using a Waters 
SYNAPT G2 QTOF spectrometer, in ESI positive mode, by the CAF at Stellenbosch University. Alternatively, high-
resolution mass spectrometry was performed using a Thermo LTQ Orbitrap in ESI positive mode, at the Technische 
Universität Dortmund. Melting points were obtained using a Gallenkamp melting point apparatus or a Kofler 
microscope melting point machine.  
3.7.1.4 Glassware, Inert Conditions and Temperature Control  
Glassware was oven dried and thereafter was placed under vacuum of ~ 0.8 mm Hg and cyclically flushed with 
nitrogen/argon and evacuated until it had reached room temperature. Standard Schlenk techniques were employed 
when necessary. All reactions were performed under a positive pressure of 2.8 kPa of 5.0 grade nitrogen or argon 
(Air Products). Low temperature reactions were performed in a dewar containing ice in acetone (~ −10 °C), dry ice 
in acetonitrile (−40 °C) or dry ice in acetone (−78 °C). Reactions requiring precise, extended low temperature 
control, were performed in a dewar regulated with a Thermo Scientific Haake EK90 Immersion Cooler. 
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3.7.2 Biochemical and Cellular Evaluation 
All biochemical and cellular evaluations, as well as the preparative procedures described below, were undertaken 
by our collaborators in the research group of Prof. Daniel Rauh at the Technische Universität Dortmund.  
3.7.2.1 Protein Expression and Purification 
EGFR-T790M and EGFR-L858R/T790M/C797S were expressed in Spodoptera frugiperda (Sf9) cells using the 
BacMagic system and purified as follows. After three days of expression (27 °C, 110 rpm) the cells were harvested 
(300 g, 20 min), resuspended in buffer A (50 mM Tris, 500 mM NaCl, 5% glycerol, 1 mM DTT, pH 7.5) and 
homogenized by French press. The lysate was cleared by centrifugation at 40.000 g for 1 h at 8 °C and loaded on a 
pre-packed GSTrap 4B Column (GE Healthcare). The elution was done with buffer B (50 mM Tris, 500 mM NaCl, 
5 % glycerol, 1 mM DTT, pH 7.5, 10 mM glutathione). Fractions containing the assay construct EGFR-
L858R/T790M/C797S were then concentrated and applied to a HiLoad 16/600 superdex 75 pg column (GE 
Healthcare) in buffer C (25 mM TRIS, 250 mM NaCl, 10% Glycerol, pH 8). The purified protein was concentrated 
to 5 mg/mL and stored at −80 °C until further use. Protein identity was confirmed by ESI-MS analysis. 
3.7.2.2 Construct Design of EGFR-L858R/T790M/C797S 
For the EGFR-L858R/T790M/C797S assay construct the DNA encoding residues compromising the juxtamembrane 
segment, the kinase domain and the C-terminal tail of human EGFR (UniProt entry P00533, residues 695-1210) 
were synthesized by GeneArt (Life Technologies). The construct was cloned into pIEX/Bac5 expression vector 
(MerckMillipore) including a GST-tag, using KpnI and Bsu36I restriction sites. Point mutations L858R, T790M and 
C797S were introduced by site-directed mutagenesis (QuikChange, Stratagene/Agilent Technologies). Transfection, 
virus generation and amplification were carried out in a Sf9 cell line following the BacMagic protocol. 
3.7.2.3 Activity-based Assay for IC50 Determination 
IC50 determinations for EGFR and its mutants (Carna Biosciences, lot13CBS-0005K for EGFR-wt; Carna, lot13CBS-
0537B for EGFR-L858R and Carna, lot12CBS-0765B for EGFR-L858R/T790M) were performed with the HTRF 
KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. Accordingly, the amount of EGFR in 
each reaction well was set to 0.60 ng EGFR-wt (0.67 nM), 0.10 ng EGFR-L858R (0.11 nM), 0.07 ng EGFR-
T790M/L858R (0.08 nM) or 0.80 ng EGFR-L858R/T790M/C797S (0.88 ng), respectively. An artificial substrate 
peptide (TK-substrate from Cisbio) was then phosphorylated by EGFR. After completion of the reaction (reaction 
times: 25 min for wt, 15 min for L858R, 20 min for T790M/L858R and 10 min for L858R/T790M/C797S), the 
reaction was stopped by the addition of a buffer containing EDTA, an anti-phosphotyrosine antibody labeled with 
europium cryptate and streptavidin labelled with the fluorophore XL665. Fluorescence resonance energy transfer 
(FRET) between europium cryptate and XL665 was then measured after an additional hour of incubation to quantify 
the phosphorylation of the substrate peptide. ATP concentrations were set at their respective Km-values (9.5 µM for 
wt, 9 µM for L858R, 4 µM for L858R/T790M and 11 µM for L858R/T790M/C797S) while a substrate concentration 
of 1 µM, 225 nM, 200 nM and 325 nM, respectively, were used.  
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Kinase and inhibitor were preincubated for 30 min before the reaction was started by addition of ATP and substrate 
peptide. An EnVision multimode plate reader (Perkin Elmer) was used to measure the fluorescence of the samples 
at λ = 620 nm (Eu3+-labeled antibody) and λ = 665 nm (XL665 labeled streptavidin) 50 µs after excitation at λ = 
320 nm. The quotient of both intensities for reactions made with eight different inhibitor concentrations was then 
analyzed using the Quattro Software Suite for IC50 determination. Each reaction was performed in duplicate and at 
least three independent determinations of each IC50 value were made. 
3.7.2.4 Cell Culture 
A431, HCC827, H1975 and A549 cells were obtained from the American Type Culture Collection (ATCC). A431 
cells were cultured in DMEM high glucose media (Life Technologies), and HCC827, H1975 and A549 cells were 
cultured in RPMI media (Life Technologies). Both contained L-glutamine and were supplemented with 10% FBS (GE 
Healthcare) and 1% PenStrep (Life Technologies) in a humidified incubator at 37 °C with a 5% CO2 atmosphere. 
Cell line authentication was been performed last in August 2018 by STR profiling of 16 alleles. 
3.7.2.5 Viability Assay (EC50 Determination) 
Cells were seeded at cell numbers that insured linearity and optimal signal intensity (150 – 300 cells/well, 25 µL) 
and cultured for 24 hours in serum- and antibiotic-containing media in a humidified chamber at 37 °C with a 
5% CO2 atmosphere. Cells were then treated with EGFR inhibitors in serial dilutions (14 nM to 30 µM) in DMSO, 
with Staurosporine as control, and incubated for 96 hours. Afterwards viability studies were carried out using the 
CellTiter-Glo Assay (Promega), a homogeneous method of determining the number of viable cells in culture. Based 
on quantification of ATP, the assay indicates the presence of metabolically active cells. For cellular evalutation, the 
CellTiter-Glo reagent was prepared according to the instructions of the kit and diluted in 1:1 ratio with the complete 
growth medium suitable for the corresponding cell line. Thereafter, the reagent and assay plates were equilibrated 
at room temperature for 20 min, with equal volumes of the reagent being added to the volume of culture medium 
present in each well (25 µL). The microplates were mixed for 2 minutes on an orbital shaker to induce cell lysis and 
were then incubated at room temperature for 20 minutes for stabilization of the luminescent signal. Following 
incubation, the luminescence was recorded on an EnVision microplate reader (Perkin Elmer) using 500 ms 
integration time. The data was then analysed using the Quattro Research Software Suite for EC
50
 determination. As 
quality control, the Z’-factor was calculated from 16 positive and negative control values. Only assay results showing 
a Z’-factor ≥0.5 were used for further analysis. All data points were measured in triplicate for each plate and were 
replicated in at least two plates. 
3.7.2.6 Covalent Mass Spectrometry Experiments 
The drug-resistant EGFR-T790M mutant variant was utilised for covalent mass spectrometry experiments. A mixture 
of 26.4 µM of protein was incubated with 79.2 µM of inhibitor in buffer (25 mM TRIS, 250 mM NaCl, 10% glycerol, 
1 mM TCEP, pH 8) on ice for 1 h. Aliquots were analused by ESI-MS using a Thermo Fisher Scientific Dionex 
UltiMate 3000 HPLC system connected to a Thermo Fisher Scientific Velos Pro (2D ion trap).  
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Accordingly, 5 µL of sample was injected and separated using a Vydac 214TP C4 5 µm column (150 mm x 2.1 mm) 
with two mobile phases which included A (0.1% TFA in water) and B (acetonitrile). Separation was initiated with 
20% solvent B for 5 min, followed by a gradient increase to 90% solvent B over 14 min at a flow rate of 210 µL/min. 
A mass range of 700 to 2000 m/z was scanned, and raw data was deconvoluted and analysed using MagTran 
software.
11
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Chapter 4 
Lead Optimisation of Pyrrolopyrimidine-derived EGFR Inhibitors  
Abstract 
The body of work discussed in this chapter comprises of the design, synthesis and biochemical and cellular evaluation of a 
combinatorial library of compounds based on a previously synthesised lead candidate. The identification and synthesis of this 
lead compound will be alluded to, followed by a report of the dual EGFR/HER2 inhibitors forming the molecular inspiration of 
this research. Derivatisation with various glycol chain moieties in key substitution positions, in the absence or presence of a 
solubilising group and/or an electrophilic Michael acceptor, resulted in the synthesis of a broad combinatorial library. This library 
consists of series A - H, containing 26 reversible and potentially irreversible inhibitors. The synthesis of these compounds is 
discussed in full, with emphasis on reactions optimized during the generation of these inhibitors. The synthesised molecules were 
then screened against numerous mutant variants of the EGFR enzyme, both biochemically and in a cellular context, revealing 
specific trends affecting the activity and binding mode of the compounds. While picomolar range IC50 values were observed for 
biochemical inhibition, these values were unfortunately not reflected against corresponding cell lines. Evaluation against HER2 
mutant cell lines exhibited the compounds potential for development as dual EGFR/HER2 inhibitors. Lastly, a crystal structure of 
a potent inhibitor in the cSrc-T338M/S345C surrogate, reinforced our postulates regarding the observed trends in activity.  
4.1 Introduction 
The work undertaken in this chapter was completed during a four-month research visit to Prof. Dr. Daniel Rauh‘s 
laboratories at the Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Germany. This 
visit was made possible by funding from the South African Medical Research Council (MRC) and National Research 
Foundation (NRF). This body of research focusses on the optimization of a pyrrolopyrimidine-based lead compound 
previously identified and synthesized by Mr. Philip Klövekorn, a student under the supervision of Prof. Rauh. We 
will briefly discuss the identification and optimization towards this lead compound, followed by the molecular muses 
and hypothesis for this body of research. This encompasses the derivatisation and interchanging of specific structural 
elements on the lead compound scaffold, providing valuable information correlating to binding characteristics and 
interactions of the inhibitor within the ATP binding cleft.   
4.2 Lead Compound Identification and Optimization 
An analysis of ligands bound to the EGFR kinase domain within the protein data bank, led the Rauh research group 
to the pyrrolopyrimidine-based compound AEE78, shown in Figure 4.1a. AEE788 is a dual family EGFR/HER2 and 
VEGFR tyrosine kinase inhibitor, with antitumor and antiangiogenic properties, which was developed by Novartis in 
2004.
1
 As a 1
st
 generation inhibitor, the compound displayed efficient inhibition of the EGFR-bearing activating 
mutations such as EGFR-L858R. However, as with other 1
st
 generation EGFR inhibitors such as gefitinib and erlotinib, 
the onset of the T790M gatekeeper mutation resulted in a drastic diminishment in efficacy. This decrease in potency 
could be attributed to the bulky mutated methionine residue creating a steric clash with the 1-phenylethylamine 
moiety of AEE788, as illustrated in Figure 4.1b, leading to an altered binding orientation. Further complications 
associated with unacceptable toxicity resulted in clinical trials of the reversible inhibitor being discontinued in 2006. 
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Figure 4.1: a) Structure of AE788 and b) Steric effects of EGFR-T790M on the binding mode of AE788 (PDB:2J6M and 2JIU). 
To circumvent the pitfalls associated with the T790M mutation, the Rauh group set about optimizing the 
pyrrolopyrimidine scaffold, with their strategy illustrated in Figure 4.2a. Firstly, the 1-phenylethylamine group was 
substituted with a methoxy group at the 4-position, shown to be small enough to avoid negative steric interference 
with the Met797 gatekeeper side chain. A variety of solubilizing groups were then assessed, with a methyl-piperazine 
moiety linked directly to the aromatic ring being found to be the most efficacious. Lastly, supported by structural 
analysis, the 5-position of the pyrrolopyrimidine scaffold was found to be most suitable for the introduction of a 
phenyl linker bearing a reactive Michael acceptor. Utilization of an acrylamide moiety in the meta-position presented 
a suitable binding orientation and adjacent proximity to Cys797, allowing the warhead to potentially undergo 
covalent bond formation. For their efforts, the group were rewarded with lead compound 1, whose binding mode 
can be seen in Figure 4.2b. The pyrrolopyrimidine core was seen to form bidentate hydrogen bond interactions 
with Met793 of the kinase hinge region, with the solubilising group directly exposed to the solvent. The favourable 
positioning of the acrylamide relative to Cys797 can also be seen below.  
Figure 4.2: a) Synthetic optimization of AE788, affording lead compound 1 and b) Binding mode of compound 1, illustrating 
hydrogen bond interactions with the hinge region, the solubilising group and proximity for covalent inhibition (PDB: 2JIT).  
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4 4 
5 
5 
Stellenbosch University https://scholar.sun.ac.za
Chapter 4 – Lead Optimisation of Pyrrolopyrimidine-derived EGFR Inhibitors 
 
65 
 
The lead compound was tested in an activity-based, EGFR HTRF biochemical assay and was shown to inhibit all 
variants of EGFR kinases with sub-nanomolar IC50 values comparable to that of osimertinib. As can be seen below in 
Figure 4.3, compound 1 inhibited the EGFR-wt kinase with an IC50 of 0.41 nM, exhibiting a 4- and almost 2-fold 
selectivity for the L858R (0.12 nM) and L858R/T790M (0.24 nM) mutant variants respectively. Moreover, the 
reversible counterpart 2, bearing a propionamide moiety in place of the Michael acceptor, showed a marked 
decrease in efficacy, with IC50 value of 305 nM against the L858R/T790M double mutant. This equated to over a 
thousand-fold loss in activity, substantiating the formation of a covalent bond and highlighting the importance of an 
irreversible mode of inhibition in targeting the double mutant.   
Similar trends were observed in subsequent cellular tests of the compounds. A wild-type bearing cell line A431, 
EGFR-delE746_A750 activating mutation-carrying HCC827 cells, the EGFR-L858R/T790M 2
nd
 generation drug 
resistant cell line H1975 and the clinically relevant EGFR-delE746_A750/T790M/C797S triple mutant cell line were 
employed in this assay. While compound 1 displayed slightly more favourable activity than osimertinib in a 
biochemical setting, the lead compound was found to be nearly 4-fold less effective against the H1975 cell line, 
with an EC50 of 60 nM compared to the blockbuster drug (16 nM).  
Examination of the biochemical results against the L858R/T790M/C797S triple drug resistant mutant revealed that 
compound 1 (50 nM) was found to be more than twice as potent as osimertinib (113 nM). However, when compared 
to the L858R/T790M double mutant, both compounds suffered a 200-fold loss of activity, reflecting the current crisis 
in clinical resistance to 3
rd
 generation inhibitors. This sentiment is mirrored in the cellular activities of the compounds 
against the PC9/T790M/C797S triple mutant. Forthwith, we strove to improve the biochemical and cellular efficacy 
of compound 1 against the double and triple mutant by creating favourable reversible interactions within the active 
site of the kinase and improving on pharmacokinetic parameters such as metabolic stability and bioavailability. The 
results of this endeavour will be described within this chapter.  
 
 
 
 
 
 
 
 
 
Figure 4.3: Biochemical and cellular assay activity of osimertinib, lead compound 1 and its reversible counterpart 2. 
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4.3 Inspiration from Dual EGFR/HER2 Inhibitors 
 
 
 
 
 
Figure 4.4: Structure of the dual family inhibitor TAK-285 with binding mode highlighting interactions with the glycine-rich 
loop. 
Tak-285, pictured above in Figure 4.4, is a dual ErbB inhibitor of EGFR and HER2 that has been investigated for 
breast, lung, gastric and prostate cancer.
2
 The pyrrolopyrimidine compound was designed to bind reversibly within 
the ATP cleft, displaying potent inhibition of wild-type and activating mutation bearing EGFR, HER2 and anti-tumour 
growth activity. The molecule exploits the hydrophobic pocket located behind the mutated Met790 residue, formed 
by side chains near the DFG motif, with a trifluoromethyl phenoxy back-pocket binding element. As Kamiyama and 
co-workers made use of 5H-pyrrolo-[3,2-d]pyrimidine as their heterocyclic scaffold, instead of the 7H-pyrrolo-[2,3-
d]pyrimidine used for lead compound 1, the driving group only formed a single hydrogen bond interaction with the 
Met793 residue in EGFR.
3
 This resulted in a nonoptimal hinge region hydrogen bonding pattern and consequent 
weak inhibitory activity against the L858R/T790M mutant. However, use of the 5H-pyrrolo-pyrimidine scaffold 
allowed the group to introduce various substituents at the N-5 position, such as the carboxamide moiety 
(Figure 4.4, blue) utilised for TAK-285. The terminal hydroxy moiety of long alkyl chain substituents were shown to 
form hydrogen bond interactions with the highly conserved glycine-rich loop (Figure 4.4, red), enhancing the 
reversible binding affinity of the inhibitor.
2
 Furthermore, derivatives bearing substituents on the N-5 position of the 
scaffold exhibited significantly more potent cellular growth inhibitory activity and improved metabolic stability.
2
  
One such derivative is the compound SYR127063, shown in Figure 4.5a on the following page, which retains the 
heterocyclic core and hydrophobic back pocket binding element of TAK-285. SYR127063 is structurally identical to 
TAK-285, with the exception of a 2-(2-hydroxyethoxy)ethyl chain substituent at the N-5 position (Figure 4.5a, blue). 
Incorporation of this glycol chain gave rise to favourable hydrogen bond interactions with the glycine-rich loop 
(Figure 4.5a, red) leading to superior biochemical inhibition of both EGFR and HER2 over TAK-285. Moreover, 
SYR127063 showed similar tumour cell growth inhibition activity, in vivo efficacy in tumour xenograft mouse models 
without body loss and excellent metabolic stability in mouse and human studies.
2
  
The desirable cellular activity, metabolic stability, pharmacokinetic profiles and in vivo antitumor efficacy of these 
two inhibitors proved to be a source of inspiration for the optimization of compound 1. It was postulated that 
incorporation of the 2-(2-hydroxyethoxy)ethyl of SYR127063 within the lead compound scaffold could be beneficial 
and lead to an improvement in the traits mentioned above. Through structural analysis we set out to determine the 
best positions on compound 1 to integrate the glycol chain and effectuate interactions with the glycine-rich loop. 
5 
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Figure 4.5: Structure and binding mode of a) TAK-285-derived compound SYR127063, b) Compound 3 with 2-hydroxyethoxy 
chain in an ortho-position to the acrylamide and c) Compound 4 with 2-hydroxyethyl chain at the N-position of the acrylamide 
(PDB: 3PPO). 
Through molecular modelling, it was found that incorporation of a 2-hydroxyethoxy motif in an ortho-position to 
the acrylamide (Figure 4.5b, compound 3, blue), would provide the highest likelihood to form interactions with the 
glycine-rich loop (Figure 4.5b, red) and enhance reversible binding affinity. The two-carbon spacer glycol chain was 
found to be optimal, able to avoid a steric clash and interact with the glycine-rich loop, while not interfering with 
the binding mode of the inhibitor. This would preserve the critically important hinge region interactions with Met793 
and covalent bond formation with Cys797. Similarly, inclusion of a 2-hydroxyethyl moiety directly onto the 
acrylamide (Figure 4.5c, compound 4, blue) was found to be an interesting prospect. Substitution on the N-position 
would not only provide the beneficial interactions proposed with compound 3, but potentially improve the 
warhead’s metabolic stability and reactivity towards covalent bond formation.4, 5  We therefore embarked on 
planning the synthesis of a library of lead-derived compounds bearing glycol chains at these desired positions.  
4.4 Objectives and Target Synthetic Combinatorial Library 
With the optimal positioning and length of the glycol chain substituents determined, we elected to make use of three 
variants based on the chain utilised in SYR12706. However, contrary to the terminal hydroxy functionality employed 
in this inhibitor, we chose to make use of a terminal ether functionality. We hypothesized that the additional electron 
donating effect, and thus electron density on the oxygen atom of the ether, would serve to form more favourable 
hydrogen bond interactions with the protonated glycine residues.
6
 The structures of these groups are highlighted in 
blue in Figure 4.6 and are namely 2-methoxyethyl, 1-methoxypropan-2-yl or 2-ethoxyethyl for the N-substituted 
position (Figure 4.6a, blue) and 2-methoxyethoxy, (1-methoxypropan-2-yl)oxy and 2-ethoxyethoxy for the ortho-
position (Figure 4.6b, blue). Our efforts were therefore focussed on synthesising a combinatorial library of 24 
compounds, where the investigation outputs were centred around three parameters.  
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Figure 4.6: Combinatorial synthetic library containing a) Series A – D, with the glycol chain installed on the N-position of the 
acrylamide and b) Series E – H, with the glycol chain in an ortho-position to the acrylamide. 
Firstly, effects of substitution of the glycol chains at either the N- or ortho-position of the acrylamide would be 
explored. We envisaged that the addition of these flexible groups would increase binding affinity by the formation 
of new reversible interaction with the glycine-rich loop, as discussed previously. The optimal total chain length and 
substitution pattern could thus be determined by the gains or losses in biochemical and cellular efficacy. Secondly, 
analogues of these compounds with and without the electrophilic Michael acceptor would be synthesised to 
specifically determine their potential as irreversible inhibitors of the T790M double mutant and as reversible 
inhibitors of the C797S triple mutant respectively. Lastly, the necessity of the phenyl methyl-piperazine solubilising 
group would be considered. The effects of its presence or absence on the scaffold, particularly with regards to cellular 
efficacy, would be scrutinised, indicating whether the addition of the glycol chain could be sufficient to replace it.  
From these considerations, a summary of the compounds to be synthesised can be seen in Figure 4.6 above. 
Figure 4.6a encompasses all compounds bearing the glycol chain moiety at the N-position of the acrylamide, while 
Figure 4.6b displays those at the ortho-position. From Figure 4.6a, series A and B would both bear the glycol chains 
(blue) without the solubilising group, and without and with the Michael acceptor (red), respectively.  
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Series C and D follow the same trend but with the presence of the solubilising group (green) for both. The conditions 
described were applied for series E – H in Figure 4.6b, with the exception of the glycol chains on the ortho-position 
of the acrylamide for this library. With the target combinatorial library and objectives outlined, we embarked on the 
synthesis of the compounds comprising series A – H.   
4.5 Combinatorial Library Synthesis  
4.5.1 Pyrrolopyrimidine Scaffold Synthesis 
The synthesis of the pyrrolopyrimidine core scaffold 10, shown in Scheme 4.1, had been previously completed in 
the synthesis of lead compound 1. However, several adjustments in reagents and reactions conditions implemented 
during the synthesis of this library of compounds, resulted in a fully optimized synthetic route. These modifications 
will be highlighted in the synthetic discussion that follows. Starting from the commercially available 4-chloro-
pyrrolopyrimidine 5, installation of an iodo functionality at the 5-position was undertaken using N-iodosuccinimide. 
While initial procedures employed acetonitrile as solvent, use of DMF in the absence of light provided a near 
quantitative yield of the iodinated compound 6, which was isolated after workup with no further purification 
required. Owing to its stability and frequent use in the protection of N-heterocycles, the 2-trimethylsilylethoxymethyl 
(SEM) group was selected as protecting group for the synthesis. Following deprotonation of the pyrrole nitrogen at 
the 7-position using sodium hydride in DMF, the SEM-group was attached affording compound 7 in a yield of 76%. 
This allowed us to introduce the sterically innocuous methoxy group at the electrophilic 4-position of the pyrimidine 
ring. While harsh conditions involving use of sodium methoxide were originally imposed, we found that simply 
stirring compound 7 in methanol with K2CO3 afforded compound 8 in excellent yields. Next, optimization of the 
Suzuki-Miyaura coupling was explicitly investigated, as this reaction would be required in other instances throughout 
the syntheses.  
 
 
 
 
 
 
 
Scheme 4.1: Five step synthesis of pyrrolopyrimidine core scaffold 10. Reagents and conditions: i) NIS (1.05 equiv.), DMF, rt, 
16 h; ii) NaH (1.17 equiv.), SEM-Cl (1.23 equiv.), DMF, −10 °C – rt, 16 h; iii) K2CO3 (2.2 equiv.), MeOH, rt, 16h; iv) (3-
nitrophenyl)boronic acid (1.2 equiv.), Pd(PPh3)4 (5 mol%), Na2CO3 (2.5 equiv.), dioxane/H2O (3:1), 80 °C, 16 h; v) Fe 
(5 equiv.), NH4Cl (1 equiv.), EtOH/H2O (1:1), ultrasonication at 60 °C, 6 h.  
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Use of multiple solvents, including toluene, ethanol, dioxane and water, in combination with either sodium or 
potassium carbonate, revealed the optimal reaction conditions for the coupling. We found that a 3:1 mixture of 
dioxane/water, a catalyst load of 5 mol% tetrakis(triphenylphosphine)palladium(0) and sodium carbonate serving as 
base, in a sealed schlenk at 80 °C, consistently provided yields above 90%. Furthermore, use of the freeze-pump-
thaw technique, typically requiring 3 – 5 cycles to sufficiently degas the solvent mixture prior to reaction, was found 
to be essential for complete consumption of the starting material 8. This provided the 3-nitrophenyl bearing 
pyrrolopyrimidine compound 9 in a yield of 92% and optimized reaction conditions for further application. Lastly, 
reduction of the aromatic nitro group was investigated using either Pd/C with ammonium formate/H2 gas or iron and 
ammonium chloride as reducing agents, while heated under reflux or ultrasonic agitation. Use of iron and 
ammonium chloride in a 1:1 mixture of ethanol/water, while undergoing ultrasonication at 60 °C, was found to be 
most robust and high yielding, affording compound 10 in an 86% yield after purification. This provided an 
economical and reliable route to the core scaffold, which could be carried out on a large scale of up to 20 g, allowing 
us to pursue the synthesis of the combinatorial library. 
4.5.2 Synthesis of Series A and B 
The first step in the synthesis of series A was the monoalkylation of the newly formed pyrrolopyrimidine-aniline 
structure 10 with our chosen glycol chain moieties. Initial attempts met with the sole formation of the undesired 
dialkylated product, necessitating optimization of reactions conditions and reagents to selectively afford the 
monoalkylated product. For this optimization, the 2-methoxyethyl chain was chosen for its structural simplicity, 
while exploring varying combinations of temperatures and heat sources, bases, solvents and leaving groups. Synthesis 
of the mesylated and tosylated 2-methoxyethyl fragments is shown below in Scheme 4.2. From the commercially 
available 11, reaction with either mesyl- or tosyl-chloride and Et3N serving as base in DCM, furnished compound 12 
and 13 respectively in excellent yields. Furthermore, once it was found that the tosyl-leaving group functionality 
provided the highest overall selectivity and yield in the monoalkylation reaction, the tosylated compounds 14 and 
15 were synthesized in a similar manner, for future use.  
Scheme 4.2: Synthesis of glycol ether chains 12 and 13 – 15 with mesyl- and tosyl-leaving groups respectively. Reagents and 
conditions: i) methanesulfonyl chloride (1.1 equiv.), Et3N (1.2 equiv.), DCM, −10 °C – rt, 16 h; ii) p-toluenesulfonyl chloride 
(1.1 equiv.), Et3N (1.2 equiv.), DCM, −10 °C – rt, 16 h. 
 
 
Stellenbosch University https://scholar.sun.ac.za
Chapter 4 – Lead Optimisation of Pyrrolopyrimidine-derived EGFR Inhibitors 
 
71 
 
Table 4.1: Optimization table for the monoalkylation of pyrrolopyrimidine scaffold 10. 
Optimization results for monoalkylation of fragment 10 is tabulated above in Table 4.1, with the mono- and 
dialkylated products 16 and 17 shown at the top. Early attempts using 2-chloroethyl methyl ether as electrophile 
with potassium carbonate or DIPEA as base in DMF at 110 °C under microwave irradiation afforded 17 as the major 
product with trace amounts of 16 (Entries 1 and 2). This included the use of potassium iodide to promote Finkelstein 
halogen exchange to potentially increase the reactivity of the electrophile. Use of sodium hydride at ambient 
temperature in Entry 3 resulted in the return of the starting material 10, with no reaction having taken place. We 
thus abandoned the use of microwave irradiation and pursued potassium carbonate as the base of choice for 
subsequent reactions. However, use of conventional heating at 100 °C in Entry 4 displayed a similar result to that of 
Entry 1, with only 12% of 16 being isolated.  
Stellenbosch University https://scholar.sun.ac.za
Chapter 4 – Lead Optimisation of Pyrrolopyrimidine-derived EGFR Inhibitors 
 
72 
 
We concluded that formation of the dialkylated product is favoured, owing to the inductive effect of the glycol chain. 
This increases the acidity of the amine and thereby the nucleophilicity of fragment 16 over the starting material 10. 
Consequently, this created a higher likelihood of a second nucleophilic attack by 16 on the glycol electrophile, 
resulting in the dialkylated 17 being driven over formation of 16. We therefore theorized that reducing the available 
amount of the alkyl halide might lessen the possibility for and occurrence of this second nucleophilic attack. 
Gratifyingly, when we reduced the 2-chloroethyl methyl ether used in the reaction to 0.66 equivalents (Entry 5), we 
saw a reversal in the product distribution, isolating 30% of 16 and a trace amount of 17. Moreover, as the leaving 
group moiety was the limiting reagent, we were able to isolate the excess starting compound 10 and recycle the 
recovered portions in successive reactions and calculate a yield base on the recovery of the starting material (BRSM).  
To further minimize the potential for a second nucleophilic attack and formation of 17, we also lowered the reaction 
temperature to 80 °C and decreased the amount of base used in Entries 6 and 7 respectively. This further reinforced 
our hypothesis, as the cumulative effects of lower temperature and base resulted in isolation of up to 41% of 16 with 
a BRSM yield of 69%. Interchange of DMF with acetonitrile as solvent in Entry 8 resulted in minor loss in the yield 
of compound 16, potentially ascribed to the slightly favoured attributes of DMF in promoting the SN2 reaction rate 
(lower dielectric constant and polarity).
7
   
Lastly, we proceeded to investigate the effect of a mesyl- or tosyl-leaving group on the mono- and dialkylated product 
substitution pattern. To our delight, reaction with the mesylated and tosylated 2-methoxyethyl glycol chain, shown 
in Entries 8 and 9, resulted in isolation of 33% and 60% of compound 16 and a BRSM yield of 63% and 82% 
respectively. Beneficially, the tosyl-functionality allowed for simple UV visualization on TLC and enhanced awareness 
of electrophile consumption rates and reaction completion time. Encouraged by this result, we continued with the 
tosylated glycol chain and doubled the reaction time in Entry 10, eliciting a 5% increase in the isolated yield to 65% 
and a BRSM yield of 90%. Based on the comprehensive optimisation parameters explored, the reaction conditions 
implemented in Entry 10 were deemed ideal and used in all subsequent monoalkylation reactions.  
After we had ascertained the optimal reaction conditions described above, compound 10 was accordingly 
monoalkylated with the previously synthesized tosylated glycol ethers 13 – 15, illustrated in Scheme 4.3, to afford 
compounds 16, 18 and 19 in good yield. Following this, acylation of these monoalkylated aniline fragments was 
executed seamlessly using acryloyl chloride and K2CO3 in THF at low temperature. This afforded the N-SEM 
protected, Michael acceptor containing compounds 20 – 22 in excellent yields and set the stage for deprotection of 
all previously synthesised compounds. N-SEM deprotection was accomplished by stirring in a 3:1 ratio of 
DCM/trifluoroacetic acid, followed by further stirring in a 1:1 ratio of a 1 M KOH/THF mixture after removal of the 
trifluoroacetic acid in vacuo. These conditions were applied to compound 10 to afford the simple aniline bearing 
pyrrolopyrimidine scaffold 23, as well as to 16, 18, 19 and 20 – 22, to afford the final compounds of series A and 
series B respectively, as seen in Scheme 4.3. Owing to the structural similarity of the final compounds of series A 
and B, and in the interest of saving time for the reader, the 
1
H and 
13
C spectra of compound 27 alone will be 
depicted and scrutinized. This system will be followed for the rest of this chapter and for the remaining series C - H 
in our combinatorial library. Full characterization of all compounds not discussed in this chapter, including 
1
H, 
13
C 
and HRMS analysis, can be accessed in the supplementary information (Section 4.10). 
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Scheme 4.3: Final synthetic steps including monoalkylation, acylation and deprotection to afford compounds 24 – 29 of series 
A and B. Reagents and conditions: i) 13 – 15 (0.66 equiv.), K2CO3 (1.5 equiv.), DMF, 80 °C, 32 h; ii) acryloyl chloride 
(1.2 equiv.), K2CO3 (1.5 equiv.), THF, −10 °C – rt, 6 h; iii) DCM/TFA (3:1), rt, 6 h, then 1 M KOH/THF (1:1), rt, 4 h. 
Examination of the 
1
H NMR spectrum, shown in Figure 4.7a, indicated formation of final compound 27. In the 
upfield region, we saw two singlets at δ 3.34 and 4.09 ppm, corresponding to the glycol (orange) and pyrimidine 
(green) methoxy groups respectively. In between these two sets of singlets, we saw two triplets at δ 3.64 and 4.05 
ppm, which correlated to the ethylene bridge of the glycol chain (dark blue). Moving downfield, the characteristic 
acrylamide signals were seen between δ 5.55 and 6.41, comprising of two doublets and a doublet of doublets (red). 
Owing to the absence of any silyl group signals at δ 0.00 ppm, and the presence of a broad singlet at δ 12.4 ppm 
(purple) which belonged to the pyrrole amine proton, we could consider the deprotection of the N-SEM protecting 
group as going to completion.  
Inspection of the 
13
C NMR spectrum in Figure 4.7b further reinforced the structural findings of the 
1
H spectrum, 
with four distinct peaks present in the aliphatic region. Working from NMR spectra of precursory structures and 
visual comparison of the peak intensity, the pyrimidine (Figure 4.7b, green) and glycol methoxy carbons signals 
could be assigned to δ 53.9 and 58.6 ppm respectively. The glycol bridge carbon signals (dark blue) were found at 
δ 48.9 and 69.4 ppm. The appearance of a signal in the furthest downfield region at δ 165.9 ppm signified the 
carbonyl carbon of the acrylamide.  
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All undiscussed proton signals were correctly accounted for, yielding anticipated integration values and splitting 
patterns. Furthermore, 18 of the 19 carbon signals could be accounted for, while the remaining absent signal was 
ascribed to a quaternary carbon and the slow relaxation times of these centres. Additionally, use of HRMS analysis 
presented a [M+H]
+
 ion of 353.1612, with a calculated mass of 353.1614, providing final confirmation for the 
successful synthesis of compound 27. Similar results were obtained for the remaining final compounds of series A 
and B, affirming the successful synthesis thereof.  
Figure 4.7: a) 
1
H and b) 
13
C NMR spectra of final compound 27. 
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4.5.3 Synthesis of Series C and D 
 
 
 
 
 
 
 
 
Scheme 4.4: Three step synthesis of the solubilising group containing pyrrolopyrimidine core structure 32. Reagents and 
conditions: i) NBS (1.05 equiv.), DCM, rt, 16 h; ii) 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]piperazine (1.2 equiv.), Pd(PPh3)4 (5 mol%), Na2CO3 (2.5 equiv.), dioxane/H2O (3:1), 80 °C, 16 h; iii) Fe (5 equiv.), 
NH4Cl (1 equiv.), EtOH/H2O (1:1), ultrasonication at 60 °C, 6 h. 
Following the successful synthesis of series A and B, carried out with the established monoalkylation reaction 
conditions, we set about synthesising series C and D which would contain the phenyl methyl-piperazine solubilising 
group shown in green in Scheme 4.4 above. Starting from the previously synthesised compound 9, selective 
bromination at the 6-position was accomplished using NBS as our source of electrophilic bromine in DCM to afford 
compound 30 in excellent yield. This allowed for coupling of compound 30 with 1-methyl-4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl]piperazine using the optimized Suzuki-Miyaura reaction conditions, furnishing 
compound 31 in outstanding yield with the solubilising group shown in green. Lastly, reduction of the aromatic nitro 
group was achieved using iron and NH4Cl under sonication at 60 °C to supply us with the core structure 32, which 
would be used for further derivatization.  
The concluding steps in the synthesis of the final compounds of series C and D were undertaken in an analogous 
manner to that of series A and B and can be seen in Scheme 4.5. These steps included the monoalkylation of core 
structure 32 with the tosylated glycol ethers 13 – 15, to afford the intermediate compounds 33 – 35. This was 
followed by the acylation of these monoalkylated aniline fragments with acryloyl chloride to install the Michael 
acceptor moiety and provide the N-SEM protected final compounds 36 - 38. Deprotection of the N-SEM 
functionality was accomplished using TFA and KOH successively for all compounds, to provide the final compounds 
40 – 42 and 43 – 45 of series C and D respectively. 1H and 13C NMR spectroscopic analysis of final compound 43 
follows. 
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 Scheme 4.5: Final synthetic steps including monoalkylation, acylation and deprotection to afford final compounds 40 – 45 of 
series C and D. Reagents and conditions: i) 13 – 15 (0.66 equiv.), K2CO3 (1.5 equiv.), DMF, 80 °C, 32 h; ii) acryloyl chloride 
(1.2 equiv.), K2CO3 (1.5 equiv.), THF, −10 °C – rt, 6 h; iii) DCM/TFA (3:1), rt, 6 h, then 1 M KOH/THF (1:1), rt, 4 h. 
Inspection of the 
1
H and 
13
C NMR spectra of compound 43, which can be seen in Figure 4.8 on the following page, 
revealed related signals corresponding to the same structural elements present in final compound 27, which 
appeared at similar chemical shifts for compound 43. For the 
1
H NMR spectrum, shown in Figure 4.7a, this included: 
the two singlets of the glycol (orange) and pyrimidine (green) methoxy groups, two sets of triplets which correlated 
to the ethylene groups of the glycol chain (dark blue), the three unsaturated protons of the Michael acceptor visible 
as three doublet of doublets (red) and the downfield pyrrole amine proton (purple). Furthest upfield at δ 2.42 ppm 
we saw the appearance of a tall singlet assigned to the N-methyl group of the piperazine group (yellow). Furthermore, 
the emergence of two triplets integrating for 4H at δ 2.46 and 3.28 ppm made up the remainder of the cyclic 
piperazine (light blue).  
Similarly, the previously assigned carbon signals which were discussed for compound 27 were evident in the 
13
C 
NMR spectrum of compound 43, shown in Figure 4.8b. These included the two methoxy methyl carbons (green 
and orange), glycol ethylene carbons (dark blue) and the carbonyl carbon of the acrylamide (red). New peaks 
included the carbon at δ 46.0 ppm, which was assigned to the N-methyl piperazine carbon (yellow), and the four 
remaining carbons of the cyclic piperazine structure, which appeared as a pair of high-intensity signals at δ 48.0 and 
54.8 ppm owing to the symmetry of the solubilising group (light blue).  
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This was equally apparent for the phenyl linker, whose two signals occurred at δ 115.6 and 129.0 ppm in the 
aromatic region (purple). As with analysis of compound 27, all unassigned protons and carbons within the spectra 
were correctly accounted for, with use of HRMS analysis presenting a [M+H]
+
 ion of 527.2773, with a calculated 
mass of 527.2777. This providing final confirmation for the successful synthesis of compound 43, and in a similar 
manner, the other compounds comprising series C and D.   
 
Figure 4.8: a) 
1
H and b) 
13
C NMR spectra of final compound 43. 
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4.5.4 Synthesis of Series E and F 
Scheme 4.6: Two step synthesis of the glycol ether-containing pyrrolopyrimidine intermediates 47 – 49. Reagents and 
conditions: i) (4-fluoro-3-nitrophenyl)boronic acid (1.2 equiv.), Pd(PPh3)4 (5 mol%), Na2CO3 (2.5 equiv.), dioxane/H2O (3:1), 80 
°C, 16 h; iii) glycol ether derivative (1.2 equiv), NaH (1.7 equiv.), THF, −10 °C – rt, 16 h. 
The final compounds comprising series E – H required installation of the glycol chain in an ortho-position to the 
aniline or Michael acceptor moiety. To accomplish this, we envisaged making use of a nucleophilic aromatic 
substitution reaction. By coupling the commercially available (4-fluoro-3-nitrophenyl)boronic acid to the previously 
synthesised 8, we would place a fluorine atom in the correct position to undergo the SNAr reaction and allow for 
introduction of the glycol ether chains, as outlined in Scheme 4.6 above. As fluorine is highly electronegative, the 
reaction rate for nucleophilic attack would be increased by its activation of the electrophilic aromatic carbon. 
Furthermore, this reaction centre would be ortho to the strongly electron-withdrawing nitro group, further activating 
the ring towards nucleophilic attack by the alkyl alcohol. Carrying out the coupling of compound 8 to (4-fluoro-3-
nitrophenyl)boronic acid under the optimised Suzuki-Miyaura conditions provided compound 46 in high yield. 
Interestingly, the 
13
C NMR spectrum of 46 showed splitting for the aromatic carbons neighbouring the fluorine atom, 
with a total of five signals split into doublets. This also indicated that the fluorine atom had survived the high 
temperature and palladium catalyst used in the prior boronic acid coupling. Subsequent SNAr reaction of the 
commercially available alkyl alcohols shown in Scheme 4.6 with 46, using sodium hydride as base, furnished the 
intermediate compounds 47 – 49 in good yield.  
With the above synthesized intermediates in hand, we embarked on the final steps in the synthesis of series E and 
F, shown in Scheme 4.7 on the next page. Aromatic nitro reduction of compounds 47 – 49, using the previously 
established conditions of iron and ammonium chloride, provided the ortho-glycol aniline fragments 50 – 52 in 
excellent yield. Subsequent acylation of these aniline fragments with acryloyl chloride installed the Michael acceptor 
moiety and afforded the protected final compounds 53 – 55. Deprotection of the N-SEM group of both sets of 
compounds, 50 – 52 and 53 – 55, furnished the final compounds 56 – 58 and 59 – 61, of series E and F, respectively.  
Due to the structural similarity of these compounds to those synthesised in series A and B, only the 
1
H NMR spectrum 
of compound 59 will be interpreted and displayed on the following page in Figure 4.9. Comparable to the spectral 
analysis of compound 27, compound 59 retained the two signals of the glycol and 4-pyrimidine position methoxy 
protons (orange and green respectively), with the three sets of signals between δ 5.75 and 6.45 ppm corresponding 
to the acryl group protons (red) and the pyrrole amine proton far downfield at δ 11.3 ppm.  
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 Scheme 4.7: Final synthetic steps of reduction, acylation and deprotection to afford compounds 56 – 61 of series E and F. 
Reagents and conditions: i) Fe (5 equiv.), NH4Cl (1 equiv.), EtOH/H2O (1:1), ultrasonication at 60 °C, 6 h; ii) acryloyl chloride 
(1.2 equiv.), K2CO3 (1.5 equiv.), THF, −10 °C – rt, 6 h; iii) DCM/TFA (3:1), rt, 6 h then 1 M KOH/THF (1:1), rt, 4 h. 
Figure 4.9: 
1
H NMR spectra of final compound 59.   
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However, where the glycol ethylene proton peaks occurred between the two methoxy signals in compound 27, we 
saw a shift in one ethylene triplet (dark blue) to a position further downfield than the pyrimidine methoxy (green) in 
the spectrum of compound 59. This could be attributed to the additional electron-withdrawing effects of direct 
substitution on the aromatic ring and the presence of the extra electronegative oxygen atom in the glycol ether chain. 
All other aromatic protons and carbon signals within the 
13
C NMR spectrum were fully accounted for. Finally, use of 
HRMS analysis presented a [M+H]
+
 ion of 369.1560, with a calculated mass of 369.1563, providing confirmation 
for the successful synthesis of compound 59 and, in a similar fashion, the remaining compounds of series E and F.   
4.5.5 Synthesis of Series G and H 
With the ortho-glycol derivatised, aromatic nitro-containing intermediates 47 – 49 in hand, the first steps in the 
synthesis of series G and H was incorporation of the phenyl methyl-piperazine solubilising group onto these scaffolds, 
as illustrated in Scheme 4.8. This required selective bromination at the 6-position, which was accomplished using 
NBS in DCM, affording compounds 62 – 64 in moderately good yield. Next, the Suzuki-Miyaura reaction was 
successfully undertaken, coupling the pinacol boronic ester of the solubilising group to compounds 62 – 64, thereby 
yielding the intermediate compound 65 – 67 shown below in Scheme 4.8.  
The concluding steps in the synthesis of the ultimate two series of compounds followed a similar pattern used 
previously and is shown in Scheme 4.9 on the following page. This included reduction of the aromatic nitro group, 
subsequent acylation of the formed aniline and deprotection. Thus, the reduction of compounds 65 – 67 was 
achieved by sonication with a mixture of iron and ammonium chloride, furnishing the three aniline fragments 68 – 
70, followed by acylation with acryloyl chloride to provide the protected compounds 71 – 73. Lastly, deprotection 
of the N-SEM functionalised compounds 68 – 73, using TFA and KOH, supplied us with the final compounds 74 – 
76 and 77 – 79, comprising of series G and H respectively.  
 
 
 
 
 
 
 
 
Scheme 4.8: Two step synthesis of the solubilising group containing pyrrolopyrimidine intermediates 65 – 67. Reagents and 
conditions: i) NBS (1.05 equiv.), DCM, rt, 16 h; ii) 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]piperazine (1.2 equiv.), Pd(PPh3)4 (5 mol%), Na2CO3 (2.5 equiv.), dioxane/H2O (3:1), 80 °C, 16 h; 
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Scheme 4.9: Final synthetic steps including reduction, acylation and deprotection to afford compounds 74 – 79 of series G 
and H. Reagents and conditions: i) Fe (5 equiv.), NH4Cl (1 equiv.), EtOH/H2O (1:1), ultrasonication at 60 °C, 6 h; ii) acryloyl 
chloride (1.2 equiv.), K2CO3 (1.5 equiv.), THF, −10 °C – rt, 6 h; iii) DCM/TFA (3:1), rt, 6 h then 1 M KOH/THF (1:1), rt, 4 h. 
 
Figure 4.10: 
1
H NMR spectra of final compound 77.   
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As implemented before with compound 59 of series F, the 
1
H NMR spectrum of final compound 77 will be discussed 
exclusively and is displayed in Figure 4.10 on the previous page. The shared structural signatures found in all 
compounds analysed thus far were evident in the 
1
H spectrum of compound 77. Furthest upfield we saw the N-
methyl piperazine singlet (yellow) and the two triplets comprising the remainder of the piperazine heterocycle (light 
blue). Moving downfield, the glycol methoxy peak (orange) occurred at δ 3.45 ppm and, following the substitution 
pattern of that seen in compound 59, we saw the two triplets of the ethylene glycol bridge (dark blue) flanking the 
pyrimidine methoxy (green). The acryl group protons (red) could be seen in the region between δ 5.70 and δ 6.40 
ppm and the pyrrole amine proton appeared as a broad singlet at δ 13.1 ppm. In line with previous spectroscopic 
analyses, all undiscussed aromatic protons and carbon signals within the 
13
C NMR spectrum were fully accounted 
for. Furthermore, use of HRMS analysis presented a [M+H]
+
 ion of 543.2717, with a calculated mass of 543.2720,  
providing final confirmation for the successful synthesis of compound 77. These analytical considerations were 
reflected in the remaining compounds of series G and H, affirming the successful synthesis thereof. 
This concluded the synthesis of our combinatorial target library, affording 26 final compounds which were evaluated 
in biochemical and cellular assays and will be discussed comprehensively in the next section.  
4.6 Biochemical and Cellular Evaluation  
Owing to the multitude of compounds encompassing the synthesised library, we chose to analyse the biochemical 
and cellular data acquired by firstly discussing and comparing similar structural features in a series vs series manner. 
This would be followed by selecting the most efficacious inhibitors in each of these comparative analyses and 
combining them to provide an overview of the results. By this method, we first compared compounds which do not 
contain the electrophilic acrylamide functionality, to determine the factors that promote favourable reversible 
inhibition. This means that series A vs C (directly substituted, without vs with solubilising group) and series E vs G 
(ortho-substitution, without vs with solubilising group) were scrutinized. Based on these results, the most potent 
reversible inhibitors, and their desirable structural features, could be identified. This same process was repeated for 
the series of compounds which contain the Michael acceptor moiety and could potentially act in an irreversible 
manner. Lastly, we provided an overview of the most efficacious reversible vs irreversible inhibitors, placing emphasis 
on the activity of the compounds against the double and triple mutant variant.  
To determine efficacy in a biochemical setting, the compounds were evaluated against the wild-type, activating 
L858R, double L858R/T790M and triple L858R/T790M/C797S mutant variants of the enzyme. For the cellular tests, 
we employed a wild-type-bearing cell line A431, the EGFR-L858R/T790M drug-resistant cell line H1975 and 
clinically relevant osimertinib resistant cell line EGFR-PC9/T790M/C797S. Compound assessment was carried out 
either by Dr. Jonas Lategahn or Dr. Marina Keul, with all measurements being executed in at least triplicate. The 
respective IC50 and EC50 values of osimertinib and lead compound 1 accompany the obtained results in each report.  
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4.6.1 Comparison of Reversible Inhibitors  
Table 4.2: Comparison of the scaffolds 23 and 39 and inhibitors 24 – 26 and 40 – 42 from series A and C respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examination of the activity profiles for the directly substituted glycol compounds of series A and C, as well as their 
unsubstituted aniline counterparts 23 and 39, revealed some interesting trends with regards to the presence or 
absence of the solubilising group and is shown in Table 3.2 above. The unsubstituted pyrrolopyrimidine aniline 
compound 23, which does not bear the solubilising group, showed very little reversible inhibition both in a 
biochemical and cellular setting. This trend was followed in the glycol substituted compounds of series A (24 – 26), 
which also do not contain the solubilising group, showing high micromolar biochemical activity against the triple 
mutant and displaying none against the double mutant in a cellular evaluation. This warranted the absence of 
screening this series against the triple mutant cell line. In contrast, we saw a large spike in activity for the compounds 
which do contain the solubilising group. The unsubstituted aniline pyrrolopyrimidine compound 39 displayed a 
dramatic increase in activity against all variants biochemically when compared with its counterpart 23. An IC50 value 
of 12 nM was found against the triple mutant - a 10- and 4-fold superiority over osimertinib and the lead compound 
1 respectively. This trend was followed in the cellular context, with low micromolar EC50 values in all cell lines and 
a 2-fold increase over osimertinib against the triple mutant. This highlighted the exemplary reversible binding affinity 
of the core pyrrolopyrimidine scaffold and the importance of the solubilising group in both cell permeability and 
promoting potent reversible interactions by anchoring the molecule in the correct orientation within the active site. 
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The weak activity against the EGFR-L858R-T790M mutant was largely expected, owing to the absence of the 
electrophilic acrylamide and the inability to covalently inhibit the enzyme.  
The directly substituted glycol variants of compound 39, which make up series C, showed similarly impressive 
reversible activity. Biochemically, compounds 40 – 42 showed sub-nanomolar IC50 values for the activating L858R 
mutant and single digit IC50 values for the T790M double mutant, even with the exclusion of the Michael acceptor. 
These compounds retained their remarkable activity against the triple mutant, with compound 40 and 41 showing 
single digit IC50 values of 1.50 and 9.27 nM respectively. We discerned that increased length and substitution of the 
glycol chain led to a loss of activity, as was exemplified by the decreased activity for compounds 41 and 42 when 
compared with 40. This notion was further supported in the cellular evaluation of compounds 40 and 41 against the 
triple mutant, displaying a similar drop in activity with increasing substitution. Importantly, both compounds 39 and 
40 showed improved cellular activity over osimertinib against this mutant variant.   
When comparing the biochemical results of the core compound 39 with the 2-methoxyethyl substituted 
pyrrolopyrimidine 40, we saw that compound 40 had a 6-fold greater activity against the triple mutant. Conversely, 
the same comparison in a cellular evaluation revealed compound 39 showing slightly better activity than its 
substituted counterpart 40. This alluded to the potential instability and ill tolerance of the glycol chain moieties 
within the cell. From the above comparison we could thus conclude that the solubilising group is extremely important 
for reversible inhibition activity, as well as shorter, less-substituted glycol chains being favoured.  
Similarly, we wished to see the effect of ortho-substitution of the glycol chain moieties on our pyrrolopyrimidine 
based inhibitors activity. The results, which can be seen on the following page in Table 4.3, mirror the findings of 
Table 4.2, with a large discrepancy in inhibition based on the absence or presence of the solubilising group, poor 
activity against the T790M double mutant and strong biochemical inhibition for series G against the C797S triple 
mutant. Furthermore, the trend of decreasing activity with increased glycol chain length and substitution was 
repeated, with compounds 75 and 76 (additional methyl substituent and longer glycol chain respectively) showing 
a decrease in biochemical efficacy across all variants of the enzyme. This reinforced the conclusions drawn in our 
previous comparison. Owing to its biochemical efficiency, we chose to evaluate compound 74 against the triple 
mutant cell line which displayed an EC50 value of roughly 3 µM and a minor increase in activity over osimertinib. 
Lastly, a comparison was drawn between the most efficacious directly and ortho-substituted reversible inhibitors to 
determine the optimal position of the glycol chain. These included the core scaffold 39 and compounds 40 – 42 
and 74 – 76 of series C and G respectively. Visual inspection of these values in Table 4.4 on the following page, 
showed that the directly substituted series C exhibited a more favourable activity profile than series G, with 
compound 40 foremost of all the reversible inhibitors synthesised. Between these series, compound 40 exhibited 
the greatest inhibitory activity against the triple mutant both biochemically and in a cellular context and was the only 
molecule to show selectivity for mutant variants of EGFR over the wild-type enzyme. However, it is important to 
note that the unsubstituted scaffold 39 retained the highest activity against the triple mutant cell line, which 
unfortunately underlines the inefficiency of our synthesised glycol-chain derivatised pyrrolopyrimidines in a cellular 
setting. With the reversible inhibitor’s efficacy investigated, we turned our attention towards the synthesised Michael-
acceptor containing compounds. 
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Table 4.3: Comparison of reversible inhibitors 56 – 58 and 74 – 76 from series E and G respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4: Comparison of reversible inhibitors 40 – 42 and 74 – 76 from series E and G respectively. 
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4.6.2 Comparison of Potentially Irreversible Inhibitors  
The same method of comparison used previously for the reversible inhibitors was applied to the potentially 
irreversible compounds. Accordingly, the activities of the directly substituted glycol-moiety, acrylamide-containing 
compounds, with or without the solubilising group, can be seen in Table 4.5 below. The first observable trend 
concerned the effects of the solubilising group in series B and D. Once again, we saw the distinct requirement of 
the solubilising group in sustaining potent inhibitory activity, with compounds 27 – 29 showing poor to almost no 
activity against EGFR-L858R/T790M biochemically and in cells. We therefore disregarded further investigation and 
discussion for the compounds of series B. Examination of the inhibitory concentrations for compounds 43 – 45, 
which comprise series D, reflected an immense increase in inhibition of the double mutant, with IC50 values in the 
low picomolar range. This elevated activity suggested irreversible inhibition through the Michael acceptor, with 
supplementary reversible interactions and binding affinity promoted by the glycol chains. Interestingly, the 
biochemical results for the activating and double mutant of the irreversible compounds did not follow the trend of 
decreasing activity with increasing substitution. Compound 44, which bears the 1-methoxypropan-2-yl chain, 
displayed the highest activity, with an IC50 of 70 pM, a 3- and 8-fold increase in activity over the lead compound 1 
and osimertinib respectively, as well as enhanced selectively over the wild-type enzyme. We believe the unique 
methyl substituent of this glycol chain could interact sterically with the proximal acryl amide electrophile, promoting 
a favourable orientation specifically for covalent bond formation with Cys797. In contrast, we saw a reversal of this 
trend against the triple mutant, with the short chain derivatised compound 43 being the most efficacious inhibitor 
with an IC50 value of 86 nM. This further substantiated our proposal, as covalent bond formation with this electrophile 
is not possible with the serine bearing triple mutant, negating the positive effect of the methyl substituent.  
Table 4.5: Comparison of irreversible inhibitors 27 – 29 and 43 – 45 from series B and D respectively. 
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Moving to the cellular evaluation, we witnessed a slight loss of activity for the compounds of series D in the T790M 
mutation-bearing H1975 cell line, when measured against lead compound 1. This was a disappointing result, as we 
anticipated an increase in activity for these compounds, as exhibited by their biochemical data. We surmised that 
this decline in activity was consequent of the cell’s intolerance towards the glycol moiety. Considering its superior 
cellular selectivity profile and biochemical inhibition properties, we incubated compound 44 within C797S triple 
mutant bearing cells but were dismayed to see a dramatic drop in activity, resulting in an EC50 value of over 17 µM. 
While a loss of activity for the resistant triple mutant was in keeping with our expectations, we did not foresee a 6- 
and 7-fold decrease when compared to osimertinib and the leading reversible inhibitor 40 respectively. As 
exemplified previously with our reversible compounds, the cells are averse to the inclusion of the glycol moiety. 
Additionally, the C797S mutation has shown strong resistance profiles to compounds bearing the acrylamide 
functionality specifically, such as osimertinib and olmutinib. We therefore speculated that this loss of efficacy could 
be attributed to a combination of the poor pharmacokinetic character of the glycol chain and unfavourable 
interactions of the acrylamide group with the mutated serine residue. 
Proceeding to the ortho-substituted, acrylamide-containing compounds of series F and H, shown in Table 4.6 on 
the following page, we see similar trends to those found in previous analyses.  While the exclusion of the solubilising 
group resulted in inactivity of series F in a cellular context, the compounds performed surprisingly well in their 
biochemical evaluation against the L858R/T790M mutant, with compound 60 having an IC50 value of 22 nM. 
Without the anchoring ability of the solubilising group present, we hypothesized that placement of the glycol group 
in an ortho-position provided sufficient reversible interactions to orient the molecule into the correct position for 
potential covalent modification of the cysteine residue. The compounds of series H, which included the solubilising 
group, showed remarkable activity in a biochemical setting with IC50 values in the low picomolar range against the 
double mutant. As expected, we see a sharp decrease in activity against the triple mutant for compounds 77 – 79. 
With the glycol chain no longer directly substituted, the methyl substituent of 78 was presumed to be too far from 
the acryl amide electrophile to have any steric effect. This was reflected in the biochemical data, with compound 
77 outperforming both 78 and 79 against both the double and triple mutant. This alluded to less substituted, shorter 
glycol chains being more advantageous for the ortho-substitution.  
Focussing on the cellular data, we saw an even larger decrease in EC50 activity against the L858R/T790M cell line for 
compounds 77 – 79, reflecting the results of series D. Furthermore, the pronounced loss of activity against the triple 
mutant for compounds 78 and 79, eliciting high micromolar EC50 values, indicated the irrelevance of the glycol chain 
substitution position when targeting this mutant variant. This further augmented our hypothesis of a poor 
pharmacokinetic profile for these glycol-derivatised molecules, when in combination with the acrylamide group. 
Notably, compound 77 showed an exceptional selectivity profile for the double mutant over the wild-type enzyme, 
with EC
50
 values of 298 nM and 27 µM respectively, equating to a 100-fold difference in inhibitory concentration. 
To conclude, we compared the compounds of series D and H to determine the most efficacious irreversible inhibitor, 
as seen in Table 4.7 on the following page. Whilst all compounds showed excellent biochemical inhibition, the 
directly substituted compounds of series D proved to be predominantly more potent than their ortho-positioned 
counterparts across all assays.  
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Table 4.6: Comparison of irreversible inhibitors 59 – 61 and 77 – 79 from series F and H respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7: Comparison of irreversible inhibitors 43 – 45 and 77 – 79 from series D and H respectively. 
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We postulated that the superior EC50 values of series D could be ascribed to a stabilising effect imparted by direct 
substitution of the glycol moiety on the acrylamide, resulting in a greater tolerance and stability of the chain. 
Consistent with previous measurements of our library of compounds, the shorter chain compounds of 43, 44 and 
77 proved to be the most efficacious, with compound 77 particularly displaying an exemplary selectivity profile.  
4.6.3 Further Evaluation of Optimal Irreversible Inhibitors 
While the synthesised irreversible inhibitors proved to be ineffectual against the clinically relevant C797S triple 
mutant, their admirable activities both biochemically and against the cell lines of the L858R and L858R/T790M 
mutant variants, warranted further investigation. Furthermore, as AEE788 formed the core scaffold structural basis of 
our library and is a dual EGFR-HER2 inhibitor, we wished to determine the potential efficacy of these compounds 
against HER2. We therefore opted to evaluate these compounds against four additional NSCLC cell lines, consisting 
of two EGFR and two clinically relevant HER2-altered NSCLC mutant cells. For EGFR, we made use of A549 cells, 
which are characterized as adenocarcinoma of the human alveolar basal epithelial cells and the EGFR-delE746_A750 
activating mutation-carrying HCC827 cells. A549 cells contain KRAS mutations and have found use in examination 
of metabolic processing and mechanisms of drug delivery to lung tissue.
8
 H1781 and BaF3 HER2-insYVMA are cells 
found in lung cancers harbouring HER2 oncogene alterations, specifically insertion mutations within the G775_G776 
region of exon 20. Ba/F3 cells are an increasingly popular tool and have gained increased use in kinase drug 
discovery, being adapted to high-throughput assay formats for candidate profiling. Furthermore, these cells have 
shown promise in predicting clinical resistance elicited by point mutations which interfere with inhibitor binding, 
providing invaluable data for drug development.
9
 The results of these assays may be seen in Table 4.8 below. 
Table 4.8: Evaluation of the irreversible inhibitors 43 – 45 and 77 – 79 from series D and H respectively against NSCLC and 
HER2 cell lines. 
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Examination of the supplementary EGFR A549 cellular results once again revealed the distinctive trend of more 
substituted and longer chain glycol functionalities resulting in increased EC50 values. All compounds of series D and 
compound 77 exhibited superior activity compared to osimertinib, with compound 43 and 77 reaching up to 2-fold 
greater inhibition of the KRAS mutant cells. The resolution limit of 14 nM was reached with all but one compound 
when measured against the HCC287 cell line, displaying their potency against the single activating mutant. This was 
encouraging to us, as it showed that in nearly all cells, excluding the PC9/T790M/C797S triple mutant, the glycol 
chain moieties seemed to be well facilitated.  
We were gratifyingly met with appealing activity profiles for the compounds of series H upon inspection of the HER2 
cellular evaluation. While series D showed similar potency to osimertinib, compounds 77 – 79 all presented superior 
EC50 values close to 100 nM. For compound 77, this equated to a 5-fold greater affinity against the H1781 HER2 
mutant cells in comparison to osimertinib and lead compound 1, with an EC50 value of 357 nM (not displayed). 
Although the pronounced gain in activity was not carried over to the BaF3 cells, good EC50 values were maintained 
for compounds 43, 77 and 78, highlighting their resilience towards potential resistance mutations. We correlated 
the compounds increased HER2 activity to the core scaffolds native dual HER2 inhibitory properties and due to TAK-
285 and SYR127063, the molecules we initially drew inspiration from for glycol chain derivatisation, being dual 
EGFR/HER2 inhibitors as well. We postulated that the incorporation of glycol chain moieties is most beneficial in 
targeting HER2, thus exhibiting the potential for further development of these compounds as HER2 inhibitors.  
4.7 Crystal Structure of Compound 77 
Taking into consideration the entirety of all inhibitors synthesised in our combinatorial library, compound 77 was 
shown to be consistently efficacious whilst maintaining an attractive selectivity profile. These results are summarized 
on the next page and notably include excellent activity against both the EGFR-L858R/T790M and HER2 mutant 
variants. For this reason, compound 77 was selected to attempt the formation of an enzyme-inhibitor complex, and 
to solve its subsequent crystal structure. This could provide valuable insight into the binding mode of the 
pyrrolopyrimidine scaffold, such as whether it undergoes covalent bond formation and illustrating any contributing 
interactions from the ortho-substituted glycol moiety.  
Although the research group of Professor Rauh has succeeded in solving a series of complex crystal structures for the 
drug resistant mutant EGFR-T790M, compound 77 did not furnish crystals suitable for the collection of high-
resolution diffraction data. Therefore, we decided to solve the structures in complex with the engineered cSrc-
T338M/S345C enzyme, which has previously been successfully used as a surrogate for the EGFR-T790M mutant.
10, 11
 
In this engineered c-Src enzyme, Thr338 is mutated to a methionine residue and Ser345 is mutated into a cysteine 
residue, corresponding to Met790 and Cys797respectively. This composition mimics the EGFR-T790M mutant, with 
a bulky methionine group providing the characteristic steric interference at the gatekeeper position and the 
nucleophilic cysteine allowing for potential covalent modification. The inhibitor was therefore co-crystallised with 
cSrc-T338M/S345C, illustrated in Figure 4.11, through incubation with an excess of compound 77, allowing for 
enzyme-inhibitor complexation prior to crystallisation, followed by crystal growth using the hanging-drop method.  
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Table 4.9: Summary of the selectivity and activity profile for compound 77.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Co-crystal structure of compound 77 with the model cSrc-T338M/S345C system. 
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The refined structure of compound 77 within the cSrc-T338M/S345C enzyme reveals a binding mode comparable 
to that of lead compound 1, with the pyrrolopyrimidine heterocycle forming bidentate hydrogen bonds with 
Met341. It is important to note that, the hinge region Met341 residue of cSrc-T338M/S345C corresponds to Met793 
of the EGFR-T790M protein kinase. Covalent bond formation between the acrylamide and Cys345 was confirmed 
by clear cluster of electron density in this region, as shown in Figure 4.11, establishing this compound as an 
irreversible inhibitor. The ortho-substituted glycol chain moiety can be seen extended towards the glycine-rich loop 
(Figure 4.11, red), potentially interacting with the amino acid residues. We believe it is these Van der Waals forces 
that account for the increased biochemical potency of compound 77, over the lead compound 1. Owing to its 
proximity, it is evident that an increase in the length of the glycol chain could cause steric clashes with the glycine-
rich loop. Furthermore, this could lead to an unfavourable inhibitor orientation within the active site, reducing 
binding affinity and in a worst-case scenario, preventing covalent bond formation. This substantiates the general 
trend of a loss in activity associated with the longer chain glycol derivatives synthesized.  
The methyl-piperazine solubilising group protrudes outwards into the solvent exposed end, anchoring the inhibitor 
within the binding cleft. We believe the presence of the solubilising group ensures proper reversible binding of the 
pyrrolopyrimidine scaffold with the hinge region, corroborating the marked loss in activity in compounds where the 
group is absent. Lastly, we see the pyrimidine methoxy group being able to avoid the steric clash with the gatekeeper 
Met338 residue, which corresponds to the Met790 residue in the EGFR-T790M mutant. Notably, the binding mode 
of compound 77 reveals that this position may serve as a platform for further derivatisation. Investigating the use of 
longer alkyl chains, which may also act as linkers for groups able to fill the conserved hydrophobic specificity pocket 
found in most protein kinases, might therefore be an interesting prospect.   
4.8 Conclusions 
The body of work described in this chapter set out to optimise and explore the effects of glycol chain derivatisation, 
alongside the presence or absence of the optimised methyl piperazine solubilising group and acrylamide moiety, on 
lead compound 1. In doing this, we wished to gain efficacy and selectivity against the T790M and C797S mutant, 
by optimizing the compounds as irreversible and reversible inhibitors respectively.  Inspired by the dual EGFR/HER2 
inhibitors of TAK-285 and SYR127063, various chain lengths, ether functionalities and substitution positions were 
investigated. This led to the synthesis of a combinatorial library comprising of 26 final compounds in 8 different 
series (A-H). Numerous reactions were optimized throughout the synthesis, including the Suzuki-Miyaura coupling, 
aromatic nitro reduction and aniline-derivative monoalkyation reactions, providing products in excellent yields and 
the viability of a multigram synthesis.  
The final compounds were evaluated against multiple mutant variants of EGFR, both biochemically and in a cellular 
setting. From these results, specific trends could be identified, providing beneficial information on the importance 
of specific functionalities in the further development of lead compound 1. Comparison of compounds with the 
methyl piperazine solubilising group being present or absent showed a large disparity in activity.  
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We believe that the solubilising group acts as an anchor for the rest of the molecule, ensuring proper reversible 
binding of the pyrrolopyrimidine core with the hinge region and proving indispensable for further optimization of 
these compounds.  
By excluding the electrophilic Michael acceptor, we were able to assess the efficacy of the synthesized compounds 
as reversible inhibitors, focussing particularly on their potential to inhibit the clinically relevant C797S triple mutant. 
As anticipated, the compounds containing the solubilising group outperformed those without by a large margin. At 
this stage we identified that shorter glycol chain substituents resulted in greater inhibitory efficacy, a trend which was 
largely preserved in future observations. Both the directly and ortho-substituted compounds of series C and G 
showed remarkable biochemical efficacy against the C797S triple mutant, with compound 40 displaying an IC50 
value of 1.50 nM, a 75-fold increase in activity over osimertnib. We hypothesize this to be a consequence of Van 
Der Waals interactions not only with the glycine-rich loop, but also with the mutated serine residue itself. However, 
this remarkable efficiency was diminished in the cellular evaluation against the PC9/T790M/C797S triple mutant, 
with compound 40 retaining a 2-fold advantage in activity over osimertinib. This was the first indication of 
intolerance towards the glycol chain moiety within a cell. We thus believe there is potential for the inclusion of these 
glycol chain moieties in generation of inhibitors specifically targeting the C797S triple mutant.  
Analysis of the Michael acceptor-derivatised irreversible inhibitors revealed a recurrence of the afore-mentioned 
trends. Both directly and ortho-substituted compounds which contained the solubilising group showed exceptional 
biochemical activity against the L858R and L858R/T790M mutant variants, with the shorter chain glycol derivatives 
advancing to picomolar IC50 values. We proposed that the methyl substituent of the 1-methoxypropan-2-yl glycol 
chain substituent could interact and promote a favourable orientation for the proximal acryl amide electrophile to 
undergo covalent bond formation with the cysteine residue. Disappointingly, these values were not maintained in 
the cellular assays, highlighting the poor pharmacokinetic properties of the glycol chains. Whilst we think further 
pursuit of these glycol moieties unprofitable, investigation into more stable and tolerable chain groups that can still 
interact with the glycine-rich loop could yield beneficial results in the development of inhibitors for the EGFR-
L858R/T790M double mutant.  
Owing to the dual EGFR/HER2 character of the original AEE788 core scaffold, we screened the most efficacious 
irreversible inhibitors against two HER2 cell lines. Encouragingly, these compounds showed good inhibitory activity, 
with compound 77 displaying outstanding efficacy. We believe the improved tolerance of the glycol chain and 
potent EC50 values of compound 77 merit the further exploration and development of these compounds as dual 
EGFR/HER2 inhibitors.  
Furthermore, we were able to obtain a crystal structure of compound 77 in the cSrc-T338M/S345C surrogate. The 
refined structure confirmed covalent bond formation with Cys345 and reinforced our proposals regarding the trends 
witnessed in the biochemical and cellular evaluation. These included visual evidence of a shorter glycol chain proving 
more efficacious and the importance of the solubilising group in anchoring the molecule for optimal reversible 
binding.  
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4.9 Ongoing and Future Work 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.10: Schematic representation for the synthesis of compound 80, which was shown to undergo a Mitsunobu reaction 
and afford the library of constitutional isomers. Reagents and Conditions: i) Alcohol substrate (5 equiv.), PPh3 (5 equiv.), DIAD 
(5 equiv.), THF, ultrasonication at 40 °C, 6 h. 
As the work undertaken in this chapter was accomplished at the Technische Universität Dortmund, research 
surrounding this scaffold and class of inhibitor is ongoing within the group of Prof. Rauh. We will therefore discuss 
the developments which have arisen post-completion of our research venture and comment on potential future 
endeavours. Based on the information gathered from the crystal structure of compound 77 within the cSrc-
T338M/S345C enzyme, the group deduced that the most promising point for further derivatisation would be at the 
4-methoxypyrimidine position. As seen in Figure 4.11, the pyrimidine methoxy was small enough to avoid a steric 
clash with the mutated methionine gatekeeper residue. This prompted the investigation of larger substituents at this 
position, with the potential to increase binding affinity through space filling and reversible interactions. The group 
was able to synthesise 4-hydroxylpyrrolopyrimidine compound 80, which was followed by a Mitsunobu reaction 
using ethanol and the conditions described in Scheme 4.10. Use of LC/MS analysis revealed the formation of two 
products with different retention times, but equivalent molecular mass, indicating the presence of two isomers. 
Subsequent separation and structural determination using 2D NMR spectroscopy unveiled the two compounds as 
the O4-substituted pyrimidine and N3-substitued pyrimidin-4-one (Scheme 4.10). This was a compelling result, 
sparking the reaction of numerous linear and cyclic alcohols (Scheme 4.10, purple) under the developed Mitsunobu 
conditions, to furnish a library of O4- and N3-substituted compounds. By doing so, the group ascertained the 
importance of both the substitution position and optimal size of alkyl or cyclic moiety to be used.  
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As a future consideration, we propose that these compounds could be further derivatised with the glycol chain 
moieties utilised in this chapter, at either the N- or ortho-position of the acrylamide. This could be beneficial in 
increasing their potency as reversible inhibitors against the C797S triple mutant or by enhancing their activity as 
irreversible inhibitors targeting the L858R/T790M double mutant, with the absence or presence of the acrylamide 
functionality respectively.  
Owing to the promising HER2 cellular results exhibited by the irreversible compounds shown in Table 4.9, the group 
considered the potential for development of these compounds as dual EGFR/HER2 inhibitors. Within Figure 4.12 
below, a variety of potent dual EGFR/HER2 inhibitors are displayed. These include the previously discussed 
SYR127063, the FDA approved inhibitor lapatinib and the preclinical candidate 81 and compound 82, both of 
which have demonstrated low nanomolar IC50 values with a high degree of selectivity for HER2.
12, 13
 Upon closer 
inspection of the structural components of these compounds, we see a shared substitution pattern at the 4-
pyrimidine position (Figure 4.12, purple). These substituents are known as back-pocket binding elements and serve 
to increase the binding affinity of the inhibitors by occupying the hydrophobic specificity pocket located behind the 
gatekeeper residue. It was therefore conceived that that these back-pocket elements could prospectively be coupled 
at the 4-position of our synthesized pyrrolopyrimidine core scaffold with either an ether or amine linker. This could 
potentially enhance their binding affinity and selectivity as dual EGFR/HER2 inhibitors and could furthermore be 
combined with the glycol chain moieties used in this body of research, which exhibited marked inhibitory activity 
against HER2 cell lines. This research is ongoing and has led to the preparation of another manuscript for publication. 
Figure 4.12: Strategy to introduce back-pocket binding elements into the synthesised pyrrolopyrimidine scaffold as potential 
dual EGFR/HER2 inhibitors.  
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4.10 Supplementary Information 
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (6)
14
 
A flame-dried, 2-neck round-bottomed flask was charged with 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
(8.00 g, 52.1 mmol, 1 equiv.), purged with Ar and dissolved in DMF (80 mL). A solution of N-
iodosuccinimide (12.3 g, 54.7 mmol, 1.05 equiv.) in DMF (20 mL) was then added dropwise over a 
period of 15 min and the reaction flask was covered in foil. The reaction mixture was then allowed 
to stir at rt for 16 h or until complete consumption of the starting material as indicated by TLC, during which time a 
deep orange colour developed. After addition of a sufficient amount of 10 mol% sodium thiosulphate so that the 
solution became clear, the reaction mixture was diluted with H2O (30 mL) and EtOAc (60 mL) and the organic layer 
was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 40 mL) and the combined organic 
layers were then washed with a saturated solution of brine (3 × 40 mL), dried over MgSO4 and filtered. After removal 
of the solvent in vacuo, the residue was dried under vacuum to afford compound 6 as an off-white solid (14.1 g, 
50.5 mmol, 97%) with no further purification required.  
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
14
 
Rf: 0.22 (50% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ 7.93 (d, J = 2.2 Hz, 1H, ArH), 8.59 (s, 1H, ArH), 
12.95 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, DMSO-d6) δ 51.7, 115.8, 133.9, 150.5, 150.8, 151.5 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C6H4N3ICl: 279.9133; found: 279.9132. 
4-Chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (7)
15
  
A flame-dried, 2-neck round-bottomed flask was charged with sodium hydride (60% dispersion 
in oil, 1.20 g, 30.1 mmol, 1.17 equiv.), purged with Ar and to this was added DMF (90 mL). The 
resulting suspension was cooled to −10 °C (acetone/ice) and to this was added a solution of 4-
chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (7.21 g, 25.8 mmol, 1 equiv.) in DMF (15 mL) 
dropwise over 15 min. The solution was then allowed to warm to rt and stirred for 1 h. After recooling the solution 
to −10 °C (acetone/ice), a solution of 2-(trimethylsilyl)ethoxymethyl chloride (5.29 g, 31.7 mmol, 1.23 equiv.) in 
DMF (15 mL) was added dropwise over 15 min and the solution turned yellow in colour. The reaction mixture was 
then allowed to warm to rt and stirred for 16 h or until complete consumption of the starting material as indicated 
by TLC. The reaction mixture was then quenched and diluted with H2O (50 mL), resulting in the formation of a 
white precipitate. The precipitate was collected by filtration, washed with H2O (3 × 30 mL) and dried under vacuum 
to afford compound 7 as white crystals (8.03 g, 19.6 mmol, 76%) with no further purification required.  
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
16
 
Rf: 0.45 (10% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ −0.11 (s, 9H, CH2Si(CH3)3), 0.81 (t, J = 8.0 Hz, 2H, 
CH2CH2Si), 3.50 (t, J = 8.0 Hz, 2H, OCH2CH2), 5.60 (s, 2H, NCH2O), 8.12 (s, 1H, ArH), 8.68 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, DMSO-d6) δ −1.4, 17.1, 52.9, 66.1, 72.9, 116.2, 136.6, 150.9, 151.1, 151.2 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C
12
H
18
N
3
OSiICl: 409.9952; found: 409.9950. 
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5-Iodo-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (8)
17
 
A 2-neck round-bottomed flask was charged with 4-chloro-5-iodo-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (3.35 g, 8.18 mmol, 1 equiv.), 
potassium carbonate (2.49 g, 18.0 mmol, 2.2 equiv.), purged with Ar and dissolved in MeOH 
(40 mL). The solution was then allowed to stir at rt for 16 h or until complete consumption of the 
starting material as indicated by TLC. After removal of the solvent in vacuo, the residue was diluted with H2O (60 mL) 
and EtOAc (60 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc 
(3 × 40 mL) and the combined organic layers were then washed with a saturated solution of brine (40 mL), dried 
over MgSO4 and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto silica and 
purification was achieved using flash column chromatography with elution gradient of 0 – 20% EtOAc in PE. Pure 
fractions were evaporated to dryness to afford compound 8 as a white solid (3.05 g, 7.53 mmol, 92%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
16
 
Rf: 0.65 (15% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ −0.11 (s, 9H, CH2Si(CH3)3), 0.80 (t, J = 8.0 Hz, 2H, 
CH2CH2Si), 3.48 (t, J = 8.0 Hz, 2H, OCH2CH2), 4.05 (s, 3H, ArOCH3), 5.53 (s, 2H, NCH2O), 7.75 (s, 1H, ArH), 8.45 
(s, 1H, ArH) ppm; 
13
C NMR (126 MHz, DMSO-d
6
) δ −1.4, 17.1, 50.9, 53.74, 65.7, 72.5, 106.3, 132.3, 151.3, 
151.9, 162.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C13H21N3O2SiI: 406.0448; found: 406.0451. 
General procedure for Suzuki-Miyaura cross coupling reaction:
18
 
A flame dried Schlenk tube was purged with Ar and to this was added a 3:1 solution of dioxane/H2O (5 mL/mmol 
aryl halide) via syringe under positive pressure Ar. The solvent was then degassed using 3 – 5 cycles of freeze-pump-
thaw technique, followed by bubbling Ar under positive pressure for 10 min. A separate Schlenk tube was charged 
with aryl halide (1 equiv.), boronic acid/ester (1.2 equiv.), Pd(PPh3)4 (5 mol%), sodium carbonate (2.5 equiv.) and 
purged with Ar. To this was added the previously degassed solvent via syringe, under positive pressure Ar. The 
reaction flask was sealed, heated to 80 °C and allowed to stir for 16 h or until complete consumption of the starting 
material as indicated by TLC, during which time the reaction mixture developed a red-brown colour. After allowing 
to cool to rt, the reaction mixture was filtered through a plug of celite, diluted with H2O (10 mL/mmol aryl halide) 
and EtOAc (20 mL/mmol aryl halide) and the organic layer was separated. The aqueous layer was extracted with 
aliquots of EtOAc (3 × 20 mL/mmol aryl halide) and the combined organic layers were then washed with a saturated 
solution of brine (10 mL/mmol aryl halide), dried over MgSO
4
 and filtered. After removal of the solvent in vacuo, the 
crude product was adsorbed onto silica and purification was achieved using flash column chromatography. Pure 
fractions were evaporated to dryness to afford the respective compound. 
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4-Methoxy-5-(3-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (9) 
Compound 9 was prepared according to the general procedure for Suzuki-Miyaura cross 
coupling reaction. 5-Iodo-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidine (405 mg, 1.00 mmol) and (3-nitrophenyl)boronic acid (200 mg, 1.20 mmol) 
were coupled and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% EtOAc in PE. Pure fractions were evaporated to dryness to 
afford compound 9 as a yellow semi-solid (368 mg, 0.918 mmol, 92%).  
Rf: 0.37 (15% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ  −0.10 (s, 9H, CH2Si(CH3)3), 0.84 (t, J = 7.9 Hz, 2H, 
CH2CH2Si), 3.56 (t, J = 8.0 Hz, 2H, OCH2CH2), 4.05 (s, 3H, ArOCH3), 5.63 (s, 2H, NCH2O), 7.68 (dd [app. t], 
J = 8.0 Hz, 1H, ArH), 8.07 (s, 1H, ArH), 8.13 – 8.10 (m, 2H, 2 × ArH), 8.59 (dd [app. t], J = 2.0 Hz, 1H, ArH), 
8.51 (s, 1H, ArH) ppm;
 13
C NMR (500 MHz, DMSO-d6) δ −1.4, 17.1, 53.8, 65.9, 72.8, 102.2, 113.8, 121.0, 122.7, 
126.9, 129.7, 134.3, 135.3, 147.9, 151.3, 152.8, 162.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C19H25N4O4Si: 401.1645; found: 401.1642. 
General procedure for aromatic nitro derivative reduction:
19
 
A 2-neck round-bottomed flask was charged with aromatic nitro derivative (1 equiv.), iron (5 equiv.) and ammonium 
chloride (1 equiv.) and to this was added a 1:1 solution of EtOH/H2O (5 mL/mmol aromatic nitro derivative). The 
resulting suspension were place under ultrasonic irradiation at 60 °C for 6 h or until complete consumption of the 
starting material as indicated by TLC, during which time the reaction mixture developed a dark-brown colour. After 
allowing to cool to rt, the reaction mixture was filtered through a plug of celite, washed with EtOH (5 mL/mmol 
aromatic nitro derivative) and the solvent was removed in vacuo. The residue was then diluted with DCM 
(10 mL/mmol aromatic nitro derivative) and H2O (10 mL/mmol aromatic nitro derivative) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of DCM (3 × 10 mL/mmol aromatic nitro derivative) and 
the combined organic layers were then washed with a saturated solution of brine (10 mL/mmol aryl halide), dried 
over MgSO4 and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto silica and 
purification was achieved using flash column chromatography. Pure fractions were evaporated to dryness to afford 
the respective compound. 
3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (10) 
Compound 10 was prepared was according to the general procedure for aromatic nitro 
derivative reduction. 4-Methoxy-5-(3-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidine (1.60 g, 4.00 mmol) was reduced and purification was 
achieved using flash column chromatography with elution gradient of 20 – 80% EtOAc in 
PE. Pure fractions were evaporated to dryness to afford compound 10 as a light-brown 
semi-solid (1.29 g, 3.48 mmol, 87%). 
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Rf: 0.44 (50% EtOAc in PE); 
1
H NMR (400 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3), 0.92 (t, J = 7.9 Hz, 
2H, CH2CH2Si), 3.56 (t, J = 7.8 Hz, 2H, OCH2CH2), 3.87 (br s, 2H, ArNH2), 4.07 (s, 3H, ArOCH3), 5.62 (s, 2H, 
NCH2O), 6.65 (ddd, J = 7.9, 2.2, 0.8 Hz, 1H, ArH), 7.00 (t, J = 1.9 Hz, 1H, ArH), 7.06 (dt, J = 7.8, 1.1 Hz, 1H, 
ArH), 7.19 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.24 (s, 1H, ArH), 8.49 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, CDCl3) 
δ −1.4, 17.8, 53.7, 66.5, 73.1, 103.4, 113.8, 115.8, 118.0, 119.5, 123.7, 129.1, 134.9, 146.0, 151.3, 153.0, 163.5 
ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C19H27N4O2Si: 371.1903; found: 371.1902.  
2-Methoxyethyl methanesulfonate (12)
20
 
A flame-dried, 2-neck round-bottom flask was charged with 2-methoxyethanol (2.00 g, 
26.3 mmol, 1 equiv.), purged with Ar and dissolved in DCM (50 mL). To this was added Et3N 
(4.40 mL, 31.5 mmol, 1.2 equiv.) and the solution was cooled to −10 °C (acetone/ice). This 
was followed by the dropwise addition of a solution of methanesulfonyl chloride (3.31 g, 28.9 mmol, 1.1 equiv.) in 
DCM (25 mL) and the reaction mixture was then allowed to warm to rt and stirred for 12 h. The reaction mixture 
was then quenched and diluted with H2O (30 mL) and DCM (30 mL) and the organic layer was separated. The 
aqueous layer was extracted with aliquots of DCM (3 × 40 mL) and the combined organic layers were then washed 
with H2O (2 × 50 mL), a solution of 0.1 M HCl (50 mL), a saturated solution of brine (50 mL), dried over MgSO4 
and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved by kugelrohr 
distillation. Fractions with boiling point between 135 °C and 145 °C at ~ 20 mbar were collected to afford 
compound 12 as a clear oil (3.57 g, 23.1 mmol, 88%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
21
 
1
H NMR (500 MHz, DMSO-d6) δ 3.17 (s, 3H, OSO2CH3), 3.28 (s, 3H, CH2OCH3), 3.61 – 3.56 (m, 2H, OCH2CH2O), 
4.33 – 4.28 (m, 2H, OCH2CH2O) ppm; 
13
C NMR (126 MHz, CDCl3) δ 36.7, 58.1, 69.4, 69.7 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C19H27N4O2Si: 371.1903; found: 371.1908. 
General procedure for tosylation of glycol ethers:
22
 
A flame-dried, 2-neck round-bottom flask was charged with glycol ether (1 equiv.), purged with Ar and dissolved in 
DCM (2 mL/mmol glycol ether). To this was added Et
3
N (1.2 equiv.) and the solution was cooled to −10 °C 
(acetone/ice). This was followed by the dropwise addition of a solution of p-toluenesulfonyl chloride (1.1 equiv.) in 
DCM (1 mL/mmol glycol ether) and the reaction mixture was then allowed to warm to rt and stirred for 12 h. The 
reaction mixture was then quenched and diluted with H2O (1 mL/mmol glycol ether) and DCM (1 mL/mmol glycol 
ether) and the organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 × 1 mL/mmol 
glycol ether) and the combined organic layers were then washed with H
2
O (2 × 2 mL/mmol glycol ether), a solution 
of 0.1 M HCl (2 mL/mmol glycol ether), a saturated solution of brine (2 mL/mmol glycol ether), dried over MgSO4 
and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto silica and purification was 
achieved using flash column chromatography. Pure fractions were evaporated to dryness to afford the respective 
compound. 
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2-Methoxyethyl 4-methylbenzenesulfonate (13) 
Compound 13 was prepared according to the general procedure for tosylation of glycol 
ethers. 2-Methoxyethanol (1.00 g, 13.1 mmol) was tosylated and purification was 
achieved using flash column chromatography with elution gradient of 10 – 40% EtOAc 
in PE. Pure fractions were evaporated to dryness to afford compound 13 as a clear oil (2.78 g, 12.1 mmol, 92%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
23
 
Rf: 0.14 (10% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ 2.41 (s, 3H, ArCH3), 3.17 (s, 3H, CH2OCH3), 3.48 
(t, J = 4.4 Hz, 2H, OCH2CH2O), 4.11 (t, J = 4.4 Hz, 2H, OCH2CH2O), 7.47 (d, J = 8.2 Hz, 2H, 2 × ArH), 7.79 
(d, J = 8.2 Hz, 2H, 2 × ArH) ppm; 
13
C NMR (126 MHz, DMSO-d
6
) δ 21.1, 57.9, 69.3, 69.8, 127.7, 130.2, 132.4, 
145.0 ppm; HRMS-TOF MS ESI+: m/z [M+Na]
+
 calculated for C10H14NaO4S: 253.0505; found: 253.0499. 
1-Methoxypropan-2-yl 4-methylbenzenesulfonate (14) 
Compound 14 was prepared according to the general procedure for tosylation of 
glycol ethers. 1-Methoxypropan-2-ol (1.00 g, 11.1 mmol) was tosylated and 
purification was achieved using flash column chromatography with elution gradient of 
10 – 40% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 14 as a clear oil (2.47 g, 10.1 
mmol, 91%).  
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
24
  
Rf: 0.18 (10% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ 1.23 (d, J = 6.8 Hz, 3H, CH3CHCH2), 2.41 (s, 3H, ArCH3), 
3.20 (s, 3H, CHCH2OCH3), 3.41 – 3.30 (m, 2H, CHCH2OCH3), 4.71 – 4.63 (m, 1H, TsOCH(CH3)CH2), 7.30 (d, J 
= 8.0 Hz, 2H, 2 × ArH), 7.77 (d, J = 8.0 Hz, 2H, 2 × ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 17.6, 21.7, 59.1, 
74.7, 78.0, 127.9, 129.7, 134.2, 144.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C11H17O4S: 
245.0848; found: 245.0848. 
2-Ethoxyethyl 4-methylbenzenesulfonate (15) 
Compound 15 was prepared according to the general procedure for tosylation of 
glycol ethers. 3-Methoxy-1-propanol (1.00 g, 11.1 mmol) was tosylated and 
purification was achieved using flash column chromatography with elution gradient 
of 10 – 40% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 15 as a clear oil (2.44 g, 
9.99 mmol, 90%).  
1
H NMR data collected for this compound compared well with the reported literature values.
25
 
Rf: 0.18 (10% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ 1.09 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.40 (s, 3H, ArCH3), 
3.40 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.56 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.11 (t, J = 4.8 Hz, 2H, OCH2CH2O), 
7.31 (d, J = 8.2 Hz, 2H, 2 × ArH), 7.76 (d, J = 8.2 Hz, 2H, 2 × ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 15.0, 
21.6, 66.7, 67.8, 69.4, 128.0, 129.8, 133.0, 144.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C11H17O4S: 245.0848; found: 245.0850. 
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General procedure for aniline derivative monoalkylation:
26
 
A microwave reaction vial was charged with aniline derivative (1.5 equiv.), tosylated glycol ether (1 equiv.) and 
potassium carbonate (1.5 equiv.) and to this was added DMF (4 mL/mmol aniline derivative). The vial was purged 
with Ar, sealed and the reaction mixture was then heated to 80 °C and stirred for 72 h. After cooling to rt, the 
reaction mixture was diluted with H2O (20 mL/mmol glycol ether) and EtOAc (20 mL/mmol glycol ether) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 10 mL/mmol glycol ether) 
and the combined organic layers were then washed with a saturated solution of brine (4 × 15 mL/mmol glycol 
ether), dried over MgSO4 and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto 
silica and purification was achieved using flash column chromatography. Pure fractions were evaporated to dryness 
to afford the respective compound and excess starting aniline derivative was recovered and reused in repeat 
experiments.  
3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-
methoxyethyl)aniline (16) 
Compound 16 was prepared according to the general procedure for aniline derivative 
monoalkylation. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)aniline (404 mg, 1.09 mmol) was alkylated with 2-methoxyethyl 4-
methylbenzenesulfonate (168 mg, 0.730 mmol) and purification was achieved using 
flash column chromatography with elution gradient of 10 – 80% EtOAc in PE. Pure 
fractions were evaporated to dryness to afford compound 16 as a yellow semi-solid 
(203 mg, 0.474 mmol, 65% isolated, 90% brsm).  
Rf: 0.58 (50% EtOAc in PE); 
1
H NMR (400 MHz, CDCl3) δ −0.04 (s, 9H, CH2Si(CH3)3), 0.94 (t, 2H, J = 8.2 Hz, 
OCH2CH2Si), 3.38 – 3.36 (m, 2H,NHCH2CH2O), 3.40 (s, 3H, CH2OCH3), 3.58 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 
3.65 (t, J = 5.2 Hz, 2H, NHCH2CH2O), 4.10 (s, 3H, ArOCH3), 5.65 (s, 2H, NCH2O), 6.64 (dd, J = 8.0, 1.5 Hz, 
1H, ArH), 7.01 (dd, J = 3.8, 1.7 Hz, 1H, ArH), 7.03 (dd, J = 7.8, 1.0 Hz, 1H, ArH), 7.22 (dd [app. t], J = 7.8 Hz, 
1H, ArH), 7.28 (dd [app. t], J = 4.2 Hz, 1H, ArH), 8.51 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, CDCl
3
) δ  −1.4, 
17.8, 43.8, 53.7, 58.8, 66.5, 71.1, 73.1, 103.4, 112.2, 113.7, 118.4, 118.5, 123.7, 129.1, 134.9, 148.0, 151.3, 
153.1, 163.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C22H33N4O3Si: 429.2322; found: 429.2321. 
3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(1-methoxypropan-2-
yl)aniline (18) 
Compound 18 was prepared according to the general procedure for aniline derivative 
monoalkylation. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)aniline (365 mg, 0.985 mmol) was alkylated with 1-methoxypropan-
2-yl 4-methylbenzenesulfonate (161 mg, 0.659 mmol) and purification was achieved 
using flash column chromatography with elution gradient of 10 – 80% EtOAc in PE. 
Pure fractions were evaporated to dryness to afford compound 18 as a yellow semi-
solid (161 mg, 0.364 mmol, 55% isolated, 78% brsm). 
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Rf: 0.74 (50% EtOAc in PE); 
1
H NMR (400 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.93 (t, J = 8.2 Hz, 2H, 
OCH2CH2Si), 1.28 (d, J = 6.8 Hz, 3H, CH3CHCH2), 3.38 (s, 3H, CHCH2OCH3), 3.52 – 3.41 (m, 2H, CHCH2OCH3), 
3.57 (t, J = 8.2 Hz,  2H, OCH2CH2Si), 3.77 – 3.68 (m, 1H, CH3CHCH2), 4.09 (s, 3H, ArOCH3), 5.64 (s, 2H, NCH2O), 
6.63 (dd, J = 8.0, 1.4 Hz, 1H, ArH), 7.03 – 6.99 (m, 2 × ArH), 7.21 (dd [app. t], J = 8.0 Hz, 1H, ArH), 7.27 (s, 1H, 
ArH), 8.50 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, CDCl3) δ −1.3, 17.8, 18.0, 48.9, 53.8, 59.2, 66.6, 73.1, 76.1, 
103.5, 112.9, 114.2, 118.4, 118.5, 123.7, 129.2, 135.0, 146.9, 151.3, 153.1, 163.6 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C23H35N4O3Si: 443.2478; found: 443.2482. 
N-(2-Ethoxyethyl)-3-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline 
(19) 
Compound 19 was prepared according to the general procedure for aniline 
derivative monoalkylation. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl)aniline (390 mg, 1.05 mmol) was alkylated with 2-
ethoxyethyl 4-methylbenzenesulfonate (171 mg, 0.700 mmol) and purification was 
achieved using flash column chromatography with elution gradient of 10 – 80% 
EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 19 as 
a yellow semi-solid (192 mg, 0.434 mmol, 62% isolated, 82% brsm). 
Rf: 0.72 (50% EtOAc in PE); 
1
H NMR (400 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.92 (t, J = 8.2 Hz, 2H, 
OCH2CH2Si), 1.22 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.35 (t, J = 5.3 Hz, 2H, NHCH2CH2O), 3.59 – 3.51 (m, 4H, 
OCH2CH2Si and OCH2CH3), 3.68 (t, J = 5.3 Hz, 2H, NHCH2CH2O), 4.09 (s, 3H, ArOCH3), 5.64 (s, 2H, NCH2O), 
6.63 (dd, J = 8.3, 2.1 Hz, 1H, ArH), 7.04 – 6.99 (m, 2H, 2 × ArH), 7.21 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.27 (s, 
1H, ArH), 8.50 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, CDCl3) δ −1.4, 15.3, 17.8, 44.0, 53.7, 66.5, 66.5, 68.9, 
73.1, 103.5, 112.3, 113.8, 118.4, 118.5, 123.7, 129.1, 134.8, 148.0, 151.3, 153.1, 163.5 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C23H35N4O3Si: 443.2478; found: 443.2479. 
General procedure for aniline derivative acylation: 
A flame-dried, 2-neck round-bottom flask was charged with aniline derivative (1 equiv.), potassium carbonate 
(1.5 equiv.), purged with Ar and to this was added THF (5 mL/mmol aniline derivative). The resulting suspension 
was cooled to −10 °C (acetone/ice) and to this was added a solution of acryloyl chloride (1.2 equiv.) in THF 
(5 mL/mmol aniline derivative) dropwise over 15 min. The reaction mixture was then allowed to warm to rt and 
stirred for 6 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was 
then quenched and diluted with H2O (20 mL/mmol aniline derivative) and EtOAc (20 mL/mmol aniline derivative) 
and the organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 10 mL/mmol 
aniline derivative) and the combined organic layers were then washed with a saturated solution of brine (20 
mL/mmol aniline derivative), dried over MgSO
4
 and filtered. After removal of the solvent in vacuo, the crude product 
was adsorbed onto silica and purification was achieved using flash column chromatography. Pure fractions were 
evaporated to dryness to afford the respective compound. 
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N-[3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl)-N-(2-
methoxyethyl)acrylamide (20) 
Compound 20 was prepared according to the general procedure for aniline 
derivative acylation. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyethyl)aniline (165 mg, 0.385 mmol) was 
acylated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 10% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 20 as a clear semi-solid (163 mg, 0.338 mmol, 89%). 
Rf: 0.29 (50% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ −0.09 (s, 9H, CH2Si(CH3)3), 0.90 (t, J = 8.1 Hz, 2H, 
OCH2CH2Si), 3.29 (s, 3H, CH2OCH3), 3.54 (t, J = 8.1 Hz, 2H, OCH2CH2Si), 3.58 (t, J = 6.0 Hz, 2H, NHCH2CH2O), 
3.98 (t, J = 6.0 Hz, 2H, NHCH2CH2O), 4.04 (s, 3H, ArOCH3), 5.51 (d, J = 10.5 Hz, 1H, CCH=CH2), 5.63 (s, 2H, 
NCH2O), 6.14 (dd, J = 16.7, 10.3 Hz, 1H, CCH=CH2), 6.37 (d, J = 16.7 Hz, 1H, CCH=CH2), 7.12 (d, J = 7.8 Hz, 
1H, ArH), 7.30 (s, 1H, ArH), 7.40 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.54 (s, 1H, ArH), 7.58 (d, J = 7.8 Hz, 1H, 
ArH), 8.48 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ −1.4, 17.7, 48.9, 53.9, 58.6, 66.6, 69.4, 73.1, 103.2, 
116.8, 124.0, 126.6, 127.7, 127.8, 128.8, 128.9, 129.3, 135.5, 142.1, 151.4, 153.0, 163.4, 165.7 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C25H35N4O3Si: 467.2478; found: 467.2473. 
N-[3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-N-(1-
methoxypropan-2-yl)acrylamide (21) 
Compound 21 was prepared according to the general procedure for aniline derivative 
acylation. 3-(4-Methoxy-7-{(2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-N-(1-methoxypropan-2-yl)aniline (89.0 mg, 0.201 mmol) was 
acylated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 10% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 21 as a clear semi-solid (89.0 mg, 0.179 mmol, 89%). 
Rf: 0.36 (50% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ −0.08 (s, 9H, CH2Si(CH3)3), 0.90 (t, J = 8.1 Hz, 2H, 
OCH2CH2Si), 1.11 (d, J = 7.0 Hz, 3H, CH3CHCH2), 3.31 – 3.26 (m, 2H, CHCH2OCH3), 3.32 (s, 3H, CHCH2OCH3), 
3.55 (t, J = 8.1 Hz, 2H, OCH2CH2Si), 4.03 (s, 3H, ArOCH3), 4.11 – 4.05 (m, 1H, CH3CHCH2), 5.46 (d, J = 10.4 
Hz, 1H, CCH=CH
2
), 5.64 (s, 2H, NCH
2
O), 5.96 (dd, J = 16.7, 10.4 Hz, 1H, CCH=CH
2
), 6.35 (dd, J = 16.7, 1.1 
Hz, 1H, CCH=CH2), 7.18 – 7.01 (m, 1H, ArH), 7.30 (s, 1H, ArH), 7.42 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.55 – 
7.44 (m, 1H, ArH), 7.63 (d, J = 7.8 Hz, 1H, ArH), 8.49 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ −1.4, 
15.7, 17.8, 54.0, 58.5, 60.5, 66.7, 73.2, 73.6, 103.2, 116.9, 124.1, 127.5, 128.3, 128.7, 129.1, 129.4, 131.3, 
135.2, 151.4, 153.0, 163.5, 165.8, 171.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C26H37N4O4Si: 
497.2584; found: 497.2588. 
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N-(2-Ethoxyethyl)-N-[3-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)phenyl]acrylamide (22) 
Compound 22 was prepared according to the general 
procedure for aniline derivative acylation. N-(2-Ethoxyethyl)-3-(4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (172 mg, 
0.389 mmol) was acylated and purification was achieved using flash column 
chromatography with elution gradient of 0 – 10% MeOH in DCM. Pure fractions 
were evaporated to dryness to afford compound 22 as a clear semi-solid (174 mg, 
0.350 mmol, 90%). 
Rf: 0.35 (50% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ −0.09 (s, 9H, CH2Si(CH3)3), 0.90 (t, J = 8.0 Hz, 2H, 
OCH2CH2Si), 1.08 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.43 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.54 (t, J = 8.0 Hz, 2H, 
OCH2CH2Si), 3.64 (t, J = 6.1 Hz, 2H, NHCH2CH2O), 3.97 (t, J = 6.1 Hz, 2H, NHCH2CH2O), 4.04 (s, 3H, ArOCH3), 
5.51 (d, J = 10.5 Hz, 1H, CCH=CH2), 5.63 (s, 2H, NCH2O), 6.15 (dd, J = 16.7, 10.3 Hz, 1H, CCH=CH2), 6.37 
(dd, J = 16.8, 1.4 Hz, 1H, CCH=CH2), 7.13 (d, J = 7.8 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 7.39 (dd [app. t], J = 7.8 
Hz, 1H, ArH), 7.56 (s, 1H, ArH), 7.58 (d, J = 8.0 Hz, 1H, ArH), 8.48 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl3) 
δ −1.4, 15.2, 17.7, 53.9, 60.4, 66.2, 66.6, 67.4, 73.1, 103.2, 116.9, 124.0, 126.6, 127.6, 127.7, 128.9, 128.9, 
129.2, 135.4, 142.3, 151.4, 153.0, 163.4, 165.7, 171.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C26H37N4O4Si: 497.2584; found: 497.2587. 
General procedure for N-SEM deprotection:
27
 
A round-bottom flask was charged with N-SEM protected pyrrolopyrimidine derivative (1 equiv.) and dissolved in 
DCM (15 mL/mmol pyrrolopyrimidine derivative). To this was added trifluoroacetic acid (5 mL/mmol 
pyrrolopyrimidine derivative) dropwise and the reaction flask was stoppered and allowed to stir for 6 h at rt, during 
which time the reaction mixture developed a brown colour. After removal of the solvent in vacuo, the residue was 
dissolved in THF (10 mL/mmol pyrrolopyrimidine derivative), followed by the slow addition of a solution of 1 M 
KOH (10 mL/mmol pyrrolopyrimidine derivative). The reaction mixture was then allowed to stir for a further 4 h, 
during which time the solution became clear. The reaction mixture was then neutralised by the slow addition of a 
solution of 1 M HCl (10 mL/mmol pyrrolopyrimidine derivative), diluted with H2O (20 mL/mmol pyrrolopyrimidine 
derivative) and DCM (30 mL mmol pyrrolopyrimidine derivative) and the organic layer was separated. The aqueous 
layer was extracted with aliquots of DCM (3 × 20 mL/mmol pyrrolopyrimidine derivative) and the combined organic 
layers were then washed with a saturated solution of brine (20 mL/mmol pyrrolopyrimidine derivative), dried over 
MgSO4 and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto silica and 
purification was achieved using flash column chromatography. Pure fractions were evaporated to dryness to afford 
the respective compound. 
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3-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (23) 
Compound 23 was prepared according to the general procedure for N-SEM deprotection. 
3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)aniline (126 mg, 0.340 mmol) was deprotected and purification was achieved using 
flash column chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 23 as a white solid (64.0 mg, 
0.266 mmol, 78%).  
Rf: 0.41 (5% MeOH in DCM); 
1
H NMR (500 MHz, DMSO-d6) δ 4.03 (s, 3H, ArOCH3), 6.81 (d, J = 7.6 Hz, 1H, 
ArH), 7.26 – 7.17 (m, 3H, 3 × ArH), 7.54 (s, 1H, ArH), 8.41 (s, 1H, ArH), 12.29 (s, 1H, ArNH) ppm; 13C NMR (126 
MHz, DMSO-d6) δ 53.5, 102.0, 115.7, 118.0, 118.4, 121.2, 122.4, 124.8, 128.9, 135.3, 150.6 ppm; HRMS-TOF 
MS ESI+: m/z [M+H]
+
 calculated for C13H13N4O: 241.1089; found: 241.1092. 
3-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyethyl)aniline (24) 
Compound 24 was prepared according to the general procedure for N-SEM 
deprotection. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-N-(2-methoxyethyl)aniline (132 mg, 0.308 mmol) was deprotected 
and purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 24 as a white solid (75.0 mg, 0.251 mmol, 81%). 
Rf: 0.36 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 3.44 (t, J = 5.1 Hz, 2H, NCH2CH2O), 3.48 (s, 3H, 
CH2OCH3), 3.73 (t, J = 5.1 Hz, 2H, NCH2CH2O),  4.15 (s, 3H, ArOCH3), 4.52 (br s, 1H, ArNHCH2), 6.71 (d, J = 
6.8 Hz, 1H, ArH), 7.07 (s, 1H, ArH), 7.10 (d, J = 7.6 Hz, 1H, ArH), 7.29 (d, J = 7.8 Hz, 1H, ArH), 7.32 (s, 1H, ArH), 
8.57 (s, 1H, ArH), 12.45 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 43.7, 53.7, 58.7, 71.0, 103.2, 111.9, 
113.7, 117.7, 118.4, 121.2, 129.0, 135.2, 147.9, 150.3, 152.9, 163.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 
calculated for C16H19N4O2: 299.1508; found: 299.1505.  
3-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(1-methoxypropan-2-yl)aniline (25) 
Compound 25 was prepared according to the general procedure for N-SEM 
deprotection. 3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-N-(1-methoxypropan-2-yl)aniline (111 mg, 0.251 mmol) was 
deprotected and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 25 as a white solid (64.0 mg, 0.205 mmol, 82%).  
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Rf: 0.35 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.31 (d, J = 6.6 Hz, 3H, CH3CHCH2), 3.39 (s, 3H, 
CHCH2OCH3), 3.54 – 3.43 (m, 2H, CHCH2OCH3), 3.79 – 3.71 (m, 1H, CH3CHCH2), 4.10 (s, 3H, ArOCH3), 4.35 
(br s, 1H, ArNHCH), 6.68 (d, J = 7.8 Hz, 1H, ArH), 7.09 – 7.03 (m, 2H, 2 × ArH), 7.23 (dd [app. t], J = 7.8 Hz, 
1H, ArH), 7.30 (s, 1H, ArH), 8.52 (s, 1H, ArH), 11.62 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 17.8, 49.4, 
53.9, 59.2, 75.8, 103.4, 113.3, 114.9, 117.9, 119.3, 121.3, 129.2, 135.4, 146.1, 150.6, 153.1, 163.7 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C17H21N4O2: 313.1664; found: 313.1665.  
N-(2-Ethoxyethyl)-3-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (26) 
Compound 26 was prepared according to the general procedure for N-SEM 
deprotection. N-(2-Ethoxyethyl)-3-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (112 mg, 0.253 mmol) was deprotected 
and purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 26 as a white solid (66.0 mg, 0.211 mmol, 83%).  
Rf: 0.36 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.23 (t, J = 7.0 Hz, 
3H, OCH
2
CH
3
), 3.37 (t, J = 5.2 Hz, 2H, NHCH
2
CH
2
O), 3.55 (q, J = 7.0 Hz, 2H, OCH
2
CH
3
), 3.70 (t, J = 5.2 Hz, 
2H, NHCH2CH2O), 4.09 (s, 3H, ArOCH3), 4.44 (br s, 1H, ArNHCH2), 6.65 (d, J = 7.3 Hz, 1H, ArH), 7.03 – 6.96 
(m, 1H, ArH), 7.05 (d, J = 8.0 Hz, 1H, ArH), 7.23 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 8.51 (s, 1H, 
ArH), 12.04 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 15.3, 44.1, 53.8, 66.5, 68.9, 103.4, 112.2, 114.0, 
117.9, 118.7, 121.2, 129.1, 135.2, 147.8, 150.5, 153.0, 163.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C17H21N4O2: 313.1665; found: 313.1666. 
N-[3-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-N-(2-methoxyethyl)acrylamide (27) 
Compound 27 was prepared according to the general procedure for N-SEM 
deprotection. N-[3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl]phenyl)-N-(2-methoxyethyl)acrylamide (120 mg, 0.249 
mmol) was deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure fractions 
were evaporated to dryness to afford compound 27 as a white solid (75.0 mg, 
0.213 mmol, 86%).  
Rf: 0.41 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 3.31 (s, 3H, CH3OCH3), 3.61 (t, J = 6.0 Hz, 2H, 
NCH
2
CH
2
O), 4.02 (t, J = 6.0 Hz, 2H, NCH
2
CH
2
O), 4.06 (s, 3H, ArOCH
3
), 5.54 (d, J = 10.3 Hz, 1H, CCH=CH
2
), 
6.18 (dd, J = 16.6, 10.3 Hz, 1H, CCH=CH2), 6.41 (d, J = 16.8 Hz, 1H, CCH=CH2), 7.14 (d, J = 7.8 Hz, 1H, ArH), 
7.37 (s, 1H, ArH), 7.42 (dd [app. t], J = 7.9 Hz, 1H, ArH), 7.58 (s, 1H, ArH), 7.62 (d, J = 7.7 Hz, 1H, ArH), 8.51 (s, 
1H, ArH), 12.40 (s, 1H, ArNH) ppm; 13C NMR (126 MHz, CDCl3) δ 48.9, 53.9, 58.7, 69.4, 103.2, 116.3, 121.8, 
124.4, 126.4, 127.8, 127.9, 128.8, 129.3, 135.9, 142.0, 150.7, 153.1, 163.6, 165.9 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C19H21N4O3: 353.1614; found: 353.1612. 
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N-[3-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-N-(1-methoxypropan-2-yl)acrylamide (28) 
Compound 28 was prepared according to the general procedure for N-SEM 
deprotection. N-[3-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)phenyl]-N-(1-methoxypropan-2-yl)acrylamide (101 mg, 0.203 
mmol) was deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure fractions were 
evaporated to dryness to afford compound 28 as a white solid (64.0 mg, 0.175 mmol, 
87%).  
Rf: 0.42 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.14 (d, J = 7.0 Hz, 3H, CH3CHCH2), 3.33 – 3.28 (m, 
2H, CHCH2OCH3), 3.33 (s, 3H, CHCH2OCH3), 4.06 (s, 3H, ArOCH3), 5.20 (br s, 1H, CH3CHCH2), 5.48 (d, J = 
10.4 Hz, 1H, CCH=CH2), 6.00 (dd, J = 16.7, 10.4 Hz, 1H, CCH=CH2), 6.38 (d, J = 16.7 Hz, 1H, CCH=CH2), 
7.39 (s, 1H, ArH), 7.13 (s, 1H, ArH), 7.43 (dd [app. t], J = 7.7 Hz, 1H, ArH), 7.51 (s, 1H, ArH), 7.66 (d, J = 7.7 Hz, 
1H, ArH), 8.52 (s, 1H, ArH), 12.37 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 15.7, 49.8, 54.0, 58.6, 73.6, 
103.2, 116.3, 121.9, 127.5, 128.4, 128.4, 129.1, 129.5, 131.3, 135.7, 137.9, 150.6, 153.1, 163.6, 166.0 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H23N4O3: 367.1770; found: 367.1770. 
N-(2-Ethoxyethyl)-N-[3-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]acrylamide (29) 
Compound 29 was prepared according to the general procedure for N-SEM 
deprotection. N-(2-Ethoxyethyl)-N-[3-(4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]acrylamide 
(154 mg, 0.310 mmol) was deprotected and purification was achieved using flash 
column chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 29 as a white solid 
(92.0 mg, 0.251 mmol, 81%). 
Rf: 0.41 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.10 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.45 (q, J = 7.0 
Hz, 2H, OCH2CH3), 3.66 (t, J = 6.2 Hz, 2H, NCH2CH2O), 4.01 (t, J = 6.2 Hz, 2H, NCH2CH2O), 4.06 (s, 3H, 
ArOCH3), 5.53 (d, J = 10.4 Hz, 1H, CCH=CH2), 6.18 (dd, J = 16.6, 10.4 Hz, 1H, CCH=CH2), 6.40 (d, J = 16.8 
Hz, 1H, CCH=CH2), 7.14 (d, J = 7.8 Hz, 1H, ArH), 7.37 (s, 1H, ArH), 7.41 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.59 
(s, 1H, ArH), 7.61 (d, J = 8.1 Hz, 1H, ArH), 8.51 (s, 1H, ArH), 12.42 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, 
CDCl3) δ 15.2, 49.3, 53.9, 66.2, 67.3, 103.2, 116.3, 121.7, 124.4, 126.3, 127.7, 127.8, 128.9, 129.2, 135.9, 142.1, 
150.6, 153.1, 163.6, 165.8 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H23N4O3: 367.1770; found: 
367.1769. 
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General procedure for pyrrolopyrimidine derivative bromination:
28
 
A flame-dried, 2-neck round-bottomed flask was charged with pyrrolopyrimidine derivative (1 equiv.), purged with 
Ar and dissolved in DCM (5 mL/mmol pyrrolopyrimidine derivative). A solution of N-bromosuccinimide (1.05 equiv.) 
in DCM (5 mL/mmol pyrrolopyrimidine derivative) was then added dropwise over a period of 15 min and the 
reaction flask was covered in foil. The reaction mixture was then allowed to stir at rt for 16 h or until complete 
consumption of the starting material as indicated by TLC, during which time an orange-brown colour developed. 
After addition of a sufficient amount of 10 mol% sodium thiosulphate so that the solution became clear, the reaction 
mixture was diluted with H2O (20 mL/mmol pyrrolopyrimidine derivative) and DCM (20 mL/mmol 
pyrrolopyrimidine derivative) and the organic layer was separated. The aqueous layer was extracted with aliquots of 
DCM (3 × 10 mL/mmol pyrrolopyrimidine derivative) and the combined organic layers were then washed with a 
saturated solution of brine (10 mL/mmol pyrrolopyrimidine derivative), dried over MgSO4 and filtered. After removal 
of the solvent in vacuo, the crude product was adsorbed onto silica and purification was achieved using flash column 
chromatography. Pure fractions were evaporated to dryness to afford the respective compound. 
6-Bromo-4-methoxy-5-(3-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (30) 
Compound 30 was prepared according to the general procedure 
for pyrrolopyrimidine derivative bromination. 4-Methoxy-5-(3-nitrophenyl)-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (2.00 g, 5.00 mmol) was 
brominated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 30% EtOAc in PE. Pure fractions were evaporated to dryness to 
afford compound 30 as a white solid (2.20 g, 4.59 mmol, 92%).  
Rf: 0.42 (15% EtOAc in PE); 
1
H NMR (500 MHz, DMSO-d6) δ −0.09 (s, 9H, CH2Si(CH3)3), 0.86 (t, J = 7.6 Hz, 2H, 
CH2CH2Si), 3.59 (t, J = 7.6 Hz, 2H, OCH2CH2), 3.93 (s, 3H, ArOCH3), 5.70 (s, 2H, NCH2O), 7.77 (dd [app. t], J = 
7.9 Hz, 1H, ArH), 7.98 (d, J = 6.8 Hz, 1H, ArH), 8.25 (d, J = 7.4 Hz, 1H, ArH), 8.35 (s, 1H, ArH), 8.54 (s, 1H, ArH) 
ppm; 
13
C NMR (500 MHz, DMSO-d6) δ −1.4, 17.1, 54.0, 66.1, 71.9, 103.4, 112.9, 113.5, 122.3, 124.9, 129.5, 
133.8, 137.0, 147.4, 151.7, 152.4, 161.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C
19
H
24
BrN
4
O
4
Si: 
479.0750; found: 479.0744. 
4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-5-(3-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (31) 
Compound 31 was prepared according to the general procedure for Suzuki-
Miyaura cross coupling reaction. 6-Bromo-4-methoxy-5-(3-nitrophenyl)-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (400 mg, 
0.834 mmol) and 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]piperazine (303 mg, 1.00 mmol) were coupled and purification 
was achieved using flash column chromatography with elution gradient of 0 – 10% MeOH in DCM. Pure fractions 
were evaporated to dryness to afford compound 31 as a yellow foam (444 mg, 0.772 mmol, 93%).  
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Rf: 0.32 (5% MeOH in DCM); 
1
H NMR (600 MHz, DMSO-d6) δ −0.12 (s, 9H, CH2Si(CH3)3), 0.79 (t, J = 8.2 Hz, 
2H, CH2CH2Si), 2.18 (s, 3H, (CH2)2NCH3), 2.39 (m [app. t], J = 4.6 Hz, 4H, 2 × NCH2CH2N), 3.15 (m [app. t], J = 
4.6 Hz, 4H, 2 × NCH2CH2N), 3.50 (t, J = 8.2 Hz, 2H, OCH2CH2), 3.93 (s, 3H, ArOCH3), 5.45 (s, 2H, NCH2O), 
6.92 – 6.87 (m, 2H, 2 × ArH), 7.22 – 7.17 (m, 2H, 2 × ArH), 7.48 (dd [app. t], J = 8.0 Hz, 1H, ArH), 7.56 (d, J = 
7.8 Hz, 1H, ArH), 8.04 – 8.02 (m, 1H, ArH), 8.12 (dd [app. t], J = 1.9 Hz, 1H, ArH), 8.50 (s, 1H, ArH) ppm; 13C 
NMR (151 MHz, DMSO-d6) δ −1.5, 17.3, 25.0, 45.7, 47.1, 53.7, 54.4, 66.0, 70.5, 73.5, 103.1, 110.8, 114.4, 
118.0, 121.0, 125.3, 128.8, 128.9, 131.5, 131.8, 135.5, 137.1, 137.6, 147.2, 150.9, 150.9, 152.5, 162.2 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H39N6O4Si: 575.2802; found: 575.2806. 
3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}aniline (32) 
Compound 32 was prepared was according to the general procedure for 
aromatic nitro derivative reduction. 4-Methoxy-6-[4-(4-methylpiperazin-1-
yl)phenyl]-5-(3-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (240 mg, 0.418 mmol) was reduced and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 32 as a white 
foam (200 g, 0.367 mmol, 88%).  
Rf: 0.24 (5% MeOH in DCM); 
1
H NMR (500 MHz, DMSO-d6) δ −0.11 (s, 9H, CH2Si(CH3)3), 0.79 (t, J = 7.7 Hz, 
2H, CH2CH2Si), 2.21 (s, 3H, (CH2)2NCH3), 2.43 (br s, 4H, 2 × NCH2CH2N), 3.17 (br s, 4H, 2 × NCH2CH2N), 3.50 
(t, J = 7.7 Hz, 2H, OCH
2
CH
2
), 3.91 (s, 3H, ArOCH
3
), 4.92 (br s, 2H, ArNH
2
), 5.45 (s, 2H, NCH
2
O), 6.32 (d, J = 7.0 
Hz, 1H, ArH), 6.40 (d, J = 7.1 Hz, 1H, ArH), 6.51 (s, 1H, ArH), 6.85 (d, J = 7.9 Hz, 1H, ArH), 6.91 – 6.87 (m, 2H, 
2 × ArH), 7.24 – 7.17 (m, 2H, 2 × ArH), 8.46 (s, 1H, ArH) ppm; 13C NMR (500 MHz, DMSO-d6) δ −1.4, 17.3, 
45.7, 47.1, 53.5, 54.5, 65.8, 70.5, 103.7, 112.3, 113.9, 114.2, 116.8, 118.9, 119.5, 127.8, 131.7, 134.4, 135.9, 
147.8, 150.4, 150.4, 152.3, 162.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H41N6O2Si: 
545.3060; found: 545.3061. 
3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-N-(2-methoxyethyl)aniline (33) 
Compound 33 was prepared according to the general procedure for aniline 
derivative monoalkylation. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-
yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}aniline (114 mg, 0.209 mmol)  was alkylated with 2-methoxyethyl 4-
methylbenzenesulfonate (32.0 mg, 0.139 mmol) and purification was 
achieved using flash column chromatography with elution gradient of 
0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 33 as a white foam (45.0 mg, 74.6 µmol, 53% isolated, 81% brsm).   
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Rf: 0.39 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.94 (t, J = 8.2 Hz, 2H, 
CH2CH2Si), 2.42 (s, 3H, (CH2)2NCH3), 2.66 (br s, 4H, 2 × NCH2CH2N), 3.16 (t, J = 5.1 Hz, 2H, NCH2CH2O), 3.30 
(br s, 4H, 2 × NCH2CH2N), 3.35 (s, 3H, CH2OCH3), 3.51 (t, J = 5.1 Hz, 2H, NCH2CH2O), 3.64 (t, J = 8.2 Hz, 2H, 
OCH2CH2), 4.01 (s, 3H, ArOCH3), 5.51 (s, 2H, NCH2O), 6.49 (dd, J = 8.0, 1.9 Hz, 1H, ArH), 6.60 (s, 1H, ArH), 
6.64 (d, J = 7.7 Hz, 1H, ArH), 6.86 – 6.83 (m, 2H, 2 × ArH), 7.03 (dd [app. t], J = 7.8 Hz, 1H, ArH), 7.31 – 7.29 
(m, 2H, 2 × ArH), 8.49 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ  −1.3, 18.1, 43.7, 45.9, 48.1, 53.7, 54.9, 
58.9, 66.6, 70.9, 71.1, 104.5, 112.0, 114.5, 115.3, 115.9, 121.0, 121.4, 128.3, 132.4, 134.9, 136.5, 147.5, 150.5, 
150.8, 153.0, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C33H47N6O3Si: 603.3479; found: 
603.3480. 
3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-N-(1-methoxypropan-2-yl)aniline (34)  
 Compound 34 was prepared according to the general procedure for aniline 
derivative monoalkylation. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-
yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}aniline (253 mg, 0.464 mmol)  was alkylated with 1-methoxypropan-2-
yl 4-methylbenzenesulfonate (76 mg, 0.311 mmol) and purification was 
achieved using flash column chromatography with elution gradient of 0 – 
20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 34 as a white foam (111 mg, 0.180 mmol, 58% isolated, 86% brsm).  
Rf: 0.43 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.93 (t, J = 8.3 Hz, 2H, 
CH2CH2Si), 1.81 – 1.73 (m, 3H, CH3CHCH2), 2.38 (s, 3H, (CH2)2NCH3), 2.61 (br s, 4H, 2 × NCH2CH2N), 3.28 – 
3.22 (m, 6H, 2 × NCH2CH2N and CHCH2OCH3), 3.31 (s, 3H, CHCH2OCH3), 3.44 (t, J = 8.3 Hz, 2H, CH2CH2Si), 
3.64 (m, 1H, CH3CHCH2), 4.01 (s, 3H, ArOCH3), 5.51 (s, 2H, NCH2O), 6.46 (dd, J = 8.0, 1.7 Hz, 1H, ArH), 6.55 
(s, 1H, ArH), 6.59 (s, 1H, ArH), 6.60 (m, 1H, ArH), 6.86 – 6.83 (m, 2H, 2 × ArH), 7.01 (dd [app. t], J = 8.0 Hz, 1H, 
ArH), 7.31 – 7.28 (m, 2H, 2 × ArH), 8.49 (s, 1H, ArNH) ppm; 13C NMR (126 MHz, CDCl3) δ −1.3, 18.1, 29.3, 
41.8, 46.0, 48.0, 48.2, 53.7, 55.0, 58.7, 58.8, 66.6, 70.9, 71.2, 104.4, 111.5, 114.6, 115.2, 115.6, 120.5, 121.2, 
128.3, 132.3, 134.8, 136.5, 147.7, 150.6, 150.7, 153.0, 163.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C34H49N6O3Si: 617.3635; found: 617.3639.  
N-(2-Ethoxyethyl)-3-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl}aniline (35) 
Compound 35 was prepared according to the general procedure for aniline derivative monoalkylation. 3-{4-
Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}aniline (267 mg, 0.490 mmol)  was alkylated with 2-ethoxyethyl 4-methylbenzenesulfonate (80.0 mg, 0.327 
mmol) and purification was achieved using flash column chromatography with elution gradient of 0 – 20% MeOH 
in DCM. Pure fractions were evaporated to dryness to afford compound 35 as a white foam (121 mg, 0.196 mmol, 
59% isolated, 85% brsm). 
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 Rf: 0.41 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ −0.05 (s, 9H, 
CH2Si(CH3)3), 0.94 (t, J = 8.2 Hz, 2H, CH2CH2Si), 1.20 (t, J = 7.0 Hz, 3H, 
OCH2CH3), 2.39 (s, 3H, (CH2)2NCH3), 2.63 (br s, 4H, 2 × NCH2CH2N), 3.17 
(t, J = 5.2 Hz, 2H, NCH2CH2O), 3.28 (br s, 4H, 2 × NCH2CH2N), 3.49 (q, J 
= 7.0 Hz, 2H, OCH2CH3), 3.55 (t, J = 5.2 Hz, 2H, NCH2CH2O), 3.64 (t, J 
= 8.2 Hz, 2H, OCH2CH2), 4.01 (s, 3H, ArOCH3), 5.51 (s, 2H, NCH2O), 6.50 
(dd, J = 8.0, 1.8 Hz, 1H, ArH), 6.62 (s, 1H, ArH), 6.63 (d, J = 7.9 Hz, 1H, 
ArH), 6.86 – 6.83 (m, 2H, 2 × ArH), 7.02 (dd [app. t], J = 7.7 Hz, 1H, ArH), 7.32 – 7.28 (m, 2H, 2 × ArH), 8.49 
(s, 1H, ArH) ppm; 13C NMR (126 MHz, CDCl3) δ −1.3, 15.3, 18.1, 43.8, 46.0, 48.2, 53.7, 55.0, 66.5, 66.6, 69.0, 
70.9, 104.5, 112.0, 114.5, 115.2, 116.0, 121.0, 121.3, 128.3, 132.4, 134.9, 136.5, 147.6, 150.6, 150.7, 153.0, 
163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C34H49N6O3Si: 617.3635; found: 617.3638. 
N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}phenyl)-N-(2-methoxyethyl)acrylamide (36) 
Compound 36 was prepared according to the general procedure for aniline 
derivative acylation. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(2-
methoxyethyl)aniline (73.0 mg, 0.121 mmol) was acylated and purification 
was achieved using flash column chromatography with elution gradient of 
0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 36 as a white solid (51.0 mg, 77.6 µmol, 65%).    
Rf: 0.33 (5% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.03 (s, 9H, CH2Si(CH3)3), 0.95 (t, J = 8.4 Hz, 2H, 
CH2CH2Si), 2.44 (s, 3H, (CH2)2NCH3), 2.68 (br s, 4H, 2 × NCH2CH2N), 3.30 (s, 3H, CH2OCH3), 3.32 (br s, 4H, 2 
× NCH2CH2N), 3.49 (t, J = 6.1 Hz, 2H, NCH2CH2O), 3.67 (t, J = 8.4 Hz, 2H, OCH2CH2), 3.86 (t, J = 6.1 Hz, 2H, 
NCH2CH2O), 4.02 (s, 3H, ArOCH3), 5.48 (dd, J = 10.3, 2.0 Hz, 1H, CCH=CH2), 5.52 (s, 2H, NCH2O), 6.01 (dd, J 
= 16.8, 10.3 Hz, 1H, CCH=CH2), 6.33 (dd, J = 16.8, 2.0 Hz, 1H, CCH=CH2), 6.88 – 6.84 (m, 2H, 2 × ArH), 7.05 
– 7.01 (m, 1H, ArH), 7.13 – 7.11 (m, 1H, ArH), 7.26 (s, 1H, ArH), 7.30 – 7.28 (m, 2H, 2 × ArH), 7.31 (dd, J = 6.1, 
1.7 Hz, 1H, ArH), 8.52 (s, 1H, ArH) ppm; 13C NMR (101 MHz, CDCl3) δ  −1.3, 18.1, 45.9, 47.9, 48.7, 53.8, 54.9, 
58.7, 66.8, 69.3, 71.0, 104.2, 113.0, 115.4, 120.5, 126.2, 127.6, 128.6, 128.8, 130.7, 131.0, 132.4, 135.9, 137.2, 
141.3, 150.8, 151.1, 153.1, 163.1, 165.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C36H49N6O4Si: 
657.3585; found: 657.3591. 
N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}phenyl)-N-(1-methoxypropan-2-yl)acrylamide (37)  
Compound 37 was prepared according to the general procedure for aniline derivative acylation. 3-{4-Methoxy-6-
[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(1-
methoxypropan-2-yl)aniline (111 mg, 0.180 mmol) was acylated and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM.  
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Pure fractions were evaporated to dryness to afford compound 37 as a white 
solid (81.0 mg, 0.121 mmol, 67%).  
Rf: 0.36 (5% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.03 (s, 9H, 
CH2Si(CH3)3), 0.95 (t, J = 8.2 Hz, 2H, CH2CH2Si), 1.81 – 1.74 (m, 3H, 
CH3CHCH2), 2.45 (s, 3H, (CH2)2NCH3), 2.70 (br s, 4H, 2 × NCH2CH2N), 
3.27 (s, 3H, CHCH2OCH3), 3.34 (br s, 4H, 2× NCH2CH2N), 3.42 – 3.35 
(m, 2H, CHCH2OCH3), 3.67 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 3.80 – 3.74 (m, 1H, CH3CHCH2), 4.02 (s, 3H, 
ArOCH3), 5.46 (dd, J = 10.3, 1.8 Hz, 1H, CCH=CH2), 5.52 (s, 2H, NCH2O), 5.98 (dd, J = 16.8, 10.3 Hz, 1H, 
CCH=CH2), 6.32 (dd, J = 16.8, 1.8 Hz, 1H, CCH=CH2), 6.88 – 6.85 (m, 2H, 2 × ArH), 7.00 – 6.96 (m, 1H, ArH), 
7.09 (s, 1H, ArH), 7.26 (s, 1H, ArH), 7.29 (m, 2H, 2 × ArH), 7.31 (dd, J = 7.0, 0.8 Hz, 1H, ArH), 8.52 (s, 1H, ArH) 
ppm; 
13
C NMR (101 MHz, CDCl3) δ −1.3, 18.1, 28.1, 45.8, 47.0, 47.8, 53.8, 54.8, 58.7, 66.8, 70.5, 71.0, 104.2, 
112.9, 115.4, 120.6, 126.0, 127.4, 128.7, 128.9, 130.7, 131.0, 132.4, 135.9, 137.2, 141.1, 150.7, 151.1, 153.1, 
163.1, 165.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C37H51N6O4Si: 671.3741; found: 671.3741.  
N-(2-Ethoxyethyl)-N-(3-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)acrylamide (38) 
Compound 38 was prepared according to the general 
procedure for aniline derivative acylation. N-(2-Ethoxyethyl)-3-{4-methoxy-
6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl}aniline (165 mg, 0.267 mmol) was acylated 
and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated 
to dryness to afford compound 38 as a white solid (160 mg, 0.238 mmol, 
89%).   
Rf: 0.36 (5% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.02 (s, 9H, CH2Si(CH3)3), 0.96 (t, J = 8.4 Hz, 2H, 
CH
2
CH
2
Si), 1.13 (t, J = 7.0 Hz, 3H, OCH
2
CH
3
), 2.52 (s, 3H, (CH
2
)
2
NCH
3
), 2.80 (br s, 4H, 2 × NCH
2
CH
2
N), 3.40 
(br s, 4H, 2 × NCH
2
CH
2
N), 3.45 (q, J = 7.0 Hz, 2H, OCH
2
CH
3
), 3.57 (t, J = 6.2 Hz, 2H, NCH
2
CH
2
O), 3.68 (t, J = 
8.4 Hz, 2H, OCH2CH2), 3.88 (t, J = 6.2 Hz, 2H, NCH2CH2O), 4.03 (s, 3H, ArOCH3), 5.48 (dd, J = 10.3, 2.0 Hz, 
1H, CCH=CH2), 5.53 (s, 2H, NCH2O), 6.01 (dd, J = 16.7, 10.3 Hz, 1H, CCH=CH2), 6.34 (dd, J = 16.8, 2.0 Hz, 
1H, CCH=CH2), 6.89 – 6.86 (m, 2H, 2 × ArH), 7.08 – 7.04 (m, 1H, ArH), 7.16 – 7.14 (m, 1H, ArH), 7.28 (s, 1H, 
ArH), 7.30 – 7.28 (m, 2H, 2 × ArH), 7.30 (dd, J = 7.0, 0.8 Hz, 1H, ArH), 8.54 (s, 1H, ArH) ppm; 13C NMR (101 
MHz, CDCl3) δ −1.3, 15.3, 18.1, 45.4, 47.6, 49.1, 53.8, 54.6, 66.3, 66.8, 67.3, 71.0, 104.2, 113.1, 115.6, 120.9, 
126.3, 127.5, 128.6, 128.9, 130.6, 131.0, 132.5, 135.8, 137.0, 141.5, 150.6, 151.1, 153.1, 163.1, 165.7 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C37H51N6O4Si: 671.3741; found: 671.3746. 
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3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}aniline (39) 
Compound 39 was prepared according to the general procedure for N-SEM 
deprotection. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}aniline 
(180 mg, 0.330 mmol) was deprotected and purification was achieved using 
flash column chromatography with elution gradient of 0 – 20% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 39 as a white solid (111 mg, 0.268 mmol, 
81%).  
Rf: 0.43 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 2.34 (s, 3H, (CH2)2NCH3), 2.53 (br s, 4H, 2 × 
NCH2CH2N), 3.10 (br s, 4H, 2 × NCH2CH2N), 3.69 (br s, 2H, ArNH2), 3.78 (s, 3H, ArOCH3), 6.58 (s, 1H, ArH), 
6.61 (d, J = 8.1 Hz, 1H, ArH), 6.69 (s, 1H, ArH), 6.76 – 6.70 (m, 2H, 2 × ArH), 6.86 (d, J = 7.2 Hz, 1H, ArH), 
7.13 – 7.09 (m, 2H, 2 × ArH), 7.13 (d, J = 7.5 Hz, 1H, ArH), 8.18 (s, 1H, ArH), 13.28 (s, 1H, ArNH) ppm; 13C NMR 
(126 MHz, CDCl3) δ 46.1, 47.9, 53.5, 55.1, 106.0, 111.2, 113.3, 115.2, 118.4, 121.9, 128.7, 129.1, 134.0, 135.9, 
146.1, 149.6, 150.2, 152.1, 163.0, 171.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C24H27N6O: 
415.2246; found: 415.2245. 
3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(2-
methoxyethyl)aniline (40) 
Compound 40 was prepared according to the general procedure for N-SEM 
deprotection. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(2-
methoxyethyl)aniline (60.0 mg, 0.100 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 40 as a white solid (36.0 mg, 76.1 µmol, 76%).  
Rf: 0.48 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 2.40 (s, 3H, (CH2)2NCH3), 2.62 (br s, 4H, 2 × 
NCH2CH2N), 3.24 (br s, 4H, 2 × NCH2CH2N), 3.29 (t, J = 6.2 Hz,  2H, NCH2CH2O), 3.37 (s, 3H, CH2OCH3), 3.58 
(t, J = 6.2 Hz, 2H, NCH2CH2O), 3.93 (s, 3H, ArOCH3), 6.61 (d, J = 7.6 Hz, 1H, ArH), 6.79 (s, 1H, ArH), 6.85 – 6.81 
(m, 2H, 2 × ArH), 7.16 (dd [app. t], J = 7.5 Hz, 1H, ArH), 7.34 – 7.30 (m, 2H, 2 × ArH), 8.34 (s, 1H, ArH), 13.15 
(s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 43.8, 46.0,  48.0, 53.7, 55.0, 58.9, 71.2, 106.2, 111.9, 111.9, 
115.4, 116.1, 121.1, 122.8, 128.7, 129.4, 133.9, 135.6, 147.9, 149.8, 150.3, 152.3, 163.3 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C27H33N6O2: 473.2665; found: 473.2661. 
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3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(1-methoxypropan-2-
yl)aniline (41) 
Compound 41 was prepared according to the general procedure for N-SEM 
deprotection. 3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-(1-
methoxypropan-2-yl)aniline (68.0 mg, 0.110 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 41 as a white solid (41.0 mg, 84.2 µmol, 77%).  
Rf: 0.54 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.18 (d, J = 6.4 Hz, 3H, CH3CHCH2), 2.44 (s, 3H, 
(CH2)2NCH3), 2.67 (br s, 4H, 2 × NCH2CH2N), 3.28 (br s, 4H, 2 × NCH2CH2N), 3.34 (s, 3H, CHCH2OCH3), 3.42 
– 3.35 (m, 2H, CHCH2OCH3), 3.67 – 3.60 (m, 1H, CH3CHCH2), 3.95 (s, 3H, ArOCH3), 6.59 (d, J = 8.1 Hz, 1H, 
ArH), 6.76 (s, 1H, ArH), 6.79 (d, J = 7.6 Hz, 1H, ArH), 6.88 – 6.82 (m, 2H, 2 × ArH), 7.14 (dd [app. t], J = 7.6 Hz, 
1H, ArH), 7.37 – 7.32 (m, 2H, 2 × ArH), 8.35 (s, 1H, ArH), 13.05 (s, 1H, ArNH) ppm; 13C NMR (126 MHz, CDCl3) 
δ 18.0, 45.9, 48.0, 48.5, 53.7, 54.9, 59.2, 76.2, 106.1, 112.0, 112.7, 115.6, 116.3, 120.8, 123.1, 128.8, 129.5, 
133.9, 135.6, 147.2, 149.9, 150.3, 152.3, 163.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C28H35N6O2: 487.2821; found: 487.2821.  
N-(2-Ethoxyethyl)-3-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}aniline (42) 
Compound 42 was prepared according to the general procedure for N-SEM 
deprotection. N-(2-Ethoxyethyl)-3-{4-methoxy-6-[4-(4-methylpiperazin-1-
yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}aniline (74.0 mg, 0.120 mmol) was deprotected and purification was 
achieved using flash column chromatography with elution gradient of 0 – 
20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 42 as a white solid (44.0 mg, 90.4 µmol, 76%).  
Rf: 0.55 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.21 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.41 (s, 3H, 
(CH
2
)
2
NCH
3
), 2.64 (br s, 4H, 2 × NCH
2
CH
2
N), 3.26 (br s, 4H, 2 × NCH
2
CH
2
N), 3.28 (t, J = 5.1 Hz, 2H, 
NCH2CH2O), 3.52 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.62 (t, J = 5.1 Hz, 2H, NCH2CH2O), 3.93 (s, 3H, ArOCH3), 
6.79 (s, 1H, ArH), 6.81 (d, J = 7.8 Hz, 1H, ArH), 6.88 – 6.82 (m, 2H, 2 × ArH), 7.16 (dd [app. t], J = 7.8 Hz, 1H, 
ArH), 7.35 – 7.31 (m, 2H, 2 × ArH), 8.35 (s, 1H, ArH), 13.14 (s, 1H, ArH) ppm; 13C NMR (126 MHz, CDCl3) δ 15.3, 
43.9, 46.0, 48.0, 53.7, 55.0, 66.5, 69.1, 106.2, 111.9, 111.9, 115.4, 116.1, 121.0, 122.9, 128.7, 129.4, 133.9, 
135.6, 148.0, 149.8, 150.3, 152.3, 163.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C
28
H
35
N
6
O
2
: 
487.2821; found: 487.2820. 
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N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-N-(2-
methoxyethyl)acrylamide (43) 
Compound 43 was prepared according to the general procedure for N-SEM 
deprotection. N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-N-
(2-methoxyethyl)acrylamide (51.0 mg, 77.6 µmol) was deprotected and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 43 as a white solid (32.0 mg, 60.7 µmol, 79%).  
Rf: 0.40 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 2.40 (s, 3H, (CH2)2NCH3), 2.64 (br s, 4H, 2 × 
NCH2CH2N), 3.29 (s, 3H, CH2OCH3), 3.30 (br s, 4H, 2 × NCH2CH2N), 3.56 (t, J = 6.0 Hz, 2H, NCH2CH2O), 3.95 
(t, J = 6.0 Hz, 2H, NCH2CH2O), 3.99 (s, 3H, ArOCH3), 5.50 (dd, J = 10.3, 1.6 Hz, 1H, CCH=CH2), 6.14 (dd, J = 
16.7, 10.3 Hz, 1H, CCH=CH2), 6.36 (dd, J = 16.8, 1.6 Hz, 1H, CCH=CH2), 6.91 – 6.88 (m, 2H, 2 × ArH), 7.12 
(d, J = 7.8 Hz, 1H, ArH), 7.30 (s, 1H, ArH), 7.34 (dd [app. t], J = 7.7 Hz, 1H, ArH), 7.37 – 7.35 (m, 2H, 2 × ArH), 
7.40 (d, J = 7.7 Hz, 1H, ArH), 8.37 (s, 1H, ArH), 13.28 (s, 1H, ArNH), ppm; 
13
C NMR (151 MHz, CDCl3) δ 46.0, 
48.1, 48.9, 53.8, 54.9, 58.7, 69.5, 105.8, 110.3, 115.6, 122.2, 126.5, 127.6, 128.9, 129.0, 129.6, 130.8, 131.1, 
134.7, 136.4, 141.7, 150.1, 150.8, 152.5, 163.2, 165.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C30H35N6O3: 527.2771; found: 527.2773.  
N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)-N-(1-
methoxypropan-2-yl)acrylamide (44) 
Compound 44 was prepared according to the general procedure for N-SEM 
deprotection. N-(3-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}phenyl)-N-(1-methoxypropan-2-yl)acrylamide (47.0 mg, 70.1 µmol) was 
deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 44 as a white solid (28.0 mg, 51.8 µmol, 75%).  
Rf: 0.42 (10% MeOH in DCM); 
1
H NMR (500 MHz, DMSO-d
6
) δ 1.68 – 1.60 (m, 3H, CH
3
CHCH
2
), 2.22 (s, 3H, 
(CH2)2NCH3), 2.44 (br s, 4H, 2 × NCH2CH2N), 3.15 (s, 3H, CHCH2OCH3), 3.16 (br s, 4H, 2 × NCH2CH2N), 3.30 
– 3.26 (m, 2H, CHCH2OCH3), 3.73 – 3.68 (m, 1H, CH3CHCH2), 3.89 (s, 3H, ArOCH3), 5.56 (d, J = 10.2 Hz, 1H, 
CCH=CH2), 6.01 (dd, J = 16.6, 10.2 Hz, 1H, CCH=CH2), 6.13 (dd, J = 16.6, 2.1 Hz, 1H, CCH=CH2), 6.90 – 6.86 
(m, 2H, 2 × ArH), 7.11 (s, 1H, ArH), 7.16 (d, J = 7.3 Hz, 1H, ArH), 7.21 – 7.19 (m, 2H, 2 × ArH), 7.33 (d, J = 7.7 
Hz, 1H, ArH), 7.42 (dd [app. t], J = 7.7 Hz, 1H, ArH), 8.38 (s, 1H, ArH), 12.43 (s, 1H, ArNH) ppm; 
13
C NMR (126 
MHz, DMSO-d6) δ 27.6, 45.7, 46.2, 47.2, 53.4, 54.5, 57.9, 69.6, 104.5, 109.2, 114.6, 120.6, 126.1, 127.4, 128.9, 
129.2, 129.4, 130.3, 130.8, 134.0, 136.3, 141.1, 150.3, 150.3, 152.3, 162.2, 164.0 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C31H37N6O3: 541.2927; found: 541.2928.    
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N-(2-Ethoxyethyl)-N-(3-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}phenyl)acrylamide (45) 
Compound 45 was prepared according to the general procedure for N-SEM 
deprotection. N-(2-Ethoxyethyl)-N-(3-{4-methoxy-6-[4-(4-methylpiperazin-
1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}phenyl)acrylamide (60.0 mg, 89.4 µmol) was deprotected 
and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated 
to dryness to afford compound 45 as a white solid (36.0 mg, 66.6 µmol, 73%).  
Rf: 0.41 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.11 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.44 (s, 3H, 
(CH2)2NCH3), 2.70 (br s, 4H, 2 × NCH2CH2N), 3.34 (br s, 4H, 2 × NCH2CH2N), 3.44 (q, J = 7.0 Hz, 2H, OCH2CH3), 
3.62 (t, J = 6.1 Hz, 2H, NCH2CH2O), 3.95 (t, J = 6.1 Hz, 2H, NCH2CH2O), 4.00 (s, 3H, ArOCH3), 5.50 (d, J = 10.6 
Hz, 1H, CCH=CH2), 6.15 (dd, J = 16.8, 10.6 Hz, 1H, CCH=CH2), 6.36 (dd, J = 16.8, 1.9 Hz, 1H, CCH=CH2), 
6.92 – 6.89 (m, 2H, 2 × ArH), 7.13 (d, J = 7.8 Hz, 1H, ArH), 7.31 (s, 1H, ArH), 7.34 (dd [app. t], J = 7.7 Hz, 1H, 
ArH), 7.38 – 7.36 (m, 2H, 2 × ArH), 7.39 (d, J = 7.7 Hz, 1H, ArH), 8.39 (s, 1H, ArH), 13.03 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ 15.3, 45.9, 48.0, 49.3, 53.8, 54.9, 66.3, 67.4, 105.8, 110.4, 115.7, 122.4, 126.5, 
127.6, 128.9, 129.0, 129.7, 130.7, 131.2, 134.5, 136.3, 142.0, 150.2, 150.7, 152.5, 163.3, 165.7 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C31H37N6O3: 541.2927; found: 541.2929. 
5-(4-Fluoro-3-nitrophenyl)-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (46) 
Compound 46 was prepared according to the general procedure for Suzuki-
Miyaura cross coupling reaction. 5-Iodo-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidine (1.00 g, 2.47 mmol) and (4-fluoro-3-nitrophenyl)boronic 
acid (548 mg, 2.96 mmol) were coupled and purification was achieved using flash column 
chromatography with elution gradient of 0 – 50% EtOAc in PE. Pure fractions were 
evaporated to dryness to afford compound 46 as a yellow semi-solid (890 mg, 2.12 mmol, 
86%).  
Rf: 0.63 (30% EtOAc in PE); 
1
H NMR (700 MHz, DMSO-d6) δ −0.09 (s, 9H, CH2Si(CH3)3), 0.84 (t, J = 8.0 Hz, 2H, 
CH
2
CH
2
Si), 3.56 (t, J = 8.0, 2H, OCH
2
CH
2
), 4.05 (s, 3H, ArOCH
3
), 5.61 (s, 2H, NCH
2
O), 7.62 (dd, J = 11.1, 8.8 
Hz, 1H, ArH), 8.03 (s, 1H, ArH), 8.11 – 8.07 (m, 1H, ArH), 8.49 (dd, J = 7.3, 2.2 Hz, 1H, ArH), 8.50 (s, 1H, ArH) 
ppm; 
13
C NMR (176 MHz, DMSO-d6) δ −1.5, 17.1, 53.8, 65.9, 72.8, 102.1, 112.8, 118.4 (d, J = 20.8 Hz), 125.2 
(d, J = 2.3 Hz), 126.7, 130.9 (d, J = 3.8 Hz), 135.5 (d, J = 8.4 Hz), 136.6 (d, J = 7.7 Hz), 151.3, 152.5, 152.7, 
162.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C19H24N4O4SiF: 419.1551; found: 419.1550. 
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General procedure for nucleophilic aromatic substitution:
29
 
A flame-dried, 2-neck round-bottomed flask was charged with sodium hydride (60% dispersion in oil, 1.7 equiv.), 
purged with Ar and to this was added THF (10 mL/mmol fluorinated aromatic derivative). The resulting suspension 
was cooled to −10 °C (acetone/ice) and to this was added a solution of glycol ether (1.2 equiv.) in THF (5 mL/mmol 
fluorinated aromatic derivative) dropwise. The solution was then allowed to warm to rt and stirred for 1 h. After 
recooling the solution to −10 °C (acetone/ice), a solution of fluorinated aromatic derivative (1 equiv.) in THF (5 
mL/mmol fluorinated aromatic derivative) was added dropwise and the reaction mixture was then allowed to warm 
to rt and stirred for 16 h or until complete consumption of the starting material as indicated by TLC.  The reaction 
mixture was then quenched and diluted with H2O (20 mL/mmol fluorinated aromatic derivative) and EtOAc (20 
mL/mmol fluorinated aromatic derivative) and the organic layer was separated. The aqueous layer was extracted 
with aliquots of EtOAc (3 × 10 mL/mmol fluorinated aromatic derivative) and the combined organic layers were 
then washed with a saturated solution of brine (3 × 20 mL/mmol fluorinated aromatic derivative), dried over MgSO4 
and filtered. After removal of the solvent in vacuo, the crude product was adsorbed onto silica and purification was 
achieved using flash column chromatography. Pure fractions were evaporated to dryness to afford the respective 
compound. 
4-Methoxy-5-[4-(2-methoxyethoxy)-3-nitrophenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidine (47) 
Compound 47 was prepared according to the general procedure for general procedure 
for nucleophilic aromatic substitution. 5-(4-Fluoro-3-nitrophenyl)-4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (440 mg, 1.05 mmol) was 
reacted with 2-methoxyethanol (95.0 mg, 1.26 mmol) and purification was achieved using 
flash column chromatography with elution gradient of 0 – 50% EtOAc in PE. Pure fractions 
were evaporated to dryness to afford compound 46 as a yellow semi-solid (354 mg, 0.746 
mmol, 71%).  
Rf: 0.29 (20% EtOAc in PE); 
1
H NMR (500 MHz, CDCl
3
) δ −0.06 (s, 9H, CH
2
Si(CH
3
)
3
), 0.92 (t, J = 8.2 Hz, 2H, 
CH
2
CH
2
Si), 3.46 (s, 3H, CH
2
OCH
3
), 3.56 (t, J = 8.2 Hz, 2H, OCH
2
CH
2
Si), 3.82 (t, J = 5.0 Hz, 2H, OCH
2
CH
2
O), 
4.10 (s, 3H, ArOCH3), 4.29 (t, J = 5.0 Hz, 2H, OCH2CH2O), 5.65 (s, 2H, NCH2O), 7.14 (d, J = 8.7 Hz, 1H, ArH), 
7.30 (s, 1H, ArH), 7.78 (dd, J = 8.7, 2.2 Hz, 1H, ArH), 8.23 (d, J = 2.2 Hz, 1H, ArH), 8.51 (s, 1H, ArH) ppm; 13C 
NMR (126 MHz, CDCl3) δ −1.3, 17.8, 54.1, 59.6, 66.8, 69.8, 70.8, 73.2, 103.2, 115.1, 115.5, 123.7, 126.0, 127.1, 
134.0, 134.0, 151.2, 151.6, 153.0, 163.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C22H31N4O6Si: 
475.2013; found: 475.2013. 
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4-Methoxy-5-{4-[(1-methoxypropan-2-yl)oxy]-3-nitrophenyl}-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (48) 
Compound 48 was prepared according to the general procedure for general procedure 
for nucleophilic aromatic substitution. 5-(4-Fluoro-3-nitrophenyl)-4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (500 mg, 1.19 mmol) was 
reacted with 1-methoxypropan-2-ol (129 mg, 1.43 mmol) and purification was achieved 
using flash column chromatography with elution gradient of 0 – 50% EtOAc in PE. Pure 
fractions were evaporated to dryness to afford compound 48 as a yellow semi-solid (425 
mg, 0.870 mmol, 73%).  
Rf: 0.37 (20% EtOAc in PE); 
1
H NMR (700 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.93 (t, J = 8.4 Hz, 2H, 
CH2CH2Si), 1.40 (d, J = 6.3 Hz, 3H, CH3CHCH2), 3.42 (s, 3H, CHCH2OCH3), 3.56 – 3.54 (m, 1H, CHCH2OCH3), 
3.57 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.68 – 3.64 (m, 1H, CHCH2OCH3), 4.12 (s, 3H, ArOCH3), 4.71 – 4.68 (m, 
1H, CH3CHCH2), 5.66 (s, 2H, NCH2O), 7.20 (d, J = 8.7 Hz, 1H, ArH), 7.31 (s, 1H, ArH), 7.76 (dd, J = 8.7, 2.1 Hz, 
1H, ArH), 8.18 (d, J = 2.1 Hz, 1H, ArH), 8.52 (s, 1H, ArH) ppm; 
13
C NMR (176 MHz, CDCl3) δ −1.3, 17.1, 17.9, 
54.1, 59.6, 66.8, 73.3, 76.1, 76.5, 103.3, 115.7, 116.8, 123.7, 125.8, 127.0, 133.7, 141.0, 150.5, 151.5, 152.9, 
163.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C23H33N4O6Si: 489.2169; found: 489.2170. 
5-[4-(2-Ethoxyethoxy)-3-nitrophenyl]-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidine (49) 
Compound 49 was prepared according to the general procedure for general procedure 
for nucleophilic aromatic substitution. 5-(4-Fluoro-3-nitrophenyl)-4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (500 mg, 1.19 mmol) was 
alkylated with 2-ethoxyethanol (129 mg, 1.43 mmol)  and purification was achieved 
using flash column chromatography with elution gradient of 0 – 50% EtOAc in PE. Pure 
fractions were evaporated to dryness to afford compound 49 as a yellow semi-solid 
(430 mg, 0.881 mmol, 74%).  
Rf: 0.38 (20% EtOAc in PE); 
1
H NMR (700 MHz, CDCl3) δ −0.04 (s, 9H, CH2Si(CH3)3), 0.94 (t, J = 8.4 Hz, 2H, 
CH2CH2Si), 1.24 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.58 (t, J = 8.4 Hz 2H, OCH2CH2Si), 3.64 (q, J = 7.0 Hz, 2H, 
OCH
2
CH
3
), 3.87 (t, J = 4.6 Hz, 2H, OCH
2
CH
2
O), 4.13 (s, 3H, ArOCH
3
), 4.31 (t, J = 4.6 Hz, 2H, OCH
2
CH
2
O), 5.67 
(s, 2H, NCH2O), 7.16 (d, J = 8.7 Hz, 1H, ArH), 7.32 (s, 1H, ArH), 7.78 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 8.23 (d, J = 
2.2 Hz, 1H, ArH), 8.53 (s, 1H, ArH) ppm; 
13
C NMR (176 MHz, CDCl3) δ −1.3, 15.3, 17.9, 54.3, 66.9, 67.3, 68.8, 
70.0, 73.4, 103.3, 115.2, 115.7, 123.8, 126.0, 126.9, 134.0, 140.0, 151.3, 151.4, 152.7, 163.5 ppm; HRMS-TOF 
MS ESI+: m/z [M+H]
+
 calculated for C23H33N4O6Si: 489.2169; found: 489.2172. 
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5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-(2-
methoxyethoxy)aniline (50)  
Compound 50 was prepared was according to the general procedure for aromatic nitro 
derivative reduction. 4-Methoxy-5-[4-(2-methoxyethoxy)-3-nitrophenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (125 mg, 0.263 mmol) was 
reduced and purification was achieved using flash column chromatography with elution 
gradient of 0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 50 as a yellow solid (112 mg, 0.252 mmol, 96%).  
Rf: 0.52 (2% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3), 
0.91 (t, J = 8.4 Hz, 2H, CH2CH2Si), 3.43 (s, 3H, CH2OCH3), 3.55 (t, J = 8.4 Hz,  2H, 
OCH2CH2Si), 3.78 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.08 (s, 3H, ArOCH3), 4.20 (t, J = 4.8 Hz, 2H, OCH2CH2O), 
4.45 (br s, 2H, ArNH2), 5.62 (s, 2H, NCH2O), 6.88 (d, J = 8.4 Hz, 1H, ArH), 7.10 (dd, J = 8.3, 2.1 Hz, 1H, ArH), 
7.20 (s, 1H, ArH), 7.21 (d, J = 2.1 Hz, 1H, ArH), 8.47 (s, 1H, ArH) ppm; 13C NMR (101 MHz, CDCl3) δ −1.3, 17.8, 
53.5, 59.2, 66.6, 68.5, 71.2, 73.1, 103.5, 112.8, 117.7, 117.7, 121.1, 123.3, 127.7, 133.7, 146.6, 151.3, 153.0, 
163.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C22H33N4O4Si: 445.2271; found: 445.2266. 
5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-[(1-methoxypropan-2-
yl)oxy]aniline (51) 
Compound 51 was prepared was according to the general procedure for aromatic nitro 
derivative reduction. 4-Methoxy-5-{4-[(1-methoxypropan-2-yl)oxy]-3-nitrophenyl}-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (102 mg, 0.209 mmol) 
was reduced and purification was achieved using flash column chromatography with 
elution gradient of 0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 51 as a yellow solid (89.0 mg, 0.194 mmol, 92%).   
Rf: 0.49 (2% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ 0.02 (s, 9H, CH2Si(CH3)3), 
0.99 (t, J = 8.2 Hz, 2H, CH2CH2Si), 1.43 (d, J = 6.3 Hz, 3H, CH3CHCH2), 3.50 (s, 3H, CHCH2OCH3), 3.60 – 3.55 
(m, 1H, CHCH2OCH3) 3.63 (t, J = 8.2 Hz,  2H, OCH2CH2Si), 3.72 – 3.66 (m, 1H, CHCH2OCH3), 4.16 (s, 3H, 
ArOCH3), 4.20 (br s, 2H, ArNH2), 4.53 (m, 1H, CH3CHCH2), 5.69 (s, 2H, NCH2O), 6.99 (d, J = 8.3 Hz, 1H, ArH), 
7.08 (dd, J = 8.3, 2.1 Hz, 1H, ArH), 7.15 (d, J = 2.1 Hz, 1H, ArH), 7.27 (s, 1H, ArH), 8.55 (s, 1H, ArH); 
13
C NMR 
(101 MHz, CDCl3) δ −1.4, 17.3, 17.8, 53.7, 59.3, 66.5, 73.1, 75.0, 76.1, 103.4, 115.8, 116.5, 117.9, 119.3, 123.1, 
128.0, 137.3, 144.8, 151.2, 153.0, 163.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C23H35N4O4Si: 
459.2428; found: 459.2428. 
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2-(2-Ethoxyethoxy)-5-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline 
(52) 
Compound 52 was prepared was according to the general procedure for aromatic nitro 
derivative reduction. 5-[4-(2-Ethoxyethoxy)-3-nitrophenyl]-4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (118 mg, 0.241 mmol) 
was reduced and purification was achieved using flash column chromatography with 
elution gradient of 0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 52 as a yellow solid (98.0 mg, 0.214 mmol, 89%).  
Rf: 0.46 (2% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.07 (s, 9H, 
CH2Si(CH3)3), 0.90 (t, J = 8.2 Hz, 2H, CH2CH2Si), 1.23 (t, J = 7.0 Hz, 3H, OCH2CH3), 
3.54 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 3.59 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.80 (t, J = 5.0 Hz, 2H, OCH2CH2O), 
4.06 (s, 3H, ArOCH3), 4.18 (t, J = 5.0 Hz, 2H, OCH2CH2O), 4.50 (br s, 2H, ArNH2), 5.60 (s, 2H, NCH2O), 6.85 (d, 
J = 8.3 Hz, 1H, ArH), 7.03 (dd, J = 8.3, 2.1 Hz, 1H, ArH), 7.09 – 7.07 (m, 1H, ArH), 7.17 (s, 1H, ArH), 8.47 (s, 1H, 
ArH) ppm; 
13
C NMR (101 MHz, CDCl3) δ  −1.4, 15.3, 17.8, 53.7, 66.5, 66.8, 68.6, 69.1, 73.0, 103.4, 112.7, 116.7, 
117.8, 119.8, 123.1, 127.5, 135.5, 146.1, 151.2, 152.9, 163.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C23H35N4O4Si: 459.2428; found: 459.2430. 
N-[5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-(2-
methoxyethoxy)phenyl]acrylamide (53) 
Compound 53 was prepared according to the general procedure for aniline derivative 
acylation. 5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-2-(2-methoxyethoxy)aniline (49.0 mg, 0.110 mmol) was acylated 
and purification was achieved using flash column chromatography with elution 
gradient of 0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 53 as a white solid (49.0 mg, 98.2 µmol, 89%). 
Rf: 0.65 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.06 (s, 9H, 
CH2Si(CH3)3), 0.92 (t, J = 8.2 Hz, 2H, CH2CH2Si), 3.46 (s, 3H, CH2OCH3), 3.56 (t, J = 8.2 Hz,  2H, OCH2CH2Si), 
3.74 (t, J = 5.2 Hz, 2H, OCH2CH2O), 4.13 (s, 3H, ArOCH3), 4.22 (t, J = 5.2 Hz, 2H, OCH2CH2O), 5.64 (s, 2H, 
NCH
2
O), 5.75 (dd, J = 10.2, 1.0 Hz, 1H, CCH=CH
2
), 6.31 (dd, J = 16.8, 10.2 Hz, 1H, CCH=CH
2
), 6.42 (d, J = 
16.8 Hz, 1H, CCH=CH2), 7.00 (d, J = 8.4 Hz, 1H, ArH), 7.32 (s, 1H, ArH), 7.38 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 
8.32 (s, 1H, ArH), 8.50 (s, 1H, ArH), 8.86 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ −1.3, 17.8, 54.1, 59.2, 
66.6, 70.1, 71.0, 73.3, 103.5, 114.2, 117.8, 120.6, 123.9, 124.4, 127.2, 128.4, 129.3, 131.9, 146.4, 151.0, 152.7, 
163.5, 163.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C25H35N4O5Si: 499.2377; found: 499.2384.  
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N-[5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-[(1-methoxypropan-
2-yl)oxy]phenyl]acrylamide (54) 
Compound 54 was prepared according to the general procedure for aniline derivative 
acylation. 5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-2-[(1-methoxypropan-2-yl)oxy]aniline (55.0 mg, 0.120 mmol) was 
acylated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 54 as a white solid (54.0 mg, 0.105 mmol, 88%).  
Rf: 0.66 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 0.00 (s, 9H, CH2Si(CH3)3), 
0.98 (t, J = 8.2 Hz, 2H, CH2CH2Si), 1.44 (d, J = 6.4 Hz, 3H, CH3CHCH2), 3.52 (s, 3H, CHCH2OCH3), 3.59 – 3.56 
(m, 1H, CHCH2OCH3), 3.61 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 3.68 – 3.63 (m, 1H, CHCH2OCH3), 4.20 (s, 3H, 
ArOCH3), 4.38 – 4.34 (m, 1H, CH3CHCH2), 5.70 (s, 2H, NCH2O), 5.80 (dd, 1H, J = 10.2, 1.0 Hz, 1H, CCH=CH2), 
6.36 (dd, J = 16.8, 10.2 Hz, 1H, CCH=CH2), 6.49 (d, J = 16.8 Hz, 1H, CCH=CH2), 7.11 (d, J = 8.4 Hz, 1H, ArH), 
7.39 (s, 1H, ArH), 7.42 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 8.56 (s, 1H, ArH), 8.76 (s, 1H, ArH), 8.96 (s, 1H, ArNH), 
ppm; 
13
C NMR (151 MHz, CDCl3) δ −1.3, 17.1, 17.8, 54.1, 59.4, 66.6, 73.3, 76.0, 77.7, 103.5, 117.8, 118.2, 
120.7, 124.0, 124.3, 127.2, 129.2, 130.8, 131.8, 145.7, 150.9, 152.7, 163.6, 163.6 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C26H37N4O5Si: 513.2533; found: 513.2536.  
N-[2-(2-Ethoxyethoxy)-5-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)phenyl]acrylamide (55) 
Compound 55 was prepared according to the general procedure for aniline derivative 
acylation. 2-(2-Ethoxyethoxy)-5-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl)aniline (56.0 mg, 0.122 mmol) was acylated and 
purification was achieved using flash column chromatography with elution gradient of 
0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 55 as a white solid (56.0 mg, 0.109 mmol, 91%). 
Rf: 0.66 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.01 (s, 9H, 
CH2Si(CH3)3), 0.97 (t, J = 8.1 Hz, 2H, CH2CH2Si), 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3), 3.60 (t, J = 8.0 Hz, 2H, 
OCH
2
CH
2
Si), 3.66 (q, J = 7.0 Hz, 2H, OCH
2
CH
3
), 3.84 (t, J = 4.9 Hz, 2H, OCH
2
CH
2
O), 4.17 (s, 3H, ArOCH
3
), 
4.29 (t, J = 4.8 Hz, 2H, OCH2CH2O), 5.68 (s, 2H, NCH2O), 5.80 (d, J = 10.5 Hz, 1H, CCH=CH2), 6.36 (dd, J = 
16.9, 10.1 Hz, 1H, CCH=CH2), 6.46 (d, J = 16.8 Hz, 1H, CCH=CH2), 7.04 (d, J = 8.4 Hz, 1H, ArH), 7.36 (s, 1H, 
ArH), 7.43 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 8.30 (s, 1H, ArH), 8.54 (s, 1H, ArH), 8.90 (s, 1H. ArNH) ppm; 13C NMR 
(151 MHz, CDCl3) δ −1.3, 15.3, 17.8, 53.9, 66.3, 66.9, 68.8, 69.9, 73.2, 103.5, 113.7, 117.7, 120.6, 123.3, 123.7, 
127.1, 128.2, 131.9, 133.2, 151.2, 153.0, 154.6, 163.6, 166.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C26H37N4O5Si: 513.2533; found: 513.2537. 
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5-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-(2-methoxyethoxy)aniline (56) 
Compound 56 was prepared according to the general procedure for N-SEM deprotection. 
5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-
(2-methoxyethoxy)aniline (66.0 mg, 0.148 mmol) was deprotected and purification was 
achieved using flash column chromatography with elution gradient of 0 – 20% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 56 as a white solid 
(37.0 mg, 0.117 mmol, 78%).  
Rf: 0.63 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 3.39 (s, 3H, CH2OCH3), 
3.71 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.01 (s, 3H, ArOCH3), 4.12 (t, J = 4.8 Hz, 2H, OCH2CH2O), 6.78 (d, J = 8.2 
Hz, 1H, ArH), 6.93 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 6.98 – 6.95 (m, 1H, ArH), 7.11 (s, 1H, ArH), 8.41 (s, 1H, ArH), 
11.35 (s, 1H, ArNH) ppm; 13C NMR (151 MHz, CDCl3) δ 53.8, 59.2, 68.4, 71.3, 103.4, 112.7, 116.2, 117.6, 119.2, 
120.5, 128.0, 136.6, 145.7, 150.6, 153.1, 163.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C16H19N4O3: 315.1457; found: 315.1458. 
5-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-[(1-methoxypropan-2-yl)oxy]aniline (57) 
Compound 57 was prepared according to the general procedure for N-SEM deprotection. 
5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-
[(1-methoxypropan-2-yl)oxy]aniline (60.0 mg, 0.131 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution gradient of 0 
– 20% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 
57 as a white solid (33.0 mg, 0.100 mmol, 77%).  
Rf: 0.65 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.36 (d, J = 6.3 Hz, 3H, 
CH3CHCH2), 3.43 (s, 3H, CHCH2OCH3), 3.53 – 3.50 (m, 1H, CHCH2OCH3), 3.64 – 3.60 (m, 1H, CHCH2OCH3), 
4.08 (s, 3H, ArOCH3), 4.11 (br s, 2H, ArNH2), 4.48 – 4.44 (m, 1H, CH3CHCH2), 6.92 (d, J = 8.4 Hz, 1H, ArH), 7.03 
(dd, J = 8.4, 1.9 Hz, 1H, ArH), 7.11 (d, J = 1.9 Hz, 1H, ArH), 7.19 (s, 1H, ArH), 8.47 (s, 1H, ArH), 11.42 (s, 1H, 
ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ 17.4, 53.8, 59.4, 75.1, 76.2, 103.4, 115.9, 117.0, 117.5, 119.8, 120.7, 
128.5, 136.7, 144.9, 150.6, 153.0, 163.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C17H21N4O3: 
329.1614; found: 329.1620. 
2-(2-Ethoxyethoxy)-5-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (58) 
Compound 58 was prepared according to the general procedure for N-SEM 
deprotection. 2-(2-Ethoxyethoxy)-5-(4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl)aniline (60.0 mg, 0.131 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution gradient of 
0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 58 as a white solid (32.0 mg, 97.5 µmol, 75%).  
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Rf: 0.63 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.26 (t, J = 7.0 Hz, 3H, OCH2OCH3), 3.62 (q, J = 
7.0 Hz, 2H, OCH2OCH3), 3.83 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.10 (s, 3H, ArOCH3), 4.21 (t, J = 4.8 Hz, 2H, 
OCH2CH2O), 6.87 (d, J = 8.2 Hz, 1H, ArH), 7.02 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.07 – 7.05 (m, 1H, ArH), 7.20 
(s, 1H, ArH), 8.49 (s, 1H ArH), 11.41 (s, 1H, ArNH) ppm; 13C NMR (151 MHz, CDCl3) δ 15.3, 53.8, 66.9, 68.7, 
69.2, 103.4, 112.8, 116.4, 117.6, 119.4, 120.5, 128.0, 136.3, 145.8, 150.6, 153.1, 163.7 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C17H21N4O3: 329.1614; found: 329.1613. 
N-[5-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-(2-methoxyethoxy)phenyl]acrylamide (59) 
Compound 59 was prepared according to the general procedure for N-SEM 
deprotection. N-[5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-2-(2-methoxyethoxy)phenyl]acrylamide (40.0 mg, 80.2 µmol) was 
deprotected and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 59 as a white solid (24.0 mg, 65.1 µmol, 81%).  
Rf: 0.60 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 3.47 (s, 3H, CH2OCH3), 
3.75 (t, J = 4.5 Hz, 2H, OCH
2
CH
2
O), 4.15 (s, 3H, ArOCH
3
), 4.23 (t, J = 4.5 Hz, 2H, OCH
2
CH
2
O), 5.76 (d, J = 
10.4 Hz, 1H, CCH=CH2), 6.32 (dd, J = 16.8, 10.4 Hz, 1H, CCH=CH2), 6.44 (d, J = 16.8 Hz, 1H, CCH=CH2), 
7.00 (d, J = 8.4 Hz, 1H, ArH), 7.34 (s, 1H, ArH), 7.37 (dd, J = 8.4, 2.0 Hz, 1H, ArH), 8.34 (s, 1H, ArH), 8.50 (s, 
1H, ArH), 8.85 (s, 1H, ArH), 11.26 (s, 1H, ArNH) ppm; 13C NMR (151 MHz, CDCl3) δ 54.1, 59.2, 70.1, 71.0,  103.6, 
114.3, 117.5, 120.7, 121.3, 124.5, 127.3, 128.6, 129.2, 131.9, 146.3, 150.0, 151.9, 163.5, 164.0 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C19H21N4O4: 369.1563; found: 369.1560. 
N-[5-(4-Methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-[(1-methoxypropan-2-yl)oxy]phenyl]acrylamide (60)  
Compound 60 was prepared according to the general procedure for N-SEM 
deprotection. N-[5-(4-Methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)-2-[(1-methoxypropan-2-yl)oxy]phenyl]acrylamide (42.0 mg, 81.2 
µmol) was deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure fractions were 
evaporated to dryness to afford compound 60 as a white solid (24.0 mg, 63.3 µmol, 
78%).  
Rf: 0.61 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.39 (d, J = 6.3 Hz, 3H, CH3CHCH2), 3.47 (s, 3H, 
CHCH
2
OCH
3
), 3.54 – 3.51 (m, 1H, CHCH
2
OCH
3
), 3.62 – 3.58 (m, 1H, CHCH
2
OCH
3
), 4.15 (s, 3H, ArOCH
3
), 4.32 
– 4.29 (m, 1H, CH3CHCH2), 5.75 (d, J = 10.2 Hz, 1H, CCH=CH2), 6.31 (dd, J = 16.8, 10.2 Hz, 1H, CCH=CH2), 
6.44 (d, J = 16.8 Hz, 1H, CCH=CH2), 7.05 (d, J = 8.4 Hz, 1H, ArH), 7.36 (s, 1H, ArH), 7.37 (dd, J = 8.4, 2.1 Hz, 
1H, ArH), 8.50 (s, 1H, ArH), 8.72 (s, 1H, ArNH), 8.90 (s, 1H, ArNH) ppm;
 13
C NMR (151 MHz, CDCl3) δ 17.1, 54.1, 
59.4, 76.0, 77.7, 103.5, 117.4, 118.3, 120.8, 121.4, 124.3, 127.2, 129.5, 130.7, 131.8, 145.6, 150.1, 152.2, 
163.6, 163.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H23N4O4: 383.1719; found: 383.1721.  
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N-[2-(2-Ethoxyethoxy)-5-(4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]acrylamide (61) 
Compound 61 was prepared according to the general procedure for N-SEM 
deprotection. N-[2-(2-Ethoxyethoxy)-5-(4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]acrylamide 
(46.0 mg, 89.7 µmol) was deprotected and purification was achieved using flash 
column chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 61 as a white solid (27.0 
mg, 70.8 µmol, 79%).  
Rf: 0.59 (10% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.27 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.62 (q, J = 7.0 
Hz, 2H, OCH2CH3), 3.80 (t, J = 4.6 Hz, 2H, OCH2CH2O), 4.16 (s, 3H, ArOCH3), 4.25 (t, J = 4.6 Hz, 2H, 
OCH2CH2O), 5.76 (d, J = 10.2 Hz, 1H, CCH=CH2), 6.33 (dd, J = 16.8, 10.2 Hz, 1H, CCH=CH2), 6.43 (d, J = 
16.8 Hz, 1H, CCH=CH2), 6.99 (d, J = 8.4 Hz, 1H, ArH), 7.33 (s, 1H, ArH), 7.36 (dd, J = 8.4, 1.9 Hz, 1H, ArH), 
8.26 (s, 1H, ArH), 8.50 (s, 1H, ArH), 8.84 (s, 1H, ArH), 11.12 (s, 1H, ArNH) ppm; 13C NMR (151 MHz, CDCl3) δ 
15.3, 54.2, 66.9, 68.8, 69.9, 103.7, 113.7, 117.7, 120.7, 121.3, 124.5, 127.3, 128.2, 129.0, 131.9, 146.4, 149.7, 
151.4, 163.5, 164.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H23N4O4: 383.1719; found: 
383.1720.  
6-Bromo-4-methoxy-5-[4-(2-methoxyethoxy)-3-nitrophenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (62) 
Compound 62 was prepared according to the general procedure for pyrrolopyrimidine 
derivative bromination. 4-Methoxy-5-[4-(2-methoxyethoxy)-3-nitrophenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (130 mg, 0.274 mmol) was 
brominated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 30% EtOAc in PE. Pure fractions were evaporated to dryness to 
afford compound 62 as a yellow solid (114 mg, 0.206 mmol, 75%). 
Rf: 0.41 (30% EtOAc in PE); 
1
H NMR (400 MHz, CDCl3) δ −0.04 (s, 9H, CH2Si(CH3)3), 
0.95 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 3.49 (s, 3H, CH2OCH3), 3.64 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 3.84 (t, J = 
4.7 Hz, 2H, OCH2CH2O), 4.03 (s, 3H, ArOCH3), 4.32 (t, J = 4.7 Hz, 2H, OCH2CH2O), 5.76 (s, 2H, NCH2O), 7.17 
(d, J = 8.7 Hz, 1H, ArH), 7.71 (dd, J = 8.7, 2.3 Hz, 1H, ArH), 8.06 (d, J = 2.2 Hz, 1H, ArH), 8.50 (s, 1H, ArH) 
ppm; 
13
C NMR (101 MHz, CDCl3) δ −1.3, 17.9, 54.3, 59.7, 67.0, 69.8, 70.8, 72.2, 104.4, 111.9, 114.4, 114.4, 
125.4, 128.1, 136.0, 139.6, 151.6, 151.6, 152.7, 162.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C22H30N4O6SiBr: 553.1118; found: 553.1113.   
Stellenbosch University https://scholar.sun.ac.za
Chapter 4 – Lead Optimisation of Pyrrolopyrimidine-derived EGFR Inhibitors 
 
125 
 
6-Bromo-4-methoxy-5-{4-[(1-methoxypropan-2-yl)oxy]-3-nitrophenyl}-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidine (63) 
Compound 63 was prepared according to the general procedure for pyrrolopyrimidine 
derivative bromination. 4-Methoxy-5-{4-[(1-methoxypropan-2-yl)oxy]-3-nitrophenyl}-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (288 mg, 0.589 mmol) 
was brominated and purification was achieved using flash column chromatography with 
elution gradient of 0 – 30% EtOAc in PE. Pure fractions were evaporated to dryness to 
afford compound 63 as a yellow solid (237 mg, 0.418 mmol, 71%). 
Rf: 0.45 (30% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ 0.00 (s, 9H, CH2Si(CH3)3), 1.00 
(t, J = 8.3 Hz, 2H, OCH2CH2Si), 1.46 (d, J = 6.3 Hz, 3H, CH3CHCH2), 3.48 (s, 2H, CHCH2OCH3), 3.63 – 3.59 (m, 
1H, CHCH2OCH3), 3.68 (t, 2H, J = 8.3 Hz, 2H, OCH2CH2Si), 3.75 – 3.70 (m, 1H, CHCH2OCH3), 4.07 (s, 3H, 
ArOCH3), 4.79 – 4.74 (m, 1H, CH3CHCH2), 5.79 (s, 2H, NCH2O), 7.27 (d, J = 8.8 Hz, 1H, ArH), 7.74 (dd, J = 8.8, 
2.2 Hz, 1H, ArH), 8.06 (d, J = 2.2 Hz, 1H, ArH), 8.53 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl3) δ −1.3, 17.1, 
17.9, 54.1, 59.6, 66.9, 72.1, 76.0, 76.3, 104.3, 111.8, 114.3, 115.8, 125.2, 127.9, 135.7, 140.5, 150.9, 151.7, 
152.8, 162.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C23H32N4O6SiBr: 567.1275; found: 567.1280. 
6-Bromo-5-[4-(2-ethoxyethoxy)-3-nitrophenyl]-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (64) 
Compound 64 was prepared according to the general procedure for pyrrolopyrimidine 
derivative bromination. 5-[4-(2-Ethoxyethoxy)-3-nitrophenyl]-4-methoxy-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (307 mg, 0.628 mmol) 
was brominated and purification was achieved using flash column chromatography 
with elution gradient of 0 – 30% EtOAc in PE. Pure fractions were evaporated to 
dryness to afford compound 64 as a yellow solid (257 mg, 0.453 mmol, 72%).  
Rf: 0.46 (30% EtOAc in PE); 
1
H NMR (500 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3) 
0.94 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 1.22 (t, J = 7.0 Hz, 3H, OCH2CH3), 3.60 (t, J = 8.2 Hz, 2H, OCH2CH2Si), 
3.63 (q, J = 7.0 Hz, 2H), 3.86 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.00 (s, 3H, ArOCH3), 4.31 (t, J = 4.8 Hz, 2H, 
OCH2CH2O), 5.73 (s, 2H, NCH2O), 7.17 (d, J = 8.7 Hz, 1H, ArH), 7.70 (dd, J = 8.7, 2.2 Hz, 1H, ArH), 8.05 (d, J 
= 2.2 Hz, 1H, ArH), 8.47 (s, 1H, ArH) ppm; 
13
C NMR (126 MHz, CDCl
3
) δ −1.4, 15.3, 17.8, 54.1, 66.9, 67.3, 
68.7, 69.8, 72.1, 104.3, 111.7, 114.2, 114.3, 125.2, 128.0, 136.0, 139.5, 151.6, 151.7, 152.8, 162.2 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C23H32N4O6SiBr: 567.1275; found: 567.1272. 
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4-Methoxy-5-[4-(2-methoxyethoxy)-3-nitrophenyl]-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (65) 
Compound 65 was prepared according to the general procedure for Suzuki-
Miyaura cross coupling reaction. 6-Bromo-4-methoxy-5-[4-(2-
methoxyethoxy)-3-nitrophenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (314 mg, 0.567 mmol) and 1-methyl-4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine (205 mg, 
0.678 mmol) were coupled and purification was achieved using flash column 
chromatography with elution gradient of 0 – 10% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 65 as a yellow 
foam (335 mg, 0.516 mmol, 91%).  
Rf: 0.48 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ −0.04 (s, 9H, CH2Si(CH3)3), 0.94 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 2.49 (s, 3H, (CH2)2NCH3), 2.76 (br s, 4H, 2 × NCH2CH2N), 3.40 (br s, 4H, 2 × NCH2CH2N), 3.46 (s, 
3H, CH2OCH3), 3.66 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.79 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.04 (s, 3H, ArOCH3), 
4.23 (t, J = 4.8 Hz, 2H, OCH2CH2O), 5.51 (s, 2H, NCH2O), 6.89 – 6.86 (m, 2H, 2 × ArH), 6.93 (dd [app. t], J = 
8.6 Hz, 1H, ArH), 7.28 (d, J = 8.6 Hz, 2H, 2 × ArH), 7.32 (dd, J = 8.6, 2.1 Hz, 1H, ArH), 7.88 (d, J = 2.1 Hz, 1H, 
ArH), 8.51 (s, 1H, ArH) ppm; 13C NMR (126 MHz, CDCl3) δ −1.3, 18.1, 47.6, 53.9, 54.5, 54.7, 59.7, 69.5, 70.8, 
71.0, 104.1, 111.5, 114.0, 115.6, 116.7, 127.2, 128.4, 129.4, 132.5, 136.5, 137.1, 139.4, 150.6, 151.3, 153.1, 
163.0 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C33H45N6O6Si: 649.3170; found: 649.3170.  
4-Methoxy-5-{4-[(1-methoxypropan-2-yl)oxy]-3-nitrophenyl}-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (66) 
Compound 66 was prepared according to the general procedure for Suzuki-
Miyaura cross coupling reaction. 6-Bromo-4-methoxy-5-{4-[(1-
methoxypropan-2-yl)oxy]-3-nitrophenyl}-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (240 mg, 0.423 
mmol) and 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]piperazine (154 mg, 0.510 mmol) were coupled and purification 
was achieved using flash column chromatography with elution gradient of 0 
– 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound (HL788 66) as a yellow foam (264 mg, 0.398 mmol, 94%).   
Rf: 0.47 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ −0.04 (s, 9H, CH2Si(CH3)3), 0.94 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 1.36 (d, J = 6.3 Hz, 3H, CH3CHCH2), 2.50 (s, 3H, (CH2)2NCH3), 2.54 (br s, 4H, 2 × NCH2CH2N), 
3.37 (br s, 4H, 2 × NCH
2
CH
2
N), 3.41 (s, 3H, CHCH
2
OCH
3
), 3.53 – 3.50 (m, 1H, CHCH
2
OCH
3
), 3.67 – 3.61 (m, 
3H, CHCH2OCH3 and OCH2CH2Si), 4.05 (s, 3H, ArOCH3), 4.64 – 4.60 (m, 1H, CH3CHCH2), 5.51 (s, 2H, NCH2O), 
6.90 – 6.87 (m, 3H, 3 × ArH), 6.97 (d, J = 8.8 Hz, 1H, ArH), 7.31 – 7.29 (m, 2H, 2 × ArH), 7.83 (d, J = 1.9 Hz, 
1H, ArH), 8.52 (s, 1H, ArH) ppm;  
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13
C NMR (126 MHz, CDCl3) δ −1.3, 17.0, 18.1, 47.6, 48.4, 53.9, 54.7, 59.6, 66.8, 70.9, 76.0, 76.1, 104.1, 111.5, 
115.6, 116.7, 120.7, 127.0, 128.2, 129.4, 132.5, 136.1, 137.0, 140.4, 149.8, 151.2, 153.1, 163.0 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C34H47N6O6Si: 663.3326; found: 663.3327. 
5-[4-(2-Ethoxyethoxy)-3-nitrophenyl]-4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (67) 
Compound 67 was prepared according to the general procedure for Suzuki-
Miyaura cross coupling reaction. 6-Bromo-5-[4-(2-ethoxyethoxy)-3-
nitrophenyl]-4-methoxy-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (240 mg, 0.423 mmol) and 1-methyl-4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine (154 mg, 0.510 
mmol) were coupled and purification was achieved using flash column 
chromatography with elution gradient of 0 – 10% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 67 as a yellow 
foam (255 mg, 0.385 mmol, 91%).  
Rf: 0.48 (5% MeOH in DCM); 
1
H NMR (500 MHz, CDCl
3
) δ −0.04 (s, 9H, CH
2
Si(CH
3
)
3
), 0.95 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 1.23 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.61 (s, 3H, (CH2)2NCH3), 2.91 (br s, 4H, 2 × NCH2CH2N), 3.46 
(br s, 4H, 2 × NCH2CH2N), 3.62 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.66 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.83 (t, J = 
4.8 Hz,  2H, OCH2CH2O), 4.04 (s, 3H, ArOCH3), 4.23 (t, J = 4.8 Hz, 2H, OCH2CH2O), 5.51 (s, 2H, NCH2O), 6.87 
(d, J = 8.7 Hz, 2H, 2 × ArH), 6.94 (d, J = 8.1 Hz, 1H, ArH), 7.30 – 7.28 (m, 2H, 2 × ArH), 7.34 (dd, J = 8.7, 2.0 
Hz, 1H, ArH), 7.83 (d, J = 2.0 Hz, 1H, ArH), 8.52 (s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl
3
) δ −1.3, 15.3, 
18.1, 47.1, 48.0, 53.9, 54.3, 66.8, 67.3, 68.7, 69.6, 71.0, 104.1, 111.6, 114.1, 115.8, 117.0, 127.0, 128.2, 129.5, 
132.6, 136.5, 136.9, 139.4, 150.7, 151.3, 153.1, 163.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C34H47N6O6Si: 663.3326; found: 663.3325. 
5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-(2-methoxyethoxy)aniline (68) 
Compound 68 was prepared was according to the general procedure for 
aromatic nitro derivative reduction. 4-Methoxy-5-[4-(2-methoxyethoxy)-3-
nitrophenyl]-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (350 mg, 0.539 
mmol) was reduced and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 68 as a white foam 
(280 mg, 0.453 mmol, 84%).  
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Rf: 0.40 (5% MeOH in DCM); 
1
H NMR (400 MHz, CDCl3) δ −0.05 (s, 9H, CH2Si(CH3)3), 0.93 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 2.44 (s, 3H, (CH2)2NCH3), 2.70 (br s, 4H, 2 × NCH2CH2N), 3.33 (br s, 4H, 2 × NCH2CH2N), 3.44 (s, 
3H, CH2OCH3), 3.65 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.75 (t, J = 4.8 Hz, 2H, OCH2CH2O), 4.00 (s, 3H, ArOCH3), 
4.13 (t, J = 4.8 Hz, 2H, OCH2CH2O), 5.50 (s, 2H, NCH2O), 6.58 (dd, J = 8.3, 2.0 Hz, 1H, ArH), 6.67 (d, J = 8.3 
Hz, 1H, ArH), 6.69 (d, J = 2.0 Hz, 1H, ArH), 6.83 (s, 1H, ArH), 6.85 (s, 1H, ArH), 7.28 (s, 1H, ArH), 7.30 (s, 1H, 
ArH), 8.48 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, CDCl3) δ  −1.3, 18.1, 45.8, 48.0, 53.8, 54.9, 59.3, 66.6, 68.0, 
71.0, 71.4, 104.6, 111.6, 114.1, 115.3, 115.4, 118.5, 121.6, 127.4, 132.4, 135.7, 136.2, 145.3, 150.4, 150.7, 
153.0, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C33H47N6O4Si: 619.3428; found: 619.3428. 
5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-(1-methoxypropan-2-yl)aniline (69) 
Compound 69 was prepared was according to the general procedure for 
aromatic nitro derivative reduction. 4-Methoxy-5-{4-[(1-methoxypropan-2-
yl)oxy]-3-nitrophenyl}-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (280 mg, 0.422 
mmol) was reduced and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 69 as a white foam 
(225 mg, 0.356 mmol, 84%).  
Rf: 0.41 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.07 (s, 9H, CH2Si(CH3)3), 0.91 (t, J = 8.4 Hz, 2H, 
OCH
2
CH
2
Si), 1.30 (d, J = 6.3 Hz, 3H, CH
3
CHCH
2
), 2.36 (s, 3H, (CH
2
)
2
NCH
3
), 2.59 (br s, 4H, 2 × NCH
2
CH
2
N), 
3.25 (br s, 4H, 2 × NCH2CH2N), 3.39 (s, 3H, CHCH2OCH3), 3.46 – 3.43 (m, 1H, CHCH2OCH3), 3.59 – 3.55 (m, 
1H, CHCH2OCH3), 3.62 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.80 (br s, 2H, ArNH2), 3.99 (s, 3H, ArOCH3), 4.42 – 4.38 
(m, 1H, CH3CHCH2), 5.48 (s, 2H, NCH2O), 6.55 (dd, J = 8.2, 1.8 Hz, 1H, ArH), 6.68 (d, J = 1.8 Hz, 1H, ArH), 
6.70 (d, J = 8.2 Hz, 1H, ArH), 6.81 (s, 1H, ArH), 6.83 (s, 1H, ArH), 7.27 (s, 1H, ArH), 7.28 (s, 1H, ArH), 8.46 (s, 
1H, ArH) ppm; 
13
C NMR (151 MHz, CDCl3) δ −1.4, 17.3, 18.0, 46.0, 48.2, 53.7, 55.0, 59.3, 66.5, 70.9, 74.4, 
76.2, 104.5, 114.0, 114.7, 115.1, 118.7, 121.2, 121.4, 127.8, 132.3, 136.2, 136.9, 144.0, 148.1, 150.5, 150.6, 
152.9, 163.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C34H49N6O4Si: 633.3585; found: 633.3588.  
2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl}aniline (70) 
Compound 70 was prepared was according to the general procedure for aromatic nitro derivative reduction. 5-[4-
(2-Ethoxyethoxy)-3-nitrophenyl]-4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (292 mg, 0.441 mmol) was reduced and purification was 
achieved using flash column chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure fractions were 
evaporated to dryness to afford compound 70 as a white foam (231 mg, 0.365 mmol, 83%).  
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Rf: 0.43 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.02 (s, 9H, 
CH2Si(CH3)3), 0.96 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 1.26 (t, J = 7.0 Hz, 3H, 
OCH2CH3), 2.39 (s, 3H, (CH2)2NCH3), 2.62 (br s, 4H, 2 × NCH2CH2N), 3.29 
(br s, 4H, 2 × NCH2CH2N), 3.62 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.67 (t, J 
= 8.4 Hz, 2H, OCH2CH2Si), 3.78 (br s, 2H, ArNH2), 3.82 (t, J = 4.8 Hz, 2H, 
OCH2CH2O), 4.03 (s, 3H, ArOCH3), 4.15 (t, J = 4.8 Hz, 2H, OCH2CH2O), 
5.53 (s, 2H, NCH2O), 6.62 (dd, J = 8.2, 1.9 Hz, 1H, ArH), 6.70 (d, J = 8.3 
Hz, 1H, ArH), 6.72 (d, J = 1.9 Hz, 1H, ArH), 6.88 – 6.85 (m, 2H, 2 × ArH), 
7.32 – 7.30 (m, 2H, 2 × ArH), 8.50 (s, 1H, ArH) ppm; 13C NMR (151 MHz, CDCl3) δ  −1.3, 15.3, 18.0, 46.1, 48.2, 
53.7, 55.0, 66.5, 66.8, 68.1, 69.2, 70.9, 104.5, 111.6, 114.0, 115.0, 118.4, 121.1, 121.5, 127.4, 132.3, 135.7, 
136.2, 145.2, 150.6, 150.6, 152.9, 163.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C34H49N6O4Si: 
633.3585; found: 633.3586. 
N-(5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-(2-methoxyethoxy)phenyl)acrylamide (71) 
Compound 71 was prepared according to the general procedure for aniline 
derivative acylation. 5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(2-
methoxyethoxy)aniline (200 mg, 0.323 mmol) was acylated and purification 
was achieved using flash column chromatography with elution gradient of 
0 – 20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 71 as a white solid (172 mg, 0.256 mmol, 79%).  
Rf: 0.59 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 0.00 (s, 9H, CH2Si(CH3)3), 0.98 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 2.38 (s, 3H, (CH2)2NCH3), 2.61 (br s, 4H, 2 × NCH2CH2N), 3.28 (br s, 4H, 2 × NCH2CH2N), 3.47 (s, 
3H, CH2OCH3), 3.68 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.74 (t, J = 4.7 Hz, 2H, OCH2CH2O), 4.05 (s, 3H, ArOCH3), 
4.17 (t, J = 4.7 Hz, 2H, OCH2CH2O), 5.55 (s, 2H, NCH2O), 5.73 (d, J = 10.2 Hz, 1H, CCH=CH2), 6.30 (dd, J = 
16.8, 10.2 Hz, 1H, CCH=CH2), 6.39 (d, J = 16.8 Hz, 1H, CCH=CH2), 6.77 (d, J = 8.3 Hz, 1H, ArH), 6.86 – 6.82 
(m, 1H, ArH), 6.87 (s, 1H, ArH), 6.89 (s, 1H, ArH), 7.73 (s, 1H, ArH), 7.75 (s, 1H, ArH), 8.24 (s, 1H, ArH), 8.52 (s, 
1H, ArH), 8.65 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ −1.4, 18.0, 46.0, 48.2, 48.9, 53.6, 55.0, 59.1, 
66.4, 69.4, 70.9, 104.5, 112.7, 113.8, 115.1, 116.1, 119.8, 120.9, 123.4, 126.4, 126.7, 128.3, 129.1, 132.0, 
132.3, 136.4, 150.6, 150.7, 152.8, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C
36
H
49
N
6
O
5
Si: 
673.3534; found: 673.3534. 
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N-(5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}-2-(1-methoxypropan-2-yl)phenyl)acrylamide (72)  
Compound 72 was prepared according to the general procedure for aniline 
derivative acylation. 5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(1-
methoxypropan-2-yl)aniline (100 mg, 0.158 mmol) was acylated and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 72 as a white solid (81.0 mg, 0.118 mmol, 75%).  
Rf: 0.60 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3), 0.93 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 1.32 (d, J = 6.3 Hz, 3H, CH3CHCH2), 2.36 (s, 3H, (CH2)2NCH3), 2.60 (br s, 4H, 2 × NCH2CH2N), 
3.26 (br s, 4H, 2 × NCH2CH2N), 3.43 (s, 3H, CHCH2OCH3), 3.49 – 3.46 (m, 1H, CHCH2OCH3), 3.57 – 3.53 (m, 
1H, CHCH2OCH3), 3.62 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 4.30 – 4.23 (m, 1H, CH3CHCH2), 5.49 (s, 2H, NCH2O), 
5.68 (d, J = 10.2 Hz, 1H, CCH=CH2), 6.25 (dd, J = 16.9, 10.2 Hz, 1H, CCH=CH2), 6.35 (dd, J = 16.9, 0.9 Hz, 
1H, CCH=CH2), 6.80 – 6.76 (m, 2H, 2 × ArH), 6.82 (s, 1H, ArH), 6.84 (s, 1H, ArH), 7.29 (s, 1H, ArH), 7.30 (s, 1H, 
ArH), 8.47 (s, 1H, ArH), 8.54 (s, 1H, ArH), 8.63 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ −1.3, 17.1, 
18.1, 46.0, 48.2, 53.7, 55.0, 59.3, 66.5, 70.9, 76.0, 77.0, 104.6, 113.9, 115.2, 116.8, 121.2, 123.6, 126.4, 126.7, 
129.3, 129.8, 132.0, 132.5, 136.5, 145.0, 150.6, 150.8, 152.9, 163.2, 163.3 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C37H51N6O5Si: 687.3690; found: 687.3691. 
N-[2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl]acrylamide (73) 
Compound 73 was prepared according to the general procedure for aniline 
derivative acylation. 2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-
methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl}aniline (120 mg, 0.190 mmol) was acylated 
and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated 
to dryness to afford compound 73 as a white solid (94.0 mg, 0.137 mmol, 
72%).  
Rf: 0.61 (5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3), 0.92 (t, J = 8.4 Hz, 2H, 
OCH2CH2Si), 1.23 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.36 (s, 3H, (CH2)2NCH3), 2.60 (br s, 4H, 2 × NCH2CH2N), 3.25 
(br s, 4H, 2 × NCH2CH2N), 3.58 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.62 (t, J = 8.4 Hz, 2H, OCH2CH2Si), 3.74 (t, J = 
4.6 Hz, 2H, OCH
2
CH
2
O), 3.99 (s, 3H, ArOCH
3
), 4.14 (t, J = 4.6 Hz, 2H, OCH
2
CH
2
O), 5.49 (s, 2H, NCH
2
O), 5.68 
(d, J = 10.0 Hz, 1H, CCH=CH2), 6.25 (dd, J = 16.8, 10.0 Hz, 1H, CCH=CH2), 6.33 (dd, J = 16.8, 1.0 Hz, 1H, 
CCH=CH2), 6.72 (d, J = 8.3 Hz, 1H, ArH), 6.79 (d, J = 7.7 Hz, 1H, ArH), 6.82 (s, 1H, ArH), 6.83 (s, 1H, ArH), 7.28 
(s, 1H, ArH), 7.29 (s, 1H, ArH),  8.11 (s, 1H, ArH), 8.47 (s, 1H, ArH), 8.57 (s, 1H, ArNH) ppm;  
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13
C NMR (151 MHz, CDCl3) δ −1.3, 15.3, 18.1, 46.0, 48.2, 53.6, 55.0, 66.5, 66.8, 68.8, 69.3, 70.9, 104.6, 112.3, 
113.9, 115.2, 121.1, 123.4, 126.5, 126.7, 128.0, 128.1, 132.1, 132.4, 136.4, 145.8, 150.6, 150.8, 152.8, 163.0, 
163.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C37H51N6O5Si: 687.3690; found: 687.3693. 
5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(2-
methoxyethoxy)aniline (74) 
Compound 74 was prepared according to the general procedure for N-SEM 
deprotection. 5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(2-
methoxyethoxy)aniline (101 mg, 0.163 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 74 as a white solid (60.0 mg, 0.123 mmol, 73%).  
Rf: 0.31 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 2.38 (s, 3H, (CH2)2NCH3), 2.59 (br s, 4H, 2 × 
NCH2CH2N), 3.21 (br s, 4H, 2 × NCH2CH2N), 3.47 (s, 3H, CH2OCH3), 3.80 (t, J = 4.6 Hz, 2H, OCH2CH2O), 3.84 
(br s, 2H, ArNH
2
), 3.90 (s, 3H, ArOCH
3
), 4.19 (t, J = 4.6 Hz, 2H, OCH
2
CH
2
O), 6.80 – 6.75 (m, 5H, 5 × ArH), 7.28 
– 7.24 (m, 2H, 2 × ArH), 8.29 (s, 1H, ArH), 13.19 (s, 1H, ArNH) ppm; 13C NMR (126 MHz, CDCl3) δ 46.0, 48.0, 
53.6, 55.0, 59.3, 67.9, 71.4, 106.2, 111.3, 111.7, 115.3, 118.5, 121.5, 122.8, 128.0, 129.2, 133.6, 136.0, 145.4, 
149.7, 150.2, 152.2, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C27H33N6O3: 489.2614; found: 
489.2610. 
5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(1-methoxypropan-2-
yl)aniline (75) 
Compound 75 was prepared according to the general procedure for N-SEM 
deprotection. 5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(1-
methoxypropan-2-yl)aniline (70.0 mg, 0.111 mmol) was deprotected and 
purification was achieved using flash column chromatography with elution 
gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 75 as a white solid (41.0 mg, 81.5 µmol, 74%).  
Rf: 0.32 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.37 (d, J = 6.3 Hz, 3H, CH3CHCH2), 2.39 (s, 3H, 
(CH
2
)
2
NCH
3
), 2.61 (br s, 4H, 2 × NCH
2
CH
2
N), 3.25 (br s, 4H, 2 × NCH
2
CH
2
N), 3.44 (s, 3H, CHCH
2
OCH
3
), 3.53 
– 3.49 (m, 1H, CHCH2OCH3), 3.66 – 3.61 (m, 1H, CHCH2OCH3), 3.89 (br s, 2H, ArNH2), 3.94 (s, 3H, ArOCH3), 
4.52 – 4.45 (m, 1H, CH3CHCH2), 6.73 (d, J = 8.1 Hz, 1H, ArH), 6.79 (s, 1H, ArH), 6.85 – 6.80 (m, J = 8.2, 5.3 Hz, 
3H, 3 × ArH), 7.33 (s, 1H, ArH), 7.35 (s, 1H, ArH), 8.32 (s, 1H, ArH), 13.21 (s, 1H, ArNH) ppm; 
13
C NMR (126 
MHz, CDCl3) δ 17.4, 46.0, 48.1, 53.7, 55.0, 59.4, 74.5, 76.3, 106.2, 111.4, 115.0, 115.3, 118.7, 121.4, 122.9, 
128.5, 129.3, 133.6, 137.3, 144.2, 149.7, 150.2, 152.2, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C
28
H
35
N
6
O
3
: 503.2771; found: 503.2770. 
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2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}aniline (76) 
Compound 76 was prepared according to the general procedure for N-SEM 
deprotection. 2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-methylpiperazin-1-
yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}aniline (70.0 mg, 0.111 mmol) was deprotected and purification was 
achieved using flash column chromatography with elution gradient of 0 – 
20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 76 as a white solid (40.0 mg, 79.6 µmol, 73%).  
Rf: 0.32 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.26 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.41 (s, 3H, 
(CH2)2NCH3), 2.63 (br s, 4H, 2 × NCH2CH2N), 3.25 (br s, 4H, 2 × NCH2CH2N), 3.63 (q, J = 7.0 Hz, 2H, OCH2CH3), 
3.84 (t, J = 4.8 Hz, 2H, OCH2CH2O), 3.89 (br s, 2H, ArNH2), 3.93 (s, 3H, ArOCH3), 4.19 (t, J = 4.8 Hz, 2H, 
OCH2CH2O), 6.76 (d, J = 8.2 Hz, 1H, ArH), 6.83 – 6.77 (m, 4H, 4 × ArH), 7.34 – 7.28 (m, 2H, 2 × ArH), 8.32 (s, 
1H, ArH), 13.08 (s, 1H, ArNH) ppm; 13C NMR (126 MHz, CDCl3) δ 15.4, 46.0, 48.0, 53.7, 55.0, 66.9, 68.2, 69.3, 
106.2, 111.4, 111.9, 115.4, 118.4, 121.5, 123.0, 128.0, 129.2, 133.6, 136.1, 145.5, 149.7, 150.2, 152.2, 163.3 
ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C28H35N6O3: 503.2771; found: 503.2773. 
N-[5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(2-
methoxyethoxy)phenyl]acrylamide (77) 
Compound 77 was prepared according to the general procedure for N-SEM 
deprotection. N-[5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(2-
methoxyethoxy)phenyl]acrylamide (171 mg, 0.254 mmol) was deprotected 
and purification was achieved using flash column chromatography with 
elution gradient of 0 – 20% MeOH in DCM. Pure fractions were evaporated 
to dryness to afford compound 77 as a white solid (99.0 mg, 0.182 mmol, 
72%).  
Rf: 0.37 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 2.38 (s, 3H, (CH2)2NCH3), 2.62 (br s, 4H, 2 × 
NCH
2
CH
2
N), 3.28 (br s, 4H, 2 × NCH
2
CH
2
N), 3.47 (s, 3H, CH
2
OCH
3
), 3.76 (t, J = 4.3 Hz, 2H, OCH
2
CH
2
O), 4.00 
(s, 3H, ArOCH3), 4.21 (t, J = 4.3 Hz, 2H, OCH2CH2O), 5.72 (d, J = 10.0 Hz, 1H, CCH=CH2), 6.30 (dd, J = 16.8, 
10.0 Hz, 1H, CCH=CH2), 6.38 (d, J = 16.8 Hz, 1H, CCH=CH2), 6.88 – 6.83 (m, 3H, 3 × ArH), 6.99 (d, J = 8.0 
Hz, 1H, ArH), 7.39 (s, 1H, ArH), 7.41 (s, 1H, ArH) 8.26 (s, 1H, ArH), 8.37 (s, 1H, ArH), 8.68 (s, 1H, ArNH), 13.11 
(s, 1H, ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 46.0, 48.2, 53.7, 55.0, 59.2, 69.5, 71.0, 106.2, 111.2, 113.1, 
115.5, 123.0, 123.5, 126.7, 127.0, 128.5, 129.0, 129.5, 132.0, 133.9, 146.1, 149.9, 150.4, 152.2, 163.2, 163.4 
ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H35N6O4: 543.2720; found: 543.2717. 
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N-[5-{4-Methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(1-
methoxypropan-2-yl)phenyl]acrylamide (78) 
Compound 78 was prepared according to the general procedure for N-SEM 
deprotection. N-[5-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-(1-
methoxypropan-2-yl)phenyl]acrylamide (81.0 mg, 0.118 mmol) was 
deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 78 as a white solid 
(52.0 mg, 93.4 µmol, 79%).  
Rf: 0.39 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.39 (d, J = 6.3 Hz, 3H, CH3CHCH2), 2.39 (s, 3H, 
(CH2)2NCH3), 2.63 (br s, 4H, 2 × NCH2CH2N), 3.29 (br s, 4H, 2 × NCH2CH2N), 3.48 (s, 3H, CHCH2OCH3), 3.56 
– 3.52 (m, 1H, CHCH2OCH3), 3.64 – 3.59 (m, 1H, CHCH2OCH3), 4.02 (s, 3H, ArOCH3), 4.38 – 4.32 (m, 1H, 
CH3CHCH2), 5.73 (d, J = 10.1 Hz, 1H, CCH=CH2), 6.31 (dd, J = 16.9, 10.1 Hz, 1H, CCH=CH2), 6.41 (d, J = 16.9 
Hz, 1H, CCH=CH2), 6.88 (s, 1H, ArH), 6.89 (s, 1H, ArH), 6.92 (d, J = 8.3 Hz, 1H, ArH), 6.99 (d, J = 8.0 Hz, 1H, 
ArH), 7.43 (s, 1H, ArH), 7.45 (s, 1H, ArH), 8.40 (s, 1H, ArH), 8.66 (s, 1H, ArH), 8.75 (s, 1H, ArNH), 13.28 (s, 1H, 
ArNH) ppm; 
13
C NMR (126 MHz, CDCl3) δ 17.1, 46.0, 48.2, 53.7, 55.0, 59.3, 76.0, 106.2, 111.2, 115.4, 117.3, 
122.9, 123.6, 126.6, 126.9, 129.5, 129.9, 130.2, 131.9, 134.0, 145.3, 149.8, 150.4, 152.2, 163.3, 163.4 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C31H37N6O4: 557.2876; found: 557.2881. 
N-[2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-
yl}phenyl]acrylamide (79) 
Compound 79 was prepared according to the general procedure for N-SEM 
deprotection. N-[2-(2-Ethoxyethoxy)-5-{4-methoxy-6-[4-(4-
methylpiperazin-1-yl)phenyl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidin-5-yl}phenyl]acrylamide (79.0 mg, 0.115 mmol) was 
deprotected and purification was achieved using flash column 
chromatography with elution gradient of 0 – 20% MeOH in DCM. Pure 
fractions were evaporated to dryness to afford compound 79 as a white solid 
(49.0 mg, 88.0 µmol, 77%).  
Rf: 0.38 (10% MeOH in DCM); 
1
H NMR (500 MHz, CDCl3) δ 1.26 (t, J = 7.0 Hz, 3H, OCH2CH3), 2.37 (s, 3H, 
(CH2)2NCH3), 2.61 (br s, 4H, 2 × NCH2CH2N), 3.27 (br s, 4H, 2 × NCH2CH2N), 3.61 (q, J = 7.0 Hz, 2H, OCH2CH3), 
3.79 (t, J = 4.5 Hz, 2H, OCH2CH2O), 3.99 (s, 3H, ArOCH3), 4.20 (t, J = 4.5 Hz, 2H, OCH2CH2O), 5.71 (d, J = 
10.0 Hz, 1H, CCH=CH
2
), 6.30 (dd, J = 16.8, 10.0 Hz, 1H, CCH=CH
2
), 6.37 (d, J = 16.8 Hz, 1H, CCH=CH
2
), 
6.88 – 6.81 (m, 3H, 3 × ArH), 6.98 (d, J = 7.7 Hz, 1H, ArH), 7.39 (s, 1H, ArH), 7.41 (s, 1H, ArH), 8.20 (s, 1H, 
ArH), 8.37 (s, 1H, ArH), 8.67 (s, 1H, ArNH), 13.22 (s, 1H, ArNH) ppm;  
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13
C NMR (126 MHz, CDCl3) δ 15.3, 46.0, 48.1, 53.7, 54.9, 66.9, 68.9, 69.3, 106.2, 111.2, 112.6, 115.5, 122.9, 
123.5, 126.7, 126.9, 128.3, 128.7, 129.5, 132.0, 133.9, 146.1, 149.8, 150.4, 152.2, 163.2, 163.4 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C31H37N6O4: 557.2876; found: 557.2874. 
Crystallisation of cSrc-T338M/S345C with compound 77 
The inhibitor 77 was co-crystallized with cSrc-T338M/S345C by incubating 5 mg/mL protein with a threefold molar 
excess of inhibitor (10 mM DMSO stock) for 1 h at 4 °C to allow enzyme–inhibitor complex formation prior to 
crystallization. Crystals were grown using the hanging drop method at 20 °C after mixing a 1 µL protein-inhibitor 
solution with a 1 µL reservoir solution (10% ethylene glycol, 1 mM sodium chloride, pH 7.0). The data sets were 
collected at the PX10SA beamline of the Swiss Light Source (PSI, Villingen, Switzerland). All data sets were processed 
with XDS and scaled using XSCALE.
30
 
The complex crystal structures of cSrc-T338M/S345C in complex with compound 77 was solved by molecular 
replacement with PHASER using structure PDB: 3G5D as template.
31
 The cSrc molecule in the asymmetric unit was 
manually adjusted using the program COOT.
32
 The refinement was performed with Phenix 1.10.
33
 Inhibitor topology 
files were generated using the Dundee PRODRG2 server and refined structures were validated with PROCHECK 
and the PDB validation server.
34
 PyMOL was utilised for generating Figure 4.11. Data collection, structure 
refinement statistics, and further details for data collection are provided in Table 4.10 below.  
Table 4.10: Data collection and refinement statistics for cSrc-T338M/S345C in complex with 77. 
cSrc-T338M/S345C with 77 
Data Collection Refinement 
Space Group P1 Resolution [Å] 43.31 – 1.90 
Cell Dimensions  No. reflections 57563 
a, b, c [Å] 42.4, 63.3, 74.6 Rwork / Rfree  27 / 30 
α, β, γ [°] 78.2, 90.7, 89.8 No. atoms  
Resolution [Å] 40.3-2.1 (2.2-2.1) Protein 4127 
Rmeas[%] 7 (62.6) Ligand/ion 76  
I / I 6.5 (2.5) Water 321 
Completeness [%] 97.6 (97) B-factors  
CC1/2 99.8 (84.3) Protein 50.72 
Redundancy 2.3 (2.4) Ligand/ion 54.38 
Water  46.61 
R.M.S. deviations  
Bond lengths [Å] 0.006 
Bond angles [°] 0.817 
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Chapter 5 
1,4-Dicarbonyl Electrophiles Targeting the EGFR Catalytic Lysine 
Residue Lys745 
Abstract 
In this chapter, our research endeavours departed from the traditional use of reversible inhibitors and acrylamide electrophiles 
which target cysteine residues within the kinase. To effectively combat the emergence of the C797S resistance mutation, we 
aspired to re-establish covalent inhibition in this mutant variant by targeting the EGFR catalytic lysine residue. The regulatory role 
of the catalytic lysine in kinase activation is discussed, followed by a review of several successful instances of lysine-targeted 
covalent inhibition. Emulating the successes in the literature, we devised a strategy employing 1,4-dicarbonyl electrophiles to 
potentially undergo Paal-Knorr pyrrole formation with the catalytic lysine, thereby covalently modifying the enzyme. This included 
use of 1,4-diketone, -dicarboxylic, -diester and -dialdehyde warheads attached to a suitably designed quinazoline driving group. 
Of these, eight final compounds were successfully synthesised, while several synthetic approaches to afford the 1,4-dialdehyde 
proved ineffective. Subsequent biochemical and cellular evaluation unfortunately yielded mostly poor results and covalent mass 
spectrometry experiments exhibited a reversible binding mode for all compounds. However, several unexpected outcomes that 
provide a platform for further development and future considerations to improve and enhance this class of inhibitor are disclosed.  
5.1 Introduction 
In the previous chapter, we utilised the traditional approach of reversible and irreversible inhibition, using the well-
established acrylamide moiety as Michael acceptor to target the Cys797 residue for irreversible kinase inhibition. 
This conventional method of covalent modification rendered effective results against the L858R/T790M double 
mutant for which it was initially developed. The compounds exhibited exceptional inhibition of the double mutant 
biochemically and retained their efficacy in a cellular setting. However, as seen with the 3
rd
 generation inhibitors 
osimertinib and olmutinib, a near complete loss of activity was witnessed against the clinically relevant C797S triple 
mutant, highlighting the ineffectiveness of this therapeutic strategy in targeting this mutant. The designed reversible 
inhibitors demonstrated impressive biochemical activity against the C797S mutant, with the most potent agent 
exhibiting a 75-fold increase over osimertinib. This advance in activity over osimertinib was preserved in the 
evaluation against the PC9/T790M/C797S cell line but was notably diminished to a mere 2-fold improvement. 
A valuable lesson was instilled over a decade ago with the development and ultimate failure of 2
nd
 generation 
inhibitors attempting to combat the emergence of the T790M resistance mutation. Trying to improve on existing 
inhibitors, as exemplified by the 2
nd
 generation inhibitors derived from gefitnib and erlotinib, proved ineffective in 
quelling the advance of acquired drug resistance at the time. It was only through the combined discovery of novel 
chemical structures, and implementation of the then experimental acrylamide moiety for covalent modification, that 
3
rd
 generation inhibitors were able to effectively overcome the T790M mutation. The C797S triple mutant, which 
replaces the nucleophilic Cys797 with a serine residue, directly counteracts the fundamental functionality of this 
irreversible inhibition strategy. Consequently, the advent of this drug resistant mutant can be seen as a reflection of 
the situation researchers found themselves in at the inception of the EGFR-T790M mutant and will require the use 
of innovative therapeutic approaches to overcome.  
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Therefore, in the following chapters, our research thrust shifts from using the traditional irreversible therapeutic 
system of targeting cysteine residues with an electrophilic Michael acceptor. Instead, we endeavoured to design and 
synthesise inhibitors containing novel electrophiles which could potentially covalently modify relatively unexplored 
amino acids within the EGFR active site. We believe that the reinstatement of irreversible inhibition by these 
molecules could restore their cellular efficacy against the C797S triple mutant, a feat that no research group has 
accomplished up until this point. The body of research described in this chapter focusses on the use of 1,4-dicarbonyl 
electrophiles to potentially undergo Paal-Knorr pyrrole formation with the catalytic lysine 745 residue.  
5.2 Targeting the EGFR Catalytic Lysine Residue 
5.2.1 Catalytic Control in EGFR and Kinase Regulatory Mechanisms 
The catalytic lysine residue is well-conserved in protein kinases and is involved in the phosphate transfer machinery 
of the substrate ATP molecule.
1
 Using EGFR as an example in Figure 5.1a, we see that the catalytic Lys745 is an 
invariant residue of the β3 strand, situated at the roof of the enzyme active site and in close proximity to helix αC of 
the N-lobe of the kinase. This residue resides in a similar position in virtually every ATP binding pocket of all human 
kinases.
1
 As discussed in Section 2.2.3 and 2.3.2, protein kinases must undergo a conformation conversion to 
become catalytically active. One of the major modes by which kinase activation is regulated is by phosphorylation 
of their activation loop, which forms part of the activation segment and includes the DFG motif.
2
 This mechanism 
induces the dynamic assembly of the regulatory spine, a well-documented part of the activation process and hallmark 
signature of an active kinase, and is accompanied by structural and conformational changes in the kinase.
2, 3
  
Figure 5.1: a) Crystal structure of the EGFR 696-1022/T790M mutant, highlighting the catalytic lys745 residue in yellow 
(PDB: 5GTZ)
4
 and b) The phosphorylated and active p38α MAP kinase, with the activation-loop forming interactions with 
multiple regions, including the important Glu-Lys salt bridge (PDB: 3PY3). Figure redrawn and reproduced from a) Grabe et al 
and b) Beenstock et al.
2
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Following activation-loop phosphorylation, a number of functional elements required for the activity of the protein 
kinase are aligned, the results of which can be seen in Figure 5.1b.
2
 The activation loop, which is mostly disorganised 
in the inactive state, is stabilised and imposes a conformational change on the entire protein which promotes activity. 
The DFG motif undergoes a conversion to the DFG-in orientation, reorienting the regulatory spine and inducing 
rotation of the helix αC to αC-in.2 It is this rotation that places the helix αC glutamic acid in a favourable position for 
the formation of the Glu-Lys salt bridge with the catalytic lysine (Figure 5.1b).
2
 In this conformation, the lysine is 
able to interact with the α- and β-phosphates of ATP, stabilising it and facilitating transfer of the phosphate group 
within the substrate phosphorylation site.
5
 Therefore, the role of the catalytic lysine residue and formation of this salt 
bridge is an essential component for ATP binding and kinase activity.  
The importance of the catalytic lysine residue is illustrated in examples of its mutation generating inactive or “kinase-
dead” forms of the enzyme. In two separate studies, the catalytic lysine residue was mutated to a corresponding 
arginine and histidine residue in the MAP kinase ERK2 and cAMP-dependant kinase respectively.
6, 7
 In the former, 
the mutation of the lysine residue created a non-productive binding mode for ATP and resulted in a dramatically 
lowered catalytic activity compared to the wild-type ERK2 enzyme, suggesting its importance in orienting ATP and 
enabling catalysis.
6
 Similar results were obtained in the latter investigation, with the mutant variant displaying a lower 
stability than the wild-type catalytic subunit.
7
   
Lastly, crystal structure studies of lapatinib, an FDA approved dual EGFR/HER2 inhibitor shown in Figure 5.2a, 
revealed a previously unseen inactive-like conformation of the EGFR enzyme. In this binding mode, the helix αC is 
displaced to the αC-out conformation, while the DFG motif remains in DFG-in.8 Following the helix αC movement, 
the conserved Glu-Lys salt bridge interaction is broken, inactivating the enzyme.  
Figure 5.2: a) Structures of lapatinib, neratinib and dacomitinib and b) Crystal structure of dacomitinib, with the activation loop 
highlighted in lime-green, helix αC in light-blue and catalytic lysine labelled K745 with the Glu-Lys salt bridge absent. Figure 
reproduced from b) Gajiwala et al.
9
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Similar findings were obtained for both neratinib and dacomitinib, shown in Figure 5.2a, with both inhibitors 
displaying the DFG-in αC-out binding mode.9, 10 A crystal structure of dacomitinib, bound in this conformation to 
the EGFR-T790M mutant, is shown in Figure 5.2b.
9
 In this binding mode we see the helix αC (Figure 5.2b, light-
blue) clearly in the out-conformation and a fair distance from the catalytic lysine K745. As the glutamic acid residue 
of the salt bridge is located on the helix αC, and owing to this distance, the salt bridge interaction is broken in this 
orientation. This highlights the importance of the salt bridge, amongst other structural features, in maintaining 
activation of the protein kinase. However, with the increasing knowledge of the role of the DFG-in and helix αC-
out form of the enzyme, recent protein kinase inhibitors have been designed to target this specific inactive binding.
11
  
5.2.2 Lysine-trapping Covalent Inhibitors 
Whilst the vast majority of irreversible inhibitors to date have been designed to target a nucleophilic cysteine residue 
in close proximity to the ligand binding site, examples of lysine-targeting covalent inhibitors, although exceedingly 
rare, have been reported.
12
 Originally, natural products were the only source of lysine-trapping covalent compounds. 
Isolated as an antibiotic produced by Penicillium wortmanni in 1957, the natural product wortmannin, shown in 
Figure 5.3a, has been shown to irreversibly inhibit the PI3K family of kinases. Depending on the isoform, these 
oncologically relevant protein kinases are covalently modified at the catalytic Lys802 or Lys833 residue within the 
ATP binding site.
13
 Through protein crystal structure studies, the mechanism of action of wortmannin was revealed 
to involve nucleophilic attack of the activated furan ring by the catalytic lysine residue, leading to its ring opening 
and finally the covalently bound enamine species shown in Figure 5.3a.
14
 The crystal structure of wortmannin 
covalently bound to PI3K, confirming the exact nature  of the binding mode and the opened furan ring, can be seen 
in Figure 5.3b.
12
 Wortmannin analogues have been successfully developed with the aim of increasing selectivity and 
reducing off-target toxicity, with PX-866 having progressed to a phase II clinical trial for treatment against NSCLC 
and glioblastoma.
15
 
Figure 5.3: a) The proposed mechanism of action for wortmannin reacting with the catalytic Lys833 of PI3K and b) Crystal 
structure of PI3K covalently bound to wortmannin (green) through the catalytic Lys833 (magenta) (PDB: 1E7U). Figure 
reproduced from b) Pettinger, Jones and Cheeseman.
12, 14 
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Figure 5.4: a) Structure of IGF-1R inhibitor 1, b) Structure and mechanism of irreversible inhibition of DBS, with covalent 
adduct 2 and by-product 3 and c) Crystal structure of 2 (green) covalently bound to Lys335 (magenta) of the LmPYK enzyme 
(PDB: 3SRK). Figure reproduced from c) Pettinger, Jones and Cheeseman.
12, 16, 17 
Bell and co-workers developed a range of pyrrole-5-carboxaldehyde-derived, type 1 insulin-like growth factor 
receptor (IGF-1R) inhibitors which showed modest activity and good selectivity over a variety of kinases.
16
 These 
aldehyde-based inhibitors, with compound 1 as example illustrated in Figure 5.4a above, underwent reversible 
covalent imine bond formation between the aldehyde and Lys1003 within the ATP-binding pocket. To understand 
the mechanism of action, the aldimine adduct was reduced within IGF-1R using sodium borohydride in situ. This 
resulted in irreversible inactivation of the kinase, allowing for subsequent protein crystallography and confirming the 
formation of a reversible covalent bond. Compound 1 demonstrated an IC50 value of 0.49 µM against IGF-1R. 
The discovery of irreversible inhibitors using high-throughput screening (HTS) is a challenging endeavour as the 
inherent reactivity of the electrophile bearing small molecules typically excludes them from screen collections.
18
 
However, Morgan et al. were able to discover a new class of irreversible inhibitor during a HTS targeting Leishmania 
Mexicana pyruvate kinase (LmPYK).
17
 Following limited development of the hit compound, the saccharin derived 
thiol-linked analogue DBS, pictured in Figure 5.4b, was found to demonstrate good biochemical potency and 
inhibitory activity in a time- and dose-dependent manner. Crystallisation of DBS with LmPYK revealed the saccharin 
moiety undergoing covalent bond formation by nucleophilic attack from the active site Lys335 residue, forming the 
covalent adduct 2 and leaving group 3 shown in Figure 5.4b.
17
 The complex of 2 can be seen in Figure 5.4b.
12
 
The research group of Shokat were able to develop a chemical method that allowed for covalent cross-linking of a 
substrate of interest to protein kinase B (AKT).
19
 The novel mechanism-based cross-linker 4, shown in Figure 5.5a, 
was derived from the general covalent linker 5-fluorosulfonylbenzoyl adenosine (FSBA) and contained an o-
phthaldialdehyde moiety. Use of this dialdehyde catered for the requirement of a bifunctional cross-linker and 
specifically targeted the invariant catalytic lysine within the ATP binding site of the kinase. Following formation of 
the reversible imine adduct 5 (Figure 5.5a), nucleophilic attack of the cysteine-containing substrate and subsequent 
hydrolysis results in the formation of the stable isoindole linked covalent complex 6 (Figure 5.5a). This covalent 
cross-linker proved to be robust and was used in the identification of various kinase-substrate pairs.  
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 Figure 5.5: a) Representation of the covalent cross-linker 4 and cross-linking reaction furnishing the substrate-kinase pair 6 
through intermediate 5 and b) The natural product polygodial and its derivatives, polygodiol and 9-epipolygodial. Reversible 
synthesis of the stable Paal-Knorr pyrrole is also shown.
19,
 
20 
The natural product polygodial, shown in Figure 5.5b, is a terpenoid dialdehyde isolated from Polygonum 
hydropiper L. and is a known agonist of transient receptor potential vanilloid (TRPV1).
21
 Kornienko and co-workers, 
our collaborators from Texas State University, prepared and investigated a series of polygodial analogues for their 
TRPV1-agonist and anticancer properties.
20
 Through these experiments, the group was able to identify and isolate 
the epimer 9-epipolygodial (Figure 5.5b), which displayed potent antiproliferative activity, exceeding that of the 
parent compound, against apoptosis- and multidrug-resistant cancer cells. Attempting to understand the mechanism 
of action, the diol derivative polygodiol (Figure 5.5b) was synthesised, leading to a complete loss of anticancer 
activity and highlighting the importance of the dialdehyde functionality. The group hypothesised that the dialdehyde 
moiety could be undergoing a modified Paal-Knorr condensation with a lysine residue on the target protein. To 
support this intriguing claim, a chemical feasibility study was successfully undertaken, resulting in the synthesis of the 
stable polygodial pyrrole derivative 7, through the proposed pathway (Figure 5.5b). Exploration and use of this novel 
mechanism of covalent modification could be thus beneficial in the development of new anticancer therapeutic 
agents.  
The examples discussed above highlight a few applications of lysine-targeting electrophiles. Further examples are 
implemented for use in synthetic affinity labels, activity-based protein profiling and inhibitors of other enzymatic 
targets.
12
 The recent developments in rational targeting of nucleophilic lysine residues demonstrates its potential for 
future drug discovery. This provided the inspiration for the body of research described in the rest of this chapter.  
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5.3  Objectives and Target Synthetic Library 
Figure 5.6: a) Use of a 1,4-dicarbonyl electrophile to potentially undergo Paal-Knorr pyrrole synthesis with the EGFR catalytic 
Lys745 residue and b) Illustration of the selected heterocyclic driving group and various 1,4-dicarbonyl electrophiles 
constituting the prospective synthetic library. 
At the time of undertaking this research endeavour, the EGFR catalytic Lys745 residue had not been covalently 
modified by a corresponding irreversible inhibitor. Owing to the basicity of the ε-amino group of a typical surface 
lysine (pKa of 10.4) and physiological pH being at 7.4, approximately 99.9% of lysine residues within the human 
body will be presented as the protonated species and thus unavailable as nucleophiles.
12
 Consequently, we were 
curious as to whether the catalytic Lys745 of EGFR, situated relatively deep within the ATP binding pocket, could 
act as a nucleophile and undergo covalent bond formation. If indeed possible, we were intrigued by the potential 
therapeutic aspects of this mechanism of irreversible inhibition. As the catalytic lysine plays a significant role in the 
activation of the kinase and phosphate transfer of ATP, covalent modification of this residue would negate its ability 
to undergo salt bridge formation, leaving the kinase permanently inactivated. As most oncogenic kinases are in a 
permanently activated state, the prospect of being able to “switch off” these mutant variants of the enzyme by 
targeting a component of its machinery seemed advantageous.  
Following suit from the examples discussed in the previous section and the work undertaken by Professor Kornienko 
with the dialdehyde containing polygodial, we devised a strategy to covalently modify the catalytic Lys745 by using 
a 1,4-dicarbonyl electrophile. As illustrated in Figure 5.6a, the warhead would be attached to a suitable heterocyclic 
driving group with high reversible binding affinity, able to form important interactions with the hinge region of the 
kinase. Following reversible binding, we envisaged the electrophile undergoing a Paal-Knorr condensation reaction 
with the catalytic Lys745 residue, resulting in the formation of a covalently bound pyrrole (Figure 5.6a).  
As discussed in Section 5.2.1, the quinazoline-based inhibitors of lapatinib, neratinib, dacomitinib and gefitinib 
possess the ability to bind to both the traditional, active confirmation of the kinase and the distinct DFG-in αC-out 
inactive conformation of the kinase. For the purpose of our investigation we found this feature desirable, as in the 
active confirmation of the kinase covalent modification of the catalytic Lys745 could result in its potential 
deactivation, whilst in the inactive confirmation the absence of the Glu-Lys salt bridge could potentially present a 
more nucleophilic lysine residue to undergo this covalent bond formation.  
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Furthermore, owing to their significant biological activity and frequent use in kinase inhibitors, a wealth of knowledge 
exists on quinazoline-based derivatives, providing us with a relatively simplified synthetic route towards these 
structures.
22
 For these reasons, we selected a quinazoline core as our heterocyclic driving group, which can be seen 
at the top of Figure 5.6b. Lastly, as this study would be focussed on a proof of concept approach, we decided to 
forego the conventional inclusion of a solubilising group and opted instead for the simplified disubstituted methoxy 
at the 6- and 7-positions on the aromatic ring (Figure 5.6b).  
We elected to employ a variety of 1,4-dicarbonyl electrophiles to potentially undergo the Paal-Knorr pyrrole 
synthesis with the catalytic lysine residue. These included the use of 1,4-diketone, 1,4-dicarboxylic acid, 1,4-diester, 
1,4-dialdehyde and masked 1,4-dialdehyde functionalities, as can be seen in the bottom right of Figure 5.6b. We 
theorised that use of different carbonyl groups with varying reactivities and steric bulk/leaving groups could provide 
insight into the rate at which the Paal-Knorr condensation occurs, tailored lipophilicity and stability of the formed 
covalent adducts. As the amine at the 4-position of most commercial quinazoline inhibitors forms a hydrogen bond 
with the solvent in the ATP binding site (Figure 5.2b), we deemed it important to preserve this interaction in our 
library of compounds. Additionally, the halogenated aniline fragments which are substituted at the 4-position in 
these clinical quinazoline inhibitors (Figure 2.11 and Figure 5.2) bind in a close proximity to the catalytic lysine 
residue.
9
 We therefore chose to derivatise with our 1,4-dicarbonly electrophiles at this 4-aminoquinazoline position, 
placing the warheads in a theoretically favourable and nearby position to undergo the Paal-Knorr condensation 
reaction with Lys745. With our objective of covalently modifying the EGFR catalytic lysine residue and our initial 
synthetic library in mind, we set about synthesising the potential irreversible inhibitors.  
5.4 Library Synthesis  
5.4.1 Heterocyclic Driving Group Synthesis 
To facilitate the future incorporation of our 1,4-dicarbonyl electrophiles at the 4-position of the 6,7-
dimethoxyquinazoline driving group, the heterocyclic scaffolds 10 and 14, shown in Scheme 5.1a, were synthesized. 
For the synthesis of compound 10, the first step required cyclization of the commercially available 4,5-
dimethoxyanthranilic acid 8 with formamide. The optimal reaction temperature was found to be a maximum of 
140 °C, with anything above this resulting in a marked decrease in yield. Additionally, the inclusion of ammonium 
formate over the use of formamide exclusively as solvent, effected a further improvement in the yield. When heated, 
ammonium formate undergoes elimination of water, releasing formamide. This provided the tautomeric 
compound 9 in an excellent yield of 90%. This was followed by conversion of the 9 into the corresponding 4-
chloroquinazoline. Initial attempts using thionyl chloride and phosphorus oxychloride required harsh conditions of 
high temperature and excessive amounts of the chlorinating reagents, resulting in a lower yield and undesirable 
purification procedures. However, the addition of a catalytic amount of DMF prompted in situ formation of the 
reactive Vilsmeier-Haack reagent, allowing for lower temperatures and lesser equivalents of thionyl chloride to be 
used. Under these conditions, the first heterocyclic driving group scaffold 10 was therefore afforded in good yield.  
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Scheme 5.1: Synthesis of the heterocyclic driving group scaffolds 10 and 14. Reagents and conditions: i) ammonium formate 
(1.5 equiv.), formamide, 140 °C, 8 h; ii) SOCl2 (20 equiv.), DMF (cat.), 80 °C, 6 h; iii) HNO3 (10 equiv.), Ac2O, −10 °C – rt, 12 
h; iv) Na2S2O4 (8 equiv.), TBAB (30 mol%), CHCl3/H2O (1:1), rt, 16 h.
23
 
The outset of the synthesis of 14, illustrated in Scheme 5.1b above, required the regioselective nitration of the 
commercially available 3,4-dimethoxybenzonitrile 11. Dropwise treatment of 11 with an excess of nitric acid in 
acetic anhydride, while maintaining a temperature below −5 °C, followed by precipitation in water and subsequent 
filtration, furnished the nitrated derivative 12 in near quantitative yield with no further purification required.
23
 While 
the combined activating/deactivating effects of the ring’s substituents indicate nitration at the 5-position, we believe 
the steric burden of a tri-substituted aromatic product outweigh these effects. Furthermore, the obtained 
1
H NMR 
spectrum compared well with the reported literature values, negating the requirement for further verification.
23
  
Due to the presence of the benzonitrile moiety, we excluded the use of hydride-based reducing agents for the 
aromatic nitro reduction of compound 12, thus avoiding the possible formation of the diamine product. Use of 
sodium dithionite, with tetrabutylammonium bromide (TBAB) as phase transfer catalyst in a mixture of chloroform 
and water, facilitated chemoselective reduction of the nitro functionality, affording compound 13. Optimization 
efforts, including use of DCM and CCl4 in different ratios, higher temperatures and varying equivalents of the 
reducing agent could not drive the reaction to completion. The reported literature yield of 56% was matched and 
unreacted starting material was iteratively recycled and used in subsequent reductions.
23
 Lastly, ring closure of 
compound 13 with the previously established ammonium formate/formamide conditions supplied the 4-
aminoquinazoine scaffold 14 in excellent yield.  
Owing to the structural similarity of the driving group scaffolds 10 and 14, only the 
1
H NMR spectrum of compound 
14 will be depicted and scrutinized. Full characterization of all compounds not analysed in this chapter, including 
IR, 
1
H, 
13
C and HRMS spectra, can be accessed in the supplementary information (Section 5.8). Inspection of the 
1
H NMR spectra in Figure 5.7 indicated structural confirmation of compound 14. In the upfield region, we saw two 
singlets at δ 3.86 and 3.89 ppm, integrating for 3H each and correlating to the 6- and 7-position methoxy groups 
(dark blue). Moving downfield, a characteristic broad peak of 2H was seen at δ 7.41 ppm, corresponding to the 4-
amino moiety (orange). Lastly, we anticipated the 2-position proton (red) to have the largest downfield shift, owing 
to the significant deshielding effects of the neighbouring nitrogen atoms in the quinazoline ring. This singlet appeared 
at δ 8.26 ppm, with the remaining aromatic protons (green) assigned to the peaks at δ 7.07 and 7.57 ppm. With the 
heterocyclic driving group scaffolds in hand, we next set about synthesising our 1,4-dicarbonyl electrophiles. 
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Figure 5.7: 
1
H NMR Spectra of the heterocyclic driving group compound 14. 
5.4.2 1,4-Diketone Compound Synthesis 
For the synthesis of the 1,4-diketone-containing compound, we envisaged coupling of the synthesised scaffold 14 
to the α-bromoketone electrophile 20, the synthesis of which can be seen in Scheme 5.2. Synthesis of electrophile 
20 began with SN2 reaction between the commercially available ethyl acetoacetate and 2,3-dibromopropene, 
compounds 15 and 16 respectively. Following vacuum distillation purification of both reagents prior to reaction, use 
of in situ generated sodium ethoxide as base furnished the intermediate enolate, allowing for nucleophilic attack on 
the electrophilic 16, affording compound 17 in good yield. Subsequent efforts to produce compound 19 via 
hydrolysis and decarboxylation of compound 17 were met with failure, repeatedly leading to isolation of the 
carboxylic acid 18, represented by a broad peak near δ 12.3 ppm in the 1H NMR spectra. This included the use of 
high temperatures, varying concentrations of acid and base and Krapcho decarboxylation conditions using LiCl and 
DMSO, all to no avail.  
Scheme 5.2: Synthesis of the 1,4-diketone electrophile 18. Reagents and conditions: i) NaOEt (generated in situ) (1 equiv.), 
EtOH/Et2O (2:1), −10 °C – rt, 24 h; ii) NaOEt (generated in situ) (1 equiv.), EtOH, 80 °C, 1 h; iii) 10% NaOH, rt – 80 °C, 2 h 
then conc. HCl, rt – 80 °C, 2 h; iv) NBS (1.3 equiv.), HBr (cat.), MeCN:H2O (4:1), rt, 4 h.24, 25 
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We therefore returned to the initial SN2 reaction and, following the formation of intermediate 17, were able to 
induce hydrolysis and decarboxylation using NaOH and HCl at 80 °C in a one-pot synthesis.
24
 This afforded the 
desired compound 19 in an acceptable yield of 59% over the three-step reaction sequence. The final step in the 
synthesis of electrophile 20 involved the oxidative hydrolysis of vinyl bromide 19 using NBS and a catalytic amount 
of hydrobromic acid in aqueous acetonitrile, a procedure developed by Morton and Leanna.
25
 Addition of these 
reagents generates a bromine-hypobromous acid equilibrium, the latter species being responsible for the oxidative 
hydrolysis. This approach furnished the α-bromoketone electrophile 20 in good yield, setting up for subsequent 
coupling with scaffold 14. It is worth noting that monobromination of 2,5-hexanedione was ruled out as a potential 
synthetic route towards 20. Competing sites within the molecule gives rise to a lack of control in regioselectivity and 
over-bromination, with resultant product separation of the mono- and dibrominated products near impossible.  
Reaction of scaffold 14 with electrophile 20 in ethanol while heating under reflux, as outlined in Scheme 5.3 below, 
led to the formation of the target compound 21 and the ring-closed imidazoquinazoline equivalent 22 as the major 
and minor products respectively. This result is comparable to the work undertaken by the Cottam research group, 
where similar reaction conditions led to production of a series of small heterocyclic compounds including the 
benzothiazoles, benzimidazoles and quinazolines, together with their corresponding ring-closed imidazo-
counterparts.
26
 As 22 contains a suitable ketone functionality, we proposed that this electrophile could potentially 
undergo reversible imine formation with the catalytic Lys745, in similar manner to compound 1 (Figure 5.4a). 
Consequently, we decided to evaluate both compounds 21 and 22 against EGFR and its mutant variants.   
The successful synthesis of both 21 and 22 could be confirmed through the comparative analysis of their respective 
1
H NMR spectra, as illustrated in Figure 5.8 on the following page. Examination of the upfield region in both spectra 
revealed the presence of several shared structural elements. These included the terminal ketone methyl peak (yellow) 
between δ 2.10 and 2.15 ppm, the signals of the 1,4-diketone ethylene bridge (light blue) between δ 2.81 and 2.91 
ppm and the aromatic dimethoxy groups (dark blue) at approximately δ 4.00 ppm, with appropriate peak 
integration. Moving to the aromatic region, we could see the signal corresponding to the 2-position quinazoline 
proton (red) furthest downfield in both spectra. For compound 21 and 22 we found two more aromatic peaks (green) 
correlating to the remaining quinazoline protons. However, compound 22 contained an extra peak (green) 
integrating for 1H, which we attributed to the newly formed imidazole proton.  
Scheme 5.3: Synthesis of the final 1,4-diketone compound 21 and the imidazoquinazoline ketone compound 22. Reagents 
and conditions: i) EtOH, 80 °C, 6 h.
26
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Figure 5.8: Comparison of the 
1
H NMR spectra of final compounds 21 and 22. 
Lastly, a singlet belonging to the linker protons (purple) between the 1,4-diketone chain and the 4-aminoquinazoline 
ring in compound 21 was visibly present at δ 5.81 ppm and evidently absent in the spectra of compound 22, further 
substantiating formation of the ring-closed product. Similarly, the 4-aminoquinazoline proton (orange) was found 
furthest downfield at δ 9.57 ppm in the spectra of compound 21 and was perceptibly lacking in the spectra of 
compound 22. The absence of these signals in compound 22 signified their participation in the formation of the 
imidazoquinazoline. While not analysed, the 
13
C spectra and HRMS results provided further confirmation for the 
formation of these two products and can be found in the supplementary information (Section 5.8). This afforded 
two ketone-based final compounds for biochemical and cellular evaluation and prompted us to move forward in 
the synthesis of the remaining final compounds.  
5.4.3 1,4-Dicarboxylic Acid and 1,4-Diester Compound Synthesis 
Synthesis of the 1,4-dicarboxylic acid and 1,4-diester-containing final compounds required the use of DL-aspartic 
acid as a building block. As outlined in Scheme 5.4 on the following page, we envisaged reaction at the electrophilic 
4-position of the quinazoline driving group 10 with the naked amino acid 23 and the esterified counterpart 24 – 26 
acting as nucleophiles to furnish final compounds 27 – 30. Accordingly, aspartic esters 24 – 26 were synthesised by 
treatment of 23, in a solution of either methanol, ethanol or isopropanol, with thionyl chloride at low temperature 
to generate the aspartic acyl chloride intermediate. The solution was subsequently heated under reflux for 6 hours, 
allowing for nucleophilic attack by the respective alcohol, followed by distillation of excess thionyl chloride and 
trituration with diethyl ether. This furnished the aspartic ester derivatives 24 – 26 as the hydrochloride salts in 
excellent yields with no further purification required (Scheme 5.4).  
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Scheme 5.4: Synthesis of the final 1,4-dicarboxylic acid compound 27 and the 1,4-ester containing compounds 28 – 30. 
Reagents and conditions: i) SOCl2 (1.4 equiv.), respective alcohol, −10 °C – reflux, 6 h; ii) DL-aspartic acid (0.83 equiv.), Et3N 
(4 equiv.), DMSO:H2O (1:1), 80 °C, 72 h; iii) aspartic ester (1.1 equiv.), 4 M HCl in dioxane (cat.), MeCN, 80 °C, 24 h. 
Formation of the 1,4-dicarboxylic acid-containing final compound 27 proved more challenging than anticipated. 
Solvent choice was problematic owing to the polarity of the reagents and formed product and the inability to use 
solvents such as methanol or ethanol which could act in a nucleophilic manner. Optimization parameters of the 
reaction included the interchanging use of acids or bases in various solvents at different temperatures. It was found 
that use of 23 as the limiting reagent aided in the subsequent purification and a 1:1 mixture of DMSO/H
2
O as solvent 
provided sufficient solubility and miscibility for both reactants. Employing the optimised conditions, coupled with 
the use of excess Et3N as base at 80 °C, furnished the final compound 27 in an excellent yield of 90%.     
Due to the improved solubility of the aspartic acid derivatives 24 – 26, optimization of their reaction with driving 
group 10 was uncomplicated. Under basic conditions the reaction proceeded sluggishly and did not reach 
completion, whereas the use of a catalytic amount of 4 M HCl in dioxane required somewhat shorter reaction times 
of up to 24 hours. We believe this increase in reaction rate stems from N1 protonation of the quinazoline 
heterocycle, with the subsequent resonance structure increasing the electrophilicity of the 4-position, thereby 
facilitating nucleophilic attack from the aspartic ester amines. Consequently, reaction in acetonitrile at 80 °C afforded 
the final compounds 28 – 30 in good yield. This provided four final compounds comprising of 1,4-dicarboxylic acid 
and -diester containing motifs for later evaluation. The 
1
H and 
13
C NMR spectral analysis of compound 28 follows 
and can be found in Figure 5.9 on the next page.  
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Figure 5.9: a) 
1
H and b) 
13
C NMR spectra of final compound 28. 
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Examination of the 
1
H NMR spectra of compound 28 (Figure 5.9a) revealed the previously identified structural 
elements of the quinazoline core, in addition to new signals belonging to the 1,4-diester functionality. To avoid 
repetition, we focussed only on the unexplored features of compound 28. Beginning in the upfield region, we saw 
the occurrence of a doublet integrating for 2H at approximately δ 3.20 ppm which we attributed to the CH2 of the 
ethyl linker of the 1,4-diester electrophile (light blue). Slightly downfield from this position were two large singlets 
between δ 3.63 and 3.67 ppm integrating for 3H each and signifying the presence of the methyl group of the 1,4-
diester (yellow). Lastly, the proton of the trisubstituted carbon centre (purple) appeared as an apparent quartet at δ 
5.42 ppm and integrated for 1H.  
Inspection of the 
13
C spectra in Figure 5.9b revealed 6 signals in the aliphatic region and 10 remaining peaks further 
downfield, which accounted for the 18 carbons of compound 28. From precursor spectra and due to the electronic 
effects of the ester functionality, we could distinguish between the two sets of two peaks in the aliphatic region 
between δ 57.5 and 52.3 ppm. The peaks furthest downfield (δ 56.9 and 57.5 ppm) belonged to the quinazoline 
dimethoxy groups (dark blue) and the other peaks (δ 56.9 and 57.5 ppm) could be ascribed to the dimethyl ester 
carbons (yellow). Adjacent to these signals, we saw the peak corresponding to the trisubstituted carbon (purple) of 
the 1,4-diester at δ 51.3 ppm. Owing to the electron donating effect of this substitution, we expected it to be in a 
more downfield position than the remaining ethyl linker carbon (light blue) of the 1,4-diester, which indeed 
appeared at δ 35.2 ppm. In the aromatic region, we saw 8 carbon signals which correctly accounted for the 
quinazoline core structure. Lastly, the dicarbonyl carbons (orange) were found furthest downfield and appeared as 
two peaks adjacent peaks at δ 170 ppm. With all remaining protons and carbons correctly accounted for, and in 
conjunction with the IR and HRMS results, the discussed 
1
H and 
13
C spectra provided confirmation for the successful 
synthesis of compound 28.  In a similar manner, the other compounds of the series (27, 29 – 30), were also validated. 
We therefore turned our attention towards the synthesis of the 1,4-dialdehyde electrophile-containing inhibitors.  
5.4.4 Attempted 1,4-Dialdehyde Compound Synthesis 
5.4.4.1 Reduction of 1,4-Diester Containing Compounds 
Our first attempt towards the synthesis of the 1,4-dialdehyde-containing compounds involved reduction of the 
previously synthesised 29 to potentially afford compound 31, as shown in Scheme 5.5. For this, we envisaged the 
use of diisobutylaluminium hydride (DIBAL), as an equimolar amount of the bulky reducing agent has been shown 
to selectively afford the aldehyde and cease further reduction at low temperature.
27
 Unfortunately, employment of 
this reducing agent at controlled temperatures ranging from −78 °C to −30 °C resulted in the formation of a 
multitude of by-products, clearly demonstrated by TLC analysis. Consequently, purification of the reaction mixture 
was found to be impractical and we shifted our focus toward other synthetic routes.  
One of the potential routes towards compound 31 entailed oxidation of the 1,4-diol-containing compound 32. To 
obtain compound 32, reduction of 29 was attempted using numerous reducing agents, including an excess of DIBAL, 
NaBH4, LiBH4 and LiAlH4. While the greatest success was attained using LiAlH4, isolation and purification of the 
crude product proved troublesome. 
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Scheme 5.5: Attempted reduction of compound 29 to 1,4-dialdehyde 31 and successful reduction to 1,4-diol 32. Reagents 
and conditions: i) LiAlH4 (3 equiv.), THF, −10 °C – reflux, 1 h.  
A variety of work-up procedures, which included use of ethanolamine and Rochelle salt (Fieser work-up), were 
found to be ineffective in removing the crude from the aqueous phase.
28
 However, this problem was circumvented 
by Soxhlet extraction of the solid salts, which were collected by filtration after quenching with isopropanol and 
water. Placement of the solid material in a Soxhlet cup, followed by continuous extraction in isopropanol while 
heating under reflux overnight, allowed for successful isolation of the crude product. Following the challenging 
purification using column chromatography, compound 32 was afforded in a low yield of 21%. While delighted with 
the effective isolation of this compound, we found the yield to be unsatisfactory and therefore sought a more feasible 
reaction sequence for the synthesis of 32 en route towards compound 31. 
5.4.4.2 Oxidation of 1,4-Diol-containing Compounds 
Wishing to emulate the success of the coupling reactions of aspartic esters 24 – 26 with driving group 10 
(Scheme 5.4), we intended to synthesise and couple compound 33 in a similar manner, as shown in Scheme 5.6a. 
Accordingly, reduction of compound 25 to 33 was carried out using LiAlH4 with the previously optimized work up 
conditions followed by Soxhlet extraction. As 33 is a low molecular weight oil with a boiling point of 269 °C, 
purification was accomplished by Kugelrohr distillation, proving more effective than column chromatography.
29
 
Fractions with boiling point between 124 °C – 126 °C at approximately 20 mbar were collected, affording compound 
33 in good yield. Successful coupling of this fragment to the heterocyclic driving group 10 furnished the 1,4-diol 
scaffold 32 in a substantially improved and workable overall yield. Preparing for the impending oxidation reactions 
of compound 32, we synthesised 2-iodoxybenzoic acid (35) and its improved derivative Dess-Martin periodinane 
(36) from the commercially available 2-iodobenzoic acid (34). Both reagents have been well-documented in the 
oxidation of primary alcohols to aldehydes.
30
 These were prepared according to their literature procedures and 
allowed for the attempted oxidation of compound 32 to the 1,4-dialdehyde 31, as  illustrated in Scheme 5.6b.
31, 32  
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Scheme 5.6: a) Alternative synthesis of compound 32 and of oxidising agents 35 and 36. Reagents and conditions: i) LiAlH4 
(3 equiv.), THF, −10 °C – reflux, 1 h; ii) 4 M HCl in dioxane (cat.), MeCN, 80 °C, 24 h; iii) Oxone (3 equiv.), H2O, 70 °C, 3 h; 
iv) TsOH·H2O (cat.), Ac2O, 80 °C, 2 h. b) Attempted oxidation of compound 32 to 31 and proposed mechanism of attack by 
intermediates resulting in the formation of lactol 38 and lactone 39 as by-products.
29, 31, 32  
Regrettably, the oxidation of compound 32 to 31, and synthesis of the 1,4-dialdehyde in this manner, proved 
unachievable. Oxidations were attempted at varying temperatures using an array of reagents, including the 
synthesised 35 and 36, pyridinium chlorochromate (PCC) and the DMSO based Pfitzner-Moffatt, Parikh-Doering 
and Swern oxidations with DCC, sulphur trioxide-pyridine complex and oxalyl chloride as activating species 
respectively.
33, 34
 However, use of these parameters invariably led to the formation of an abundance of by-products 
and consequently inseparable crude reaction mixtures.  
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We postulated that singly oxidised intermediates such as 37 could potentially undergo nucleophilic attack from the 
neighbouring alcohol, resulting in formation of one of many compounds such as lactol 38 and with further oxidation 
lactone 39. We were able to find two separate studies in 1,4-diol oxidation that substantiated our hypothesis. In the 
first of these studies, use of several oxidizing agents such as potassium permanganate, Collins reagent or PCC resulted 
in the formation of the γ-lactone, thought to proceed through an intermediate lactol which was readily oxidised to 
the corresponding lactone.
35
 In the second study, Corey et al. were able to selectively oxidise 1,4-bis-primary 
alcohols to the equivalent γ-lactols using IBX.36 Lastly, the quinazoline N3 and 4-amino group could potentially 
participate in a ring-closure reaction, similar to that seen in the formation of the imidazoquinazoline 22 in 
Scheme 5.3. For these reasons we chose to abandon this method and focus on an alternate synthetic route.  
Combing through the literature, we uncovered a procedure that allowed for the oxidation of the Boc-protected 
compound 40 to 41 under Swern conditions, as shown in Scheme 5.7a.
37
 Although the group did not isolate 
compound 41, as it was immediately used in the succeeding Wittig reaction, we were encouraged by these findings. 
We believed that the absence of the quinazoline and presence of the Boc-protecting group could potentially prevent 
nucleophilic attack on the aldehyde intermediates. Following this idea, the use of di-tert-butyl dicarbonate with Et3N 
as base in methanol furnished the intermediate 42 in good yield, as illustrated in Scheme 5.7b. This was followed 
by subsequent reduction using LiAlH4 to afford the Boc-protected 1,4-diol 40. Use of the documented oxidation 
procedure resulted in what we believed to be formation of the 1,4-dialdehyde product 41, but to our dismay proved 
too unstable to isolate and verify by spectroscopic analysis. Finally, the attempted reduction of compound 42, using 
DIBAL at low temperatures, succumbed to the now expected formation of by-products and inseparable crude 
reaction mixtures.  
  
 
 
 
 
 
 
 
 
 
Scheme 5.7: Synthesis of Boc-protected analogues 42 and 40 and their attempted oxidation and reduction to afford 
compound 41. Reagents and conditions: i) Boc2O (1.1 equiv.), Et3N (2.2 equiv.), MeOH, 0 °C – rt, 16 h; ii) LiAlH4 (3 equiv.), 
THF, −10 °C – reflux, 1 h.37, 38 
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5.4.4.3 Ozonolysis and Wacker Oxidation of 1,4-Diene Containing Compounds 
In our final effort to produce the 1,4-dialdehyde final compound, we envisioned the synthesis of the 1,4-diene 
compound 49 illustrated in Scheme 5.8. We believed we could access the 1,4-dialdehyde or 1,4-diketone from 49 
through oxidative cleavage under ozonolysis or implementation of a Wacker oxidation respectively. Hence, the 
synthesis of 49 commenced with a Grignard reaction between the commercially available acrolein (43) and allyl 
bromide (44), using magnesium turnings to generate the allylmagnesium bromide Grignard reagent in situ. Heating 
under reflux in diethyl ether, followed by purification via Kugelrohr distillation, furnished compound 45 in an 
acceptable yield of 57%.  
Conversion of the hydroxyl group of 45 into the corresponding amine 48 was accomplished via a traditional Gabriel 
synthesis. Accordingly, the synthesised hydroxyl 45 and phthalimide 46 underwent a Mitsunobu reaction, employing 
the standard reagents of di-tert-butyl azodicarboxylate (DBAD) and PPh3, affording the 1,4-diene phthalimide 
intermediate 47. Subsequent aminolysis of intermediate 47 proved challenging, mainly due to the problematic 
isolation and purification of the product 48. However, use of excess hydrazine hydrate in ethanol heated under 
reflux overnight, followed by acidic workup and filtration, allowed for successful cleavage and separation of the 
phthalhydrazide by-products. This afforded compound 48 as the hydrochloride salt in a yield of 72% and allowed 
for coupling with driving group 10 using the established conditions of catalytic acid in acetonitrile heated under 
reflux. The coupling proceeded smoothly, furnishing the 1,4-dialkene containing compound 49 in a good yield of 
74%. The 
1
H NMR spectral analysis of compound 49 follows on the next page.   
  
 
  
 
 
 
 
 
 
 
Scheme 5.8: Synthesis of 1,4-diene 48 via Grignard and Mitsunobu reaction intermediates 44 and 47. Reagents and 
conditions: i) 43 (1.2 equiv.), Mg turnings (1.4 equiv.), Et2O, 45 °C, 3 h; ii) 45 (1.1 equiv.), DBAD (1.3 equiv.), PPh3 
(1.1 equiv.), THF, 0 °C – rt, 16 h; iii) hydrazine hydrate (1.5 equiv.), EtOH, 80 °C, 6 h; iv) 4 M HCl in dioxane (cat.), MeCN, 80 
°C, 24 h.
39
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Figure 5.10: 
1
H NMR spectra of final compound 49. 
Inspection of the 1H NMR spectra of compound 49, displayed above in Figure 5.10, revealed the presence of both 
familiar structural elements and the appearance of unique signals belonging to the 1,4-dialkene functionality. 
Regarding the former, we saw the signal of the ethyl linker CH2 at δ 2.54 ppm (light blue), which appeared as a 
multiplet due to overlap with the DMSO-d6 solvent peak. Slightly downfield from this position, we saw the aromatic 
methoxy groups appear as two tall singlets between δ 3.93 and 3.95 ppm, which integrated correctly for 6H. In the 
aromatic region, we saw 3 singlets which corresponded to the three aromatic protons of the quinazoline ring (green 
and red). Lastly, we found the signal of the amine proton appearing as doublet at δ 7.78 ppm (orange), in agreement 
with spectra of previously synthesised intermediates.  
For the dialkene portion of compound 49, we looked to the remaining signals between ~ δ 5.00 and 6.00 ppm. 
The splitting pattern of the set of peaks between δ 5.28 and 5.02 ppm could not be resolved and was therefore 
designated as a multiplet. As this multiplet integrated for 5H, we ascribed this signal to be a combination of both the 
terminal alkene protons (yellow) and the proton of the trisubstituted carbon centre (purple). This left the two 
remaining alkene protons, which appeared as two sets of signals slightly downfield. Interestingly, the nearest set at δ 
5.88 ppm (brown) appeared as a doublet of doublet of triplets, with J coupling values of 17.2, 10.3 and 6.8 Hz, 
whilst the adjacent set of peaks at δ 6.03 ppm was resolved as a doublet of doublet of doublets, with J = 17.2, 10.3 
and 5.8 Hz. From the predicted and observed splitting patterns it was clear that the proton adjacent to the CH
2
 of 
the ethylene bridge should be assigned to the ddt (brown) and the remaining proton (pink) to the ddd. While not 
analysed, the 
13
C spectra was correctly accounted for and may be accessed in the supplementary information 
(Section 5.8). Furthermore, HRMS analysis provided an [M+H]
+
 ion of 286.1559, matching the calculated mass of 
286.1556, which offered final confirmation for the successful synthesis of compound 49. Therefore, with compound 
49 in hand, we ventured into the ozonolysis and Wacker oxidation reactions which are shown in Scheme 5.9. 
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Scheme 5.9: Attempted ozonolysis and Wacker oxidation of compound 49 to afford 31 and 50. 
To our disappointment, the attempted ozonolysis of the 1,4-diene 49 was unsuccessful. Bubbling ozone through a 
solution of 49 for approximately 15 minutes at −78 °C induced the characteristic blue colour change which stems 
from unreacted ozone. This alluded to complete consumption of the 1,4-diene and formation of the corresponding 
ozonides. To convert the intermediate ozonide into the aldehyde derivative 31, a variety of reductive work-up 
conditions were employed, which included use of zinc and acetic acid, dimethyl sulphide or triphenylphosphine. 
However, it was during this process that the reaction erupted into a slew of by-products, as visualised by TLC analysis. 
This once again this led to inseparable crude reaction mixtures which we believe occurred in a similar manner to 
that described in Scheme 5.6b. Lastly, we attempted the reaction in methanol with the hope of trapping the 1,4-
dialdehyde as the methoxy acetal but to no avail.  
Comparable outcomes were found in the attempted Wacker oxidation of compound 49 to obtain the 1,4-diketone 
50. Use of the Tsuji-Wacker protocol, with PdCl2 as catalyst and a stoichiometric amount of CuCl in a mixture of 
DMF and water, resulted in consumption of the starting material and formation of numerous products.
40
 This made 
the subsequent separation and purification near impossible. Furthermore, utilisation of Pd(OAc)2 and trifluoroacetic 
acid was found to be similarly ineffective.
41
  
Several alternative synthetic strategies were employed in the attempted synthesis of 1,4-dialdheyde final compounds 
and their acetal protected equivalents. While these routes led to the synthesis of assorted intermediate compounds, 
none proved successful and these attempts will therefore not be elaborated on. At this point it was decided to 
evaluate the inhibitory properties of the successfully synthesised final compounds. From the relevant biochemical 
and cellular activity, we wished to ascertain whether it would be worthwhile proceeding in the synthesis of this class 
of compounds. We elected to include the 1,4-diol and 1,4-diene-containing compounds 32 and 49 respectively to 
expand the scope of the compounds structure activity relationship. This meant that a total of 8 final compounds 
were evaluated against the wild type and mutant variant forms of EGFR and follows in the next section. 
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5.5 Biochemical and Cellular Evaluation 
To determine efficacy in a biochemical setting, the synthesised compounds were evaluated against the wild-type, 
activating L858R and double L858R/T790M mutant variants of the enzyme. For the cellular tests, we employed a 
wild type-bearing cell line A431 and the EGFR-L858R/T790M drug resistant cell line H1975. Compound assessment 
was carried out by Dr. Jonas Lategahn, with all measurements being executed in at least triplicate. As the synthesised 
compounds are quinazoline based, the respective IC50 and EC50 values of gefitinib accompanied the obtained results. 
An overview of the results from the biochemical and cellular evaluation of the compounds synthesised in this chapter 
can be seen below in Table 5.1. Inspection of the cellular results (CTG) revealed all compounds showing no activity 
below the limit of 30 µM. This could be ascribed to several oversights in the fundamental compound design, the first 
of which is the lack of a solubilising group. We underestimated the significance of including the solubilising group, 
which is a conventional attribute in kinase inhibitor drug design.  
Table 5.1: Biochemical and cellular evaluation results for the synthesised 1,4-dicarbonyl final compounds. 
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Its inclusion plays an important role not only in the pharmacokinetic profile and overall solubility of the compound 
within the cell, but also in anchoring the inhibitor within the active site. This allows for a favourable orientation of 
the molecule and thus improved reversible interactions with the hinge region. Furthermore, these results reflect the 
findings of the previous chapter, when comparing the compounds synthesised with and without a solubilising group. 
In hindsight, we believe that several of the included 1,4-dicarbonyl warheads negatively affected the overall 
pharmacokinetic dynamics of the synthesised inhibitors. As an example, compound 27 contains a dicarboxylic acid 
moiety, a functional group that has been shown to promote metabolic instability, toxicity and limited passive 
diffusion across biological membranes in medicinal applications.
42
 Moreover, the other 1,4-dicarbonyl compounds 
such as the 1,4-diester compounds 28 – 30 may hydrolyse within the cell to the carboxylic acid equivalents.  
While the above discussed factors do translate negatively to the biochemical activity (HTRF) of the compounds, 
mainly by influencing reversible binding affinity, we do see some noteworthy IC50 activities. Surprisingly, we see 
inhibition over the limiting threshold of 10 µM for the 1,4-diketone compound 21 which is therefore considered 
inactive. We believe the root of this inactivity to lie in a steric clash between the 1,4-diketone chain and the β3 
sheet or helix αC strand at the roof of the enzyme. This is suggested from the length and linear character of the 1,4-
diketone chain, as well as the angle from which it extends at the 4-position of the quinazoline scaffold. Our posit is 
further validated by a comparison with the ring closed counterpart compound 22, which shows limited activity 
against the wild-type and sub-micromolar IC50 values against the single activating EGFR-L858R mutant. Counting 
from the quinazoline ring, compound 22 is two carbons shorter than 21 with a far more horizontal angle of extension, 
which could avoid a potential steric clash.  
Compound 22 displays a desirable selectivity profile, with an 8-fold increase in activity against the L858R mutant 
variant over the wild-type. Visual inspection of the activity table reveals this selectivity to be a recurrent trend amongst 
all compounds that displayed biochemical inhibitory activity. Furthermore, all compounds except 28 and 49 were 
considered inactive against the L858R/T790M double mutant. This however was to be expected, as quinazoline-
based 1
st
 generation inhibitors such as gefitinib and erlotinib were specifically identified and designed to target the 
activated EGFR-L858R enzyme. Additionally, and further validating this anticipated outcome, the L858R/T790M 
double mutant was responsible for bringing about resistance to 1
st
 generation EGFR inhibitors through the steric bulk 
of the methionine residue and increased affinity to ATP. Both of these concepts were discussed in Section 2.4.1 and 
Section 2.4.2 respectively. As this study was focussed on the possibility of covalently modifying the catalytic lysine 
residue within the active site, we were unperturbed by the lack of activity against the L858R/T790M double mutant.  
Compound 27 was shown to be completely inactive across the board. As previously discussed, we believe this to be 
due to a poor pharmacokinetic profile, with the double carboxylic acid moieties disrupting the ability for the inhibitor 
to bind reversibly. The 1,4-diester compounds 28 – 30 all showed activity against the wild-type and L858R mutant. 
Closer examination of these activities displays a clear trend, with a decrease in activity accompanying a more bulkier 
ester substituent. In near linear fashion, the ethyl (29) and isopropyl (30) ester were outperformed by the methyl 
ester 28, with an IC50 value of 61 nM against EGFR-L858R. This alludes to the limited space in the hydrophobic 
pocket and potential steric clashes in this region, as mentioned for compound 21. Furthermore, as with compound 
21 and 22, the horizontal, branched 1,4-dicarbonyl chain systems proved superior to longer and linear chains.  
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To our astonishment, the final two compounds 32 and 49 proved to be the most efficacious of the inhibitors 
evaluated. The 1,4-diol containing compound 32 exhibited an IC50 value of 17 nM against the L858R activating 
mutant, with an outstanding 75-fold selectivity over the wild-type. We postulated that the enhanced activity of this 
compound arises from several factors. Firstly, the absence of a bulky carbonyl substituent at the terminal end of the 
branched chain eliminated the possibility of a steric clash within the active site. Additionally, it appears the hydrogen 
bond donor features of these terminal hydroxyl moieties are more favourable than the hydrogen bond acceptor 
character of the 1,4-dicarbonyl counterparts. This could be due to the formation of reversible interactions with either 
the Glu-Lys salt bridge or the nearby glycine rich loop. These proposed interactions prompted us to speculate on the 
compound’s selective inhibition of the activating mutant. The L858R mutation induces a constitutively activated 
form of the receptor, leading to the sustained formation of the Glu-Lys salt bridge and a DFG-in motif as explained 
in Section 5.2.1. In these circumstances, the 1,4-diol compound 32 would be able to form the aforementioned 
reversible interactions, whilst with the inactive wild-type enzyme it would not. This provides a potential explanation 
for the exceptional selectivity profile.  
The 1,4-diene compound 49 displayed a single digit activity of approximately 2 nM against the L858R-EGFR variant, 
with a nearly 9-fold selectivity over the wild-type – similar to that found for compounds 22 and 28 – 30. Interestingly, 
49 also demonstrated good activity against the L858R/T790M double mutant, with an IC50 value of 356 nM. Activity 
against this variant was unobserved in any of the other synthesised compounds. Owing to the difficulty in explaining 
the gain in activity for this compound, the biochemical and cellular evaluation for this compound were undertaken 
5 times to ensure the correct IC50 values. As with 32, we believe the smaller terminal alkene functionality of 
compound 49 would likely aid in eliminating potential steric clashes within the active site. This feature, coupled with 
the binding mode of the compound, could be particularly favourable in avoiding the bulky methionine residue of 
EGFR-T790M. Furthermore, the results indicate that the non-polar, electron-rich olefins could be forming π-
interactions with specific residues. With the available information in hand this is unsubstantiated and any further 
attempts to clarify this enhanced activity would be conjecture. However, this remains an intriguing result and it is 
our endeavour to investigate this functional group and the source of this activity further. This examination is outlined 
within the future work section (Section 5.7).  
To conclude, confirmation of the compounds binding properties and mode of inhibition was investigated using mass 
spectrometry experiments. For this, wild-type EGFR was incubated with the synthesised final compounds and DMSO 
was used as control. Unfortunately, none of the incubated enzymes resulted in a mass increase equivalent to the 
corresponding compound labelled protein and the masses obtained were found to be comparable to the control 
wild-type EGFR treated with DMSO. These results indicated a reversible binding mode for all synthesised 
compounds, corroborating with the biochemical and cellular data and thereby ruling out covalent bond formation 
with the targeted catalytic lysine.  
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5.6 Conclusions 
The research outputs described in this chapter focussed on exploring the viability of covalent bond formation 
between a 1,4-dicarbonyl electrophile and the EGFR catalytic lysine residue. To asses this feasibility, we successfully 
synthesised a gefitinib-based heterocyclic driving group derivatised with 1,4-diketone, 1,4-dicarboxylic and 1,4-
diester electrophiles to potentially undergo covalent modification. Despite numerous attempts and synthetic 
strategies, the 1,4-dialdehyde counterpart could regrettably not be produced. We believe this stems from reactivity 
complications inherent to the dialdehyde system, which is particularly relevant to the linear and branched alkyl 
systems we attempted to synthesise. The sp
3
 hybridisation of these compounds allowed for rotational freedom and 
proximity of the reactant groups, which in turn expedited intramolecular reactions and formation of numerous by-
products. To overcome this, we envisage the use of either aromatic or cyclic derived 1,4-dialdehydes, as these are 
the only systems which have found success in the literature, as discussed in Section 5.2.2.  Prospective studies in 
the use of these electrophiles and their synthesis will be discussed in detail in the following section.  
Evaluation of the synthesised compounds revealed oversights taken on our part and some unexpected outcomes, 
the first being inactivity of all compounds in a cellular context. We strongly believe this to be due to a poor 
pharmacokinetic profile, elicited mainly by the lack of a solubilising group, as the compounds retained some activity 
biochemically. Therefore, we will be including a solubilising group within the structure in future studies concerning 
this class of inhibitor. A comprehensive procedure for its inclusion can be found in the next section.  
We were able to identify several trends from the biochemical data. Generally, a reduction in steric bulk led to greater 
inhibitory activity, with shorter, non-linear chains proving the most effective. This was evident in the 1,4-diketone 
21 and the three 1,4-diester compounds 28 – 30. This tendency extended to the 1,4-diol and 1,4-diene compounds 
32 and 49 respectively, produced en route to the 1,4-dialdehyde, where the smaller terminal functional groups were 
able to evade steric clashes. Compound 49 showed an atypically superior activity profile against both the single and 
double mutant variants of EGFR and demands further investigation to understand the underlying mechanisms of its 
efficacy. To retain and transfer the identified desirable SAR characteristics, we envisage incorporation of an aromatic 
group at the 4-position of the driving group, similar to that found in gefitinib, with the appropriate electrophile 
attached. Elaboration and exposition of this, and how compound 49 may be explored   further, is conferred in the 
following future work section (Section 5.7).  
Covalent mass spectrometry studies disclosed that all the synthesised inhibitors bound to the enzyme in a reversible 
manner. Failure to promote covalent modification can be ascribed to two factors. Firstly, we maintain that the 
synthesised electrophiles were unable achieve an optimal position and orientation to undergo covalent bond 
formation with the catalytic lysine residue. This is attributed to the previously discussed electrophile chain 
length/structure and steric interactions within the active site. Secondly, we suspect that the electrophilic reactivity of 
the synthesised 1,4-dicarbonyl fragments was inadequate to allow for irreversible inhibition. From its inception, this 
research endeavour has focussed on the synthesis of the 1,4-dialdehyde-containing compounds as the primary 
objective, with the other 1,4-dicarbonyl electrophiles as a supplementary for reactivity comparison.  
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Thus, we believe that the synthesis of this functionality and its subsequent screening will provide the best platform 
to substantiate this claim and the feasibility of this study. This is addressed as a large portion of the future work 
(Section 5.7).  
Targeting lysine residues with irreversible inhibitors is an emerging but burgeoning field of medicinal chemistry, 
where a high degree of serendipity is often required to achieve covalent bond formation.
12
 With increasing examples 
of its use, and improved knowledge of optimal lysine-selective electrophile development and required reactivity, the 
factors determining successful lysine-targeting covalent inhibition will become more understood and appreciated. 
This will lead to broader application and utilisation within the drug discovery process.  
While we maintain that the strategy of lysine-targeting covalent inhibition described in this chapter holds potential, 
we elected to postpone further investigation of this approach. Concurrent to the completion of this body of work, 
the first reported crystal structure of EGFR, in which the catalytic lysine is covalently modified, was published.
43
 It is 
upon the premise of this publication that the succeeding chapters research is based. This leads directly to the 
following chapter, where this publication and our new research endeavour will be comprehensively discussed.  
5.7 Future Work 
Owing to the synthesised 1,4-dicarbonyl compounds poor performance in their cellular assessment, the first step in 
improving these values will be through the inclusion of a solubilising group. We believe this will drastically improve 
the pharmacokinetic profile and binding affinity by anchoring the scaffold and allowing for stronger reversible 
interactions. In Scheme 5.10 on the following page, we have outlined a synthesis for the introduction of a propyl 
linked morpholine solubilising group, the same that is utilised in gefitinib. All yields shown in schemes within this 
section are those provided within the relevant literature procedures.  
A coupling reaction at the 3-hydroxyl of the commercially available 51 with 4-(3-chloropropyl)morpholine and 
K2CO3 serving as base will provide compound 52, as shown in Scheme 5.10a. This will be followed by selective 
nitration (53) and reduction to form the anthranilic ester derivative 54. Subsequent reactions can then be performed 
in a similar manner to that described in Scheme 5.1, affording the 4-chloro heterocyclic scaffold 55 with a solubilising 
group. Looking at Scheme 5.10b, a similar coupling will be carried out on isovanillin to produce compound 57, 
after which the nitrile-containing compound 59 may be synthesised via formation of oxime 58 using hydroxylamine 
hydrochloride. Once again, subsequent reactions to afford the heterocyclic driving group 60 will be performed in a 
similar manner to that described in Scheme 5.1.  
Following the successful synthesis of driving groups 55 and 60, pursuit of compound 61, illustrated in Scheme 5.10c, 
could provide insight into the unexplained potency of our most efficacious inhibitor 49. This compound can be 
easily furnished through coupling of 48 and 55 under the previously established conditions. Addition of the 
solubilising group could not only impart a potential increase in inhibitory efficacy, but also allow for incubation and 
co-crystallisation with the L858R single mutant enzyme due to the improved binding affinity. This would paint an 
unequivocal picture and explanation pertaining to the compound’s unforeseen effectiveness. 
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Scheme 5.10: a) Proposed synthesis of the heterocyclic driving group scaffold 55 and b) 60 with gefitinib solubilising group and 
c) Proposed synthesis of compound 61 for further biochemical and cellular investigation. Reagents and conditions: i) 4-(3-
chloropropyl)morpholine, K2CO3, TBAI, 2-butanone, 80 °C; ii) HNO3, Ac2O, −10 °C – rt; iii) H2, Pd/C, EtOH:EtOAc; iv) 4-(3-
chloropropyl)morpholine, K2CO3, DMF, 100 °C; v) NH2OH·HCl, pyridine, MeOH, 70 °C; vi) Ac2O, 100 °C.
44, 45
 
In a similar approach to that described in Section 5.2.2 and illustrated in Figure 5.5a, Statsuk et al. developed a 
three-component chemical reaction for trapping kinase substrate complexes.
46
 Initial failures using a weakly 
reversible binding adenosine scaffold, which resulted in nonspecific side reactions, led to replacement with the 
potent kinase inhibitor scaffold 62, shown in Scheme 5.11a. This compound contains an acetal protected o-
phthaldialdehyde fragment which served as the lysine trap. Furthermore, the group were also able to use the less 
reactive acetal protected thiophene-2,3-dicarboxaldehyde containing compound 63, to effectively cross-link with 
cysteine-containing substrates.  
Based on this work, we wish to incorporate the o-phthaldialdehyde and thiophene-2,3-dicarboxaldehyde moiety 
into our heterocyclic driving group at the 4-position. Inclusion of these functionalities can be beneficial in several 
ways. Stability is imparted by the attachment of these groups to aromatic systems, which assists in counteracting the 
unwanted formation of intramolecular by-products. Furthermore, an aromatic substitution at the 4-position mimics 
that which is found in gefitinib, potentially providing an optimal position and orientation for the electrophiles to 
covalently modify the catalytic lysine. Lastly, use of the acetal-protected counterpart allows for a more convenient 
synthetic route and provides easy access to the desired 1,4-dialdehyde electrophile through a final deprotection.   
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Scheme 5.11: a) Kinase substrate trapping complexes 62 and 63, b) Proposed synthesis of the acetal protected phthalaldehyde 
fragments 67, 69 and 70 and c) Proposed synthesis of the thiophene counterpart 73. Reagents and conditions: i) NBS, CCl4, 80 
°C; ii) Na2CO3, H2O, 70 °C; iii) Sc(OTf)3, MeOH, rt; iv) NHS, DCC, MeCN, rt; v) NaBH4, THF, rt - 70 °C; vi) COCl2,  Et3N, 
DMSO, −78 °C; vii) ethylene glycol, TsOH·H2O (cat.), benzene, 80 °C; viii) BuLi, DMF, THF,  −78 °C – rt.46  
Synthesis of the acetal protected o-phthaldialdehyde fragment 70 proceeds through several useful intermediates and 
can be seen in Scheme 5.11b.
46
 Benzylic bromination of the commercially available 64 affords the tetra-brominated 
compound 65, which may then undergo subsequent hydrolysis to the dialdehyde (66), followed by acetal formation 
using scandium triflate as the highly active Lewis acid to furnish intermediate 67. Amide coupling with N-
hydroxysuccinimide using N,N'-dicyclohexylcarbodiimide will afford compound 68, setting up for the successive 
reduction to the alcohol intermediate 69. Lastly, compound 69 may be oxidised to the 5-position aldehyde-
containing o-phthaldialdehyde 70 using a Swern oxidation.
46
 
The synthesis of the thiophene counterpart 73 is illustrated in Scheme 5.11c above.
46
 Initial acetal protection of the 
commercially available 71 with ethylene glycol, making use of a Dean-Stark apparatus to eliminate water, will 
provide the acetal protected equivalent 72. This is followed by formylation at the activated 2-position using butyl 
lithium and quenching with DMF, affording fragment 73 for future use.  
We envisage producing the final compounds shown in Scheme 5.12 through a variety of reactions between driving 
groups 55 and 60 and the synthesised fragments 67, 69 – 70 and 73. Amide coupling between 60 and 67, potentially 
using a carbodiimide reagent and additive, could afford the 4-position amide compound 74. Substitution between 
the electrophilic 4-chloro quinazoline 55 and alcohol nucleophile 69, with K2CO3 or Et3N as base, may serve to 
furnish the ether linked final compound 75.  
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Scheme 5.12: Proposed synthesis to afford the acetal protected 1,4-dialdehydes 74 - 77. 
Lastly, reductive amination between the 4-amino quinazoline 60 and aldehydes 70 and 73, using sodium cyano- or 
triacetoxy-borohydride, could furnish the desired amine-linked acetal protected o-phthaldialdehyde and thiophene-
2,3-dicarboxaldehyde compounds 76 and 77 respectively. It is important to note that all the synthesised acetal-
protected compounds may also be deprotected to their 1,4-dialdehyde counterparts. This can be carried out using 
TFA, as achieved by Shokat and co-workers in their kinase substrate crosslinking experiments.
46
 Synthesis of these 
compounds could provide valuable insight pertaining to the targeted covalent inhibition of the EGFR catalytic lysine 
residue.  
5.8 Supplementary Information 
6,7-Dimethoxyquinazolin-4-ol (9)
47
  
A 2-neck round-bottom-flask was charged with methyl 2-amino-4,5-dimethoxybenzoate 
(5.00 g, 23.7 mmol, 1 equiv.), ammonium formate (2.24 g, 35.5 mmol, 1.5 equiv.), purged 
with Ar and dissolved in formamide (50 mL). The solution was then allowed to stir at 140 °C 
for 8 h or until complete consumption of the starting material as indicated by TLC, during which time the solution 
changed from orange to yellow in colour. After allowing to cool to rt, the solution was then poured into ice-cold 
H2O (100 mL) resulting in the formation of a light-brown precipitate. The precipitate was then collected by filtration 
and washed with aliquots of cold H2O (3 × 40 mL) and dried under vacuum to afford compound 9 as an off-white 
solid (4.40 g, 21.3 mmol, 90%) with no further purification required. 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
47
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Rf: 0.26 (5% MeOH in DCM); mp: 296 – 298 °C; 1H NMR (300 MHz, DMSO-d6) δ 3.86 (s, 3H, ArOCH3), 3.90 (s, 
3H, ArOCH3), 7.12 (s, 1H, ArH), 7.43 (s, 1H, ArH), 7.98 (s, 1H, ArH), 12.07 (br s, 1H, ArOH) ppm; 
13
C NMR (75 
MHz, DMSO-d6) δ 55.7, 55.9, 104.9, 108.0, 115.6, 143.9, 144.9, 148.5, 154.4, 160.1 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C10H11N2O3: 207.0770; found: 207.0769. 
4-Chloro-6,7-dimethoxyquinazoline (10)
48
 
A flame-dried, 2-neck round-bottomed flask was charged with 6,7-dimethoxyquinazolin-4-ol 
(1.00 g, 4.85 mmol, 1 equiv.), purged with Ar and to this was slowly added an excess of thionyl 
chloride (7.00 mL, 97.0 mmol, 20 equiv.). To the resulting solution was added a catalytic 
amount of DMF (0.110 mL, 1.46 mmol, 30 mol%) dropwise and the reaction mixture was then allowed to stir at 
80 °C for 6 h. The excess thionyl chloride was removed by vacuum distillation and the residue was then diluted with 
DCM (50 mL) and H2O (50 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots 
of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated solution of NaHCO3 
(3 × 20 mL), brine (20 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved by recrystallisation with DMF to afford compound 10 as white crystals (959 mg, 
4.27 mmol, 88%).   
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
47, 48
  
Rf: 0.66 (5% MeOH in DCM); mp: 184 – 186 °C; 1H NMR (400 MHz, DMSO-d6) δ 3.98 (s, 1H, ArOCH3), 3.98 (s, 
1H, ArOCH3), 4.00 (s, 1H, ArH), 7.34 (s, 1H, ArH), 7.40 (s, 1H, ArH), 8.85 (s, 1H, ArH) ppm; 
13
C NMR (75 MHz, 
DMSO-d6) δ 56.1, 56.5, 102.1, 106.7, 118.5, 148.5, 151.3, 152.1, 156.6, 157.8 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C10H10N2O2Cl: 225.0431; found: 225.0427. 
4,5-Dimethoxy-2-nitrobenzonitrile (12)
23
  
A flame-dried, 2-neck round-bottomed flask was charged with 3,4-dimethoxybenzonitrile 
(4.00 g, 24.5 mmol, 1 equiv.), purged with Ar and dissolved in acetic anhydride (35 mL). The 
resulting solution was cooled to −10 °C (acetone/ice) and this was followed by the dropwise 
addition of nitric acid (10.2 mL, 245 mmol, 10 equiv.) over 20 min. The reaction mixture was then allowed to warm 
to rt and stirred for 12 h or until complete consumption of the starting material as indicated by TLC. The solution 
was then poured into ice-cold H2O (150 mL) resulting in the formation of a yellow precipitate. The precipitate was 
then collected by filtration and washed with aliquots of H2O (3 × 50 mL) and dried under vacuum to afford 
compound 12 as a yellow solid (5.05 g, 24.3 mmol, 99%) with no further purification required. 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
23, 49, 50
   
Rf: 0.46 (30% EtOAc in PE); mp: 167 – 168 °C; 1H NMR (300 MHz, DMSO-d6) δ 3.96 (d, J = 1.4 Hz, 6H, 2 × 
ArOCH3), 7.68 (s, 1H, ArH), 7.86 (s, 1H, ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 56.7, 57.1, 99.6, 108.4, 115.8, 
116.4, 142.3, 151.8, 153.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C9H9N2O4: 209.0562; found: 
209.0560. 
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2-Amino-4,5-dimethoxybenzonitrile (13)
23
  
A 2-neck round-bottom flask was charged with 4,5-dimethoxy-2-nitrobenzonitrile (5.00 g, 
24.0 mmol, 1 equiv.), purged with Ar and dissolved in chloroform (70 mL). To this was added 
tetrabutylammonium bromide (1.93 g, 6.00 mmol, 25 mol%) in one portion, followed by the 
slow addition of a solution of sodium dithionite (33.4 g, 192 mmol, 8 equiv.) in H2O (70 mL). The reaction mixture 
was then allowed to stir at rt for 16 h, basified to pH = 9 with a solution of 2 M NaOH and the organic layer was 
separated. The aqueous layer was extracted with aliquots of DCM (3 × 50 mL) and the combined organic layers 
were concentrated to ~ 30 mL. Whilst stirring gently, a solution of 4 M HCl in dioxane was added slowly until 
precipitation occurred and the resulting precipitate was collected by filtration and dissolved in 2 M NaOH solution 
(50 mL). The aqueous layer was extracted with aliquots of DCM (3 × 50 mL) and the combined organic layers were 
then washed with a saturated solution of NaHCO3 (30 mL), brine (30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, compound 13 was afforded as a yellow solid (2.39 g, 13.4 mmol, 56%) with no 
further purification required.  
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23, 51 
Rf: 0.58 (60% EtOAc in PE); mp: 99 – 100 °C; 1H NMR (400 MHz, DMSO-d
6
) δ 3.64 (s, 3H, ArOCH
3
), 3.73 (s, 3H, 
ArOCH3), 5.61 (s, 2H, ArNH2), 6.41 (s, 1H, ArH), 6.87 (s, 1H, ArH) ppm; 
13
C NMR (101 MHz, DMSO-d6) δ 55.3, 
56.2, 83.5, 98.9, 114.0, 118.7, 140.3, 148.4, 154.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for 
C9H11N2O2: 179.0821; found: 179.0823. 
6,7-Dimethoxyquinazolin-4-amine (14)
47
  
A 2-neck round-bottom flask was charged with 2-amino-4,5-dimethoxybenzonitrile (2.20 g, 
12.3 mmol, 1 equiv.), ammonium formate (1.17 g, 18.5 mmol, 1.5 equiv.), purged with Ar 
and dissolved in formamide (25 mL). The solution was then allowed to stir at 140 °C for 10 h 
or until complete consumption of the starting material as indicated by TLC. After allowing to cool to rt, the solution 
was then poured into ice-cold H2O (50 mL) and left overnight to allow for precipitation. The precipitate was then 
collected by filtration and washed with aliquots of cold H2O (3 × 40 mL) and dried under vacuum to afford 
compound 14 as a tan solid (2.37 g, 11.6 mmol, 94%) with no further purification required. 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
52
  
Rf: 0.46 (10% MeOH in DCM); mp: 206 – 208 °C; 1H NMR (300 MHz, DMSO-d6) δ 3.86 (s, 3H, ArOCH3), 3.89 (s, 
3H, ArOCH3), 7.07 (s, 1H, ArH), 7.41 (s, 2H, ArNH2), 7.57 (s, 1H, ArH), 8.26 (s, 1H, ArH) ppm; 
13
C NMR (75 MHz, 
DMSO-d6) δ 55.7, 56.0, 102.6, 106.8, 108.0, 146.6, 148.2, 153.9, 154.0, 160.4 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C10H12N3O2: 206.0930; found: 206.0930. 
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Ethyl 2-acetyl-4-bromopent-4-enoate (17)
53
  
A flame-dried, 2-neck round-bottomed flask was purged with Ar and to this was added 
anhydrous EtOH (11 mL). This was followed by the portion wise addition of sodium (782 
mg, 23.0 mmol, 1 equiv.) and the resulting mixture was then allowed to stir vigorously until 
a homogeneous solution formed. After cooling to −10 °C (acetone/ice), ethyl acetoacetate 
(4.34 mL, 34.0 mmol, 1 equiv.) was added dropwise to the solution and the reaction mixture was then allowed to 
warm to rt and stirred for 1 h before being cooled to −10 °C (acetone/ice) again. A solution of 2,3 dibromopropene 
(6.80 g, 34.0 mmol, 1 equiv.) in diethyl ether (5 mL) was added dropwise to the reaction mixture, which was then 
allowed to warm to rt and stirred for 24 h, during which time a brown suspension formed. The suspension was 
filtered through a plug of celite and the solvent removed in vacuo. Purification of the crude product was achieved 
using flash column chromatography with elution gradient of 2 – 10% EtOAc in PE. Pure fractions were evaporated 
to dryness to afford compound 17 as a clear oil (7.18 g, 28.8 mmol, 85%). 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
53
 
Rf: 0.44 (10% EtOAc in PE); 
1
H NMR (400 MHz, DMSO-d6) δ 1.19 (t, J = 7.2 Hz, 3H, OCH2CH3), 2.23 (s, 3H, 
CHCOCH
3
), 2.95 – 2.82 (m, 2H, BrCCH
2
CH), 3.95 (t, J = 7.2 Hz, 1H, CH
2
CHCO), 4.14 (q, J = 7.2 Hz, 2H, 
OCH2CH3), 5.49 (d, J = 2.0 Hz, 1H, CH2=CBr), 5.75 (d, J = 2.0 Hz, 1H, CH2=CBr) ppm; 
13
C NMR (101 MHz, 
DMSO-d6) δ 13.9, 29.1, 38.8, 57.3, 61.2, 119.6, 129.7, 168.0, 201.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ 
calculated for C9H13O3Br: 249.0126; found: 249.0122. 
5-Bromohex-5-en-2-one (19)
24
  
A flame-dried, 2-neck round-bottomed flask was purged with Ar and to this was added anhydrous 
EtOH (32 mL). This was followed by the portion-wise addition of sodium (1.84 g, 80.0 mmol, 
1 equiv.) and the resulting mixture was then allowed to stir vigorously until a homogeneous 
solution formed. After cooling to −10 °C (acetone/ice), ethyl acetoacetate (11.2 mL, 88.0 mmol, 1.1 equiv.) was 
added dropwise to the solution and the reaction mixture was then allowed to warm to rt and stirred for 1 h before 
being cooled to −10 °C (acetone/ice) again. This was followed by the dropwise addition of 2,3 dibromopropene 
(16.0 g, 80.0 mmol, 1 equiv.) and the reaction mixture was then allowed to stir at 80 °C for 1 h. After cooling to 
room temperature, 10% NaOH solution (64 mL) was added and the reaction mixture was then allowed to stir at 
80 °C for a further 2 h, during which time the solution turned orange in colour. After cooling to room temperature, 
the reaction mixture was then acidified to pH = 3 with concentrated HCl and allowed to stir at 80 °C for a further 
2 h. After cooling to room temperature, the aqueous layer was extracted with aliquots of diethyl ether (3 × 50 mL) 
and the combined organic layers were then washed with a saturated solution of NaHCO3 (30 mL), brine (30 mL), 
dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved 
using flash column chromatography with elution gradient of 5 – 10% Et
2
O in PE. Pure fractions were evaporated to 
dryness to afford compound 19 as a clear liquid (8.36 g, 47.2 mmol, 59%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
24, 54
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Rf: 0.25 (10% Et2O in PE); 
1
H NMR (300 MHz, CDCl3) δ 2.11 (s, 3H, CH2COCH3), 2.66 – 2.62 (m, 4H, CCH2CH2C 
and CCH2CH2C), 5.34 (d, J = 1.8 Hz, 1H, CH2=CBr), 5.55 (d, J = 1.8 Hz, 1H, CH2=CBr) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ 30.1, 35.4, 41.9, 117.5, 132.8, 206.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C6H10OBr: 
176.9915; found: 176.9913. 
1-Bromohexane-2,5-dione (20)
25
 
A 2-neck round-bottom flask was charged with 5-bromohex-5-en-2-one (300 mg, 1.69 
mmol, 1 equiv.), purged with Ar and dissolved in a 4:1 solution of acetonitrile/H2O (10 mL). 
To this was added N-bromosuccinimide (391 mg, 2.20 mmol, 1.3 equiv.) in one portion, 
followed by the addition of a catalytic amount of hydrobromic acid. The resulting yellow solution was then allowed 
to stir at rt for 4 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture 
was diluted with diethyl ether (30 mL), treated with a sufficient amount of 10 mol% sodium thiosulphate so that the 
solution became clear and the organic layer was then separated. The organic layer was then washed with a saturated 
solution of NaHCO3 (20 mL), brine (20 mL), dried over MgSO4 and filtered.  After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 5 – 10% 
EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 20 as a clear oil (245 mg, 1.27 mmol, 
75%).  
Rf: 0.22 (10% EtOAc in PE); 
1
H NMR (300 MHz, DMSO-d6) δ 2.17 (s, 3H, CH2COCH3), 2.80 – 2.74 (m, 2H, 
CCH2CH2C), 2.88 – 2.82 (m, 2H, CCH2CH2C), 3.97 (s, 2H, BrCH2CO) ppm; 
13
C NMR (75 MHz, CDCl3) δ 29.8, 
33.5, 34.5, 37.6, 201.1, 206.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C6H10O2Br: 192.9864; 
found: 192.9869. 
1-[(6,7-Dimethoxyquinazolin-4-yl)amino]hexane-2,5-dione (21)
26
  
A 2-neck round-bottom flask was charged with 6,7-dimethoxyquinazolin-4-amine 
(530 mg, 2.58 mmol, 1 equiv.), purged with Ar and dissolved in of anhydrous EtOH 
(20 mL). To this was added a solution of 1-bromohexane-2,5-dione (619 mg, 3.21 
mmol, 1.25 equiv.) in anhydrous EtOH (5 mL) and the reaction mixture was then 
allowed to stir at 80 °C for 6 h during which time a precipitate formed. After cooling 
to rt, the solvent was removed in vacuo and the residue was diluted with H2O (10 
mL), 1 M NaOH solution (20 mL) and DCM (50 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers 
were then washed with a saturated solution of NaHCO3 (30 mL), brine (30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography 
with elution gradient of 2 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 21 
as a tan solid (168 mg, 1.36 mmol, 53%). 
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Rf: 0.22 (10% MeOH in DCM); IR (ATR) cm
-1
: 3303 (m, N-H stretch), 1724 (s, C=O stretch), 1701 (s, C=O stretch), 
1621 (m, N-H bend), 1507 (m, C-H bend), 1287 (s, C-N stretch), 1219 (s, C-O-C stretch), 772 (s, N-H wag); 
1
H 
NMR (300 MHz, DMSO-d6) δ 2.10 (s, 3H, CH2COCH3), 2.93 – 2.75 (m, 4H, CCH2CH2C and CCH2CH2C), 3.94 (s, 
3H, ArOCH3), 4.04 (s, 3H, ArOCH3), 5.81 (s, 2H, ArNHCH2CO), 7.10 (s, 1H, ArH), 8.00 (s, 1H, ArH), 8.68 (s, 1H, 
ArH), 9.57 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 29.5, 33.4, 36.8, 56.9, 57.1, 58.8, 98.8, 105.1, 
105.8, 135.5, 149.7, 152.5, 156.7, 161.5, 202.3, 207.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C16H20N3O4: 318.1456; found: 318.1454. 
4-(8,9-Dimethoxyimidazo[1,2-c]quinazolin-3-yl)butan-2-one (22)  
Compound 22 was prepared in the same manner as the as the previous 
compound 21. 6,7-Dimethoxyquinazolin-4-amine (530 mg, 2.58 mmol, 
1 equiv.) was coupled and purification was achieved using flash column 
chromatography with elution gradient of 2 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 22 as an off-white solid (154 mg, 0.514 mmol, 20%). 
Rf: 0.44 (10% MeOH in DCM); IR (ATR) cm
-1
: 1705 (s, C=O stretch), 1497 (m, C-H bend), 1223 (s, C-O-C stretch); 
1
H NMR (300 MHz, DMSO-d
6
) δ 2.15 (s, 3H, CH
2
COCH
3
), 2.91 (br s, 4H, CCH
2
CH
2
C and CCH
2
CH
2
C), 3.91 (s, 3H, 
ArOCH3), 3.95 (s, 3H, ArOCH3), 7.34 (s, 1H, ArH), 7.64 (s, 1H, ArH), 7.70 (s, 1H, ArH), 9.08 (s, 1H, ArH) ppm; 
13
C 
NMR (75 MHz, DMSO-d6) δ 22.5, 29.8, 42.0, 55.8, 55.8, 101.6, 108.7, 109.0, 112.4, 135.8, 141.4, 145.1, 149.8, 
151.1, 207.6 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C16H18N3O3: 300.1348; found: 300.1347. 
General procedure for aspartic acid esterification:
55
  
A 2-neck round-bottom flask was charged with aspartic acid (1 equiv.) and to this was added the respective alcohol 
for esterification (2 mL/mmol aspartic acid). The resulting suspension was cooled to −10 °C (acetone/ice) and this 
was followed by the dropwise addition of thionyl chloride (1.4 equiv.) over 15 min. The reaction mixture was then 
allowed to stir at reflux for 6 h and the excess thionyl chloride was then removed by vacuum distillation. The oily 
residue was triturated with diethyl ether and the white solid that formed was collected by filtration and dried under 
vacuum to afford the respective compound as the hydrochloride salt with no further purification required. 
Dimethyl aspartate hydrochloride (24)  
Compound 24 was prepared according to the general procedure for aspartic acid 
esterification. Aspartic acid (4.00 g, 27.2 mmol) was esterified with MeOH to afford 
compound 24 as a white solid (5.10 g, 25.8 mmol, 95%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literaturevalues.
55, 56
 
Mp: 115 – 117 °C; 1H NMR (300 MHz, DMSO-d6) δ 3.00 (d, J = 5.4 Hz, 2H, COCH2CH), 3.63 (s, 3H, COOCH3), 
3.71 (s, 3H, COOCH3), 4.24 (t, J = 5.5 Hz, 1H, CH2CHNH2), 8.32 (br s, 3H, CHNH2·HCl) ppm; 
13
C NMR (75 MHz, 
DMSO-d6) δ 34.11, 48.47, 52.12, 52.99, 168.82, 169.62 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for 
C6H12NO4: 162.0766; found: 162.0769. 
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Diethyl aspartate hydrochloride (25)  
Compound 25 was prepared according to the general procedure for aspartic 
acid esterification. Aspartic acid (4.00 g, 27.2 mmol) was esterified with EtOH 
to afford compound 25 as a white solid (6.01 g, 26.6 mmol, 98%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
57, 58
 
mp: 108 – 110 °C; 1H NMR (300 MHz, DMSO-d6) δ 1.19 (2 × t, J = 7.2, 6H, 2 × OCH2CH3), 3.04 – 2.87 (m, 2H, 
COCH2CH), 4.23 – 4.05 (m, 5H, CH2CHNH2 and 2 × OCH2CH3), 8.29 (br s, 3H, CHNH2·HCl) ppm; 
13
C NMR (75 
MHz, DMSO-d6) δ  13.9, 14.0, 34.7, 48.7, 60.8, 61.8, 168.8, 169.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ 
calculated for C
8
H
16
NO
4
: 190.1079; found: 190.1077. 
Diisopropyl aspartate hydrochloride (26)  
Compound 26 was prepared according to the general procedure for aspartic 
acid esterification. Aspartic acid (4.00 g, 27.2 mmol) was esterified with IPA to 
afford compound 26 as a white solid (6.63 g, 26.1 mmol, 96%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
59
 
1
H NMR (300 MHz, DMSO-d6) δ 1.26 – 1.44 (m, 12H, 2 × (CH3)2CHO), 3.03 – 2.83 (m, 2H, CH2CHNH2), 4.18 (t, 
J = 5.2 Hz, 1H, CH2CHNH2), 5.04 – 4.84 (m, 2H, 2 × (CH3)2CHO), 8.54 (s, 3H, CH2CHNH2·HCl) ppm; 
13
C NMR 
(75 MHz, DMSO-d6) δ 21.3, 21.4, 21.5, 21.5, 34.6, 48.6, 68.5, 69.8, 168.0, 168.7 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C10H20NO4: 218.1392; found: 218.1388. 
(6,7-Dimethoxyquinazolin-4-yl)aspartic acid (27)  
A microwave vial was charged with aspartic acid (272 mg, 2.04 mmol, 1 equiv.), 4-
chloro-6,7-dimethoxyquinazoline (550 mg, 2.45 mmol, 1.2 equiv.), purged with Ar and 
to this was added a 1:1 solution of H2O/DMSO (10 mL). Et3N (1.14 mL, 8.16 mmol, 
4 equiv.) was then added and after capping the vial the resulting suspension was warmed 
to 80 °C and allowed to stir for 72 h. After allowing to cool to rt, the solvent was removed 
by freeze drying and the residue was then diluted with DCM (30 mL), filtered and 
washed with aliquots of DCM (3 × 10 mL) and cold MeOH (10 mL). The collected solid was dried under vacuum 
to afford compound 27 as a white solid (590 mg, 1.84 mmol, 90%) with no further purification required.  
Rf: 0.10 (30% MeOH in DCM); IR (ATR) cm
-1
: 3141 (m, N-H stretch), 2971 (s, O-H stretch), 1765 (s, C=O), 1627 
(m, N-H bend), 1509 (m, C-H bend), 1277 (s, C-N stretch), 1247 (m, C-O-C stretch), 770 (s, N-H wag); 
1
H NMR 
(300 MHz, DMSO-d6) δ 2.89 (ddd, J = 24.5, 16.5, 7.0 Hz, 2H, CH2CHNH), 3.90 (s, 6H, 2 × ArOCH3), 5.14 (d, J 
= 5.3 Hz, 1H, CH2CHNH), 7.12 (s, 1H, ArH), 7.64 (s, 1H, ArH), 8.17 (d, J = 6.3 Hz, 1H, ArNH), 8.37 (s, 1H, ArH) 
ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 36.1, 50.4, 55.8, 56.1, 102.0, 106.7, 108.4, 145.7, 148.6, 152.9, 154.1, 
157.9, 171.9, 173.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C14H16N3O6: 322.1039; found: 
322.1046. 
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General procedure for aspartic derivative coupling: 
A microwave vial was charged with 4-chloro-6,7-dimethoxyquinazoline (1 equiv.), aspartic derivative (1.1 equiv.), 
purged with Ar and to this was added acetonitrile (5 mL/mmol 4-chloro-6,7-dimethoxyquinazoline). After the 
addition of a catalytic amount of 4 M HCl in dioxane the vial was capped, and the resulting suspension was warmed 
to 100 °C and allowed to stir for 24 h. After allowing to cool to room temperature, the reaction mixture was diluted 
with a saturated solution of NaHCO3 (10 mL/mmol 4-chloro-6,7-dimethoxyquinazoline), H2O (10 mL/mmol 4-
chloro-6,7-dimethoxyquinazoline) and DCM (10 mL/mmol 4-chloro-6,7-dimethoxyquinazoline) and the organic 
layer was separated. The aqueous layer was then extracted with aliquots of DCM (3 × 10 mL/mmol 4-chloro-6,7-
dimethoxyquinazoline) and the combined organic layers were then washed with a saturated solution of brine 
(10 mL/mmol 4-chloro-6,7-dimethoxyquinazoline), dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, purification of the crude product was achieved using flash column chromatography. Pure fractions were 
evaporated to dryness to afford the respective compound. 
Dimethyl (6,7-dimethoxyquinazolin-4-yl)aspartate (28)  
Compound 28 was prepared was according to the general procedure for aspartic 
derivative coupling. 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.11 mmol) was 
coupled with dimethyl aspartate hydrochloride (242 mg, 1.22 mmol) and purification 
was achieved using flash column chromatography with elution gradient of 2 – 5% MeOH 
in DCM. Pure fractions were evaporated to dryness to afford compound 28 as a yellow 
solid (287 mg, 0.821 mmol, 74%). 
Rf: 0.39 (5% MeOH in DCM); IR (ATR) cm
-1
: 3283 (m, N-H stretch), 1732 (s, C=O stretch), 1616 (m, N-H bend), 
1506 (m, C-H bend), 1289 (s, C-N stretch), 1219 (s, C-O-C stretch), 1170 (s, C-O stretching), 844 (s, N-H wag); 
1
H 
NMR (300 MHz, DMSO-d6) δ 3.19 (d, J = 6.9 Hz, 2H, CH2CHNH), 3.63 (s, 3H, COOCH3), 3.67 (s, 3H, COOCH3), 
3.97 (s, 3H, ArOCH3), 3.98 (s, 3H, ArOCH3), 5.42 (td [app. q], J = 7.0 Hz, 1H, CH2CHNH), 7.40 (s, 1H, ArH), 8.26 
(s, 1H, ArH), 8.87 (s, 1H, ArH), 10.62 (d, J = 7.4 Hz, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 34.8, 50.9, 
51.9, 52.7, 56.4, 57.0, 99.5, 104.0, 106.6, 134.6, 148.5, 150.2, 156.3, 159.1, 170.1, 170.4 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C
16
H
20
N
3
O
6
: 350.1352; found: 350.1350. 
Diethyl (6,7-dimethoxyquinazolin-4-yl)aspartate (29)  
Compound 29 was prepared was according to the general procedure for aspartic 
derivative coupling. 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.11 mmol) was 
coupled with diethyl aspartate hydrochloride (275 mg, 1.22 mmol) and purification was 
achieved using flash column chromatography with elution gradient of 2 – 5% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 29 as a yellow-
brown solid (331 mg, 0.877 mmol, 79%). 
Rf: 0.35 (5% MeOH in DCM); IR (ATR) cm
-1
: 3233 (m, N-H stretch), 1732 (s, C=O stretch), 1616 (m, N-H bend), 
1501 (m, C-H bend), 1248 (s, C-N stretch), 1211 (s, C-O-C stretch), 1167 (s, C-O stretching), 838 (s, N-H wag); 
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1
H NMR (400 MHz, DMSO-d6) δ 1.15 (2 × t, J = 7.0 Hz, 6H, 2 × OCH2CH3), 3.16 (d, J = 7.0 Hz, 2H, CH2CHNH), 
3.96 (s, 3H, ArOCH3), 3.98 (s, 3H, ArOCH3), 4.15 – 4.07 (m, 4H, OCH2CH3), 5.38 (td [app. q], J = 7.0 Hz, 1H, 
CH2CHNH), 7.42 (s, 1H, ArH), 8.28 (s, 1H, ArH), 8.86 (s, 1H, ArH), 10.63 (d, J = 7.4 Hz, 1H, ArNH) ppm; 
13
C 
NMR (101 MHz, DMSO-d6) δ 13.9, 14.0, 35.1, 51.1, 56.4, 57.1, 60.5, 61.4, 99.5, 104.1, 106.5, 134.5, 148.5, 
150.2, 156.3, 159.2, 169.6, 169.8 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C18H24N3O6: 378.1665; 
found: 378.1666. 
Diisopropyl (6,7-dimethoxyquinazolin-4-yl)aspartate (30)  
Compound 30 was prepared was according to the general procedure for aspartic 
derivative coupling. 4-Chloro-6,7-dimethoxyquinazoline (250 mg, 1.11 mmol) was 
coupled with diisopropyl aspartate hydrochloride (310 mg, 1.22 mmol) and 
purification was achieved using flash column chromatography with elution gradient of 
2 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 
30 as a yellow solid (373 mg, 0.921 mmol, 83%). 
Rf: 0.36 (5% MeOH in DCM); IR (ATR) cm
-1
: 3233 (m, N-H stretch), 1730 (s, C=O stretch), 1618 (m, N-H bend), 
1505 (m, C-H bend), 1250 (s, C-N stretch), 1213 (s, C-O-C stretch), 1170 (s, C-O stretching), 840 (s, N-H wag); 
1
H 
NMR (400 MHz, DMSO-d6) δ 1.16 (2 × d, J = 6.2 Hz, 12H, 2 × (CH3)2CHO), 3.13 – 3.07 (m, 2H, CH2CHNH), 
3.96 (s, 3H, ArOCH3), 3.98 (s, 3H, ArOCH3), 4.98 – 48.7 (m, 2H, 2 × (CH3)2CHO), 5.30 (td [app. q], J = 7.2 Hz, 
1H, CH2CHNH), 7.41 (s, 1H, ArH), 8.26 (s, 1H, ArH), 8.86 (s, 1H, ArH), 10.56 (d, J = 7.2 Hz, 1H, ArNH) ppm; 
13
C 
NMR (101 MHz, DMSO-d6) δ 21.4, 21.4, 21.5, 21.5, 35.5, 51.3, 56.4, 57.0, 67.9, 69.1, 99.6, 104.0, 106.5, 134.6, 
148.5, 150.2, 156.2, 159.1, 169.0, 169.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H28N3O6: 
406.1978; found: 406.1977. 
2-[(6,7-Dimethoxyquinazolin-4-yl)amino]butane-1,4-diol (32)  
Compound 32 was prepared was according to the general procedure for aspartic 
derivative coupling. 4-Chloro-6,7-dimethoxyquinazoline (712 mg, 3.17 mmol) was 
coupled with 2-aminobutane-1,4-diol (367 mg, 3.49 mmol) and purification was 
achieved using flash column chromatography with elution gradient of 10 – 15% MeOH 
in DCM. Pure fractions were evaporated to dryness to afford compound 32 as a yellow 
solid (772 mg, 2.631 mmol, 83%). 
Rf: 0.29 (10% MeOH in DCM); IR (ATR) cm
-1
: 3359 (s, O-H stretch), 3279 (m, N-H stretch), 3001 (w, O-H stretch), 
1623 (m, N-H bend), 1505 (m, C-H bend), 1250 (s, C-N stretch), 1215 (s, C-O-C stretch), 838 (s, N-H wag); 
1
H 
NMR (300 MHz, DMSO-d6) δ 1.83 – 1.69 (m, 1H, OHCH2CH2CH), 2.00 – 1.86 (m, 1H, OHCH2CH2CH), 3.63 – 
3.45 (m, 4H, 2 × CH2OH), 3.88 (s, 3H, ArOCH3), 3.90 (s, 3H, ArOCH3), 4.50 – 4.44 (m, 1H, CH2CHNH), 4.81 (br 
s, 1H, CH2OH), 4.55 (br s, 1H, CH2OH), 7.07 (s, 1H, ArH), 7.50 (d, J = 8.0 Hz, 1H, ArNH), 7.66 (s, 1H, ArH), 8.30 
(s, 1H, ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 34.2, 49.7, 55.7, 56.2, 58.1, 63.1, 102.3, 107.0, 108.5, 146.0, 
148.2, 153.4, 153.7, 158.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C14H20N3O4: 294.1454; found: 
294.1461. 
Stellenbosch University https://scholar.sun.ac.za
Chapter 5 – 1,4-Dicarbonyl Electrophiles Targeting the EGFR Catalytic Lysine Residue Lys745 
 
174 
 
2-Aminobutane-1,4-diol (33)
29
 
A flame-dried, 2-neck round-bottomed flask was charged with lithium aluminum hydride 
(1.20 g, 31.7 mmol, 3 equiv.), purged with Ar and to this was added THF (20 mL). The 
resulting grey slurry was cooled to −10 °C (acetone/ice) and a solution of diethyl aspartate (2.00 g, 10.6 mmol, 1 
equiv.) in THF (10 mL) was added dropwise over 15 min during which time vigorous bubbling occurred. The resulting 
solution was then allowed to stir at 70 °C for 1 h and after allowing to cool to rt was then cooled to −10 °C 
(acetone/ice). To this solution was added 2-propanol (15 mL), followed by the addition of H2O (3.71 mL, 206 mmol, 
6.5 equiv. [to LiAlH4]) and the resulting slurry was then allowed to stir vigorously for 15 min. After removal of the 
solvent in vacuo, the dry aluminum salts were placed in a Soxhlet cup and continuously extracted with 2-propanol 
for 12 h via Soxhlet extraction. After removal of the solvent in vacuo, purification of the crude product was achieved 
by kugelrohr distillation. Fractions with boiling point between 124 °C – 126 °C at ~ 20 mbar were collected to afford 
compound 33 as a light-yellow oil (914 mg, 8.70 mmol, 82%). 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
29
 
1
H NMR (300 MHz, CD3OD) δ 1.57 – 1.43 (m, 1H, OHCH2CH2CH), 1.74 – 1.61 (m, 1H, OHCH2CH2CH), 2.97 – 
2.88 (m, 1H, CH
2
CHCH
2
), 3.40 – 3.32 (m, 1H, CHCH
2
OH), 3.56 – 3.49 (m, 1H, CHCH
2
OH), 3.68 (m [app t.], J = 
6.4 Hz, 2H, OHCH2CH2CH) ppm; 
13
C NMR (75 MHz, CD3OD) δ 37.0, 51.7, 60.5, 67.7 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C4H12NO2: 106.0868; found: 106.0872. 
Dimethyl (tert-butoxycarbonyl)aspartate (42)
38
  
A 2-neck round-bottom flask was charged with dimethyl aspartate hydrochloride (1.95 g, 
9.87 mmol, 1 equiv.), purged with Ar and dissolved in anhydrous MeOH (20 mL). After the 
addition of Et3N (3.03 mL, 21.7 mmol, 2.2 equiv.), the solution was cooled to 0 °C and a 
solution of Boc2O (2.37, 10.8 mmol, 1.1 equiv.) in anhydrous MeOH (10 mL) was added slowly. The reaction was 
then allowed to warm to rt and stirred for 16 h or until complete consumption of the starting material as indicated 
by TLC. After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of 20 – 40% EtOAc in PE. Pure fractions were evaporated to dryness to afford 
compound 42 as a white solid (2.22 g, 8.49 mmol, 86%).  
Mp, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature 
values.
38, 60
 
Rf: 0.35 (30% EtOAc in PE); mp: 64 – 66 °C;  1H NMR (300 MHz, DMSO-d6) δ 1.37 (s, 9H, (CH3)3OCO), 2.82 – 
2.62 (m, 2H, COCH2CH), 3.60 (s, 3H, COOCH3), 3.63 (s, 3H, COOCH3), 4.45 – 4.31 (m, J = 13.8, 7.6 Hz, 1H, 
NHCHCH2), 7.27 (d, J = 8.2 Hz, 1H, CONHCH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 28.1, 35.7, 50.1, 51.6, 
52.1, 78.5, 155.2, 170.5, 171.6 ppm; HRMS-TOF MS ESI+: m/z [M+Na]
+
 calculated for C11H19NO6Na: 284.1105; 
found: 284.1113. 
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tert-Butyl (1,4-dihydroxybutan-2-yl)carbamate (40)
29
  
A flame-dried, 2-neck round-bottomed flask was charged with lithium aluminum hydride 
(871 mg, 23.0 mmol, 3 equiv.), purged with Ar and to this was added THF (20 mL). The 
resulting grey slurry was cooled to −10 °C (acetone/ice) and a solution of dimethyl (tert-
butoxycarbonyl)aspartate (2.00 g, 7.65 mmol, 1 equiv.) in THF (10 mL) was added dropwise over 15 min during 
which vigorous bubbling occurred. The resulting solution was then allowed to stir at 70 °C for 1 h and after allowing 
to cool to rt was then cooled to −10 °C (acetone/ice). To this solution was added 2-propanol (15 mL), followed by 
the addition of H2O (2.69 mL, 149 mmol, 6.5 equiv. [to LiAlH4]) and the resulting slurry was then allowed to stir 
vigorously for 15 min. After removal of the solvent in vacuo, the dry aluminum salts were placed in a Soxhlet cup 
and continuously extracted with 2-propanol for 12 h via Soxhlet extraction. After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 5 – 20% 
MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 40 as a white solid (1.27 g, 
6.20 mmol, 81%). 
Mp, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature 
values.
60, 61
 
Rf: 0.29 (10% MeOH in DCM); mp: 62 – 63 °C; 1H NMR (300 MHz, CDCl3) δ 1.28 (s, 9H, (CH3)3OCO), 1.53 – 
1.39 (m, 1H, CH2CH2CH), 1.70 – 1.56 (m, 1H, 1H, CH2CH2CH), 3.61 – 3.38 (m, 5H, 2 × CH2OH and CH2CHNH), 
4.30 (t, J = 5.0 Hz, 1H, CH2OH), 4.42 (t, J = 5.0 Hz, 1H, CH2OH), 5.44 (d, J = 8.2 Hz, 1H, CONHCH), ppm; 
13
C 
NMR (75 MHz, CDCl3) δ 28.2, 34.4, 49.4, 58.5, 64.4, 79.4, 156.8 ppm; HRMS-TOF MS ESI+: m/z [M+Na]+ 
calculated for C9H19NO4Na: 228.1207; found: 228.1201. 
Hexa-1,5-dien-3-ol (45)
39
  
A flame-dried, 2-neck round-bottomed flask was charged with oven-dried magnesium turnings 
(8.51 g, 350 mmol, 1.4 equiv.) and purged with Ar. To this was added of diethyl ether (25 mL), 
followed by the dropwise addition of allyl bromide (4.32 mL, 50.0 mmol, 20 mol%) to initiate the Grignard reaction. 
This was followed by the dropwise addition of a solution of allyl bromide (21.6 mL, 250 mmol, 1 equiv.) and acrolein 
(16.7 mL, 250 mmol, 1 equiv.) in diethyl ether (75 mL) over 3 h whilst maintaining a gentle reflux. The reaction 
mixture was then allowed to stir at 45 °C for 3 h and cooled to 0 °C. A saturated solution of NH4Cl (100 mL) was 
added dropwise resulting in an exotherm, followed by the addition of H
2
O (125 mL) and the resulting suspension 
was then allowed to stir at rt for 16 h. The reaction mixture was acidified to pH = 2 with a solution of 2 M HCl and 
the aqueous layer was then extracted with aliquots of diethyl ether (3 × 100 mL). The combined organic layers were 
then washed with a saturated solution brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, purification of the crude product was achieved by kugelrohr distillation. Fractions with boiling point between 
65 °C – 70 °C at ~ 60 mbar were collected to afford compound 45 as a clear oil (14.1 g, 143 mmol, 57%). 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
39,
 
62
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Rf: 0.38 (15% EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 2.34 – 2.24 (m, 2H, CHCH2CH), 4.18 – 4.08 (m, 1H, 
CH2CHCH), 5.09 (dd, J = 10.3, 1.2 Hz, 2H, CH=CH2), 5.14 – 5.10 (m, 1H, CH=CH2), 5.21 (dt, J = 16.2, 1.2 Hz, 
1H, CH2CH=CH2), 5.92 – 5.69 (m, 2H, CH=CH2 and CH=CH2) ppm; 
13
C NMR (75 MHz, CDCl3) δ 41.7, 71.9, 
114.8, 118.2, 134.2, 140.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C6H11O: 98.0731; found: 
98.0732. 
2-(Hexa-1,5-dien-3-yl)isoindoline-1,3-dione (46)
63
  
A flame-dried, 2-neck round-bottomed flask was charged with hexa-1,5-dien-3-ol (1.20 g, 12.2 
mmol, 1 equiv.), purged with Ar and dissolved in THF (100 mL). After cooling the solution to 0 
°C, triphenylphosphine (3.53 g, 13.4 mmol, 1.1 equiv.) and phthalimide (1.98 g, 13.4 mmol, 
1.1 equiv.) were added as a single portion and this was followed by the dropwise addition of a 
solution of di-tert-butyl azodicarboxylate (3.66 g, 15.9 mmol, 1.3 equiv.) in THF (20 mL). The solution was then 
allowed to warm to rt and stirred for 16 h or until complete consumption of the starting material as indicated by 
TLC. After removal of the solvent in vacuo, the residue was triturated with a 1:1 solution of diethyl ether/PE (60 mL) 
which resulted in the precipitation of triphenylphosphine oxide. The slurry was then filtered through a plug of celite 
and the solvent removed in vacuo. Purification of the crude product was achieved using flash column 
chromatography with elution gradient of 5 – 20% EtOAc in PE. Pure fractions were evaporated to dryness to afford 
compound 46 as a clear oil (2.11 g, 9.29 mmol, 76%). 
Rf: 0.67 (20% MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ 2.65 – 2.53 (m, 1H, NCHCH2), 2.93 – 2.77 (m, 1H, 
NCHCH2), 4.86 – 4.73 (m, 1H, NCHCH2), 4.93 (d, J = 10.1 Hz, 1H, CH=CH2), 5.01 (dd, J = 17.2, 1.0 Hz, 1H, 
CH=CH2), 5.15 (d, J = 10.2 Hz, 1H, CH=CH2), 5.20 (d, J = 17.2 Hz, 1H, CH=CH2), 5.76 – 5.57 (m, 1H, 
CH=CH2), 6.25 – 6.09 (m, 1H, CH=CH2), 7.71 – 7.61 (m, 2H, 2 × ArH), 7.82 – 7.72 (m, 2H, 2 × ArH) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ 36.5, 53.4, 117.4, 118.2, 123.2, 131.9, 133.9, 134.0, 135.3, 168.0 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C14H14NO2: 228.1025; found: 228.1019. 
Hexa-1,5-dien-3-amine hydrochloride (48)
63
 
A 2-neck round-bottomed flask was charged with 2-(hexa-1,5-dien-3-yl)isoindoline-1,3-
dione (1.80 g, 7.92 mmol, 1 equiv.), purged with Ar and dissolved in EtOH (40 mL). To the 
resulting solution was added hydrazine hydrate (0.58 mL, 11.9 mmol, 1.5 equiv.) and the solution was then allowed 
to stir at 80 °C for 6 h or until complete consumption of the starting material as indicated by TLC. After cooling to 
room temperature, the reaction mixture was then acidified to pH = 2 with concentrated HCl and allowed to stir at 
rt for 1 h. The slurry was then filtered through a plug of celite and the solvent removed in vacuo. Purification of the 
crude product was achieved using flash column chromatography with elution gradient of 10 – 20% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 48 as a white solid (762 mg, 5.70 mmol, 72%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
64
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Rf: 0.28 (10% MeOH in DCM); 
1
H NMR (300 MHz, CD3OD) δ 1.01 – 0.85 (m, 2H, NH2CHCH2), 3.82 – 3.66 (m, 
1H, NH2CHCH2), 4.95 (s, 3H, CHNH2·HCl), 5.24 – 5.11 (m, 2H, CH=CH2), 5.41 – 5.31 (m, 2H, CH=CH2), 5.99 
– 5.71 (m, 2H, 2 × CH=CH2) ppm; 
13
C NMR (75 MHz, CD3OD) δ 38.6, 54.4, 120.4, 120.7, 133.0, 134.9 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C6H11N: 98.0970; found: 98.0967. 
N-(Hexa-1,5-dien-3-yl)-6,7-dimethoxyquinazolin-4-amine (49) 
Compound 49 was prepared was according to the general procedure for aspartic 
derivative coupling. 4-Chloro-6,7-dimethoxyquinazoline (170 mg, 0.757 mmol) was 
coupled with hexa-1,5-dien-3-amine hydrochloride (112 mg, 0.851 mmol) and 
purification was achieved using flash column chromatography with elution gradient of 
2 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 
49 as an off-white solid (160 mg, 0.561 mmol, 74%). 
Rf: 0.45 (5% MeOH in DCM); IR (ATR) cm
-1
: 3283 (m, N-H stretch), 3073 (m, =CH stretch), 1648 (s, C=C stretch), 
1621 (m, N-H bend), 1503 (m, C-H bend), 1242 (s, C-N stretch), 1217 (s, C-O-C stretch), 986 (m, C-H bend), 912 
(m, C-H bend), 848 (s, N-H wag); 
1
H NMR (300 MHz, DMSO-d6) δ 2.56 – 2.51 (m, 2H, NHCHCH2), 3.89 (s, 3H, 
ArOCH
3
), 3.90 (s, 3H, ArOCH
3
), 5.28 – 5.02 (m, 5H, 4 x CH=CH
2
 and NHCHCH
2
), 5.83 (ddt, J = 17.2, 10.3, 6.8 
Hz, 1H, CH2CH=CH2), 5.99 (ddd, J = 17.2, 10.3, 5.8 Hz, 1H, CHCH=CH2), 7.09 (s, 1H, ArH), 7.68 (s, 1H, ArH), 
7.74 (d, J = 8.2 Hz, 1H, ArNH), 8.32 (s, 1H, ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 38.4, 51.8, 55.7, 56.2, 
102.0, 107.1, 108.4, 114.6, 117.0, 135.4, 138.9, 146.2, 148.3, 153.4, 153.8, 157.8 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C16H20N3O2: 286.1556; found: 286.1559. 
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Chapter 6 
Osimertinib-derived Inhibitors Targeting the EGFR Catalytic Lysine 
Residue Lys745 
Abstract 
The research efforts described in this chapter continue with the development of inhibitors potentially capable of irreversibly 
targeting the EGFR catalytic Lys745. Acting as a catalyst for this work, the first reported crystal structure of EGFR, in which the 
catalytic Lys745 was covalently modified, will be reviewed. Inspired by this, we chose to adapt our therapeutic targeting strategy 
to include the successful sulfonyl fluoride electrophile, as well as other lysine targeting electrophiles including ethenesulfonamide, 
nitriles, aliphatic chain sulfonyl fluorides and α- and β-haloketones. Perusal of the literature and use of molecular modelling led 
selection of an osimertinib-derived scaffold as prime candidate for our new heterocyclic driving group. The synthesis of this 
heterocyclic driving group, proving arduous and requiring exploration of several synthetic strategies and pathways, will be 
described in full. Ultimately, we were able to develop an optimised route with high overall yield, with five intermediate 
compounds submitted for evaluation. Installation of the chosen electrophiles proved challenging, with numerous contributing 
factors identified and rationalised. Overcoming these difficulties led to the successful synthesis of four final compounds, whose 
inhibitory properties were measured in subsequent biochemical and cellular evaluation. While ineffective in covalently modifying 
the catalytic lysine residue, the assessment of several inhibitors demonstrated intriguing results which will be disclosed. Finally, 
improvements of synthetic methodology and expansion toward new electrophiles and driving group scaffolds are considered.  
6.1 Introduction 
As stated in the concluding paragraph of the previous chapter, the following body of research was instigated to a 
large extent by work undertaken by Taunton and co-workers.
1
 As protein kinases comprise one of the largest families 
of structurally related enzymes, a major aim in the development of their inhibitors lies in selectively targeting a 
singular desired kinase, whilst avoiding the myriad of potential off-target kinases. However, the capacity to accurately 
quantify inhibitor interactions with multiple off-target kinases in live cells remains problematic. The Taunton research 
group was able to design and successfully synthesise several chemical probes that covalently labelled a broad 
spectrum of the intracellular kinome with high efficiency. These clickable piperazine-linked probes, illustrated in 
Figure 6.1a as 1 – 3, made use of an electrophilic sulfonyl fluoride moiety attached to a pyrimidine 3-aminopyrazole 
driving group.
1
 This scaffold can form three hydrogen bond interactions with the hinge region of the kinase, and as 
such, has been shown to inhibit an extensive number of kinases, including those with bulky gatekeeper residues 
such as the EGFR-T790M mutant.
2
  
Remarkably, the optimized probe 2 managed to capture up to 133 endogenous kinases from a single cell line, with 
the previous best pan-kinase probe, a photoreactive diazirine, only able to detect up to 22 intracellular kinases.
3
 
Furthermore, probe 2 was able to compete effectively with high concentrations of intracellular ATP in these 
demanding chemoproteomic applications, highlighting its utility. Use of protein crystallography and mass 
spectrometry experiments confirmed that covalent modification occurred chemoselectively with the conserved 
catalytic lysine residue within the ATP binding site. Of the labelled 133 kinases, the first covalently modified EGFR 
wild-type catalytic Lys745 residue co-crystal structure was solved and is shown on the following page in Figure 6.1b.  
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Figure 6.1: a) Pyrimidine 3-aminopyrazole based compounds 1 - 3 with piperazine linked sulfonyl fluorides acting as lysine-
targeting chemical probes, b) Co-crystal structure of probe 2 (orange) covalently bound to the catalytic Lys745 (green) through a 
sulfonyl fluoride electrophile (PDB: 5U8L). Figure reproduced from b) Zhao et al.
1
 
The announcement that the EGFR catalytic lysine could indeed be covalently modified was a welcome and 
encouraging revelation. However, this compelled us to re-evaluate our previously implemented strategy of using 
1,4-dicarbonyl warheads to potentially undergo Paal-Knorr pyrrole formation with the catalytic lysine. Seeking to 
emulate the success of Taunton’s research group in targeting and covalently modifying the catalytic Lys745 residue, 
we envisaged replacement of the 1,4-dicarbonly electrophiles with the implemented reactive sulfonyl fluoride 
warheads. Furthermore, we considered the selection of a quinazoline-based driving group inadequate to successfully 
compete with and overcome the EGFR-T790M and -C797S mutant variants, which possess a restored and increased 
binding affinity for endogenous ATP.
4
 While probe 2 displayed a mediocre wild-type EGFR inhibition of 36% at 1 
µM, we believed that the use of an optimised and selective EGFR heterocyclic driving group, in combination with 
electrophiles such as the sulfonyl fluoride employed in probe 2, had the potential to produce therapeutically relevant 
lysine-targeting irreversible inhibitors. Perusal and a structural analysis search of the literature led us to several 
prospective electrophiles and heterocyclic scaffold candidates, which will be discussed in the following section.    
6.2 Electrophile and Heterocyclic Scaffold Selection 
6.2.1 Additional Lysine-trapping Electrophiles  
6.2.1.1 Sulfonyl Fluorides 
Sulfonyl fluorides are hydrolysis-resistant electrophiles that have found substantial utility as reactive probes in 
chemical biology and molecular pharmacology.
5
 They are considered privileged warheads, owing to their inherent  
balance of favourable biocompatibility and protein reactivity. As such, they are known to modify not only serine 
(particularly as protease inhibitors) but also lysine, threonine, histidine and cysteine residues in a context specific 
manner.
6
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Figure 6.2: a) Chemical probe FSBA, with sulfonyl fluoride electrophile, b) TTR stabilizer 4 and its aromatic sulfonyl fluoride 
derived analogue 5, c) Crystal structure of 5 (green) covalently bound to Lys15 (pink) through the aromatic sulfonyl fluoride 
(PDB: 4FI7). Figure reproduced from c) Pettinger, Jones and Cheeseman.
7
 
Despite their desirable traits, sulfonyl fluorides have seldom been employed in the structure-based design and 
development of lysine-targeted covalent inhibitors. Originally developed 40 years ago, Colman et al. designed and 
pioneered the use of the adenosine derivative 5’-fluorosulfonylbenzoyl 5’-adenosine (FSBA), shown in Figure 6.2a, 
to explore nucleophilic residues in the glutamate dehydrogenase binding site.
8
 The ATP analogue contains an 
aromatic sulfonyl fluoride functionality that replaces the phosphoryl group of ATP and serves as a hard electrophile 
able to readily react with a pKa-perturbed lysine residue, allowing for covalent bond formation.
7
 FSBA has become 
frequently used as a covalent inhibitor and probe of ATP-binding enzymes, serving as inspiration for the 1,4-
dialdehyde probe discussed in Section 5.2.2 and the chemical probes 1 – 3. 
Outside of kinases, sulfonyl fluoride inhibitors of transthyretin (TTR) have been developed to react covalently with 
the pKa perturbed Lys15 in the thyroxine binding site, thereby stabilizing the enzyme and preventing fibrillation.
9
 
Initially, Kelly et al. adapted a reversible stabilizer of TTR to afford compound 4, illustrated in Figure 6.2b, which 
was able to covalently modify the non-catalytic Lys15 via the activated ester.
10
 Further development led to the 
sulfonyl fluoride-containing compound 5, which displayed superior reactivity towards covalent bond formation. This 
was hypothesised to proceed via a stabilised Glu54 mediated transition-state, allowing for effective covalent 
inhibition of Lys15 as shown in Figure 6.2c.
9
 These examples highlight the potential utility of sulfonyl fluorides in 
covalent enzyme inhibition.  
6.2.1.2 Michael Acceptors  
Michael acceptors have traditionally been tailored to target a soft nucleophilic cysteine residue within the ATP 
binding site. For covalent lysine modification, harder electrophiles are expected to react more readily with the hard 
ε-amine of lysine.11 To evaluate the inherent reactivity profile of lysine, Dahal and co-workers determined the rate 
reaction of N-α-acetyl-lysine as nucleophile with several electrophilic moieties typically used as irreversible inhibitor 
warheads, the results of which is tabulated in Figure 6.3a.
12
 To best mimic the hypothetical perturbed pKa of a lysine 
within the protein microenvironment, the assessment was carried out at pH 10.2 and compared with the reactivity 
of the soft thiol nucleophile glutathione (GSH).   
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 Figure 6.3: a) Tabulated reactivities of hard and soft electrophiles with N-α-acetyl-lysine and GSH, b) Structure of compound 
10, which was able to covalently modify the CDK2 catalytic Lys89, as shown in the crystal structure (PDB: 5CYI). Figure 
reproduced from b) Pettinger, Jones and Cheeseman.
7
 
The lysine nucleophile displayed good reactivity with the conventional acrylamide 6, with reactivity increasing 
relative to additional electron-withdrawing effects, as seen with pyridine 7. As expected, this trend was more 
pronounced for the soft GSH. Introduction of a methyl group at the vinyl terminus (8) drastically slowed the reaction 
with the lysine nucleophile due to steric hindrance. Interestingly, the vinyl sulfone 9 exhibited the greatest reactivity 
for the N-α-acetyl-lysine and apparent selectivity over GSH. This was hypothesised to stem from the net negative 
charge of the sulfone, leading to a more polarizable vinyl moiety and significant decrease in softness.
12
  
Based upon previous work which identified a series of potent reversible inhibitors of CDK2, Anscombe et al. 
identified a proximal interaction between the inhibitor’s sulfonamide moiety and Lys89. Consequently, the group 
synthesised the vinyl sulfone analogue 10, shown in Figure 6.3b, which was confirmed to bind covalently to Lys89 
through  protein crystallography and single-point mutation studies.
13
 This was the first example of an irreversible 
CDK2 inhibitor and successful application of this warhead in kinases, with compound 10 exhibiting superior cellular 
activity over its reversible counterpart. We found this particularly intriguing, as this highlighted the vinyl sulfone as a 
potential electrophile in targeting the EGFR catalytic Lys745.    
6.2.1.3 Nitriles and α-Haloketones   
In recent decades, a continual stream of nitrile-containing pharmaceuticals has resulted in over 30 agents being 
prescribed for a diverse variety of diseases and more than 20 additional candidates in clinical trials.
14
 This prevalence 
attests to the functional groups advantages and biocompatibility in drug design. These moieties are unconventional 
by nature due to their short polarised triple bond, which has been described as being 8 times smaller than that of a 
methyl group, resulting in a miniscule steric demand along its axis.
14  
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They are also fairly robust and not readily metabolized, mostly passing through the body unchanged.
15
 While nitriles 
are not principally electrophilic to free nucleophiles, activation by adjacent structural components, such as electron-
withdrawing groups, has been shown to facilitate covalent modification.
16
 Furthermore, nitriles often act as hydrogen 
bond acceptors with various amino acid residue such as lysine, serine or arginine.
17
 For these reasons, we wished to 
incorporate a nitrile functionality within our library of compounds to either form favourable reversible interactions 
or potentially undergo covalent modification of the EGFR catalytic Lys745 residue.   
Lastly, we propose the utilisation of α-haloketone electrophiles, which have been shown to undergo nucleophilic 
attack by oxygen, nitrogen and sulphur nucleophiles.
18
 Owing to their high reactivity, haloketones take part in several 
reaction types and serve as versatile synthons in the synthesis of various classes of heterocycles.
19
 In reactions with 
nucleophiles, two electrophilic sites are available - the carbonyl functionality itself or the carbon carrying the halogen 
atom. The inherent reactivity of the α-haloketone stems from the inductive effect of the carbonyl group. This 
enhances the polarity of the carbon-halogen bond, facilitating increased electron deficiency and electro positivity of 
the α-carbon. Furthermore, this feature is augmented with the more polar carbon-halogen bond, allowing for faster 
reaction with nucleophiles.
19
 Consequently, we imagined the use of this class of electrophile to potentially label the 
catalytic lysine residue of EGFR.   
6.2.2 Heterocyclic Scaffolds Exploiting Catalytic Lysine Interactions  
In a recent study, Katayama and co-workers found the dual ALK/EGFR inhibitor brigatinib to be an effective inhibitor 
of EGFR-C797S triple mutant-harbouring cells, both in vitro and in vivo.
20
 While the potency of the drug as 
monotherapy was found to be unsatisfactory, its combination with anti-EGFR antibodies dramatically increased the 
efficacy by inducing surface degradation of the receptor and halting EGFR overexpression. This in turn led to a 
decrease in tumour size of C797S mutation-bearing cells and a prolonged survival period for xenograft mice. 
Molecular modelling simulations of brigatinib within the ATP binding site, revealed a compatible binding affinity and 
several key components which have potential for further development. The group believed this could afford more 
potent analogues capable of combating the therapeutically relevant EGFR triple mutant.   
Building on these efforts, a publication by Jang et al. rationally designed and synthesised a host of dual inhibitors of 
ALK and EGFR.
21
 This was carried out by combining the critical functional elements of the ALK inhibitors, ceritinib 
and brigatinib, with features of the EGFR inhibitors osimertinib and WZ4002, shown in Figure 6.4a. Whilst retaining 
the 2,4-diarylaminopyrimidine scaffold, the use and interchange of numerous solubilising and other functional 
groups such as isopropylsulfone, dimethylsulfonamide and dimethylphosphine oxide were investigated. This resulted 
in the identification of 11 as the most potent dual ALK/EGFR inhibitor, which exhibited low nanomolar IC50 values 
biochemically and maintained activity in cellular growth inhibition studies. As such, compound 11 has been 
identified as a lead candidate, with further optimization to improve metabolic stability and kinase selectivity currently 
underway.  
One of the most striking features of 11, when modelled and visualised within the ATP binding pocket, is the proximity 
and interactions of the isopropylsulfone moiety with the catalytic Lys745 residue, as shown in Figure 6.4b.  
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 Figure 6.4: a) Structures of the ALK inhibitors ceritinib and brigatinib, EGFR inhibitors osimertinib and WZ4002 and the most 
efficacious dual ALK/EGFR inhibitor compound 11, b) Compound 11 docked into the EGFR-T790M double mutant, illustrating 
hydrogen bond interactions between the isopropylsulfone group and the catalytic Lys745 residue (PDB: 5GTZ).  
Similar to the dimethylphosphine oxide in brigatinib, the carbonyl groups are able to act as hydrogen bond acceptors 
and form favourable reversible interactions with Lys745. This was particularly importance to us, as substitution of 
the isopropylsulfone group with an appropriate electrophile, such as a sulfonyl fluoride, could potentially induce 
covalent bond formation with this residue. We therefore envisioned use of the 2,4-diarylaminopyrimidine scaffold 
in the design of our lysine targeting inhibitors. 
Osimertinib displays a 200-fold selectivity for the L858R/T790M double mutant over wild-type EGFR.
22
 In an attempt 
to understand the molecular basis of this selectivity, many groups have sought to produce crystal structures of the 
inhibitor within the wild-type, T790M and L858R/T790M variants of the enzyme. In 2015, a crystal structure of 
osimertinib bound to the wild-type EGFR enzyme was solved and is shown in Figure 6.5a.
22
 While the binding mode 
of the blockbuster drug was revealed for the wild-type, the researchers could unfortunately not complex the inhibitor 
with the single activating and double mutant variants. This remains the case to date, with no crystal structure of 
osimertinib bound to the mutated enzymes found in the literature or uploaded to the PDB. 
Without a crystal complex of osimertinib bound to the EGFR-T790M kinase domain, Zhang et al. employed 
molecular modelling studies to determine a predicted binding mode of the FDA approved inhibitor.
23
 From the 2D 
representation shown in Figure 6.5b, the pyrimidine core was found to act as a hydrogen bond donor and acceptor, 
thereby interacting with Met793 (red) of the hinge region and effectively evading steric interactions with the mutated 
Met790 residue (red). As expected, the acrylamide electrophile was found to covalently bind to Cys797 (green), 
whilst the dimethylamine moiety was appropriately protruding into the solvent channel (blue). Interestingly, the 
group observed the presence of a hydrophobic pocket (yellow) between the indole functionality and the specificity 
pocket of the kinase. One of these neighbouring residues was the catalytic Lys745 (purple), forming the well-known 
salt bridge with Glu762 (orange). This piqued our curiosity, leading us to run our own modelling simulations of 
osimertinib within the ATP binding site. From this, we calculated the distance between the N-methyl carbon of the 
indole and the charged amine of Lys745 to be 5.39 Å. 
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Figure 6.5: a) Crystal structure of osimertinib (yellow) bound to the wild-type EGFR domain (PDB: 4ZAU), b) 2D representation 
of osimertinib modelled into the EGFR L858R/T790M double mutant, with selected van der Waals and covalent interactions 
with specific amino acids highlighted in colour (PDB: 3IKA), c) SAR investigation of osimertinib affording the most potent 
compound 12. Figure reproduced from a) Yosaatmadja et al.
22
  
Based on the modelled binding mode of osimertinib with the T790M mutant, the group undertook a SAR 
investigation to clarify the inherent selectivity of the inhibitor. This included modification of the substitution position 
of the pyrimidine ring, interchange of the amine solubilising group, and importantly, expansion of the indole ring 
into the exposed hydrophobic pocket as shown in Figure 6.5c. As expected, osimertinib was found to be optimised 
in all parameters except one – the expansion of the indole ring. This led the group to the 5,6-dihydro-4H-
pyrrolo[3,2,1-ij]quinoline compound 12, which retained excellent selectivity and sub-nanomolar IC50 activity values 
for the single L858R and double L858R/T790M mutants. Furthermore, compound 12 displayed enhanced 
microsomal stability and pharmacokinetic properties, with a lower binding affinity to the human ether-à-go-go-
related gene (hERG) ion channel than osimertinib, resulting in lower cardiotoxicity.
23
 On the basis of this 
experimental investigation, we envisaged the potential for covalent modification of the adjacent catalytic Lys745. 
We believed this could be accomplished through the installation of a suitable electrophile at the indole nitrogen of 
the osimertinib scaffold. With this intention in mind, we designed a library of compounds to be synthesised which 
is described in the following section.  
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6.3 Objectives and Target Synthetic Library  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Target synthetic library for osimertinib derived catalytic lysine-targeting inhibitors.  
On the grounds of the previous section’s discourse, we opted to employ the osimertinib heterocyclic driving group 
in the synthesis of our lysine-targeting library of compounds. The design elements of this library are illustrated above 
in Figure 6.6. Utilisation of this scaffold was considered desirable for several reasons, the first being inclusion of the 
2-aminopyrimidine motif (green) as hinge binder, which has been shown to be effective in inhibitors of both ALK 
and EGFR that were able to overcome resistance mutations.
21
 Furthermore, as established by Zhang et al. in their 
SAR studies and by Jang and co-workers in the synthesis of the dual ALK/EGFR inhibitor 11, the solubilising group 
(green) and other constituents of osimertinib were found to be optimised, leading us to use an otherwise unaltered 
structure.
21, 23
  
For the lysine-targeting electrophiles, we envisaged derivatisation at the indole nitrogen (blue). On the basis of our 
molecular modelling, we proposed that incorporation at this position could theoretically place the warhead in a 
favourable orientation and proximal to the catalytic Lys745, increasing the likelihood of covalent bond formation. 
These electrophilic functionalities, shown in blue in Figure 6.6, would include the previously highlighted Michael 
acceptors, nitriles, sulfonyl fluorides and α-, β-haloketones.  
In conjunction with this, we wished to synthesise the reversible propionamide and irreversible acrylamide derivatives 
of osimertinib, highlighted in red in Figure 6.6. Understandably, this could provide valuable insight and a 
comparative platform in the case of covalent bond formation at the catalytic lysine residue. We therefore set out in 
the pursuit of these target compounds, in the hope of covalently modifying the EGFR catalytic Lys745 and thereby 
improving the efficacy and selectivity against the C797S mutant. 
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6.4 Library Synthesis  
6.4.1 Osimertinib-derived Scaffold Synthesis  
 
 
 
 
 
 
 
 
 
Scheme 6.1: a) Retrosynthesis of scaffold 13 and b) Synthesis of heterocyclic fragment 14. Reagents and conditions: i) indole 
(1.5 equiv.), 2,4-dichloropyrimidine (1 equiv.), EtMgBr (generated in situ) (1.5 equiv.), THF, −10 °C – 80 °C, 5 h. 
For the synthesis of our osimertinib based lysine-targeting inhibitors, we envisaged heterocyclic scaffold 13, seen in 
Scheme 6.1 above, to serve as a platform for further electrophile derivatisation. Preliminary retrosynthetic analysis 
of 13 led us to a disconnection at the pyrimidine aniline bond and the two heterocyclic fragments 14 and 15. 
Successful synthesis of the indole-pyrimidine 14 and the acryl- and propionamide variant of fragment 15 would set 
up for a subsequent SNAR reaction between these two fragments to afford the desired 13. We believed that execution 
of this strategy would accommodate a more divergent synthesis, allowing for the combination of 14 with other 
aniline fragments such as 15 in future synthetic endeavours. We therefore set about designing and implementing a 
synthetic pathway to these two fragments.   
For coupling of the commercially available indole (16) and 2,4-dichloropyrimidine (17) at the 4-position, we 
employed the use of a Grignard reagent to act as base. Deprotonation of the N-indole proton would negate its 
participation as a nucleophile in the reaction while simultaneously activating the 3-position of the indole. The 
Grignard reagent used in this reaction was formed in situ with an excess of magnesium turnings and iodine as catalyst, 
with the appropriate alkyl halide. Initial attempts using methylmagnesium bromide in DCE furnished inadequate 
and unreliable yields, necessitating optimization of the reaction parameters. Optimization included use of various 
solvents, temperatures and more substituted alkyl halides in Grignard reagent formation. By using a 1.5 equivalent 
excess of ethylmagnesium bromide and indole while heating under reflux in THF, we were able to repeatedly 
reproduce a yield of roughly 60%, a slight improvement on that provided in the literature.
24
 Furthermore, these 
reactions could be scaled up to 8 grams, thereby affording us with a large amount of the heterocyclic building block 
14 to be used for future coupling reactions.  
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Scheme 6.2: Three step synthesis of intermediate fragment 21. Reagents and conditions: i) methyl iodide (1.1 equiv.), K2CO3 
(1.2 equiv.), acetone, 0 °C – 60 °C, 12 h; ii) H2, Pd/C (10 mol%), EtOH, rt, 24 h; iii) KNO3 (1 equiv.), 85% H2SO4 (25 equiv.), 
−10 °C – rt, 4 h.24 
The first steps toward the other heterocyclic building block proceeded smoothly and commenced with methylation 
of the commercially available phenol 18, as seen above in Scheme 6.2. Use of methyl iodide and potassium 
carbonate as base in acetone provided a near quantitative yield of 19, with no further purification required. This 
was followed by aromatic nitro reduction using the standard conditions of Pd/C with hydrogen atmosphere in 
ethanol, to provide compound 20 in excellent yield. Lastly, regioselective nitration was carried out in slightly diluted 
sulphuric acid by portion-wise addition of potassium nitrate, while maintaining a temperature below −5 °C.  This 
afforded the intermediate fragment 21 in good yield, with 
1
H NMR spectrum shown in Figure 6.7 below.  
Furthest upfield we see a singlet at δ 3.90 ppm which correctly integrates for 3H and thus corresponds to the methoxy 
peak (blue). Whilst the combined activating/deactivating effects of the ring’s substituents suggest nitration at the 2-
position, we propose the steric interactions of the tri-substituted aromatic product formed by this, to outweigh these 
effects. Analysis of the obtained 
1
H NMR spectrum lends credence to this, with the broad amine peak (purple) 
appearing at the unchanged (relative to the starting material) position of δ 5.22 ppm. Were the nitro functionality 
ortho to the aniline, we would expect a large downfield shift in this peak due to the electron-withdrawing nature of 
the nitro group. Furthermore, we would expect the appearance of doublet of doublets in the aromatic region were 
nitration to occur at either the 2- or 5-position, as each of the available protons would be able to couple to both a 
neighbouring fluorine and proton.  
Figure 6.7: 
1
H NMR spectrum of intermediate fragment 21. 
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However, the two aromatic peaks appeared as doublets, with the 2-position proton (J = 7.8 Hz, green) occurring 
more downfield in comparison to the 5-position proton (J = 13.4 Hz, red), as it is ortho to the electron withdrawing 
nitro moiety. Furthermore, the difference in J-coupling values are indicative of 
2
J (red) and 
3
J (green) H-F coupling to 
the fluorine atom. Lastly, the found HRMS [M+H]
+
 ion of 187.0524 (calculated: 187.0519), 
1
H and 
13
C NMR spectra 
all compared well with the reported literature values.
25
  
Continuing with the synthesis of the heterocyclic building block 26 in Scheme 6.3, we anticipated the required 
protection of the aniline group to avoid reaction centre competition in the forthcoming acylation. We therefore 
initiated the synthesis with a Boc-protection of compound 21. Interestingly, our first attempts to introduce the Boc-
protecting group using non-nucleophilic bases such as Et3N and DIPEA resulted in the preferred formation of a 
couple of by-products. Due to the highly electronegative nature of the fluorine atom and its placement ortho to the 
electron-withdrawing nitro group, we postulated the occurrence of a rapid intermolecular SNAr reaction between 
the nucleophilic aniline and another equivalent of starting material prior to protection. Formation of these by-
products was witnessed even at low temperatures, leading us to avoid the use of bases which could expedite the 
incidence of the hypothesised SNAr reaction. Following several optimization reactions, use of di-tert-butyl 
dicarbonate with a catalytic amount of DMAP in DCM afforded the Boc-protected analogue 22 in good yield, albeit 
over a long reaction time.  
Introduction of the solubilising group in the subsequent SNAr reaction between 22 and N
1
,N
1
,N
2
-trimethylethane-
1,2-diamine proceeded flawlessly with DIPEA acting as base, furnishing a near quantitative yield of compound 23. 
The reactivity exhibited in this conversion can be construed as validation for our previously outlined hypothesis 
concerning the difficulties with the Boc-protection. This allowed for aromatic nitro reduction of compound 23, which 
was carried out using Pd/C under hydrogen atmosphere, with methanol discerned as the optimal solvent. Filtration 
through a plug of diatomaceous earth and purification of the crude product using flash column chromatography 
afforded compound 24 as a brown oil in excellent yield.  
Scheme 6.3: Five step synthesis of heterocyclic fragment 26 to undergo coupling with 14. Reagents and conditions: i) Boc2O 
(1.05 equiv.), DMAP (cat.), DCM, rt, 24 h; ii) N
1
,N
1
,N
2
-trimethylethane-1,2-diamine (1.25 equiv.), DIPEA (1.05 equiv.), DMA, 
60 °C, 4 h; iii) H2, Pd/C (10 mol%), MeOH, rt, 12 h; iv) propionyl chloride (1.05 equiv.), DIPEA (1.1 equiv.), DCM, −10 °C – 
rt, 2 h; v) DCM/TFA (3:1), rt, 6 h. 
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Advancing with the synthetic route, we chose to progress with the propionamide version of the fragment for 
optimization purposes. Following the successful synthesis and future coupling reaction, we could return to build the 
acrylamide counterpart at a later stage. Accordingly, acylation of the aniline fragment 24 with propionyl chloride at 
low temperature in DCM furnished the propionamide 25 in a yield of 89%. To conclude the synthesis, deprotection 
of the Boc group was facilitated by a 3:1 mixture of DCM/trifluoroacetic acid, to afford compound 26 a beige solid. 
From compound 18, the overall yield for the 8-step synthesis was calculated to be approximately 45%.  
With the heterocyclic fragment 26 in hand we looked towards coupling with the previously synthesised indole-
pyrimidine fragment 14, illustrated in Scheme 6.4 below. However, this reaction proved exceedingly problematic, 
requiring numerous attempts to optimize and attain the yield shown below. The reaction was found to proceed best 
under acidic conditions, requiring 1.2 equivalents of recrystallised p-toluenesulfonic acid monohydrate. Additionally, 
2-pentanol was identified as the optimal solvent choice, determined from a pool of high boiling point solvents 
including, amongst others, NMP, ethylene glycol and DMSO. Application of these conditions afforded the 
osimertinib derived scaffold 27 in a maximum yield of 61%. Unfortunately, yields were found to be inconsistent and 
could only be reliably reproduced in small scale quantities of up to ~ 0.50 mmol. Furthermore, increasing the scale 
of the reaction resulted in the formation of by-products, complicating the isolation, separation and purification of 
the desired compound. We were however able to isolate pure samples of compound 27 and acquire the relevant 
analytical data which will be discussed in the following section.  
The 
1
H and 
13
C NMR spectra of compound 27 can be found on the following page in Figure 6.8, indicating structural 
confirmation for the synthesis of the heterocyclic scaffold.  Examination of the most upfield region of the 
1
H spectrum 
in Figure 6.8a shows evidence of the propionamide moiety, with the terminal methyl (red) protons appearing as a 
triplet at δ 1.30 ppm and the neighbouring ethyl linker (green) as a quartet at δ 2.45 ppm. Moving downfield, the 
large peak found at δ 2.26 ppm was ascribed to the dimethylamine (light blue) element of the solubilising group. 
However, this signal was found to integrate for 8H instead of 6H, which was revealed to arise from overlap with 
another triplet upon closer inspection. This triplet was assigned to the protons of one of the ethylene bridge (dark 
blue) carbons, with the corresponding proximal triplet identified at δ 2.88 ppm. Lastly, the singlet appearing at δ 
2.67 ppm and integrating for 3H was correlated to the methylamine (orange) of the solubilising group, expectedly 
more downfield than the aryl methoxy (yellow) moiety, appearing at δ 3.85 ppm. 
 
 
 
 
 
Scheme 6.4: Coupling of fragments 14 and 26 to afford osimertinib-derived scaffold 27. Reagents and conditions: i) TsOH·H2O 
(1.2 equiv.), 2-pentanol, 105 °C, 8 h. 
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Figure 6.8: a) 
1
H and b) 
13
C NMR spectra of scaffold 27. 
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Assessment of the aromatic region of the 
1
H NMR spectrum presented the correct integration amount for compound 
27, with all protons accounted for and peak splitting patterns to be in good order. This left us with three singlets at 
the farthest region downfield of the spectrum, corresponding to the remaining three amine protons in our structure. 
Working from NMR spectra of precursory structures and inherent differences in electron withdrawing substituents, 
we were able to assign the peak at δ 9.64 ppm to the aniline (purple) bridging the pyrimidine and aryl fragment, the 
propionamide (brown) at δ 9.97 ppm and lastly, the indole (grey) proton to the singlet at δ 10.38 ppm.  
Inspection of the 
13
C spectrum in Figure 6.8b further reinforces the structural findings of the 
1
H spectrum, with 
several distinct peaks indicating the successful coupling of the two fragments. In the aliphatic region, the two peaks 
at δ 10.33 and 30.79 ppm correlate to the propionamide terminal methyl (green) and ethyl (red) carbons 
respectively. The remaining aliphatic region signals were assigned based upon visual comparison of the peak 
intensities and their position in the precursor fragments NMR spectra. Based on this, we assigned the most intense 
peak at δ 45.34 ppm to the dimethylamine (light blue) carbons and the methylamine (orange) carbon to the adjacent 
signal at δ 44.08 ppm. The three signals between δ 56.00 and 57.50 ppm proved more complex in their assignment, 
although we know they constituted the ethylene bridge (dark blue) carbons of the solubilising group and the aryl 
methoxy (yellow). Peak intensity, shape and previous spectra of isolated building blocks led us to assign the peaks 
as shown in Figure 6.8b, with the middle, more intense peak at δ 56.14 ppm belonging to the aryl methoxy (yellow) 
and the neighbouring peaks to the ethylene bridge (dark blue). At this point and with the information available, these 
assignments could not be confirmed and were considered speculative. However, 2D NMR spectroscopic analysis of 
a final compound with a similar osimertinib-derived heterocyclic driving group in the following chapter (Section 
7.4.3.9) clarified these peak assignments.  
To conclude, the carbons present in the aromatic region of the 
13
C spectra were all correctly accounted for. The 
signal furthest downfield was indicative of a carbonyl carbon, which we ascribed to the propionamide (brown). Use 
of HRMS analysis presented a [M+H]
+
 ion of 488.2783, with a calculated mass of 488.2774, providing final 
confirmation for the successful synthesis of compound 27.  
While pleased with the effective isolation and characterisation of compound 27, we found the lower yields and 
inconvenient purification associated with scale-up to be unacceptable. We therefore sought an improved and more 
feasible reaction sequence for the synthesis of this compound. In the coupling between 14 and 26, we suspected 
that the indole amine could be participating as a nucleophile owing to the high temperature of the reaction. We 
therefore proposed the introduction of protecting groups at this position to circumvent the unwanted formation of 
by-products, aspiring to improve the purification process and yield. As illustrated in Scheme 6.4, installation of a 
Boc-protecting group was carried out smoothly to afford compound 28 in excellent yield. Nonetheless, subsequent 
coupling between 28 and 26 led to the formation of numerous by-products, amongst which the deprotected 
compound 27 and the Boc-protected analogue 29 were identified by their isolation in trace amounts. We believed 
the requisite use of high temperatures and p-toluenesulfonic acid to be responsible for deprotection of the Boc-
group, leading to several potential reactants and possible products. This prompted investigation into a more stable 
and chemically inert protecting group.  
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 Scheme 6.4: Introduction of protecting groups to improve synthesis of scaffold 27. Reagents and conditions: i) Boc2O 
(1.2 equiv.), Et3N (1.3 equiv.), DMAP (cat.), DCM, rt, 12 h; ii) NaH (1.16 equiv.), SEM-Cl (1.23 equiv.), −10 °C – rt, 4 h; iii) 
TsOH·H2O (1.2 equiv.), 2-pentanol, 105 °C, 8 h.  
This led us to the SEM-protecting group, with which we found marked success in the synthesis and protection of the 
pyrrolopyrimidine compounds of Chapter 3. Deprotonation of the indole amine with sodium hydride, followed by 
dropwise treatment with 2-(trimethylsilyl)ethoxymethyl chloride in DMF at low temperature, furnished the SEM-
protected compound 30 in good yield. Fortunately, we found the coupling between 30 and 26 to proceed far more 
smoothly than in previous instances, with the SEM-protecting group surviving the harsh reaction conditions. 
Moreover, incorporation of the SEM-group resulted in the synthesis of “greasier” molecules with a lower polarity, 
facilitating easier handling and purification and resulting in an isolated yield of 77% of compound 31.   
Deprotection of the SEM-group, shown in Scheme 6.5, proved unusually problematic. Unexpectedly, the previously 
effective established reaction conditions of trifluoroacetic acid in DCM, followed by 1 M KOH in THF, afforded the 
hydroxymethyl intermediate 32 almost exclusively amidst a few by-products. We therefore made use of 
trifluoroacetic acid in DCM independently to facilitate isolation of compound 32 in 72% yield. Following this, 32 
was stirred in a 1:1 mixture of 1 M KOH and THF in a prolonged reaction which proceeded sluggishly and resulted 
in a maximum yield of 43% following challenging purification procedures.  
Scheme 6.5: Deprotection of SEM-protected compound 31 to afford intermediate 32 and scaffold 27. Reagents and 
conditions: i) DCM/TFA (3:1), rt, 6 h; ii) 1 M KOH/THF (1:1), rt, 4h. 
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Assessment of the implemented synthetic strategy left much to be desired. The length of the pathway, requirement 
of protecting groups and incompatibility with reaction scale-up led to a final attempt towards route optimization, 
displayed below in Scheme 6.6. While coupling of fragments 14 and 21 and the stepwise building of the molecule 
in a linear fashion was originally contemplated, pursuit of this synthetic avenue posed several intrinsic chemo- and 
regioselective issues. The main concern was the inherent reactivity of the aryl fluorine centre of compound 21, as 
exhibited previously in its Boc-protection to afford compound 22. Exposing this fragment to high temperatures could 
result in multiple SNAr reactions taking place, by nucleophilic attack of the indole amine or another equivalent of 21 
to afford the dimerized product. While we hypothesised that this could potentially be overcome by prior introduction 
of the solubilising group, we nevertheless carried out the coupling of 14 and 21 using the optimized conditions.  
To our surprise and delight, the reaction proceeded exceedingly well. This good fortune was augmented further by 
a serendipitous discovery regarding the purification of compound 33. Contrary to the routine immediate purification 
of the crude reaction mixture, the reaction flask was left to cool overnight. This prompted the formation of a yellow 
precipitate, which was subsequently filtered and washed with acetonitrile. NMR spectroscopic analysis of this crude 
material revealed the presence of both the desired product 33 and excess p-toluenesulfonic acid.  
Scheme 6.6: Optimal synthetic route towards scaffold 27 by linear synthesis. Reagents and conditions: i) TsOH·H2O 
(1.2 equiv.), 2-pentanol, 105 °C, 4 h; ii) N
1
,N
1
,N
2
-trimethylethane-1,2-diamine (1.25 equiv.), DIPEA (1.05 equiv.), DMA, 60 °C, 
4 h; iii) NaH (1.2 equiv.), SEM-Cl (1.2 equiv.), −10 °C – rt, 4 h; iv) Boc2O (1.1 equiv.), DIPEA (1.1 equiv.), DMAP (cat.), DMF, 
rt, 6 h; v) H2, Pd/C (10 mol%), MeOH, rt, 12 h. 
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Removal of the excess p-toluenesulfonic acid was achieved by dissolving the crude product in a 10% methanol in 
DCM solution, followed by successive washing of the organic phase with saturated sodium bicarbonate. The 
obtained yellow solid was then triturated with acetonitrile to afford compound 33 in 89% yield, with no further 
purification required. Exceptionally, this reaction could be scaled up to 6 grams with no repercussions to the obtained 
yield. Although the SNAr mechanism remains a source of much investigation and debate, it is evident from the 
outcome of this reaction that protonation of the pyrimidine nitrogen, and thus facilitation of substitution at the centre 
ortho to this, is preferred.
26
 In contrast, reaction at the fluorine centre is clearly favoured under basic conditions, as 
exemplified by the facile substitution and incorporation of the solubilising group in formation of 34. Accordingly, 
mild heating of compound 33 and N
1
,N
1
,N
2
-trimethylethane-1,2-diamine in DMA, with DIPEA serving as base, 
afforded compound 34 as a bright red solid in good yield.   
To avoid chemoselective complications between the indole amine and the aniline fragment in the forthcoming 
acylation reaction, we sought to introduce a protecting group at the indole nitrogen. Our first and singular attempt 
at the SEM-protection thereof resulted in a below average yield of 48% for compound 35. Discouraged by this, we 
turned to the incorporation of a Boc-protecting group, using DMF as solvent for solubility purposes. The Boc-
protection proceeded superbly, providing the protected analogue 36 in a near quantitative yield which was retained 
in subsequent scaled-up reactions. This allowed for subsequent aromatic nitro reduction using Pd/C under a 
hydrogen atmosphere to produce the aniline fragment 37 in excellent yield.  
With 37 in hand, we advanced to the acylation using both propionyl and acryloyl chloride, as shown in Scheme 6.7 
below, which led to the formation of the penultimate protected compounds 38 and 39 respectively. For the 
installation of the Michael acceptor, yields were dramatically improved through implementation of low temperatures 
generated using an acetonitrile and dry ice bath.   
Scheme 6.7: Incorporation of propionamide and acrylamide followed by deprotection to afford compound 27 and 40. 
Reagents and conditions: i) propionyl chloride (1.1 equiv.), DIPEA (1.2 equiv.), DCM, −10 °C – rt, 2 h; ii) DCM/TFA (3:1), rt, 4 
h; iii) acryloyl chloride (1.1 equiv.), DIPEA (1.2 equiv.), DCM, −40 °C – −20 °C, 2 h. 
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Lastly, deprotection of the Boc-group was affected by stirring in a solution of trifluoroacetic acid in DCM. This 
afforded the desired scaffold 27 in near quantitative yield and the previously unattained Michael acceptor 
counterpart 40 in a decreased but acceptable yield of 70%. Development and use of this stepwise synthetic route 
resulted in an improvement of the overall yield, calculated to be 55.4% from the coupling of compound 14 and 21 
to produce compound 27. Moreover, the strategy was tolerant towards execution of multi-gram scale reactions, 
furnishing large amounts of scaffold 27 and 40 to carry forward in electrophile derivatisation. The synthesis of these 
electrophiles and the resultant final compounds will be disclosed in the following section. 
6.4.2 Electrophile Synthesis and Derivatisation 
As the primary goal of this study was to gauge the feasibility of labelling the catalytic Lys745 residue, we chose to 
proceed exclusively with derivatization of the propionamide scaffold 27 in the generation of the first set compounds. 
This would eliminate any competition and avoid confusion as to whether covalent modification had occurred at the 
catalytic Lys745 or the traditional Cys797 residue. This would be relevant in covalent mass spectrometry experiments 
and the biochemical and cellular assays of enzyme variants other than the C797S mutant. Following evaluation of 
this preliminary library, we could decide whether to pursue the synthesis of compounds containing the Michael 
acceptor moiety derived from compound 40.   
6.4.2.1 Michael Acceptors 
To our dismay, overall derivatization of the indole nitrogen proved extremely challenging, due largely to the 
unforeseen poor nucleophilicity of this functionality. Efforts at incorporating Michael acceptor electrophiles into 
scaffold 27 is illustrated in Scheme 6.8 and the discussion thereof follows. Our first attempt, the seemingly 
straightforward acylation with acryloyl chloride using conventional conditions, resulted in no product formation and 
return of the starting material. A similar outcome was found in further experiments using an array of reaction 
parameters. This included the use of Et3N, DIPEA or potassium carbonate as base at a range of reaction temperatures 
in various solvents such as DCM, THF and DMF. This was a source of much puzzlement and frustration, leading us 
to affect formal deprotonation of the indole nitrogen with sodium hydride. After being left to stir for 30 minutes at 
room temperature, the solution was cooled to −40 °C and treated dropwise with acryloyl chloride. Understandably, 
requirement of these harsh reaction conditions led to the formation of several side products. However, amidst these 
by-products, compound 41 was successfully isolated and afforded in a 72% yield, with DMF as optimal solvent.  
For inclusion of the propiolamide Michael acceptor, shown in Scheme 6.8, we had to contend with the 
aforementioned nucleophilicity issues. Initial failures towards amide bond formation using propiolic acid (42), led us 
to purify the corrosive liquid via kugelrohr distillation. However, similar results were obtained in subsequent 
attempted acid couplings, using an assortment of reagents such as DCC, EDC, DIC and CDI in combination with 
HOBt hydrate and DMAP as additives. Hoping to emulate the workable conditions achieved with acryloyl chloride, 
conversion of 42 into the corresponding acid chloride 43 was successfully carried out using phosphorous 
pentachloride in DCM. Unfortunately, use of sodium hydride and subsequent treatment with 43 led to a myriad of 
side reactions, making it near impossible to distinguish and isolate 44.   
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Scheme 6.8: Synthesis of the Michael acceptor-containing compound 41 and the attempted synthesis of final compounds 44. 
Reagents and conditions: i) NaH (1.3 equiv.), −10 °C – rt, 30 min then acryloyl chloride (1.2 equiv.), DMF, −40 °C – − 20 °C, 
2h; ii) PCl5 (1.05 equiv.), DCM, rt, 4h.
27
 
 We shifted our focus to the devised synthetic strategy outlined in Scheme 6.9. To obtain ethenesulfonamide 48, 
acylation of 27 with the synthesised 46 would be undertaken, followed by elimination of 47. Accordingly, neat 
reaction of the commercially available sodium salt of bromoethansulfonate (45) with phosphorous pentachloride 
under thermal conditions provided 46 in good yield.
28
 Regrettably, compound 47, and therefore compound 48, 
could not be successfully isolated. Once again, acylation of the weakly nucleophilic indole nitrogen required strong 
basic conditions to facilitate any reaction, resulting in the formation of numerous side-products and a substantial 
remainder of starting material.  
 Scheme 6.9: Synthesis of reactive intermediate 46 and the attempted synthesis of final compounds 48 and 50. Reagents and 
conditions: i) PCl5 (1 equiv.), neat, 130 °C, 30 min.
28, 29 
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We believe these difficulties stem from an inherent catch-22 situation, where requisite use of a strong base induces 
spontaneous elimination of 46 to form the ethenesulfonyl moiety in situ, mainly attributed to the highly reactive 
bromo-leaving group. This could occur prior to or post acylation and generates multiple electrophilic sites, evinced 
by the observed mass of by-products. While unsuccessful in the synthesis of compound 48, it is worthy to note that 
this strategy was successfully implemented in the generation of a different compound, where use of strong base was 
not obligatory. The synthesis of this compound will be discussed in Section 7.4.3.1 in the following chapter.  
To overcome this dilemma, we envisioned use of the commercially available chloro-variant of 47, which contained 
a weaker leaving group and would thus be less prone to undergo the untimely elimination. Unfortunately, due to 
the reactive and unstable nature of the compound, the danger posed to its transport and delivery inflated the cost 
to exorbitant amounts. Additionally, shipping times would be in the vicinity of 6 – 8 months, leading us to suspend 
efforts towards the synthesis of compound 48. However, prospective routes towards the synthesis of 48 can be found 
in the future work section of this chapter. Due to similar constraints, the inability to access commercially available 
electrophiles required for the synthesis of final compounds in this and the following chapter became a recurring 
trend. This meant that these reactive fragments had to be synthesised in house, adding a further layer of complexity 
and synthetic labour to the research project.  
In recent years, ynamides have found increased use as Michael acceptors in the development of covalent kinase 
inhibitors that target the traditional cysteine residue.
18
 We therefore attempted the synthesis of ynamide 50, shown 
in Scheme 6.9, using the robust protocol developed by Tu and co-workers.
29
 The group found that following reaction 
of amines with 1,1-dichloroethylene (49), the masked alkynyl halide could be transformed further under basic 
conditions into the corresponding ynamide using a broad substrate scope. However, the prescribed use of 5 
equivalents of sodium hydride in heated DMSO was simply too harsh for our heterocyclic scaffold. This led to the 
now familiar formation of inseparable crude reaction mixtures and consequent abandonment of the synthesis of 
compound 50.  
6.4.2.2 Nitriles 
Equipped with a greater understanding of the indole nitrogen reactivity, we were pleased to find that introduction 
of the nitrile functional groups proved simpler and more fruitful. As illustrated in Scheme 6.10, initial reaction 
between 27 and bromoacetontrile (51) using sodium hydride as base was met with no product formation and a 
return of the starting material. Accordingly, exchange of electrophile to the highly reactive iodoacetonitrile (52) and 
application of the same conditions rewarded us with the efficient production of compound 53 in 68% yield.  
Comparatively, the synthesis of 56 was met with failure when reacting 3-proprionitrile (54) with 27 using a variety 
of bases and Finkelstein type conditions at elevated temperatures. Interestingly, success was attained through use of 
acrylonitrile (55) and benzyltrimethylammonium hydroxide (Triton B), a quaternary salt that can act as an effective 
organic base catalyst in Michael addition reactions.
30
 Consistent with the literature, the addition proceeded smoothly 
at ambient temperature over a slightly longer reaction time, furnishing 56 in excellent yield. While not discussed. 
both compound 53 and 56 underwent full characterization which may be accessed in the supplementary 
information.    
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Scheme 6.10: Synthesis of nitrile-containing final compounds 53 and 56 and the attempted synthesis of compound 59. 
Reagents and conditions: i) NaH (1.3 equiv.), −10 °C – rt, 30 min then iodoacetonitrile (1.2 equiv.), DMF, −10 °C – rt, 2 h; ii) 
Triton B (cat.), acrylonitrile (4 equiv.), DMF, −10 °C – rt, 24 h; iii) oxalyl chloride (1.2 equiv.), DMF (cat.), DCM, 40 °C, 4 h.30, 
31 
Finally, venture into the incorporation of a cyanoacetamide moiety into structure 27, to potentially afford compound 
59, is shown above in Scheme 6.10. The attempted synthesis of 59 was carried out in a manner comparable to that 
undertaken for propiolamide 44 in Scheme 5.8. As such, the synthesis fell prey to the same pitfalls discussed for 
compound 44 and we were unable to successfully isolate compound 60, even from reaction of 27 with the 
synthesised 2-cyanoacetyl chloride (58). It is noteworthy that execution of this strategy with a more nucleophilic 
aniline fragment was met with success and will be reviewed in Section 7.4.3.8 in the following chapter.   
6.4.2.3 Sulfonyl Fluorides 
Until recently, ethenesulfonyl fluoride (ESF) and its use as a reactive building block remained relatively obscure. 
Shown in Scheme 6.11 as compound 61, ESF was first reported by Hedrick in 1953 and its reactivity systematically 
investigated by Krutak and co-workers in 1979.
32
 By virtue of its highly reactive C=C bond, which has been 
distinguished as one of the most electrophilic monosubstituted ethylenes, reaction with a variety of nucleophiles is 
facilitated whilst sparing the sulfonyl fluoride moiety which remains unaffected.
33
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Scheme 6.11: Synthesis of model compound 62 and its final compound counterpart 63. Reagents and conditions: i) ESF 
(1.05 equiv.), DMF, 0 °C – rt, 3 h; ii) ESF (1.3 equiv.), K2CO3 (1.5 equiv.), DMF, 0 °C – rt, 6 h.32 
ESF has found numerous applications in cross-coupling and click chemistry, leading to it being named “the most 
perfect Michael acceptor ever found,” by Sharpless and his research group.6, 34 In light of our inexperience in handling 
sulfonyl fluoride-containing molecules, we undertook a preliminary model reaction between aniline (60) and ESF 
(61), illustrated in Scheme 6.11 above. By doing so, we wished to gain a better understanding of the functional 
group’s reactivity, sensitivity and stability towards purification procedures such as aqueous work-up and column 
chromatography. It was found that dropwise treatment of 60 with diluted ESF (61) at low temperatures in DMF 
facilitated the Michael addition effortlessly. Aqueous work-up was well tolerated and extraction with ethyl acetate 
ensured removal of any excess DMF. This was followed by purification using column chromatography which afforded 
62 in a near quantitative yield, highlighting the facile conversion and stability of the sulfonyl fluoride.  
With our curiosity and apprehension towards the reactive group allayed, we applied the same reaction conditions 
to the synthesis of compound 63. While this resulted in formation of 63, the reaction proceeded sluggishly with 
limited yields. Inclusion of potassium carbonate in the reaction, serving as base and driving the Michael addition 
forward, gave rise to improved yields and reaction times. Consequently, we were able to isolate final compound 63 
in an acceptable yield of 63%.  
With both the model compound 62 and final compound 63 in hand, we were able to perform comparative 
spectroscopic analysis using 
1
H and 
19
F NMR spectroscopy. These spectra are shown on the following page in 
Figure 6.9 and were used to provide confirmation for the successful synthesis of 63. All 
19
F NMR spectroscopy 
experiments were self-run, with chemical shifts within spectra referenced to trichlorofluoromethane which served 
as the internal standard. Inspection of the 
19
F NMR spectra of 62, found in the top right of Figure 6.9a, displays a 
singular peak (red) at δ 56.70 ppm which coincides with the lone fluorine atom of the sulfonyl fluoride (red). 
Interestingly, this peak was revealed as a triplet coupling through the sulfonyl moiety to the neighbouring protons of 
the ethyl chain linker, with a J-coupling value of 4.6 Hz. Combing through the literature, we found similar 
compounds whose 
19
F NMR shifts coincides with this peak (~57 ppm) and corroborated with the observed 
multiplicity and J-coupling value (~ 4.8 Hz).
35
 Interestingly, 
19
F NMR spectroscopy reporting for this class of 
compound is very sparse, with only several examples found in publications spanning the last two years.  
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Figure 6.9: 
1
H and 
19
F NMR of a) compound 62 and b) final compound 63. 
From the 
1
H NMR spectra we gained confirmation of the synthesis of compound 62, with all protons correctly 
accounted for. Importantly, the presence of the two peaks (blue and green) between δ 3.60 and 3.90 ppm were 
ascribed to the ethylene bridge of the sulfonyl fluoride. The most upfield peak at δ 3.67 ppm, which appeared as 
an apparent quartet, was assigned to the methylene (blue) closest to the sulfonyl group. We believe this multiplicity 
arose from coupling to the neighbouring methylene and long-range coupling through the sulfonyl group to the 
fluorine atom, resulting in the overlap of a triplet of doublets and the observed quartet.  
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This left the remaining bridge methylene (green) signal, which occurred slightly downfield at δ 3.86 ppm as an 
apparent triplet.  
With the model compound fully characterised, we undertook a comparative analysis between final compound 63. 
Examination of the 
19
F NMR spectrum of 63, shown in the top right inset of Figure 6.9b, revealed a striking similarity 
to that of 62. A single peak was observed at δ 57.69 ppm, less than 1 ppm from the model compound signal and in 
the vicinity of similar compounds found in the literature. Furthermore, both peaks appeared as triplets, with 63 
exhibiting a slightly higher J-coupling value of 6.1 Hz. Successful synthesis of the sulfonyl fluoride containing final 
compound 63 was endorsed further by the obtained 
1
H NMR spectra. As with the model compound, the emergence 
of two new signals between δ 4.60 and 5.00 ppm, correlating to the ethylene bridge of the sulfonyl fluoride, was 
witnessed. These peaks (blue and green), while slightly downfield from the model counterpart, retained the same 
multiplicity and analogous J-coupling values, substantiating successful sulfonyl fluoride functionalisation. All other 
protons, including those of amino, aliphatic and aromatic, were correctly accounted for. Except for the absence of 
the indole nitrogen proton, the 
1
H NMR spectra of 63 compares well with the precursor scaffold 27 in Figure 6.8 
and will therefore not be discussed further. Lastly, HRMS analysis provided an [M+H]
+
 ion of 598.2620, matching 
the calculated mass of 598.2612, providing final confirmation for the successful synthesis of compound 63. 
To diversify our library of sulfonyl fluoride compounds, we wished to synthesise the propyl (66) and butyl (69) bridge 
counterparts of 63, illustrated in Scheme 6.12 below. To accomplish this, we envisioned ring-opening reaction 
between scaffold 27 and both the 1,3-propane and 1,4-butane sultone 64 and 67 respectively. This would afford 
the sulfonate intermediates 65 and 68, which could then be converted into the corresponding sulfonyl fluorides.  
Scheme 6.12: Attempted synthesis of final compounds 66 and 69. 
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While we believe the ring-opening reaction was affected successfully using sodium hydride and heating in DMF, 
purification and characterization of the intermediate sulfonate compounds 65 and 68 proved impractical. These 
compounds were found to be extremely polar and water-soluble, leaving all products, by-products and excess 
starting materials within the aqueous phase following work-up, as visualised by TLC analysis. Subsequent removal of 
water using a lyophilizer afforded a crude mass which was subjected to NMR spectroscopic analysis. While it could 
be surmised that the reaction was successful, this could not be confirmed as the obtained spectra was largely 
indecipherable due to the presence of numerous by-products. Furthermore, purification of the crude mixture proved 
futile due to the compound’s solubility and polarity. 
Nevertheless, conversion of the crude sulfonates 65 and 68 to the corresponding sulfonyl fluorides 66 and 69 was 
attempted using several reagents and reaction conditions. This included use of the fluorinating reagent 
diethylaminosulfur trifluoride (DAST), conversion to the equivalent sulfonyl chloride using oxalyl chloride followed 
by substitution with potassium fluoride and numerous one-pot syntheses, all to no avail. We believe implementation 
of reverse-phase column chromatography to isolate pure samples of the sulfonate intermediates 65 and 68 will allow 
for the successful synthesis of final compounds 66 and 69. Unfortunately, this purification technique was unavailable 
to us, but it remains our endeavour to synthesise these compounds as part of future work of this chapter.  
6.4.2.4 α-, β-Haloketones   
Efforts towards the synthesis of α- and β-haloketone-containing final compounds, depicted in Scheme 6.13 below, 
will be discussed briefly. For the synthesis of both the halide-variants of 73 and 76, acid coupling and acylation 
reactions were attempted using a variety of carboxylic acid and acyl halide derivatives.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.13: Attempted synthesis of final compounds 73 and 76. 
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All of the electrophiles employed in these reactions were distilled or recrystallised prior to use. Unfortunately, no 
product formation occurred for the acid coupling of 27 with either 70 or 74, owing to the inherent weak 
nucleophilicity of the indole nitrogen. However, for the duration of acylation reactions carried out at low 
temperatures, it appeared as though single product formation was taking place, as per visualisation by TLC analysis. 
However, following the attempted isolation and purification of the crude reaction mixtures, the compounds were 
found to have degraded, evident by the abundant formation of side-products. This led to our inability to furnish 
compounds 73 and 76.  
In the following chapter, similar reactions were carried using a stronger nucleophilic aniline fragment. However, 
these compounds also succumbed to the same outcomes of side-product formation and degradation. Our theories 
towards the reactivity and instability of these compounds will be broached in the next chapter and a full explanation, 
with compelling evidence provided by by-product formation, will be given in Section 7.4.3.6.  
As we wished to ascertain whether our strategy was viable in targeting interactions with the catalytic Lys745, it was 
decided to evaluate the inhibitory properties of the successfully synthesised final compounds until this point. This 
concluded the synthesis of our osimertinib derived lysine-targeting compounds and allowed for the biochemical and 
biological assessment of all final compounds and interesting intermediates. These compounds were tested against 
the wild-type and mutant variant forms of EGFR, the results of which are discussed in the following section.  
6.5 Biochemical and Cellular Evaluation  
Unfortunately, complications within the biology lab of our collaborators at the Technische Universität in Dortmund 
prevented biochemical inhibitory measurements of the synthesized final compounds against the triple 
L858R/T790M/C797S mutant variant of the enzyme. However, we were able to acquire the EC50 values against the 
clinically relevant osimertinib resistant cell line EGFR-PC9/T790M/C797S in the cellular evaluation, with the PC9 
mutation being the predominant activating mutation found in osimertinib resistant patients. Furthermore, a wild-
type-bearing cell line A431 and the EGFR-L858R/T790M drug resistant cell line H1975 was employed. Additionally, 
promising compounds were further evaluated against BaF3 cell lines of both the single activating EGFR-L858R and 
the EGFR-T790M/C797S mutant variants of the enzyme (Section 4.6.3). Compound assessment was carried out 
either by Dr. Jonas Lategahn, Dr. Marina Keul or Mr. Tobias Grabe, with all measurements being executed in at least 
triplicate. The respective IC50 and EC50 values of osimertinib and the underivatized analogue 27 accompany the 
obtained results in each report.  
6.5.1 Evaluation of Intermediate Compounds 
An overview of the results from the biochemical and cellular evaluation of all intermediate compounds synthesised 
en route to the final compounds of the chapter can be seen in Table 6.1 on the following page. As these precursors 
are derivatised at the N-indole position with a SEM- or Boc-protecting group, we wished to investigate any potential 
interactions that the silyl ether or carbamate may have with the Lys795 residue and the optimal chain length for 
derivatisation. These compounds could then be compared to the underivatized analogue 27, whose entry is found 
just below osimertinib in Table 6.1.  
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Table 6.1: Biochemical and cellular evaluation results for the synthesised intermediate compounds. 
Analysis of the biochemical data for model compound 27 reveals a reasonable activity profile, with understandable 
loss of efficacy when compared to osimertinib, owing to the absence of the Michael acceptor and covalent bond 
formation with Cys797. Surprisingly, the IC50 values against the single activating L858R and double L858R/T790M 
mutant variants remains within the double digit nanomolar range. However, analysis of the corresponding cellular 
data reveals the significance of exclusion of the Michael acceptor moiety and loss of covalent bond formation, with 
a dramatic loss in activity across the board. We see low nanomolar inhibitory concentrations in the biochemical 
assessment translating to high single digit micromolar values in the cellular assays, highlighting the potentially 
misleading presentation of biochemical data and the importance of attaining good cellular activity as a benchmark 
for further investigation.  
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Scrutiny of the SEM-protected and partially deprotected compounds 31 and 32 respectively, reveals interesting 
trends regarding chain length and potential metabolite formation. Biochemically, compound 32 globally outperforms 
the SEM-protected counterpart 31, with a 3- to 5-fold improvement in IC50 values. This alludes to the shorter 
hydroxymethyl chain of 32 being superior to the longer trimethylsilylethoxymethyl chain of the SEM-protecting group 
of 31. Furthermore, the more polar terminal hydroxyl of 32 may induce hydrogen bond interactions with the polar 
residues of the β3 sheet or helix αC strand at the roof of the enzyme, where the trimethylsilyl ether of 31 cannot. 
This matches with the hydrogen bond donor capabilities of the indole nitrogen of model compound 27, which 
exhibits slightly improved IC50 values over compound 32.    
As witnessed in compound 27, we see a large diminishment of activity in the EC50 values of the both 31 and 32, 
ascribed to the absence of covalent modification of the cysteine residue. Interestingly, compound 31 displays an 
improved cellular activity against the PC9/T790M/C797S triple mutant, surpassing both the model compound 27 
and 32. As such, compound 32 was evaluated against BaF3 cell lines of both the single activating L858R and the 
T790M/C797S EGFR mutants. As mentioned in Chapter 3, the use of Ba/F3 cells in chemical biology has shown 
promise in predicting resistance by point mutations which interfere with inhibitor binding, allowing for an estimation 
of the candidate compounds susceptibility to clinical resistance.
36
 While compound 31 retained efficacy comparable 
to osimertinib against the BaF3/L858R cell line, a complete loss in activity was observed against BaF3/T790M/C797S, 
with an EC50 value of 25 µM.  
Next, we inspected the performance of the Boc-protected compound 38 and 39. The propionamide derivative 38 
was shown to be universally less efficacious than the SEM-protected analogues biochemically and essentially inactive 
in the cellular screening. This strengthened our hypothesis of shorter chain length and a polarised terminal 
functionality, as the carbamate chain is both long and contains a tert-butyl end group. Intriguingly, the unsaturated 
counterpart 39 displayed incredible efficacy biochemically, outperforming both the model compound 27 and 
osimertinib with IC50 values in the picomolar range. Compound 39 exhibited an IC50 value of 80 pM against the 
L858R/T790M double mutant, nearly 7-fold more potent than the structurally related osimertinib. With the presence 
of the Michael acceptor restored, these values were retained in the cellular assays. Double digit nanomolar activity 
against the L858R/T790M and a slightly improved EC
50
 value of 2.57 µM for the triple mutant was observed. Excited 
by this, compound 39 was run against the BaF3 cell lines which revealed an activity profile comparable to 
osimertinib.  
Seeking an explanation for this remarkable activity, we scoured the literature for conceivable answers. Reading 
through the original manuscript describing the development of osimertinib, we came across the evaluation of 
compound 40 (Table 6.1), which we also synthesised but did not screen.
37
 According to the authors and following 
in vivo metabolic studies in murine plasma samples, this compound is a metabolite of osimertinib, resultant from 
loss of the indole N-methyl group. While profiling of compound 40 showed impressive double and activating mutant 
potency, the candidate was not developed further due to the modest in vitro wild-type margin and in vivo efficacy. 
As compound 39 displays a similar inhibitory profile, we propose that the Boc-protecting group is being cleaved 
during incubation, potentially resulting in formation of metabolite 40. Additionally, this theorem correlates with the 
observed superior activity of model compound 27, which is also unsubstituted at the indole nitrogen.  
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From a drug-delivery perspective, we believe there is potential in the further development of similar compounds 
containing protecting groups which are readily metabolizable. This concluded the evaluation of the precursor 
compounds, with discussion of the final compounds inhibitory performance to follow.  
6.5.2 Evaluation of Final Compounds 
Final compounds bearing electrophiles targeting the catalytic Lys745 residue were screened both biochemically and 
in a cellular setting, the results of which may be found in Table 6.2. Foremost inspection of the IC50 values associated 
with the indole acrylamide-substituted 41 showed a general loss in activity when compared with model compound 
27. These unimpressive values were reflected in the cellular data, with high micromolar EC50 values indicating 
intolerance and a lack of favourable interactions generated by acryloyl derivatisation at this position.  
Proceeding to the nitrile derivatives 53 and 56, we witnessed improved inhibition values and several noteworthy 
trends. Comparative analysis of the biochemical data between these two compounds revealed a superior activity 
profile for 56, with enhanced activity over 27 against both the activating and double mutant. Furthermore, this 
compound displayed a favourable wild-type selectivity margin, exhibiting 8- and 10-fold selectivity for the L858R 
and L858R/T790M mutant variants respectively. We believe this enhanced activity could stem from the nitrile chain, 
with compound 56 being lengthened by an extra carbon and potentially allowing for reversible interactions of the 
terminal nitrile with the catalytic Lys795 or polar residues at the roof of the kinase.  
Cellular assessment of compound 53 presented EC50 values that were nearly identical to 27, barring a slight 
improvement against the PC9/T790M/C797S mutant. Interestingly, compound 56 retained its positive selectivity 
profile and displayed the greatest inhibition of the triple mutant. This warranted an examination of the BaF3 cell 
lines, where compound 56 excelled over its shorter chain counterpart with an over 2-fold improved activity of 5.70 
µM. Although this value is inferior to that of osimertinib, we still maintain that use of the long chain nitrile 
functionality of compound 56 bears potential in the development of future drug candidates.  
This brought us to the final compound of the series, the sulfonyl fluoride containing 63. To our disappointment, 
compound 63 was found to be completely inactive in the cellular assays, reaching the EC50 value limit of 30.0 µM. 
Consequently, our collaborators who undertook the screening chose not to submit this compound for biochemical 
evaluation. It is our belief that this inhibitor either did not survive the journey from South Africa to Germany, which 
could have potentially occurred through compound degradation or hydrolysis or the inhibitor was being hydrolysed 
to the corresponding sulfonic acid within the cells during their assessment. As such, we still intend to resynthesise 
and dispatch this compound to our associates, along with another derivative which will be discussed in the future 
work section. The hydrolytic stability of sulfonyl fluoride inhibitors is thoroughly discussed in Section 7.5 in the 
following chapter. 
Lastly, confirmation of the compounds binding properties and mode of inhibition was investigated using covalent 
mass spectrometry experiments. As evident from the poor biochemical and cellular data, the results indicated a 
reversible binding mode for all synthesised compounds, ruling out covalent bond formation with the targeted 
catalytic Lys745.  
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Table 6.2: Biochemical and cellular evaluation results for the synthesised final compounds. 
6.6 Conclusions  
Building upon the previous chapter, the primary focus of our research efforts was centred on further expanding the 
irreversible targeting of the EGFR catalytic lysine residue and the feasibility thereof. To undertake this, we envisaged 
use of an osimertinib derived driving group scaffold and incorporation of various electrophiles that were deemed 
more reactive than the previously used 1,4-dicarbonyls. Following an arduous synthetic investigation, which required 
numerous strategies and various protecting groups, we established an optimised route to both the propionamide 
and acrylamide containing driving groups 27 and 40 respectively. Both compounds were obtained in high overall 
yield, allowing for easy access in their potential in the future.  
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Furthermore, during development of the optimised synthetic pathway, we were able to isolate several interesting 
intermediates of which we submitted four for biochemical and cellular evaluation.  
For this initial study, we elected to make use of scaffold 27 exclusively. However, incorporation of the electrophile 
within the driving group was plagued by inertness. This was caused by the unexpectedly poor nucleophilicity of the 
indole nitrogen centre, making the overall synthesis of our final compounds extremely challenging. The consequently 
harsh reaction conditions required for derivatisation, such as strong base and higher temperatures, led to encounters 
and further compounding of other difficulties. These arose from the highly reactive nature of the electrophilic 
fragments and undesirable interactions from the scaffold solubilising group which will be elaborated on further in 
the following chapter. However, despite these complications, we were able to synthesise four final compounds 
containing Michael acceptor, nitrile and sulfonyl fluoride moieties. Moreover, improvements of methodology and 
new procedures to synthesise the unafforded compounds can be found in the future work section.   
Evaluation of the synthesised precursor compounds revealed unremarkable activity for the propionamide derived 
intermediates. However, the Michael acceptor-containing Boc-protected analogue 39 displayed incredible potency, 
with values superior osimertinib. This was hypothesised to occur via metabolic cleavage of the Boc-protecting to 
yield the documented potent inhibitor 40, which we also synthesised but did not submit for evaluation. While we 
speculate that this unintentional discovery could hold promise in the development of inhibitors containing readily 
metabolizable protecting groups, it is out of the scope of this project and will therefore be disregarded.    
Unfortunately, the synthesised final compounds were not able to covalently modify the catalytic Lys795 residue, as 
indicated by covalent mass spectrometry experiments. However, the best performing nitrile-bearing compound 56 
did show improved activity over the model compound 27 biochemically, and against the clinically relevant triple 
mutant in a cellular context, warranting its further investigation in targeting EGFR Lys745. Being a rudimentary study, 
we believe there is potential in pursuing targeted irreversible inhibition of this residue. However, the initial envisaged 
compounds must first be successfully synthesised and assessed both biochemically and in a cellular setting. This will 
give an indication on the viability of this strategy and whether the exploration and synthesis of additional lysine-
targeting electrophiles, on this and other scaffold systems, is justifiable. Should these compounds prove ineffective 
or unable to undergo covalent bond formation, we propose a model reactivity study of these electrophiles be 
undertaken. While unable to mimic biological conditions, this study would entail reaction of the warhead bearing 
final compounds with a nucleophilic amine such as p-nitroaniline. As mentioned in the previous chapter (Section 
5.2.2), this approach was successfully used by Kornienko and co-workers in their chemical feasibility study of 
polygodial.
38
 Subsequent examination of product formation, through either isolation or analysis conducted by mass 
spectrometry, would provide valuable information regarding the reactivity of these lysine-targeting electrophiles and 
their potential for covalent bond formation.  
The work undertaken in this chapter was carried out concurrently with that of the following chapter and was 
accomplished at the end of our entire research campaign. As such, time constraints played a large role in our decision 
making. With the uncovering of the synthetic complications encountered throughout this chapter, we decided to 
commit more time and effort towards the research endeavours of the next chapter.  
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The successes of the following chapter, which build upon targeting unconventional residues using novel 
electrophiles, were made largely possible by the synthetic achievements of this chapter. After discussion of the future 
efforts to be undertaken for this body of research, we will delve directly into examination of the ensuing chapter.  
6.7 Future Work 
In light of the difficulties faced during the synthesis of our final compounds in this chapter, we have compiled various 
improvements to the synthetic procedures employed to potentially furnish these unsynthesised inhibitors. These 
refinements may be found in Scheme 6.14. To gain access to the ethenesulfonamide-containing compound 48, we 
ordered the commercially available chloro-variant electrophile 77, as shown in Scheme 6.14a. As alluded to in 
Section 6.4.1.2, with the passing of new legislation at the end of 2017, purchasing and shipping of reactive and 
flammable reagents to South Africa has skyrocketed the costs involved and lengthened transportation time to periods 
exceeding six-months. For this reason, we were unable to originally synthesise 48, as we were waiting for delivery 
of this reagent and hesitated to partake in the hazardous synthesis of this building block.  
With this electrophile in hand, we plan to sulfonate the indole nitrogen of scaffold 27 via deprotonation with sodium 
hydride at very low temperatures. It is our hope that substitution of the bromo- for a chloro-leaving group will 
diminish the reactivity of the system enough to prevent spontaneous elimination which is believed to have occurred 
in our attempted synthesis. Following isolation of intermediate 78, which could also be considered for evaluation in 
targeting the Lys745, we would promote elimination through treatment with excess triethylamine. Use of this 
procedure is well-documented in the literature and could conceivably afford the sought-after inhibitor 48. 
Scheme 6.14: Proposed synthetic alteration to potentially afford a) ethenesulfonamide 48 and b) propyl and butyl bridged 
sulfonyl fluorides 66 and 69 respectively. Reagents and conditions: i) NaH (1.05 equiv.), DMF, −40 °C – rt, 30 min then 77 
(1.2 equiv.), DMF, −40 °C – − 20 °C, 2 h; ii) Et3N (2 equiv.), DCM, −10 °C – rt, 2 h; iii) NaH (1.05 equiv.), DMF, −40 °C – rt, 
30 min then 64 or 67 (1.5 equiv.), DMF, −10 °C – rt, 2 h; iv) DAST (1.05 equiv.), DCM, −78 °C, 1h. 
  
Stellenbosch University https://scholar.sun.ac.za
Chapter 6 – Osimertinib-derived Inhibitors Targeting the EGFR Catalytic Lysine Residue Lys745 
 
212 
 
As encountered in Section 6.4.2.3, all efforts to synthesise and isolate the propyl and butyl bridged sulfonyl fluorides, 
66 and 69 respectively in Scheme 6.14b, were met with failure. This was mainly ascribed to impracticalities 
surrounding purification of the water-soluble intermediates 65 and 68. Consulting with colleagues at the 
biochemistry department at Stellenbosch University, we were pointed towards the use of Amberlyst 15 resin.  
This resin acts as a sulfonic ion-exchange acid resin and may serve as a plausible option for purification of these 
sulfonate derived compounds. Furthermore, should this method prove unsuccessful, we intend to utilise reverse-
phase column chromatography (C18 bonded silica gel) as an alternate plan. Therefore, application of the original 
reaction conditions that were suspected to have worked will afford the crude sulfonate reaction mixture. 
Implementation of either of the above discussed methods of purification could then furnish pure samples of 65 and 
68. These compounds will then be exposed to the fluorinating reagent DAST at low temperatures, potentially 
affording the desired final compounds 66 and 69. We believe that synthesis of these particular compounds are 
imperative for the success of this research venture, as the only known covalent modification of the EGFR catalytic 
lysine was accomplished through a sulfonyl fluoride warhead.
1
  
Another priority is the resynthesis and submission for screening of final compound 63, suspected to have 
degraded/hydrolysed en route to our collaborators in Germany. The synthesis of 63 will be carried out according to 
the parameters shown in Scheme 6.15a, where after it will be carefully stored and delivered by express courier. 
Additionally, we propose synthesis of the unsaturated sulfonyl fluoride compound 79, another electrophile capable 
of potentially undergoing covalent bond formation with the catalytic Lys745 residue. In the following chapter, use 
of excess manganese dioxide to facilitate oxidation of the activated ethylene bridge to the alkene was successfully 
carried out on a structurally related analogue.  
 
Scheme 6.15: a) Resynthesis of the presumed degraded final compound 63 and proposed synthesis of unsaturated sulfonyl 
fluoride compound 79 and b) Michael acceptor containing final compounds targeting the EGFR-L858R/T790M double mutant. 
Reagents and conditions: i) ESF (1.3 equiv.), K2CO3 (1.5 equiv.), DMF, 0 °C – rt, 6 h; ii) MnO2 (15 equiv.), CHCl3, rt, 8 h. 
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This generated a “dual warhead” or compound containing two electrophilic centres, which forms a major part of 
our therapeutic targeting strategy and will be comprehensively discussed as Section 7.4.3.2 in the next chapter. 
Therefore, we wish to reproduce this synthetic approach to potentially yield the dual warhead incorporated inhibitor 
79 for irreversible targeting of the catalytic lysine residue. 
Following the effective synthesis of all originally planned inhibitors derived from the propionamide driving group 27, 
we seek to replicate the synthetic methodology utilising the Michael acceptor-containing heterocyclic scaffold 40. 
Illustrated in Scheme 6.15b, this will furnish a similar group of final compounds (80) with the enhanced ability of 
targeting the Cys797 residue covalently. These compounds can then be evaluated explicitly against the double 
L858R/T790M mutant variant, potentially improving on the inhibitory properties of osimertinib through 
supplementary interactions at the roof of the enzyme. Furthermore, covalent bond formation will provide enhanced 
cellular binding and longer residence, increasing the likelihood of our incorporated lysine-targeting electrophiles to 
covalently modify Lys745. Regardless of the outcome, evaluation of these inhibitors will provide valuable information 
toward the development of this research endeavour.  
Though not visually represented, we chose to abandon any further pursuit in the synthesis of α- and β-haloketone 
containing compounds. This decision is based on the complications surrounding their production, both in this 
chapter and in the following, which is mainly ascribed to their highly reactive nature.  In a recent study, these 
functional groups were shown to be exceedingly promiscuous, leading to off-target protein modification.
39
 Therefore, 
we are not in a position to endorse and have not included any synthesis of these electrophiles in our future 
considerations.   
Lastly, we looked towards expansion of this research thrust to two other heterocyclic driving scaffolds. The first of 
these, displayed in Figure 6.10 on the following page, draws inspiration from the dual ALK/EGFR inhibitor 11. As 
outlined in Section 6.2.2, molecular modelling of compound 11 revealed the isopropylsulfone moiety to be in a 
proximal location to the catalytic Lys745 residue, resulting in reversible interactions with the hydrogen bond-
accepting carbonyl groups. This compound bears a striking resemblance to the osimertinib scaffold, with the 
exception of a substituted phenyl ring in place of the indole group and a chloro-substituent on the 5-position of the 
pyrimidine heterocycle. This similarity will allow for easy synthetic access to the envisaged group of final compounds 
(81), containing the various electrophiles (R1, blue) capable of labelling the catalytic lysine residue.  
In lieu of the electrophiles being attached to a more nucleophilic aniline fragment rather than the unreactive indole 
nitrogen, the final installation step should be far less complicated. Furthermore, this would facilitate inclusion of the 
cyanoacetamide moiety and allow for use of a sulfonyl fluoride directly attached to the phenyl ring. Once again, we 
would synthesise the propionamide and Michael acceptor analogues (R
2
, red), with the option of substituting the 
troublesome osimertinib solubilising group with the widely used alternative N-methylpiperazine moiety (R3, green). 
The combination of these features makes this scaffold a prime candidate for developing a library of lysine-targeting 
compounds. 
 
Stellenbosch University https://scholar.sun.ac.za
Chapter 6 – Osimertinib-derived Inhibitors Targeting the EGFR Catalytic Lysine Residue Lys745 
 
214 
 
 Figure 6.10: Proposed library of lysine-targeting compounds inspired by the dual ALK/EGFR inhibitor 11. 
The final consideration and second driving group that could be employed will be based on the gefitinib core utilised 
in Chapter 4. As summarised in Section 5.7, the synthesis of heterocyclic scaffold 82 (Figure 6.11), which contains 
the gefitinib solubilising group, will accommodate derivatisation at the 4-amino position of the quinazoline ring. This 
will allow for either direct substitution of electrophiles (R1, blue) on the amino quinazoline (83) or incorporation at 
the 3- or 4-position (R2, blue) of an installed aniline ring (84). Synthesis of these compounds, with warheads installed 
at various positions, will allocate a wide range of exploitable chemical space for the electrophiles, thereby increasing 
the probability for covalent modification of the EGFR catalytic lysine residue. This strategy can be used in conjunction 
with the incorporation of 1,4-dicarbonyl electrophiles laid out in Chapter 5.  
Figure 6.11: Proposed library of lysine-targeting compounds building on the gefitinib scaffold 82. 
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6.8 Supplementary Information 
3-(2-Chloropyrimidin-4-yl)-1H-indole (14)
24
 
A 1 M solution of ethylmagnesium bromide was prepared as follows: A flame-dried, 2-neck 
round-bottomed flask was charged with oven-dried magnesium turnings (1.54 g, 64.0 mmol, 2 
equiv.) and purged with Ar. To this was added THF (48 mL), followed by the dropwise addition 
of previously distilled bromoethane (5.23 g, 48.0 mmol, 1.5 equiv.) which resulted in an 
exotherm. The solution was then allowed to stir for 45 min, during which time the solution cooled 
and developed a grey colour. A separate 2-neck round-bottom flask was charged with indole (5.62 g, 48.0 mmol, 
1.5 equiv.) and purged with Ar. To this was added THF (50 mL) and the solution was cooled to −10 °C (acetone/ice). 
The prepared 1 M ethylmagnesium bromide solution (48.0 mL, 48.0 mmol, 1.5 equiv.) was then added dropwise 
to this solution over 20 minutes, being careful to keep the temperature below 0 °C. The solution was then allowed 
to warm to rt over 90 minutes, resulting in the formation of a white precipitate. The suspension was then recooled 
to −10 °C and 2,4-dichloropyrimidine (4.78 g, 32.0 mmol, 1 equiv.) was added as a single portion with no exotherm. 
The reaction mixture was placed at 80 °C and allowed to stir for 5 h, undergoing a colour change from orange to 
deep red. After allowing to cool to rt, the reaction was quenched by the slow addition of MeOH (2.00 mL, 
48.0 mmol, 1.5 equiv.) resulting in an exotherm. After removal of the solvent in vacuo, the crude product was 
adsorbed onto silica and purification was achieved using flash column chromatography with elution gradient of 
0 – 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 14 as a white-yellow powder 
(4.48 g, 19.5 mmol, 61%).  
1
H NMR and MS data collected for this compound compared well with the reported literature values.
24
 
Rf: 0.51 (1 % MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 7.25 – 7.21 (m, 2H, 2 × ArH), 7.53 – 7.49 (m, 
1H, ArH), 7.90 (d, J = 5.5 Hz, 1H, ArH), 8.40 – 8.44 (m, 1H, ArH), 8.50 (s, 1H, ArH), 8.52 (d, J = 5.5 Hz, 1H, ArH), 
12.08 (br s, 1H, ArNH) ppm;
 13
C NMR (75 MHz, DMSO-d6) δ 111.9, 112.36, 114.5, 121.4, 121.6, 122.7, 124.9, 
131.1, 137.3, 158.5, 160.3, 165.0 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C12H9N3Cl: 230.0485; 
found: 230.0480. 
4-Fluoro-2-methoxy-1-nitrobenzene (19)
24
 
A 2-neck round-bottomed flask was charged with 5-fluoro-2-nitrophenol (8.00 g, 50.9 mmol, 
1 equiv.) and potassium carbonate (8.45 g, 61.1 mmol, 1.2 equiv.) and purged with Ar. To this 
was added acetone (150 mL) and the resulting suspension was allowed to stir for 30 min at rt. 
The suspension was cooled to 0 °C and methyl iodide (3.49 mL, 56.0 mmol, 1.1 equiv.) was 
added dropwise. The reaction mixture was placed at 60 °C and allowed to stir for 12 h, during which time a deep 
red colour developed. After allowing to cool to rt, the solvent was removed in vacuo and the reaction mixture was 
diluted with EtOAc (50 mL) and H2O (100 mL) and the organic layer was separated. The aqueous layer was extracted 
with aliquots of EtOAc (3 × 50 mL) and the combined organic layers were washed with a 1 M solution of NaOH 
(2 × 50 mL), a saturated solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, compound 19 was afforded as a beige solid (8.54 g, 49.9 mmol, 98%) with no further purification required.  
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1
H NMR data collected for this compound compared well with the reported literature value.
24
  
Rf: 0.66 (30 % EtOAc in PE); 
1
H NMR (600 MHz, CDCl3) δ 3.96 (s, 3H, ArOCH3), 6.74 – 6.70 (m, 1H, ArH), 6.79 
(dd, J = 10.8, 2.7 Hz, 1H, ArH), 7.95 (dd, J = 8.6, 6.1 Hz, 1H, ArH) ppm; 
13
C NMR (151 MHz, CDCl3) δ 57.0, 
101.5 (d, J = 27.1 Hz), 107.4 (d, J = 23.5 Hz), 128.3 (d, J = 11.5 Hz), 155.5 (d, J = 11.4 Hz), 165.1, 166.8 ppm; 
no ionization was found in MS as reported in the literature.  
4-Fluoro-2-methoxyaniline (20)  
A 3-neck round-bottom flask was charged with 4-fluoro-2-methoxy-1-nitrobenzene (6.00 g, 
35.1 mmol, 1 equiv.) and Pd/C (375 mg, 3.51 mmol, 10 mol%), placed under vacuum and EtOH 
(35 mL) was added. A hydrogen atmosphere was introduced via balloon and the suspension was 
then allowed to stir at rt for 24 h or until complete consumption of starting material as indicated 
by TLC. The reaction mixture was filtered through a plug of celite, washed with EtOH (35 mL) and the solvent was 
removed in vacuo. Purification of the crude product was achieved using flash column chromatography with elution 
gradient of 10 – 30% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 20 as a brown oil 
(4.55 g, 32.3 mmol, 92%).  
Rf: 0.52 (30 % EtOAc in PE); 
1
H NMR (300 MHz, DMSO-d6) δ 3.76 (s, 3H, ArOCH3) , 4.53 (br s, 2H, ArNH2), 6.49 
(tdd, J = 8.6, 2.7, 1.3 Hz, 1H, ArH), 6.59 (ddd, J = 8.6, 6.1, 1.3 Hz, 1H, ArH), 6.71 (dt, J = 10.8, 1.3 Hz, 1H, ArH) 
ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 55.6, 99.1 (d, J = 26.7 Hz), 105.9 (d, J = 21.4 Hz), 113.2 (d, J = 9.1 Hz) , 
133.9 (d, J = 2.2 Hz), 146.8 (d, J = 9.7 Hz), 152.9; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C7H9NOF: 
142.0668; found: 142.0668. 
4-Fluoro-2-methoxy-5-nitroaniline (21) 
To a solution of 85% aqueous H2SO4 (v/v 35.0 mL, 531 mmol, 25 equiv.), cooled to −10 °C 
(acetone/ice), was added 4-fluoro-2-methoxyaniline (3.00 g, 21.3 mmol, 1 equiv.) dropwise over 
10 min. The solution was then allowed to stir at −10 °C for 30 min followed by portion wise 
addition of KNO3 (2.15 g, 21.3 mmol, 1 equiv.) over 15 min. The reaction mixture was then 
allowed to stir at 0 °C for 4 h and poured onto a mixture of ice/water (70 mL). The slurry was 
carefully neutralized with concentrated NH4OH and the resulting precipitate was collected by filtration, washed with 
water (3 × 20 mL), PE (2 × 20 mL) and dried in vacuo. Purification of the crude product was achieved using flash 
column chromatography with elution gradient of 30 – 90% DCM in PE. Pure fractions were evaporated to dryness 
to afford compound 21 as an orange powder (3.48 g, 18.7 mmol, 88%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
25
 
Rf: 0.22 (20 % DCM in PE); 
1
H NMR (300 MHz, DMSO-d6) δ  3.90 (s, 3H, ArOCH3), 5.22 (br s, 2H, ArNH2), 7.02 
(d, J = 13.4 Hz, 1H, ArH), 7.34 (d, J = 8.0 Hz, 1H, ArH) ppm; 
13
C NMR (75 MHz, dmso) δ 56.7, 100.4 (d, J = 26.5 
Hz), 106.9 (d, J = 2.2 Hz), 134.8 (d, J = 1.8 Hz), 146.6, 150.0, 152.1 (d, J = 9.0 Hz) ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C
7
H
8
N
2
O
3
F: 187.0519; found: 187.0524. 
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tert-Butyl (4-fluoro-2-methoxy-5-nitrophenyl)carbamate (22)
40
 
A 2-neck round-bottom flask was charged with 4-fluoro-2-methoxy-5-nitroaniline (3.00 g, 
16.1 mmol, 1 equiv.), purged with Ar, dissolved in DCM (35 mL) and cooled to 0 °C. A 
solution of Boc2O (3.69 g, 16.9 mmol, 1.05 equiv.) in DCM (16 mL) was added dropwise, 
followed by the addition of a catalytic amount of DMAP. The reaction mixture was then 
allowed to warm to rt and stirred for 24 h or until complete consumption of the starting 
material as indicated by TLC. After removal of the solvent in vacuo, purification of the crude product was achieved 
using flash column chromatography with elution gradient of 30 – 80% DCM in PE. Pure fractions were evaporated 
to dryness to afford compound 22 as a white-yellow solid (3.78 g, 13.2 mmol, 82%).  
Mp, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
40
 
Rf: 0.61 (50 % DCM in PE); mp: 88 – 90 °C; 1H NMR (300 MHz, DMSO-d6) δ 1.47 (s, 9H, OC(CH3)3), 3.94 (s, 3H, 
ArOCH3), 7.27 (d, J = 13.3 Hz, 1H, ArH), 8.50 (s, 1H, ArNHBoc), 8.52 (d, J = 8.0 Hz, 1H, ArH) ppm; 
13
C NMR (75 
MHz, DMSO-d6) δ 27.9, 57.2, 80.0, 101.3 (d, J = 26.2 Hz), 116.6, 124.4 (d, J = 2.7 Hz), 128.5 (d, J = 6.6 Hz), 
150.8, 152.7, 154.2, 155.6 (d, J = 10.2 Hz) ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C12H14N2O5F: 
285.0887; found: 285.0891.  
tert-Butyl (4-fluoro-2-methoxy-5-nitrophenyl)carbamate (23)
40
 
A 2-neck round-bottom flask was charged with tert-butyl (4-fluoro-2-methoxy-5-
nitrophenyl)carbamate (3.38 g, 11.8 mmol, 1 equiv.), purged with Ar and dissolved 
in DMA (30 mL). To this solution was added DIPEA (2.16 mL, 12.4 mmol, 
1.05 equiv.), followed by the slow addition of a solution of N
1
,N
1
,N
2
-trimethylethane-
1,2-diamine (1.51 g, 14.8 mmol, 1.25 equiv.) in DMA (5 mL) at rt. The reaction was 
placed at 60 °C and allowed to stir for 4 h, during which time the reaction mixture developed a deep red colour. 
After allowing to cool to rt, the reaction mixture was then diluted with H2O (70 mL) and EtOAc (70 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 30 mL) and the combined 
organic layers were then washed with successive aliquots of a saturated solution of brine (3 × 30 mL), dried over 
MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using flash 
column chromatography with elution gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 23 as an orange powder (4.31 g, 11.7 mmol, 99%). 
Mp, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
40
 
Rf: 0.43 (10 % MeOH in DCM); mp: 92 – 94 °C; 1H NMR (300 MHz, DMSO-d6) δ 1.45 (s, 9H, OC(CH3)3), 2.16 (s, 
6H, CH2N(CH3)2), 2.47 (t, J = 6.8 Hz, 2H, NCH2CH2N), 2.80 (s, 3H, ArNCH3), 3.23 (t, J = 6.8 Hz, 2H, NCH2CH2N), 
3.90 (s, 3H, ArOCH3), 6.74 (s, 1H, ArH), 8.14 (br s, 2H, ArH and ArNHBoc) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 
28.0, 40.4, 45.3, 52.5, 56.2, 79.4, 101.9, 119.1, 119.6, 131.7, 144.3, 153.0, 154.7 ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C17H29N4O5: 369.2138; found: 369.2143. 
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tert-Butyl (5-amino-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxyphenyl)carbamate (24)  
A 3-neck round-bottom flask was charged with tert-butyl (4-fluoro-2-methoxy-5-
nitrophenyl)carbamate (4.20 g, 11.4 mmol, 1 equiv.) and Pd/C (121 mg, 1.14 mmol, 
10 mol%), placed under vacuum and MeOH (50 mL) was added. A hydrogen 
atmosphere was introduced via balloon and the suspension was then allowed to stir 
at rt for 12 h or until complete consumption of starting material as indicated by TLC. The reaction mixture was 
filtered through a plug of celite, washed with MeOH (35 mL) and the solvent was removed in vacuo. Purification of 
the crude product was achieved using flash column chromatography with elution gradient of 10 – 30% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 24 as a brown oil (3.51 g, 10.4 mmol, 91%). 
Rf: 0.19 (10 % MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 1.44 (s, 9H, OC(CH3)3), 2.51 (s, 3H, ArNCH3), 
2.60 (s, 6H, CH2N(CH3)2), 3.14 – 2.97 (m, 4H, 2 × NCH2CH2N), 3.69 (s, 3H, ArOCH3), 6.69 (s, 1H, ArH), 7.09 (s, 
1H, ArH), 7.57 (s, 1H, ArNHBoc) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 28.1, 41.4, 42.7, 50.4, 54.2, 56.5, 78.8, 
105.8, 108.0, 124.25, 133.0, 137.2, 141.1, 152.7 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C17H31N4O3: 339.2396; found: 339.2401. 
tert-Butyl (4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-propionamidophenyl)carbamate (25) 
A 2-neck round-bottom flask was charged with tert-butyl (5-amino-4-{[2-
(dimethylamino)ethyl](methyl)amino}-2-methoxyphenyl)carbamate (1.35 g, 3.99 
mmol, 1 equiv.), purged with Ar and dissolved in DCM (30 mL). The solution was 
cooled to −10 °C (acetone/ice) and DIPEA (0.760 mL, 4.39 mmol, 1.1 equiv.) was 
added. A solution of propionyl chloride (387 mg, 4.19 mmol, 1.05 equiv.) in DCM 
(5 mL) was then added dropwise to the solution over 10 min. The reaction mixture 
was then allowed to warm to rt and stirred for 2 h. The reaction mixture was then quenched and diluted with H2O 
(30 mL), a saturated solution of NaHCO3 (30 mL) and DCM (50 mL) and the organic layer was separated. The 
aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed 
with a saturated solution of brine (50 mL), dried over MgSO
4
 and filtered. After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 5 – 10% 
MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 25 as a brown foam (1.43 g, 
3.63 mmol, 89%). 
Rf: 0.37 (10 % MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ 1.24 – 1.12 (m, 3H, COCH2CH3), 1.47 (s, 9H, 
OC(CH3)3), 2.25 (s, 6H, CH2N(CH3)2), 2.38 – 2.27 (m, 4H, NCH2CH2N and COCH2CH3), 2.61 (s, 3H, ArNCH3), 
2.84 (br s, 2H, NCH2CH2N), 3.77 (s, 3H, ArOCH3), 6.65 (s, 1H, ArH), 6.86 (s, 1H, ArH), 8.92 (s, 1H, ArNHBoc), 
9.63 (s, 1H, ArNHCO) ppm; 
13
C NMR (75 MHz, CDCl3) δ 10.0, 28.4, 30.5, 43.8, 45.2, 55.8, 56.0, 57.1, 80.3, 
104.4, 111.5, 125.3, 129.6, 136.0, 144.1, 152.6, 171.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C
20
H
35
N
4
O
4
: 395.2658; found: 395.2665. 
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N-(5-Amino-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxyphenyl)propionamide (26) 
A 2-neck round-bottom flask was charged with tert-butyl (4-{[2-
(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-propionamidophenyl)carbamate 
(1.22 g, 3.09 mmol, 1 equiv.), purged with Ar and dissolved in DCM (15 mL). The 
solution was cooled to 0 °C and trifluoroacetic acid (3 mL) was added dropwise to the 
solution. The reaction mixture was then allowed to warm to rt and stirred for 6 h or until 
complete consumption of the starting material as indicated by TLC. After removal of the 
solvent in vacuo, the residue was diluted with DCM (50 mL) and a 1 M solution of NaOH (50 mL) and the organic 
layer was separated. The organic layer was then washed with a saturated solution of NaHCO3 (30 mL), a saturated 
solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 5 – 15% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 26 as a brown oil (782 mg, 2.66 mmol, 86%). 
Rf: 0.25 (10 % MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ 1.18 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.20 – 2.15 
(m, 8H, CH2N(CH3)2 and NCH2CH2N), 2.30 (q, J = 7.6 Hz, 2H, COCH2CH3), 2.58 (s, 3H, ArNCH3), 2.79 (t, J = 6.0 
Hz, 2H, NCH2CH2N), 3.71 (br s, 2H, ArNH2), 3.74 (s, 3H, ArOCH3), 6.61 (s, 1H, ArH), 7.81 (s, 1H, ArH), 9.67 (s, 
1H, ArNHCO) ppm; 
13
C NMR (75 MHz, CDCl3) δ 10.0, 30.6, 44.2, 45.4, 55.8, 56.3, 57.3, 105.1, 106.8, 130.1, 
131.8, 133.8, 143.2, 171.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C15H27N4O2: 295.2134; found: 
295.2140. 
N-(5-{[4-(1H-Indol-3-yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (27) 
A 2-neck round-bottomed flask was charged with 3-(2-chloropyrimidin-4-
yl)-1H-indole (96.0 mg, 0.42 mmol, 1 equiv.) and N-(5-amino-2-{[2-
(dimethylamino)ethyl](methyl)amino}-4-methoxyphenyl)propionamide (123 
mg, 0.418 mmol, 1 equiv.) and purged with Ar. To this was added 2-
pentanol (10 mL) and the resulting suspension was placed at 105 °C. p-
Toluenesulfonic acid monohydrate (96.0 mg, 0.505 mmol, 1.2 equiv.) was 
added as a single portion and the reaction mixture was then allowed to stir for 4 h or until complete consumption 
of the starting material as indicated by TLC. The reaction mixture was then allowed to cool and stand for 8 h 
which resulted in the formation of a brown precipitate. The precipitate was collected by filtration, washed with 
aliquots of acetonitrile (3 × 30 mL) and dried in vacuo. The solid was dissolved in 10% MeOH in DCM and 
washed with a saturated solution of NaHCO3 (3 × 30 mL), a saturated solution of brine (30 mL), dried over 
MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using 
flash column chromatography with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated to 
dryness to afford compound 27 as a beige solid (126 mg, 0.258 mmol, 61%). 
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Rf: 0.21 (10 % MeOH in DCM); IR (ATR) cm
-1
: 3412 (m, N-H stretch), 3171 (m, N-H stretch), 2953 (m, C-H stretch), 
2819 (m, C-H stretch), 1656 (s, C=O stretch), 1577 (m, N-H bend), 1447 (m, C-H bend), 1400 (m, C-H bend), 
1340 (s, C-N stretch), 1056 (s, C-O stretch), 741 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ  1.30 (t, J = 7.6 Hz, 
3H, COCH2CH3), 2.31 – 2.21 (m, 8H, CH2N(CH3)2 and NCH2CH2N), 2.45 (q, J = 7.6 Hz, 2H, COCH2CH3), 2.67 (s, 
3H, ArNCH3), 2.88 (t, J = 5.8 Hz, 2H, NCH2CH2N), 3.85 (s, 3H, ArOCH3), 6.76 (s, 1H, ArH), 6.96 (d, J = 5.3 Hz, 
1H, ArH), 7.18 – 7.10 (m, 2H, 2 × ArH), 7.32 (d, J = 7.2 Hz, 1H, ArH), 7.65 (s, 1H, ArH), 8.22 – 8.15 (m, 2H, 2 × 
ArH), 8.37 (s, 1H, ArH), 9.64 (s, 1H, ArNH), 9.97 (s, 1H, ArNH), 10.38 (s, 1H, ArNH) ppm; 13C NMR (75 MHz, 
CDCl3) δ 10.3, 30.8, 44.1, 45.3, 56.0, 56.1, 57.3, 104.7, 108.2, 111.0, 112.1, 114.7, 120.8, 120.8, 122.0, 125.4, 
127.5, 129.4, 129.7, 134.9, 137.5, 144.6, 157.3, 159.8, 162.8, 172.3 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 
calculated for C27H34N7O2: 488.2774; found: 488.2783. 
tert-Butyl 3-(2-chloropyrimidin-4-yl)-1H-indole-1-carboxylate (28) 
A 2-neck round-bottom flask was charged with 3-(2-chloropyrimidin-4-yl)-1H-indole (500 mg, 
2.18 mmol, 1 equiv.), purged with Ar, dissolved in DCM (20 mL) and Et3N (0.390 mL, 2.83 mmol, 
1.3 equiv.) was added. After cooling to 0 °C, a solution of Boc2O (570 mg, 2.61 mmol, 1.2 equiv.) 
in DCM (10 mL) was added dropwise, followed by the addition of a catalytic amount of DMAP. 
The reaction mixture was then allowed to warm to rt and stirred for 12 h or until complete 
consumption of the starting material as indicated by TLC. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 50 – 90% DCM in PE. Pure 
fractions were evaporated to dryness to afford compound 28 as a yellow solid (639 mg, 1.94 mmol, 89%).  
Rf: 0.69 (DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 1.67 (s, 9H, OC(CH3)3), 7.45 – 7.34 (m, 2H, 2 × ArH), 8.11 (dd, 
J = 7.0, 2.0 Hz, 1H, ArH), 8.14 (d, J = 5.4 Hz, 1H, ArH), 8.47 (dd, J = 7.0, 2.0 Hz, 1H, ArH), 8.68 (dd [app. t], J 
= 2.7 Hz, 2H, 2 × ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 27.6, 85.2, 114.9, 116.2, 116.3, 122.2, 123.8, 
125.3, 126.7, 130.0, 135.4, 148.5, 159.6, 160.1, 163.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C17H17N3O2Cl: 330.1009; found: 330.0999. 
3-(2-Chloropyrimidin-4-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indole (30) 
A flame-dried, 2-neck round-bottomed flask was charged with sodium hydride (60% dispersion 
in mineral oil, 465 mg, 11.6 mmol, 1.16 equiv.), purged with Ar and to this was added DMF 
(30 mL). The resulting suspension was cooled to −10 °C (acetone/ice) and a solution of 3-(2-
chloropyrimidin-4-yl)-1H-indole (2.30 g, 10.0 mmol, 1 equiv.) in DMF (10 mL) was added 
dropwise over 15 min. The solution was then allowed to warm to rt and stirred for 30 min. After 
recooling the solution to −10 °C (acetone/ice), a solution of SEM-Cl (2.05 g, 12.3 mmol, 1.23 equiv.) in DMF (10 
mL) was added dropwise over 10 min. The reaction mixture was then allowed to warm to rt and stirred for 4 h or 
until complete consumption of the starting material as indicated by TLC, changing from yellow to colourless during 
this period. The reaction mixture was then quenched and diluted with H
2
O (50 mL) and EtOAc (30 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 30 mL) and the combined 
organic layers were then washed with a saturated solution of brine (3 × 50 mL), dried over MgSO4 and filtered.  
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After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of DCM to 2% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 30 as an off white solid (2.74 g, 7.61 mmol, 76%). 
Rf: 0.43 (DCM); 
1
H NMR (300 MHz, CDCl3) δ −0.06 (s, 9H, CH2Si(CH3)3), 0.90 (t, J = 8.0 Hz, 2H, CH2CH2Si), 
3.51 (t, J = 8.0 Hz, 2H, OCH2CH2),  5.51 (s, 2H, NCH2O), 7.37 – 7.31 (m, 2H, ArH) , 7.49 (d, J = 5.4 Hz, 1H, 
ArH), 7.55 (dd, J = 6.4, 2.7 Hz, 1H, ArH), 8.00 (s, 1H, ArH), 8.33 (dd, J = 6.4, 2.7 Hz, 1H, ArH), 8.45 (d, J = 5.4 
Hz, 1H, ArH) ppm; 
13
C NMR (75 MHz, CDCl3) δ −1.3, 17.8, 66.6, 76.4, 111.0, 113.6, 114.4, 121.6, 122.6, 123.7, 
126.1, 131.6, 137.6, 158.6, 161.5, 164.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C18H22N3OSiCl: 
360.1220; found: 360.1296. 
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-
indol-3-yl)pyrimidin-2-yl]amino}phenyl)propionamide (31) 
A 2-neck round-bottomed flask was charged with 3-(2-chloropyrimidin-4-yl)-
1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indole (230 mg, 0.640 mmol, 
1 equiv.) and N-(5-amino-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-
methoxyphenyl)propionamide (186 mg, 0.640 mmol, 1 equiv.) and purged 
with Ar. To this was added 2-pentanol (10 mL) and the resulting suspension 
was placed at 105 °C. p-Toluenesulfonic acid monohydrate (145 mg, 0.762 
mmol, 1.2 equiv.) was added as a single portion and the reaction mixture was then allowed to stir for 4 h or until 
complete consumption of the starting material as indicated by TLC. After allowing to cool to rt, the reaction mixture 
was diluted with DCM (30 mL), H
2
O (20 mL) and neutralised with a saturated solution of NaHCO
3
 (50 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 × 20 mL) and the combined 
organic layers were then washed with a saturated solution of brine (30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography 
with elution gradient of 5% – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 
31 as a tan foam (302 mg, 0.489 mmol, 77%). 
Rf: 0.6 10 % MeOH in DCM); IR (ATR) cm
-1
:  3419 (m, N-H stretch), 3118 (m, N-H stretch), 2947 (m, C-H stretch), 
2817 (m, C-H stretch), 1670 (s, C=O stretch), 1577 (m, N-H bend), 1454 (m, C-H bend), 1400 (m, C-H bend), 
1347 (s, C-N stretch), 1069 (s, C-O stretch), 737 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ -0.08 (s, 9H, 
CH2Si(CH3)3), 0.90 (t, J = 8.0 Hz, 2H, CH2CH2Si), 1.31 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.30 – 2.24 (m, 8H, 
CH2N(CH3)2 and NCH2CH2N), 2.45 (q, J = 7.6 Hz, 2H, COCH2CH3), 2.68 (s, 3H, ArNCH3), 2.90 (t, J = 5.8 Hz, 2H, 
NCH2CH2N), 3.59 (t, J = 8.0 Hz 2H, OCH2CH2), 3.87 (s, 3H, ArOCH3), 5.79 (s, 2H, NCH2O), 6.78 (s, 1H, ArH), 
7.23 (d, J = 5.3 Hz, 1H, ArH), 7.30 – 7.27 (m, 2H, 2 × ArH), 7.63 (dd, J = 6.3, 2.7 Hz, 1H, ArH), 7.75 (s, 1H, 
ArH), 8.08 (dd, J = 6.3, 2.7 Hz, 1H, ArH), 8.40 (d, J = 5.3 Hz, 1H, ArH), 9.20 (s, 1H, ArH),  9.73 (s, 1H, ArNH), 
9.75 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ -1.3, 10.3, 17.9, 30.9, 44.1, 45.6, 56.2, 57.5, 65.9, 76.5, 
104.7, 108.2, 109.5, 111.5, 114.6, 120.4, 121.6, 122.3, 126.7, 127.7, 129.9, 134.2, 134.4, 137.68, 143.9, 158.1, 
159.7, 162.1, 171.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C33H48N7O3Si: 618.3588; found: 
618.3601. 
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N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-5-({4-[1-(hydroxymethyl)-1H-indol-3-yl]pyrimidin-2-
yl}amino)-4-methoxyphenyl)propionamide (32) 
A 2-neck round-bottomed flask was charged with N-(2-{[2-
(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-{[2-
(trimethylsilyl)ethoxy]methyl}-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)propionamide (140 mg, 0.227 mmol, 1 equiv.), purged with 
Ar and dissolved in DCM (9 mL). This was followed by the dropwise addition 
of trifluoroacetic acid (3 mL) and the reaction mixture was then allowed to 
stir for 2 h or until complete consumption of the starting material as indicated 
by TLC. After removal of the solvent in vacuo, the reaction mixture was diluted with DCM (30 mL), H2O (20 mL) 
and neutralised with a saturated solution of NaHCO3 (50 mL) and the organic layer was separated. The aqueous 
layer was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a 
saturated solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification 
of the crude product was achieved using flash column chromatography with elution gradient of 5 – 12.5% MeOH 
in DCM. Pure fractions were evaporated to dryness to afford compound 32 as an off white solid (84.6 mg, 0.163 
mmol, 72%). 
Rf: 0.44 (10% MeOH in DCM); IR (ATR) cm
-1
: 3408 (m, N-H stretch), 3213 (s, O-H stretch), 3110 (m, N-H stretch), 
2935 (m, C-H stretch), 2817 (m, C-H stretch), 1672 (s, C=O stretch), 1565 (m, N-H bend), 1460 (m, C-H bend), 
1400 (m, C-H bend), 1342 (s, C-N stretch), 1036 (s, C-O stretch), 729 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ 
1.33 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.26 – 2.22 (m, 8H, CH2N(CH3)2 and NCH2CH2N), 2.45 (q, J = 7.6 Hz, 2H, 
COCH2CH3), 2.67 (s, 3H, ArNCH3), 2.90 (t, J = 5.8 Hz, 2H, NCH2CH2N), 3.87 (s, 3H, ArOCH3),  5.75 (s, 2H, 
NCH2O), 6.78 (s, 1H, ArH),  7.19 (d, J = 5.3 Hz, 1H, ArH), 7.30 – 7.25 (m, 2H, 2 × ArH), 7.56 (dd, J = 6.4, 2.2 
Hz, 1H, ArH), 7.78 (s, 1H, ArH), 7.98 (dd, J = 6.4, 2.2 Hz, 1H, ArH), 8.39 (d, J = 5.3 Hz, 1H, ArH), 9.25 (s, 1H, 
ArH), 9.61 (s, 1H, ArNH), 10.13 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 10.6, 31.3, 44.3, 45.3, 56.0, 
56.1, 57.3, 69.4, 104.7, 107.9, 109.6, 110.3, 115.2, 119.9, 121.2, 122.1, 125.9, 129.3,  127.9, 134.0, 134.5, 
137.2, 144.4, 158.3, 159.3, 161.6, 173.0 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C27H34N7O2: 
488.2774; found: 488.2783. 
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine (33)
24
 
A 2-neck round-bottomed flask was charged with 3-(2-chloropyrimidin-4-yl)-1H-
indole (1.97 g, 8.59 mmol, 1 equiv.) and 4-fluoro-2-methoxy-5-nitroaniline (1.60 g, 
8.59 mmol, 1 equiv.) and purged with Ar. To this was added 2-pentanol (90 mL) and 
the resulting suspension was placed at 105 °C. p-Toluenesulfonic acid monohydrate 
(1.96 g, 10.3 mmol, 1.2 equiv.) was added as a single portion and the reaction mixture 
was then allowed to stir for 4 h or until complete consumption of the starting material 
as indicated by TLC. The reaction mixture was then allowed to cool and stand for 8 h which resulted in the formation 
of a yellow precipitate.  
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The precipitate was collected by filtration, washed with aliquots of acetonitrile (3 × 30 mL) and dried in vacuo. The 
solid was dissolved in 10% MeOH in DCM and washed with a saturated solution of NaHCO3 (3 × 40 mL), a saturated 
solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, the solid was then 
triturated with acetonitrile and dried under vacuum to afford compound 33 as a mustard-yellow powder (2.90 g, 
7.65 mmol, 89%) with no further purification required. 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
24
 
Rf: 0.43 (2% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 4.01 (s, 3H, ArOCH3), 7.14 – 7.07 (m, 1H, ArH), 
7.23 – 7.16 (m, 1H, ArH), 7.32 (d, J = 13.4 Hz, 1H, ArH), 7.37 (d, J = 5.4 Hz, 1H, ArH), 7.47 (d, J = 8.0 Hz, 1H, 
ArH), 8.22 (s, 1H, ArNH), 8.41 – 8.33 (m, 3H, 3 × ArH), 9.13 (d, J = 8.5 Hz, 1H, ArH), 11.89 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 57.4, 101.1 (d, J = 26.3 Hz), 108.5, 112.1, 113.2, 116., 120.7, 121.7, 122.2, 
125.0, 125.9, 128.6 (d, J = 6.7 Hz), 129.4, 137.2, 155.3 (d, J = 10.0 Hz), 157.1, 159.4, 162.6 ppm; HRMS-TOF 
MS ESI+: m/z [M+H]
+
 calculated for C19H15N5O3F: 380.1159; found: 380.1148. 
N1-[4-(1H-indol-3-yl)pyrimidin-2-yl]-N4-[2-(dimethylamino)ethyl]-2-methoxy-N4-methyl-5-nitrobenzene-1,4-
diamine (34)
37
 
A 2-neck round-bottom flask was charged with N-(4-fluoro-2-methoxy-5-
nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine (3.20 g, 8.44 mmol, 
1 equiv.), purged with Ar and dissolved in DMA (50 mL). To this solution was 
added DIPEA (2.94 mL, 16.9 mmol, 2 equiv.), followed by the slow addition 
of a solution of N
1
,N
1
,N
2
-trimethylethane-1,2-diamine (1.08 g, 10.5 mmol, 
1.25 equiv.) in DMA (10 mL) at rt. The reaction was placed at 60 °C and 
allowed to stir for 4 h, during which time the reaction mixture developed a deep red colour. After allowing to cool 
to rt, reaction mixture was then diluted with H2O (70 mL) and EtOAc (70 mL) and the organic layer was separated. 
The aqueous layer was extracted with aliquots of EtOAc (3 × 30 mL) and the combined organic layers were then 
washed with successive aliquots of a saturated solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography 
with elution gradient of 2 – 15% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 34 
as an orange powder (2.74 g, 6.83 mmol, 81%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
37
 
Rf: 0.32 (10% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 2.17 (s, 6H, CH2N(CH3)2), 2.50 (t, J = 6.8 Hz, 
2H, NCH
2
CH
2
N), 2.85 (s, 3H, ArNCH
3
),  3.27 (t, J = 6.8 Hz, 2H, NCH
2
CH
2
N), 3.96 (s, 3H, ArOCH
3
), 6.85 (s, 1H, 
ArH), 7.08 (dd [app. t], J = 7.2 Hz, 1H, ArH), 7.18 (dd [app. t], J = 7.2 Hz, 1H, ArH), 7.29 (d, J = 5.4 Hz, 1H, ArH), 
7.46 (d, J = 8.0 Hz, 1H, ArH), 8.08 (s, 1H, ArH), 8.38 – 8.30 (m, 3H, 3 × ArH), 8.67 (s, 1H, ArNH), 11.87 (s, 1H, 
ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 40.6, 45.4, 52.8, 56.3, 56.4, 102.1, 107.6, 112.0, 113.4, 119.2, 
120.6, 121.4, 121.9, 122.1, 125.1, 129.1, 132.3, 137.1, 143.7, 154.7, 157.0, 160.1, 162.6 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C24H28N7O3: 462.2252; found: 462.2246. 
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N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-2-nitro-N4-[4-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-
indol-3-yl)pyrimidin-2-yl]benzene-1,4-diamine (35) 
 A flame-dried, 2-neck round-bottomed flask was charged with sodium 
hydride (60% dispersion in mineral oil, 26.0 mg, 0.649 mmol, 1.2 equiv.), 
purged with Ar and to this was added DMF (10 mL). The resulting suspension 
was cooled to −10 °C (acetone/ice) and a solution of N1-[4-(1H-indol-3-
yl)pyrimidin-2-yl]-N4-[2-(dimethylamino)ethyl]-2-methoxy-N4-methyl-5-
nitrobenzene-1,4-diamine (250 mg, 0.542 mmol, 1 equiv.) in DMF (5 mL) 
was added dropwise over 15 min. The orange solution was then allowed to warm to rt and stirred for 30 min, during 
which time the solution darkened. After recooling the solution to −10 °C (acetone/ice), a solution of SEM-Cl 
(108 mg, 0.648 mmol, 1.2 equiv.) in DMF (5 mL) was added dropwise over 10 min. The reaction mixture was then 
allowed to warm to rt and stirred for 4 h or until complete consumption of the starting material as indicated by TLC, 
changing to a light orange colour during this period. The reaction mixture was then quenched and diluted with H2O 
(30 mL) and EtOAc (20 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of 
EtOAc (3 × 20 mL) and the combined organic layers were then washed with a saturated solution of brine 
(3 × 30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product 
was achieved using flash column chromatography with elution gradient of 5 – 10% MeOH in DCM. Pure fractions 
were evaporated to dryness to afford compound 35 as an orange solid (153 mg, 0.259 mmol, 48%). 
Rf: 0.45 (10% MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ -0.09 (s, 9H, CH2Si(CH3)3), 0.91 (t, J = 8.1 Hz, 2H, 
CH2CH2Si), 2.26 (s, 6H, CH2N(CH3)2), 2.57 (t, J = 7.0 Hz, 2H, NCH2CH2N), 2.88 (s, 3H, ArNCH3), 3.27 (t, J = 
7.0 Hz, 2H, NCH2CH2N), 3.57 (t, J = 8.1 Hz 2H, OCH2CH2), 3.93 (s, 3H, ArOCH3), 5.59 (s, 2H, NCH2O), 6.63 (s, 
1H, ArH), 7.16 (d, J = 5.3 Hz, 1H, ArH), 7.32 – 7.28 (m, 2H, 2 × ArH), 7.53 (s, 1H, ArH), 7.57 (dd, J = 6.4, 2.8 
Hz, 1H, ArH), 8.14 (dd, J = 6.4, 2.8 Hz, 1H, ArH), 8.30 (s, 1H, ArH), 8.37 (d, J = 5.3 Hz, 1H, ArH), 9.52 (s, 1H, 
ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ -1.4, 17.7, 41.2, 45.9, 54.1, 56.1, 57.0, 66.2, 76.6, 101.7, 108.4, 111.2, 
114.7, 116.3, 120.8, 121.9, 122.8, 123.1, 126.3, 132.1, 133.9, 137.5, 143.0, 152.3, 158.1, 159.3, 161.6 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H42N7O4Si: 592.3068; found: 592.3069. 
tert-Butyl 3-{2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-nitrophenyl)amino]pyrimidin-4-
yl}-1H-indole-1-carboxylate (36)  
 A 2-neck round-bottom flask was charged with N1-[4-(1H-indol-3-
yl)pyrimidin-2-yl]-N4-[2-(dimethylamino)ethyl]-2-methoxy-N4-methyl-5-
nitrobenzene-1,4-diamine (2.17 g, 4.70 mmol, 1 equiv.), purged with Ar, 
dissolved in DMF (25 mL) and DIPEA (0.900 mL, 5.17 mmol, 1.1 equiv.) was 
added. After cooling to 0 °C, a solution of Boc2O (1.13 g, 5.17 mmol, 
1.1 equiv.) in DMF (10 mL) was added dropwise, followed by the addition of 
a catalytic amount of DMAP. The reaction mixture was then allowed to warm to rt and stirred for 6 h or until 
complete consumption of the starting material as indicated by TLC. The reaction mixture was then diluted with H2O 
(100 mL) and EtOAc (70 mL) and the organic layer was separated.  
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The aqueous layer was extracted with aliquots of EtOAc (3 × 30 mL) and the combined organic layers were then 
washed with successive aliquots of a saturated solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography 
with elution gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 36 
as an orange foam (2.58 g, 4.60 mmol, 98%).  
Rf: 0.45 (10% MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ 1.71 (s, 9H, OC(CH3)3), 2.26 (s, 6H, CH2N(CH3)2), 
2.56 (t, J = 7.0 Hz, 2H, NCH2CH2N) 2.87 (s, 3H, ArNCH3), 3.26 (t, J = 7.0 Hz, 2H, NCH2CH2N), 3.97 (s, 3H, 
ArOCH3), 6.67 (s, 1H, ArH), 7.14 (d, J = 5.2 Hz, 1H, ArH), 7.40 – 7.35 (m, 2H, 2 × ArH), 7.57 (s, 1H, ArH), 8.25 
– 8.21 (m, 1H, ArH), 8.28 (s, 1H, ArH), 8.36 – 8.31 (m, 1H, ArH), 9.19 (s, 1H, ArNH) ppm; 13C NMR (75 MHz, 
DMSO-d6) δ 27.6, 40.4, 45.4, 52.7, 56.3, 56.4, 84.8, 102.0, 108.6, 114.7, 118.1, 120.6, 120.7, 122.7, 123.3, 
124.9, 127.3, 128.2, 131.9, 135.4, 144.3, 148.7, 155.7, 158.0, 160.4, 160.7 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C29H36N7O5: 562.2778; found: 562.2776. 
tert-Butyl 3-{2-[(5-amino-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxyphenyl)amino]pyrimidin-4-
yl}-1H-indole-1-carboxylate (37)  
 A 3-neck round-bottom flask was charged with 4-fluoro-2-methoxy-1-
nitrobenzene (2.59 g, 4.61 mmol, 1 equiv.) and Pd/C (49.0 mg, 0.460 mmol, 
10 mol%), placed under vacuum and MeOH (30 mL) was added. A hydrogen 
atmosphere was introduced via balloon and the suspension was then allowed 
to stir at rt for 12 h or until complete consumption of starting material as 
indicated by TLC. The reaction mixture was filtered through a plug of celite, 
washed with MeOH (35 mL) and the solvent was removed in vacuo. Purification of the crude product was achieved 
using flash column chromatography with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated 
to dryness to afford compound 37 as a brown foam (2.11 g, 3.96 mmol, 86%). 
Rf: 0.38 (10% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 1.67 (s, 9H, OC(CH3)3), 2.19 (s, 6H, CH2N(CH3)2), 
2.39 (t, J = 6.7 Hz, 2H, NCH
2
CH
2
N), 2.64 (s, 3H, ArNCH
3
), 2.91 (t, J = 6.7 Hz, 2H, NCH
2
CH
2
N), 3.71 (s, 3H, 
ArOCH
3
)), 4.59 (br s, 2H, ArNH
2
), 6.77 (s, 1H, ArH), 7.31 – 7.25 (m, 2H, 2 × ArH), 7.36 (s, 1H, ArH), 7.38 (s, 1H, 
ArH), 8.15 – 8.09 (m, 2H, 2 × ArH), 8.37 (d, J = 5.3 Hz, 1H, ArH), 8.51 (s, 1H, ArNH), 8.53 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 27.7, 41.5, 45.6, 53.8, 56.4, 57.3, 84.7, 105.4, 107.8, 110.6, 114.6, 118.2, 123.1, 
123.4, 124.6, 124.9, 127.4, 128.0, 134.4, 135.4, 136.7, 142.9, 148.8, 157.8, 160.6, 160.8 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C29H38N7O3: 532.3036; found: 532.3034. 
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tert-Butyl 3-{2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-
propionamidophenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate (38) 
 A 2-neck round-bottom flask was charged with tert-butyl                                      
3-{2-[(5-amino-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-
methoxyphenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate (2.00 g, 
3.76 mmol, 1 equiv.), purged with Ar and dissolved in DCM (30 mL). The 
solution was cooled to −10 °C (acetone/ice) and DIPEA (0.790 mL, 
4.51 mmol, 1.2 equiv.) was added. A solution of propionyl chloride (383 mg, 
4.14 mmol, 1.1 equiv.) in DCM (10 mL) was then added dropwise to the solution over 10 min. The reaction mixture 
was then allowed to warm to rt and stirred for 2 h. The reaction mixture was then quenched and diluted with H2O 
(30 mL), a saturated solution of NaHCO3 (30 mL) and DCM (50 mL) and the organic layer was separated. The 
aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed 
with a saturated solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 
5 – 12.5% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 38 as a brown solid 
(2.10 g, 3.57 mmol, 95%). 
Rf: 0.53 (10% MeOH in DCM); IR (ATR) cm
-1
: 3419 (m, N-H stretch), 3132 (m, N-H stretch), 2935 (m, C-H stretch), 
2815 (m, C-H stretch), 1732 (s, C=O stretch), 1674 (s, C=O stretch), 1581 (m, N-H bend), 1452 (m, C-H bend), 
1402 (m, C-H bend), 1357 (s, C-N stretch), 1149 (s, C-O stretch), 1054 (s, C-O stretch), 764 (s, N-H wag), 753 (s, 
N-H wag); 
1
H NMR (300 MHz, DMSO-d6) δ 1.05 (t, J = 7.6 Hz, 3H, COCH2CH3), 1.66 (s, 9H, OC(CH3)3), 2.24 (s, 
6H, CH2N(CH3)2), 2.30 (q, J = 7.6 Hz, 2H, COCH2CH3), 2.35 (t, J = 5.5 Hz, 2H, NCH2CH2N), 2.71 (s, 3H, ArNCH3), 
2.91 (t, J = 5.5 Hz, 2H, NCH2CH2N), 3.78 (s, 3H, ArOCH3), 7.00 (s, 1H, ArH), 7.22 (dd [app t.], J = 7.5 Hz, 1H, 
ArH), 7.41 – 7.31 (m, 2H, 2 × ArH), 8.11 (d, J = 8.3 Hz, 1H, ArH), 8.33 (s, 1H, ArH), 8.37 (d, J = 5.3 Hz, 1H, 
ArH), 8.43 (d, J = 7.5 Hz, 1H, ArH), 8.52 (s, 1H, ArH), 8.55 (s, 1H, ArNH), 9.75 (s, 1H, ArNH), ppm; 
13
C NMR (75 
MHz, DMSO-d6) δ 9.8, 27.7, 29.5, 42.4, 45.3, 55.8, 56.9, 84.7, 105.4, 108.0, 114.6, 117.2, 118.2, 123.1, 123.2, 
124.4, 124.9, 127.4, 127.6, 128.1, 135.4, 139.1, 148.1, 148.8, 157.9, 160.6, 160.8, 171.1 ppm; HRMS-TOF MS 
ESI+: m/z [M+H]
+
 calculated for C32H42N7O4: 588.3298; found: 588.3300. 
N-(5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (27) 
 A 2-neck round-bottomed flask was charged with tert-butyl                                 
3-{2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-
propionamidophenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate 
(1.80 g, 3.06 mmol, 1 equiv.), purged with Ar and dissolved in DCM (18 mL). 
This was followed by the dropwise addition of trifluoroacetic acid (6 mL) and 
the reaction mixture was then allowed to stir for 4 h or until complete 
consumption of the starting material as indicated by TLC.  
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After removal of the solvent in vacuo, the reaction mixture was diluted with DCM (30 mL), H2O (30 mL) and 
neutralised with a saturated solution of NaHCO3 (60 mL) and the organic layer was separated. The aqueous layer 
was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed with a saturated 
solution of brine (30 mL), dried over MgSO4 and filtered.  
After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 27 as an off-white foam (1.43 g, 2.94 mmol, 96%). 
For spectroscopic characterization data please see compound 27 on page 219/220.   
tert-Butyl 3-{2-[(5-acrylamido-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-
methoxyphenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate (39) 
 A 2-neck round-bottom flask was charged with tert-butyl                                      
3-{2-[(5-amino-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-
methoxyphenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate (200 mg, 
0.376 mmol, 1 equiv.), purged with Ar and dissolved in DCM (30 mL). DIPEA 
(80.0 µL, 0.450 mmol, 1.2 equiv.) was added and the solution was cooled to 
−40 °C (acetonitrile/ CO2). A solution of acryloyl chloride (37.0 mg, 
0.409 mmol, 1.1 equiv.) in DCM (10 mL) was then added dropwise to the solution over 10 min. The reaction 
mixture was then allowed to warm to −20 °C and stirred at this temperature for 2 h or until complete consumption 
of the starting material as indicated by TLC. The reaction mixture was then quenched and diluted with H2O (20 mL), 
a saturated solution of NaHCO3 (20 mL) and DCM (30 mL) and the organic layer was separated. The aqueous layer 
was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (40 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 5 – 10% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 39 as a white foam (178 mg, 0.304 mmol, 81%). 
Rf: 0.48 (10% MeOH in DCM); IR (ATR) cm
-1
: 3423 (m, N-H stretch), 3141 (m, N-H stretch), 2949 (m, C-H stretch), 
2832 (m, C-H stretch), 1738 (s, C=O stretch), 1676 (s, C=O stretch), 1581 (m, N-H bend), 1452 (m, C-H bend), 
1402 (m, C-H bend), 1357 (s, C-N stretch), 1151 (s, C-O stretch), 1062 (s, C-O stretch), 970 (s, C=C bend), 764 (s, 
N-H wag); 
1
H NMR (300 MHz, CDCl
3
) δ 1.68 (s, 9H, OC(CH
3
)
3
), 2.26 (s, 6H, CH
2
N(CH
3
)
2
), 2.31 (t, J = 5.5, 2H, 
NCH2CH2N), 2.68 (s, 3H, ArNCH3), 2.87 (t, 2H, J = 5.5, NCH2CH2N), 3.87 (s, 3H, ArOCH3), 5.65 (dd, J = 10.6, 
3.2 Hz, 1H, CCH=CH2), 6.39 – 6.35 (m, 2H, CCH=CH2 and CCH=CH2), 6.78 (s, 1H, ArH), 7.10 (d, J = 5.2 Hz, 
1H, ArH), 7.36 – 7.29 (m, 2H, 2 × ArH), 7.61 (s, 1H, ArH), 8.19 (d, J = 7.5 Hz, 1H, ArH), 8.31 (s, 1H, ArH), 8.38 
(d, J = 7.5 Hz, 1H, ArH), 8.50 (d, J = 5.2 Hz, 1H, ArH), 9.59 (s, 1H, ArNH), 10.05 (s, 1H, ArNH) ppm; 
13
C NMR 
(75 MHz, CDCl
3
) δ  28.2, 43.5, 45.4, 56.1, 56.2, 57.3, 84.5, 104.6, 109.1, 112.0, 115.2, 119.2, 122.0, 123.5, 
124.8, 125.9, 126.6, 127.6, 127.8, 129.3, 132.4, 135.9, 136.2, 145.1, 149.4, 158.0, 160.2, 161.4, 163.3 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C32H40N7O4: 586.3142; found: 586.3151. 
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N-(5-{[4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)acrylamide (HL1116 40)
37
 
 A 2-neck round-bottomed flask was charged with tert-butyl 3-{2-[(5-
acrylamido-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-
methoxyphenyl)amino]pyrimidin-4-yl}-1H-indole-1-carboxylate (140 mg, 
0.239 mmol, 1 equiv.), purged with Ar and dissolved in DCM (12 mL). This 
was followed by the dropwise addition of trifluoroacetic acid (4 mL) and the 
reaction mixture was then allowed to stir for 6 h or until complete 
consumption of the starting material as indicated by TLC. After removal of the solvent in vacuo, the reaction mixture 
was diluted with DCM (30 mL), H2O (30 mL) and neutralised with a saturated solution of NaHCO3 (60 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined 
organic layers were then washed with a saturated solution of brine (30 mL), dried over MgSO4 and filtered. After 
removal of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography 
with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 40 
as a white foam (81.0 mg, 0.167 mmol, 70%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
37
 
Rf: 0.23 (10% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 2.25 (s, 6H, CH2N(CH3)2), 2.37 (br s, 2H, 
NCH2CH2N), 2.71 (s, 3H, ArNCH3), 2.92 (br s, 2H, NCH2CH2N), 3.84 (s, 3H, ArOCH3), 5.75 (d, J = 8.1 Hz, 1H, 
CCH=CH2), 6.28 (d, J = 16.2 Hz, 1H, CCH=CH2),  6.46 (dd, J = 16.2, 10.2 Hz, 1H, CCH=CH2), 7.02 (s, 1H, 
ArH), 7.11 – 7.04 (m, 1H, ArH), 7.20 – 7.12 (m, 1H, ArH), 7.26 (d, J = 5.0 Hz, 1H, ArH), 7.45 (d, J = 7.8 Hz, 1H, 
ArH), 7.96 (s, 1H, ArH), 8.29 (s, 1H, ArH), 8.30 (s, 1H, ArH), 8.50 (s, 1H, ArH), 8.97 (s, 1H, ArH), 10.14 (s, 1H, 
ArNH), 11.81 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 42.6, 45.0, 55.9, 56.7, 105.2, 107.2, 111.9, 
113.5, 115.1, 120.5, 121.8, 121.9, 125.1, 125.2, 125.2, 126.2, 127.4, 129.5, 132.3, 137.2, 138.1, 146.8, 157.2, 
160.2, 162.4, 162.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C27H32N7O2: 486.2617; found: 
486.2622.  
N-(5-{[4-(1-Acryloyl-1H-indol-3-yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (41) 
A flame-dried, 2-neck round-bottomed flask was charged with sodium 
hydride (60% dispersion in mineral oil, 5.20 mg, 0.134 mmol, 1.3 equiv.), 
purged with Ar and to this was added DMF (4 mL). The resulting suspension 
was cooled to −10 °C (acetone/ice) and a solution of N-(5-{[4-(1H-indol-3-
yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (50.0 mg, 0.103 mmol, 1 equiv.) in DMF 
(1 mL) was added dropwise over 5 min. The solution was then allowed to 
warm to rt and stirred for 30 min, during which time the colour darkened.  
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After recooling the solution to −40 °C (acetonitrile/CO2), a solution of acryloyl chloride (11.1 mg, 0.124 mmol, 1.2 
equiv.) in DMF (1 mL) was added dropwise over 5 min. The reaction mixture was then allowed to warm to −20 °C 
and stirred at this temperature for 2 h or until complete consumption of the starting material as indicated by TLC, 
the colour changing from dark to light brown during this period. The reaction mixture was then quenched and 
diluted with H2O (30 mL), a saturated solution of NaHCO3 (20 mL) and EtOAc (30 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 20 mL) and the combined organic layers 
were then washed with a saturated solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After removal of 
the solvent in vacuo, purification of the crude product was achieved using flash column chromatography with elution 
gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 41 as yellow 
solid (40.0 mg, 73.9 µmol, 72%).  
Rf: 0.37 (10% MeOH in DCM); IR (ATR) cm
-1
: 3453 (m, N-H stretch), 3149 (m, N-H stretch), 2937 (m, C-H stretch), 
2852 (m, C-H stretch), 1695 (s, C=O stretch), 1666 (s, C=O stretch), 1579 (m, N-H bend), 1452 (m, C-H bend), 
1402 (m, C-H bend), 1349 (s, C-N stretch), 1155 (s, C-O stretch), 1021 (s, C-O stretch), 976 (s, C=C bend), 768 (s, 
N-H wag); 
1
H NMR (300 MHz, CDCl3) δ 1.26 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.36 (s, 6H, CH2N(CH3)2), 2.53 – 
2.40 (m, 4H, NCH2CH2N and COCH2CH3), 2.70 (s, 3H, ArNCH3), 2.98 (br s, 2H, NCH2CH2N), 3.89 (s, 3H, 
ArOCH3), 6.06 (dd, J = 16.2, 10.2 Hz, 1H, CCH=CH2), 6.81 – 6.69 (m, 2H, CCH=CH2 and CCH=CH2), 7.24 (d, 
J = 5.1 Hz, 1H, ArH), 7.26 (s, 1H, ArH), 7.47 – 7.35 (m, 2H, 2 × ArH), 7.74 (s, 1H, ArH), 7.92 – 7.81 (m, 1H, ArH), 
8.03 (d, J = 7.2 Hz, 1H, ArH), 8.50 (d, J = 5.1 Hz, 1H, ArH), 8.68 (d, J = 7.2 Hz, 1H, ArH), 8.91 (s, 1H, ArH), 9.68 
(s, 1H, ArNH), 9.75 (s, 1H, ArNH), ppm; 
13
C NMR (75 MHz, CDCl3) δ 10.6, 31.1, 43.3, 44.1, 45.3, 56.3, 57.2, 
104.5, 110.2, 110.4, 115.1, 117.6, 120.2, 121.3, 122.1, 124.6, 125.5, 127.0, 127.8, 128.2, 129.1, 129.6, 132.2, 
137.3, 144.3, 158.6, 160.2, 160.8, 165.0 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H36N7O3: 
542.2880; found: 542.2881. 
2-Bromoethane-1-sulfonyl chloride (46)
28
 
A flame-dried, 2-neck round-bottomed flask was charged with sodium 2-bromoethane-1-
sulfonate (6.33 g, 30.0 mmol, 1 equiv.) and purged with Ar. To this was added PCl5 (6.24 g, 30.0 
mmol, 1 equiv.) portion wise over 5 min with vigorous stirring which resulted in an exotherm and 
the reaction mixture becoming a yellow slurry. The reaction mixture was then allowed to stir at 130 °C for 30 
minutes, followed by an additional 30 minutes at 70 °C. After allowing to cool to rt, the reaction mixture was slowly 
poured into vigorously stirring H2O (80 mL) and allowed to stir for 10 minutes. The reaction mixture was diluted 
with DCM (40 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 
× 40 mL) and the combined organic layers were then washed with H2O (50 mL), an ice-cold solution of 5% NaHCO3 
(30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was 
achieved by kugelrohr distillation. Fractions with boiling point between 135 °C and 145 °C at ≈ 20 mbar were 
collected to afford compound 46 as a clear liquid (5.04 g, 24.3 mmol, 81%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
28
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1
H NMR (300 MHz, CDCl3) δ 3.81 – 3.74 (m, 2H, BrCH2CH2SO2Cl), 4.15 – 4.07 (m, 2H, BrCH2CH2SO2Cl) ppm; 
13
C NMR (75 MHz, CDCl3) δ 20.11, 65.88 ppm.  
N-[5-({4-[1-(Cyanomethyl)-1H-indol-3-yl]pyrimidin-2-yl}amino)-2-{[2-(dimethylamino)ethyl](methyl)amino}-
4-methoxyphenyl]propionamide (53) 
A flame-dried, 2-neck round-bottomed flask was charged with sodium 
hydride (60% dispersion in mineral oil, 10.7 mg, 0.267 mmol, 1.3 equiv.), 
purged with Ar and to this was added DMF (4 mL). The resulting suspension 
was cooled to −10 °C (acetone/ice) and a solution of N-(5-{[4-(1H-indol-3-
yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (100 mg, 0.205 mmol, 1 equiv.) in DMF 
(1 mL) was added dropwise over 5 min. The solution was then allowed to 
warm to rt and stirred for 30 min, during which time the colour darkened. 
After recooling the solution to −10 °C (acetone/ice), a solution of iodoacetonitrile (41.1 mg, 0.246 mmol, 1.2 equiv.) 
in DMF (1 mL) was added dropwise over 5 min. The reaction mixture was then allowed to warm to rt and stirred at 
this temperature for 2 h or until complete consumption of the starting material as indicated by TLC. The reaction 
mixture was then quenched and diluted with H2O (30 mL), a saturated solution of NaHCO3 (20 mL) and EtOAc 
(30 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 20 mL) 
and the combined organic layers were then washed with a saturated solution of brine (3 × 30 mL), dried over 
MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using flash 
column chromatography with elution gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 53 as yellow solid (73.0 mg, 0.139 mmol, 68%). 
Rf: 0.40 (10% MeOH in DCM); IR (ATR) cm
-1
: 3402 (m, N-H stretch), 3118 (m, N-H stretch), 2912 (m, C-H stretch), 
2819 (m, C-H stretch), 2772 (m, C-H stretch), 2236 (w, C≡N stretch), 1662 (s, C=O stretch), 1579 (m, N-H bend), 
1464 (m, C-H bend), 1396 (m, C-H bend), 1342 (s, C-N stretch), 1013 (s, C-O stretch), 731 (s, N-H wag); 
1
H NMR 
(300 MHz, CDCl3) δ 1.31 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.28 (s, 6H, CH2N(CH3)2), 2.31 (t, J = 5.8 Hz, 2H, 
NCH2CH2N), 2.48 (q, J = 7.6 Hz, 2H, COCH2CH3), 2.68 (s, 3H, ArNCH3), 2.92 (t, J = 5.8 Hz, 2H, NCH2CH2N), 
3.88 (s, 3H, ArOCH3), 5.44 (s, 2H, NCH2C≡N), 6.78 (s, 1H, ArH), 7.18 (d, J = 5.3 Hz, 1H, ArH), 7.37 – 7.30 (m, 
2H, 2 × ArH), 7.48 (dd, J = 6.6, 2.2 Hz, 1H, ArH), 7.78 (s, 1H, ArH), 8.03 (dd, J = 6.6, 2.2 Hz, 1H, ArH), 8.39 (d, 
J = 5.2 Hz, 1H, ArH), 9.37 (s, 1H, ArH), 9.58 (s, 1H, ArNH), 9.87 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) 
δ 10.3, 30.8, 34.4, 44.3, 45.4, 55.8, 56.2, 57.3, 104.7, 108.0, 109.8, 110.0, 114.6, 115.9, 120.7, 122.1, 123.0, 
126.3, 127.6, 129.5, 134.5, 134.7, 137.1, 144.2, 158.6, 159.4, 161.1, 171.9 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C29H35N8O2: 527.2883; found: 527.2889.  
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N-[5-({4-[1-(2-cyanoethyl)-1H-indol-3-yl]pyrimidin-2-yl}amino)-2-{[2-(dimethylamino)ethyl](methyl)amino}-
4-methoxyphenyl]propionamide (56) 
A 2-neck round-bottomed flask was charged with N-(5-{[4-(1H-indol-3-
yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (40.0 mg, 82.0 µmol, 1 equiv.) and purged 
with Ar. To this was added DMF (4 mL) and the resulting suspension cooled 
to 0 °C, followed by the dropwise addition of a solution of acrylonitrile 
(17.4 mg, 0.328 mmol, 4 equiv.) in DMF (1 mL) and a catalytic amount of 
Triton B. The reaction mixture was then allowed to warm to rt and stirred for 
6 h or until complete consumption of the starting material as indicated by 
TLC. The reaction mixture was then diluted with H2O (30 mL) and EtOAc (20 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 20 mL) and the combined organic layers 
were then washed with a saturated solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After removal of 
the solvent in vacuo, purification of the crude product was achieved using flash column chromatography with elution 
gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 56 as an off 
white solid (36.0 mg, 66.6 µmol, 81%). 
Rf: 0.42 (10% MeOH in DCM); IR (ATR) cm
-1
: 3417 (m, N-H stretch), 3116 (m, N-H stretch), 2937 (m, C-H stretch), 
2851 (m, C-H stretch), 2203 (w, C≡N stretch), 1666 (s, C=O stretch), 1577 (m, N-H bend), 1464 (m, C-H bend), 
1394 (m, C-H bend), 1347 (s, C-N stretch), 1023 (s, C-O stretch), 739 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ 
1.34 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.31 (s, 6H, CH2N(CH3)2), 2.36 (br s, 2H, NCH2CH2N), 2.51 (q, J = 7.6 Hz, 
2H, COCH2CH3), 2.69 (s, 3H, ArNCH3), 2.96 (t, J = 5.6 Hz, 2H, NCH2CH2N), 3.10 (t, J = 7.6 Hz, 2H, 
NCH2CH2C≡N), 3.88 (s, 3H, ArOCH3), 4.71 (t, J = 7.6 Hz, 2H, NCH2CH2C≡N), 6.78 (s, 1H, ArH), 7.22 (d, J = 5.2 
Hz, 1H, ArH), 7.35 – 7.27 (m, 2H, 2 × ArH), 7.43 (d, J = 6.8 Hz, 1H, ArH), 7.77 (s, 1H, ArH), 8.04 (d, J = 6.8 Hz, 
1H, ArH), 8.40 (d, J = 5.2 Hz, 1H, ArH), 9.31 (s, 1H, ArH), 9.67 (s, 1H, ArNH), 9.79 (s, 1H, ArNH) ppm; 
13
C NMR 
(75 MHz, CDCl3) δ 10.7, 19.0, 31.2, 42.1, 44.3, 45.4, 55.7, 56.3, 57.3, 104.7, 108.1, 109.4, 109.7, 115.5, 117.4, 
120.6, 121.6, 122.5, 126.1, 127.7, 129.7, 133.7, 134.1, 137.1, 144.0, 158.4, 159.6, 161.5, 172.0 ppm; HRMS-
TOF MS ESI+: m/z [M+H]
+
 calculated for C30H37N8O2: 541.3039; found: 541.3034. 
2-(Phenylamino)ethane-1-sulfonyl fluoride (62)
32
 
A 2-neck round-bottomed flask was charged with aniline (250 mg, 2.68 mmol, 1 equiv.) 
and purged with Ar. To this was added DMF (10 mL) and the resulting solution was then 
cooled to 0 °C, followed by the dropwise addition of a solution of ethenesulfonyl fluoride 
(310 mg, 2.81 mmol, 1.05 equiv.) in DMF (5 mL). The reaction mixture was then allowed to warm to rt and stirred 
for 3 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was then 
diluted with H2O (30 mL) and EtOAc (20 mL) and the organic layer was separated. The aqueous layer was extracted 
with aliquots of EtOAc (3 × 20 mL) and the combined organic layers were then washed with a saturated solution of 
brine (3 × 30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude 
product was achieved using flash column chromatography with elution gradient of 5 – 20% EtOAc in PE.  
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Pure fractions were evaporated to dryness to afford compound 62 as a brown oil (535 mg, 2.63 mmol, 98%). 
IR and 
1
H NMR data collected for this compound compared well with the reported literature values.
32
 
Rf: 0.58 (30% PE in EtOAc); 
1
H NMR (300 MHz, CDCl3) δ 3.63 (m [app. dd], J = 11.2, 5.5 Hz, 2H, NCH2CH2S), 
3.82 (t, J = 6.2 Hz, 2H, NCH2CH2S), 4.10 (br s, 1H, ArNHCH2), 6.71 – 6.63 (m, 2H, 2 × ArH), 6.87 (dd [app. t], J 
= 7.2 Hz, 1H, ArH),  7.34 – 7.24 (m, 2H, 2 × ArH) ppm; 13C NMR (75 MHz, CDCl3) δ 38.1, 49.8 (d, J = 13.7 Hz), 
113.2, 119.0, 129.7, 145.7 ppm; 19F NMR (282 MHz, CDCl
3
) δ 56.70 (t, J = 4.6 Hz) ppm; HRMS-TOF MS ESI+: 
m/z [M+H]
+
 calculated for C8H11NO2SF: 204.0495; found: 204.0489. 
2-(3-{2-[(4-{[2-(Dimethylamino)ethyl](methyl)amino}-2-methoxy-5-propionamidophenyl)amino]pyrimidin-4-
yl}-1H-indol-1-yl)ethane-1-sulfonyl fluoride (63)  
A 2-neck round-bottomed flask was charged with N-(5-{[4-(1H-indol-3-
yl)pyrimidin-2-yl]amino}-2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxyphenyl)propionamide (80.0 mg, 0.164 mmol, 1 equiv.) and 
potassium carbonate (34.0 mg, 0.246 mmol, 1.5 equiv.) and purged with Ar. 
To this was added DMF (8 mL) and the resulting suspension cooled to 0 °C, 
followed by the dropwise addition of a solution of ethenesulfonyl fluoride 
(23.5 mg, 0.213 mmol, 1.3 equiv.) in DMF (2 mL). The reaction mixture was 
then allowed to warm to rt and stirred for 6 h or until complete consumption 
of the starting material as indicated by TLC. The reaction mixture was then diluted with H2O (30 mL) and EtOAc (20 
mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 20 mL) and 
the combined organic layers were then washed with a saturated solution of brine (3 × 20 mL), dried over MgSO4 
and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound (HL1238 63) as an off white solid (62.0 mg, 0.103 mmol, 63%). 
Rf: 0.47 (15% MeOH in DCM); IR (ATR) cm
-1
: 3419 (m, N-H stretch), 3116 (m, N-H stretch), 2961 (m, C-H stretch), 
2860 (m, C-H stretch), 1660 (s, C=O stretch), 1577 (m, N-H bend), 1466 (m, C-H bend), 1396 (m, C-H bend), 
1351 (s, C-N stretch), 1161 (s, S=O stretch), 1025 (s, C-O stretch), 743 (s, N-H wag);
 1
H NMR (300 MHz, DMSO-
d6) δ 1.13 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.35 (s, 6H, CH2N(CH3)2), 2.43 – 2.36 (m, 4H, NCH2CH2N and 
COCH
2
CH
3
), 2.68 (s, 3H, ArNCH
3
), 2.99 (br s, 2H, NCH
2
CH
2
N), 3.85 (s, 3H, ArOCH
3
), 4.69 – 4.63 (m, 2H, 
NCH2CH2S), 4.89 (t, J = 6.4 Hz, 2H, NCH2CH2S), 7.00 (s, 1H, ArH), 7.19 (dd [app. t], J = 7.5 Hz, 1H, ArH), 7.23 
(d, J = 5.2 Hz, 1H, ArH), 7.28 (dd [app. t], J = 7.5 Hz, 1H, ArH), 7.65 (d, J = 8.0 Hz, 1H, ArH), 7.94 (s, 1H, ArH), 
8.28 (d, J = 8.0 Hz, 1H, ArH), 8.36 (d, J = 5.2 Hz, 1H, ArH), 8.70 (s, 1H, ArH), 8.94 (s, 1H, ArNH), 9.78 (s, 1H, 
ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 10.0, 29.7, 42.9, 44.7, 49.5, 49.7, 56.0, 56.3, 105.2, 107.3, 110.7, 
113.7, 114.1, 121.2, 121.6, 122.4, 125.2, 125.4, 127.7, 132.7, 136.8, 137.3, 145.9, 156.0, 157.9, 161.3, 171.5 
ppm; 
19
F NMR (282 MHz, DMSO-d
6
) δ 57.69 (t, J = 6.1 Hz); HRMS-TOF MS ESI+: m/z [M+H]+ calculated for 
C29H37N7O4SF: 598.2612; found: 598.2620.  
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Chapter 7 
Osimertinib-derived Inhibitors Targeting the Mutated Serine 
Residue Ser797  
Abstract 
In this chapter, our research focus shifted from targeting the EGFR catalytic lysine residue to the development of inhibitors 
containing functional groups able to either reversibly interact or covalently modify the mutated Ser797 residue. As this mutant 
serine residue contains a harder, more inert hydroxyl nucleophile, we implemented a strategy of including electrophiles known 
to interact and irreversibly inhibit serine-containing enzymes. These included the use of Michael acceptors, sulfonyl fluorides, 
fluorophosphonates and phosphonate esters, boronic esters and acids, trifluoromethyl ketones, α-, β-haloketones, imidazoles and 
nitriles. Additionally, we envisaged the synthesis of dual warhead containing compounds, based on the premise of the catalytic 
triad in serine proteases. Building on the synthetic achievements of the previous chapter, these electrophiles were incorporated 
into the previously implemented osimertinib-derived scaffold on the aniline conventionally derivatised with the acrylamide 
Michael acceptor. The synthesis of this heterocyclic scaffold, our chosen electrophiles and the incorporation thereof are 
comprehensively discussed. Synthetic highlights included the unexpected development of original synthetic methodology, 
synthesis of novel electrophiles and effective use of multi-nuclear NMR spectroscopy as structural confirmation technique. This 
resulted in the synthesis of 14 final compounds which were assessed in both a biochemical and cellular setting. Amongst overall 
positive and encouraging results, this evaluation provided compelling trends and contrasts in activity which were successfully 
rationalised. Lastly, we discussed the future development of these inhibitors in overcoming the EGFR-C797S resistance mutation. 
7.1 Introduction 
In the previous two chapters, our research efforts extended to the covalent modification and targeted inhibition of 
the EGFR catalytic lysine residue (Lys745). In the body of work presented in this chapter, our focus shifts towards 
targeting the hydroxyl nucleophile of the mutated serine residue (Ser797) which is present in the clinically relevant 
EGFR-C797S mutant. As discussed in Section 2.4.3, this mutation is proposed to be the main mechanism of 
resistance towards 3
rd
 generation inhibitors such as osimertinib.
1
 In order to overcome resistance mediated by the 
T790M mutation, 3
rd
 generation inhibitors incorporated an acrylamide electrophile in an appropriate position to 
covalently modify the Cys797 residue, as displayed in Figure 7.1a. The premise of this irreversible inhibition lies in 
the nucleophilicity of the soft thiol functionality and the reactivity-tuned acrylamide moiety, allowing for the desired 
Michael addition reaction to take place.
2
 With the advent of the EGFR-C797S mutant, point mutation of the 
nucleophilic Cys797 covalent anchor to that of a serine residue resulted in the termination and inability of these 
compounds to undergo covalent bond formation under physiological conditions, as illustrated in Figure 7.1b. This 
inability stems primarily from the harder and less nucleophilic nature of the serine residue and the now inappropriate 
electrophile installed on these inhibitors.  
As with the preceding chapters, our main aspiration was the reinstatement of irreversible inhibition through covalent 
bond formation, coupled with exploration of reversible interactions with Ser797. To do this, we envisioned alteration 
of the acrylamide group of a 3
rd
 generation inhibitor, such as osimertinib, to a more suitably reactive electrophile or 
functional group which would be able to covalently modify the less nucleophilic Ser797.  
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Figure 7.1: a) Irreversible inhibition through a Michael addition reaction between the acrylamide electrophile and Cys797 
residue and b) No covalent bond formation as harder, less nucleophilic serine residue cannot undergo Michael addition.    
We believed several inherent factors could enhance the probability of success with the implementation of this 
strategy. Firstly, use of 3
rd
 generation inhibitor scaffolds, which were specifically developed with a superior and 
potent reversible binding affinity, would negate the requirement for preliminary driving group optimization. 
Furthermore, the ideal position and placement for electrophiles to target the mutated Ser797 residue would already 
be established, allowing us to bypass any molecular modelling and docking simulations. Thus, all that remained for 
us was to peruse the literature and identify the suitably reactive electrophiles and functionalities that can undergo 
covalent modification or favourably interact with serine residues.  
7.2 Targeting Serine Residues 
7.2.1 The Catalytic Triad 
A catalytic triad is a combination of three concerted amino acids present in the active site of certain enzymes.
3
 
Catalytic triads are prevalent in hydrolase and transferase enzymes, such as proteases, and typically consist of an 
Acid-Base-Nucleophile motif, shown in Figure 7.2a. This catalytic machinery aids in activation of the nucleophilic 
potential of specific residues, enabling their participation in covalent catalysis. As illustrated in Figure 7.2b, the 
composition of a specific enzyme’s triad can differ, built from an array of amino acids in varying combinations. 
Keeping in line with our research topic, we will only discuss the catalytic triad where serine acts as nucleophile. 
Figure 7.2: a) An example of a catalytic triad present in the active site of the Tobacco Etch Virus (TEV) protease (PDB: 1LVM) 
and b) Amino acid combinations constituting the catalytic triad of different enzymes. Figure reproduced from a) Phan et al.
4
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Figure 7.3: Example mechanism of catalytic triad undergoing covalent catalysis with serine as nucleophile (green), histidine as 
base (blue) and aspartic acid as acid (red). 
An example mechanism for covalent catalysis by a catalytic triad is shown in Figure 7.3. As can be seen, triads are 
inter-dependant and perform in concert with other residues to achieve nucleophilic catalysis. A charge-relay system 
commonly found in serine proteases is depicted in the first step of Figure 7.3.1. The acidic triad member (red), 
typically an aspartate or glutamate residue, interacts with the histidine base (blue), thereby aligning and restricting 
its side-chain rotation and promoting stabilisation of the positive charge by polarisation. This allows for deprotonation 
and activation of the nucleophilic residue (green), exemplified by a serine residue. The three-dimensional structure 
of the enzyme assembles these residues in the precise position and orientation to affect this sequence.
5
  
With its pKa lowered, the nucleophilic residue attacks the carbonyl of the substrate (maroon), leading to a tetrahedral 
intermediate, shown in Figure 7.3.2. The negative charge of this transition state is stabilised by an oxyanion hole 
(purple), a backbone pocket typically consisting of amides and other positively charged residues. This stabilisation 
lowers the activation energy required and promotes the catalysis.
6
 This transition state collapses back to the carbonyl 
and ejects the first half of the substrate (maroon), leaving the second half covalently bound to the enzyme as an acyl-
enzyme intermediate shown in Figure 7.3.3. This is often promoted by proton transfer from the base member.  
Enzymes containing a catalytic triad may catalyse one of two reaction types, which is decided in the second stage of 
catalysis. Nucleophilic attack of the acyl-enzyme intermediate by water (orange), as depicted in Figure 7.3.3, results 
in splitting of the original substrate and is characteristic of hydrolases. In contrary, nucleophilic attack by an additional 
substrate on the acyl-enzyme intermediate leads to transfer of this portion to this secondary substrate, typified by 
transferase enzymes.  
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In our example mechanism, nucleophilic attack by water (orange) affects formation of a new tetrahedral intermediate 
(Figure 7.3.4) which is resolved by ejection of the original serine nucleophile (green), releasing the second product 
and regenerating the catalytic triad to allow for further catalysis. 
Owing to the activated nature of these catalytic serine residues, numerous studies of their covalent targeting through 
probes and inhibitors can be found in the literature.
7
 However, examples for the successful targeting of their non-
catalytic counterparts may also be found. Instances of serine-targeting electrophiles for both the catalytic and non-
catalytic serine residues will be discussed in the following section. Also, the design and implementation of a covalent 
serine-targeting strategy, built upon the principles of the catalytic triad machinery, will be discussed in Section 7.3.  
7.2.2 Serine-targeting Covalent Inhibitors 
7.2.2.1 Previously Discussed Electrophiles 
Many of the functional groups found suitable for investigation in this study have already been introduced in the 
previous chapter and will therefore be discussed only briefly. Reactive electrophiles such as sulfonyl fluorides have 
been shown to modify both catalytic and non-catalytic serine residues, particularly in serine proteases, and act as 
selective probes in a variety of enzymes.
8, 9 
Nitriles are known to form strong hydrogen bond interactions as acceptors 
with serine amino acids and have been documented to form imidates with serine proteases.
10, 11
 While archetypal 
Michael acceptors such as acrylamides are unreactive toward serine nucleophiles without activation by catalytic 
machinery, we nevertheless wished to investigate the reactivity of a vinyl sulfonamide. Intrigued by the additional 
electron-withdrawing capacity and hardier nature granted by the sulfonamide, we believed this electrophile could 
be compatible with the Ser797 residue.
7
 Lastly, α-haloketone warheads, similar to those attempted in the previous 
chapter, were amongst the first affinity probes utilised for serine proteases.
7
 In particular, chloromethyl ketones have 
found marked success as serine protease inhibitors, while their bromo- and iodomethyl analogues are typically more 
reactive, but less stable in aqueous solution, and are therefore used less frequently. In our opinion, inclusion of these 
functionalities and electrophiles in this research venture is warranted by their successful application in the literature.  
7.2.2.2 Fluorophosphonates 
Fluorophosphonates have been known as potent inhibitors of both serine proteases and esterases for almost a 
century.
7
 Prototype phosphonyl fluoride inhibitors included sarin and soman, shown in Figure 7.4a on the following 
page. Owing to their extreme reactivity with acetylcholinesterase, both agents are severely toxic and are regarded 
as weapons of mass destruction when considered as chemical warfare agents. The more stable and less reactive 
derivative, diisopropyl phosphonofluoridate (DFP) (Figure 7.4a), irreversibly inhibits many serine proteases and has 
found use in ophthalmology in the treatment of chronic glaucoma and as an irreversible anti-cholinesterase 
inhibitor.
7
 Similarly, methoxy arachidonyl fluorophosphonate (MAFP), inhibits nearly all serine hydrolases and 
proteases, displaying marked potency in the low nanomolar IC50 range in the inhibiton of phospholipase A2 and fatty 
acid amide hydrolase. Although the above-mentioned substances lack resemblance to a peptide substrate, and as 
such retain no selectivity toward a particular serine protease or hydrolase, these agents have found use as diagnostic 
tools for the identification and classification of active site serine residues in these enzymes.
7
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Figure 7.4: a) Examples of non-selective phosphonyl fluoride inhibitors of serine proteases and hydrolases, and b) Peptidyl 
substrate phosphonyl fluoride and phosphonate inhibitors able to covalently modify serine proteases.  
To overcome this issue of selectivity, several peptide phosphonyl fluoride inhibitors, derived from and mimicking 
the serine peptide substrate, have been reported.
12
 The general structure of these compounds can be seen as 1 in 
Figure 7.4b and these inhibitors have been shown to exhibit good selectivity towards their target serine proteases, 
especially that of chromotrypsin and elastase.
7
 The chemical stability and reactivity of these organophosphorus 
compounds in inhibiting serine proteases irreversibly is dictated by the electrophilicity of the central phosphorus 
atom. Regarding phosphonyl fluorides, the phosphorous being adjacent to an electronegative fluorine atom leads to 
high reactivity and low stability. This means that while effective as serine protease inhibitors, these agents are often 
unstable in aqueous conditions and undergo nonenzymatic hydrolysis.
12
  
Compromising between reactivity and chemical stability, Oleksyszyn and Powers. developed the peptidyl R-
aminoalkylphosphonates 2, shown in Figure 7.4b, which were able to irreversibly inhibit serine proteases.
13
 While 
similar to the peptide phosphonyl fluorides 1, the adjoining phenoxy groups are less electronegative than their 
fluorine counterparts. This engenders sufficient electrophilicity at the phosphorous atom to allow for reaction by the 
active site serine, while remaining hydrolytically stable.
13
 Due to the perceived weak reactivity of the Ser797 residue, 
we wished to explore the inclusion of highly reactive fluorophosphonate and alkylphosphonate electrophiles in our 
attempt to covalently modify the triple mutant serine residue.  
7.2.2.3 Boronic Acids 
Heretofore, the understanding and use of boron in therapeutics has been minimal relative to carbon, nitrogen, 
oxygen and sulphur.
14
 Boron has atomic number 5, with three electrons in its outer shell, and is considered a 
metalloid. The elements unique electronic configuration and ability to form covalent bonds with carbon has led to 
its wide use in synthetic chemistry.
15
 However, recent progress in the field of boron chemistry has expanded its 
application as synthetic reagent to use in the development of drug candidates.
16
 Most trivalent boron reagents are 
electrophilic, with the sp
2
 hybridized trigonal boron atom able accept an electron pair from a nucleophile, leading 
to adoption of a sp
3
 tetrahedral configuration and thereby satisfying the octet rule (Figure 7.5a). It is this ease of 
conversion from trigonal planar to tetrahedral that forms the basis of covalent inhibition of serine, threonine and 
lysine residues by boronic acid enzyme inhibitors.
17
 This is coupled with an inherent affinity to form strong reversible 
interactions with amine and hydroxyl functionalities in biological systems.
14
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Figure 7.5: a) Configurational modifications of boron, b) Structure of the FDA approved inhibitor Bortezomib and c) Structure 
of boronic acid containing EGFR inhibitors 3 and 4.  
The pioneering exploration of boron’s physical, chemical and biological properties by medicinal chemists has led to 
the representation of a new class of boron-based drugs. Bortzeomib, shown in Figure 7.5b, received FDA approval 
in 2003 as the first proteasome inhibitor used for treatment of multiple myeloma and non-Hodgkins lymphoma and 
remains the only drug in clinical use with boron as an active element.
18
 The success of this discovery has motivated 
researchers to further explore boron chemistry, resulting in several drug candidates with anticancer, antiviral, 
antibacterial and other disease-specific activities reaching various phases of clinical trials.
16
  
Implementation of boron chemistry has even extended into the development of EGFR inhibitors. As shown in 
Figure 7.5c, the boron-conjugated 4-anilinoquinazoline compound 3 was shown to effectively inhibit EGFR in a 
prolonged manner.
19
 Following mechanical docking simulations and time dependant in-vitro incubation assays, the 
prolonged inhibition was believed to result from irreversible inhibition of the enzyme, occurring through formation 
of a B-O bond with the Asp800 residue. Furthermore, separate studies have led to the development of compound 4, 
showing single digit nanomolar efficacy against EGFR, while maintaining a good selectivity profile.
20
  
Due to the characteristic preference of boron for hard oxygen over soft sulphur nucleophiles, boronic acids have 
been utilised in the development of selective inhibitors of serine proteases.
17
 This is desirable in the context of our 
research objective and validates the inclusion of boronic acids in our arsenal of Ser797 targeting electrophiles.  
7.3 Objectives and Target Synthetic Library 
With the synthetic groundwork at our disposal and the desirable characteristics thereof discussed in Section 6.2.2, 
we chose to retain osimertinib as our heterocyclic scaffold for the synthesis of our target synthetic library. Similar to 
our lysine-targeting library, the design elements of our serine-targeting library may be found in Figure 7.6 on the 
following page. Negating the need for molecular modelling, derivatisation with the selected serine-targeting 
electrophiles would occur at the aniline fragment which normally houses the acrylamide Michael acceptor in 
osimertinib. Incorporation at this position would place the warhead in an optimal orientation and proximal location 
to interact and potentially covalently modify the Ser797 mutant residue. 
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 Figure 7.6: Target synthetic library for osimertinib-derived Ser797 targeting inhibitors.  
Our envisaged electrophilic warheads can be seen above (purple, Figure 7.6) and include those discussed in previous 
instances such as ethenesulfonamide, cyanoacetamide, sulfonyl fluorides, α- and β-haloketones, fluorophosphonates 
and boronic acids. While not discussed in the same detail, we wished to investigate the potential interactions of the 
trifluoromethyl ketone functionality with the mutated Ser797 residue. Serine proteases have been shown to interact 
with trifluoromethyl ketones by forming stable hemiacetals.
21
 This exemplifies the covalent, albeit reversible, 
inhibitory effects that trifluoromethyl ketones may have on certain enzymes and their potential for inclusion in our 
serine-targeting library. Lastly, we wished to utilise the imidazole moiety to mimic the histidine catalytic triad base 
(Figure 7.3) and potentially establish favourable reversible interactions with the Ser797 residue.  
Special consideration was given to the unsaturated sulfonyl fluoride functional group which is shown in Figure 7.7a 
on the next page. This specific electrophile can be seen as a “dual warhead,” as it contains both a Michael acceptor 
and a reactive sulfonyl centre adjacent to an electronegative fluorine atom which serves as a leaving group. This 
piqued our interest, as the two electrophilic centres are inherently selective in nature by their preference for either 
hard or soft nucleophiles. This infers that the Michael acceptor portion would facilitate covalent bond formation 
with the soft thiol nucleophile of a cysteine residue, while the sulfonyl fluoride fragment would be far more disposed 
to nucleophilic attack by a hard serine hydroxyl group (Figure 7.7a). If in concordance, this warhead could be 
capable of covalently modifying both the cysteine containing T790M double mutant and the mutated serine residue 
of the C797S triple mutant.  
In keeping with the use of dual warheads, we devised a strategy built upon the previously discussed catalytic triad 
of serine proteases (Figure 7.3). The electrophiles shown in Figure 7.7b contain two functional groups, namely a 
cyano- or imidazole-acetamide fragment and a sulfonyl fluoride moiety.  
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Figure 7.7: a) Dual warhead able to potentially covalently modify both cysteine and serine, b) Envisaged dual warheads and c) 
Mechanism of activation based on the catalytic triad of serine proteases.  
Simulating the role of the histidine base in activating the serine residue of the catalytic triad, we envisaged the 
imidazole (or cyano) moiety interacting with Ser797 through hydrogen bonding (Figure 7.7c). With the electron 
withdrawing effects of the adjacent amide emulating the acid part of the catalytic triad in activating the base, these 
hydrogen bond interactions could in turn activate the Ser797 residue, potentially creating a more nucleophilic 
hydroxyl group. In conjunction with this, these interactions would provide a proximal location and orientation for 
the second part of the dual warhead, the electrophilic sulfonyl fluoride, to undergo nucleophilic attack from the 
activated Ser797. Intrigued by this prospect, we aimed at synthesising the cyano- and imidazole-containing dual 
warheads to explore the potential of our hypothesis, as well as the other compounds pertaining to our Ser797-
targeting library.  
7.4 Library Synthesis  
7.4.1 Osimertinib-derived Scaffold Synthesis 
Owing to the incredible success of osimertinib in the clinical treatment of lung cancer, a wealth of approaches 
towards its synthesis can be found in the literature.
22, 23
 This allowed for the effective and large-scale synthesis of the 
osimertinib driving group scaffold, shown as compound 12 in Scheme 7.1 on the following page. Starting from 
compound 5, methylation of the indole nitrogen was carried out through deprotonation using sodium hydride as 
base, followed by dropwise treatment with methyl iodide.
24
 Due to its exothermic nature, the reaction was carried 
out at −10 °C (acetone/ice), affording compound 6 in near quantitative yield. Coupling of the synthesised fragment 6 
and the commercially available 7 was next accomplished using AlCl3 as lewis acid in DME. Use of this solvent allowed 
for a higher reaction temperature of 85 °C, which afforded the indole pyrimidine fragment 8 in 68% yield.
23
  
The remaining steps of the synthesis towards compound 12 was carried out in a linear fashion, similar to the route 
developed in the previous chapter. Furthermore, compound 9 was synthesised according to the procedure outlined 
in the previous chapter (Section 6.4.1, 21) and will therefore not be discussed.  
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Scheme 7.1: Synthesis of the osimertinib driving group scaffold 12. Reagents and conditions: i) NaH (2 equiv.), MeI 
(1.2 equiv.), THF, −10 °C – rt, 3 h; ii) 5 (1 equiv.), 7 (1.1 equiv.), AlCl3 (1 equiv.), DME, 0 °C – 60 °C, 12 h; iii) TsOH·H2O 
(1.2 equiv.), 2-pentanol, 105 °C, 4 h; iv) N
1
,N
1
,N
2
-trimethylethane-1,2-diamine (1.25 equiv.), DIPEA (1.05 equiv.), DMA, 60 
°C, 4 h; v) Fe (6 equiv.), NH4Cl (1 equiv.), EtOH/H2O (3:1), 85 °C, 4 h.
23, 24  
Coupling between compound 8 and 9 was achieved using the previously optimised reaction conditions, employing 
p-toluenesulfonic acid monohydrate in 2-pentanol at 105 °C. Following collection of the precipitate by filtration and 
a simple work-up procedure, the coupled fragment 10 was afforded in the excellent yield of 93% with no further 
purification required. Installation of the solubilising group was carried out in the subsequent nucleophilic aromatic 
substitution reaction, furnishing compound 11 as a bright red solid. Lastly, reduction of the aromatic nitro group was 
executed using iron and ammonium chloride in a 3:1 mixture of ethanol/water while heating under reflux. This 
afforded compound 12 in 85% yield, with the obtained 
1
H, 
13
C and MS data comparing well with the reported 
literature values, and concluded the synthesis of our osimertinib driving group scaffold.
22, 23
   
 7.4.2 Model Compounds 
To allow for comparative analysis with our library of serine-targeting compounds in the biochemical and cellular 
evaluation, we envisaged synthesis of both the non-covalent propionamide analogue 13 and osimertinib (14) as 
model compounds. As illustrated in Scheme 7.2, both compounds were synthesised using acylating agent, potassium 
carbonate as base and acetone as solvent. However, yields for compound 14 were found to improve dramatically 
through implementation of low temperatures generated by an acetonitrile and dry ice bath, thereby avoiding 
polymerisation of the acryloyl chloride and side product formation. This furnished both 13 and 14 in excellent yields 
of 90 and 88% respectively which were fully characterised using IR, MS and NMR spectroscopy.   
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Scheme 7.2: Synthesis of compounds 13 and 14. Reagents and conditions: i) propionyl chloride (1.3 equiv.), K2CO3 
(1.5 equiv.), acetone, −10 °C – rt, 2 h; ii) acryloyl chloride (1.1 equiv.), K2CO3 (1.5 equiv.), acetone, −40 °C – −20 °C, 2 h. 
7.4.3 Electrophile Synthesis and Derivatisation 
7.4.3.1 Ethenesulfonamide 
With the effective synthesis of our osimertinib driving group scaffold 12, we set our sights on aniline derivatization 
with the various designated serine-targeting electrophiles. Our synthetic pursuit began within the Michael acceptor 
category, with the singular ethansulfonamide 17 shown in Scheme 7.3 below. Due to the more nucleophilic nature 
of aniline 12, we did not require the problematic use of strong base and harsh reaction conditions which led to the 
unsuccessful isolation of the indole analogue in the previous chapter. Initially, reaction of 12 with the previously 
synthesised 15, using one equivalent of DIPEA in DCM, led to the formation of two prominent spots when visualised 
by TLC analysis. Interestingly, upon exposure to a dilute basic solution during workup, only one of the two spots 
remained. Purification of this crude product using column chromatography was followed by NMR spectroscopic 
analysis, confirming the successful isolation of compound 17. We gathered that spontaneous elimination of 
intermediate 16 had occurred during the workup, easily ascribed to the good bromine leaving group and the highly 
acidic nature of the proton alpha to the electron-withdrawing sulfonamide which both facilitate elimination. Indeed, 
subsequent reactions using an excess of base resulted in the development of one spot when visualised by TLC analysis 
and the sole formation of 17. This strategy furnished ethenesulfonamide 17 in a good yield of 68%, with discussion 
of the 
1
H NMR spectroscopic characterisation to follow.  
Scheme 7.3: Synthesis of ethenesulfonamide 17. Reagents and conditions: i) 15 (1.3 equiv.), DIPEA (3 equiv.), DCM, −40 °C – 
−20 °C, 2 h. 
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The 
1
H NMR spectra of compound 17 can be found below in Figure 7.8, giving structural confirmation for the 
synthesis of the ethenesulfonamide. Examination of the most upfield region reveals the presence of a triplet at δ 2.27 
ppm, with the peak mirrored by another triplet at δ 2.87 ppm, both integrating for 2H and with identical J-coupling 
values. These two triplets were assigned to the ethylene bridge (dark blue) of the solubilising group. The two large 
singlets in between constitute the remainder of the solubilising group, with the peak at δ 2.35 ppm integrating for 
6H ascribed to the dimethylamine (green) element and the signal integrating for 3H at δ 2.73 ppm correlating to the 
methylamine (light blue) of the solubilising group. Moving downfield, two characteristic methyl signals, both 
integrating for 3H, could be found at δ 3.90 and 3.97 ppm. Based on spectra of previously synthesised building 
blocks, these peaks were assigned to the indole methyl (orange) and the aryl methoxy (yellow) respectively. 
Indication of the ethenesulfonamide moiety (red) was found by the three signals between δ 5.70 and 6.65 ppm. 
These signals comprised of two doublets at δ 5.74 and 6.16 ppm (J = 10.0 Hz and 16.7 Hz respectively), and a 
doublet of doublets δ 6.58 ppm (J = 16.7 Hz), characteristic of vinyl sulfone protons. Assessment of the aromatic 
region of the 
1
H NMR spectrum presented the correct integration amount for compound 17, with all protons 
accounted for and peak splitting patterns within expectations. This left us with two singlets at the farthest region 
downfield of the spectrum, corresponding to the remaining two amine protons within our structure. Working with 
NMR spectra of precursory structures and the inherent electron-withdrawing nature of the sulfonamide, the broader 
singlet at δ 8.70 ppm was assigned to bridging aniline (purple) and the sharper singlet furthest downfield at δ 9.02 
ppm to the sulfonamide proton (brown). While not displayed for interpretation, all carbons were correctly accounted 
for in the corresponding 
13
C spectra. Furthermore, use of HRMS analysis presented a [M+H]
+
 ion of 536.2450, with 
a calculated mass of 536.2444, providing final confirmation for the successful synthesis of compound 17. 
Figure 7.8:  
1
H NMR spectra of compound 17. 
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7.4.3.2 Sulfonyl Fluorides 
Scheme 7.4: Synthesis of model dual warhead 19 and the osimertinib derived sulfonyl fluoride 21 and dual warhead 22. 
Reagents and conditions: i) MnO2 (15 equiv.), CHCl3, rt, 8 h; ii) ESF (1.05 equiv.), DMF, −10 °C – rt, 4 h. 
In the previous chapter, compound 18, shown in Scheme 7.4 above, was synthesised as a model to perform 
comparative spectroscopic analysis with the sulfonyl fluoride molecules synthesised using 
1
H and 
19
F NMR 
spectroscopy. Wishing to repeat the successful application of this principal, we synthesised the dual warhead 
compound 19 as a model representation (Scheme 7.4). Use of excess manganese dioxide in chloroform facilitated 
smooth oxidation to the alkene at room temperature, affording 19 in a yield of 69% without optimization.
25
  
Utilising similar conditions to afford sulfonyl fluorides in the previous chapter, scaffold 12 was dissolved in DMF and 
treated dropwise with ESF (20) at low temperature (Scheme 7.4). As before, the Michael addition was found to 
proceed effectively without the use of base. Following basic work-up and purification of the crude product using 
flash column chromatography, compound 21 was afforded as a yellow solid in good yield. This allowed us to attempt 
conversion of 21 into 22 using the same oxidation reaction parameters developed for compound 19. To our delight, 
the osimertinib-derived dual warhead 22 was furnished in an improved yield of 75% when compared with the 
model system. To the best of our knowledge, besides oxidation of 18 to the model compound 19, no other 
application of this reaction sequence exists within the literature, highlighting the obscurity and potential for use of 
this class of warhead.  
The most discernible substantiation for the successful synthesis of compounds 21 and 22 can be found in the 
comparison of their respective 
19
F spectra with that of the model compounds 18 and 19, illustrated in Figure 7.9. 
For the model compounds (Figure 7.9a), the saturated sulfonyl fluoride (red) 18 appears as a well-formed triplet at 
δ 56.7 ppm, coupling to the neighbouring protons of the ethyl bridge carbon. Following oxidation, the model dual 
warhead 19 fluoride peak (blue) shifts approximately δ 15.4 ppm downfield to arise at δ 72.1 ppm. This is 
anticipated, as formation of the conjugated alkene system would withdraw electron density from the sulfonyl system, 
thereby deshielding and causing a downfield shift in the signal. Furthermore, the signal multiplicity changes from 
that of a triplet to a doublet, in line with the loss of coupling to one proton in the unsaturated system. 
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Figure 7.9: Comparison of the 
19
F NMR spectra of a) model compounds 18 and 19 and b) final compounds 21 and 22. 
The model compounds spectroscopic features are mirrored in the 
19
F NMR spectra of 21 and 22, found above in 
Figure 7.9b. Parallel to its model counterpart, the fluorine signal of compound 21 appears at δ 57.7 ppm maintaining 
an albeit broadened triplet multiplicity. Analogous to the shift found in the model system, the signal of 22 moves 
downfield by roughly δ 15.5 ppm to emerge at δ 73.2 ppm, noticeably changing to the expected doublet. Further 
corroborating the successful synthesis of these compounds, all signals within the 
1
H and 
13
C NMR spectra were 
correctly accounted for. Final validation was provided by HRMS analysis, revealing a [M+H]
+
 ion of 556.2494, with 
calculated mass of 556.2506 for 21 and a [M+H]
+
 ion of 554.2352 for 22, with a calculated mass of 554.2350. 
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Scheme 7.5: Attempted synthesis of final compounds 25 and 28.  
The attempted synthesis of the propyl (25) and butyl (28) bridge sulfonyl fluoride counterparts is shown above in 
Scheme 7.5. Unfortunately, due to the same issues experienced in the synthesis of the previous chapter analogues, 
this synthesis was met with failure and we were unable to obtain these compounds. The major pitfalls associated 
with this failure surrounded the isolation and purification of the sulfonic acid intermediate compounds 24 and 27. 
As these difficulties were outlined in detail at the end of Section 6.4.2.3, we chose not to discuss this synthesis 
further, thereby concluding the synthesis of our sulfonyl fluoride library of serine-targeting inhibitors. 
7.4.3.3 Phosphonates and Fluorophosphonates 
To furnish our phosphonate and fluorophosphonate based serine-targeting inhibitors, we envisaged the synthesis of 
the phosphonate fragments 33 and 34 found in Scheme 7.6a. Thereafter, subsequent coupling acid coupling, mono-
hydrolysis and fluorination could afford the fluorophosphonate-containing compounds able to potentially covalently 
modify the mutant Ser797. Starting from the commercially available bromoacetic acid (29), esterification using 
sulfuric acid as catalyst, whilst stirring in ethanol heated under reflux, afforded the ethyl ester (30) in 86% yield.
26
 
This allowed us to undertake the Michaelis-Arbuzov reaction between alkyl halide 30 and a respective trivalent 
phosphorous ester to afford the corresponding alkyl phosphonate. Accordingly, trimethyl- or triethyl-phosphite were 
rapidly added to neat ethyl bromoacetate (30) at 80 °C, followed by swiftly ramping the temperature up to 130 °C, 
which allowed for distillation of the bromoethane by-product released during the formation of 31 and 32.
27
 
Purification was achieved by kugelruhr vacuum distillation, with fractions boiling between 145 – 150 °C and 150 – 
155 °C at ~ 20 mbar collected to afford phosphonate esters 31 and 32 respectively, as clear oils. Subsequent 
hydrolysis of the ethyl ester moiety for both 31 and 32 was carried out by treatment with an equimolar amount of 
sodium hydroxide, followed by acidification to pH = 1 with 1 M HCl and aqueous extraction. Finally, removal of 
the solvent in vacuo afforded both carboxylic acid phosphonate fragments 33 and 34 in excellent yield with no 
further purification required.  
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Scheme 7.6: Synthesis of a) phosphonate electrophile fragments 33 and 34 and b) model compound 36 and 37. Reagents and 
conditions: i) H2SO4 (cat.), EtOH, 85 °C, 24 h; ii) trialkylphosphite (1 equiv.), neat, 80 °C – 130 °C, 3 h; iii) NaOH (1 equiv.), 
1 M HCl, H2O, rt, 2 h; iv) 34 (1.85 equiv.), CDI (1.85 equiv.), DCM, 0 °C – rt, 12 h; v) MgCl2 (1.2 equiv.), NaI (1.2 equiv.), 
MeCN, 60 °C, 12 h.  
To gain a better understanding of the handling and reactivity of the desired fluorophosphonates, and the reaction 
sequence to be applied to driving group scaffold 12, we undertook a preliminary model synthesis towards 
fluorophosphonate 38, shown in Scheme 7.6b. Mono-hydrolysis of the phosphonate ester and isolation of the highly 
reactive fluorophosphonate was anticipated to be particularly problematic. Following the employment of numerous 
coupling reagents, it was found that treatment of excess carboxylic acid 34 and CDI with aniline (35) in DCM 
facilitated optimal amide bond formation. This provided 36 in the excellent yield of 94%, allowing us to tackle 
mono-hydrolysis of the ethyl ester phosphonate.  
The selective mono-hydrolysis of 36 proved to be a challenging endeavour, with initial attempts being met with 
failure. Conventional hydrolysis methods utilising NaOH or KOH led to a loss of hydrolytic control, resulting in the 
formation of the di-hydrolysed phosphonic acid. We therefore turned towards investigation of Lewis acids with 
varying strength as potential hydrolytic reagents. Use of the weaker Lewis acids LiCl and LiBr in high boiling point 
solvents such as toluene, acetonitrile and N-methyl-2-pyrrolidone resulted in no reaction at varying temperatures.
28
 
By contrast, use of stronger Lewis acids such as AlCl3 and TiCl4 provoked di-hydrolysis and the formation of a several 
by-products, which was also the case when implementing use of the silylating agent TMSCl with various additives.
29
 
Following many attempts and much frustration, successful mono-hydrolysis was finally attained using the unfamiliar 
Lewis acid magnesium chloride with sodium iodide as additive.
29
 Optimal reaction conditions were found to require 
acetonitrile as solvent at a temperature of 60 °C. This provided the mono-hydrolysed phosphonate 37 in good yield, 
with successful synthesis confirmed by HRMS and 
1
H, 
13
C and 
31
P NMR spectroscopic analysis. Distinct shifts in the 
signals of the 
31
P clearly evinced this and will be used for comparative analysis with the final compound analogues 
at a later stage.  
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Formation of fluorophosphonate 38 was attempted using the fluorinating reagent DAST at temperatures ranging 
from −78 °C – 0 °C in both DCM and DMSO. While we believe that these efforts were successful, owing to the 
disappearance of starting material 37 and formation of a new spot when visualised by TLC analysis, the instability of 
38 out of solution unfortunately impeded structural confirmation by spectroscopic analysis. It was due to this 
compound degradation that we were unable to isolate 38 and while disheartening, we still endeavoured to attempt 
the synthesis of the fluorophosphonate final compound counterparts.  
The previously determined model compound reaction parameters were then adopted to our final compound 
synthesis, illustrated in Scheme 7.7. Using excess carboxylic acid and CDI in DCM, amide bond formation was 
successfully carried out between driving group scaffold 12 and 33 to afford the dimethyl phosphonate compound 39 
in excellent yield. While no model reaction was carried out for the mono-hydrolysis of the dimethyl phosphonate 
ester moiety, we discovered a procedure by Gray and Smith in the literature which describes the selective cleavage 
of methyl phosphorous esters by tert-butylamine.
30
 The researchers found that use of tert-butylamine as solvent, 
while heating under reflux, effected demethylation of methyl phosphonate esters exclusively. Furthermore, dimethyl 
phosphonates were selectively mono-hydrolysed due to the formation of a sterically bulky tert-butylamine salt 
intermediate, effectively blocking the reaction site and preventing di-hydrolysis. Gratifyingly, application of these 
conditions to 39 afforded the mono-hydrolysed phosphonate ester 40 in acceptable yield. Compound 40 was 
isolated by treatment of the crude product with HCl in dioxane, followed by purification by trituration.  
For the ethyl phosphonate compounds, acid coupling between 12 and 34 was affected by the same reaction 
conditions described above to afford diethyl phosphonate 41 in 88% yield. Similarly, conditions derived from the 
model reaction sequence successfully facilitated the subsequent mono-hydrolysis of 41 to provide final 
compound 42 in a yield of 64%,  
 Scheme 7.7: Synthesis of phosphonate compounds 40 and 42. Reagents and conditions: i) 33 or 34 (1.85 equiv.), CDI 
(1.85 equiv.), DCM, 0 °C – rt, 4 h; ii) tert-butylamine, 55 °C, 16 h; iii) MgCl2 (1.2 equiv.), NaI (1.2 equiv.), MeCN, 60 °C, 12 h. 
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As was performed with the synthesised sulfonyl fluoride inhibitors, comparative analysis of the respective 
31
P NMR 
spectra of model compounds 36 and 37 and final compounds 41 and 42 may be found below in Figure 7.10. All 
31
P NMR spectroscopy experiments were self-run, with chemical shifts within spectra referenced to 85% H3PO4 in 
H2O, which served as the internal standard. Correlation of this spectroscopic data provides verification of both the 
diethyl phosphonate and mono-hydrolysed analogue. As can be seen in Figure 7.10a, the phosphorous signal of 36 
(red) appeared as a singlet at δ 23.4 ppm. Mono-hydrolysis of this model compound induces an upfield shift of δ 
10.6 ppm, resulting in the signal of 37 appearing at δ 12.8 ppm. Furthermore, this peak is visibly broader than that 
of its predecessor, possibly due to interactions with the newly formed protic hydroxyl moiety.    
Figure 7.10: Comparison of the 
31
P NMR spectra of a) model compounds 36 and 37 and b) final compounds 41 and 42. 
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Inspection of the final compounds 41 and 42 
31
P NMR spectra, shown in Figure 7.10b, reveals a near 
indistinguishable reflection of that seen for the model compounds. Comparable to its model equivalent, the 
phosphorous signal of 41 shows up at δ 23.1 ppm with a similar elongated peak shape. Following mono-hydrolysis, 
the anticipated peak shift for the phosphorous signal of compound 42 is identical to that of the model system, moving 
δ 10.6 ppm upfield to appear at δ 12.5 ppm. Additionally, the peak shape of 42 is observably broader, mirroring 
that of 37. Beyond the use of 
31
P NMR spectroscopy, all signals within the 
1
H and 
13
C NMR spectra were correctly 
accounted for, with the integration of the alkyl phosphonate signals correctly changing from a total of 10H to 5H. 
Lastly, HRMS analysis revealed a [M+H]
+
 ion of 623.2920, with calculated mass of 623.2925 for 41 and a [M+H]
+
 
ion of 596.2769 for 42, with a calculated mass of 596.2750. While not shown or directly discussed, the same 
considerations were evident in all analytical data retrieved for the methyl phosphonate compounds 39 and 40, 
confirming the successful synthesis of all phosphonate final compounds.  
The attempted synthesis of the fluorophosphonate analogues of these compounds was met the same pitfalls 
associated with product instability found in the model system. Sending the mono-hydrolysed phosphonate esters 40 
and 42 to our colleagues at the lab of Prof. Daniel Rauh in Germany, we had hoped that the fluorination could be 
carried out and followed by immediate biochemical and cellular evaluation. Unfortunately, this plan did not come 
to fruition due to the highly reactive and instable nature of the fluorophosphonate group. This concluded the 
synthesis of our phosphorous containing serine-targeting inhibitors.   
6.4.3.4 Boronic Esters and Acids 
The introduction of a boronic ester and acid motif within our serine-targeting library would require a multi-step 
synthetic protocol. As such, we proposed the synthesis of the model boronic ester and acid compounds illustrated 
in Scheme 7.8 on the following page. By undertaking this synthesis, we wished to reproduce the previous successes 
attained in model systems with respect to method development of optimal reaction conditions and comparative 
spectroscopic analysis.  
Embarking on the model synthesis, the first step entailed acylation of aniline (35) with acryloyl chloride while cooling 
with an acetonitrile/dry ice bath, furnishing acrylamide 43 as a white solid in excellent yield. Building on the work 
of Molander and co-workers, we envisaged copper-catalysed β-boration of the newly formed α-,β-unsaturated 
carbonyl with bis(pinacolato)diboron to produce the model boronic ester.
31
 While this procedure makes use of 
CyJohnPhos as phosphine ligand and sodium tert-butoxide as base, we found that alteration of these reagents to 
available xantphos and potassium tert-butoxide unproblematic. Following a small sample screening of catalyst and 
ligand loading amounts, optimal conditions were found and implemented in a Schlenk vessel to afford compound 44 
as a clear oil in a yield of 81%. To our knowledge, this is the first instance of this reaction being performed on an 
aromatic unsubstituted acrylamide group using a copper catalyst.  
We were intrigued by the publication of a two-step procedure for the deprotection of alkylpincolyl boronate esters 
developed by Santos et al.
32
 This method, which involved transesterification using diethanolamine followed by 
hydrolysis with dilute hydrochloric acid, was attractive to us due to its varied functional group tolerance and ease of 
product purification (simple filtration). This allowed us to avoid the other relatively harsh routes found in literature. 
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Scheme 7.8: Synthesis of model boron containing compounds 44 – 46. Reagents and conditions: i) acryloyl chloride 
(1.1 equiv.), DIPEA (1.2 equiv.), DCM, −40 °C – −20 °C, 2 h; ii) bis(pinacolato)diboron (1.2 equiv.), CuCl (10 mol%), 
potassium tert-butoxide (30 mol%), xantphos (10 mol%), EtOH, rt, 6 h; iii) diethanolamine (1.1 equiv.), diethyl ether, rt, 8 h; iv) 
0.1 M HCl, diethyl ether, rt, 2 h. 
Solution of boronic ester 44 in diethyl ether, followed by treatment with a slight excess of diethanolamine, facilitated 
precipitation of the diethanolamine salt adduct within the ethereal solution over an 8-hour period. As prescribed, 
filtration and successive washing of the white precipitate with diethyl ether afforded 45 in an acceptable yield. Lastly, 
subsequent hydrolysis was affected by suspension of 45 within a diethyl ether solution and the addition of 0.1 M HCl. 
Dilution of the reaction mixture with water, followed by extraction with ethyl acetate, afforded the boronic acid 46 
with no need for further purification, thereby highlighting the simplicity and effectiveness of this methodology.  
A comparison of the 
11
B NMR spectra of each boron containing model compound is illustrated on the following page 
in Figure 7.11. When running boron NMR spectroscopy experiments with regular NMR tubes, broad interference 
signals are typically seen in any region upfield from approximately δ 20.0 ppm, as these tubes are made from 
borosilicate glass and consequently contain boron. It is therefore preferential to make use of quartz tubes, which are 
more expensive and fragile. All the collected 
11
B NMR spectra were self-run in quartz tubes with chemical shifts 
referenced to 15% BF3·OEt2 in CDCl3, which served as the internal standard.  
The NMR spectra of alkylpinacolyl boronate ester 44 exhibits a broad boron signal (red) appearing at δ 34.5 ppm, 
typical of this functional group with signals exemplified to occur between approximately δ 32.0 and 35.0 ppm.33, 34 
Following transesterification to the diethanolamine salt adduct 45, we see a large upfield shift of δ 21.5 ppm in the 
boron signal (blue) which appears as a broad peak at δ 13.0 ppm. This shift can be attributed to the cluster of 
electron density surrounding the now negatively charged boron atom with four bonds, creating a substantial shielding 
effect and the movement of the signal to an upfield position. Analysis of the 
11
B NMR spectroscopic values of the 
diethanolamine adducts reported in the literature procedure reveals a chemical shift range between δ 10.0 and 13.0 
ppm, corroborating the successful isolation of intermediate 45.
32
 Lastly, mild hydrolysis of the adduct with 0.1 M HCl 
to provide boronic acid 46 reverts the upfield shift witnessed in the previous spectra, with the respective boron signal 
(green) arising at δ 33.1 ppm. Once again, appearance at this chemical shift is supported by the study undertaken 
in the literature, with typical boronic acid shifts lying anywhere between δ 19.0 and 35.0 ppm.32  
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Figure 7.11: Comparison of the 
11
B NMR spectra of model compounds 44 – 46. 
With the model synthesis of boronic ester and acid compounds completed, we focused our attention on the 
application of the derived reaction parameters towards final compound synthesis. The first of these steps entailed 
copper-catalysed β-boration of the previously synthesised osimertinib (14) with bis(pinacolato)diboron, illustrated in 
Scheme 7.9. To our surprise, employment of the model reaction conditions resulted in no reaction taking place and 
a full return of starting material 14. We hypothesised that the root of this inactivity lay within the use of a copper 
catalyst and the coordinative nature of the osimertinib solubilising group (green, 14), which is structurally related to 
the ligand tetramethylethylenediamine 48 (TMEDA) shown in Scheme 7.9b. TMEDA is widely employed as a ligand 
for metal ions and is able to form stable complexes with many metal halides such as copper(I) chloride.
35
 In such 
complexes, TMEDA serves as a bidentate ligand (Scheme 7.9b). As such, we believe that the CuCl catalyst utilised 
in our β-boration reaction was potentially coordinating/complexing to the osimertinib solubilising group and 
therefore unable to participate in the reaction. Frustratingly, further attempts to overcome complexation using 
stoichiometric amounts of copper catalyst, in tandem with elevated temperatures and different solvents, met with 
the same result. We chose to abandon installation of the pinacol boronic ester group in this manner and proposed 
a new synthetic route via an acid coupling reaction, analogous to that used for the phosphonate esters 39 and 41. 
Scheme 7.9: a) Attempted synthesis of pinacolyl boronate ester 47 and b) TMEDA (48) and its copper complex. 
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Scheme 7.10: a) Attempted synthesis and b) synthesis of carboxylic acid pinacolyl boronate ester fragment 51. Reagents and 
conditions: i) bis(pinacolato)diboron (1.2 equiv.), CuCl (10 mol%), potassium tert-butoxide (30 mol%), xantphos (10 mol%), 
EtOH, rt, 6 h; ii) bis(pinacolato)diboron (1.05 equiv.), CuCl (5 mol%), potassium tert-butoxide (10 mol%), xantphos (5 mol%), 
THF/MeOH (20:1), rt, 5 h; iii) DCM/TFA (3:1), rt, 6 h.   
Execution of our alternative synthetic strategy required the successful synthesis of the carboxylic acid fragment 51 
(Scheme 7.10), which could then undergo amide bond formation with driving scaffold 12. Accordingly, ethyl acrylate 
(49) was subjected to copper-catalysed β-boration to afford the pinacolyl boronate ester 50 in excellent yield, as 
illustrated in Scheme 7.10a. Disappointingly, the attempted selective hydrolysis of ethyl ester 50 proved impractical, 
as we were unable to extract and isolate the formed carboxylic acid 51 from the aqueous phase during work-up 
neutralisation. This included the use of various metal salts (LiBr, LiOH, KOH, NaOH) at adjusting temperatures, 
followed by treatment with acid (HCl, H2SO4) - all to no avail.  
To circumvent the obstacle posed by post-hydrolysis neutralisation and extraction from the aqueous phase, we 
envisaged replacement of the ethyl ester with that of a tert-butyl ester. Facile and effective cleavage of a tert-butyl 
ester functional group by stirring in trifluoroacetic acid is well documented and we believed we could implement 
this to our advantage.
36
 While sceptical at the prospect of the pinacol boronic ester surviving this treatment, we 
maintained the venture was worth a try. Interestingly, the discovery of a similar literature procedure for β-boration 
of the commercially tert-butyl acrylate (52) resulted in a near quantitative yield of 53, as illustrated in 
Scheme 7.10b.
37
 Solvent exchange from ethanol to a tetrahydrofuran/methanol mixture, smaller catalytic amounts 
of reagents and the order of addition were the major contributing factors to this yield increase. To our delight, 
treatment of the newly furnished 53 with trifluoroacetic acid whilst stirring in DCM, followed by simple removal of 
the solvent in vacuo, afforded the desired fragment 51 in exceptional yield with no further purification required. 
Survival of the pinacol group and the successful synthesis of carboxylic acid 51 was confirmed by HRMS, 
1
H, 
13
C 
and 
11
B NMR spectroscopy, with the latter revealing the appearance of a boron signal at δ 34.5 ppm.   
Illustrated in Scheme 7.11 on the next page, efforts towards the synthesis, isolation and purification of 47 proved to 
be an incredibly frustrating endeavour. The use of an array of conventional amide-coupling reagents including CDI, 
various carbodiimides (DCC, DIC, EDC) and PyBOP was perceived to affect successful amide bond formation as 
visualised by TLC. However, following the work-up procedure, subsequent purification by flash column 
chromatography would consistently result in the loss of this product spot, presumably due to degradation on the 
silica column.  
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Scheme 7.11: Synthesis of pinacolyl boronic ester 53 and attempted hydrolysis towards boronic acid 55. Reagents and 
conditions: i) 51 (2 equiv.), HOBt·H2O (2 equiv.), EDC·HCl (2 equiv.) DCM, 0 °C – rt, 8 h. 
As column chromatography was not tolerated, we devised a synthetic procedure that could afford the pure product 
using only the work-up as the method of purification. Following numerous attempts, the optimal parameters of two 
equivalents of the carboxylic acid 51, EDC hydrochloride and HOBt hydrate in DCM were established. Use of an 
excess of reagents was required to ensure complete conversion to the desired product. During the work-up 
procedure, washing of the organic phase with water ensured removal of the water-soluble EDC coupling agent and 
the activating additive HOBt. This was followed by successive washing with a 1 M NaOH solution to remove any 
excess carboxylic acid 51. Gratifyingly, removal of the solvent in vacuo afforded the coupled product 47 as a white 
foam in a yield of 72%, allowing us to proceed towards hydrolysis of the pinacol boronic ester.  
Unfortunately, utilisation of diethanolamine in diethyl ether to facilitate hydrolysis of boronic ester 47 was met with 
no reaction and a return of the starting material. Integral to precipitation of the intermediate adduct 54, the 
requirement of diethyl ether as solvent was also found to be the main impediment, due to the insolubility of 47. 
While replacement of diethyl ether with other non-polar solvents such as tetrahydrofuran, toluene and chloroform 
did permit the solution of 53, no precipitation of any product was found to occur, highlighting the necessity of an 
ethereal solution. Furthermore, any attempts at purification of the formed polar products using column 
chromatography resulted in the invariable degradation and loss of compound experienced in the synthesis of 47.  
In a final effort, direct hydrolysis of the boronic ester 53 was attempted using the conventional harsh method of 
heating in concentrated hydrochloric acid. To our dismay, this resulted in the formation of numerous by-products, 
with purification by column chromatography plagued by product degradation. Due to time constraints, it was 
decided at this point to submit 47 for biochemical and cellular evaluation to ascertain whether there was any merit 
in pursuing the synthesis of boronic acid 55.   
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Figure 7.12: 
1
H and 
11
B NMR spectra of final compound 53. 
The 
1
H and 
11
B (inset) NMR spectra of 47 may be found in Figure 7.12 above. As full characterisation of the driving 
group scaffold has already been undertaken in the 
1
H NMR spectroscopic analysis of compound 17 (Figure 7.8), we 
will focus solely on the newly incorporated elements of the boronic ester. Examination of the most upfield region 
reveals the presence of a large singlet at δ 1.21 ppm integrating for 12H, ascribed to the four methyl groups of the 
pinacol moiety (blue). This singlet was flanked by a nearby triplet at δ 1.26 ppm which integrated for 2H. Working 
from the NMR spectra of precursory structure 12, we assigned this triplet to one of the ethyl bridge (red) methylene 
protons. Assignment of the other unresolved methylene linker was expedited through comparison of the relevant J-
coupling values. Appropriately, the triplet with a J-coupling value of 6.2 Hz appearing at δ 2.57 ppm was prescribed 
to the remaining methylene (red), as this value was identical to that of the previously assigned triplet. Additionally, 
the neighbouring triplets J-coupling values were both found to be 5.9 Hz, validating this assignment. Lastly, the 
11
B 
NMR spectra revealed the presence of a broad singlet at δ 33.3 ppm, corresponding to the boron atom signal of the 
pinacol ester (green).   
Assessment of the unassigned signals within the 
1
H NMR spectrum presented the correct integration amount for 
compound 47, with all protons accounted for and peak splitting patterns to be in good order. While not displayed 
for interpretation, all carbons were correctly accounted for in the corresponding 
13
C NMR spectra, with the pinacol 
group and newly installed amide carbonyl carbon particularly evident. Use of HRMS analysis presented a [M+H]
+
 
ion of 628.3775, with a calculated mass of 628.3783, providing final confirmation for the successful synthesis of 
compound 47. While this brought an end to the synthesis of our boron-containing final compounds, further 
considerations towards the synthesis of this class of inhibitors will be discussed in the future work section of this 
chapter (Section 7.7). 
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7.4.3.5 Trifluoromethyl ketones  
 
 
 
 
 
 
 
 
Scheme 7.12: Synthesis of trifluoromethyl ketone 57 and attempted synthesis of trifluoromethyl ketone 59. Reagents and 
conditions: i) TFAA (2 equiv.), DIPEA (1.2 equiv.), THF, −10 °C – rt, 4 h. 
The synthesis of our trifluoromethyl ketone containing final compounds, illustrated above in Scheme 7.12, was 
unambiguous and will therefore be discussed briefly. Treatment of the osimertinib-derived scaffold 12 with 
trifluoroacetic anhydride at low temperature, with DIPEA serving as base, facilitated production of trifluoromethyl 
ketone compound 57 in a yield of 74%. This compound was fully characterised using IR, HRMS and NMR 
spectroscopic techniques, verifying its successful synthesis. Acquisition of the commercially available electrophilic 
fragment 58 and its subsequent reaction with 12 was met with the formation of a multitude of inseparable by-
products, even at reaction temperatures of −78 °C. We believe the generation of by-products stems from the 
inherent reactivity of this fragment (two electrophilic sites) and the availability of nucleophilic amines within 
scaffold 12 to promote undesired secondary reactions. Consequently, we were unable to successfully isolate 
trifluoromethyl ketone 59 and continued towards the synthesis of our remaining serine-targeting inhibitors.  
7.4.3.6 α-, β-Haloketones 
Due to the difficulties experienced in the previous chapters synthesis of α-, β-haloketones, we wished to investigate 
incorporation of this electrophile on a model system, shown on the following page in Scheme 7.13a. Treatment 
of 35 with the previously distilled bromoacetyl bromide (60), at low temperatures generated by an acetonitrile/dry 
ice bath, furnished the model α-haloketone 61 in 90% yield. This was unanticipated, as previous encounters with 
this class of compounds had displayed their highly reactive and unstable nature.    
Discouragingly, applications of these reaction conditions to scaffold 12 with various electrophiles (60, 62) to afford 
the α-haloketones (63) were met with failure, as illustrated in Scheme 7.13b. We found the synthesis of the α-
haloketones 63 to mirror the circumstances of the previous chapter. Whilst maintaining the low reaction 
temperatures, it appeared as though single product formation had taken place when visualised by TLC analysis. 
However, upon warming to room temperature, the previously identified product spot degraded into a profusion of 
by-products, making the attempted the isolation and purification of these compounds impossible.  
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 Scheme 7.13: a) Synthesis of model α-haloketone 61 and b) attempted synthesis of α-, β-haloketones 63 and 65. Reagents and 
conditions: i) 60 (1.1 equiv.), DIPEA (1.2 equiv.), DCM, −40 °C – −20 °C, 2 h. 
In an attempt to diminish the reactivity of the system, the temperature was lowered to −78 °C, in conjunction with 
removal of any external base. Unfortunately, this led to same outcome of degraded and inseparable crude reaction 
mixtures and the inability to furnish 63.    
Focussing on the synthesis of β-haloketone 65, acylation of 12 with electrophile 64 also led to the formation of a 
single spot as per visualisation by TLC analysis. In contrast to the α-haloketone system, warming of the crude reaction 
mixture to room temperature and subsequent work-up procedure did not lead to compound degradation, allowing 
us to isolate and purify the crude product. To our surprise, spectroscopic analysis by HRMS and NMR spectroscopy 
experiments yielded spectra matching that of osimertinib (14), postulated to have occurred through the unexpected 
elimination of the desired 65. A search through the literature revealed a recently developed procedure employing a 
similar two-step acylation/elimination sequence.
38
 This was accomplished using the chloro-variant of 64, followed 
by treatment with Et3N in acetonitrile heated under reflux.  
Intriguingly, removal of all base to circumvent spontaneous elimination in the acylation of 12 with 64 generated a 
single polar spot when visualised by TLC. Curiously, upon subjection to aqueous work-up and neutralisation, this 
spot shifted to the Rf value corresponding to that of osimertinib (14), which it was later confirmed as by NMR 
spectroscopic analysis. Witnessing these transformations, we hypothesised that the solubilising group (green) was 
serving as an intra-molecular base in these reactions. This is supported by the basic nature of the disubstituted amine 
groups and the rotational freedom of the solubilising group, permitting a proximal location to the β-haloketone. 
Therefore, in the absence of any external base, we believe that the trimethylethylenediamine solubilising group 
(green) facilitates elimination of the formed intermediate 65, producing the hydrobromide salt of osimertinib. This 
would correlate to the polar spot visualised during TLC analysis and its conversion into 14 following neutralisation. 
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While speculative, this would provide an explanation for the problems encountered in the synthesis of the α- and 
β-haloketone-containing final compounds in both this chapter and the previous one. This hypothesis is further 
corroborated in the attempted synthesis of α- and β-haloketones through an amide coupling reaction, resulting in 
the unforeseen formation of imidazole bearing final compounds. The discussion of this reaction sequence and its 
relation to our hypothesis will continue in the following section.  
7.4.3.7 Imidazole Compounds  
During the synthetic exploration of the α- and β-haloketones 63 and 65, we attempted amide coupling reactions 
between driving scaffold 12 and the carboxylic acid electrophiles 66 and 68, shown below in Scheme 7.14. For the 
initial reaction between 12 and 66, we utilised the previously established conditions of excess carboxylic acid and 
CDI as coupling reagent. During this reaction, we observed the preliminary formation of a single product spot 
through use of TLC analysis. Interestingly, this was followed by the slow conversion of this spot into another more 
polar product over a prolonged period. Accordingly, reaction times were extended to allow for full conversion to 
this unidentified adduct. Fascinated by the unconventional stability following isolation after work-up, purification of 
the unknown compound was achieved using flash column chromatography. Subsequent IR, HRMS and 
1
H and 
13
C 
NMR experiments pointed towards the unanticipated, but welcome synthesis of imidazole-containing compound 67 
in an unoptimized yield of 48%. Following the initial amide coupling to produce intermediate α-haloketone 63, it 
was evident that nucleophilic attack by excess imidazole (released during this amide bond formation) at the 
electrophilic α-position of 63 resulted in formation of the stable compound 67. Exceptionally, application of the 
same coupling parameters between 12 and 68 led to the generation of compound 69 in an improved yield, despite 
the less reactive β-halide electrophile centre. This compound was also fully characterised using IR, HRMS and NMR 
spectroscopy. 
Scheme 7.14: a) Synthesis of model α-haloketone 61 and b) attempted synthesis of α-, β-haloketones 63 and 65. Reagents and 
conditions: i) 66 or 69 (1.85 equiv.), CDI (1.85 equiv.), DCM, 0 °C – rt, 12 h. 
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As no external source of base was present in either reactions, we are presented with two potential candidates which 
may have fulfilled this role and expedited the substitution reaction. As we utilised an excess of CDI in the coupling 
reaction, the remaining imidazole that did not participate in the substitution reaction could have functioned as a 
base. Alternatively, building upon the speculations and reasons outlined in the previous section, the 
trimethylethylenediamine solubilising group could have acted as an intra-molecular base. Appraisal of the relevant 
pKa values of the conjugate acids of imidazole and TMEDA, which is structurally related to our solubilising group, 
shows values of 6.95 and 8.97 respectively.
35, 39
 Based on these numbers, the solubilising group is the more basic, 
aiding weight to our rational of its potential role as intra-molecular base.  
While no studies were undertaken to investigate these claims, acid coupling reactions could be performed on a 
model system, such as aniline, which excludes the solubilising group. Use of excess CDI, in the presence or absence 
of external base, will provide pertinent information needed to ascertain the roles of the reactants. Finally, we could 
find no occurrence of this reaction in our perusal of the literature, highlighting it as a new method for potential one-
pot installation of these imidazole-bearing functional groups.   
Sceptical of the above discussed transformations, we elected to proceed with what would have been our original 
synthetic route towards our imidazole-containing final compounds. The route, displayed below in Scheme 7.15, 
emulated the synthesis developed for the boron-containing carboxylic acid 50 shown in Scheme 7.10b. In doing so, 
we would take advantage of the tert-butyl ester functional group and its facile hydrolysis using trifluoroacetic acid. 
Moreover, successful isolation of reactive fragment 72 would cater for convergent synthesis in future synthetic 
libraries.  
 
 
 
 
 
 
 
 
 
Scheme 7.15: a) Synthesis of imidazole carboxylic acid 72 and b) imidazole-containing final compound 67. Reagents and 
conditions: i) 60 (1.1 equiv.), tert-butanol (1 equiv.), pyridine (1.5 equiv.), DCM, −10 °C – rt, 4 h; ii) 70 (1.1 equiv.), imidazole 
(1 equiv.), Cs2CO3 (1.2 equiv.), DMF, 0 °C – rt, 4 h; iii) DCM/TFA (3:1), rt, 6 h; iv) 72 (2 equiv.), HOBt·H2O (2 equiv.), 
EDC·HCl (2 equiv.) DCM, 0 °C – rt, 12 h.  
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Initial attempts to obtain compound 70 (Scheme 7.15a) using Steglich esterification were met with low yields and 
tedious reaction times. We therefore revised our synthetic strategy, utilising an acylation reaction between the highly 
reactive bromoacetyl bromide 60 and tert-butanol, with pyridine serving as base.
40
 Following a simple work-up 
procedure, which included a dilute acid wash and extraction with diethyl ether, compound 70 was afforded in good 
yield with no further purification required. The subsequent substitution reaction of 70 with imidazole proceeded 
smoothly at room temperature using caesium carbonate as base in DMF.
41
 This furnished the penultimate product 71 
as a tan solid in a yield of 84%. Lastly, stirring of compound 71 with trifluoroacetic acid in DCM for 6 hours was 
followed by removal of the solvent in vacuo to produce the desired imidazole carboxylic acid 72 in excellent yield. 
This highlights the robust and effective nature of this methodology in cleaving tert-butyl ester functional groups.  
With fragment 72 in hand, we set out towards the ensuing amide formation with driving group scaffold 12, shown 
in Scheme 7.15b. Employing the optimized conditions developed for our boron-containing final compounds, two 
equivalents of 72, EDC hydrochloride and HOBt hydrate was stirred with 12 at ambient temperature for 12 hours. 
Following facile consumption of the starting material, the crude product was isolated and purified by flash column 
chromatography. To our delight, scrutiny of the compound by HRMS and NMR spectroscopy revealed identical 
spectra to that obtained in Scheme 7.14 utilising CDI, confirming the successful synthesis of 67 in an improved yield 
of 75%. To discern this, the 
1
H NMR spectra of both the tert-butyl ester imidazole building block 71 and final 
compound 67 will be examined and interpreted. Fragment 71 was chosen over the carboxylic acid 72, as the latter 
was only soluble in deuterated methanol.  
Inspection of the basic 
1
H NMR spectra of 71, illustrated on the following page in Figure 7.13a, provides structural 
confirmation for the successful synthesis of this intermediate. While not relevant in comparison with 67, we see a 
large singlet furthest upfield at δ 1.45 ppm integrating for 9H which was easily ascribed to the tert-butyl group 
(purple) of 71. Moving downfield, a lone peak corresponding to the methylene linker (red) can be found at δ 4.56 
ppm. This left three signals in the aromatic region which all appeared as relatively broad singlets and integrated for 
1H each. Based on the deshielding effects of the neighbouring nitrogen atoms, the 2-position proton (blue) of the 
imidazole was assigned to the peak farthest downfield at δ 7.47 ppm. By process of elimination, the final two signals 
at δ 6.93 and 7.07 ppm were correlated to the remaining imidazole protons (green). Surprisingly, these signals did 
not appear as the anticipated doublets but rather as broad singlets. This peak broadening can possibly be explained 
by the tautomeric and conformational properties of the imidazole group.  
Comparative analysis with the 
1
H NMR spectra of 67 (Scheme 7.13b) reveals the emergence of four new peaks in 
positions correlating with those found in the spectra of 71 thereby supporting successful installation of the imidazole 
carbonyl functional group. As with the 71, we see a solitary singlet that has surfaced at δ 4.87 ppm which integrates 
for 2H, clearly indicative of the methylene group (red) which serves as a linker between the carbonyl and imidazole 
moiety. Scrutiny of the aromatic region reveals a similar peak pattern to that found in the 
1
H NMR spectra of 71, 
namely three broad singlets that integrate for 1H each. Additionally, these peaks were not evident in the spectra of 
the precursory driving group structure 12. By these factors and logical deduction, the two peaks at δ 7.07 and 7.17 
ppm were assigned to the neighbouring imidazole protons (green), while the singlet at δ 7.63 ppm was ascribed to 
the final 2-position proton (blue) of the imidazole functionality.  
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Figure 7.13: 
1
H NMR spectra of a) imidazole building block 71 and b) final compound 67. 
Assessment of all other signals within the 
1
H NMR spectra presented the correct integration amount for 
compound 67, with all protons accounted for and peak splitting patterns to be in good order. The same held for the 
13
C NMR spectrum. Use of HRMS analysis presented a [M+H]
+
 ion of 554.3007, with a calculated mass of 
554.2992, providing final confirmation for the successful synthesis of compound 67.  
While not described, all signals within the 
1
H and 
13
C NMR spectra of the structurally related final compound 69 
were correctly accounted for. Furthermore, compound 69 displayed a [M+H]
+
 ion of 568.3158, with a calculated 
mass of 568.3148, verifying its effective isolation and concluding the synthesis for our imidazole-based final 
compounds.  
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7.4.3.8 Nitriles 
 
 
 
 
Scheme 7.16: Synthesis of nitrile-containing final compound 74. Reagents and conditions: i) 73 (2 equiv.), HOBt·H2O 
(2 equiv.), EDC·HCl (2 equiv.) DCM, 0 °C – rt, 5 h. 
Only one compound bearing a nitrile functionality was synthesised in our serine-targeting library of inhibitors, the 
synthesis of which is displayed above in Scheme 7.16. Application of the optimized acid-coupling parameters 
between 12 and cyanoacetic acid (73) afforded final compound 74 effortlessly in excellent yield. Full characterisation 
by IR, HRMS and NMR spectroscopy - providing a [M+H]
+
 ion of 513.2727 with a calculated mass of 513.2726 -
validated the successful synthesis of the cyanoacetamide-containing final compound 74. This led us to the last 
synthetic endeavour of this chapter involving exploration of dual functional warheads.  
7.4.3.9 Dual Warheads 
As outlined in Section 7.3, we conceived of several electrophiles that contain two functional groups, thereby able 
to simultaneously reversibly interact with and potentially covalently modify the mutated Ser797 residue. This design 
was based on the catalytic triad of serine proteases and our envisioned inhibitors incorporated the use of either a 
cyano- or imidazole-acetamide fragment in combination with a sulfonyl fluoride moiety. Accordingly, the synthesis 
relating to the cyano-based dual functional warhead is illustrated on the following page in Scheme 7.17 and will be 
discussed first.  
Our strategy towards the synthesis of these dual functional warheads was focused on the use of a Michael addition 
reaction. We proposed treatment of the previously synthesised 74 with mild base would facilitate deprotonation of 
the acidic cyanoacetamide α-proton, thereby creating a nucleophilic enolate at this position. Introduction of the 
appropriate electrophile, ESF (20), would then allow for the Michael addition reaction to take place and potentially 
afford dual warhead 75. Due to its frequent use in deprotonation of 1,3-dicarbonyl compounds (pKa ~ 9 – 12) and 
Michael addition reactions, we advocated potassium carbonate as a suitable base.
42
 As ESF contains two electrophilic 
sites (Michael acceptor and sulfonyl fluoride), we wished to avoid the competing reaction of nucleophilic substitution 
at the sulfonyl fluoride. However, Sharpless et al. demonstrated the remarkable stability and inertness of the 
generated sulfonyl fluoride, which only readily reacts with nucleophiles under specific conditions (aqueous solvent).
43
 
We therefore opted to employ acetonitrile as solvent, as it would facilitate solvation of the starting material 74 and 
provide low solubility/surface reaction with the commonly paired potassium carbonate.  
Implementation of these parameters (Scheme 7.17), with an excess of 20 and potassium carbonate to ensure 
reaction completion, resulted in the observation of a single spot as per visualisation by TLC analysis. 
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 Scheme 7.17: Attempted synthesis of compound 75 resulting in isolation of final compound 76. Reagents and conditions: i) 20 
(1.85 equiv.), K2CO3 (2 equiv.), MeCN, −10 °C – rt, 8 h. 
Enthused by this, we avoided a work-up procedure and the potential hazard of compound degradation and chose 
to directly purify the crude product using flash column chromatography. Demonstrated to be stable, the compound 
was subsequently subjected to initial analysis by 
1
H and 
13
C NMR spectroscopy. Perplexingly, the processed spectra 
did not match that of the expected compound 75, with proton integration and carbons signals equating to a larger 
amount than anticipated. The unknown compound was therefore submitted for HRMS analysis, presenting a 
[M+H]
+
 ion of 733.2407. This was strikingly similar to the calculated mass of 733.2402, which matched that of the 
di-substituted product 76. At this point, we surmised that this could indeed be the structure of the isolated product. 
However, to authenticate this presumption, we obtained and processed the relevant 2D NMR spectra. 
Consequently, a variety of 2D NMR experiments were performed which included APT, COSY, HSQC and HMBC. 
The processed 
1
H, 
19
F, 
13
C and portions of the HSQC and HMBC NMR spectra will be displayed and analysed.  
The 
1
H NMR spectrum of compound 76 may be found in Figure 7.14a on the following page. Visual inspection 
revealed the familiar structural signature of the osimertinib derived driving group, as well as the emergence of several 
unidentified signals. As full characterisation of the heterocyclic core had been previously undertaken, we focussed 
our efforts solely on the placement and identification of these unknown elements, which consisted of two sets of 
signals. Starting from the most upfield position, we saw the appearance of a triplet of doublets at δ 2.59 ppm which 
integrated for 2H. Scrutiny of the adjacent set of peaks at δ 2.34 ppm, which contained the dimethylamine (dark 
blue) element of the solubilising group, revealed an integration of 8H instead of 6H. Upon closer inspection, we see 
two sets of peaks flanking the outer edge of the large singlet. This signified an overlap with another triplet of doublets 
(green) which integrated for 2H. We proposed that these signals corresponded to the ethylene protons (green) of 
the doubly substituted sulfonyl fluoride groups which are situated closest to the quaternary carbon centre. Due to 
the unequivalence of these protons, we expected to observe two sets of signals and a peak splitting pattern similar 
to that displayed within the spectrum, thereby corroborating our assumption.  
Moving downfield, we identified two multiplets at δ 3.34 and 3.53 ppm (red) which also integrated for 2H each. 
We ascribed this set of peaks to the neighbouring ethylene protons (red) of the double sulfonyl fluoride functionality. 
As with the adjacent ethylene (green), these protons are unequivalent and would therefore give rise to two signals. 
Furthermore, coupling to the fluorine atom of the sulfonyl fluoride would likely result in a more complex peak 
splitting pattern. Observation of both suppositions within the 
1
H NMR spectrum validated the proposed structure of 
compound 76. Lastly, the 
19
F NMR spectrum (inset) confirmed the presence of a sulfonyl fluoride (purple) moiety, 
with a triplet observed at δ 53.4 ppm – comparable to the spectra obtained for compounds 18 and 21 (Figure 7.9).  
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Figure 7.14: a) 
1
H and 
19
F (inset) NMR spectra and b) HSQC NMR spectra of final compound 76. 
19F NMR Spectrum 
1H NMR Spectrum 
HSQC NMR Spectrum 
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A selected portion of the HSQC NMR spectrum of compound 76 is shown on the previous page in Figure 7.14b. 
Working from this spectrum, we were able to correlate the protons of the solubilising group (dark blue, light blue, 
brown), aromatic methyl ether (yellow) and indole methyl (orange) to their appropriate carbons, which can be 
referenced to their respective colours in the structure displayed in Figure 7.14a. However, we were most interested 
in identifying the carbons of the proposed doubly substituted sulfonyl fluoride functionality. Agreeably, both sets of 
ethylene protons (green and red) suspected to belong to this moiety coupled to one carbon each. Examination of 
the most upfield of these sets revealed both of the triplet of doublet signals at δ 2.34 and 2.59 ppm (green) coupling 
to the carbon signal at δ 31.3 ppm. Comparison of the larger relative peak intensity of this carbon signal to the 
neighbouring indole methyl substituted carbon (orange) at δ 33.4 ppm reinforced our belief that this was two 
ethylene carbon signals instead of one.  
Focussing on the more downfield set of multiplets (red) at δ 3.34 and 3.53 ppm, we again saw a correlation of both 
of these sets of protons to a single carbon signal at δ 46.4 ppm. Interestingly, this carbon signal appeared to be split 
into an apparent triplet. However, this was not unexpected, as the proposed carbon centres (red) were in close 
proximity to the fluorine atom of the sulfonyl fluoride moiety. As fluorine atoms are known to couple to neighbouring 
carbon nuclei due to the high abundance of the 
19
F isotope and lack of C-F decoupling in standard 
13
C NMR 
spectroscopy pulse sequences, C-F splitting is observed and has been found in the 
13
C NMR spectra of several 
fluorine containing compounds synthesised in this thesis. Therefore, we believed that the observed triplet was the 
result of an overlap between the two anticipated doublets of the two respective carbon centres (red). The observed 
coupling to and splitting of this carbon centre provided further weight to our assignments and the proposed structure 
of final compound 76.  
To gain further insight into the structural elucidation and confirmation of compound 76, we undertook an HMBC 
NMR spectroscopy experiment, with a truncated section of the afforded spectrum shown in Figure 7.15a on the 
next page. We were able to identify several new carbon centres through long range interactions with previously 
identified proton signals, which are displayed as numbers on the structure provided in Figure 7.15b. These included 
the aromatic carbons 3, 4 and 5, which were identified from coupling to the solubilising group, indole methyl and 
aromatic methyl ether respectively.  
Once again, investigation of the long-range interactions of the sulfonyl fluoride ethylene bridge protons (green and 
red) was the main priority in our spectral analysis. Therefore, inspection of the upfield region showed the first of 
these ethylene proton sets (green) coupling to two different two carbon signals at δ 117.8 and 161.6 ppm. While 
not displayed but notable, these protons also coupled to the other ethylene bridge carbon (red) at δ 46.4 ppm which 
appeared as a triplet, verifying its proximity to this carbon centre. By logical deduction of the shielding/deshielding 
effects experienced by the suggested neighbouring carbon centres, we proposed that the most upfield of these 
carbons at δ 117.8 ppm belonged to the quaternary carbon centre (1) and assigned the most downfield coupled 
carbon signal at δ 161.6 ppm to the carbonyl carbon (2) of the amide moiety. These assignments fulfilled the criteria 
of our postulated structure and further substantiated formation of the doubly substituted final compound 76.  
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Figure 7.15: a) HMBC and b) 
13
C NMR spectra of final compound 76. 
HMBC NMR Spectrum 
13C NMR Spectrum 
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Moving downfield to the remaining set of ethylene bridge protons (red), we did not discern any coupling to carbons 
within this region. While we did expect coupling to the proposed quaternary carbon centre (1), long-range coupling 
interactions are often dictated by the coupling constants and local geometry across the molecule, known as the 
Karplus relationship.
44
 The Karplus equation, which describes a correlation between the 
3
J-coupling constants and 
dihedral torsion angles in NMR spectroscopy, shows that the magnitude of these couplings are near zero when the 
dihedral angles are near 90°. We believed this to be the case for the long-range coupling between the ethylene 
protons (red) and the quaternary carbon centre (1), as this take place through an aliphatic chain. As observed 
previously, we did see coupling of the ethylene protons (red) to the carbon (green) of the neighbouring ethylene 
protons at δ 31.3 ppm.   
Lastly, the 
13
C NMR spectrum of compound 76 is shown in Figure 7.15b, with all assignments discerned through 
our 2D NMR analysis displayed either by colour or number. With all carbons correctly accounted for, the [M+H]
+
 
ion of 733.2407 provided by HRMS matching the calculated mass of 733.2402 and investigation by 2D NMR 
spectroscopy substantiating the proposed structure of compound 76, we were able to confidently conclude that di-
substitution had occurred and resulted in exclusive formation of compound 76.  
With structural confirmation of compound 76, we considered the synthetic adjustments required to afford the 
desired mono-alkylated compound 75. Multiple attempts with replacement of solvent, lowering of reaction 
temperature and alteration of the equivalents of potassium carbonate only afforded the di-substituted product 76 in 
lower yields than the optimal conditions of Scheme 7.17. Interestingly, utilisation of a 2-fold excess of the 
cyanoacetamide driving group 74 also resulted in exclusive synthesis of the di-substituted product and a return of 
the excess starting material. Observing only sole formation of the dialkylated product 76 in these experiments, we 
sought to explore the implications of exchanging the base.  
Piperidine possesses a similar pKaH (~ 11)  to potassium carbonate and is customarily used to affect enol formation 
in 1,3-dicarbonyl compounds, particularly in the Knoevenagel Condensation reaction.
45, 46
 Finding these properties 
desirable, we elected to employ piperidine as base in the reaction of 74 and ESF (20).  Unfortunately, use of a 
catalytic, equimolar and excess amount resulted in no reaction taking place and return of the starting material. As 
piperidine is a nucleophilic base, we ascribed the absence of any product formation to a pre-emptive reaction 
between piperidine and the highly reactive ESF electrophile. When used catalytically, the piperidine would be 
completely consumed before being able to facilitate deprotonation of 74. Similarly, in a stoichiometric or excess 
amount, all the ESF would react with piperidine, resulting in non-availability of electrophile and the observed event 
of no reaction taking place.   
As recourse, we altered the base to the sterically congested potassium tert-butoxide. Owing to its non-nucleophilicity 
and relatively high strength (pKaH ~ 17), potassium tert-butoxide has found utility as a base catalyst in organic 
synthesis for nearly 70 years.
47
 However, as witnessed in previous reactions with potassium carbonate, use of either 
catalytic or stoichiometric amounts of potassium tert-butoxide led to conversion of 74 into the di-substituted 
product 76. This was observed even at low temperatures ranging between −40 °C and −78 °C, with the amount of 
starting material returned inversely proportional to the equivalents of electrophile 20 employed.   
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Frustrated by the lack of control in product outcome, we ventured toward full deprotonation of 74 prior to treatment 
with the electrophile 20. Consequently, a suspension of excess sodium hydride in THF was treated with 74 at −40 
°C, allowed to warm to room temperature and stirred for one hour. After recooling to −40 °C, this solution was 
treated with 20, followed by immediate TLC analysis. Intriguingly, visualisation revealed a very faint secondary 
product spot in between the starting material 74 and an intense spot correlating to the di-alkylated product 76, 
potentially indicating minor generation of the mon-substituted product. Disappointingly, all attempts to isolate and 
purify this spot resulted in a mixture with either 74 or 76, or too little product to discern and confirm successful 
synthesis of the mono-substituted 75.  
Perusal of the literature revealed a single publication related to fluorosulfonylethylation of active methylene 
substrates. With results comparable to those obtained in our synthetic endeavours, Krutak and co-workers were also 
unable to monoalkylate various malonyl derivatives in the presence of triethylamine, as rapid formation of the 
bis(fluorosulfonylethyl) derivatives observed and exclusively obtained.
48
 From these and our experimental 
observations and outcomes, we put forth a plausible reaction mechanism to explain selective di-alkylation over 
mono-alkylation. This proposed mechanism may be found on the following page, illustrated in Figure 7.16 and will 
be reviewed comprehensively.  
Upon treatment of 74 with an applicable base (green), we believe deprotonation of the acidic cyanoacetamide α-
proton leads to formation of a carbanion. This carbanion is stabilised by the neighbouring electron-withdrawing 
groups, able to form resonance structures such as the enolate structure 77. This nucleophile then reacts with the 
electrophile alkene of ESF (red) to form intermediate 78 in a conjugate addition reaction. Hitherto, this is the 
standard reaction mechanism for a Michael addition reaction. Traditionally, proton abstraction by the enolate 
intermediate of 78 (red, left) would occur from either the protonated base or solvent. Owing to its proximal location 
and acidity from the adjacent electron-withdrawing groups, one could propose that the remaining active methine 
proton (purple) could be abstracted by the neighbouring enolate functionality (78, red, left). However, such a shift 
would require an antarafacial [1,3] sigmatropic rearrangement. Although allowed, these rearrangements are virtually 
unknown and not observed, due mainly to the unfavourable orbital arrangement/asymmetry and consequent 
geometric requirements for the reaction.
49
 Yet, this intermediate is able to invert to the anion stabilised resonance 
form of 78 (red, right). The tetrahedral character of the sulfonyl fluoride group and adjacent anion (red) allows for 
stabilisation of the neighbouring methine proton (purple) through induction. Therefore, we postulate that the enolate 
functionality could act as an intermolecular base, either reinitiating the reaction through deprotonation of another 
equivalent of 74 or abstracting an active methine proton (purple) from another formed resonance intermediate such 
as 78. Additionally, abstraction from the protonated base may also occur, which may in turn deprotonate this active 
methylene proton (purple). Furthermore, this exchange may be driven by the inductive effect of the sulfonyl fluoride 
group, stabilising the newly formed anion. In doing so, a carbanion similar to that formed in the initial steps of the 
reaction could then be generated at the α-position of the malonyl derivative, which may in turn convert into the 
nucleophilic resonance structure shown in 79. We propose that this nucleophile then attacks a second equivalent 
of ESF (blue), to produce intermediate 80.  
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 Figure 7.16: Proposed mechanism for the formation of compound 76 
Once again, the newly generated enolate functionality (blue) of 80 could potentially act as a base and deprotonate 
another equivalent of 74, driving the reaction forward, abstract a proton from the external base or be ultimately 
quenched during the work-up procedure. All these possibilities lead to the generation of 76, the major product 
isolated in all our reaction attempts.  
Illustrated in Scheme 7.18 on the next page, our final synthetic effort involved a Michael addition reaction between 
the imidazole-bearing compound 67 and ESF (20), in the hopes of obtaining the dual functional warhead 81. Given 
the weaker electron-withdrawing capabilities of the adjacent imidazole group, we perceived the acidity of the active 
methylene proton to be reduced. We therefore reasoned that only potassium tert-butoxide and sodium hydride 
would be appropriate to facilitate deprotonation of 67. To our disappointment, all attempts to synthesise final 
compound 81, utilising these bases and parameters derived from the cyanoacetamide counterpart 74, were met 
with no visible reaction taking place and a diminished return of starting material 67. Due to time constraints, synthesis 
of both 75 and 81 could not be completed or investigated further. However, potential solutions to the problems 
encountered with this class of compound will be examined in the future work section (Section 7.7).  
This concluded the synthesis of our osimertinib derived serine-targeting compounds, allowing us to proceed with 
biochemical and cellular evaluation of the successfully synthesised final compounds up until this point. These 
compounds were screened against the wild-type and various mutant forms of EGFR, with the intention of either 
reversibly interacting or covalently modifying the mutant Ser797 residue. An in-depth discussion of the results 
obtained from this assessment will be undertaken in the following section.  
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Scheme 7.18: Attempted synthesis of compound 81.  
7.5 Biochemical and Cellular Evaluation 
As with the previous chapter, complications within the biology lab of our collaborators at the Technische Universität 
in Dortmund prevented biochemical inhibitory measurements of the synthesized final compounds against the triple 
L858R/T790M/C797S mutant variant of the enzyme. However, we were able to acquire IC50 values against the 
L858R/C797S double mutant, which could still provide valuable insight into potential interactions with the mutated 
Ser797 residue. Furthermore, a wild-type-bearing cell line A431, the EGFR-L858R/T790M drug resistant cell line 
H1975 and clinically relevant osimertinib resistant cell line EGFR-PC9/T790M/C797S was also employed.  
Additionally, promising compounds were further evaluated against BaF3 cell lines of both the single activating EGFR-
L858R and the EGFR-T790M/C797S mutant variants of the enzyme (Section 4.6.3). Compound assessment was 
carried out either by Dr. Jonas Lategahn, Dr. Marina Keul or Mr. Tobias Grabe, with all measurements being 
executed in at least triplicate. The respective IC50 and EC50 values of osimertinib, the unsubstituted scaffold 12 and 
the reversible propionamide counterpart of osimertinib 13 accompany the obtained results in the report. 
An overview of the results from the biochemical and cellular evaluation of the Michael acceptor- and sulfonyl 
fluoride-containing final compounds may be found on the following page in Table 7.1. Inspection of the first entries 
of the assessed inhibitors, the unsubstituted aniline scaffold 12 and propionamide analogue of osimertinib 13, 
revealed an anticipated loss in activity when compared to osimertinib. This decrease was witnessed across-the-board, 
both biochemically and in a cellular setting, and can be ascribed to the loss of irreversible inhibition of the EGFR 
enzyme in the absence of the acrylamide Michael acceptor moiety. While compound 12 displayed a stronger 
biochemical profile than 13, these results were reversed for the cellular assessment. This pointed towards an 
intolerance for the naked aniline within cells and a preference for substitution at this position with an appropriate 
functional group. Notably, the reduction in efficacy for 13, when compared with osimertinib in the cellular 
measurement against the PC9/T790M/C797S triple mutant, was not as pronounced, with respective EC50 values of 
3.9 and 3.1 µM. As we wished to investigate the potential interactions of our electrophilic fragments with the mutated 
Ser797 residue, our principal manner of comparison was with the unsubstituted aniline 12 and the propionamide-
bearing compound 13, and secondarily with osimertinib where applicable.  
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      Table 7.1: Biochemical and cellular evaluation results for the Michael acceptor and sulfonyl fluoride containing synthesised 
final compounds. 
Examination of the biochemical data of the sole Michael acceptor-containing final compound 17 exhibited an overall 
improved inhibitory profile in comparison to the reference compounds 12 and 13. Whilst minor for the wild-type 
and single activating L858R mutation, this enhancement was a more than 3- and 14-fold improvement over 12 and 
13 respectively for the L858R/T790M mutant, with an IC50 value of 3.87 nM. This alluded to potential covalent 
modification of the mutant enzyme through a Michael addition reaction between the ethenesulfonamide moiety of 
17 and the Cys797 residue. Notably, compound 17 also demonstrated a 1.7-fold improved IC50 value against the 
L858R/C797S double mutant when compared to osimertinib. While this improvement was not indicative of 
irreversible binding, it implied that the more electron-deficient system of the ethenesulfonamide electrophile was 
more suitable for reversible interactions with the mutated serine residue than the traditional acrylamide electrophile.  
As seen with the unsubstituted scaffold 12 and propionamide 13, the EC50 values of compound 17 drastically 
increased in the cellular assessment against the enzyme. This inflation to single digit micromolar values strongly 
supported a lack of covalent inhibition taking place within the cellular setting. Comparable to the biochemical results, 
compound 17 retained a 2-fold superiority over both model compounds 12 and 13 against the H1975 double 
mutant containing cell line.  
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This highlighted the ethenesulfonamides greater affinity for reversible interaction with the Cys797 residue over the 
unsubstituted aniline (12) or propionamide (13) functionalities. However, this edge in activity was surprisingly not 
reflected in the EC50 values obtained against the PC9/T790M/C797S triple mutant, with compound 17 exhibiting an 
EC50 value of approximately 6.3 µM – weaker than both reference compounds 12 and 13. This signified a 2-fold loss 
of activity compared to osimertinib against this mutant variant. These results suggest that this electrophile is more 
applicable for targeting cysteine residues and ill-suited for interactions with the mutated Ser797 residue in a cellular 
setting. Additionally, as osimertinib was specifically developed to contain an acrylamide Michael acceptor, we 
propose that the interchange to an ethenesulfonamide electrophile in compound 17 could have negatively affected 
the pharmacokinetic profile of the inhibitor.  As such, we believe these factors to be responsible for the poor 
performance of this compound against the PC9/T790M/C797S.  
Owing to the superior biochemical activity of 17 over osimertinib in inhibiting the clinically relevant L858R/C797S 
mutant, the ethenesulfonamide-containing compound was subsequently evaluated against the available Ba/F3 cell 
lines. Compound 17 matched the assay limit of 14 nM displayed by osimertinib against the single Ba/F3-L858R 
mutant but exhibited a dramatic loss in activity to nearly 25 µM against the double Ba/F3-T790M/C797S mutant. 
This result, combined with the PC9/T790M/C797S data, suggests that use of this electrophile will not be applicable 
in overcoming enzymes bearing the C797S mutation.  
Moving to the sulfonyl fluoride-containing inhibitors 21 and 22, we found an inhibitory profile similar to that of 
compound 17 against the wild-type, single and double mutant bearing enzymes. However, the biochemical data 
obtained for the key L858R/C797S double mutant variant was particularly compelling. Inspection of the entries for 
the saturated (21) and unsaturated (22) sulfonyl fluorides demonstrated IC50 values of 693 and 92 nM respectively. 
Impressively, this equated to a 3-fold improvement in inhibition for compound 22 when compared to osimertinib, 
and a 2.7-fold loss in activity for the structural counterpart 21. Exploring the obtained values of the cellular assays, 
the saturated 21 displayed little to no activity for the wild-type and double mutant H1975 cell lines but showed 
improved efficacy against the PC9/T790M/C797S triple mutant. These results were mirrored for compound 22, with 
the unsaturated analogue exhibiting an EC50 value of ~ 5 µM against the triple mutant - a 2-fold improvement over 
the double mutant. Favourably, this observation indicated an interaction preference of these electrophiles for the 
mutated serine residue of the triple mutant over the typical cysteine residue present in the wild-type and double 
mutant variants of the enzyme.  
We were most intrigued by the 7.5-fold difference in biochemical activity between the two sulfonyl fluorides, a trend 
which was preserved in the results of the cellular assays. The unsaturated sulfonyl fluoride 22 outperformed its 
saturated equivalent 21 by nearly 5-fold against the PC9/T790M/C797S cell line. Enthused by this variation in activity 
brought about by the presence of the adjacent double bond, we scoured the literature for a suitable explanation. 
From our search we uncovered a recent publication by Mukherjee et al. surrounding sulfonyl fluoride reactivity and 
hydrolytic stability.
50
 In this study, the group investigated the reaction of various sulfonyl-fluoride containing 
warheads with nucleophilic N-acetyl amino-acid side chains of cysteine, tyrosine and lysine under physiological 
conditions. With emphasis on the influence of steric and electronic factors, numerous substituted aryl sulfonyl 
fluorides (activating and deactivating) and closely related vinyl and aliphatic sulfonyl fluorides were utilised.  
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For the aryl sulfonyl fluorides, the group found that their reactivity towards the amino acids could be modulated 
accordingly by altering the electronic properties of the electrophile. Furthermore, the aryl sulfonyl fluorides stability 
towards hydrolysis was found to be inversely proportional to their displayed reactivity. However, these trends were 
not reflected in the highly reactive aliphatic and vinyl sulfonyl fluoride warheads. As these reactive groups are 
pertinent to our synthesised final compounds, we will focus solely on these results which can be seen in Figure 7.17a.  
Phenylmethanesulfonyl fluoride (PMSF), pictured in Figure 7.17a, has found wide use in biological sciences as a 
protease/esterase inhibitor and covalent probe.
51
 Upon incubation with nucleophilic amino acid residues in a 
buffered aqueous solution of pH 7.5 at 37 °C , PMSF was found to rapidly hydrolyse. While in accordance with 
previous reports on the inhibitor, the group found that this decrease in hydrolytic stability did not correlate with an 
increase in reactivity, as was witnessed with the aryl sulfonyl fluoride electrophiles. By contrast, the rate of hydrolysis 
of the structurally related phenylethanesulfonyl fluoride (PESF, Figure 7.17a) was found to be approximately 13-fold 
slower than that of PMSF. However, despite this increased stability, the group did not observe sulfonylation of the 
nucleophilic tyrosine amino acid by PESF. Although less reactive than the aryl sulfonyl fluorides investigated, 2-
phenylethenesulfonyl fluoride (82, Figure 7.17a) did undergo sulfonylation of tyrosine and was found to be a great 
deal more hydrolytically stable that PSMF and PESF. As a side note, no 1,4-addition of N-acetyltyrosine to the strongly 
electron-deficient olefin of the vinylsulfonyl fluoride was witnessed in any of the reactivity studies.     
All the above observations are consistent with the proposed mechanism of hydrolysis for aliphatic sulfonyl fluorides, 
displayed in Figure 7.17b.  Sulfonyl halides, including fluorides, which bear acidic protons in the α-position (red) 
have been documented to undergo an elimination reaction to form sulfene-type intermediates such as (83), with 
PMSF as prime example (Figure 7.17b).
52, 53
 Hydrolysis of this highly reactive intermediate then proceeds via an 
addition reaction, resulting in formation of compound 84. This mechanism is supported by the low stability and 
reactivity displayed by PMSF, owing to the presence of the acidic benzylic α-proton (red). 
 
 
 
 
 
 
 
 
Figure 7.17: a) Depiction of the reactivity and hydrolytic stability trends displayed by the aliphatic and vinyl sulfonyl fluorides 
and b) Proposed mechanism of hydrolysis occurring through a sulfene-like intermediate 83 rather than via SN2 reaction.
50
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The greater stability exhibited by PESF can be attributed to the decreased acidity of the non-benzylic α-proton 
(purple), while its inert nature suggests that sulfene formation and subsequent hydrolysis occurs more rapidly than 
nucleophilic addition to the sulfonyl group by tyrosine.
51
 Importantly, the absence of an acidic proton in the α-
position for the vinyl sulfonyl fluoride 82 resulted in a stable electrophile able to react with N-acetyltyrosine. 
Considering these mechanistic insights, the disparity in inhibitory activity displayed by the aliphatic and unsaturated 
sulfonyl fluoride 21 and 22 respectively becomes transparent. We propose that the noticeably lower IC50 and EC50 
values exhibited by the aliphatic sulfonyl fluoride 21, compared to 22, can be ascribed to circumstantial hydrolysis 
of the warhead, as the biochemical and cellular evaluation is carried out at pH 7.4. This is plausible, owing to the 
presence of an acidic α-proton, thereby allowing for hydrolysis via the discussed elimination/addition reaction 
sequence and formation of the sulfene-type intermediate. Hydrolysis by this mechanism is not possible for the 
unsaturated sulfonyl fluoride 22, which does not contain an available acidic proton in the α-position. We believe it 
is this stability, and the ability of the sulfonyl fluoride warhead to survive and interact with mutated Ser797 residue, 
that gives rise to the greater inhibitory activity displayed by this compound. This is an interesting and positive result, 
as moderate reactivity and hydrolytic stability are favourable characteristics of electrophiles undergoing covalent 
modification. Therefore, it is our opinion that this class of warhead could see further use in the prospective 
development of new irreversible inhibitors which will be discussed in the future work section (Section 7.7).  
The biochemical and cellular evaluation outcomes for the second set of compounds is illustrated in Table 7.2. Of 
this group, the first functionality we wished to scrutinize was the methyl and ethyl mono-phosphonate esters 40 and 
42 respectively. As we were unable to isolate the highly reactive fluorophosphonate derivatives, covalent 
modification of Ser797 was ruled out. Therefore, we wished to investigate the potential for favourable reversible 
interactions between the phosphonate moiety and the mutant residue. Surveying the obtained values, we saw little 
difference in activity between the two inhibitors, with the smaller methyl counterpart exhibiting a slightly improved 
inhibitory profile. Biochemical evaluation of compound 40 against the L858R/C797S double mutant displayed a 10-
fold drop in activity in comparison to osimertinib and the first indication of incompatible interactions between this 
functional group and the Ser797 residue.  
As with all the compounds analysed thus far, a decrease in activity was observed in the cellular assessment of both 
40 and 42. However, this increase was significantly greater for these compounds, which resulted in high micromolar 
EC50 values across all cell lines. Believed to stem from a poor pharmacokinetic profile provoked by the phosphonic 
acid part of the mono-phosphonate ester, we wished to gain a better understanding of this cellular intolerance. 
Confirmation of this speculation was made evident in the assessment of the methyl mono-phosphonate ester 40 
against the two Ba/F3 cell lines. Of all compounds screened against the Ba/F3-L858R cell line, compound 40 was 
the only inhibitor to display a dramatic loss of activity. With an EC50 value of 263 nM - nearly 19-fold greater than 
the assay limit of 14 nM which was achieved by all other candidates – it was apparent that this functional group 
induced a negative impact and was not tolerated in cells. This was further reflected in the results of the Ba/F3-
PC9/T790M/C797S triple mutant, with an 8-fold loss of efficacy when compared to osimertinib. Thus, it was evident 
from these findings that use of this functional group will not be effective in creating favourable reversible interactions 
with the Ser797 residue and overcoming resistance mediated by the C797S mutation in EGFR inhibition. 
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   Table 7.2: Biochemical and cellular evaluation results for the mono-phosphonate ester, boronic ester and trifluoromethyl 
ketone containing synthesised final compounds. 
Analysis of the inhibitory values of the boronic ester-containing compound 47 revealed some interesting features. 
Firstly, as this compound displayed an equivalent or improved biochemical profile over the unsubstituted aniline 
scaffold 12 and propionamide-bearing compound 13, we concluded that the sizeable boronic ester was tolerated 
within the binding pocket. This was a pleasant surprise, as we expected the bulky pinacol group to create an 
unfavourable steric clash within the active site. Incubation of 47 with the L858R/C797S double mutant resulted in a 
~ 4.5-fold loss of activity when compared to osimertinib, with an IC50 value of 1.1 µM. While a moderate decrease, 
we found this result to be encouraging, as we maintain that the propenamide-linked boronic ester moiety is suitable 
for inhibition of mutant variants of the EGFR enzyme. Suitably, we anticipate that the hydrolysed boronic acid 
counterpart, while not afforded in this synthetic attempt, will be capable of surpassing compound 47 in its efficacy. 
This is due to its potential to form favourable reversible interactions with and irreversibly inhibit the mutant serine 
residue.
14, 17
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Inspection of the A431 wild-type and H1975 double mutant cell lines reveals a similar trend to that found in the 
biochemical results, with 47 exhibiting improved selectivity and EC50 values over the unsubstituted aniline 
scaffold 12. This however was not reflected in the results of the PC9/T790M/C797S cellular assay, with the boronic 
ester faring worse than both reference compounds 12 and 13 and displaying a near 2-fold loss in efficacy when 
compared to osimertinib. However, the obtained value of 6.8 µM was an improvement on most of the compounds 
already measured and on par with the ethenesulfonamide and unsaturated sulfonyl fluoride 17 and 22 respectively 
(Table 7.1). Encouragingly, compound 47 showed improved cellular inhibition of Ba/F3-T790M/C797S over the 
PC9/T790M/C797S triple mutant, with an EC50 value of 5.3 µM. This result contrasts with the measurements 
obtained for ethenesulfonamide 17 and the methyl mono-phosphonate ester 40, which both sustained major losses 
of activity against this cell line. The exclusive enhanced efficacy exhibited by 47 against the Ba/F3-T790M/C797S 
cell line underlines the potential development and utilisation of boronic ester and acid moieties in overcoming 
C797S mediated resistance. Prospective employment of these functional groups and the synthesis thereof will be 
reviewed in the future work section (Section 7.7).  
Unfortunately, all results obtained for the trifluoromethyl ketone-containing compound 57 were found to be 
lacklustre. High micromolar IC50 and EC50 values indicated intolerance for the electronegative character of the 
trifluoromethyl moiety. As with the mono-phosphonate esters, this functional group negatively impacted the 
pharmacokinetic profile of the inhibitor. Furthermore, the compound was found to be inactive against the 
PC9/T790M/C797S cell line, indicating incompatibility for reversible interactions between this group and the 
mutated Ser797 residue. As such, we decided not to deliberate further nor include this electrophile within future 
considerations.  
The results of the final collection of compounds to be examined, tabulated in Table 7.3, included those containing 
an imidazole, nitrile and dual-warhead functionality. Beginning with the imidazole-bearing compounds 67 and 69, 
we observed positive trends which reinforced the inclusion of this scarcely utilised moiety. In the biochemical 
evaluation against the single activating L858R and double L858R/T790M mutant, both compounds displayed 
adequate inhibition values. While more efficacious than propionamide 13, both compounds were roughly 2-fold 
less active than the unsubstituted scaffold 12. In these variants, the longer propenamide-substituted imidazole 
compound 69 exhibited marginally superior values. As witnessed with the large propenamide-substituted boronic 
ester 47, this alludes to space within the binding pocket at this region capable of accommodating larger substituents. 
Against the L858R/C797S mutant, 67 and 69 displayed similar activity, with both compounds approximately 2-fold 
less potent than osimertinib and the smaller imidazole-bearing 67 edging over 69 with an IC50 value of 471 nM vs 
578 nM respectively. We found these results acceptable, as these compounds were amongst the most effective 
inhibitors of this mutant variant when compared with all other synthesised final compounds. 
As demonstrated in the biochemical evaluation, compound 69 proved marginally more efficacious than the shorter 
chain 67 and was exclusively selective for the double mutant H1975 cell line over the wild-type in the cellular 
assessment. While this trend was mirrored in the cellular assay, the full spectrum of EC50 values obtained for 67 and 
69 were found to be superior to both the unsubstituted aniline scaffold 12 – the inverse of what was observed for 
the biochemical inhibition – and the more potent propionamide 13. 
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Table 7.3: Biochemical and cellular evaluation results for the imidazole, nitrile and dual-warhead containing synthesised final 
compounds. 
This result was significant for several reasons, the first being that this gave an indication of the imidazole moiety being 
well-tolerated within cells. Secondly, as compounds 67 and 69 were shown to be more effective than both reference 
compounds 12 and 13 against the double mutant H1975 cell line, we could conclude that the imidazole group was 
a more favourable substituent at this position. This outcome thereby implied that this functionality interacted more 
favourably with the Cys797 residue than the unsubstituted aniline 12 or propionamide 13, as observed for 
ethenesulfonamide 17 (Table 7.1). 
Even more compelling was the results obtained for the PC9/T790M/C797S triple mutant bearing cell line. 
Compounds 67 and 69 exhibited a near 2-fold improvement over their respective results from the H1975 assay, 
both with values of ~ 3.2 µM. Accordingly, this increased efficacy could be ascribed to the imidazole functional 
group interacting more favourably with the mutant Ser797 residue of the triple mutant than the Cys797 residue 
found in the H1975 cell line. Furthermore, these EC50 values were comparable with that of osimertinib (3.1 µM).  
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Enthused by these results, we assessed the potency of compound 67 against the available Ba/F3 cell lines, which 
reached the assay limit of 14 nM for the single activating mutant. Interestingly, with an EC50 value of 3.1 µM, the 
imidazole compound 67 was found to retain and slightly improve its activity against the BaF3-T790M/C797S cell 
line when compared with the PC9/T790M/C797S triple mutant. This outcome, coupled with all other encouraging 
results afforded in the cellular assessment of compound 67 and 69, highlights the prospect for development and 
employment of these imidazole functional groups in the therapeutic targeting of the EGFR-C797S mutant variant. 
We will review strategies for the incorporation and utilisation of this moiety within the future work section 
(Section 7.7).   
Examination of the biochemical inhibitory profile of the cyanoacetamide-containing compound 74 reveals a striking 
similarity to that of the imidazole-bearing compound 67 and 69. As such, our analysis of 74 will focus solely on the 
cellular evaluation and attempt to provide an explanation for the differences in activity observed between these 
functional groups in this setting. Accordingly, inspection of the values obtained in the H1975 cellular assessment of 
compound 74 reveals a major discrepancy when compared with the results of the imidazole-bearing compounds 
67 and 69. Compounds 67 and 69 were shown to be more efficacious than the reference compounds 12 and 13, 
with EC50 values of 7.1 and 5.8 µM respectively. In contrast, compound 74 exhibited a moderately weaker EC50 
value of 9 µM, comparable to that of the reference compounds. Intriguingly, evaluation against the 
PC9/T790M/C797S revealed a restoration of efficacy for the nitrile containing compound, with an exhibited EC50 
value of 3.4 µM - equivalent to both 67 and 69. We postulate that this disparity in inhibition efficacy of compound 
74, which exists between both the Cys797 and Ser797 bearing enzymes and the imidazole-based inhibitors, may 
be explained on the premise of key differences in the structural and electronic elements of the interactive functional 
groups.  
As both the imidazole and nitrile functional group contain nitrogen atoms that can serve as hydrogen bond acceptors, 
both classes of compounds are able to interact reversibly with the hard Ser797 hydroxyl functionality. This could 
provide an explanation for the improved activity witnessed for both the imidazole-bearing compounds 67 and 69 
and the nitrile containing inhibitor 74. Additionally, this gives clarity on why both imidazole compounds are nearly 
identical in potency and the nitrile slightly less so, proposed by observation to be a marginally weaker hydrogen 
bond acceptor.
54
 This is further corroborated by the slightly higher obtained EC50 value of 4.3 µM for 74 against the 
Ba/F3-L858R/C797S cell line, in comparison to the 3.1 µM displayed for imidazole 67.  
Although not favoured and leading to the observed drop in efficacy, both sets of compounds would have the nitrogen 
hydrogen bond acceptor at their disposal for interactions with the softer, more electron rich Cys797 residue. 
However, we believe the superior EC50 values demonstrated by the imidazole compounds 67 and 69, stems from 
the π-electron cloud of its heteroaromatic ring and rotational capabilities, which have been documented to 
participate in non-covalent interactions within protein structures.
55
 Furthermore, sulphur-π interactions are prevalent 
in biochemistry and protein receptors, with cysteine/aromatic interactions playing important roles in protein folding 
and stabilisation and their presence being reported recently in solid state crystal structures of proteins.
56, 57, 58
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We therefore propound that it is the presence of an additional sulphur-π interaction between the heteroaromatic 
π-electron cloud of the imidazole moiety and the Cys797 residue that is responsible for the enhanced activity 
displayed against the H1975 and A431 cell line in comparison to 74. As the nitrile lacks this aromatic nature and 
the ability for sulphur-π interactions, we witness a decrease in activity to 9 µM for compound 74 for the H1975 cell 
line. Notably, this loss of activity is also observed in the Cys797-containing wild-type variant of the enzyme. 
Lastly, we propose that the longer propenamide-substituted imidazole 69 showed marginally superior activity over 
the shorter analogue 67 potentially due to a more favourable orientation and proximal location to the Cys797 
residue. Importantly, the above hypotheses remain conjecture and cannot be confirmed until further studies are 
undertaken. This may include the use of molecular modelling or procurement of a crystal structure of either of the 
imidazole compounds complexed within any Cys797-containing form of the EGFR enzyme. Notably, as the nitrile 
exhibits a near 3-fold selectivity for the Ser797-bearing triple mutant over the Cys797 bearing enzymes, this 
electrophile could be developed and utilised in the selective inhibition of the EGFR-C797S mutant. This selectivity, 
combined with the other attractive inhibitory features discussed for the imidazole-bearing compounds, warrants 
further investigation of these functional groups in targeting the EGFR-C797S mutant.  
The final inhibitor to be discussed for this chapter is the dual-warhead containing compound 76. As the α-position 
of the cyanoacetamide was doubly derivatised with the saturated sulfonyl fluoride warhead, we anticipated a loss of 
activity due to the large size of 76 and the proclivity of the sulfonyl fluorides towards hydrolysis. The obtained results 
conformed to our expectations, with the dual-warhead displaying a dramatic decrease in biochemical inhibitory 
potency. Furthermore, the dual-warhead 76 was found to be inactive against all cell lines, presumably due to 
hydrolysis of the aliphatic sulfonyl fluoride moieties. This result would be in keeping with the poor EC50 values 
measured for the sulfonyl fluoride inhibitor 21 (Table 7.1) and would almost certainly occur via the sulfene-type 
intermediate mechanism described previously (Figure 7.15b). Although this could be seen as a negative result, we 
believe that potential lies in the synthesis of the originally intended mono-substituted dual-warheads, particularly 
due to the interesting selectivity profile displayed by the nitrile compound 74.  
In conclusion, confirmation of the compounds binding properties and mode of inhibition was investigated using 
mass spectrometry experiments. Incubation of the synthesised final compounds with wild-type EGFR resulted in 
none of the incubated enzymes exhibiting an increase in mass equivalent to the corresponding compound labelled 
protein. This indicated a reversible binding mode for all inhibitors, which could be construed from the corresponding 
biochemical and cellular data of these compounds.  
7.6 Conclusions 
In this chapter, our research focus shifted from targeting the EGFR catalytic lysine residue to the development of 
inhibitors targeting the mutated Ser797 residue. As this mutant serine residue contains a harder, more inert hydroxyl 
nucleophile, we implemented a strategy of including electrophiles known to interact and irreversibly inhibit serine 
containing enzymes such as proteases and esterases. These electrophiles included Michael acceptors, sulfonyl 
fluorides, fluorophosphonates and phosphonate esters, boronic esters and acids, trifluoromethyl ketones, α-, β-
haloketones, imidazoles and nitriles.  
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Furthermore, we envisaged the synthesis of dual-warhead-containing compounds, built on the premise of the 
catalytic triad in serine proteases. Building on the synthetic achievements of the previous chapter, these electrophiles 
would be incorporated on the osimertinib-derived scaffold at the aniline conventionally derivatised with the 
acrylamide Michael acceptor.  
The synthesis of the osimertinib-derived driving group 12 proceeded smoothly, with high yielding intermediates 
contributing to an excellent overall yield and a multigram synthesis of the scaffold. This optimised synthetic pathway 
could allow for easy access in the future use of this heterocyclic driving group. For our electrophile synthesis and 
derivatisation, we were able to effectively synthesise the ethenesulfonamide-containing final compound 17 through 
spontaneous elimination of the sulfonylated intermediate. This was a noteworthy success, as we were unable to 
synthesise the lysine-targeting counterpart in the previous chapter. Similarly, oxidation of the aliphatic sulfonyl 
fluoride 21 to the unsaturated sulfonyl fluoride 22, utilising manganese dioxide, was successfully carried out. To our 
knowledge, this is the first documented use of this class of electrophile in a potentially therapeutic context. This 
obscurity, combined with the encouraging inhibitory profile obtained, highlights the prospective development and 
employment of this rarely used functional group.  
While unable to isolate the highly reactive fluorophosphonate final compounds, we were able to develop useful 
synthetic methodology and isolate valuable intermediates en route towards these inhibitors. This included the 
isolation of the carboxylic acid phosphonate ester fragments 33 and 34, which could be employed in future large 
library syntheses through an amide coupling or Mitsunobu reaction with various driving group scaffolds. Additionally, 
the arduous identification and optimisation of a synthetic method for selective mono-hydrolysis of the ethyl 
phosphonate ester, using magnesium chloride as Lewis acid, may be of use in future synthetic endeavours.  
Similarly, the hydrolysed boronic acid of compound 47 proved too sensitive for isolation. However, we were able 
to overcome difficulties generated by both the complexing/coordinative properties of the osimertinib solubilising 
group and hydrolysis of intermediate reactive fragments through employment of a tert-butyl ester functional group. 
Adaptation of our synthetic strategy rewarded us with the carboxylic acid boronic ester fragment 51, which may be 
utilised in a similar manner described for fragments 33 and 34 in the generation of prospective compounds. 
Furthermore, there is no documented usage of this synthetic methodology to afford the amide boronic ester, 
underlining the novelty and potential of this approach.  
The attempted synthesis of the α-, β-haloketone-containing compounds resulted in several interesting outcomes. 
Firstly, we were able to provide a potential explanation for the observed instability and inability to furnish this class 
of compound, both in this and the previous chapter. We proposed this mainly stemmed from interference by the 
basic osimertinib amine solubilising group. This was most clearly evinced in the attempted synthesis of the β-
haloketone 65, which underwent elimination to exclusively afford osimertinib (14). To our surprise, utilisation of α-
and β-haloketone carboxylic acid fragments and CDI as amide coupling reagent resulted in the formation of the 
imidazole-bearing final compounds 67 and 69. We have found no mention or use of this synthetic pathway within 
the literature, which provides a new and convenient one-pot method for the synthesis of this class of compound. 
Formation of compound 67 was confirmed by synthesis and coupling of the carboxylic acid imidazole fragment 72.  
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While amide coupling with 72 has found application within the literature, our developed synthetic route towards 
this fragment, which makes use of the stable and easily removed tert-butyl ester group, has improved on all routes 
and yields towards this compound.  
Lastly, synthesis of the envisioned dual-warhead-containing compounds proved difficult and ultimately unattainable. 
Employment of several bases in varying amounts, carried out in numerous solvents and at a range of temperatures 
all led to isolation of the doubly derivatised compound 76. Spectroscopic analysis, using an array of techniques 
including 2D NMR spectroscopy, authenticated the successful synthesis of this compound. From the observations of 
our diverse experimental efforts, we proposed a mechanism for formation of compound 76. Further strategies to 
obtain the desired mono-substituted dual-warhead will be disclosed within the following future work section.  
Evaluation of the 14 synthesised final compounds revealed several compelling and encouraging results. While the 
ethenesulfonamide 17 exhibited a good biochemical inhibitory profile, particularly against the cysteine-bearing 
EGFR enzymes, this efficacy was not reflected in the cellular assays. Furthermore, this compound displayed a loss in 
efficacy against both the PC9/T790M/CYS797 and Ba/F3-T790M/C797S cell lines. As both these enzymes bear the 
mutant Ser797 residue, we concluded that use of this electrophile would not be suitable in overcoming resistance 
mediated by the EGFR-C797S mutation.  
We were able to rationalise the disparity in activity between the aliphatic and unsaturated sulfonyl fluorides 21 and 
22 respectively, through an investigation into the proposed hydrolysis pathway of these electrophiles. This 
mechanism, which proceeds via a sulfene-type intermediate, was shown to be exclusively available to the aliphatic 
sulfonyl fluoride 21. This provided an explanation for the greater hydrolytic stability and consequent potency 
exhibited by the unsaturated counterpart 22. This attractive feature, coupled with the previously mentioned novelty 
of this electrophile, emphasises its prospective use in medicinal chemistry. This will be discussed further in the 
following future work section. 
The unremarkable activity displayed by the mono-hydrolysed phosphonate esters 40 and 41, and the trifluoromethyl 
ketone-containing compound 57, was attributed to the negative impact of these functional groups on the 
pharmacokinetic profile of the structure. As such, these compounds were not tolerated within a cellular context and 
we do not promote their further inclusion in targeting the EGFR-C797S mutant enzyme.  
Contrary to our expectations, the data acquired for the bulky boronic ester compound 47 was found to be moderate 
but promising. We believe that successful hydrolysis of this moiety to the corresponding boronic acid, and the 
synthesis of similar boronic ester/acid warheads, could prove applicable and advantageous in overcoming the 
clinically relevant EGFR-C797S mutant variant. These boronic esters/acids, and the respective synthetic procedures 
required to access them, will be comprehensively discussed in the future work section.  
Evaluation of the imidazole-bearing compounds 67 and 69 revealed positive results and interesting comparisons. 
The compounds performed well overall and were notably found to be the most efficacious inhibitors of both the 
mutant Ser797 residue containing cell lines PC9/T790M/CYS797 and Ba/F3-T790M/C797S. This was ascribed to 
interactions between the hydrogen bond acceptor nitrogen of the imidazole ring and the target serine residue.  
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As the cyanoacetamide compound 74 contains a terminal nitrogen with similar hydrogen bond acceptor capabilities, 
the inhibitor displayed comparable activity to 67 and 69 against the C797S mutant variants of the enzyme. However, 
the EC50 values deteriorated against enzymes bearing a cysteine residue at the 797 position. To rationalise this 
disparity in activity, we compared the structural and electronic elements of these functional groups. Accordingly, we 
attributed the enhanced activity of 67 and 69 to the aromatic nature of the imidazole ring and its ability to form 
sulphur-π interactions with the cysteine residue - a capability which the nitrile moiety lacks. Consequently, we see 
potential in the development of inhibitors containing either of these functional groups – the imidazole for its good 
overall interactive capabilities and the nitrile as a selective inhibitor of enzymes bearing the C797S mutation. 
Prospective examples of this may be found in the ensuing future work section.  
Lastly, owing to the poor biochemical and cellular results exhibited, the doubly derivatised dual-warhead inhibitor 
76 was presumed to have hydrolysed in a similar manner to that of the aliphatic sulfonyl fluoride 21. While 
disappointing, we maintain that the synthesis of the initially envisioned dual-warheads, as well as other prospective 
electrophiles built on this principal, may serve as a worthwhile platform for investigation. The synthesis and 
application of these dual-warheads will be discussed in the future work section.  
This brings us to the end of this chapter and concludes the research efforts of this PhD thesis. We will provide 
comprehensive concluding remarks on the project as a collective, future prospects for this research avenue and the 
outlook of EGFR inhibition and its clinical relevance in cancer treatment.  
7.7 Future Work 
For this section, we wish to showcase the broad applicability of incorporating the electrophiles and functional groups 
utilised within this chapter, as well as introducing new analogues of these functionalities. Based on their performance 
and potential for further development, we will focus exclusively on boronic esters/acids, sulfonyl fluorides, imidazoles 
and dual-warheads. As such, we will identify an appropriate example scaffold and outline the synthesis of our chosen 
functional groups and the requirements for their installation. All yields shown in schemes within this section are those 
provided within the relevant literature procedures.  
As osimertinib was precisely designed to overcome resistance mediated by the EGFR-L858R/T790M double mutant, 
and not the EGFR-C797S variant, we will need to identify a driving group devised specifically for the triple mutant 
bearing enzyme. Furthermore, no crystal structure of osimertinib bound to this mutated enzyme exists within the 
literature or on the PDB. Therefore, for future considerations and development of this work, we would require a 
scaffold that fulfils the above-mentioned criteria. Compound 85, shown in Figure 7.18a, was first mentioned in 
Section 2.4.4 (Figure 2.15b) as a potent inhibitor of the EGFR-del19/T790M/C797S triple mutant variant.
59
 The de 
novo designed inhibitor utilises an unconventional phenolic hydroxy as hinge-binding motif and interacts reversibly 
with the mutant Ser797 residue through two hydrogen-bond interactions with the aminomethylpyrazine group 
(Figure 7.18a, orange). This resulted in 85 displaying an unprecedented 1000-fold selectivity for the triple mutant 
over the wild type, with an IC50 value of 18 nM against the clinically relevant EGFR-del19/T790M/C797S mutant 
enzyme. This observed efficacy and selectivity, combined with the relative simplicity of the scaffold, leads to its 
selection as a prime candidate scaffold for inclusion and development of our electrophiles and functional groups.  
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Figure 7.18: a) Binding mode of compound 85, with novel hinge motif and two hydrogen bond interactions with the mutated 
Ser797 residue and b) Proposed heterocyclic scaffolds 86 and 87 to be utilised for derivatisation. Figure a) reproduced from 
Grabe et al. 
59, 60
 
We envisage incorporation of these functional groups to occur at the 4-position of the quinazoline ring 
(Figure 7.18b), thereby replacing the aminomethylpyrazine. This will ensure a proximal location to the Ser797 
residue, creating a high probability for formation of reversible interactions or potential covalent modification of the 
mutant serine. To do this, we propose synthesis of the 4-amino- and 4-chloroquinaozline driving groups 86 and 87 
respectively (Figure 7.18b). In doing so, we will allow for derivatisation at the designated 4-position with our chosen 
electrophiles and functional groups, in a similar manner to the heterocyclic scaffolds synthesised in Section 5.4.1.  
The first functional group we will discuss is the boronic ester/acid, with the relevant prospective syntheses illustrated 
in Scheme 7.19. We wish to include and utilise two new and easily obtained aliphatic boronic esters, which are the 
commercially available bromomethane pinacol boronic ester 88 and the propyl analogue 90 (Scheme 7.19a). 
Boronic ester 90 may be afforded through triethylsilane mediated boration of allyl bromide (89) using boron 
trichloride at low temperatures.
61
 Owing to the successful use of a tert-butyl ester moiety in affording the carboxylic 
acid pinacol boronic ester fragment 51 (Scheme 7.10), we wished to repeat this route using propiolic acid (91) to 
afford the unsaturated boronic ester 94, as shown in Scheme 7.19b. We find the proposed synthesis of 
compound 94 to be intriguing, as this fragment contains two electrophilic sites – namely the Michael acceptor and 
boronic ester/acid. Therefore, this fragment could be used in the potential synthesis of dual-warhead inhibitors. The 
route towards 94 will begin with Steglich esterification of propiolic acid 91 using DCC and DMAP as additive to 
afford propiolic ester 92.
62
 Following this, pinacol boronic ester 93 could be furnished through utilisation of the 
optimised parameters for copper catalysed β-boration using potassium tert-butoxide as base in a 
tetrahydrofuran/methanol mixture.
37
 Subsequent hydrolysis of 93 could then be accomplished by stirring in a 
DCM/trifluoroacetic acid mixture at room temperature. This will afford the carboxylic acid fragment 94, which may 
be further employed in amide coupling reactions.  
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Scheme 7.19: Structures and proposed synthesis of a) Aliphatic boronic esters 88 and 90, b) The unsaturated carboxylic acid 
boronic ester fragment 94 and c) Various aryl boronic esters with activating or deactivating substituents and the hydrolysis 
thereof. Reagents and conditions: i) triethylsilane (1.05 equiv.), BCl3 (1.1 equiv.), pinacol (1 equiv.), Et2O, −78 °C – rt; ii) tert-
butanol (1 equiv.), DCC (1 equiv), DMAP (10 mol%), DCM, 0 °C – rt; iii) bis(pinacolato)diboron (1.05 equiv.), CuCl (5 mol%), 
potassium tert-butoxide (10 mol%), xantphos (5 mol%), THF/MeOH (20:1), rt; iv) DCM/TFA (3:1), rt; v) pinacol (1.2 equiv.), 
MgSO4 (2 equiv.), MeOH, rt then NaBH4 (0.5 equiv.), MeOH, rt; vi) MsCl (1.5 equiv.), DIPEA (2 equiv.), DCM, 0 °C – rt then 
phthalimide (1.5 equiv.), K2CO3 (3 equiv.), DMF, rt; vii) hydrazine hydrate (3 equiv.), THF, 70 °C; viii) KHF2 (6 equiv.), 
MeOH/H2O (1:1), rt then SiO2 (1.1 equiv.) EtOAc/H2O (1:1), rt.
61,
 
62 , 63 
  
Pan and co-workers were able to develop a synthetic method towards boron-containing primary amines such as 
compound 98, pictured in Scheme 7.19c.
63
 The route, which begins from the appropriately substituted (3-
formylphenyl)boronic acids 95, proceeds via a Gabriel synthesis. This class of compounds piqued our interest, as 
these fragments would be able to mimic the structural elements of the aminomethylpyrazine of compound 85, while 
incorporating a boronic ester/acid warhead. Furthermore, the inclusion of an activating or deactivating substituent 
at the para-position of the boronic acid would allow for an informative investigation into the effects of these groups 
on the reactivity of the warhead. These effects would be reflected in the biochemical and cellular evaluation of these 
compounds, evident as differences in efficacy. Furthermore, the substituted (3-formylphenyl) boronic acids 95 are 
commercially available, allowing for a favourable start to the synthesis. The first steps include boronic acid 
esterification with pinacol and reduction of the benzaldehyde to afford the corresponding alcohols 96. This is 
followed by a Gabriel synthesis using pthalimide and hydrazine hydrate to facilitate aminolysis and furnish the 
desired boronic-ester containing benzylamines 98. Lastly, the group were able to develop a mild hydrolysis 
procedure for the pinacol boronic esters using potassium bifluoride and silicon dioxide.
63
 Following the subsequent 
coupling of 98 to our heterocyclic driving group 87 (Figure 7.18), this methodology could be utilised to hydrolyse 
the boronic esters of 99, furnishing the desired boronic acid inhibitors 100.  
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Opportunely, with the hydrolysed boronic acids (100) coupled to our driving group scaffold in hand, we will be able 
to employ an oxidative boron-Heck coupling developed by the research group of Arvidsson.
64
 This will allow easy 
access to the vinyl sulfonyl fluorides 101 shown in Scheme 7.20a. This operationally simple, ligand- and additive-
free reaction is compatible with the frequently used ethenesulfonyl fluoride and proceeds at room temperature using 
palladium(II)acetate, copper(II)acetate as oxidant and lithium acetate as base. As observed by the Grimster group in 
their study on sulfonyl fluoride reactivity, which was outlined in Figure 7.17a, we anticipate the vinyl sulfonyl 
fluorides (101) to be a great deal more stable than their aliphatic counterparts.
50
 This can be mainly ascribed to the 
absence of an acidic proton at the α-position of the reactive group. Furthermore, as with the boronic acids, we will 
be able to explore the effects of the para-substituted electron-donating/withdrawing substituents with regards to the 
electrophile’s interactions with the mutant Ser797 residue.  
Due to their enhanced propensity towards hydrolysis, we wish to avoid the future use of aliphatic sulfonyl fluorides. 
Therefore, we envisage the synthesis of the stable aromatic sulfonyl fluorides 103 through a one-pot palladium-
catalysed synthesis from the corresponding aryl halides 102 (Scheme 7.20b). Treatment of either a bromo- or iodo-
equivalent aryl halide with the bis(sulphur dioxide) adduct 1,4-diazabicyclo[2.2.2]octane (DABSO) as sulphur 
dioxide source and Selectfluor as source of electrophilic fluorine has been documented to afford the matching 
aromatic sulfonyl fluorides in good yield.
65, 66
 Application of these reaction conditions could afford the aromatic 
sulfonyl fluorides 103, of which the reactivity towards the mutated Ser797 residue could be compared through the 
various para-substituted activating and deactivating groups. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.20: Proposed synthesis of a) Vinyl aromatic sulfonyl fluorides 101, b) Aromatic sulfonyl fluorides 103 and c) 
Fluorosulfates 105 and sulfamoyl fluorides 106. Reagents and conditions: i) ESF (3 equiv.), Pd(OAc)2 (10 mol%), LiOAc 
(1.2 equiv.), Cu(OAc)2 (2 equiv.), THF, rt; ii) Pd(OAc)2 (5 mol%), DABSO (1.2 equiv), PdAd2Bu (8 mol%),  Et3N (3 equiv.), i-
PrOH, 75 °C then Selectflour (2 equiv.), MeCN, rt; iii) 104 (1.2 equiv.), Et3N (1.5 equiv.), MeCN, rt.
64, 65, 66, 67 
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In pioneering work from the Sharpless laboratory, synthesis of the fluorosulfuryl imidazolium salt reagent 104 allowed 
the group to transform phenols and anilines to their corresponding fluorosulfates 105 and sulfamoyl fluorides 106 
respectively (Scheme 7.20c).
67
 We believe this innovative synthetic protocol may be used to our advantage in the 
synthesis of warheads targeting and potentially covalently modifying the mutated Ser797 residue.  
To complement the imidiazole-containing carboxylic acid fragment 72 (Scheme 7.15a) synthesised in the last 
chapter, we wish to furnish the propyl analogue 109, shown in Scheme 7.21a. As exhibited in the publication by 
Hou et al., this may be accomplished through a mild and efficient Michael addition of imidazole to the α, β-
unsaturated tert-butyl acrylate (52) utilising potassium phosphate as base, thereby affording the tert-butyl ester 
imidazole 108.
68
 Subsequent hydrolysis of this ester, mediated by trifluoroacetic acid, will then provide the desired 
fragment 109.  
By including the amino-imidazoles 116 and 117, found in Scheme 7.21b, a comparison of the reversible interaction 
capabilities of these moeties and that of the original aminomethylpyrazine used in compound 85 could be 
undertaken. Undergoing a Gabriel synthesis, dibromoethane or dibromopropane (110 and 111 respectively) may 
be reacted with pthalimide to afford the intermediate derivatives 112 and 113.
69
 This will be followed by 
substitutuion of the alkyl halide with imidazole and aminolysis brought about by hydrazine hydrate whilst heating 
under reflux.
70
 This will afford the amino-imidazole fragments, which may be coupled with the heterocyclic driving 
group scaffold 87.  
  
Scheme 7.21: Proposed synthesis of a) Carboxylic acid imidazole fragment 108 and b) Ethyl and propyl linked amino-
imidazoles 116 and 117 respectively. Reagents and conditions: i) imidazole (1 equiv.), 107 (1.2 equiv.), K3PO4 (25 mol%), 
MeCN, rt; ii) DCM/TFA (3:1), rt; iii) phthalimide (1 equiv), 110 or 111 (3 equiv.)  K2CO3 (3 equiv.), TBAB (10 mol%), rt; ii) 
imidazole (1.2 equiv.), K2CO3 (2 equiv.), MeCN, 85 °C; iii) hydrazine hydrate (3 equiv.), aqueous EtOH, 80 °C.
68, 69, 70 
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Scheme 7.22: Proposed synthesis of dual-warheads 121 and 122. 
Finally, we wish to discuss the potential development of the dual-warhead-containing inhibitors 121 and 122, 
illustrated in Scheme 7.22. Due to the time constraints of this research venture, we were unable to effectively 
investigate mono-substitution at the α-position of cyanoacetamide 118 and the imidazole acetamide 119. We 
maintain that with sufficient time and experimental effort, this novel synthetic transformation may be achieved and 
optimised. In addition to the originally intended use of ethenesulfonyl fluoride (20), we may attempt reactions with 
other electrophiles such as the commercially available bromomethane boronic ester 88 and chloroethane sulfonyl 
chloride 120. As per our mechanistic investigation in Section 7.4.3.9, we propose that these reactions will not 
experience the same pitfalls associated with use of ESF (20), which resulted in double derivatisation at the α-position. 
Subsequent hydrolysis of the boronic ester intermediate, and elimination of the chloroethane sulfonamide, will result 
in the respective boronic ester and ethenesulfonamide dual-warhead of 121 and 122.  
To conclude, Figure 7.19 features all the previously used and newly proposed electrophiles and functional groups 
that could be included on the 4-position of driving scaffold 85. This will result in the library of compounds labelled 
123, able to reversibly interact with, and potentially covalently modify the mutant Ser797 residue. This example 
study highlights the versatility of utilising these reactive fragments. Once in hand, they may be incorporated in various 
other scaffolds at will to generate large libraries in an efficient and divergent manner.  
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Figure 7.19: Envisaged library of inhibitors 123, based on driving group scaffold 85 and incorporating previously used and 
newly proposed electrophiles and functional groups. 
7.8 Supplementary Information 
1-Methyl-1H-indole (6)
24
 
A flame-dried, 2-neck round-bottomed flask was charged with sodium hydride (60% dispersion in 
mineral oil, 4.10 g, 102 mmol, 2 equiv.), purged with Ar and to this was added THF (35 mL). The 
resulting suspension was cooled to −10 °C (acetone/ice) and a solution of indole (6.00 g, 51.2 mmol, 
1 equiv.) in THF (35 mL) was added dropwise over 25 min. The solution was then allowed to warm to rt and stirred 
for 1 h. After recooling the solution to −10 °C (acetone/ice), a solution of MeI (8.72 g, 61.4 mmol, 1.2 equiv.) in 
THF (15 mL) was added dropwise over 10 min. The reaction mixture was then allowed to warm to rt and stirred for 
3 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was then cool 
to −10 °C and quenched with a saturated solution of NH4Cl (50 mL), diluted with EtOAc (40 mL) and the organic 
layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 30 mL) and the combined organic 
layers were then washed with a saturated solution of brine (30 mL), dried over MgSO4 and filtered. After removal 
of the solvent in vacuo, purification of the crude product was achieved using flash column chromatography with 
elution gradient of 5 – 20% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 6 as a clear 
oil (6.58 g, 50.2 mmol, 98%). 
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1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
24
  
Rf: 0.75 (20 % EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 3.83 (s, 3H, ArNCH3), 6.57 (dd, J = 3.1, 0.8 Hz, 1H, 
ArH), 6.57 (dd, J = 3.1, 0.8 Hz, 1H, ArH), 7.11 (d, J = 3.1 Hz, 1H, ArH), 7.21 (dd, J = 8.0, 1.0 Hz, 1H, ArH), 7.33 
(dd, J = 6.9, 1.1 Hz, 1H, ArH), 7.40 (dd, J = 8.0, 1.0 Hz, 1H, ArH), 7.75 – 7.70 (m, 1H, ArH) ppm; 13C NMR (75 
MHz, CDCl3) δ 32.9, 101.0, 109.3, 119.4, 121.0, 121.6, 128.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated 
for C9H10N: 132.0813; found: 132.0813.  
3-(2-Chloropyrimidin-4-yl)-1-methyl-1H-indole (8)
23
  
A flame-dried, 2-neck round-bottomed flask was charged with 2,4-dichloropyrimidine (8.19 g, 
55.0 mmol, 1.1 equiv.), purged with Ar and dissolved in DME (40 mL). The resulting solution 
was cooled to 0 °C and AlCl3 (6.67 g, 50.0 mmol, 1 equiv.) was added portionwise over 5 min. 
The solution was then allowed to warm to rt and stirred for 30 min. After recooling the solution 
to 0 °C, a solution of 1-methyl-1H-indole (6.60 g, 50.0 mmol, 1 equiv.) in DME (35 mL) was 
added dropwise over 10 min, during which time the reaction mixture developed into a white-pink slurry. The 
reaction mixture was then incrementally increased in temperature from rt to 60 °C over 30 min and then stirred for 
12 h or until complete consumption of the starting material as indicated by TLC. After allowing to cool to rt, the 
reaction mixture was slowly poured into vigorously stirring H2O (80 mL) and allowed to stir for 1 h. The precipitate 
that formed was then collected by filtration and washed with aliquots of H2O (3 × 40 mL) and MeOH (3 × 5 mL). 
Purification of the crude collected precipitate was achieved using flash column chromatography with elution gradient 
of 0 – 2% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 8 as a white solid (8.29 g, 
34.0 mmol, 68%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23
 
Rf: 0.53 (DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 3.89 (s, 3H, ArNCH3), 7.32 – 7.26 (m, 2H, 2 × ArH), 7.57 (dd, J 
= 6.5, 2.0 Hz, 1H, ArH), 7.81 (d, J = 5.5 Hz, 1H, ArH), 8.41 (dd, J = 6.5, 2.0 Hz, 1H, ArH), 8.48 (s, 1H, ArH), 
8.52 (d, J = 5.5 Hz, 1H, ArH) ppm; 
13
C NMR (151 MHz, DMSO-d6) δ  33.2, 110.7, 110.8, 114.3, 121.6, 121.7, 
122.7, 125.2, 134.7, 137.8, 158.7, 160.3, 164.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C12H9N3Cl: 
244.0642; found: 244.0640.  
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine (10)
23
 
A 2-neck round-bottomed flask was charged with 3-(2-chloropyrimidin-4-yl)-1-
methyl-1H-indole (6.41 g, 26.3 mmol, 1 equiv.) and 4-fluoro-2-methoxy-5-
nitroaniline (4.90 g, 26.3 mmol, 1 equiv.) and purged with Ar. To this was added 2-
pentanol (80 mL) and the resulting suspension was placed at 105 °C. p-
Toluenesulfonic acid monohydrate (1.96 g, 31.6 mmol, 1.2 equiv.) was added as a 
single portion and the reaction mixture was then allowed to stir for 4 h or until 
complete consumption of the starting material as indicated by TLC. The reaction mixture was then allowed to cool 
and stand for 8 h which resulted in the formation of a yellow precipitate.  
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The precipitate was collected by filtration, washed with aliquots of acetonitrile (3 × 30 mL) and dried in vacuo. The 
solid was dissolved in 10% MeOH in DCM and washed with a saturated solution of NaHCO3 (3 × 50 mL), a saturated 
solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, the solid was then 
triturated with acetonitrile and dried under vacuum to afford compound 10 as a yellow solid (9.63 g, 24.5 mmol, 
93%) with no further purification required. 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23
 
Rf: 0.74 (1% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 3.89 (s, 3H, ArNCH3), 3.98 (s, 3H, ArOCH3), 7.11 
(dd [app. t], J = 7.5 Hz, 1H, ArH), 7.29 (dd [app. t], J = 7.1 Hz, 1H, ArH), 7.45 – 7.41 (m, 1H, ArH), 7.47 (d, J = 
8.2 Hz, 1H, ArH), 7.56 (d, J = 8.2 Hz, 1H, ArH), 8.14 (d, J = 7.7 Hz, 1H, ArH), 8.34 (d, J = 6.5 Hz, 1H, ArH), 8.67 
(s, 1H, ArH), 8.75 (d, J = 8.2 Hz, 1H, ArH), 9.99 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 33.6, 57.6, 
101.9, 107.0, 110.8, 111.1, 111.6, 114.3, 121.7, 121.9, 122.2, 122.7, 123.3, 125.2, 134.7, 138.1, 154.0, 158.7, 
164.5, 165.9 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C20H17N5O3F: 394.1315; found: 394.1309. 
N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-2-
nitrobenzene-1,4-diamine (11)
23
 
A 2-neck round-bottom flask was charged with N-(4-fluoro-2-methoxy-5-
nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine 
(9.13 g, 23.2 mmol, 1 equiv.), purged with Ar and dissolved in DMA (60 mL). 
To this solution was added DIPEA (4.24 mL, 24.4 mmol, 1.05 equiv.), 
followed by the slow addition of a solution of N
1
,N
1
,N
2
-trimethylethane-1,2-
diamine (2.96 g, 29.0 mmol, 1.25 equiv.) in DMA (20 mL) at rt. The reaction 
was placed at 60 °C and allowed to stir for 4 h, during which time the reaction mixture developed a deep red colour. 
After allowing to cool to rt, the reaction mixture was then diluted with H2O (80 mL) and EtOAc (100 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 40 mL) and the combined 
organic layers were then washed with successive aliquots of a saturated solution of brine (3 × 40 mL), dried over 
MgSO
4
 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using flash 
column chromatography with elution gradient of 5 – 15% MeOH in DCM. Pure fractions were evaporated to dryness 
to afford compound 11 as a red-orange powder (10.6 g, 22.3 mmol, 96%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23
 
Rf: 0.43 (10% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 2.22 (s, 6H, CH2N(CH3)2), 2.56 (t, J = 6.8 Hz, 
2H, NCH
2
CH
2
N), 2.85 (s, 3H, ArNCH
3
), 3.29 (t, J = 6.8 Hz, 2H, NCH
2
CH
2
N), 3.86 (s, 3H, ArNCH
3
), 3.95 (s, 3H, 
ArOCH3), 6.85 (s, 1H, ArH), 7.12 (dd [app. t], J = 7.6 Hz, 1H, ArH), 7.21 (d, J = 5.6 Hz, 1H, ArH), 7.26 (dd [app. 
t], J = 7.6 Hz, 1H, ArH), 7.50 (d, J = 8.0 Hz, 1H, ArH), 8.08 (s, 1H, ArH), 8.31 (s, 1H, ArH), 8.32 (d, J = 5.6 Hz, 
1H, ArH), 8.36 (d, J = 8.0 Hz, 1H, ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 33.0, 40.7, 45.2, 52.5, 56.1, 56.4, 
102.2, 107.4, 110.4, 112.3, 119.1, 120.9, 121.5, 122.0, 122.2, 125.4, 132.3, 133.0, 137.6, 143.6, 154.7, 157.1, 
160.0, 162.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C25H30N7O3: 476.2410; found: 476.2403. 
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N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]benzene-
1,2,4-triamine (12)
23
 
 A 2-neck round-bottom flask was charged with N1-[2-(dimethylamino)ethyl]-
5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]-2-
nitrobenzene-1,4-diamine (4.00 g, 8.41 mmol, 1 equiv.), iron (2.82 g, 
50.5 mmol, 6 equiv.) and NH4Cl (450 mg, 8.41 mmol, 1 equiv.) and purged 
with Ar. To this was added EtOH (75 mL) and H2O (25 mL) and the resulting 
suspension was placed at 85 °C and allowed to stir for 4 h, during which time 
the reaction mixture changed from brown red to a purple green colour. After allowing to cool to rt, the reaction 
mixture was filtered through a plug of celite, washed with EtOH (50 mL) and the solvent was removed in vacuo. The 
residue was then diluted with DCM (50 mL) and H2O (30 mL) and the organic layer was separated. The aqueous 
layer was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed with a 
saturated solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification 
of the crude product was achieved using flash column chromatography with elution gradient of 5 – 15% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 12 as a brown foam (3.19 g, 7.15 mmol, 85%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23
 
Rf: 0.43 (10% MeOH in DCM); IR (ATR) cm
-1
: 3419 (m, N-H stretch); 2933 (m, C-H stretch), 2778 (m, C-H stretch), 
1573 (m, N-H bend), 1444 (m, C-H bend), 1402 (m, C-H bend), 1363 (s, C-N stretch), 1097 (s, C-O stretch), 807 
(s, C-H bend), 741 (s, N-H wag); 
1
H NMR (300 MHz, DMSO-d6) δ 2.25 (s, 6H, CH2N(CH3)2), 2.46 (t, J = 6.6 Hz, 
2H, NCH
2
CH
2
N), 2.62 (s, 3H, ArNCH
3
), 2.93 (t, J = 6.6 Hz, 2H, NCH
2
CH
2
N), 3.75 (s, 3H, ArNCH
3
), 3.87 (s, 3H, 
ArOCH3), 4.92 (br s, 2H, ArNH2), 7.16 – 7.13 (m, 1H, ArH), 7.18 (dd, J = 8.0, 1.0 Hz, 1H, ArH), 7.28 – 7.22 (m, 
1H, ArH), 7.51 (d, J = 8.2 Hz, 1H, ArH), 7.53 (s, 1H, ArH), 7.79 (s, 1H, ArH), 8.27 (d, J = 5.4 Hz, 1H, ArH), 8.30 (s, 
1H, ArH), 8.43 (d, J = 8.0 Hz, 1H, ArH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 33.0, 41.6, 45.3, 53.5, 56.5, 57.0, 
105.3, 106.8, 109.0, 110.3, 112.4, 120.9, 122.1, 125.4, 125.5, 132.8, 133.2, 136.8, 137.6, 141.7, 157.0, 160.4, 
162.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C25H32N7O: 446.2668; found: 446.2673. 
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)propionamide (13)  
A 2-neck round-bottom flask was charged with N1-[2-(dimethylamino)ethyl]-
5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]benzene-1,2,4-triamine (60.0 mg, 0.135 mmol, 1 equiv.) and potassium 
carbonate (28.0 mg, 0.203 mmol, 1.5 equiv.) and purged with Ar. To this was 
added acetone (4 mL) and the solution was cooled to −10 °C (acetone/ice). 
A solution of propionyl chloride (16.0 mg, 0.176 mmol, 1.3 equiv.) in acetone 
(2 mL) was then added dropwise to the solution over 5 min. The reaction mixture was then allowed to warm to rt 
and stirred for 2 h. The reaction mixture was then quenched and diluted with H2O (20 mL), a saturated solution of 
NaHCO3 (20 mL) and DCM (30 mL) and the organic layer was separated.  
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The aqueous layer was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then 
washed with a saturated solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, purification of the crude product was achieved using flash column chromatography with elution gradient of 
5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 13 as a white foam (60 
mg, 0.120 mmol, 90%). 
Rf: 0.33 (10% MeOH in DCM); IR (ATR) cm
-1
: 3419 (m, N-H stretch), 3116 (m, N-H stretch), 2953 (m, C-H stretch), 
2819 (m, C-H stretch), 1670 (s, C=O stretch), 1575 (m, N-H bend), 1447 (m, C-H bend), 1402 (m, C-H bend), 
1336 (s, C-N stretch), 1099 (s, C-O stretch), 805 (s, C-H bend), 739 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ 
1.33 (t, J = 7.6 Hz, 3H, COCH2CH3), 2.29 (s, 6H, CH2N(CH3)2), 2.33 (t, J = 5.8 Hz, 2H, NCH2CH2N), 2.49 (q, J = 
7.6 Hz, 2H, COCH2CH3), 2.70 (s, 3H, ArNCH3), 2.93 (t, J = 5.8 Hz, 2H, NCH2CH2N), 3.90 (s, 3H, ArNCH3), 4.03 
(s, 3H, ArNOCH3), 6.80 (s, 1H, ArH), 7.22 (d, J = 5.3 Hz, 1H, ArH), 7.32 – 7.27 (m, 2H, 2 × ArH), 7.44 – 7.39 (m, 
1H, ArH), 8.14 – 8.07 (m, 1H, ArH), 7.76 (s, 1H, ArH), 8.41 (d, J = 5.3 Hz, 1H, ArH), 9.11 (s, 1H, ArH), 9.77 (s, 
2H, ArH and ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 10.1, 30.7, 33.1, 44.0, 45.5, 56.2, 56.2, 57.4, 104.6, 107.9, 
109.7, 110.1, 113.7, 120.3, 120.9, 121.8, 126.0, 127.7, 129.8, 134.1, 135.2, 138.3, 157.9, 159.6, 143.9, 162.2, 
171.4 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C28H36N7O2: 502.2930; found: 502.2938. 
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino)phenyl}acrylamide (14)
23
 
A 2-neck round-bottom flask was charged with N1-[2-(dimethylamino)ethyl]-
5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]benzene-1,2,4-triamine (300 mg, 0.673 mmol, 1 equiv.) and potassium 
carbonate (139 mg, 1.01 mmol, 1.5 equiv.) and purged with Ar. To this was 
added acetone (12 mL) and the solution was cooled to −40 °C 
(acetonitrile/CO2). A solution of acryloyl chloride (67.0 mg, 0.740 mmol, 1.1 
equiv.) in acetone (4 mL) was then added dropwise to the solution over 5 min. The reaction mixture was then 
allowed to warm to −20 °C and stirred at this temperature for 2 h or until complete consumption of the starting 
material as indicated by TLC. The reaction mixture was then quenched and diluted with H2O (20 mL), a saturated 
solution of NaHCO3 (20 mL) and DCM (50 mL) and the organic layer was separated. The aqueous layer was 
extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (40 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 5 – 10% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 14 as a cream foam (296 mg, 0.592 mmol, 88%). 
1
H NMR and MS data collected for this compound compared well with the reported literature values.
23
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Rf: 0.44 (10% MeOH in DCM); 
1
H NMR (400 MHz, DMSO-d6) δ 2.25 (s, 6H, CH2N(CH3)2), 2.36 (br s, 2H, 
NCH2CH2N), 2.71 (s, 3H, ArNCH3), 2.91 (t, J = 5.4 Hz, 2H, NCH2CH2N), 3.86 (s, 3H, ArNCH3), 3.91 (s, 3H, 
ArOCH3), 5.77 (dd, J = 10.1, 1.9 Hz, 1H, CCH=CH2), 6.28 (dd, J = 16.9, 1.9 Hz, 1H, CCH=CH2), 6.49 (dd, J = 
16.9, 10.1 Hz, 1H, CCH=CH2), 7.03 (s, 1H, ArH), 7.18 – 7.13 (m, 1H, ArH), 7.26 – 7.22 (m, 2H, 2 × ArH), 7.52 
(d, J = 8.0 Hz, 1H, ArH), 7.91 (s, 1H, ArH), 8.25 (d, J = 8.0 Hz, 1H, ArH), 8.33 (d, J = 5.3 Hz, 1H, ArH), 8.68 (s, 
1H, ArH), 9.16 (s, 1H, ArH), 10.18 (s, 1H, ArNH) ppm; 
13
C NMR (101 MHz, DMSO-d6) δ 32.9, 42.7, 44.9, 55.3, 
56.0, 56.6, 105.2, 107.1, 110.5, 112.4, 113.6, 120.9, 121.3, 121.9, 125.3, 125.4, 126.1, 127.5, 132.4, 133.8, 
137.5, 137.7, 146.0, 157.7, 159.9, 161.6, 162.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C28H34N7O2: 500.2774; found: 500.2775. 
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)ethenesulfonamide (17) 
A flame-dried, 2-neck round-bottom flask was charged with N1-[2-
(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]benzene-1,2,4-triamine (150 mg, 0.337 mmol, 1 equiv.), 
purged with Ar and dissolved in DCM (8 mL). To this was added DIPEA 
(0.180 mL, 1.01 mmol, 3 equiv.) and the solution was cooled to −40 °C 
(acetonitrile/CO2). A solution of 2-bromoethane-1-sulfonyl chloride 
(91.0 mg, 0.438 mmol, 1.3 equiv.) in DCM (4 mL) was then added dropwise to the solution over 5 min. The reaction 
mixture was then allowed to warm to rt and stirred at this temperature for 4 h or until complete consumption of the 
starting material as indicated by TLC. The reaction mixture was then quenched and diluted with H2O (20 mL), a 
saturated solution of NaHCO3 (20 mL) and DCM (50 mL) and the organic layer was separated. The aqueous layer 
was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (40 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 5 – 10% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 17 as a tan solid (123 mg, 0.23 mmol, 68%). 
Rf: 0.64 (10% MeOH in DCM); IR (ATR) cm
-1
: 3427 (m, N-H stretch), 3023 (w, C=C-H stretch), 2953 (m, C-H 
stretch), 2819 (m, C-H stretch), 1575 (m, N-H bend), 1447 (m, C-H bend), 1404 (m, C-H bend), 1322 (s, C-N 
stretch), 1147 (s, S=O stretch), 885 (s, C=C bend), 803 (s, C-H bend), 735 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) 
δ 2.27 (t, J = 5.6 Hz, 2H, NCH2CH2N), 2.35 (s, 6H, CH2N(CH3)2), 2.73 (s, 3H, ArNCH3), 2.87 (t, J = 5.6 Hz, 2H, 
NCH
2
CH
2
N), 3.90 (s, 3H), ArNCH
3
, 3.97 (s, 3H, ArOCH
3
), 5.74 (d, J = 10.0 Hz, 1H, SCH=CH
2
), 6.16 (d, J = 16.7 
Hz, 1H, SCH=CH2), 6.58 (dd, J = 16.7, 10.0 Hz, 1H, SCH=CH2), 6.78 (s, 1H, ArH), 7.22 (d, J = 5.3 Hz, 1H, ArH), 
7.33 – 7.27 (m, 2H, 2 × ArH), 7.44 – 7.39 (m, 1H, ArH), 7.72 (s, 1H, ArH),  8.13 – 8.07 (m, 1H, ArH), 8.39 (d, J = 
5.3 Hz, 1H, ArH), 8.76 (s, 1H, ArNH), 9.02 (s, 1H, ArNHSO2) ppm; 
13
C NMR (75 MHz, CDCl3) δ 33.3, 44.4, 44.4, 
56.1, 56.5, 57.0, 104.8, 108.2, 110.3, 113.6, 113.7, 120.4, 121.1, 122.0, 125.3, 125.9, 128.1, 128.5, 134.7, 
136.6, 137.2, 138.3, 145.7, 158.0, 159.6, 162.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C
27
H
34
N
7
O
3
S: 536.2444; found: 536.2450. 
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2-(Phenylamino)ethene-1-sulfonyl fluoride (19)
25
 
A 2-neck round-bottomed flask was charged with 2-(phenylamino)ethane-1-sulfonyl 
fluoride (300 mg, 1.48 mmol, 1 equiv.) and purged with Ar. To this was added CHCl3 
(10 mL), followed by the addition of MnO2 (1.92 g, 22.1 mmol, 15 equiv.) in one portion. 
The reaction mixture was allowed to stir for 5 h or until complete consumption of the starting material as indicated 
by TLC. The reaction mixture was filtered through a plug of celite, washed with CHCl3 (40 mL) and the solvent was 
removed in vacuo. Purification of the crude product was achieved using flash column chromatography with elution 
gradient of 5 – 25% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 19 as a white solid 
(205 mg, 1.02 mmol, 69%). 
Rf: 0.50 (30% PE in EtOAc); 
1
H NMR (400 MHz, DMSO-d6) δ 5.72 (d, J = 10.8 Hz, 1H, CH=CHS), 7.10 (dd [app. 
t], J = 6.2 Hz, 1H, ArH), 7.21 (d, J = 7.8 Hz, 2H, ArH), 7.35 (dd [app. t], J = 7.8 Hz, 2H, ArH), 8.10 – 7.98 (m, 1H, 
NHCH=CH), 10.48 (s, 1H, ArNH) ppm; 
13
C NMR (101 MHz, DMSO-d6) δ 87.0, 87.2, 116.3, 123.7, 129.7, 139.6, 
148.0 ppm; 
19
F NMR (282 MHz, DMSO-d6) δ 72.12 (d, J = 2.2 Hz) ppm;  HRMS-TOF MS ESI−: m/z [M−H]+ 
calculated for C8H7NO2SF: 200.0182; found: 200.0191. 
2-[(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)amino]ethane-1-sulfonyl fluoride (21)  
A flame-dried, 2-neck round-bottomed flask was charged with N1-[2-
(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]benzene-1,2,4-triamine (100 mg, 0.224 mmol, 1 equiv.) 
and purged with Ar. To this was added DMF (4 mL) and the resulting solution 
was then cooled to −10 °C (acetone/ice), followed by the dropwise addition 
of a solution of ethenesulfonyl fluoride (26.0 mg, 0.235 mmol, 1.05 equiv.) 
in DMF (1 mL). The reaction mixture was then allowed to warm to rt and 
stirred for 4 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was 
then diluted with H
2
O (30 mL) and EtOAc (20 mL) and the organic layer was separated. The aqueous layer was 
extracted with aliquots of EtOAc (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of 
the crude product was achieved using flash column chromatography with elution gradient of 5% – 10% MeOH in 
DCM. Pure fractions were evaporated to dryness to afford compound 21 as a yellow solid (91.0 mg, 0.164 mmol, 
73%). 
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Rf: 0.40 (10% MeOH in DCM); IR (ATR) cm
-1
: 3418 (m, N-H stretch), 3283 (m, N-H stretch), 2920 (m, C-H stretch), 
2819 (m, C-H stretch), 1579 (m, N-H bend), 1447 (m, C-H bend), 1402 (m, C-H bend), 1367 (s, C-N stretch), 1192 
(s, S=O stretch), 1099 (s, C-O stretch), 1033 (s, S=O stretch), 801 (s, C-H bend), 737 (s, N-H wag); 
1
H NMR (600 
MHz, DMSO-d6) δ 2.57 (br s, 2H, NCH2CH2N), 2.59 (s, 6H, CH2N(CH3)2), 3.03 (br s, 2H, NCH2CH2N), 3.13 (s, 3H, 
ArNCH3), 3.65 (br s, 2H, NHCH2CH2S), 3.79 (s, 3H ArNCH3), 3.87 (s, 3H, ArOCH3), 4.19 (br s, 2H, NHCH2CH2S), 
5.84 (s, 1H, ArH), 6.89 (s, 1H, ArH), 7.15 (d, J = 7.4 Hz, 1H, ArH), 7.17 (d, J = 5.2 Hz, 1H, ArH), 7.25 (t, J = 7.4 
Hz, 1H, ArH), 7.54 – 7.47 (m, 2H, 2 × ArH), 7.90 (s, 1H, ArH), 8.26 (d, J = 5.2 Hz, 1H, ArH), 8.28 (s, 1H, ArNH), 
8.42 (d, J = 7.4 Hz, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 33.0, 38.0, 41.8, 43.0, 49.3, 49.5, 50.9, 54.4, 
54.9, 56.5, 105.3, 106.4, 107.1, 110.4, 112.4, 120.8, 122.2, 125.5, 126.2, 132.7, 133.9, 136.0, 137.6, 142.0, 
156.9, 160.4, 162.2 ppm; 
19
F NMR (282 MHz, DMSO-d6) δ 57.69 (t, J = 6.1 Hz) ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C27H35N7O3SF: 556.2506; found: 556.2494. 
(E)-2-[(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)amino]ethene-1-sulfonyl fluoride (22)  
A 2-neck round-bottomed flask was charged with 2-[(2-{[2-
(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-
3-yl]pyrimidin-2-yl}amino)phenyl]amino)ethane-1-sulfonyl fluoride 
(70.0 mg, 0.126 mmol, 1 equiv.) and purged with Ar. To this was added 
CHCl3 (5 mL), followed by the addition of MnO2 (164 mg, 1.890 mmol, 15 
equiv.) in one portion. The reaction mixture was then allowed to stir for 8 h 
or until complete consumption of the starting material as indicated by TLC. 
The reaction mixture was filtered through a plug of celite, washed with CHCl3 (40 mL) and the solvent was removed 
in vacuo. Purification of the crude product was achieved using flash column chromatography with elution gradient 
of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 22 as a tan solid (52.0 
mg, 94.5 µmol, 75%). 
Rf: 0.73 (15 % MeOH in DCM); IR (ATR) cm
-1
: 3414 (m, N-H stretch), 2959 (m, C-H stretch), 2850 (m, C-H stretch), 
1631 (s, C=C stretch), 1577 (m, N-H bend), 1447 (m, C-H bend), 1404 (m, C-H bend), 1371 (s, C-N stretch), 1151 
(s, S=O stretch), 1099 (s, C-O stretch), 1021 (s, S=O stretch), 879 (s, C=C bend), 803 (s, C-H bend), 735 (s, N-H 
wag); 
1
H NMR (600 MHz, DMSO-d6) δ 2.32 (s, 6H, CH2N(CH3)2), 2.54 (br s, 2H, NCH2CH2N), 2.70 (s, 3H, ArNCH3), 
3.00 (br s, 2H, NCH2CH2N), 3.86 (br s, 6H, ArOCH3 and ArNCH3), 5.82 (d, J = 11.2 Hz, 1H, NHCH=CHS), 7.01 
(d, J = 7.4 Hz, 1H, ArH), 7.12 (s, 1H, ArH), 7.26 – 7.19 (m, 2H, 2 × ArH), 7.51 (d, J = 8.1 Hz, 1H, ArH), 7.92 (d, 
J = 11.2 Hz, 1H, NHCH=CHS), 8.02 (s, 1H, ArH), 8.06 (s, 1H, ArH), 8.36 – 8.26 (m, 2H, 2 × ArH), 8.40 (s, 1H, 
ArNH), 10.20 (s, 1H, ArNH), ppm; 
13
C NMR (151 MHz, CDCl3) δ 33.0, 42.0, 42.6, 44.4, 56.1, 105.1, 106.0, 107.5, 
109.8, 110.4, 112.3, 120.9, 121.9, 122.2, 125.5, 126.3, 128.3, 132.9, 137.2, 137.6, 147.2, 148.6, 157.0, 160.1, 
162.2 ppm; 19F NMR (282 MHz, DMSO-d6) δ 73.25 (d, J = 101.8 Hz) ppm; HRMS-TOF MS ESI+: m/z [M+H]+ 
calculated for C27H33N7O3SF: 554.2350; found: 554.2352. 
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Ethyl 2-bromoacetate (30)
26
 
A 2-neck round-bottomed flask was charged with 2-bromoacetic acid (13.9 g, 100 mmol, 
1 equiv.), purged with Ar and dissolved in EtOH (100 mL). To this was added H2SO4 (20 mL) 
and the resulting solution was then allowed to stir at 85 °C for 24 h. The reaction mixture was then diluted with H2O 
(100 mL) and the organic layer was separated. The organic layer was then washed with H2O (2 × 20 mL), an ice-
cold solution of 5% NaHCO3 (20 mL) and a saturated solution of brine (20 mL) to afford compound 30 as a clear oil 
(14.1 g, 86.2 mmol, 86%).  
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
71
  
1
H NMR (400 MHz, CDCl
3
) δ 1.29 (t, J = 7.2 Hz, 3H, CH
3
CH
2
O), 3.81 (s, 2H, COCH
2
Br), 4.22 (q, J = 7.2 Hz, 2H, 
CH3CH2O) ppm; 
13
C NMR (101 MHz, CDCl3) δ 14.1, 26.1, 62.4, 167.3 ppm; no ionization was found in MS. 
Ethyl 2-(dimethoxyphosphoryl)acetate (31)
27
 
 A 2-neck round-bottomed flask was charged with ethyl 2-bromoacetate (5.39 g, 32.3 mmol, 
1 equiv.), purged with Ar and heated to 80 °C. Trimethyl phosphite (3.81 mL, 32.3 mmol, 
1 equiv.) was added rapidly via syringe and the reaction mixture was placed at 130 °C to 
allow distillation of bromomethane. The reaction mixture was then allowed to stir for a further 3 h. Purification of 
the crude product was achieved by kugelrohr distillation. Fractions with boiling point between 145 °C – 150 °C at 
~ 20 mbar were collected to afford compound 31 as a clear oil (4.72 g, 28.0 mmol, 86%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
72
 
1
H NMR (300 MHz, CDCl3) δ 1.21 (t, J = 7.1 Hz, 3H, CH3CH2O), 2.90 (d, J = 21.5 Hz, 2H, COCH2P), 3.72 (s, 3H, 
P(OCH3)2), 3.74 (s, 3H, P(OCH3)2) 4.13 (q, J = 7.1 Hz, 2H, CH3CH2O) ppm; 
13
C NMR (75 MHz, CDCl3) δ 14.0, 
33.4 (d, J = 135.1 Hz), 53.1 (J = 6.0 Hz), 61.6, 165.6 (d, J = 6.0 Hz) ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 
calculated for C6H14O5P: 197.0579; found: 197.0580. 
Ethyl 2-(diethoxyphosphoryl)acetate (32)
27
  
A 2-neck round-bottomed flask was charged with ethyl 2-bromoacetate (1.00 g, 
5.99 mmol, 1 equiv.), purged with Ar and heated to 80 °C. Triethyl phosphite (1.03 mL, 
5.99 mmol, 1 equiv.) was added rapidly via syringe and the reaction mixture was placed 
at 130 °C to allow distillation of bromoethane. The reaction mixture was then allowed to 
stir for a further 3 h. Purification of the crude product was achieved by kugelrohr distillation. Fractions with boiling 
point between 150 °C – 155 °C at ~ 20 mbar were collected to afford compound 32 as a clear oil (1.13 g, 5.03 
mmol, 84%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
73
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1
H NMR (300 MHz, CDCl3) δ 1.37 – 1.22 (m, 9H, CH3CH2O and P(OCH2CH3)2), 2.90 (d, J = 1.3 Hz, 2H, COCH2P), 
2.97 (d, J = 1.3 Hz, 2H, COCH2P),  4.22 – 4.08 (m, 6H, CH3CH2O and P(OCH2CH3)2) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ 14.1, 16.3 (d, J = 6.2 Hz), 34.4 (d, J = 134.4 Hz), 61.6, 62.8 (d, J = 6.0 Hz), 165.9 (d, J = 6.0 Hz) ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C8H18O5P: 225.0892; found: 225.0892. 
2-(Dimethoxyphosphoryl)acetic acid (33)
74
 
A 2-neck round-bottom flask was charged with sodium hydroxide (409 mg, 10.2 mmol, 
1 equiv.) and dissolved in H2O (5 mL). Ethyl 2-(dimethoxyphosphoryl)acetate (1.68 mL, 10.2 
mmol, 1 equiv) was added dropwise to this solution and the reaction mixture was allowed to 
stir for 2 h at rt. After removal of the ethanol in vacuo, the residue was acidified to pH = 1 with a solution of 1 M 
HCl, diluted with DCM (30 mL) and the organic layer separated. The aqueous layer was extracted with aliquots of 
DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated solution of brine (30 mL), 
dried over MgSO4 and filtered. After removal of the solvent in vacuo, compound 33 was afforded as a white solid 
(1.51 g, 8.98 mmol, 88%) with no further purification required. 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
75
 
1
H NMR (300 MHz, CDCl3) δ 2.99 (d, J = 21.7 Hz, 2H, COCH2P), 3.85 – 3.75 (m, 6H, P(OCH3)2), 9.58 (br s, 1H, 
HOCOCH2) ppm; 
13
C NMR (75 MHz, CDCl3) δ 33.3 (d, J = 135.5 Hz), 53.6 (d, J = 6.4 Hz), 167.8 (d, J = 5.4 Hz) 
ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C4H10O5P: 169.0266; found: 169.0268. 
2-(Diethoxyphosphoryl)acetic acid (34)
74
 
A 2-neck round-bottom flask was charged with sodium hydroxide (900 mg, 22.2 mmol, 
1 equiv.) and dissolved in H
2
O (11 mL). Ethyl 2-(diethoxyphosphoryl)acetate (4.40 mL, 22.2 
mmol, 1 equiv.) was added dropwise to this solution and the reaction mixture was allowed 
to stir for 2 h at rt. After removal of the ethanol in vacuo, the residue was acidified to pH = 
1 with a solution of 1 M HCl, diluted with DCM (50 mL) and the organic layer separated. The aqueous layer was 
extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed with a saturated 
solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, compound 34 was 
afforded as a clear oil (4.14 g, 21.1 mmol, 91%) with no further purification required. 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
76
 
1
H NMR (400 MHz, DMSO-d
6
) δ 1.23 (2 × t, J = 7.1, 6H, 2 × POCH
2
CH
3
), 2.96 (d, J = 21.4 Hz, 2H, COCH
2
P), 
4.03 (2 × q, J = 7.1 Hz, 4H, 2 × POCH2CH3) ppm; 
13
C NMR (101 MHz, DMSO-d6) δ 16.1 (d, J = 6.2 Hz), 33.9 
(d, J = 130.7 Hz), 61.8 (d, J = 6.2 Hz), 167.2 (d, J = 5.7 Hz) ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated 
for C6H14O5P: 197.0579; found: 197.0579. 
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Diethyl [2-oxo-2-(phenylamino)ethyl]phosphonate (36) 
A 2-neck round-bottomed flask was charged with 1,1'-carbonyldiimidazole (322 mg, 
1.99 mmol, 1.85 equiv.), purged with Ar and dissolved in DCM (10 mL). The resulting 
solution was then cooled to 0 °C, followed by the dropwise addition of a solution of 
2-(diethoxyphosphoryl)acetic acid (390 mg, 1.99 mmol, 1.85 equiv.) in DCM (4 mL). 
The reaction mixture was then allowed to warm to rt and stirred for 1 h before being recooled to 0 °C. A solution of 
aniline (100 mg, 1.07 mmol, 1 equiv.) in DCM (1 mL) was then added dropwise to the solution and the reaction 
mixture was then allowed to warm to rt and stir for 12 h or until complete consumption of the starting material as 
indicated by TLC. The reaction mixture was then diluted with H2O (20 mL), a saturated solution of NaHCO3 (20 mL) 
and DCM (10 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 
× 20 mL) and the combined organic layers were then washed with a saturated solution of brine (30 mL), dried over 
MgSO4 and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using 
flash column chromatography with elution gradient of 70 – 90% EtOAc in PE. Pure fractions were evaporated to 
dryness to afford compound 36 as a clear oil (272 mg, 1.00 mmol, 94%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
77
 
Rf: 0.33 (EtOAc); 
1
H NMR (300 MHz, CDCl3) δ 1.34 (2 × t, J = 7.1 Hz, 6H, 2 × POCH2CH3), 3.05 (d, J = 21.0 
Hz, 2H, COCH2P), 4.18 (2 × q, J = 7.1 Hz, 4H, 2 × POCH2CH3), 7.06 – 6.99 (m, 1H, ArH), 7.22 (dd [app. t], J = 
7.9 Hz, 2H, 2 × ArH), 7.49 (m, 2H, 2 × ArH), 9.20 (s, 1H, ArNH) ppm; 
13
C NMR (101 MHz, CDCl3) δ 16.4 (d, J = 
6.1 Hz), 36.4 (d, J = 129.8 Hz), 63.1 (d, J = 6.6 Hz), 119.9, 124.3, 128.9, 138.0, 162.3 (d, J = 4.1 Hz) ppm; 
31
P 
NMR (121 MHz, CDCl3) δ 23.40 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C12H19NO4P: 272.1052; 
found: 272.1050. 
Ethyl hydrogen [2-oxo-2-(phenylamino)ethyl]phosphonate (37)
29
 
A microwave vial was charged with diethyl [2-oxo-2-(phenylamino)ethyl]phosphonate 
(140 mg, 0.516 mmol, 1 equiv.), sodium iodide (93.0 mg, 0.619 mmol, 1.2 equiv.), 
magnesium chloride (59.0 mg, 0.619 mmol, 1.2 equiv.) and purged with Ar. To this was 
added acetonitrile (5 mL) and after capping the vial the resulting suspension was warmed 
to 60 °C and allowed to stir for 12 h or until complete consumption of the starting material as indicated by TLC 
during which time a cream precipitate formed. The reaction mixture was then allowed to cool to rt and the white 
precipitate was collected by filtration. The solid was suspended in dioxane (10 mL) and a solution of 4 M HCl in 
dioxane (0.15 mL, 0.619 mmol, 1.2 equiv.) was then added dropwise and the reaction mixture was allowed to stir 
for 1 h. The reaction mixture was then filtered and after removal of the solvent in vacuo, compound 37 was afforded 
as a tan solid (95.0 mg, 0.392 mmol, 76%) with no further purification required. 
Rf: 0.1 (10% MeOH in DCM); 
1
H NMR (300 MHz, DMSO-d6) δ 1.12 (t, J = 7.0 Hz, 3H, POCH2CH3), 3.10 (d, J = 
20.4 Hz, 2H, COCH2P), 3.96 – 3.81 (m, 2H, POCH2CH3), 7.09 (dd [app. t], J = 7.3 Hz, 1H, ArH), 7.31 (dd [app. 
t], J = 7.8 Hz, 2H, 2 × ArH), 7.74 (d, J = 7.8 Hz, 2H, 2 × ArH), 11.12 (s, 1H, ArNH) ppm;  
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13
C NMR (101 MHz, DMSO-d6) δ 16.6, 29.0, 59.8, 120.2, 124.1, 128.6, 138.3, 169.8 ppm; 31P NMR (121 MHz, 
DMSO-d6) δ 12.82 ppm; HRMS-TOF MS ESI−: m/z [M−H]+ calculated for C10H13NO4P: 242.0582; found: 
252.0588. 
Dimethyl {2-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (39) 
A 2-neck round-bottomed flask was charged with 1,1'-carbonyldiimidazole 
(173 mg, 1.07 mmol, 1.85 equiv.), purged with Ar and dissolved in DCM (20 
mL). The resulting solution was then cooled to 0 °C, followed by the dropwise 
addition of a solution of 2-(dimethoxyphosphoryl)acetic acid (185 mg, 1.07 
mmol, 1.85 equiv.) in DCM (5 mL). The reaction mixture was then allowed 
to warm to rt and stirred for 1 h before being recooled to 0 °C. A solution of 
N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-
indol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine (257 mg, 0.579 mmol, 1 equiv.) in DCM (6 mL) was then added 
dropwise to the solution and the reaction mixture was then allowed to warm to rt and stir for 12 h or until complete 
consumption of the starting material as indicated by TLC. The reaction mixture was then diluted with H2O (20 mL), 
a saturated solution of NaHCO3 (20 mL) and DCM (10 mL) and the organic layer was separated. The aqueous layer 
was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of the 
crude product was achieved using flash column chromatography with elution gradient of 5 – 20% MeOH in DCM. 
Pure fractions were evaporated to dryness to afford compound 39 as an off-white foam (296 mg, 0.498 mmol, 86%). 
Rf: 0.38 (10 % MeOH in DCM); 
1
H NMR (300 MHz, CDCl3) δ 2.32 (s, 6H, CH2N(CH3)2), 2.39 – 2.34 (m, 2H, 
NCH2CH2N), 2.72 (s, 3H, ArNCH3), 2.77 (s, 2H, COCH2P), 2.98 – 2.95 (m, 2H, NCH2CH2N), 3.84 (s, 3H, 
PO(OCH3)2), 3.87 (s, 3H, PO(OCH3)2), 3.91 (s, 3H, ArNCH3), 4.03 (s, 3H, ArOCH3), 6.81 (s, 1H, ArH), 7.22 (d, J = 
5.4 Hz, 1H, ArH), 7.32 – 7.28 (m, 2H, 2 × ArH), 7.43 (dd, J = 6.0, 2.0 Hz, 1H, ArH), 7.73 (s, 1H, ArH), 8.13 – 
8.10 (m, 1H, ArH), 8.40 (d, J = 5.4 Hz, 1H, ArH), 8.95 (s, 1H, ArH), 9.66 (s, 1H, ArNH), 10.17 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 33.1 (d, J = 10.2 Hz), 35.6, 37.4, 44.9, 45.4, 53.3 (d, J = 6.3 Hz), 55.7, 56.2, 57.3, 
104.6, 108.0, 110.2, 113.6, 116.6, 120.4, 121.0, 121.9, 126.0, 127.7, 130.1, 134.3, 136.3, 138.3, 144.6, 157.9, 
159.6, 161.4, 162.2 ppm; 
31
P NMR (121 MHz, CDCl3) δ 25.53 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated 
for C29H39N7O5P: 596.2750; found: 596.2742. 
Methyl hydrogen {2-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (40)
30
 
A 2-neck round-bottomed flask was charged with dimethyl {2-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-
methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (150 mg, 
0.252 mmol, 1 equiv.), purged with Ar and dissolved in tert-butylamine (6 mL).  
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The resulting solution was then warmed to 55 °C and allowed to stir for 16 h 
or until complete consumption of the starting material as indicated by TLC. 
The reaction mixture was then allowed to cool to rt, during which time a 
white precipitate formed. After removal of the solvent in vacuo, the white 
solid was suspended in dioxane (10 mL) and a solution of 4 M HCl in dioxane 
(756 µL, 0.302 mmol, 1.2 equiv.) was then added dropwise and the reaction 
mixture was allowed to stir for 1 h. The reaction mixture was then filtered and 
after removal of the solvent in vacuo, compound 40 was afforded as an off-white solid (95.0 mg, 0.164 mmol, 65%) 
with no further purification required. 
Rf: 0.11 (30 % MeOH in DCM); IR (ATR) cm
-1
: 3363 (m, N-H stretch), 3267 (m, P-OH stretch), 2976 (m, C-H 
stretch), 1629 (s, C=O stretch), 1565 (m, N-H bend), 1466 (m, C-H bend), 1421 (m, C-H bend), 1328 (s, C-N 
stretch), 1207 (s, P=O stretch), 1097 (s, C-O stretch), 799 (s, C-H bend), 745 (s, N-H wag); 
1
H NMR (600 MHz, 
CD3OD) δ 2.42 (s, 6H, CH2N(CH3)2), 2.74 – 2.68 (m, 2H, NCH2CH2N), 2.79 (s, 2H, COCH2P), 3.14 (s, 3H, ArNCH3), 
3.62 – 3.57 (m, 2H, NCH2CH2N), 3.81 (s, 3H, POOCH3), 3.84 (s, 3H, ArNCH3), 3.93 (s, 3H, ArOCH3), 7.08 (d, J = 
8.0 Hz, 1H, ArH), 7.35 – 7.24 (m, 2H, 2 × ArH), 7.42 (d, J = 8.0 Hz, 1H, ArH), 7.59 (dd, J = 8.0, 5.3 Hz, 1H, 
ArH), 8.06 – 8.01 (m, 1H, ArH), 7.67 (s, 1H, ArH), 8.44 – 8.38 (m, 1H, ArH), 8.85 (d, J = 5.3 Hz, 1H, ArH), 9.13 
(s, 1H, ArNH), 10.13 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CD3OD) δ 36.2, 39.4, 43.7, 46.6 52.7, 55.7, 56.9, 
58.1, 103.4, 106.3, 111.6, 112.1, 114.6, 118.9, 120.1, 122.1, 123.8, 130.1, 130.5, 134.3, 137.7, 139.3, 146.1, 
158.3, 160.0, 163.5, 164.6 ppm; 
31
P NMR (162 MHz, CD3OD) δ 15.93 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ 
calculated for C28H37N7O5P: 582.2594; found: 582.2603. 
Diethyl {2-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-
2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (41)  
A 2-neck round-bottomed flask was charged with 1,1'-carbonyldiimidazole (81.0 mg, 0.498 mmol, 1.85 equiv.), 
purged with Ar and dissolved in DCM (10 mL). The resulting solution was then cooled to 0 °C, followed by the 
dropwise addition of a solution of 2-(diethoxyphosphoryl)acetic acid (98.0 mg, 0.498 mmol, 1.85 equiv.) in DCM 
(4 mL). The reaction mixture was then allowed to warm to rt and stirred for 1 h before being recooled to 0 °C. A 
solution of N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]benzene-1,2,4-triamine (120 mg, 0.269 mmol, 1 equiv.) in DCM (3 mL) was then added dropwise to the solution 
and the reaction mixture was then allowed to warm to rt and stir for 12 h or until complete consumption of the 
starting material as indicated by TLC. The reaction mixture was then diluted with H
2
O (20 mL), a saturated solution 
of NaHCO3 (20 mL) and DCM (10 mL) and the organic layer was separated. The aqueous layer was extracted with 
aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed with a saturated solution of brine 
(30 mL), dried over MgSO4 and filtered.  
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After removal of the solvent in vacuo, purification of the crude product was 
achieved using flash column chromatography with elution gradient of 5 – 20% 
MeOH in DCM. Pure fractions were evaporated to dryness to afford 
compound 41 as a tan solid (147 mg, 0.237 mmol, 88%). 
Rf: 0.42 (12.5% MeOH in DCM); 
1
H NMR (600 MHz, CDCl3) δ 1.26 (t, J = 
6.8 Hz, 6H, PO(OCH2CH3)2), 2.32 (s, 6H, CH2N(CH3)2), 2.45 (t, J = 5.1 Hz, 
2H, NCH2CH2N), 2.62 (s, 3H, ArNCH3), 2.94 (br s, 2H, NCH2CH2N), 3.13 (d, 
J = 21.4 Hz, 2H, COCH2P), 3.81 (s, 3H, ArNCH3), 3.91 (s, 3H, ArOCH3), 4.15 – 4.09 (m, 4H, PO(OCH2CH3)2), 
6.71 (s, 1H, ArH), 7.12 (d, J = 5.1 Hz, 1H, ArH), 7.24 – 7.18 (m, 2H, 2 × ArH), 7.33 (d, J = 7.6 Hz, 1H, ArH), 7.66 
(s, 1H, ArH), 8.05 (d, J = 7.1 Hz, 1H, ArH), 8.30 (d, J = 5.1 Hz, 1H, ArH), 8.80 (s, 1H, ArH), 9.59 (s, 1H, ArNH), 
9.92 (s, 1H, ArNH) ppm; 
13
C NMR (151 MHz, CDCl3) δ 16.4 (d, J = 6.1 Hz), 33.0, 37.1 (d, J = 133.2 Hz), 43.9, 
44.7, 54.6, 56.0, 56.5, 62.5 (d, J = 6.1 Hz), 104.2, 107.9, 110.0, 110.2, 113.4, 120.3, 120.9, 121.8, 125.8, 127.4, 
128.7, 134.6, 138.1, 144.5, 157.6, 159.5, 161.7 (d, J = 5.5 Hz), 162.1 ppm; 
31
P NMR (243 MHz, CDCl3) δ 23.10 
ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C31H42N7O5P: 623.2925; found: 623.2920.  
Ethyl hydrogen {2-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (42)
29
  
A microwave vial was charged with diethyl {2-[(2-{[2-
(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-
3-yl)pyrimidin-2-yl]amino}phenyl)amino]-2-oxoethyl}phosphonate (152 mg, 
0.244 mmol, 1 equiv.), sodium iodide (44.0 mg, 0.292 mmol, 1.2 equiv.), 
magnesium chloride (27.0 mg, 0.292 mmol, 1.2 equiv.) and purged with Ar. 
To this was added acetonitrile (5 mL) and after capping the vial the resulting 
suspension was warmed to 60 °C and allowed to stir for 12 h or until complete 
consumption of the starting material as indicated by TLC during which time a cream precipitate formed. The reaction 
mixture was then allowed to cool to rt and the white precipitate was collected by filtration. The solid was suspended 
in dioxane (10 mL) and a solution of 4 M HCl in dioxane (730 µL, 0.292 mmol, 1.2 equiv.) was then added dropwise 
and the reaction mixture was allowed to stir for 1 h. The reaction mixture was then filtered and after removal of the 
solvent in vacuo, compound 42 was afforded as a tan solid (93.0 mg, 0.156 mmol, 64%) with no further purification 
required. 
Rf: 0.16 (30% MeOH in DCM); IR (ATR) cm
-1
: 3375 (m, N-H stretch), 3287 (m, P-OH stretch), 2978 (m, C-H 
stretch), 1633 (s, C=O stretch), 1522 (m, N-H bend), 1452 (m, C-H bend), 1417 (m, C-H bend), 1371 (s, C-N 
stretch), 1229 (s, P=O stretch), 1089 (s, C-O stretch), 803 (s, C-H bend), 745 (s, N-H wag); 
1
H NMR (300 MHz, 
CDCl3) δ 1.28 – 1.20 (m, 3H, POOCH2CH3), 2.74 (br s, 2H, NCH2CH2N), 2.88 (s, 6H, CH2N(CH3)2), 3.13 (br s, 2H, 
NCH2CH2N), 3.27 – 3.25 (m, 2H, COCH2P), 3.30 (s, 3H, ArNCH3), 3.80 (s, 3H, ArNCH3), 3.87 (s, 3H, ArOCH3), 
4.11 – 4.00 (m, 2H, POOCH2CH3), 6.56 – 6.48 (m, 1H, ArH), 6.70 (s, 1H, ArH), 6.73 (s, 1H, ArH), 6.82 – 6.75 (m, 
1H, ArH), 7.04 (s, 1H, ArH), 7.13 – 7.07 (m, 1H, ArH), 7.58 (dd, J = 7.8, 1.4 Hz, 1H, ArH), 7.83 (s, 1H, ArH), 8.06 
(s, 1H, ArNH), 8.44 (s, 1H, ArNH) ppm;  
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13
C NMR (101 MHz, DMSO-d6) δ 17.1, 42.6, 50.0, 56.5, 60.1, 105.2, 105.7, 107.3, 110.8, 112.8, 114.7, 116.6, 
121.4, 122.5, 125.9, 133.8, 133.9, 157.5,  138.1, 157.8, 158.1, 160.8, 162.7, 170.3 ppm; 
31
P NMR (162 MHz, 
DMSO-d6) δ 12.53 ppm HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C29H39N7O5P: 596.2750; found: 
596.2769. 
N-Phenylacrylamide (43) 
A flame-dried, 2-neck round-bottom flask was charged with aniline (1.00 g, 10.7 mmol, 
1 equiv.), purged with Ar and dissolved in DCM (30 mL). DIPEA (2.24 mL, 12.9 mmol, 
1.2 equiv.) was added and the solution was cooled to −40 °C (acetontrile/ CO2). A solution of 
acryloyl chloride (1.07 g, 11.8 mmol, 1.1 equiv.) in DCM (10 mL) was then added dropwise to the solution over 
10 min. The reaction mixture was then allowed to warm to −20 °C and stirred at this temperature for 2 h or until 
complete consumption of the starting material as indicated by TLC. The reaction mixture was then quenched and 
diluted with H2O (20 mL), a saturated solution of NaHCO3 (20 mL) and DCM (30 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers 
were then washed with a saturated solution of brine (40 mL), dried over MgSO4 and filtered. After removal of the 
solvent in vacuo, purification of the crude product was achieved using flash column chromatography with elution 
gradient of 10 – 25% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 43 as a white 
solid (1.37 g, 9.34 mmol, 87%). 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
78
 
Rf: 0.24 (20% EtOAc in PE); 
1
H NMR (400 MHz, DMSO-d6) δ 5.75 (dd, J = 10.1, 2.1 Hz, 1H, CCH=CH2), 6.27 
(dd, J = 17.0, 2.1 Hz, 1H, CCH=CH2), 6.45 (dd, J = 17.0, 10.1 Hz, 1H, CCH=CH2), 7.09 – 7.04 (m, 1H, ArH), 
7.35 – 7.29 (m, 2H,), 7.70 – 7.65 (m, 2H, 2 × ArH), 10.13 (s, 1H, ArNH) ppm; 13C NMR (101 MHz, DMSO-d6) δ 
119.3, 123.5, 126.8, 128.8, 131.9, 139.0, 163.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C9H10NO: 
148.0762; found: 148.0753. 
N-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanamide (44)
31
  
A flame-dried Schlenk tube was charged with N-phenylacrylamide (100 mg, 0.679 
mmol, 1 equiv.), bis(pinacolato)diboron (207 mg, 0.815 mmol, 1.2 equiv.), CuCl 
(7.00 mg, 67.9 µmol, 10 mol%), potassium tert-butoxide (23.0 mg, 0.204 mmol, 
30 mol%) and xantphos (38.0 mg, 67.9 µmol, 10 mol%) and purged with Ar. To 
this was added EtOH (6 mL) and the resulting grey suspension was then allowed to stir for 6 h, filtered through a 
plug of celite and washed with EtOAc (30 mL). After removal of the solvent in vacuo, purification of the crude 
product was achieved using flash column chromatography with elution gradient of 10 – 25% EtOAc in PE. Pure 
fractions were evaporated to dryness to afford compound 44 as a clear oil (151 mg, 0.549 mmol, 81%). 
Rf: 0.30 (20% EtOAc in PE); 
1
H NMR (400 MHz, CDCl
3
) δ 1.11 (t, J = 7.3 Hz, 2H COCH
2
CH
2
B), 1.24 (s, 12H, 
(CH3)2CC(CH3)2), 2.47 (t, J = 7.3 Hz, 2H, COCH2CH2B), 7.04 (t, J = 7.4 Hz, 1H, ArH), 7.30 – 7.22 (m, 2H, 2 × 
ArH), 7.52 – 7.46 (m, 2H, 2 × ArH), 7.83 (s, 1H, ArNH) ppm;  
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13
C NMR (101 MHz, CDCl3) δ 24.9, 32.1, 75.0, 83.5, 119.7, 123.9, 128.9, 138.4, 172.5 ppm; 11B NMR (96 MHz, 
CDCl3) δ 34.49 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C15H23NO3B: 276.1171; found: 276.1171. 
N-phenyl-3-(tetrahydro-8λ4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-8-yl)propenamide (45)32 
A 2-neck round-bottom flask was charged with N-phenyl-3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)propenamide (360 mg, 1.31 mmol, 1 equiv.), purged with 
Ar and dissolved in diethyl ether (5 mL). To this was added diethanolamine (151 mg, 
1.44 mmol, 1.1 equiv.) and the resulting solution was left to stir for 8 h or until 
complete consumption of the starting material as indicated by TLC, during which time a white precipitate formed. 
The precipitate was collected by filtration, washed with diethyl ether (3 × 20 mL) and dried under vacuum to afford 
compound 45 as a white solid (223 mg, 0.852 mmol, 65%). 
Rf: 0.63 (50% EtOAc in PE); 
1
H NMR (300 MHz, DMSO-d6) δ 0.60 – 0.49 (m, 2H, COCH2CH2B), 2.24 – 2.14 (m, 
2H, COCH2CH2B), 2.80 – 2.69 (m, 2H, OCH2CH2NH), 3.09 – 2.94 (m, 2H, OCH2CH2NH), 3.66 – 3.55 (m, 2H, 
OCH2CH2NH), 3.78 – 3.67 (m, 2H, OCH2CH2NH), 6.81 (s, 1H, CH(NH)BCH), 7.03 – 6.94 (m, 1H, ArH), 7.31 – 
7.19 (m, 2H, 2 × ArH), 7.62 – 7.53 (m, 2H, 2 × ArH), 9.81 (s, 1H, ArNH) ppm; 13C NMR (75 MHz, DMSO-d6) δ 
33.5, 50.7, 62.3, 118.9, 122.5, 128.5, 139.8, 174.9 ppm; 
11
B NMR (96 MHz, DMSO-d
6
) δ 13.01 ppm; HRMS-TOF 
MS ESI+: m/z [M+H]
+
 calculated for C13H20N2O3B: 263.1567; found: 263.1562. 
(3-Oxo-3-(phenylamino)propyl)boronic acid (46)
32
 
A 2-neck round-bottom flask was charged with N-phenyl-3-(tetrahydro-8λ4-
[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-8-yl)propanamide (70 mg, 0.267 mmol, 
1 equiv.) and dissolved in diethyl ether (3 mL). To this was added 0.1 M HCl (5 mL) 
and the resulting solution was left to stir for 2 h or until complete consumption of the starting material as indicated 
by TLC. The reaction mixture was then diluted with H2O (5 mL) and EtOAc (20 mL) and the organic layer was 
separated. The aqueous layer was extracted with aliquots of EtOAc (3 × 10 mL) and the combined organic layers 
were then washed with a saturated solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the 
solvent in vacuo, the residue was dried under vacuum to afford compound 46 as a white solid (45 mg, 0.232 mmol, 
87%) with no further purification required.  
Rf: 0.64 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6) δ 0.85 (t, J = 7.3 Hz, 2H, COCH2CH2B), 2.35 (t, J = 7.3 Hz, 2H, 
COCH2CH2B), 6.99 (dd [app. t], J = 7.4 Hz, 1H, ArH), 7.30 – 7.21 (m, 2H, 2 × ArH), 7.50 (s, 2H, B(OH)2), 7.58 
(d, J = 7.6 Hz, 2H, 2 × ArH), 9.77 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, DMSO-d6) δ 31.6, 118.9, 122.7, 128.6, 
139.5, 173.1 ppm; 
11
B NMR (96 MHz, DMSO-d
6
) δ 33.13 ppm; HRMS-TOF MS ESI−: m/z [M−H]+ calculated for 
C9H11NO3B: 192.0832; found: 192.0836. 
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Ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (50)
31
  
A flame-dried schlenk tube was charged with ethyl acrylate (300 mg, 3.00 mmol, 
1 equiv.), bis(pinacolato)diboron (913 mg, 3.60 mmol, 1.2 equiv.), CuCl (30.0 mg, 
0.300 mmol, 10 mol%), potassium tert-butoxide (101 mg, 0.900 mmol, 30 mol%) and 
xantphos (174 mg, 0.300 mmol, 10 mol%) and purged with Ar. To this was added 
EtOH (18 mL) and the resulting grey suspension was then allowed to stir for 6 h, filtered through a plug of celite and 
washed with EtOAc (30 mL). After removal of the solvent in vacuo, purification of the crude product was achieved 
using flash column chromatography with elution gradient of 1 – 2.5% EtOAc in PE. Pure fractions were evaporated 
to dryness to afford compound 50 as a clear oil (602 mg, 2.64 mmol, 88%). 
1
H, 
13
C and 
11
B NMR and MS data collected for this compound compared well with the reported literature values.
79
 
Rf: 0.37 (2.5% EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 0.97 (t, J = 7.5 Hz, 2H, COCH2CH2B), 1.23 – 1.17 (m, 
15H, CH3CH2CO and (CH3)2CC(CH3)2), 2.38 (t, J = 7.5 Hz, 2H, COCH2CH2B), 4.07 (q, J = 7.1 Hz, 2H, CH3CH2CO) 
ppm; 
13
C NMR (75 MHz, CDCl3) δ 14.3, 24.6, 24.8, 28.9, 60.3, 83.3, 174.7 ppm; 11B NMR (96 MHz, cdcl3) δ 
34.45 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C11H22O4B: 229.1611; found: 229.1597. 
tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (53)
37
 
A flame-dried Schlenk tube was charged with CuCl (34.0 mg, 0.340 mmol, 5 mol%), 
potassium tert-butoxide (76.0 mg, 0.680 mmol, 10 mol%) and xantphos (200 mg, 
0.340 mmol, 5 mol%), purged with Ar and to this was added THF (6 mL). The resulting 
suspension was then allowed to stir for 30 min at rt, followed by the dropwise addition 
of a solution of bis(pinacolato)diboron (1.81 g, 7.14 mmol, 1.05 equiv.) in THF (5 mL). After stirring for a further 30 
min at rt, tert-butyl acrylate (1.00 mL, 6.80 mmol, 1 equiv.) was added dropwise, followed by the addition of MeOH 
(0.5 mL) during which time a slight exotherm was witnessed. The resulting grey slurry was then allowed to stir for 5 
h, filtered through a plug of celite and washed with EtOAc (30 mL). After removal of the solvent in vacuo, purification 
of the crude product was achieved using flash column chromatography with elution gradient of 2 – 10% EtOAc in 
PE. Pure fractions were evaporated to dryness to afford compound 53 as a clear liquid (1.71 g, 6.66 mmol, 98%). 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
37
 
Rf: 0.38 (5% EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 0.92 (t, J = 7.5 Hz, 2H, COCH2CH2B), 1.20 (s, 12H, 
(CH3)2CC(CH3)2), 1.39 (s, 9H, (CH3)3CCO), 2.31 (t, J = 7.5 Hz, 2H, COCH2CH2B) ppm; 
13
C NMR (75 MHz, CDCl3) 
δ 24.9, 28.2, 30.0, 79.8, 83.2, 174.1 ppm; 11B NMR (96 MHz, CDCl3) δ 34.45 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C12H20O5B: 255.1404; found: 255.1400. 
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3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)propanoic acid (51)
36
  
A 2-neck round-bottomed flask was charged with tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)propanoate (500 mg, 1.95 mmol, 1 equiv.), purged with Ar and 
dissolved in DCM (15 mL). This was followed by the dropwise addition of trifluoroacetic 
acid (5 mL) and the reaction mixture was then allowed to stir for 6 h or until complete 
consumption of the starting material as indicated by TLC. After removal of the solvent in vacuo, the residue was 
dried under vacuum to afford compound 51 as a brown oil (365 mg, 1.83 mmol, 94%) with no further purification 
required. 
Rf: 0.06 (10% EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 1.01 (t, J = 7.3 Hz, 2H, COCH2CH2B), 1.23 (s, 12H, 
(CH3)2CC(CH3)2), 2.50 (t, J = 7.3 Hz, 2H, COCH2CH2B), 10.97 (br s, 1H, HOOCCO) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ 24.6, 28.6, 53.5, 84.1, 181.5 ppm; 11B NMR (96 MHz, CDCl3) δ 34.71 ppm; HRMS-TOF MS ESI+: m/z 
[M+H]
+
 calculated for C9H18O4B: 200.1334; found: 200.1338. 
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanamide (47)  
A flame dried 2-neck round-bottom flask was charged with 3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)propanoic acid (45.0 mg, 0.224 mmol, 
2 equiv.), purged with Ar and dissolved in DCM (5 mL). The resulting solution 
was cooled to 0 °C and this was followed by the portion wise addition of 1-
hydroxybenzotriazole monohydrate (34.0 mg, 0.224 mmol, 2 equiv.) and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (43.0 mg, 
0.224 mmol, 2 equiv.) successively over 5 min. After allowing to stir for 30 
min at 0 °C, a solution of N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-
methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine (50.0 mg, 0.112 mmol, 1 equiv.) in 
DCM (3 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 1 h and then allowed to warm to rt 
and stirred for a further 8 h or until complete consumption of the starting material as indicated by TLC. The reaction 
mixture was then diluted with H
2
O (30 mL), a saturated solution of NaHCO
3
 (30 mL) and DCM (30 mL) and the 
organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined 
organic layers were then washed with H2O (30 mL), a solution of 1 M NaOH (2 × 20 mL), a saturated solution of 
brine (40 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, the residue was dried under 
vacuum to afford compound 47 as a white foam (51.0 mg, 80.8 µmol, 72%) with no further purification tolerated. 
Rf: 0.53 (10% MeOH in DCM); IR (ATR) cm
-1
: 3421 (m, N-H stretch), 3122 (m, N-H stretch), 2961 (m, C-H stretch), 
2852 (m, C-H stretch), 1672 (s, C=O stretch), 1577 (m, N-H bend), 1450 (m, C-H bend), 1402 (m, C-H bend), 
1342 (s, C-N stretch), 1099 (s, C-O stretch), 805 (s, C-H bend), 739 (s, N-H wag);  
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1
H NMR (300 MHz, CDCl3) δ 1.21 (s, 12H, (CH3)2CC(CH3)2), 1.27 (t, J = 6.2 Hz, 2H, COCH2CH2B), 2.30 (s, 6H, 
CH2N(CH3)2), 2.35 (t, J = 5.9 Hz, 2H, NCH2CH2N), 2.57 (t, J = 6.2 Hz, 2H, COCH2CH2B), 2.68 (s, 3H, ArNCH3), 
2.93 (t, J = 5.9 Hz, 2H, NCH2CH2N), 3.87 (s, 3H, ArNCH3), 4.03 (s, 3H, ArOCH3), 6.78 (s, 1H, ArH), 7.20 (d, J = 
5.3 Hz, 1H, ArH), 7.31 – 7.23 (m, 2H, 2 × ArH), 7.41 (dd, J = 6.0, 2.8 Hz, 1H, ArH), 7.71 (s, 1H, ArH), 8.10 – 
8.03 (m, 1H, ArH), 8.37 (d, J = 5.3 Hz, 1H, ArH), 9.09 (s, 1H, ArH), 9.60 (s, 1H, ArNH), 9.70 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 1.1, 24.9, 31.9, 33.4, 44.0, 45.6, 56.0, 56.3, 57.5, 83.3, 104.6, 107.9, 109.7, 110.2, 
113.6, 120.3, 120.9, 121.8, 126.1, 127.7, 129.8, 134.1, 135.4, 138.4, 143.9, 157.9, 159.7, 162.2, 171.5 ppm; 
11
B NMR (96 MHz, CDCl3) δ 33.35 ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for C34H37N7O4B: 628.3783; 
found: 628.3775. 
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)-2,2,2-trifluoroacetamide (57)
80
 
A flame-dried, 2-neck round-bottom flask was charged with N1-[2-
(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]benzene-1,2,4-triamine (75.0 mg, 0.168 mmol, 1 equiv.), 
purged with Ar and dissolved in THF (4 mL). DIPEA (35.0 µL, 0.202 mmol, 
1.2 equiv.) was added and the solution was cooled to −10 °C (acetone/ ice). 
A solution of trifluoroacetic anhydride (39.0 mg, 0.185 mmol, 1.1 equiv.) in 
THF (1 mL) was then added dropwise to the solution over 2 min. The reaction mixture was then allowed to warm 
to rt and stirred for 4 h or until complete consumption of the starting material as indicated by TLC. The reaction 
mixture was then quenched and diluted with H2O (20 mL), a saturated solution of NaHCO3 (20 mL) and DCM 
(30 mL) and the organic layer was separated. The aqueous layer was extracted with aliquots of DCM (3 × 20 mL) 
and the combined organic layers were then washed with a saturated solution of brine (30 mL), dried over MgSO4 
and filtered. After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of 5 – 10% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 57 as a white foam (66 mg, 0.121 mmol, 74%). 
Rf: 0.46 (10% MeOH in DCM); IR (ATR) cm
-1
: 3423 (m, N-H stretch), 3133 (m, N-H stretch), 2924 (m, C-H stretch), 
2846 (m, C-H stretch), 1715 (s, C=O stretch), 1588 (m, N-H bend), 1445 (m, C-H bend), 1402 (m, C-H bend), 
1340 (s, C-N stretch), 1213 (s, CF3 stretch), 1099 (s, C-O stretch), 799 (s, C-H bend), 739 (s, N-H wag); 
1
H NMR 
(300 MHz, CDCl3) δ 2.18 (t, J = 5.9 Hz, 2H, NCH2CH2N), 2.22 (s, 6H, CH2N(CH3)2), 2.72 (s, 3H, ArNCH3), 2.98 (t, 
J = 5.9 Hz, 2H, NCH
2
CH
2
N), 3.93 (s, 3H, ArNCH
3
), 3.99 (s, 3H, ArOCH
3
), 6.84 (s, 1H, ArH), 6.84 (s, 1H, ArH), 
7.25 (d, J = 5.3 Hz, 1H, ArH), 7.32 – 7.28 (m, 2H, 2 × ArH), 7.46 – 7.40 (m, 1H, ArH), 7.81 (s, 1H, ArH), 8.11 – 
8.02 (m, 1H, ArH), 8.41 (d, J = 5.3 Hz, 1H, ArH), 8.89 (s, 1H, ArH), 9.59 (s, 1H, ArNH), 11.84 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 32.9, 44.4, 45.5, 55.7, 56.1, 56.9, 105.1, 108.3, 110.3, 111.2, 113.6, 116.7 (d, J = 
288.2 Hz), 120.2, 121.1, 122.0, 126.0, 128.0, 128.4, 135.0, 135.4, 138.4, 146.0, 154.8 (d, J = 36.7 Hz), 158.0, 
159.6, 162.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C27H31N7O2F3: 542.2491; found: 542.2493. 
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2-Bromo-N-phenylacetamide (61) 
A flame-dried, 2-neck round-bottom flask was charged with aniline (500 mg, 5.37 mmol, 
1 equiv.), purged with Ar and dissolved in DCM (15 mL). To this was added DIPEA (1.12 mL, 
6.44 mmol, 1.2 equiv.) and the solution was cooled to −40 °C (acetonitrile/CO2). A solution 
of 2-bromoacetyl bromide (1.19 g, 5.91 mmol, 1.1 equiv.) in DCM (10 mL) was then added dropwise to the solution 
over 5 min. The reaction mixture was then allowed to warm to −20 °C and stirred at this temperature for 2 h or 
until complete consumption of the starting material as indicated by TLC. The reaction mixture was then quenched 
and diluted with H2O (40 mL), a saturated solution of NaHCO3 (40 mL) and DCM (50 mL) and the organic layer 
was separated. The aqueous layer was extracted with aliquots of DCM (3 × 40 mL) and the combined organic layers 
were then washed with a saturated solution of brine (50 mL), dried over MgSO4 and filtered. After removal of the 
solvent in vacuo, purification of the crude product was achieved using flash column chromatography with elution 
gradient of 10 – 25% EtOAc in PE. Pure fractions were evaporated to dryness to afford compound 61 as a white 
solid (1.03 g, 4.82 mmol, 90%). 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
81
 
Rf: 0.18 (20% EtOAc in PE); 
1
H NMR (400 MHz, DMSO-d
6
) δ 4.04 (s, 2H, COCH
2
Br), 7.11 – 7.06 (m, 1H, ArH), 
7.36 – 7.29 (m, 2H, 2 × ArH), 7.62 – 7.56 (m, 2H, 2 × ArH), 10.37 (s, 1H, ArNH) ppm; 13C NMR (101 MHz, 
DMSO-d6) δ 30.4, 119.2, 123.8, 128.8, 138.6, 164.8 ppm; HRMS-TOF MS ESI−: m/z [M−H]+ calculated for 
C8H7NOBr: 211.9711; found: 211.9706. 
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)-2-(1H-imidazol-1-yl)acetamide (67) 
A flame dried 2-neck round-bottom flask was charged with 2-(1H-imidazol-
1-yl)acetic acid (37.0 mg, 0.292 mmol, 2 equiv.), purged with Ar and 
dissolved in DCM (6 mL). The resulting solution was cooled to 0 °C and this 
was followed by the portion wise addition of 1-hydroxybenzotriazole 
monohydrate (45.0 mg, 0.292 mmol, 2 equiv.) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (56.0 mg, 0.292 mmol, 
2 equiv.) successively over 5 min. After allowing to stir for 30 min at 0 °C, a 
solution of N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]benzene-1,2,4-triamine (65.0 mg, 0.146 mmol, 1 equiv.) in DCM (4 mL) was added dropwise. The reaction 
mixture was stirred at 0 °C for 1 h and then allowed to warm to rt and stirred for a further 12 h or until complete 
consumption of the starting material as indicated by TLC. The reaction mixture was then diluted with H2O (30 mL), 
a saturated solution of NaHCO3 (30 mL) and DCM (30 mL) and the organic layer was separated. The aqueous layer 
was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then washed with a saturated 
solution of brine (40 mL), dried over MgSO
4
 and filtered.  
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After removal of the solvent in vacuo, purification of the crude product was achieved using flash column 
chromatography with elution gradient of 10% – 25% MeOH in DCM. Pure fractions were evaporated to dryness to 
afford compound 67 as a light-brown solid (61.0 mg, 0.110 mmol, 75%). 
Rf: 0.21 (10% MeOH in DCM); IR (ATR) cm
-1
: 3425 (m, N-H stretch), 3120 (m, N-H stretch), 2924 (m, C-H stretch), 
2848 (m, C-H stretch), 1697 (s, C=O stretch), 1577 (m, N-H bend), 1452 (m, C-H bend), 1410 (m, C-H bend), 
1342 (s, C-N stretch), 1099 (s, C-O stretch), 805 (s, C-H bend), 751 (s, N-H wag); 
1
H NMR (300 MHz, CDCl3) δ 
2.30 (t, J = 5.7 Hz, 2H, NCH2CH2N), 2.34 (s, 6H, CH2N(CH3)2), 2.65 (s, 3H, ArNCH3), 2.92 (t, J = 5.7 Hz, 2H, 
NCH2CH2N), 3.61 (s, 3H, ArNCH3), 3.89 (s, 3H, ArOCH3), 4.87 (s, 2H, COCH2NCH), 6.77 (s, 1H, ArH), 7.07 (s, 
1H, NCHCHN), 7.14 (s, 1H, NCHCHN), 7.20 (d, J = 5.3 Hz, 1H, ArH), 7.25 (dd, J = 6.2, 2.7 Hz, 1H, ArH), 7.28 
(s, 1H, CH2NCHN), 7.36 (dd, J = 6.2, 2.7 Hz, 1H, ArH), 7.63 (s, 1H, ArH), 7.75 (s, 1H, ArH), 8.04 (dd, J = 6.2, 2.7 
Hz, 1H, ArH), 8.36 (d, J = 5.3 Hz, 1H, ArH), 8.88 (s, 1H, ArNH), 9.67 (s, 1H, ArNH) ppm;  
13
C NMR (75 MHz, CDCl3) δ  32.9, 44.3, 45.4, 50.4, 55.5, 56.2, 57.2, 104.5, 108.1, 109.4, 110.3, 113.4, 120.2, 
120.3, 121.0, 121.9, 125.9, 128.0, 128.6, 129.7, 134.2, 135.0, 138.3, 144.6, 158.0, 159.5, 162.2, 163.7 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C30H36N9O2: 554.2992; found: 554.3007.  
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-
yl]amino}phenyl)-3-(1H-imidazol-1-yl)propanamide (69) 
A 2-neck round-bottomed flask was charged with 1,1'-carbonyldiimidazole 
(201 mg, 1.25 mmol, 1.85 equiv.), purged with Ar and dissolved in DCM (10 
mL). The resulting solution was then cooled to 0 °C, followed by the dropwise 
addition of a solution of 3-bromopropanoic acid (191 mg, 1.25 mmol, 1.85 
equiv.) in DCM (2 mL). The reaction mixture was then allowed to warm to rt 
and stirred for 1 h before being recooled to 0 °C. A solution of N1-[2-
(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-
yl)pyrimidin-2-yl]benzene-1,2,4-triamine (300 mg, 0.673 mmol, 1 equiv.) in 
DCM (6 mL) was then added dropwise to the solution and the reaction mixture was then allowed to stir for 12 h or 
until complete consumption of the starting material as indicated by TLC. The reaction mixture was then diluted with 
H2O (30 mL), a saturated solution of NaHCO3 (20 mL) and DCM (20 mL) and the organic layer was separated. The 
aqueous layer was extracted with aliquots of DCM (3 × 20 mL) and the combined organic layers were then washed 
with a saturated solution of brine (30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 5 – 25% 
MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 69 as a tan solid (241 mg, 0.424 
mmol, 63%). 
Rf: 0.24 (10% MeOH in DCM); IR (ATR) cm
-1
: 3412 (m, N-H stretch), 3114 (m, N-H stretch), 2937 (m, C-H stretch), 
2819 (m, C-H stretch), 1666 (s, C=O stretch), 1577 (m, N-H bend), 1447 (m, C-H bend), 1402 (m, C-H bend), 
1336 (s, C-N stretch), 1099 (s, C-O stretch), 807 (s, C-H bend), 739 (s, N-H wag);  
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1
H NMR (300 MHz, CDCl3) δ 2.22 (s, 6H, CH2N(CH3)2), 2.28 (t, J = 5.9 Hz, 2H, NCH2CH2N), 2.65 (s, 3H, ArNCH3), 
2.92 – 2.84 (m, 4H, NCH2CH2N and COCH2CH2N), 3.89 (s, 3H, ArNCH3), 3.97 (s, 3H, ArOCH3), 4.44 (t, J = 6.6 
Hz, 2H, COCH2CH2N), 6.78 (s, 1H, ArH), 7.03 (s, 2H, NCHCHN), 7.20 (d, J = 5.3 Hz, 1H, ArH), 7.32 – 7.27 (m, 
2H, 2 × ArH), 7.41 (dd, J = 6.2, 2.8 Hz, 1H, ArH), 7.58 (s, 1H, CH2NCHN), 7.73 (s, 1H, ArH), 8.16 (dd, J = 6.2, 
2.8 Hz, 1H, ArH), 8.41 (d, J = 5.3 Hz, 1H, ArH), 8.81 (s, 1H, ArH), 9.61 (s, 1H, ArNH), 10.19 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 33.2, 39.0, 43.2, 44.1, 45.2, 55.9, 56.2, 57.1, 104.7, 108.1, 110.1, 110.5, 113.9, 
119.2, 120.7, 121.1, 122.1, 126.0, 127.7, 129.2, 129.7, 134.2, 134.7, 137.2, 138.2, 144.7, 157.9, 159.7, 162.2, 
167.1 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C31H38N9O2: 568.3148; found: 568.3158. 
tert-Butyl 2-bromoacetate (70)
40
 
A flame-dried, 2-neck round-bottom flask was charged with anhydrous tert-butanol (1.90 mL, 
20.0 mmol, 1 equiv.), purged with Ar and dissolved in DCM (40 mL). To this was added pyridine 
(2.42 mL, 30.0 mmol, 1.5 equiv.) and the solution was cooled to −10 °C (acetone/ice). A solution of 2-bromoacetyl 
bromide (4.44 g, 22.0 mmol, 1.1 equiv.) in DCM (20 mL) was then added dropwise to the solution over 20 min. 
The reaction mixture was then allowed to stir at 0 °C for 4 h or until complete consumption of the starting material 
as indicated by TLC. The reaction mixture was then quenched and diluted with H2O (40 mL), a saturated solution 
of NaHCO3 (40 mL) and diethyl ether (50 mL) and the organic layer was separated. The aqueous layer was extracted 
with aliquots of diethyl ether (3 × 40 mL) and the combined organic layers were then washed with a solution of 
1 M NaOH (30 mL), saturated solution of brine (50 mL), dried over MgSO
4
 and filtered. After removal of the solvent 
in vacuo, the residue was dried under vacuum to afford compound 70 as a clear oil (2.73 g, 14.0 mmol, 70%) with 
no further purification required. 
IR, 
1
H and 
13
C NMR data collected for this compound compared well with the reported literature values.
40
 
1
H NMR (300 MHz, CDCl3) δ 1.48 (s, 9H, (CH3)3COC), 3.75 (s, 2H, COCH2Br) ppm; 13C NMR (75 MHz, CDCl3) δ 
27.8, 28.0, 83.0, 166.4 ppm; no ionization was found in MS. 
tert-Butyl 2-(1H-imidazol-1-yl)acetate (71)
41
 
A 2-neck round-bottom flask was charged with imidazole (68.0 mg, 1.00 mmol, 1 equiv.), 
Cs2CO3 (391 mg, 1.20 mmol, 1.2 equiv.), purged with Ar and dissolved in DMF (4 mL). The 
resulting solution was cooled to 0 °C and to this was added a solution of tert-butyl 2-bromoacetate (215 mg, 1.10 
mmol, 1.1 equiv.) in DMF (1 mL) dropwise over 2 min. The reaction mixture was then allowed to warm to rt and 
stirred for 4 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was 
then diluted with H
2
O (30 mL) and EtOAc (20 mL) and the organic layer was separated. The aqueous layer was 
extracted with aliquots of EtOAc (3 × 20 mL) and the combined organic layers were then washed with a saturated 
solution of brine (3 × 30 mL), dried over MgSO4 and filtered. After removal of the solvent in vacuo, purification of 
the crude product was achieved using flash column chromatography with elution gradient of 50% – 90% EtOAc in 
PE. Pure fractions were evaporated to dryness to afford compound 71 as a tan solid (153 mg, 0.840 mmol, 84%). 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature values.
82, 83
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Rf: 0.17 (60% EtOAc in PE); 
1
H NMR (300 MHz, CDCl3) δ 1.45 (s, 9H, (CH3)3COC), 4.56 (s, 2H, COCH2NCH), 6.93 
(s, 1H, NCHCHN), 7.07 (s, 1H, NCHCHN), 7.47 (s, 1H, CH2NCHN) ppm; 
13
C NMR (75 MHz, CDCl3) δ 28.0, 48.9, 
83.3, 120.1, 129.7, 166.5 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C9H15N2O2: 183.1134; found: 
183.1128. 
2-(1H-Imidazol-1-yl)acetic acid (72)
36
 
A 2-neck round-bottomed flask was charged with tert-butyl 2-(1H-imidazol-1-yl)acetate (80.0 
mg, 0.439 mmol, 1 equiv.), purged with Ar and dissolved in DCM (6 mL). This was followed by 
the dropwise addition of trifluoroacetic acid (2 mL) and the reaction mixture was then allowed to stir for 6 h or until 
complete consumption of the starting material as indicated by TLC. After removal of the solvent in vacuo, the residue 
was dried under vacuum to afford compound (HL1184 72) as a beige solid (49.0 mg, 0.386 mmol, 88%) with no 
further purification required. 
IR, 
1
H and 
13
C NMR and MS data collected for this compound compared well with the reported literature 
values.
84, 85, 86
 
Rf: 0.08 (EtOAc); 
1
H NMR (300 MHz, CD3OD) δ 4.46 (s, 2H, COCH2NCH), 6.86 (s, 1H, NCHCHN), 6.92 (s, 1H, 
NCHCHN), 8.26 (s, 1H, CH2NCHN) ppm; 
13
C NMR (75 MHz, CD3OD) δ 50.6, 120.6, 124.6, 137.7, 169.4 ppm; 
HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for C12H9N3Cl: 230.0485; found: 230.0480.  
2-Cyano-N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-
2-yl]amino}phenyl)acetamide (74) 
A flame dried 2-neck round-bottom flask was charged with 2-cyanoacetic 
acid (85.0 mg, 2.00 mmol, 2 equiv.), purged with Ar and dissolved in DCM 
(12 mL). The resulting solution was cooled to 0 °C and this was followed by 
the portion wise addition of 1-hydroxybenzotriazole monohydrate (153 mg, 
2.00 mmol, 2 equiv.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (192 mg, 2.00 mmol, 2 equiv.) successively over 5 min. After 
allowing to stir for 30 min at 0 °C, a solution of N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-
1H-indol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine (445 mg, 1.00 mmol, 1 equiv.) in DCM (8 mL) was added 
dropwise. The reaction mixture was stirred at 0 °C for 1 h and then allowed to warm to rt and stirred for a further 4 
h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was then diluted 
with H2O (30 mL), a saturated solution of NaHCO3 (30 mL) and DCM (40 mL) and the organic layer was separated. 
The aqueous layer was extracted with aliquots of DCM (3 × 30 mL) and the combined organic layers were then 
washed with a saturated solution of brine (40 mL), dried over MgSO4 and filtered. After removal of the solvent in 
vacuo, purification of the crude product was achieved using flash column chromatography with elution gradient of 
5% – 10% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 74 as a light-brown solid 
(466 mg, 0.909 mmol, 91%). 
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Rf: 0.48 (10% MeOH in DCM); IR (ATR) cm
-1
: 3419 (m, N-H stretch), 3120 (m, N-H stretch), 2939 (m, C-H stretch), 
2819 (m, C-H stretch), 2253 (w, C≡N stretch), 1687 (s, C=O stretch), 1577 (m, N-H bend), 1450 (m, C-H bend), 
1402 (m, C-H bend), 1345 (s, C-N stretch), 1099 (s, C-O stretch), 807 (s, C-H bend), 739 (s, N-H wag); 
1
H NMR 
(600 MHz, CDCl3) δ 2.26 (t, J = 5.4 Hz, 2H, NCH2CH2N), 2.30 (s, 6H, CH2N(CH3)2), 2.70 (s, 3H, ArNCH3), 2.88 (t, 
J = 5.4 Hz, 2H, NCH2CH2N), 3.58 (s, 2H, COCH2CN), 3.89 (s, 3H, ArNCH3), 4.06 (s, 3H, ArOCH3), 6.79 (s, 1H, 
ArH), 7.23 (d, J = 5.3 Hz, 1H, ArH), 7.27 (d, J = 4.0 Hz, 1H, ArH), 7.33 – 7.29 (m, 1H, ArH), 7.42 (dd, J = 6.2, 
2.8 Hz, 1H, ArH), 7.76 (s, 1H, ArH), 8.05 (dd, J = 6.2, 2.8 Hz, 1H, ArH), 8.38 (d, J = 5.3 Hz, 1H, ArH), 9.02 (s, 
1H, ArH), 9.66 (s, 1H, ArNH), 10.57 (s, 1H, ArNH) ppm; 
13
C NMR (75 MHz, CDCl3) δ 27.2, 33.43, 44.1, 45.5, 
56.2, 56.4, 57.4, 104.6, 108.2, 109.6, 110.4, 113.5, 115.0, 120.2, 121.0, 121.9, 126.0, 128.1, 128.8, 134.5, 
135.1, 138.4, 144.8, 158.0, 158.5, 159.6, 162.2 ppm; HRMS-TOF MS ESI+: m/z [M+H]
+
 calculated for 
C28H33N8O2: 513.2726; found: 513.2726. 
3-Cyano-3-[(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-
2-yl]amino}phenyl)carbamoyl]pentane-1,5-disulfonyl difluoride (76)
48
 
A 2-neck round-bottom flask was charged with 2-cyano-N-(2-{[2-
(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-
3-yl)pyrimidin-2-yl]amino}phenyl)acetamide (50.0 mg, 97.5 µmol, 1 equiv.) 
and potassium carbonate (27.0 mg, 0.195 mmol, 2 equiv.) and purged with 
Ar. To this was added acetonitrile (8 mL) and the suspension was cooled to 
−10 °C (acetone/ice). A solution of ethenesulfonyl fluoride (20.0 mg, 0.180 
mmol, 1.85 equiv.) in acetonitrile (2 mL) was then added dropwise to the 
solution over 2 min. The reaction mixture was then allowed to warm to rt and 
stirred for 8 h or until complete consumption of the starting material as indicated by TLC. The reaction mixture was 
then filtered through a plug of celite and washed with EtOAc (30 mL). After removal of the solvent in vacuo, 
purification of the crude product was achieved using flash column chromatography with elution gradient of 5 – 
12.5% MeOH in DCM. Pure fractions were evaporated to dryness to afford compound 76 as an off-white foam 
(51.0 mg, 69.2 µmol, 71%). 
Rf: 0.61 (10% MeOH in DCM); IR (ATR) cm
-1
: 3398 (m, N-H stretch), 3120 (m, N-H stretch), 2935 (m, C-H stretch), 
2236 (w, C≡N stretch), 1682 (s, C=O stretch), 1579 (m, N-H bend), 1450 (m, C-H bend), 1404 (m, C-H bend), 
1335 (s, C-N stretch), 1198 (s, S=O stretch), 1099 (s, C-O stretch), 1033 (s, S=O stretch), 809 (s, C-H bend), 743 
(s, N-H wag); 
1
H NMR (300 MHz, CDCl
3
) δ 2.20 (t, J = 5.4 Hz, 2H, NCH
2
CH
2
N), 2.41 – 2.28 (m, 8H, CH
2
N(CH
3
)
2
 
and CCH2CH2S), 2.59 (m [app. td], J = 13.1, 4.5 Hz, 2H, CCH2CH2S), 2.70 (s, 3H, ArNCH3), 2.99 (t, J = 5.4 Hz, 
2H, NCH2CH2N), 3.41 – 3.27 (m, 2H, CCH2CH2S), 3.60 – 3.47 (m, 2H, CCH2CH2S), 3.88 (s, 3H, ArNCH3), 3.92 (s, 
3H, ArOCH3), 7.06 (d, J = 5.3 Hz, 1H, ArH), 7.37 – 7.27 (m, 2H, 2 × ArH), 7.44 – 7.39 (m, 1H, ArH), 7.77 (s, 1H, 
ArH), 8.01 (s, 1H, ArH), 8.34 (d, J = 5.3 Hz, 1H, ArH), 8.43 (dd, J = 6.4, 2.4 Hz, 1H, ArH), 9.23 (s, 1H, ArNH), 
10.91 (s, 1H, ArNH) ppm;  
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13
C NMR (75 MHz, CDCl3) δ 31.3, 33.4, 45.0, 45.4, 46.2, 46.4, 46.7, 55.7, 56.1, 58.0, 104.4, 108.3, 110.6, 113.9, 
114.0, 117.8, 121.4, 121.8, 122.5, 126.0, 127.5, 128.5, 132.2, 136.3, 138.3, 146.9, 157.5, 159.6, 161.6, 162.4 
ppm; 
19
F NMR (282 MHz, CDCl3) δ 53.35 (t, J = 4.8 Hz) ppm; HRMS-TOF MS ESI+: m/z [M+H]+ calculated for 
C32H39N8O6S2F2: 733.2402; found: 733.2407. 
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Chapter 8 
Project Summary and Concluding Remarks  
8.1 The Future of EGFR as Therapeutic Target 
From the revelation of its existence and mechanistic functions in the 1950s, to the awarding of the 1986 Nobel Prize 
in Physiology and Medicine to Stanley Cohen for its discovery, EGFR has remained a relevant target in cancer therapy 
for 36 years.
1
 The FDA approval of gefitinib as the first TKI for treatment of NSCLC in 2003 marked a major triumph 
in the development of targeted therapeutics against cancer.
2
 However, this victory was short-lived. The past 16 years 
has seen the development of four generations of EGFR inhibitors attempting to overcome the emergence of multiple, 
major resistance mechanisms which are brought about by point mutations within the enzyme.
3
 During this time, 
researchers have been forced to re-evaluate and implement numerous innovative strategies, both in the identification 
and targeting of EGFR mutant variants. This includes the discovery of novel chemical structures, binding modes and 
means of inhibition. This is most celebrated in the success story that is the development of osimertinib, the first 
inhibitor to effectively overcome resistance mediated through the most prevalent mechanism - the EGFR-
L858R/T790M double mutation.
4
  
Yet, four years since its emergence in 2015, resistance to 3
rd
 generation inhibitors conferred by the EGFR-C797S 
mutation remains unanswered.
5
 To date, no major breakthroughs have been achieved in subduing the clinically 
relevant mutant variant. Furthermore, the EGFR-G724S mutation was recently identified for the first time and shown 
to limit the activity of 3
rd
 generation inhibitors both in vitro and in vivo.
6
 The drought in successful strategies targeting 
3
rd
 generation inhibitor resistance, as well as the emergence of novel contributing mutations, highlights our lack of 
knowledge and understanding in this current wave of resistance mechanisms. While sombre, this describes the 
present situation of EGFR inhibition.  
Owing to the inherent relationship between receptor overexpression and cancer, EGFR will remain a therapeutic 
target in combating various forms of cancer for the foreseeable future. Consequently, researchers must examine the 
successes of the past to overcome the obstacles of the future. As was learnt with the emergence of the EGFR-T790M 
mutation over a decade ago, simply trying to improve on existing inhibitors does not necessarily counteract new 
mechanisms of acquired drug resistance. With the complexity of multimutated forms of EGFR exponentially 
increased, researchers find themselves in a similar but more demanding and challenging situation. Therefore, the 
development of novel therapeutic strategies and innovative approaches, through collaboration between academia 
and industry, will be required to overcome mutant forms of the enzyme which mediate resistance toward 3
rd
 
generation inhibitors. This was the intention of this research project.  
The research efforts described within this thesis focussed on overcoming EGFR-C797S-mediated resistance through 
development of both highly potent reversible inhibitors and re-establishment of irreversible inhibition. This was 
undertaken by attempting covalent modification of previously untargeted amino acid residues utilising novel 
electrophiles. In the next section, we will examine the positive and negative outcomes of each strategy employed, 
which will be followed by the prospective application of these approaches in the future of EGFR inhibition.  
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8.2 Summary, Outcomes and Future Applications of this Project  
In Chapter 4, we implemented the use of traditional reversible and acrylamide-containing irreversible inhibitors, 
synthesising a total of 26 final compounds. For the reversible analogues, successful biochemical inhibition of the 
clinically relevant EGFR-L858R/T790M/C797S mutant variant was reflected in the highly potent picomolar IC
50
 
values of these compounds. Unfortunately, this efficacy was not maintained in the cellular assays, presumably due 
to intolerance of the glycol chain moiety within the cell. However, with careful selection of a cellularly tolerated 
glycol chain group, and optimisation of the relevant pharmacokinetic parameters, we believe inclusion of this 
functional group will be beneficial in creating favourable reversible interactions within the enzyme. Therefore, it is 
our belief that the design and synthesis of highly potent reversible inhibitors could be a viable strategy in overcoming 
resistance mediated by the EGFR-C797S mutation. 
For the irreversible counterparts, similar activity within the low nanomolar to picomolar range was observed against 
the EGFR-L858R/T790M double mutant biochemically, while a decrease in the respective EC50 values of these 
compounds was observed in a cellular context. Irreversible inhibition was confirmed through procurement of a 
crystal structure of compound 77 complexed with the cSrc-T338M/S345C surrogate. Additionally, this provided 
valuable insight and reinforcement for our postulates regarding the optimal position and substitution pattern of the 
glycol chain moiety for favourable reversible interactions with the glycine rich loop. While the effectiveness of 
osimertinib against the EGFR-L858R/T790M double mutant has rendered its therapeutic targeting a secondary 
objective, the development of more potent and selective inhibitors of this aberrant enzyme remains a continual 
research endeavour. Thereby, the aforementioned work has led to the submitting of a manuscript for publication. 
Lastly, the most efficacious inhibitors synthesised in this chapter were submitted for evaluation as dual EGFR/HER2 
inhibitory agents. The promising activity profiles exhibited by these compounds in cellular-based assays laid the 
foundation for a further research platform, which remains ongoing.  
Chapter 5 witnessed a departure from the conventional methods of EGFR inhibition. Seeking to re-establish covalent 
inhibition in the EGFR-C797S mutant, we envisaged the use of 1,4-dicarbonyl electrophiles to potentially undergo 
Paal-Knorr pyrrole formation with the EGFR catalytic Lys745 residue. This included synthesis of 1,4-diketone-, 1,4-
dicarboxylic acid-, 1,4-diester-, 1,4-diol- and 1,4-dialkene-containing inhibitors and a gefitinib-based heterocyclic 
driving group. This amounted to 8 final compounds which were submitted for biochemical and cellular evaluation. 
While covalent mass spectrometry revealed a reversible binding mode for these inhibitors, several interesting activity 
profiles warrants further investigation into these novel electrophiles, with the most notable example being the 1,4-
dialkene functional group. Furthermore, we believe that the inclusion of an appropriate solubilising group will 
dramatically improve the poor EC50 values displayed by these compounds.  
Building on the premise of the preceding chapter, we continued with our study of the reversible/irreversible 
interactive capabilities of numerous functional groups with the EGFR catalytic Lys745 residue in Chapter 6. An 
arduous synthetic route afforded 10 final compounds functionalised at the N-indole position with various protecting 
groups, nitriles, acrylamide and sulfonyl fluoride moieties. In addition, an optimised route towards the osimertinib-
derived heterocyclic scaffold was established.  
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Unfortunately, no irreversible inhibition of the EGFR catalytic Lys745 residue was found to take place, as 
demonstrated by covalent mass spectrometry experiments. While covalent labelling of this residue was achieved by 
Taunton and co-workers, effective irreversible inhibition of EGFR through this mechanism remains a challenging 
endeavour.
7
 Rationally targeting nucleophilic lysine residues in a therapeutic context is currently in its infancy, with 
the relatively few available reported examples a testament to this.
8
 With a greater selection as these examples 
increase, and improved knowledge of optimal lysine-selective electrophiles and the required reactivity thereof, 
lysine-targeting covalent inhibition will become more prevalent and considered earlier in the drug discovery process. 
Nevertheless, we still maintain that covalent bond formation with the catalytic Lys745 residue remains a potentially 
realizable strategy in overcoming resistance conferred by the EGFR-C797S mutation. Efforts towards this goal remains 
ongoing in our research group.  
The final approach implemented in Chapter 7 aimed to irreversibly inhibit the mutated Ser797 residue present in 
the EGFR-C797S mutant enzyme. Based on the synthetic achievements of the previous chapter, we utilised an 
osimertinib-derived driving group derivatised with various reactive electrophiles and functional groups capable of 
interacting irreversibly or reversibly with the Ser797 residue respectively. Wishing to emulate the catalytic triad in 
serine proteases, we also envisaged the use of dual-warhead-containing compounds. This amounted to a total of 14 
final compounds which included nitrogen-, boron-, phosphorous-, sulphur- and fluorine-containing functionalities. 
While none of these compounds were able to undergo covalent bond formation with the mutant Ser797 residue, a 
number of encouraging trends and results were obtained from the biochemical and cellular evaluation. This included 
the enhanced stability of the vinyl sulfonyl fluoride warhead over its aliphatic counterpart, rationalised to stem from 
the prevailing mechanism of hydrolysis. Additionally, the favourable selectivity and efficacy offered by the imidazole- 
and nitrile-bearing inhibitors between the double and triple mutant form of the enzyme was ascribed to the sulphur-
π interaction capabilities of the heteroaromatic imidazole ring. These attractive features, coupled with the novelty 
of these underutilised moieties, emphasises their prospective development and use in combating the EGFR-C797S 
mutation. With serine residues being notoriously non-nucleophilic, we remain unsure as to whether covalent bond 
formation with the mutated Ser797 residue is indeed possible. However, further investigation into the envisioned 
dual warhead strategy, which allows for activation and simultaneous irreversible inhibition of the unreactive residue. 
This remains a main priority in the activities of our research group.  
To conclude, an extensive amount of synthetic methodology was developed and implemented in the synthesis of 
the 48 final compounds presented in this thesis. Most notable is the discovery of a novel and convenient one-pot 
transformation of anilines to their corresponding acetamide- or propanamide-functionalised imidazoles, utilising 
1,1’-carbonyldiimidazole and the respective α-, β-halo-carboxylic acid. We intend on examining the scope of this 
reaction, with the purpose of publishing the compiled parameters. It is our hope that this synthetic sequence, along 
with the synthesis of the numerous electrophilic fragments and heterocycles furnished throughout this research 
project, will provide a platform for future drug candidates in the successful inhibition of EGFR. 
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